REMARKS

Claims 8, 9 and 16-23 are pending in this application. Claims 19-20 and 22-23 are withdrawn. Claims 1-7, and 10-15 are cancelled. Claims 8, 16, 17 and 18 are amended. Support for the amendments to these claims can be found, for example, in cancelled claim 1, and in the specification on page 5, lines 6-12. The amendments are being made to place the application in condition for allowance. Reconsideration is respectfully requested in view of the following remarks.

I. Revised Sequence Listing

Upon review of the instant application, Applicants note that the sequence listing submitted on September 12, 2001 included an error in the sequence for SEQ ID NOS: 1 and 2. The error consisted of inadvertently translated amino acids in the 5' end of the protein sequence. Applicants respectfully submit herewith a revised sequence listing for the Examiner's consideration.

II. Claim Rejection Under 35 U.S.C. 101

The Examiner rejected claims 8, 9, 16-18 and 21 under 35 U.S.C. § 101, as being allegedly not supported by either a credible asserted utility or a well established utility. Applicants respectfully traverse this rejection.

The Examiner states that the "state of the art in protein function prediction from amino acid sequence" is represented by Whisstock et al. (Q Rev. Biophys. 36:307-340 (2003)). The Examiner characterizes Whisstock's teachings as stating that: 1) protein function prediction is a difficult problem since homologous proteins often have different and multiple functions; 2) methods for inferring function based on similarity in sequence and/or structure between an unknown protein and one or more well-understood proteins is tenuous and only provide guesses at function; 3) protein function predictions suggest function but do not determine function; 4) the most useful effect of protein function prediction is to guide laboratory experimentation to confirm, refute or correct the prediction; and 5) protein function prediction from protein

sequence and structure is useful but is not a substitute for laboratory experimentation. See Office Action, pg. 3.

Firstly, Applicants respectfully point out to the Examiner that the Federal Circuit and the Patent Office guidelines have consistently rejected the use of a *per se* rule rejecting homology-based assertions of utility because such assertions are not based on relevant scientific evidence. Fed. Reg. 66:1096 (Jan. 5, 2001), citing *In re Brana*, 51 F.3d 1560, 1566 (Fed. Cir. 1995) (rejection of claims improper where claims did "not suggest an inherently unbelievable undertaking or involve implausible scientific principles" and where "prior art ... discloses structurally similar compounds to those claimed by the applicants which have been proven ... to be effective"). Instead, relevant precedent consistently supports a case-by-case analysis, taking into account "both the nature and degree of the homology." *Id.* The Federal Circuit has echoed this sentiment by establishing a broad presumption when an applicant asserts a claim for utility, as well as the lack of a need for absolute correlation when asserting function of a nucleic acid or protein sequence based on homology studies. "[A] 'rigorous correlation' need not be shown in order to establish practical utility; 'reasonable correlation' is sufficient." *Id.*, citing *Fujikawa v. Wattanasin*, 93 F.3d 1559, 1565 (Fed. Cir. 1996).

Applicants here have asserted a specific and substantial utility for use of the protease-related protein ("PVP") in the regulation of keratinization of hair, which has utility in either hair loss or excess body hair therapeutic scenarios, by establishing a "reasonable correlation" using experimental data, as well as data available to one of ordinary skill in the art at the time of filing of the instant patent application. Applicants base this assertion partially on PVP's homology with respect to "a protease of the kallikrein family, optionally a protease activity." See Specification, pg. 2, lines 16-17. For clarification purposes, kallikrein proteins are a group of serine proteases that were first introduced in the 1930's. *See infra* Exhibit B. Although the actual sequence comparisons with various proteases and kallikrein protease proteins are not included with the specification, one of ordinary skill in the art could easily perform a protein sequence search, for example, through the publicly available and widely used National Center for Biotechnology Information protein-BLAST search engines to visualize the high degree of homology of PVP with proteases, including kallikreins, from various species. Applicants respectfully provide herewith for the Examiner's consideration, an example of results from a

BLAST search of the amino acid sequence of the claimed invention with protein sequences, demonstrating the significant structural relationships between PVP and proteases, including kallikrein proteins, that were known to one of ordinary skill in the art at the time of filing of the instant application. See Exhibit A, attached herein. The BLAST search found significant homology with several kallikrein and protease proteins, including: Kallikrein 6 [Rattus norvegius]; Kallikrein 8, isoform 2 [Homo sapiens]; Kallikrein 14 preproprotein [Homo sapiens]; KLK (kallikrein) 15 [Saguinus oedipus]; Kallikrein 11 isoform 2 precursor [Homo sapiens]; Serine protease [Rattus rattus]; Serine protease [Mus musculus]; and Trypsin precursor [Xenopus laevis].

Applicants assert, therefore, that even if the Whisstock reference is taken into account, the conclusion based on the BLAST search results can only be that significant homology is present between known kallikrein proteins and PVP, and that PVP's function can be reasonably correlated with that of a protease, including serine proteases of the kallikrein family. For example, Whisstock teaches that "the most favorable result is to find that the query sequence is identical or very closely related to that of a well-characterized protein." See Whisstock, pg. 321. In addition, Whisstock teaches that sequence similarity in regions of active site residues is also important in obtaining reliable functional predictability from homology comparisons. *Id.* at pg. 321-22. Whisstock concludes, "In general, if an unknown protein shares significant sequence similarity with a family of known function, possesses the 'right essential conserved residues' (e.g. active site residues) then a prediction as to function (proteinase, exonuclease, etc.) can reasonably be proposed." *Id.* at pg. 324.

Applicants assert that, as supported by Whisstock, the high degree of homology of greater than 50% with protease proteins, particularly with the well-characterized family kallikrein serine proteases, supports the function of PVP as a protease. Combined with the showing of homology across multiple species, from humans to monkeys to rats, the homology evidence points to the function of PVP as a member of a protease family. See Exhibit A. Moreover, the strong degree of homology within the active catalytic subunits of the protein, namely amongst histidine (WVLTAAHC), serine (GDSGGPL), and to a lesser extent, aspartic acid (DLMLL) motifs, only further supports the contention that PVP shares enzymatic protease function with the kallikrein protein family. See Yousef and Diamandis, Endocrine Rev. 22:184-

204 (2001) and active site comparisons, herein attached respectively as Exhibits B and C. As seen from Exhibit C, which compares kallikrein protein sequences with PVP and highlights active site residues for both kallikrein and PVP proteins, PVP shares extensive homology with rat, monkey and human kallikreins in the active site regions. Importantly, the active site residues characteristic for kallikrein proteins are highly conserved in PVP. Based on the homology and active site comparison data alone, Applicants have sufficiently shown, therefore, that PVP is related to a protease protein, lending support to their utility of PVP as a protease protein.

Moreover, Applicants have shown, in addition to the knowledge of one of ordinary skill in the art at the time of filing, important functional data in regards to PVP and hair growth regulation. One of ordinary skill in the art would know at the time of filing of the role that serine proteases play in keratinocyte regulation. For example, past studies have shown that serine proteases can induce apoptosis in keratinocyte cell lines, as well as in vivo in actively growing hair follicles. *See* Seiberg, M. et al., "Trypsin-induced follicular papilla apoptosis results in delayed hair growth and pigmentation," Dev. Dyn. 208: 553-564 (1997), Exhibit D, attached herein. Apoptosis, or programmed cell death, plays a large role in the active growth cycle of hair follicles in the catagen phase, where the hair follicle shortens as its lower two third of the follicle structure undergoes programmed cell death and apoptosis. *Id.* at pg. 553, col. 1, 1st paragraph. Treatment of mice with the serine protease trypsin triggers induction of apoptosis in follicular papillae, which results in a delay in hair growth and pigmentation. *See Id.* at col. 2, last paragraph.

Although the high homology of PVP with serine proteases and the knowledge of serine proteases' role in keratinization are enough to reasonably correlate PVP's role with keratinization, Applicants provide even further support by showing that gene expression of PVP is increased when hair growth is perturbed in *whn*(-/-) mice, as opposed to two keratin genes, Ha3 and Ck15. This experimental evidence demonstrating a causal relationship in the regulation of PVP and hair keratinization only strengthens Applicant's assertion of PVP's role in hair regulation. See Specification, pg. 2, lines 20-22. The experimental evidence, combined with the homology relationships and the known role of proteases in keratinization provides sufficient support for a specific and substantial utility of the present application.

Based on the remarks above, Applicants respectfully request withdrawal of this rejection.

III. Claim Rejection Under 35 U.S.C. 112, First Paragraph:

The Examiner rejected claims 8, 9, 16-18 and 21 under 35 U.S.C. 112, first paragraph, as allegedly not providing guidance to one skilled in the art to make and use the claimed invention, based on the Examiner's contention that the claimed invention is not supported by either a credible asserted utility or a well-established utility. Applicants respectfully traverse this rejection.

The Examiner contends that any nucleotide sequence which hybridizes to SEQ ID NO:1 at 20 °C below the DNA melting point requires undue experimentation. See Office Action, pg. 4. Applicants have amended claim 8 to remove the limitation of hybridization to a complement of SEQ ID NO:1 at 20 °C below the DNA melting point. Applicants respectfully request that the rejection be withdrawn.

The Examiner further contends that the specification, based on the lack of utility, lack evidence of a causal relationship between the protease-related protein and regulation of the keratinization of hair. The Examiner also contends that "if the specification disclosed *in vivo* working examples to show this, then this may overcome the enablement rejection. However, since the specification does not show any *in vivo* working examples, it is not clear that the claimed method is enabled." See Office Action, pg. 4. For the reasons above regarding the assertion of utility in the instant application, Applicants respectfully disagree with the Examiner that the instant application fails to establish a causal relationship between the protease-related protein and regulation of the keratinization of hair based on an alleged lack of utility. In addition, for the reasons outlined below, Applicants respectfully disagree with the Examiner that working examples are required in order to enable the claimed invention.

Applicants wish to point out that the existence of working examples is only one of a lengthy list of factors that the Federal Circuit has suggested in determining whether the scope of claims in a patent application or patent are enabled by the disclosure. The list of the factors to be considered are:

- (A) The breadth of the claims;
- (B) The nature of the invention;
- (C) The state of the prior art;

- (D) The level of one of ordinary skill;
- (E) The level of predictability in the art;
- (F) The amount of direction provided by the inventor;
- (G) The existence of working examples; and
- (H) The quantity of experimentation needed to make or use the invention based on the content of the disclosure.

Furthermore, the court in Wands states:

It is improper to conclude that a disclosure is not enabling based on an analysis of only one of the above factors while ignoring one or more of the others. The examiner's analysis must consider all the evidence related to each of these factors, and any conclusion of nonenablement must be based on the evidence as a whole. *In re Wands*, 858 F.2d 731 at 737,740 (Fed. Cir. 1988).

In regards to the absence of working examples, Applicants submit that they have provided sufficient guidance in the specification to one of ordinary skill in the art to make and use the claimed invention. The level of predictability for one of ordinary skill in the art is minimized due to the teachings of the nucleic acid and amino acid sequences necessary to perform the invention. The endpoints of the claimed invention are not highly unpredictable as the Examiner contends. One of ordinary skill in the art, without extensive assays or devices, can perform routine experimentation on a therapeutically effective level of the nucleic acid and amino acid sequence without undue experimentation, looking only for the growth of hair or lack thereof. In addition, Applicants respectfully point out that the test for undue experimentation itself "is not merely quantitative, since a considerable amount of experimentation is permissible if it is merely routine, or if the specification in question provides a reasonable amount of guidance with respect to the direction in which the experimentation should proceed to enable the determination of how to practice a desired embodiment of the claimed invention." *In re Wands*, 858 F.2d at 736-740. Applicants submit that the specification provides sufficient guidance to enable the amended claims in the instant application.

Claims 16, 17, and 18 have been revised for purposes of clarity.

Based on the amendment to the claims and the remarks above, Applicants respectfully request withdrawal of this rejection.

CONCLUSION

In light of the remarks and amendments set forth above, Applicant believes that the claims are in condition for allowance. Applicant respectfully solicits the Examiner to expedite the prosecution of this patent application to issuance. Should the Examiner have any questions, the Examiner is encouraged to telephone the undersigned.

Respectfully submitted,

Date: May 16, 2005

By:

Albert P. Halluin

Registration No. 25,227

Lorelei P. Westin

Registration No. 52,353

650 Page Mill Road Palo Alto, California 94304-1050 (650) 565-3585 Customer No. 021971 Office Action Response U.S. Ser. No. 09/486,247

EXHIBIT A:

1. Kallikrein 6 – [Rattus norvegicus]

Score = 492 bits (1266), Expect = e-138 Identities = 223/251 (88%), Positives = 241/251 (96%)

- Query: 1 MPMKMLTMKMLALCLVLAKSAWSEEQEKVVHGGPCLKDSHPFQAALYTSGHLLCGGVLID 60
 MP KMLT+K LALCL+LAKSAWSE+Q+KVVHGGPCLK+SHPFQAALYTSGHLLCGGVL+
 Sbjct: 1 MPTKMLTVKTLALCLILAKSAWSEDQDKVVHGGPCLKNSHPFQAALYTSGHLLCGGVLVG 60

 Query: 61 PQWVLTAAHCKKPNLQVILGKHNLRQTETFQRQISVDRTIVHPRYNPETHDNDIMMVHLK 120
 PQWVLTAAHCKKPNL+V LGKHNLRQTETFQRQISVDRTIVHPRYNP+THDNDIMMVHLK 120

 Query: 121 NPVKFSKKIQPLPLKNDCSEENPNCQILGWGKMENGDFPDTIQCADVHLVPREQCERAYP 180
 PVKFS++IQPLPLK DCSE+NP+CQILGWGKMENG+FPDTIQCADV LV RE+CERAYP
 Sbjct: 121 RPVKFSQRIQPLPLKKDCSEKNPDCQILGWGKMENGEFPDTIQCADVQLVSREECERAYP 180

 Query: 181 GKITQSMVCAGDMKEGNDSCQGDSGGPLVCGGRLRGLVSWGDMPCGSKEKPGVYTDVCTH 240
 Sbjct: 181 GKITRSMVCAGDKREGNDSCQGDSGGPLVCGGHLRGIVSWGDMPCGSKEKPGVYTDVCTH 240
- Query: 241 IRWIQNILRNK 251 IRWIQNI+RNK Sbjct: 241 IRWIQNIIRNK 251

SNO	Bl sees	00 00 00 00	S VEGA	06 00	••• 🐉	Protein	
PubMed	Nucleotide	Protein	Genome	Structure	PMC		OMIM Books
Search Prote		for					lear
· ·	Limits	Previev	v/Index	History	Clipboard	Details	
Display	GenPept	Send	all to file				
Range: from	begin	to end	Feat	tures: SN	P CDD	✓ MGC HPR	.D
□1: <u>NP_06</u>	2048. Reports	kallikrein 6 [Rat[gi:9	506997]			BLink, Domains, Links
LOCUS DEFINITION ACCESSION VERSION DBSOURCE	NP_062048 kallikrein NP_062048 NP_062048. REFSEQ: ac	1 GI:9506	997	cus].	linear	ROD 28-OCT	'-2004
KEYWORDS SOURCE ORGANISM	Mammalia;	vegicus Metazoa; Eutheria;	Chordata Euarchon		lires; Rod	a; Euteleosto lentia;	omi;
REFERENCE AUTHORS TITLE JOURNAL PUBMED	1 (residu Scarisbric Nervous sy	es 1 to 25 k,I.A., To stem-speci in the ad	1) wner,M.D fic expre ult rat	. and Isack ession of a spinal cord	son,P.J. novel ser	rine protease: otoxic injury	
COMMENT	PROVISIONA					subject to fi rom <u>AF016269</u> .	
FEATURES source	substrate I e 1 / / / /	specificit ocation/Qu 251 organism=" strain="Sp db_xref="t chromosome	y; expre lalifiers Rattus norague-Dalaxon: 101	ssed in the orvegicus" wley"	ease which nervous s	n has trypsin- system [RGD].	·like
Prote	<u>in</u> 1 / / z	yme); prot	tallikrei .ikrein 6 .tease ser	(neurosin) ine 9; prot	ease serir	ein 6 (neurosi	
<u>CDS</u>	1 / / <u>c</u>	251 gene="Klk6 coded_by=" note="go_f	5" NM_01917 Tunction: evidence GeneID:29	5.1:18594 tissue kal TAS] [pmid <u>245</u> "	:0" .likrein ac	osin, zyme)" ctivity [goid	
ORIGIN							
1 r 61 p	mptkmltvkt l oqwvltaahc k	kpnlevylg	khnlrqte	tf qrqisvdr	ti vhpryng	ytsg hllcggvl oqth dndimmvh	lk

181 gkitrsmvca gdkregndsc qgdsggplvc gghlrgivsw gdmpcgskek pgvytdvcth 241 irwiqniirn k

//

<u>Disclaimer | Write to the Help Desk</u> <u>NCBI | NLM | NIH</u> -

C_{λ}	CGCTC.	GGATA GACTIC	ବ୍ୟୁଟ୍ଟେଲ୍କ	gardeekiid eedee	CAN CONTAIN	TATACCTCGATCGAT	: <u>C</u> 7	
S N	CBI			FATATACACACA TUCGCATACGUG	Nucl	eotide	IT基 IT基 ITA	
PubMed	Nucleotide	Protein	Genome	Structure	PMC	Taxonomy	OMIM	Books
Search Nu	cleotide	for				Go	Clear	
****	Limits	Previe	w/Index	History	Clipboard	Details		
Display	GenBank	Send	all to file					
Range: fro ✓ MGC	m begin	to end	□ Re	everse comple	emented strar	nd Features:	SNP	CDD
	_	Rattus norve	gicus [gi:2	853365]				Links
	<u>0209</u> . ((opula	Ttuttuo 1101 vo	51045[51.2	0000001				
LOCUS DEFINITION	AF016269 N Rattus no cds.	orvegicus m	1110 yelencepha					
ACCESSION	AF016269							
VERSION KEYWORDS	AF016269	.1 GI:2853	365					
SOURCE		orvegicus (1	Norway rat	=)				
ORGANIS		orvegicus a; Metazoa;	Chordata	: Craniata	: Vertebrat	ta: Euteleos	stomi;	
	Mammalia	; Eutheria;	Euarchont	coglires; (Glires; Roo		•	
REFERENCE		athi; Murida s 1 to 1110		ae; Rattus	•			
AUTHORS		ick, I.A., To		. and Isacl	kson,P.J.			
TITLE		system-spec						
JOURNAL	_	on in the acsci. 17 (21)		_	d by excito	otoxic inju	сy	
PUBMED	9334391	501. 17 (21	, 0130-01		,			
REFERENCE	•	s 1 to 1110						
AUTHORS		ick,I.A., To ubmission	owner,M.D.	. and Isacl	cson, P.J.			
TITLE JOURNAL		domission d (28-JUL-1:	997) Molec	rular Neuro	oscience. N	Mavo Foundat	ion.	
COOlania		t St., SW, 1				iayo rounda	22011,	
FEATURES		Location/Q	ualifiers					
sour	ce	11110	UD - 6 6					
		<pre>/organism= /mol type=</pre>		orvegicus"				
		/strain="S		wley"				
		/db_xref="	axon: 1011	16"				
CDS		185940			/ -2			
		protease fa		or the try	osin/cnymo	trypsin seri	ine	
		/codon sta:						
		/product="t	-	_	ific protea	ase"		
		/protein_io						
		/db_xref="0"/translatio			TLAKSAWSED	QDKVVHGGPCLI	KNSHPFOA	
						LRQTETFQRQIS		
						NPDCQILGWGK		
		TIQCADVQLVS SWGDMPCGSKI				CQGDSGGPLVC	3GHLRGIV	
ORIGIN		DWODILE COOK		LIIIIN EQNE.	£ 4 LA T A L			
		tcttcagcac						
		ctctgcccct						
121	gugalaggtg	gtgtcgtttc	CCCCCCCCCC	i aayittet	yyc ayytaca	adig digged	ayca .	

```
181 gcagatgccc acgaagatgc tgacagtgaa gacgctggcc ctgtgcttga ttcttgctaa
     241 qtcaqcctqq tcqqaaqatc aqqataaggt ggtacatgga ggcccctgtt tgaagaactc
     301 tcaccettte caagetqeee tetacacete qqqtcacttq etqtqtggtq gggteetegt
     361 cggcccacag tgggtgctga cagctgccca ctgcaaaaaa ccgaatctgg aggtgtactt
     421 ggggaaacac aatctacggc aaactgagac tttccaaagg caaatctctg tggacaggac
     481 tattgtccat ccccgttaca atccccaaac ccatgacaat gatatcatga tggtgcatct
     541 gaaacgtcca gtcaaattct ctcaaaggat ccagccctg cctttgaaga aagactgctc
     601 tgagaagaat cccgactgtc agatcctcgg ctggggcaag atggaaaacg gtgaattccc
     661 agataccatc cagtgtgctg atgtccagct ggtgtcccgg gaagagtgtg agcgcgccta
     721 ccctggcaag atcacccgaa gcatggtgtg cgcaggcgac aagagagaag ggaacgattc
     781 ctgccagggt gattctggag gtcccctggt atgcggtggt cacctccgag ggattgtgtc
     841 atggggtgac atgccctgtg gatcaaagga aaagccggga gtttacacag atgtctgcac
     901 tcatatcaga tggatccaaa acatcatcag aaacaagtga ctctggcatg agacatgcag
     961 ttettqacet qteteteece tgacectage tggetacata ttetetetee etgaaaceet
    1021 gccccactct cagageette agatgtecag etetgeece teatgettaa taaatgeagt
    1081 gaaaaaaaaa aaaaaaaaaa aaaaaaaaa
//
```

<u>Disclaimer | Write to the Help Desk</u> <u>NCBI | NLM | NIH</u>

U.S. Ser. No. 09/486,247 Exhibit A

2. Kallikrein 8, isoform 2 [Homo sapiens]

```
>gi|21464127|ref|NP 653088.1| G kallikrein 8 isoform 2 [Homo sapiens]
gi|5672479|dbj|BAA82666.1| G neuropsin type2 [Homo sapiens]
         Length = 305
Score = 238 bits (608), Expect = 8e-62
Identities = 108/232 (46%), Positives = 158/232 (68%), Gaps = 6/232 (2%)
Ouery: 25 EQEKVVHGGPCLKDSHPFQAALYTSGHLLCGGVLIDPQWVLTAAHCKKPNLQVILGKHNL 84
          +++KV+ G C S P+QAAL+
                                    LLCGGVL+
                                                WVLTAAHCKKP
                                                            V LG H+L
Sbjct: 74 QEDKVLGGHECQPHSQPWQAALFQGQQLLCGGVLVGGNWVLTAAHCKKPKYTVRLGDHSL 133
Query: 85 RQTETFQRQISVDRTIVHPRYNP---ETHDNDIMMVHLKNPVKFSKKIQPLPLKNDCSEE 141
          + + +++I V ++I HP YN
                                    E H++D+M++ L++
                                                        K++P+ L + C++
Sbjct: 134 QNKDGPEQEIPVVQSIPHPCYNSSDVEDHNHDLMLLQLRDQASLGSKVKPISLADHCTQP 193
Query: 142 NPNCQILGWGKMENG--DFPDTIQCADVHLVPREQCERAYPGKITQSMVCAGDMKEGNDS 199
             C + GWG + + +FPDT+ CA+V + P+++CE AYPG+IT MVCAG K G D+
Sbjct: 194 GQKCTVSGWGTVTSPRENFPDTLNCAEVKIFPQKKCEDAYPGQITDGMVCAGSSK-GADT 252
Query: 200 CQGDSGGPLVCGGRLRGLVSWGDMPCGSKEKPGVYTDVCTHIRWIQNILRNK 251
          CQGDSGGPLVC G L+G+ SWG PCG +KPGVYT++C ++ WI+ I+ +K
Sbjct: 253 COGDSGGPLVCDGALOGITSWGSDPCGRSDKPGVYTNICRYLDWIKKIIGSK 304
```

S NO	BI seese			••• ¾	rotein	
PubMed	Nucleotide	Protein Genome	Structure	PMC	Taxonomy Of	MIM Books
Search Prote	in [for			GoCle	ear
una ,	Limits	Preview/Index	History	Clipboard	Details	
Display	GenPept	Send all to file				
Range: from	begin to	end Fe	atures: SNF	CDD [✓MGC HPRD)
☐1: <u>NP_653</u>	3088. Reports kall	ikrein 8 isof[gi::	21464127]			BLink, Domains, Links
LOCUS DEFINITION ACCESSION VERSION DBSOURCE KEYWORDS SOURCE ORGANISM	NP_653088 NP_653088.1 REFSEQ: acces Homo sapiens Homo sapiens Eukaryota; Me	isoform 2 [Hom GI:21464127 sion NM 144505 (human) tazoa; Chordat	.1 a; Craniata;		a; Euteleostom	
REFERENCE AUTHORS	1 (residues	heria; Primate 1 to 305) .P., Yu,X.J.,				I.,
JOURNAL	Recent origin gene involved Mol. Biol. Ev	of a hominoid in learning a ol. 21 (11), 2	nd memory		of neuropsin,	a
PUBMED REFERENCE AUTHORS	15282331 2 (residues Shigemasa, K., O'Brien, T.J.	Tian, X., Gu, L	., Tanimoto,l	H., Underwo	ood,L.J.,	
TITLE JOURNAL	early clinica	ein 8 (hK8/TAD l stage and fa l (6), ll53-ll	vorable prog			an
PUBMED REMARK		ession of hK8 r and down-reg		_	_	of
REFERENCE AUTHORS TITLE	3 (residues Can, Bignotti Roman, J.J., P The novel ser	,E., Bellone,S ecorelli,S., C ine protease t	annon,M.J., (umor-associa	O'brien,T. ted differe	and Santin, A. entially expre	essed
	cancer	/Neuropsin/Ova	_	_	ressed in cerv	rical
JOURNAL PUBMED	Am. J. Obstet 14749636	. Gynecol. 190	(1), 60-66	(2004)		
REMARK	<pre>important rol abundance in</pre>	ical cancer ex e in invasion tumor tissue a nostic use or	and metastas: nd contains	is. Appears secretion s	s only in	_
REFERENCE AUTHORS	4 (residues Clark, H.F., G Chen, J., Chow Dowd, P., Eato Heldens, S., H		aya,E., Bake: Crowley,C., (., Grimaldi,(.S., Klimows)	r,K., Baldv Currell,B., C., Gu,Q., ki,L., Jin,	, Deuel,B., Hass,P.E., ,Y., Johnson,S	

```
Schoenfeld, J., Seshagiri, S., Simmons, L., Singh, J., Smith, V.,
            Stinson, J., Vagts, A., Vandlen, R., Watanabe, C., Wieand, D., Woods, K.,
            Xie, M.H., Yansura, D., Yi, S., Yu, G., Yuan, J., Zhang, M., Zhang, Z.,
            Goddard, A., Wood, W.I., Godowski, P. and Gray, A.
            The secreted protein discovery initiative (SPDI), a large-scale
  TITLE
            effort to identify novel human secreted and transmembrane proteins:
            a bioinformatics assessment
            Genome Res. 13 (10), 2265-2270 (2003)
  JOURNAL
   PUBMED
            12975309
               (residues 1 to 305)
REFERENCE
            Magklara, A., Scorilas, A., Katsaros, D., Massobrio, M., Yousef, G.M.,
  AUTHORS
            Fracchioli, S., Danese, S. and Diamandis, E.P.
            The human KLK8 (neuropsin/ovasin) gene: identification of two novel
  TITLE
            splice variants and its prognostic value in ovarian cancer
            Clin. Cancer Res. 7 (4), 806-811 (2001)
  JOURNAL
   PUBMED
            11309326
               (residues 1 to 305)
REFERENCE
            Harvey, T.J., Hooper, J.D., Myers, S.A., Stephenson, S.A.,
  AUTHORS
            Ashworth, L.K. and Clements, J.A.
            Tissue-specific expression patterns and fine mapping of the human
  TITLE
            kallikrein (KLK) locus on proximal 19q13.4
            J. Biol. Chem. 275 (48), 37397-37406 (2000)
  JOURNAL
            10969073
   PUBMED
               (residues 1 to 305)
REFERENCE
            7
            Gan, L., Lee, I., Smith, R., Argonza-Barrett, R., Lei, H., McCuaig, J.,
  AUTHORS
            Moss, P., Paeper, B. and Wang, K.
            Sequencing and expression analysis of the serine protease gene
  TITLE
            cluster located in chromosome 19q13 region
  JOURNAL
            Gene 257 (1), 119-130 (2000)
            11054574
   PUBMED
REFERENCE
                (residues 1 to 305)
            Underwood, L.J., Tanimoto, H., Wang, Y., Shigemasa, K., Parmley, T.H.
  AUTHORS
            and O'Brien, T.J.
            Cloning of tumor-associated differentially expressed gene-14, a
  TITLE
            novel serine protease overexpressed by ovarian carcinoma
  JOURNAL
            Cancer Res. 59 (17), 4435-4439 (1999)
   PUBMED
            10485494
REFERENCE
               (residues 1 to 305)
            Mitsui, S., Tsuruoka, N., Yamashiro, K., Nakazato, H. and Yamaguchi, N.
  AUTHORS
            A novel form of human neuropsin, a brain-related serine protease,
  TITLE
            is generated by alternative splicing and is expressed
            preferentially in human adult brain
            Eur. J. Biochem. 260 (3), 627-634 (1999)
  JOURNAL
            10102990
   PUBMED
            10 (residues 1 to 305)
REFERENCE
            Yoshida, S., Taniguchi, M., Hirata, A. and Shiosaka, S.
  AUTHORS
            Sequence analysis and expression of human neuropsin cDNA and gene
  TITLE
            Gene 213 (1-2), 9-16 (1998)
  JOURNAL
   PUBMED
            9714609
            REVIEWED REFSEQ: This record has been curated by NCBI staff. The
COMMENT
            reference sequence was derived from AB008927.1, AB009849.1 and
            AF095742.1.
            Summary: Kallikreins are a subgroup of serine proteases having
            diverse physiological functions. Growing evidence suggests that
            many kallikreins are implicated in carcinogenesis and some have
            potential as novel cancer and other disease biomarkers. This gene
            is one of the fifteen kallikrein subfamily members located in a
            cluster on chromosome 19. Alternate splicing of this gene results
            in four transcript variants encoding four different isoforms. The
```

ن جنرہ =

```
in brain plasticity and ovarian cancer.
           Transcript Variant: This variant (2) uses an alternate in-frame
           splice site in the 5' coding region, compared to variant 1,
           resulting in a longer protein compared to isoform 1.
                     Location/Qualifiers
FEATURES
                     1..305
    source
                     /organism="Homo sapiens"
                     /db xref="taxon:9606"
                     /chromosome="19"
                     /map="19q13.3-q13.4"
                     1..305
     Protein
                     /product="kallikrein 8 isoform 2"
                     /note="protease, serine, 19; neuropsin; ovasin;
                     tumor-associated differentially expressed gene 14;
                     neuropsin type 1; neuropsin type 2"
     CDS
                     1..305
                     /gene="KLK8"
                     /coded by="NM 144505.1:180..1097"
                     /note="isoform 2 is encoded by transcript variant 2;
                     go function: trypsin activity [goid 0004295] [evidence
                     IEA];
                     go function: hydrolase activity [goid 0016787] [evidence
                     IEA];
                     go function: peptidase activity [goid 0008233] [evidence
                     IEA];
                     go function: chymotrypsin activity [goid 0004263]
                     [evidence IEA];
                     go_process: neurogenesis [goid 0007399] [evidence TAS]
                     [pmid 10102990];
                     go process: proteolysis and peptidolysis [goid 0006508]
                     [evidence IEA] "
                     /db xref="GeneID: 11202"
                     /db xref="MIM:605644"
ORIGIN
        1 mgrprpraak twmfllllgg awaacgsldl ltklyaenlp cvhlnpqwps qpshcprgwr
       61 snplppaagh sraqedkvlg ghecqphsqp wqaalfqgqq llcggvlvgg nwvltaahck
      121 kpkytvrlqd hslqnkdqpe qeipvvqsip hpcynssdve dhnhdlmllq lrdqaslgsk
      181 vkpisladhc tqpgqkctvs gwgtvtspre nfpdtlncae vkifpqkkce daypgqitdg
      241 mvcagsskga dtcqgdsggp lvcdgalqgi tswgsdpcgr sdkpgvytni cryldwikki
      301 igskg
//
```

isoforms exhibit distinct patterns of expression that suggest roles

<u>Disclaimer | Write to the Help Desk</u> <u>NCBI | NLM | NIH</u>

3. Kallikrein 14 preproprotein [Homo sapiens]

```
sqi|11545747|ref|NP 071329.1| G kallikrein 14 preproprotein [Homo sapiens]
qi|10799399|qb|AAG23260.1| G Homo sapiens kallikrein-like protein 6
protein 6) (KLK-L6)
       Length = 251
Score = 238 bits (606), Expect = 1e-61
Identities = 107/241 (44%), Positives = 156/241 (64%), Gaps = 4/241 (1%)
Query: 15 LVLAKSAWSEEQEKVVHGGPCLKDSHPFQAALYTSGH--LLCGGVLIDPQWVLTAAHCKK 72
                                        LCGG L+ QWV+TAAHC +
               E++ K++ G C + S P+QAAL
Sbjct: 11 LAIAMTQSQEDENKIIGGHTCTRSSQPWQAALLAGPRRRFLCGGALLSGQWVITAAHCGR 70
Ouery: 73 PNLQVILGKHNLRQTETFQRQISVDRTIVHPRYNPETHDNDIMMVHLKNPVKFSKKIQPL 132
        P LOV LGKHNLR+ E Q+ + V R + HP YN THDND+M++ L+ P + +++P+
Sbjct: 71 PILQVALGKHNLRRWEATQQVLRVVRQVTHPNYNSRTHDNDLMLLQLQQPARIGRAVRPI 130
Query: 133 PLKNDCSEENPNCQILGWGKMEN--GDFPDTIQCADVHLVPREQCERAYPGKITQSMVCA 190
                             +P ++QC ++++ P E C++AYP IT MVCA
                 +C++ GWG + +
Sbjct: 131 EVTQACASPGTSCRVSGWGTISSPIARYPASLQCVNINISPDEVCQKAYPRTITPGMVCA 190
Ouery: 191 GDMKEGNDSCOGDSGGPLVCGGRLRGLVSWGDMPCGSKEKPGVYTDVCTHIRWIQNILRN 250
        G + G DSCOGDSGGPLVC G+L+GLVSWG C
                                        PGVYT++C + WI+ +R+
Sbjct: 191 GVPQGGKDSCQGDSGGPLVCRGQLQGLVSWGMERCALPGYPGVYTNLCKYRSWIEETMRD 250
Query: 251 K 251
Sbjct: 251 K 251
```

SNO	BI Protein							
PubMed	Nucleotide Protein Genome Structure PMC Taxonomy OMIM Books							
Search Prote	in Go Clear							
	Limits Preview/Index History Clipboard Details							
Display	GenPept Send all to file							
Range: from	to the control of the							
☐1: <u>NP_071</u>	329. Reports kallikrein 14 pre[gi:11545747] Link							
LOCUS DEFINITION ACCESSION VERSION DBSOURCE KEYWORDS	NP_071329 251 aa linear PRI 02-MAR-2005 kallikrein 14 preproprotein [Homo sapiens]. NP_071329 NP_071329.1 GI:11545747 REFSEQ: accession NM 022046.3 .							
SOURCE ORGANISM	Homo sapiens (human) Homo sapiens Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae; Homo.							
REFERENCE AUTHORS TITLE	1 (residues 1 to 251) Yousef,G.M., Stephan,C., Scorilas,A., Ellatif,M.A., Jung,K., Kristiansen,G., Jung,M., Polymeris,M.E. and Diamandis,E.P.							
JOURNAL PUBMED REMARK	Differential expression of the human kallikrein gene 14 (KLK14) in normal and cancerous prostatic tissues Prostate 56 (4), 287-292 (2003) 12858357 GeneRIF: KLK14 expression upregulated in advanced and more aggressive prostate tumors; may play role in tumor spread and may							
REFERENCE AUTHORS	be new marker for prostate cancer diagnosis and prognosis 2 (residues 1 to 251) Yousef,G.M., Borgono,C.A., Scorilas,A., Ponzone,R., Biglia,N., Iskander,L., Polymeris,M.E., Roagna,R., Sismondi,P. and Diamandis,E.P.							
TITLE JOURNAL PUBMED	Quantitative analysis of human kallikrein gene 14 expression in breast tumours indicates association with poor prognosis Br. J. Cancer 87 (11), 1287-1293 (2002) 12439719							
REMARK	GeneRIF: KLK14 overexpression was found to be a significant predictor of decreased disease-free survival and overall survival in breast cancer patients							
REFERENCE AUTHORS	3 (residues 1 to 251) Yousef,G.M., Magklara,A., Chang,A., Jung,K., Katsaros,D. and Diamandis,E.P.							
TITLE JOURNAL	Cloning of a new member of the human kallikrein gene family, KLK14, which is down-regulated in different malignancies Cancer Res. 61 (8), 3425-3431 (2001)							
PUBMED	11309303							
REFERENCE AUTHORS	4 (residues 1 to 251) Hooper,J.D., Bui,L.T., Rae,F.K., Harvey,T.J., Myers,S.A., Ashworth,L.K. and Clements,J.A.							
TITLE	Identification and characterization of KLK14, a novel kallikrein serine protease gene located on human chromosome 19q13.4 and expressed in prostate and skeletal muscle							

```
Genomics 73 (1), 117-122 (2001)
  JOURNAL
   PUBMED
            11352573
REFERENCE
               (residues 1 to 251)
            Harvey, T.J., Hooper, J.D., Myers, S.A., Stephenson, S.A.,
 AUTHORS
            Ashworth, L.K. and Clements, J.A.
            Tissue-specific expression patterns and fine mapping of the human
  TITLE
            kallikrein (KLK) locus on proximal 19q13.4
  JOURNAL
            J. Biol. Chem. 275 (48), 37397-37406 (2000)
   PUBMED
            10969073
            REVIEWED REFSEQ: This record has been curated by NCBI staff. The
COMMENT
            reference sequence was derived from AF283670.1 and AF161221.1.
            Summary: Kallikreins are a subgroup of serine proteases having
            diverse physiological functions. Growing evidence suggests that
            many kallikreins are implicated in carcinogenesis and some have
            potential as novel cancer and other disease biomarkers. This gene
            is one of the fifteen kallikrein subfamily members located in a
            cluster on chromosome 19. An additional transcript variant has been
            described but its full length nature has not been determined.
FEATURES
                     Location/Qualifiers
                     1..251
     source
                     /organism="Homo sapiens"
                     /db xref="taxon:9606"
                     /chromosome="19"
                     /map="19q13.3-q13.4"
                     1..251
     Protein
                     /product="kallikrein 14 preproprotein"
                     /note="kallikrein-like protein 6"
     CDS
                     1..251
                     /gene="KLK14"
                     /coded by="NM 022046.3:268..1023"
                     /db xref="CCDS:CCDS12823.1"
                     /db xref="GeneID:43847"
                     /db_xref="MIM:606135"
ORIGIN
        1 mfllltalqv laiamtqsqe denkiigght ctrssqpwqa allagprrrf lcggallsgq
       61 wvitaahcqr pilqvalqkh nlrrweatqq vlrvvrqvth pnynsrthdn dlmllqlqqp
      121 ariqravrpi evtqacaspq tscrvsqwqt isspiarypa slqcvninis pdevcqkayp
      181 rtitpgmvca gvpqggkdsc qgdsggplvc rgqlqglvsw gmercalpgy pgvytnlcky
      241 rswieetmrd k
//
```

Disclaimer | Write to the Help Desk NCBI | NLM | NIH

U.S. Ser. No. 09/486,247 Exhibit A

4. KLK (kallikrein) 15 [Saguinus oedipus]

```
gi|42759849|gb|AAS45302.1| KLK15 [Saguinus oedipus]
         Length = 255
Score = 221 bits (564), Expect = 1e-56
Identities = 100/252 (39%), Positives = 154/252 (61%), Gaps = 14/252 (5%)
Query: 10 MLALCLVLAKSAWSEEQEKVVHGGPCLKDSHPFQAALYTSGHLLCGGVLIDPQWVLTAAH 69
          +L L +L +A ++ K++ G C
                                      S P+Q ALY G CG LI P WVL+AAH
          LLPLSFLLTSTA--QDGGKLLEGEECAPHSQPWQVALYERGRFNCGASLISPHWVLSAAH 61
Query: 70 CKKPNLQVILGKHNLRQTETFQRQISVDRTIVHPRYNPETHDNDIMMVHLKNPVKFSKKI 129
          C+ ++V LG+HNLR+ + ++ + R I HPRY +H +DIM++ L P + ++
Sbjct: 62 CQSRFMRVRLGEHNLRKRDGPEQLRTASRVIPHPRYEARSHRHDIMLLRLVQPARLTPQV 121
Query: 130 QPLPLKNDCSEENPNCQILGWGKMENGD-----FPDTIQCADVHLVPREQCER 177
          +P+ L C
                        C + GWG + + +
                                                 PDT+ CA++ ++
Sbjct: 122 RPVVLPTRCPHPGEACVVSGWGLVSHNEPGTTGRPQSQVSLPDTLHCANISIISDASCDK 181
Query: 178 AYPGKITQSMVCAGDMKEGNDSCQGDSGGPLVCGGRLRGLVSWGDMPCGSKEKPGVYTDV 237
           YPG++T +MVCAG
                           G +SC+GDSGGPLVCGG L+G+VSWGD+PC + KPGVYT V
Sbjct: 182 NYPGRLTNTMVCAGAEGRGAESCEGDSGGPLVCGGILQGIVSWGDVPCDNTTKPGVYTKV 241
Query: 238 CTHIRWIQNILR 249
          C +++WI+ ++
```

Chiat. 242 CDVVVWTDERMY 252

Sbjct: 242 CRYVKWIRETMK 253

8 NO	181 500		college.		••• 🐒	ez Protoir	. •	
D. Maria	2015 :		* 5500	0	் பூட்	roteir		Donler
PubMed Search Prote	Nucleotide in	Protein for	Genome	Structure	PMC	Taxonomy	Clear	Books
Search Trote		for		I Batan	Ct:-kd			
	Limits	Previev		History	Clipboard	Details		
Display	GenPept	Send	all to file					
Range: from	begin	to end	Feat	ures: SN	P CDD	✓MGC 🗆	HPRD	
☐1: <u>AAS45</u>	302. Reports	KLK15 [Sagu	iinus o[g	i:42759849]			BLink	, Domains Links
LOCUS DEFINITION ACCESSION VERSION DBSOURCE	AAS45302 AAS45302.	guinus oedi 1 GI:42759 AF173845.2	849	aa	linear	PRI 23-	FEB-2004	
KEYWORDS SOURCE ORGANISM	Saguinus Eukaryota Mammalia;	oedipus (co oedipus ; Metazoa; Eutheria; hidae; Sagu	Chordata; Euarchont	Craniata;				
REFERENCE AUTHORS TITLE	1 (resid Olsson, A. Glandular	lues 1 to 25 Y., Persson kallikrein ne encoding	5) ,A.M., Va s of the	cotton-top	tamarin:			
JOURNAL PUBMED	11177570	Biol. 19 (1		727 (2000)				
REFERENCE AUTHORS TITLE	•	lues 1 to 25 , Persson,M Obmission	•	ndwall,A.				
JOURNAL	Universit	l (29-JUL-19 y Hospital,	Malmo S		-	University	ı	
REFERENCE AUTHORS TITLE		lues 1 to 25 , Persson,M		ndwall,A.				
JOURNAL	Submitted	l (23-FEB-20 Ly Hospital,			-	University	,	
REMARK COMMENT FEATURES	Method: c	update by sonceptual to Location/Qu	ranslatio	on.				
source		<pre>1255 /organism=" /db xref="t</pre>	_	. •				
Protein	_	1255 /product="K	LK15"	_				
CDS		1255 /coded_by=" AF173845.2: AF173845.2:	join(AF17 4716499	99,AF173845			14221,	
ORIGIN	ນໄປກາ <u>ຈ</u> ະເ] + a + a = 41-	11000	h aan		nal damber		
61 h	cqsrfmrvr	ltstaqdggk lgehnlrkrd	gpeqlrtas	r viphprye	ar shrhdim	llr lvqpar	ltpq	
		phpgeacvvs mvcagaegrg						

241 vcryvkwire tmkrn

Disclaimer | Write to the Help Desk NCBI | NLM | NIH

Feb 9 2005 14:31:10

//

5. Kallikrein 11 isoform 2 precursor [Homo sapiens]

```
sapiensl
G prostate-type hippostasin [Homo sapiens]
gi|8574439|dbj|BAA96797.1|
        Length = 282
Score = 221 bits (563), Expect = 1e-56
Identities = 104/249 (41%), Positives = 151/249 (60%), Gaps = 6/249 (2%)
         MKMLALCLVLAKSAWSEEQEKVVHGGPCLKDSHPFQAALYTSGHLLCGGVLIDPQWVLTA 67
Query: 8
         M++L L L+ + ++++ G C S P+QAAL+
                                            LLCG LI P+W+LTA
Sbjct: 33 MRILQLILLALATGLVGGETRIIKGFECKPHSQPWQAALFEKTRLLCGATLIAPRWLLTA 92
Query: 68 AHCKKPNLQVILGKHNLRQTETFQRQISVDRTIVHPRYNP----ETHDNDIMMVHLKNPV 123
                                             + H NDIM+V + +PV
         AHC KP
               V LG+HNL++ E ++ + + HP +N
Sbjct: 93 AHCLKPRYIVHLGQHNLQKEEGCEQTRTATESFPHPGFNNSLPNKDHRNDIMLVKMASPV 152
Ouery: 124 KFSKKIQPLPLKNDCSEENPNCQILGWGKMENGDF--PDTIQCADVHLVPREQCERAYPG 181
                          +C I GWG +
                                         P T++CA++ ++ ++CE AYPG
           + ++PL L + C
Sbjct: 153 SITWAVRPLTLSSRCVTAGTSCLISGWGSTSSPQLRLPHTLRCANITIIEHQKCENAYPG 212
Query: 182 KITQSMVCAGDMKEGNDSCQGDSGGPLVCGGRLRGLVSWGDMPCGSKEKPGVYTDVCTHI 241
                                                  KPGVYT VC ++
                  + G DSCOGDSGGPLVC L+G++SWG PC
          IT +MVCA
Sbjct: 213 NITDTMVCASVQEGGKDSCQGDSGGPLVCNQSLQGIISWGQDPCAITRKPGVYTKVCKYV 272
Query: 242 RWIQNILRN 250
          WIO ++N
Sbjct: 273 DWIQETMKN 281
```

SNO	BI	• ° ° ° ° ° ° ° ° ° ° ° ° ° ° ° ° ° ° °		••• ST	rotein			
PubMed	Nucleotide	Protein Genon	ne Structure	РМС	Taxonomy OMIM	Books		
Search Prote	in	for			Go Clear			
karapari emakkar karama e e kadar e	Limits	Preview/Index	History	Clipboard	Details			
Display	GenPept	Send all to f	ile	The second secon				
Range: from	begin to	end	Features: SN	P CDD	☑ MGC □ HPRD			
☐1: <u>NP_659</u>	0196. Reports kalli	ikrein 11 iso[g	gi:21618357]		BLir	ik, Domains, Links		
LOCUS DEFINITION ACCESSION VERSION DBSOURCE KEYWORDS SOURCE ORGANISM	•	isoform 2 pr GI:21618357 sion <u>NM 14494</u> (human) tazoa; Chorda	.7.1 uta; Craniata;	Vertebrata	PRI 02-MAR-2005 a; Euteleostomi; atarrhini;			
REFERENCE AUTHORS TITLE JOURNAL PUBMED REMARK	Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae; Homo. 1 (residues 1 to 282) Shigemasa, K., Gu, L., Tanimoto, H., O'Brien, T.J. and Ohama, K. Human kallikrein gene 11 (KLK11) mRNA overexpression is associated with poor prognosis in patients with epithelial ovarian cancer Clin. Cancer Res. 10 (8), 2766-2770 (2004) 15102682							
REFERENCE AUTHORS	GeneRIF: KLK11 expression may play an important role in ovarian cancer development 2 (residues 1 to 282) Clark, H.F., Gurney, A.L., Abaya, E., Baker, K., Baldwin, D., Brush, J., Chen, J., Chow, B., Chui, C., Crowley, C., Currell, B., Deuel, B., Dowd, P., Eaton, D., Foster, J., Grimaldi, C., Gu, Q., Hass, P.E., Heldens, S., Huang, A., Kim, H.S., Klimowski, L., Jin, Y., Johnson, S., Lee, J., Lewis, L., Liao, D., Mark, M., Robbie, E., Sanchez, C., Schoenfeld, J., Seshagiri, S., Simmons, L., Singh, J., Smith, V., Stinson, J., Vagts, A., Vandlen, R., Watanabe, C., Wieand, D., Woods, K., Xie, M.H., Yansura, D., Yi, S., Yu, G., Yuan, J., Zhang, M., Zhang, Z., Goddard, A., Wood, W.I., Godowski, P. and Gray, A.							
TITLE JOURNAL PUBMED		ntify novel hics assessmer	numan secreted nt		a large-scale membrane proteins	:		
REFERENCE AUTHORS	3 (residues Borgono, C.A., Longrais, I.A. Scorilas, A.,	Fracchioli,S , Luo,L.Y., S Diamandis,E.I	Soosaipillai,A P. and Katsarc	., Puopolo s,D.	,M., Grass,L.,			
TITLE JOURNAL PUBMED	Favorable propatients with Int. J. Cance 12845660	ovarian card	cinoma	ıman kallik:	rein 11 (hK11) in			
REMARK			_	marker of f	avorable prognosis	3		
REFERENCE	4 (residues							

```
Nakamura, T., Stephan, C., Scorilas, A., Yousef, G.M., Jung, K. and
 AUTHORS
           Diamandis, E.P.
            Quantitative analysis of hippostasin/KLK11 gene expression in
 TITLE
            cancerous and noncancerous prostatic tissues
            Urology 61 (5), 1042-1046 (2003)
 JOURNAL
  PUBMED
            12736044
            GeneRIF: There is a significant association between lower
 REMARK
            expression of prostate-type KLK11 and higher tumor stage, Gleason
            score, and tumor grade.
               (residues 1 to 282)
REFERENCE
            Nakamura, T., Mitsui, S., Okui, A., Miki, T. and Yamaguchi, N.
 AUTHORS
            Molecular cloning and expression of a variant form of
 TITLE
            hippostasin/KLK11 in prostate
            Prostate 54 (4), 299-305 (2003)
  JOURNAL
   PUBMED
            12539228
            GeneRIF: Hippostasin isoform 3 may play a role in the prostate,
  REMARK
            including reproductive and/or tumorigenic functions.
               (residues 1 to 282)
REFERENCE
            Diamandis, E.P., Okui, A., Mitsui, S., Luo, L.Y., Soosaipillai, A.,
 AUTHORS
            Grass, L., Nakamura, T., Howarth, D.J. and Yamaguchi, N.
            Human kallikrein 11: a new biomarker of prostate and ovarian
  TITLE
            carcinoma
            Cancer Res. 62 (1), 295-300 (2002)
  JOURNAL
   PUBMED
            11782391
            GeneRIF: Human kallikrein 11: a new biomarker of prostate and
  REMARK
            ovarian carcinoma.
REFERENCE
            7 (residues 1 to 282)
            Nakamura, T., Mitsui, S., Okui, A., Kominami, K., Nomoto, T.,
  AUTHORS
            Ukimura, O., Kawauchi, A., Miki, T. and Yamaguchi, N.
            Alternative splicing isoforms of hippostasin (PRSS20/KLK11) in
  TITLE
            prostate cancer cell lines
            Prostate 49 (1), 72-78 (2001)
  JOURNAL
   PUBMED
            11550212
            GeneRIF: may be useful marker for distinguishing prostate cancer
  REMARK
            and benign prostatic hypertrophy
REFERENCE
               (residues 1 to 282)
            Gan, L., Lee, I., Smith, R., Argonza-Barrett, R., Lei, H., McCuaig, J.,
  AUTHORS
            Moss, P., Paeper, B. and Wang, K.
            Sequencing and expression analysis of the serine protease gene
  TITLE
            cluster located in chromosome 19q13 region
            Gene 257 (1), 119-130 (2000)
  JOURNAL
   PUBMED
            11054574
REFERENCE
               (residues 1 to 282)
            Mitsui, S., Yamada, T., Okui, A., Kominami, K., Uemura, H. and
  AUTHORS
            Yamaquchi, N.
            A novel isoform of a kallikrein-like protease, TLSP/hippostasin,
  TITLE
            (PRSS20), is expressed in the human brain and prostate
            Biochem. Biophys. Res. Commun. 272 (1), 205-211 (2000)
  JOURNAL
            10872828
   PUBMED
REFERENCE
            10 (residues 1 to 282)
            Yousef, G.M., Scorilas, A. and Diamandis, E.P.
  AUTHORS
            Genomic organization, mapping, tissue expression, and hormonal
  TITLE
            regulation of trypsin-like serine protease (TLSP PRSS20), a new
            member of the human kallikrein gene family
  JOURNAL
            Genomics 63 (1), 88-96 (2000)
   PUBMED
            10662548
            11 (residues 1 to 282)
REFERENCE
            Yoshida, S., Taniguchi, M., Suemoto, T., Oka, T., He, X. and Shiosaka, S.
  AUTHORS
            cDNA cloning and expression of a novel serine protease, TLSP
  TITLE
            Biochim. Biophys. Acta 1399 (2-3), 225-228 (1998)
  JOURNAL
```

```
PUBMED 9765601
```

COMMENT

REVIEWED REFSEQ: This record has been curated by NCBI staff. The reference sequence was derived from $\underline{AB041036.1}$ and $\underline{BC022068.1}$.

Summary: Kallikreins are a subgroup of serine proteases having diverse physiological functions. Growing evidence suggests that many kallikreins are implicated in carcinogenesis and some have potential as novel cancer and other disease biomarkers. This gene is one of the fifteen kallikrein subfamily members located in a cluster on chromosome 19. Alternate splicing of this gene results in two transcript variants encoding two different isoforms which are differentially expressed.

Transcript Variant: This variant (2) encodes the longer isoform (2) which is preferentially expressed in prostate.

FEATURES Location/Qualifiers

1..282

source

/organism="Homo sapiens"
/db_xref="taxon:9606"
/chromosome="19"
/map="19q13.3-q13.4"

Protein 1..282

/product="kallikrein 11 isoform 2 precursor"

/note="protease, serine, trypsin-like; protease, serine,

20 trypsin-like; hippostasin"

mat_peptide 54..282

/product="kallikrein 11, isoform 2"

CDS 1..282

/gene="KLK11"

/coded by="NM 144947.1:113..961"

/note="isoform 2 precursor is encoded by transcript

variant 2"

/db_xref="CCDS:CCDS12818.1" /db_xref="GeneID:11012" /db_xref="MIM:604434"

ORIGIN

//

1 mqrlrwlrdw kssgrgltaa kepgarsspl qamrilqlil lalatglvgg etriikgfec

61 kphsqpwqaa lfektrllcg atliaprwll taahclkpry ivhlgqhnlq keegceqtrt

121 atesfphpgf nnslpnkdhr ndimlvkmas pvsitwavrp ltlssrcvta gtsclisgwg

181 stsspqlrlp htlrcaniti iehqkcenay pgnitdtmvc asvqeggkds cqgdsggplv

241 cnqslqgiis wgqdpcaitr kpgvytkvck yvdwiqetmk nn

<u>Disclaimer | Write to the Help Desk</u> <u>NCBI | NLM | NIH</u>

6. Serine protease [Rattus rattus]

```
gi|3559978|emb|CAA06643.1|
                               serine protease [Rattus rattus]
gi|6093538|sp|088780|NRPN RAT
                                Neuropsin precursor (NP) (Kallikrein 8) (Brain
serine protease 1)
         Length = 260
 Score = 233 bits (594), Expect = 4e-60
 Identities = 110/245 (44%), Positives = 155/245 (63%), Gaps = 10/245 (4%)
Query: 13 LCLVLAKSAWS----EEQEKVVHGGPCLKDSHPFQAALYTSGHLLCGGVLIDPQWVLTAA 68
          + L L AW+
                      + K++ G C S P+Q AL+
                                                    L+CGGVL+ +WVLTAA
Sbjct: 13 ILLFLLMGAWAGLTRAQGSKILEGQECKPHSQPWQTALFQGERLVCGGVLVGDRWVLTAA 72
Query: 69 HCKKPNLQVILGKHNLRQTETFQRQISVDRTIVHPRY---NPETHDNDIMMVHLKNPVKF 125
                  V LG H+L++ + +++I V R+I HP +
          HCKK
                                                 NPE H +DIM++ L+N
Sbjct: 73 HCKKDKYSVRLGDHSLQKRDEPEQEIQVARSIQHPCFNSSNPEDHSHDIMLIRLQNSANL 132
Query: 126 SKKIQPLPLKNDCSEENPNCQILGWGKMEN--GDFPDTIQCADVHLVPREQCERAYPGKI 183
            K++P+ L N C +
                             C I GWG + +
                                           +FP+T+ CA+V + + +CERAYPGKI
Sbjct: 133 GDKVKPIELANLCPKVGQKCIISGWGTVTSPQENFPNTLNCAEVKIYSQNKCERAYPGKI 192
Query: 184 TQSMVCAGDMKEGNDSCQGDSGGPLVCGGRLRGLVSWGDMPCGSKEKPGVYTDVCTHIRW 243
           T+ MVCAG
                      G D+CQGDSGGPLVC G L+G+ +WG PCG EKPGVYT +C + W
Sbjct: 193 TEGMVCAGS-SNGADTCQGDSGGPLVCNGVLQGITTWGSDPCGKPEKPGVYTKICRYTNW 251
Query: 244 IQNIL 248
          I+ +
Sbjct: 252 IKKTM 256
```

SN	BI	999 99 99 99		`@@ @@@ (•••	Protein	
PubMed	Nucleotide	Protein	Genome	Structure	PMC		OMIM Books
Search Prote	ein	for			· · ·	Go C	lear
	Limits	Previe	w/Index	History	Clipboard	Details	
Display	GenPept	Send	all to file				
Range: from	begin	to end	Feat	ures: SNF	CDD	₩MGC HPR	YD
1: <u>CAA06</u>	6643. Reports	serine protea	se [[gi:35	59978]			BLink, Domains Link
LOCUS DEFINITION ACCESSION VERSION DBSOURCE	CAA06643 CAA06643.	otease [Rat 1 GI:35599 s RRA5641,	78	s].	linean	r ROD 07-SEF	?-1998
KEYWORDS SOURCE ORGANISM	Rattus ra Eukaryota Mammalia;		Chordata; Euarchont	oglires; G		ta; Euteleosto dentia;	omi;
REFERENCE AUTHORS TITLE JOURNAL PUBMED REFERENCE AUTHORS TITLE JOURNAL	Davies, B. Serine production of the production o	J., Pickard coteases in Chem. 273 d dues 1 to 26	1,B.S., St rodent hi (36), 2300 (50) (98) Lathe	eel,M., Mor ppocampus 4-23011 (19 R., Ctr.	998) for Genome	and Lathe,R e Research and	·
FEATURES source		Location/Qu 1260 /organism=' /strain="Fi /db_xref="t /clone="BSI /tissue_tyr /dev_stage= 1260	Rattus ra Rattus ra Sher" Caxon: 1011 Pl" De="brain"	ttus" 7"			
sig pe	ptide	/product="s 126 27260 /product="s	_				
CDS		1260 /gene="bsp: /coded_by=' /db_xref="0" /db_xref="0"	-" 'AJ005641. GOA:088780	1:146928			
ORIGIN	grpppcaid	twillfllma	awaqltrad	ra skileade	ck phsapw	qtal fqgerlvc	gg .
61 v 121 i	lvgdrwvlt mlirlqnsa	aahckkdkys nlgdkvkpie	vrlgdhslq lanlcpkvg	k rdepeqei q kciisgwg	qv arsiqh tv tspqen	pcfn ssnpedhsl fpnt lncaevkiy	hd ys

241 vytkicrytn wikktmgkrd

Disclaimer | Write to the Help Desk NCBI | NLM | NIH

· Feb 9 2005 14:31:10

//

Office Action Response

U.S. Ser. No. 09/486,247

EXHIBIT A:

7. Serine Protease 19 [Mus musculus]

```
qi|7229069|dbj|BAA92435.1| G neuropsin [Mus musculus]
gi|1020091|dbj|BAA06451.1|
                       G neuropsin [Mus musculus]
gi | 1582323 | prf | | 2118319A
                       neuropsin
        Length = 260
Score = 239 bits (611), Expect = 4e-62
Identities = 113/248 (45%), Positives = 159/248 (64%), Gaps = 10/248 (4%)
Ouery: 13 LCLVLAKSAWS----EEOEKVVHGGPCLKDSHPFQAALYTSGHLLCGGVLIDPQWVLTAA 68
                     + K++ G C+ S P+QAAL+
                                             L+CGGVL+ +WVLTAA
               AW+
         ILLLLFMGAWAGLTRAQGSKILEGRECIPHSQPWQAALFQGERLICGGVLVGDRWVLTAA 72
Ouery: 69 HCKKPNLOVILGKHNLROTETFORQISVDRTIVHPRYN---PETHDNDIMMVHLKNPVKF 125
                V LG H+L+ + +++I V ++I HP YN
                                           PE H +DIM++ L+N
Sbjct: 73 HCKKQKYSVRLGDHSLQSRDQPEQEIQVAQSIQHPCYNNSNPEDHSHDIMLIRLQNSANL 132
Ouery: 126 SKKIOPLPLKNDCSEENPNCQILGWGKMENG--DFPDTIQCADVHLVPREQCERAYPGKI 183
           K++P+ L N C + C I GWG + + +FP+T+ CA+V + + +CERAYPGKI
Sbjct: 133 GDKVKPVQLANLCPKVGQKCIISGWGTVTSPQENFPNTLNCAEVKIYSQNKCERAYPGKI 192
Query: 184 TQSMVCAGDMKEGNDSCQGDSGGPLVCGGRLRGLVSWGDMPCGSKEKPGVYTDVCTHIRW 243
                   G D+CQGDSGGPLVC G L+G+ SWG PCG EKPGVYT +C + W
         T+ MVCAG
Sbjct: 193 TEGMVCAGS-SNGADTCQGDSGGPLVCDGMLQGITSWGSDPCGKPEKPGVYTKICRYTTW 251
Query: 244 IQNILRNK 251
         I + + N +
Sbjct: 252 IKKTMDNR 259
```

SNO	BI ••••	9 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	SUPP	00 000 00 000		roteir	₹,	
PubMed	Nucleotide	Protein	Genome	Structure	PMC	Taxonomy Go	Clear	Books
Search Prote	In	for		a anti-material along anti-material with a consequence of the conseque	manus remarkamenta and a secondar state of the	:	Clear	
	Limits	Preview	//Index	History	Clipboard	Details		
Display	GenPept	Send	all to file					
Range: from	begin to	end	Feat	tures: SNF	CDD	✓MGC □H		STS
☐1: <u>NP_032</u>	2966. Reports pro	tease, seri	ne,[gi:60	579487]			BLink	k, Domaii Lir
LOCUS DEFINITION ACCESSION VERSION DBSOURCE KEYWORDS	NP_032966 protease, se NP_032966 NP_032966.1 REFSEQ: acce	GI:66794	187	sculus].	linear	ROD 15- <i>F</i>	APR-2005	
SOURCE ORGANISM	Mus musculus Mus musculus Eukaryota; M Mammalia; Eu Sciurognathi	etazoa; (theria; l	Chordata Euarchon	coglires; G			stomi;	
REFERENCE AUTHORS TITLE	1 (residues Terayama,R., Differential oligodendroc	1 to 26 Bando, Y express:	0) ., Takah ion of ne	ashi,T. and europsin and	d protease		n in	
JOURNAL PUBMED REMARK	Glia 48 (2), 15378660 GeneRIF: stu and protease of the spina	91-101 dy demona M/neuroa	(2004) strates	changes in	the expres			
REFERENCE AUTHORS	2 (residues Matsumoto-Mi Nakamura, Y.	1 to 26 yai,K., 1	Ninomiya	,A., Yamasa	ki,H., Tam	ura,H.,		
TITLE	NMDA-depende the hippocam	nt prote	olysis o		ic adhesio	n molecule	L1 in	
JOURNAL PUBMED REMARK	J. Neurosci. 12944500 GeneRIF: Pre neuropsin in	synaptic	adhesio	n molecule	L1 is a su	bstrate for	r	
REFERENCE AUTHORS TITLE JOURNAL	3 (residues Wong,G.W., Y Mouse mast c Biochem. Bio	1 to 26 ang,Y., ells exp	0) Yasuda,S ress the	., Li,L. an tryptic pr	otease neu	ropsin/Prss	s19	
PUBMED REMARK	12646205 GeneRIF: mou tryptic-like PRSS19	proteas	es in th				ng	
REFERENCE AUTHORS	4 (residues Matsumoto-Mi and Shiosaka	yai,K.,		,R., Ninomi	ya,A., Mom	ota,Y., Yo	shida,S.	
TITLE JOURNAL	Decidualizat extracellula Biol. Reprod	ion indu r protea	se neuro	psin in mou		tion of an		
PUBMED REMARK	12390870 GeneRIF: Neu	ropsin i	s the fi	rst extrace	llular pro	tease to s	how the	

```
evident induction of expression and activity by decidualization and
            might contribute to the remodeling of extracellular components
            after decidualization.
REFERENCE
            5 (residues 1 to 260)
            Katsu, Y., Takasu, E. and Iguchi, T.
  AUTHORS
            Estrogen-independent expression of neuropsin, a serine protease in
  TITLE
            the vagina of mice exposed neonatally to diethylstilbestrol
            Mol. Cell. Endocrinol. 195 (1-2), 99-107 (2002)
  JOURNAL
   PUBMED
            12354676
  REMARK
            GeneRIF: gene expression of a serine-protease neuropsin in the
            mouse vagina, and as a marker of the estrogen-independent
            persistent proliferation and cornification of the vaginal
            epithelium
            6 (residues 1 to 260)
REFERENCE
  AUTHORS
            Oka, T., Hakoshima, T., Itakura, M., Yamamori, S., Takahashi, M.,
            Hashimoto, Y., Shiosaka, S. and Kato, K.
  TITLE
            Role of loop structures of neuropsin in the activity of serine
            protease and regulated secretion
  JOURNAL
            J. Biol. Chem. 277 (17), 14724-14730 (2002)
   PUBMED
            11854276
  REMARK
            GeneRIF: role of loop structures in the activity of serine protease
            and regulated secretion
REFERENCE
            7 (residues 1 to 260)
  AUTHORS
            Oka, T., Akisada, M., Okabe, A., Sakurai, K., Shiosaka, S. and Kato, K.
  TITLE
            Extracellular serine protease neuropsin (KLK8) modulates neurite
            outgrowth and fasciculation of mouse hippocampal neurons in culture
  JOURNAL
            Neurosci. Lett. 321 (3), 141-144 (2002)
   PUBMED
            11880192
  REMARK
            GeneRIF: Neuropsin was localized extracellularly in neuronal cell
            bodies and their neurites in mouse hippocampus. Neuropsin may be
            involved in neurite outgrowth during the development of the nervous
            system.
REFERENCE
            8 (residues 1 to 260)
  AUTHORS
            Chen, Z.L., Yoshida, S., Kato, K., Momota, Y., Suzuki, J., Tanaka, T.,
            Ito, J., Nishino, H., Aimoto, S., Kiyama, H. et al.
  TITLE
            Expression and activity-dependent changes of a novel limbic-serine
            protease gene in the hippocampus
  JOURNAL
            J. Neurosci. 15 (7 PT 2), 5088-5097 (1995)
   PUBMED
            7623137
            PROVISIONAL REFSEQ: This record has not yet been subject to final
COMMENT
            NCBI review. The reference sequence was derived from D30785.1.
FEATURES
                     Location/Qualifiers
                     1..260
     source
                     /organism="Mus musculus"
                     /strain="BALB/c"
                     /db xref="taxon:10090"
                     /chromosome="7"
     Protein
                     1..260
                     /product="protease, serine, 19"
                     /note="Brain Serine protease 1; neuropsin"
     CDS
                     1..260
                    /qene="Prss19"
                     /coded by="NM 008940.1:487..1269"
                     /note="go_function: hydrolase activity [goid 0016787]
                     [evidence IEA];
                     go_function: peptidase activity [goid 0008233] [evidence
                     IEA];
                     go_function: serine-type endopeptidase activity [goid
                     0004252] [evidence IEA];
                     go_process: negative regulation of blood coagulation [goid
```

```
ORIGIN

| 1 mgrpppcaiq pwilllfmg awagltraqg skilegreci phsqpwqaal fqgerlicgg
| 61 vlvgdrwvlt aahckkqkys vrlgdhslqs rdqpeqeiqv aqsiqhpcyn nsnpedhshd
| 121 imlirlqnsa nlgdkvkpvq lanlcpkvgq kciisgwgtv tspqenfpnt lncaevkiys
| 181 qnkceraypg kitegmvcag ssngadtcqg dsggplvcdg mlqgitswgs dpcgkpekpg
| 241 vytkicrytt wikktmdnrd | 125 | 125 | 125 | 125 | 125 | 125 | 125 | 125 | 125 | 125 | 125 | 125 | 125 | 125 | 125 | 125 | 125 | 125 | 125 | 125 | 125 | 125 | 125 | 125 | 125 | 125 | 125 | 125 | 125 | 125 | 125 | 125 | 125 | 125 | 125 | 125 | 125 | 125 | 125 | 125 | 125 | 125 | 125 | 125 | 125 | 125 | 125 | 125 | 125 | 125 | 125 | 125 | 125 | 125 | 125 | 125 | 125 | 125 | 125 | 125 | 125 | 125 | 125 | 125 | 125 | 125 | 125 | 125 | 125 | 125 | 125 | 125 | 125 | 125 | 125 | 125 | 125 | 125 | 125 | 125 | 125 | 125 | 125 | 125 | 125 | 125 | 125 | 125 | 125 | 125 | 125 | 125 | 125 | 125 | 125 | 125 | 125 | 125 | 125 | 125 | 125 | 125 | 125 | 125 | 125 | 125 | 125 | 125 | 125 | 125 | 125 | 125 | 125 | 125 | 125 | 125 | 125 | 125 | 125 | 125 | 125 | 125 | 125 | 125 | 125 | 125 | 125 | 125 | 125 | 125 | 125 | 125 | 125 | 125 | 125 | 125 | 125 | 125 | 125 | 125 | 125 | 125 | 125 | 125 | 125 | 125 | 125 | 125 | 125 | 125 | 125 | 125 | 125 | 125 | 125 | 125 | 125 | 125 | 125 | 125 | 125 | 125 | 125 | 125 | 125 | 125 | 125 | 125 | 125 | 125 | 125 | 125 | 125 | 125 | 125 | 125 | 125 | 125 | 125 | 125 | 125 | 125 | 125 | 125 | 125 | 125 | 125 | 125 | 125 | 125 | 125 | 125 | 125 | 125 | 125 | 125 | 125 | 125 | 125 | 125 | 125 | 125 | 125 | 125 | 125 | 125 | 125 | 125 | 125 | 125 | 125 | 125 | 125 | 125 | 125 | 125 | 125 | 125 | 125 | 125 | 125 | 125 | 125 | 125 | 125 | 125 | 125 | 125 | 125 | 125 | 125 | 125 | 125 | 125 | 125 | 125 | 125 | 125 | 125 | 125 | 125 | 125 | 125 | 125 | 125 | 125 | 125 | 125 | 125 | 125 | 125 | 125 | 125 | 125 | 125 | 125 | 125 | 125 | 125 | 125 | 125 | 125 | 125 | 125 | 125 | 125 | 125 | 125 | 125 | 125 | 125 | 125 | 125 | 125 | 125 | 125 | 125 | 125 | 125 | 125 | 125 | 125 | 125 | 125 | 125 | 125 | 125 | 12
```

<u>Disclaimer | Write to the Help Desk</u> <u>NCBI | NLM | NIH</u>

Office Action Response

U.S. Ser. No. 09/486,247

EXHIBIT A:

Trypsin Precursor [Xenopus laevis]

```
>gi | 2499865 | sp | P70059 | TRY2_XENLA
                                   Trypsin precursor
 gi|1621633|gb|AAB17274.1|  Gtrypsinogen [Xenopus laevis]
         Length = 244
 Score = 223 \text{ bits } (567), \text{ Expect = } 5e-57
 Identities = 105/243 (43%), Positives = 154/243 (63%), Gaps = 4/243 (1%)
          MKMLALCLVLAKSAWSEEQEKVVHGGPCLKDSHPFQAALYTSGHLLCGGVLIDPOWVLTA 67
          MK L + ++L +
                          E+ +K+V G C K++ P+Q +L +G+ CGG LI+ QWV++A
Sbjct: 1
          MKFLVILVLLGAAVAFEDDDKIVGGFTCAKNAVPYQVSL-NAGYHFCGGSLINSQWVVSA 59
Query: 68 AHCKKPNLQVILGKHNLRQTETFQRQISVDRTIVHPRYNPETHDNDIMMVHLKNPVKFSK 127
          AHC K +QV LG+HN+
                             E ++ I
                                        + I HP YN
                                                      DNDIM++ L
Sbjct: 60 AHCYKSRIQVRLGEHNIALNEGTEQFIDSQKVIKHPNYNSRNLDNDIMLIKLSTTARLSA 119
Query: 128 KIQPLPLKNDCSEENPNCQILGWGK-MENG-DFPDTIQCADVHLVPREQCERAYPGKITQ 185
           IQ + PL + C+
                          NC I GWG + +G ++PD +QC + ++
                                                           QC +YPG+IT+
Sbjct: 120 NIQSVPLPSACASAGTNCLISGWGNTLSSGTNYPDLLQCLNAPILTDSQCSNSYPGEITK 179
Query: 186 SMVCAGDMKEGNDSCQGDSGGPLVCGGRLRGLVSWGDMPCGSKEKPGVYTDVCTHIRWIQ 245
           +M CAG + G DSCQGDSGGP+VC G+L+G+VSWG
                                                 C + PGVYT VC + WIQ
Sbjct: 180 NMFCAGFLAGGKDSCQGDSGGPVVCNGQLQGVVSWG-YGCAQRNYPGVYTKVCNFVTWIQ 238
Query: 246 NIL 248
```

Sbjct: 239 STI 241

SNO	BI 20000	9 9 9 6 9 9 9 6		· ⊝ ⊗ • • • • • • • • • • • • • • • • • •		्र Proteir	1		
PubMed	Nucleotide	Protein	Genome	Structure	PMC	Taxonomy	OMIM	Books	
Search Prote	in	for			or time on the party of the contraction	Go	Clear		
	Limits	Preview	//Index	History	Clipboard	Details			
Display	GenPept 🔣	Send	all to file						
Range: from	begin to	end	Feațı	ures: 🗌 SNF	CDD	✓ MGC □H	HPRD S	TS	
□1: <u>P70059</u>	. Reports Trypsii	n precursor	[gi:2499	865]			BLink,	Domains Link	
LOCUS DEFINITION ACCESSION VERSION DBSOURCE	P70059 Trypsin prec P70059 P70059 GI:2 swissprot: l class: stand created: Nov sequence upd annotation u xrefs: U7233 xrefs (non-s MEROPSS01.12 InterProIPRO	499865 ocus TRY2 ard. 1, 1997. ated: Nov pdated: M 0.1, AAB1 equence of 6, Intern 01314, Pf	7 1, 1997 May 1, 20 17274.1 databases ProIPR009	accession <u>I</u> . 05.): HSSPP00' 003, Interl 9, PRINTSP	760, SMRP ProIPR0012 R00722, SN	70059, 254,			
KEYWORDS	PROSITEPS502 Calcium; Cal					Multigene fa	amily;		
SOURCE ORGANISM	Xenopus laev Xenopus laev Eukaryota; M	Calcium; Calcium-binding; Digestion; Hydrolase; Multigene family; Protease; Serine protease; Signal; Zymogen. Xenopus laevis (African clawed frog) Xenopus laevis Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Amphibia; Batrachia; Anura; Mesobatrachia; Pipoidea; Pipidae;							
REFERENCE AUTHORS TITLE JOURNAL REMARK COMMENT	1 (residues Wang, K., Lyt Direct Submi Submitted (? NUCLEOTIDE S [CATALYTIC A [COFACTOR] B [SUBCELLULAR	1 to 244 le,L., Ga ssion ?-SEP-199 EQUENCE. CTIVITY] inds 1 ca LOCATION	an, L. and Preferential cium io Extrac	Hood,L.E. tial cleava n per subur ellular.	nit (By s		-Xaa.		
FEATURES	[SIMILARITY]	Belongs ation/Qua		eptidase S.	I ramily.				
source	1 /or	244 ganism="2 _xref="ta	Kenopus l						
Protei		244 oduct="Ti	cvosin.pr	ecursor"					
Region	/EC 1 /re /no	_number='	' <u>3.4.21.4</u> e="Signal imilarity	" " "					
Region	16. /re /no	.21 gion_name	="Propep vation pe	tide" ptide (By :	similarity	/) . "			

```
Region
                     22..244
                      /region name="Mature chain"
                      /note="Trypsin."
                      /evidence=experimental
                     bond (28, 158)
     Bond
                      /bond_type="disulfide"
                      /note="By similarity."
                      /evidence=not_experimental
                     bond (46,62)
     Bond
                      /bond_type="disulfide"
                      /note="By similarity."
                      /evidence=not experimental
     Site
                     61
                      /site_type="active"
                      /note="Charge relay system (By similarity)."
                      /evidence=not_experimental
     Site
                      /site_type="metal-binding"
                      /note="Calcium (By similarity)."
                      /evidence=not experimental
     Site
                      /site type="metal-binding"
                      /note="Calcium (via carbonyl oxygen) (By similarity)."
                      /evidence=not_experimental
     Site
                      /site_type="metal-binding"
                      /note="Calcium (By similarity)."
                      /evidence=not experimental
     Site
                      105
                      /site type="active"
                      /note="Charge relay system (By similarity)."
                      /evidence=not_experimental
     Bond
                     bond (130,231)
                      /bond type="disulfide"
                      /note="By similarity."
                      /evidence=not experimental
                     bond (137, 204)
     Bond
                      /bond_type="disulfide"
                      /note="By similarity."
                      /evidence=not experimental
     Bond
                     bond (169, 183)
                      /bond_type="disulfide"
                      /note="By similarity."
                      /evidence=not_experimental
     Site
                      /site_type="unclassified"
                     /note="Required for specificity (By similarity)."
                      /evidence=not_experimental
     Bond
                     bond (194, 218)
                     /bond_type="disulfide"
                      /note="By similarity."
                     /evidence=not_experimental
                     198
     Site
                     /site_type="active"
                     /note="Charge relay system (By similarity)."
                     /evidence=not_experimental
ORIGIN
        1 mkflvilvll gaavafeddd kivggftcak navpyqvsln agyhfcggsl insqwvvsaa
       61 hcyksriqvr lgehnialne gteqfidsqk vikhpnynsr nldndimlik lsttarlsan
      121 iqsvplpsac asagtnclis gwgntlssgt nypdllqcln apiltdsqcs nsypgeitkn
```

181 mfcagflagg kdscqgdsgg pvvcngqlqg vvswgygcaq rnypgvytkv cnfvtwiqst 241 issn

//

Disclaimer | Write to the Help Desk NCBI | NLM | NIH

Feb 9 2005 14:31:10



results of BLAST

BLASTP 2.2.10 [Oct-19-2004]

Reference:

Altschul, Stephen F., Thomas L. Madden, Alejandro A. Schäffer, Jinghui Zhang, Zheng Zhang, Webb Miller, and David J. Lipman (1997), "Gapped BLAST and PSI-BLAST: a new generation of protein database search programs", Nucleic Acids Res. 25:3389-3402.

RID: 1110912140-32509-164324574163.BLASTQ4

Query=

(253 letters)


Database: All non-redundant GenBank CDS translations+PDB+SwissProt+PIR+PRF excluding environmental samples 2,366,628 sequences; 802,641,970 total letters

If you have any problems or questions with the results of this search please refer to the **BLAST FAQS**

Taxonomy reports

Distribution of 509 Blast Hits on the Query Sequence

Mouse-over to show defline and scores. Click to show alignments



Related Structures

	Score	E
Sequences producing significant alignments:	(bits)	Value
gi 21411424 gb AAH31119.1 Prss18 protein [Mus musculus] >g	544	e-154 G
gi 6755180 ref NP 035307.1 protease, serine, 18 [Mus muscu	530	e-149 G
gi 9506997 ref NP 062048.1 kallikrein 6 [Rattus norvegicus	492	e-138 G
gi 57036286 ref XP 533605.1 PREDICTED: similar to Kallikre	367	e-100 G
gi 15930186 gb AAH15525.1 KLK6 protein [Homo sapiens] >gi gi 30585043 gb AAP36794.1 Homo sapiens kallikrein 6 (neuro gi 55233182 gb AAV48554.1 kallikrein 6 preproprotein [synt	366 366 366	e-100 G e-100 e-100
gi 21465525 pdb 1GVL A Chain A, Human Prokallikrein 6 (Hk6)	347	1e-94 S
gi 21466131 pdb 1L06 A Chain A, Human Kallikrein 6 (Hk6) Ac	346	4e-94 S
gi 37183190 gb AAQ89395.1 KLK8 [Homo sapiens] >gi 6005844	241	2e-62 G
gi 55649729 ref XP 512847.1 PREDICTED: similar to kallikre	241	2e-62 G
gi 26454807 gb AAH40887.1 Kallikrein 8, isoform 1 prepropr	240	3e-62 G
gi 6679487 ref NP 032966.1 protease, serine, 19 [Mus muscu	239	4e-62 G
gi 21464127 ref NP 653088.1 kallikrein 8 isoform 2 [Homo s	238	8e-62 G
gi 11545747 ref NP 071329.1 kallikrein 14 preproprotein [H	238	1e-61 G
gi 50959826 gb AAH74905.1 Kallikrein 14, preproprotein [Ho	237	2e-61 G
gi 34856166 ref XP 218643.2 similar to glandular kallikrei	235	7e-61 G
gi 26891548 gb AAN78420.1 glandular kallikrein KLK13 [Mus	235	7e-61 G

ш*₽*=111U/141™0=363U/>=10∀36च∂/Т10Э.₽₽£361.Qт,

gi 39645087 gb AAH63763.1 Unknown (protein for MGC:70078)	235	9e-61
gi 27731521 ref XP 218648.1 similar to Neuropsin precursor gi 3559978 emb CAA06643.1 serine protease [Rattus rattus]	234	2e-60 G
gi 57037485 ref XP 541468.1 PREDICTED: similar to kallikre	233	4e-60
	233	5e-60 G
	233	5e-60 G
	233	5e-60 G
gi 4699765 pdb 1NPM B Chain B, Neuropsin, A Serine Protease	<u>233</u>	5e-60 S
gi 33469049 ref NP 777355.1 kallikrein 14 [Mus musculus] >	232	6e-60 G
gi 34856164 ref XP 218641.2 similar to glandular kallikrei	231	1e-59 G
gi 28422450 gb AAH44756.1 Klk14 protein [Mus musculus]	230	2e-59 G
gi 34856172 ref XP 218607.2 similar to prostin [Rattus nor	229	4e-59 G
gi 34856168 ref XP 218645.2 similar to hippostasin prostat	228	9e-59 G
gi 11244759 gb AAG33354.1 ACO protease [Homo sapiens]	228	1e-58 G
gi 47480780 gb AAH69507.1 Kallikrein 15, isoform 4 preprop	227	3e-58 G
gi 47480768 gb AAH69480.1 Kallikrein 15, isoform 4 preprop	226	4e-58 G
gi 14484922 gb AAK62813.1 prostinogen [Homo sapiens]	226	6e-58 G
gi 12834991 dbj BAB23113.1 unnamed protein product [Mus mu	225	1e-57 G
gi 57037473 ref XP 541465.1 PREDICTED: similar to glandula	224	1e-57 G
gi 33585653 gb AAH56068.1 LOC397853 protein [Xenopus laevis]	224	1e-57 G
gi 33469045 ref NP 777354.1 kallikrein 15 [Mus musculus] >	224	2e-57 G
gi 47481100 gb AAH69334.1 Kallikrein 13, precursor [Homo s	224	2e-57 • G
gi 49256006 gb AAH73410.1 LOC397853 protein [Xenopus laevis] gi 59808136 gb AAH89741.1 Unknown (protein for MGC:108396)	224 224	2e-57 G 2e-57
gi 65163 emb CAA37538.1 unnamed protein product [Xenopus 1	223	3e-57 G
gi 32484229 gb AAH54194.1 MGC64344 protein [Xenopus laevis]	223	3e-57 G
gi 57037469 ref XP 541464.1 PREDICTED: similar to kallikre	223	3e-57 G
gi 51714013 ref XP 489832.1 similar to trypsinogen 10 [Mus	223	4e-57 G
gi 2499865 sp P70059 TRY2 XENLA Trypsin precursor >gi 16216 gi 42759849 gb AAS45302.1 KLK15 [Saguinus oedipus]	223 221	5e-57 G 1e-56
gi 37183146 gb AAQ89373.1 KLK11 [Homo sapiens] > gi 5803199	221	1e-56 G
gi 21618357 ref NP 659196.1 kallikrein 11 isoform 2 precur	221	1e-56 G
gi 51714016 ref XP 489833.1 similar to trypsinogen 12 [Mus	221	2e-56 G
	220	3e-56 G
	220	3e-56 G
	219	4e-56
	219	5e-56 G
gi 67548 pir TRRT2 trypsin (EC 3.4.21.4) II precursor - rat	219 218	5e-56 G 9e-56
	218 218	1e-55 G 2e-55
	217	2e-55 G
11.071.05.00 m. 51.VD. 444.450 ml	217	3e-55 G
1000F00GF N to Form to the second	217 217	3e-55 S
'Irana coal clara a coal		3e-55 G
	216	3e-55
	216	5e-55 🤤

gi 34855588 ref XP 342672.1 similar to trypsin (EC 3.4.21	216	6e-55 G
gi 56541274 gb AAH87610.1 Hypothetical LOC496627 [Xenopus	216	6e-55 G
gi 51711962 ref XP 487918.1 PREDICTED: similar to trypsino	215	8e-55 G
gi 27573668 pdb 1J14 A Chain A, Benzamidine In Complex With	215	8e-55 S
gi 4139560 pdb 3TGJ E Chain E, S195a Trypsinogen Complexed	215	1e-54 S
gi 14719441 pdb 1F7Z A Chain A, Rat Trypsinogen K15a Comple	214	2e-54 S
gi 6755891 ref NP 035775.1 protease, serine, 3 [Mus muscul	213	3e-54 G
gi 37182171 gb AAQ88888.1 KLK12 [Homo sapiens] > gi 2220898	213	3e-54 G
gi 64388 emb CAA49679.1 trypsin III [Salmo salar] > gi 4225	213	4e-54
gi 27731519 ref XP 218644.1 similar to kallikrein 12 isofo	213	4e-54 G
gi 27465583 ref NP 775150.1 cationic trypsinogen [Rattus n	213	5e-54 G
gi 54035518 gb AAH83528.1 Zgc:92590 [Danio rerio] > gi 5574	213	5e-54 G
gi 1633123 pdb 1SLW B Chain B, Rat Anionic N143h, E151h Try	213	5e-54 S
gi 34855586 ref XP 342670.1 similar to trypsinogen 8 [Ratt	212	7e-54 G
gi 1633121 pdb 1SLX B Chain B, Rat Anionic N143h, E151h Try	212	7e-54 S
gi 57097397 ref XP 532744.1 PREDICTED: similar to trypsin	212	9e-54 G
gi 4139558 pdb 3TGI E Chain E, Wild-Type Rat Anionic Trypsi	212	9e-54 S
gi 2098543 pdb 1AND Anionic Trypsin Mutant With Arg 96 Re	212	9e-54 S
gi 559311 dbj BAA07516.1 pancreas cationic pretrypsinogen	211	1e-53 G S
gi 67549 pir TRBOTR trypsin (EC 3.4.21.4) precursor - bovi	211	1e-53 🕏
gi 13096615 pdb 1G3E A Chain A, Bovine Beta-Trypsin Bound T	211	1e-53
gi 5542503 pdb 1ZZZ A Chain A, Trypsin Inhibitors With Rigi	211	1e-53 ⁵
gi 1421532 pdb 1TGB Trypsinogen-Ca From Peg	211	1e-53 🙎
gi 17942679 pdb 1K90 E Chain E, Crystal Structure Of Michae	211	2e-53
gi 2358083 gb AAB69055.1 trypsinogen 4 [Mus musculus] >gi	211	2e-53 G
gi 50054435 ref NP 001001911.1 kallikrein 1, renal/pancrea	211	2e-53 G
gi 27819626 ref NP 777115.1 pancreatic anionic trypsinogen	211	2e-53 G
gi 27545370 ref NP 775423.1 preprotrypsinogen IV [Rattus n	210	2e-53 G
gi 67550 pir TRPGTR trypsin (EC 3.4.21.4) precursor - pig gi 67552 pir TRDG trypsin (EC 3.4.21.4) precursor, anionic	$\frac{210}{210}$	2e-53 2e-53
gi 51714019 ref XP 489834.1 similar to Try10-like trypsino	210	2e-53 G
gi 6851258 gb AAF29490.1 tissue kallikrein [Saguinus oedipus]	210	2e-53
gi 34810822 pdb 10PH B Chain B, Non-Covalent Complex Betwee	210	2e-53 S
gi 2098545 pdb 1ANC Anionic Trypsin Mutant With Ser 214 R	210	2e-53 🕏
gi 2098541 pdb 1ANB Anionic Trypsin Mutant With Ser 214 R	210	2e-53 S
gi 11513886 pdb 1FY8 E Chain E, Crystal Structure Of The De	210	3e-53 💲
gi 9257000 pdb 1EZU D Chain D, Ecotin Y69f, D70p Bound To D	210	3e-53 💆
gi 2392288 pdb 1DPO Structure Of Rat Trypsin	210	3e-53 S
gi 230776 pdb 2TRM Asn102Trypsin (E.C.3.4.21.4) (Mutant W	210	3e-53 🕏
gi 56541161 gb AAH87563.1 Unknown (protein for MGC:97681)	209	4e-53 G
gi 2781042 pdb 1AMH B Chain B, Uncomplexed Rat Trypsin Muta	209	4e-53 😫
gi 55649807 ref XP 524358.1 PREDICTED: similar to variant	209	6e-53 G
gi 58257847 gb AAW69366.1 tryl4 [Macaca mulatta]	209	6e-53
gi 50979094 ref NP_001003284.1 kallikrein 2, prostatic [Ca	209	7e-53 G
gi 45382397 ref NP 990715.1 trypsinogen [Gallus gallus] >g	209	7e-53 G
gi 56971223 gb AAH88079.1 Hypothetical LOC496920 [Xenopus	209	7e-53 G

gi 25814806 gb AAN75630.1 trypsinogen [Gallus gallus]	208	9e-53 G
<u>gi 14719439 pdb 1F5R A</u> Chain A, Rat Trypsinogen Mutant Comp <u>gi 108957 pir S13813</u> trypsin (EC 3.4.21.4) - bovine >gi 24	208 208	9e-53 S 1e-52
gi 108118 pir A37938 tissue kallikrein (EC 3.4.21.35), pro	208	1e-52 G
gi 2358072 gb AAB69044.1 trypsinogen 7 [Mus musculus] >gi	208	1e-52 G
gi 56556311 gb AAH87753.1 LOC496635 protein [Xenopus tropi	208	1e-52 G
gi 14719487 pdb 3TGK E Chain E, Trypsinogen Mutant D194n An	208	1e-52 S
gi 57415 emb CAA41752.1 trypsin V b-form [Rattus rattus] >	207	2e-52
gi 27530958 dbj BAC54105.1 variant form hippostasin/KLK11gi 47220857 emb CAG00064.1 unnamed protein product [Tetrao	207	2e-52
gi 47220856 emb CAG00063.1 unnamed protein product [Tetrao	<u>207</u> 207	2e-52 2e-52
gi 4389387 pdb 1A0J D Chain D, Crystal Structure Of A Non-P	207	2e-52 S
gi 2392548 pdb 1TAW A Chain A, Bovine Trypsin Complexed To	207	2e-52 S
gi 60593451 pdb 1S0R A Chain A, Bovine Pancreatic Trypsin I	207	2e-52 S
<pre>gi 6981132 ref NP 036725.1 kallikrein 7 [Rattus norvegicus gi 2358071 gb AAB69043.1 trypsinogen 5 [Mus musculus]</pre>	207 207	2e-52 G 2e-52
gi 22652265 gb AAN03662.1 kallikrein 7 long variant protei	207	3e-52 G
gi 51094518 gb EAL23773.1 protease, serine, 1 (trypsin 1)	207	3e-52 G
gi 230196 pdb 1NTP Modified Beta Trypsin (Monoisopropylph	207	3e-52 S
gi 27710074 ref XP 231718.1 similar to Trypsin V-A precurs	206	4e-52 G
gi 67551 pir TRDGC trypsin (EC 3.4.21.4) precursor, cation	206	4e-52
gi 10835849 pdb 1FNI A Chain A, Crystal Structure Of Porcin	206	4e-52
gi 576019 pdb 1BRC E Chain E, Trypsin (E.C.3.4.21.4) Varian	206	4e-52
gi 45382399 ref NP 990716.1 trypsinogen [Gallus gallus] >g	<u> 206</u>	5e-52 G
gi 51746022 ref XP 355892.2 RIKEN cDNA 2310008B01 [Mus mus	206	5e-52 G
gi 34811715 pdb 1HJ9 A Chain A, Atomic Resolution Structure gi 5441855 dbj BAA82363.1 trypsinogen 2 [Paralichthys oliv	<u>206</u> 206	5e-52 S
gi 12843871 dbj BAB26143.1 unnamed protein product [Mus mu	206	5e-52 G
gi 56611170 gb AAH87830.1 Hypothetical LOC496697 [Xenopus gi 60599777 gb AAT11803.2 pancreatic trypsinogen [Struthio	206 206	6e-52 G 6e-52
gi 11244763 gb AAG33358.1 stratum corneum trypsin-like ser	206	6e-52 G
gi 2118087 pir S55067 trypsin (EC 3.4.21.4) I precursor, p	206	6e-52
gi 2499863 sp Q90628 TRY2 CHICK Trypsin I-P38 precursor >gi	206	6e-52 G
gi 51247093 pdb 1H9I E Chain E, Complex Of Eeti-Ii Mutant W	206	6e-52 S
gi 2392803 pdb 5PTP Structure Of Hydrolase (Serine Protei gi 33126535 gb AAL14243.1 protease serine 4 isoform B [Hom	206	6e-52 S
gi 18777665 ref NP 036002.1 kallikrein 7 [Mus musculus] >g	205	8e-52 8e-52 G
gi 93017 pir A27207 tissue kallikrein (EC 3.4.21.35), pros	205 205	8e-52 2 8e-52
gi 3318722 pdb 1AN1 E Chain E, Leech-Derived Tryptase Inhib	205	8e-52 5
gi 31541863 ref NP 075822.2 RIKEN cDNA 2210010C04 [Mus mus	205	1e-51 G
gi 51593533 gb AAH78492.1 MGC85264 protein [Xenopus laevis]	205	1e-51 G
gi 476488 pir KQPG tissue kallikrein (EC 3.4.21.35), pancr gi 58257845 gb AAW69364.1 try13 [Macaca mulatta]	205	1e-51
•	205	1e-51
gi 20141454 sp P00752 KLK PIG Glandular kallikrein precurso	204 204	2e-51 G 2e-51
gi 34856015 ref XP 214932.2 similar to GLANDULAR KALLIKREI	204	2e-51 G
gi 27731319 ref XP 218649.1 similar to thymopsin [Rattus n	203	4e-51 G
gi 56611173 gb AAH87759.1 Hypothetical LOC496640 [Xenopus	203	4e-51 G
gi 54038747 gb AAH84612.1 LOC495211 protein [Xenopus laevis]	203	4e-51 G

gi 30584501 gb AAP36503.1 Homo sapiens kallikrein 5 [synth	202	5e-51
gi 37183138 gb AAQ89369.1 KLK5 [Homo sapiens] >gi 31075483	202	5e-51 G
gi 112403 pir A34079 tissue kallikrein (EC 3.4.21.35) P1 p	202	5e-51 G
gi 21594212 gb AAH32005.1 Stratum corneum chymotryptic enz	202	5e-51 G
qi 41054557 ref NP 955899.1 Unknown (protein for MGC:66382 gi 57162224 emb CAI39655.1 OTTHUMP00000045395 [Homo sapien	202 202	5e-51 G 9e-51
gi 55741639 ref NP 001003262.1 kallikrein 1, renal/pancrea	202	9e-51 G
<pre>gi 55662968 emb CAH69873.1 protease, serine, 3 (mesotrypsi gi 41350549 gb AAS00515.1 trypsin [Oreochromis niloticus]</pre>	202 202	9e-51 G 9e-51
gi 55649803 ref XP 524356.1 PREDICTED: similar to Kallikre	201	1e-50 G
gi 2564751 gb AAC13322.1 mesotrypsinogen [Homo sapiens] >g	201	1e-50 G
gi 20988417 gb AAH30238.1 Unknown (protein for IMAGE:45379	201	1e-50 G
gi 1064991 pdb 1TRN B Chain B, Trypsin (E.C.3.4.21.4) Compl	201	1e-50 S
gi 6066378 emb CAB58178.1 trypsinogen IV a-form [Homo sapi	<u>201</u>	1e-50 G
gi 423134 pir S33496 trypsin (EC 3.4.21.4) IV form a - hum gi 30584977 gb AAP36761.1 Homo sapiens kallikrein 2, prost	$\frac{201}{201}$	1e-50 G 2e-50
<u>gi 30582139 gb AAP35296.1 </u> kallikrein 2, prostatic [Homo sa <u>gi 422723 pir S33772</u> tissue kallikrein (EC 3.4.21.35) prec	201 201	2e-50 G 2e-50
gi 46402490 ref NP 571783.1 trypsin [Danio rerio] >gi 2746	201	2e-50 G
gi 58257846 gb AAW69365.1 try12 [Macaca mulatta] gi 41350551 gb AAS00516.1 trypsin [Oreochromis aureus]	$\frac{201}{201}$	2e-50 2e-50
gi 27573671 pdb 1J17 T Chain T, Factor Xa Specific Inhibito gi 5441853 dbj BAA82362.1 trypsinogen 1 [Paralichthys oliv	$\frac{201}{201}$	2e-50 2
gi 9665236 ref NP 062544.1 kallikrein 12 isoform 1 [Homo s	201	2e-50 G
<u>gi 52345790 ref NP 001004941.1 </u> MGC89184 protein [Xenopus t <u>gi 13516891 dbj BAB40329.1 </u> trypsinogen [Engraulis japonicus]	200 200	3e-50 G 3e-50
gi 230765 pdb 2TLD E Chain E, Bovine Trypsin (E.C.3.4.21.4)	200	3e-50 🚨
gi 29366812 ref NP 036447.1 kallikrein 9 [Homo sapiens] >g	199	4e-50 G
gi 57113723 ref XP 537938.1 PREDICTED: similar to KLK15 [C gi 32402373 gb AAP81159.1 trypsinogen [Pangasius hypophtha	<u>199</u> 199	4e-50 G 4e-50
gi 34856017 ref XP 214931.2 similar to kallikrein [Rattus gi 559508 emb CAA57701.1 trypsin [Paranotothenia magellani	199 199	6e-50 G 6e-50
gi 49259459 pdb 1V2M T Chain T, Benzamidine In Complex With	199	6e-50 S
gi 609585 gb AAA58782.1 kallikrein gi 1552516 gb AAC80208.1 trypsinogen C [Homo sapiens]	199 198	6e-50 G 1e-49
gi 51094519 gb EAL23774.1 protease, serine, 2 (trypsin 2)	198	1e-49 G
gi 55629564 ref XP 519441.1 PREDICTED: similar to trypsino	198	1e-49 G
qi 49259460 pdb 1V2N T Chain T, Potent Factor Xa Inhibitor	198	1e-49 🕏
gi 3024066 sp Q28773 KLK1 PAPHA Kallikrein 1 precursor (Tis	198	1e-49
gi 2136330 pir 138363 trypsin (EC 3.4.21.4) IV form b prec	<u>198</u>	1e-49
gi 3980129 emb CAA50484.1 trypsinogen IV b-form [Homo sapi gi 51539252 gb AAU06121.1 trypsinogen [Takifugu rubripes]	<u>198</u> 197	1e-49 G 2e-49
gi 4809136 gb AAD30107.1 trypsinogen-like serine protease	197	2e-49
gi 971196 gb AAA75001.1 trypsinogen	197	2e-49 G
gi 13994131 ref NP_113711.1 nerve growth factor, gamma [Ra	197	2e-49 G
gi 34856011 ref XP 214947.2 similar to Glandular kallikrei	197	2e-49 G
gi 57113389 ref XP 537905.1 PREDICTED: similar to trypsin	<u>197</u>	2e-49 G
gi 33126583 gb AAL14244.1 protease serine 2 isoform B [Hom	<u>197</u>	2e-49 G
<u>gi 20988034 gb AAH30260.1 </u> PRSS2 protein [Homo sapiens]	<u>197</u>	2e-49 G

gi 56611148 gb AAH87751.1 Hypothetical LOC496633 [Xenopus gi 3452120 gb AAC32752.1 trypsinogen 2 precursor [Pseudopl gi 51539247 gb AAU06120.1 trypsinogen [Takifugu rubripes]	197 197 197	2e-49 G 2e-49 3e-49
gi 49259469 pdb 1V2W T Chain T, Trypsin Inhibitor In Comple	197	3e-49 S
gi 20149993 pdb 1H4W A Chain A, Structure Of Human Trypsin gi 223207 prf 0608151A kallikrein B	<u>197</u> 197	3e-49 S 3e-49
gi 13516893 dbj BAB40330.1 trypsinogen II [Engraulis japon	196	4e-49
gi 1399811 gb AAB57732.1 pretrypsinogen-like serine protea	196	4e-49
gi 58257842 gb AAW69361.1 Try4 [Macaca mulatta]	<u>196</u>	4e-49
gi 49259466 pdb 1V2T T Chain T, Trypsin Inhibitor In Comple gi 1213631 emb CAA40068.1 trypsin [Pleuronectes platessa]	<u>196</u>	4e-49 S
gi 1213631 emb CAA40068.1 trypsin [Pleuronectes platessa] gi 2102686 gb AAB57728.1 preprotrypsin-like protease [Diss	<u>196</u> 196	5e-49 5e-49
gi 481641 pir S39048 trypsin (EC 3.4.21.4) X - Atlantic co	196	5e-49
gi 49259464 pdb 1V2R T Chain T, Trypsin Inhibitor In Comple	196	5e-49 S
gi 49259463 pdb 1V2Q T Chain T, Trypsin Inhibitor In Comple	196	5e-49 S
gi 42543835 pdb 1UTM A Chain A, Trypsin Specificity As Eluc	196	5e-49 S
gi 547788 sp P00758 KLK1 RAT Glandular kallikrein, pancreat	196	6e-49 G
gi 57037493 ref XP 541470.1 PREDICTED: similar to enamel m	196	6e-49 G
gi 49259462 pdb 1V2P T Chain T, Trypsin Inhibitor In Comple	196	6e-49 S
gi 34856013 ref XP 214939.2 similar to kallikrein [Rattus	195	8e-49 G
gi 40647097 gb AAR88364.1 pretrypsinogen [Tautogolabrus ad	1 95	8e-49
gi 58257844 gb AAW69363.1 try10 [Macaca mulatta]	195	8e-49
gi 3452117 gb AAC32751.1 trypsinogen 1 precursor [Pseudopl	<u>195</u>	8e-49
gi 609583 gb AAA58781.1 kallikrein gi 1334753 emb CAA54215.1 trypsinogen X [Gadus morhua]	195	8e-49 G
<u>gi 1334753 emb CAA54215.1 </u> trypsinogen X [Gadus morhua] <u>gi 58257848 gb AAW69367.1 </u> try16 [Macaca mulatta]	<u>195</u> 195	1e-48 1e-48
gi 476825 pir A44284 tissue kallikrein (EC 3.4.21.35) homo	195	1e-48 G
gi 2507250 sp P16049 TRY1 GADMO Trypsin I precursor	194	2e-48
gi 57037489 ref XP 541469.1 PREDICTED: similar to kallikre	194	2e-48 G
gi 33307101 gb AAQ02911.1 serine protease KN13 precursor [gi 33637113 gb AAQ23713.1 glandular kallikrein precursor [194	2e-48
gi 1334752 emb CAA54214.1 trypsinogen I [Gadus morhua] >qi	<u>194</u> 193	2e-48 4e-48
gi 64382 emb CAA49676.1 trypsin IA [Salmo salar] >gi 42258	193	4e-48
gi 64380 emb CAA49680.1 trypsin I [Salmo salar] > gi 422581	193	4e-48
gi 27731317 ref XP 218647.1 similar to Kallikrein 9 precur	193	4e-48 G
gi 52851385 ref NP 001005382.1 glandular kallikrein 12, su	<u> 193</u>	4e-48 G
gi 64386 emb CAA49678.1 trypsin II [Salmo salar] >gi 42258	<u>192</u>	5e-48
gi 51591907 ref NP 001003977.1 glandular kallikrein 11 [Ra	192	5e-48 G
gi 809221 pdb 1BIT The Crystal Structure Of Anionic Salmo	192	5e-48 S
gi 67558 pir KQHU tissue kallikrein (EC 3.4.21.35) precurs	192	7e-48 G
gi 31980868 ref NP 034769.4 kallikrein 6 [Mus musculus] >g	192	9e-48 G
gi 49256121 gb AAH72978.1 MGC82534 protein [Xenopus laevis]	<u>192</u>	9e-48 G
gi 107984 pir S12764 trypsin (EC 3.4.21.4) III precursor	<u>191</u>	1e-47 G
gi 4504875 ref NP 002248.1 kallikrein 1 preproprotein [Hom	191	1e-47 G
gi 24266796 gb AAN52348.1 stejnefibrase 1 [Trimeresurus st	<u>191</u>	1e-47
gi 9989702 gb AAG11389.1 kallikrein [Mus musculus] > gi 918	<u>191</u>	1e-47 G
gi 51873218 gb AAU12569.1 kallikrein precursor [Homo sapiens] gi 4006842 emb CAA07055.1 pallabin2 [Gloydius halys] >gi 1	<u>191</u> 191	2e-47 G 2e-47
gi 2293478 gb AAB65411.1 trypsinogen Al [Petromyzon marinu	191 191	2e-47 2e-47
gi 2367495 gb AAB69654.1 trypsinogen a2 [Petromyzon marinus]	191	2e-47
gi 52851403 ref NP 032719.1 nerve growth factor, gamma [Mu	191	2e-47 G

gi 20160213 gb AAM11874.1 kallikrein 1, renal/pancreas/sal gi 33307086 gb AAQ02906.1 serine protease KN12 precursor [191 190	2e-47 G 3e-47
gi 5001993 gb AAD37247.1 chimeric AFGP/trypsinogen-like se gi 47523236 ref NP 998967.1 enamel matrix serine proteinas	<u>190</u> 190	3e-47 3e-47 G
gi 3212609 pdb 1SGF Z Chain Z, Crystal Structure Of 7s Ngf:	189	5e-47 S
gi 55629686 ref XP 527930.1 PREDICTED: similar to Trypsin	189	5e-47 G
gi 2367501 gb AAB69657.1 trypsinogen b2 [Petromyzon marinus]	189	5e-47
gi 30583345 gb AAP35917.1 kallikrein 1, renal/pancreas/sal	<u>189</u>	6e-47 G
gi 386843 gb AAA59201.1 kallikrein gi 67553 pir TRDFS trypsin (EC 3.4.21.4) precursor - spiny	<u>189</u> 189	8e-47 G 8e-47
gi 47479455 gb AAH69325.1 Kallikrein 4, preproprotein [Hom	$\frac{188}{180}$	1e-46 G
gi 4006844 emb CAA04612.1 pallabin [Gloydius halys] > gi 13 gi 1334246 emb CAA25930.1 NGF-gamma [Mus musculus]	<u>188</u> 188	1e-46 1e-46
gi 26006097 dbj BAC41392.1 anionic trypsin [Oncorhynchus k	188	1e-46
gi 4883930 gb AAD31711.1 chimeric antifreeze glycoprotein gi 4512032 gb AAD21581.1 serine protease prostase [Homo sa	188	1e-46 2e-46 G
gi 4512032 gb AAD21581.1 serine protease prostase [Homo sa gi 6980535 pdb 2STB E Chain E, Anionic Salmon Trypsin In Co	<u>187</u> 187	2e-46 S
gi 6010462 gb AAF01139.1 stratum corneum chymotryptic enzy	187	2e-46 G
gi 2367499 gb AAB69656.1 trypsinogen B1 [Petromyzon marinus]	187	2e-46
gi 28875780 ref NP_034770.1 kallikrein 11 [Mus musculus] >	<u>187</u>	3e-46 G
gi 9910516 ref NP 064312.1 kallikrein 4 (prostase, enamel	187	3e-46 G
gi 13959656 sp Q9PT41 VSP1 VIPLE Factor V activating enzyme	186	4e-46 4e-46
gi 18158713 pdb 1HJ8 A Chain A, 1.00 Aa Trypsin From Atlant gi 226064 prf 1409287A urinary prokallikrein	<u>186</u> 186	4e-46 5e-4 6
gi 8659568 ref NP 034775.1 kallikrein 1 [Mus musculus] >gi	186	5e-46 G
gi 12002224 gb AAG43246.1 enamel matrix serine proteinase	186	5e-46 G
<u>gi 515295 pdb 2TB5 </u> Trypsin (E.C.3.4.21.4) Complexed With <u>gi 223665 prf 0906268A</u> kallikrein	$\frac{186}{186}$	5e-46 S
gi 57037481 ref XP 541467.1 PREDICTED: similar to kallikre	186	7e-46 G
gi 24266802 gb AAN52350.1 venom serine protease 5 [Trimeregi 20520629 emb CAD30563.1 trypsinogen Y precursor [Gadus	186 186	7e-46 7e-46
gi 60593495 pdb 1SPJ A Chain A, Structure Of Mature Human T gi 3915685 sp P05620 VSP1 TRIFL Flavoxobin precursor > gi 21	<u>185</u> 185	9e-46 9e-46
gi 27573862 pdb 1MBQ A Chain A, Anionic Trypsin From Pacifi gi 6815045 dbj BAA82364.2 trypsinogen 3 [Paralichthys oliv	185	1e-45 S
gi 21426851 ref NP 034246.1 kallikrein 9 [Mus musculus] >g	<u>185</u> 184	1e-45 1e-45 G
gi 742152 prf 2009261A kallidinogenase	184	1e-45
gi 55650315 ref XP 524486.1 PREDICTED: similar to kallikre gi 2118085 pir JC4803 venombin A (EC 3.4.21.74) precursor	$\frac{184}{184}$	1e-45 G 1e-45
gi 9230643 gb AAF85937.1 enamel matrix serine proteinase 1	184	1e-45 G
gi 26354462 dbj BAC40859.1 unnamed protein product [Mus mu	184	1e-45 G
gi 32329782 emb CAD86932.1 proaggregant serine proteinase gi 19032293 dbj BAB85634.1 trypsinogen [Anguilla japonica]	<u>184</u> 183	2e-45 3e-45
gi 1373148 gb AAB02196.1 trypsinogen I	183	4e-45
gi 51871599 ref NP 001004101.1 kallikrein 4 [Rattus norveg	182	6e-45 G
gi 21309888 gb AAM46086.1 thrombin-like enzyme [Gloydius u gi 55527 emb CAA35232.1 pre-pro-protein for kallikrein [Ma	$\frac{182}{181}$	6e-45 1e-44
gi 38085510 ref XP 145260.2 similar to Trypsin V-A precurs	181	le-44 G
gi 8567985 gb AAF76378.1 thrombin-like protein DAV-PA prec	181	1e-44
gi 4102926 gb AAD01624.1 plasminogen activator precursor [gi 64384 emb CAA49677.1 trypsin IB [Salmo salar]	$\frac{181}{181}$	2e-44 2e-44
		·•

gi 7949064 ref NP 032482.1 kallikrein 5 [Mus musculus] >gi	181	2e-44 G
gi 39841069 ref NP 082936.1 kallikrein 9 homolog [Mus musc	180	3e-44 G
gi 3318901 pdb 1FXY A Chain A, Coagulation Factor Xa-Trypsi	180	3e-44 S
gi 602604 emb CAA58225.1 mucofirase 5 [Protobothrops mucro gi 311844 emb CAA51957.1 prostate specific antigen [Macaca	<u>180</u> 179	4e-44 5e-44
gi 24266793 gb AAN52347.1 stejnobin [Trimeresurus stejnegeri]	179	5e-44
gi 32396014 gb AAP42416.1 serine protease [Bothrops jarara	179	5e-44
gi 24637205 gb AAN63607.1 kallikrein 5 variant [Homo sapie gi 602600 emb CAA58223.1 mucofirase 3 [Protobothrops mucro	<u>179</u> 179	6e-44 G 6e-44
<u>gi 6981670 ref NP 036809.1 </u> tonin [Rattus norvegicus] >gi 6	<u>179</u>	8e-44 G
gi 23956056 ref NP 034772.1 kallikrein 21 [Mus musculus] > gi 33307047 gb AAQ02893.1 serine protease KN4 precursor [T gi 3552036 gb AAC34898.1 pallase [Gloydius halys]	179 179 179	8e-44 8e-44 8e-44
gi 11036673 gb AAG27253.1 serpentokallikrein-2 [Protobothr	179	8e-44
gi 52693913 ref NP 034244.1 kallikrein 22 [Mus musculus] >	178	1e-43 G
gi 387167 gb AAA37682.1 epidermal growth factor binding pr	178	1e-43 G
gi 3212607 pdb 1SGF X Chain X, Crystal Structure Of 7s Ngf:	<u>178</u>	1e-43 🙎
gi 12313877 ref NP 064664.1 kallikrein 27 [Mus musculus] >	177	2e-43 G
gi 52551331 gb AAU84664.1 trypsin [Oreochromis niloticus] gi 49781153 gb AAT68459.1 prostate specific antigen precur	$\frac{177}{177}$	2e-43 2e-43
gi 20563016 dbj BAB92021.1 neuropsin [Mus musculus]	177	2e-43 G
gi 52551333 gb AAU84665.1 trypsin [Oreochromis aureus]	177	2e-43
gi 8393675 ref NP 034773.1 kallikrein 24 [Mus musculus] >g	177	2e-43 G
gi 602598 emb CAA58222.1 mucofirase 2 [Protobothrops mucro	<u>177</u>	2e-43
gi 189524 gb AAA59995.1 prostate specific antigen precursor	<u>177</u>	3e-43 G
gi 54696586 gb AAV38665.1 kallikrein 3, (prostate specific gi 6691473 dbj BAA89310.1 protease A [Bothrops jararaca] >	$\frac{177}{177}$	3e-43 G 3e-43
gi 951152 gb AAB01070.1 preprotrimubin	$\frac{177}{177}$	3e-43
gi 22208984 ref NP 665895.1 kallikrein 10 precursor [Homo	176	4e-43 G
gi 602602 emb CAA58224.1 mucofirase 4 [Protobothrops mucro gi 13959638 sp Q9DF66 VSP3 TRIJE Venom serine proteinase 3	176	4e-43
gi 464965 sp P35034 TRYP PLEPL Trypsin precursor >gi 345579	<u>176</u> 176	4e-43 4e-43
gi 86006 pir A32121 snake venom factor V activator (EC 3.4	176	5e-43
gi 2118079 pir 155608 complement factor D (EC 3.4.21.46) p	176 176	5e-43
gi 225915 prf 1403294A gamma seminoprotein gi 818030 emb CAA27247.1 kallikrein [Rattus norvegicus]	<u>176</u> 176	5e-43 5e-43 G
gi 6693854 gb AAF25008.1 salmonase Gloydius halys brevica	$\frac{176}{176}$	5e-43 5 e-43
gi 4102924 gb AAD01623.1 serine protease; Haly 2 [Gloydius	176	5e-43
gi 602596 emb CAA58221.1 mucofirase 1 [Protobothrops mucro	<u>176</u>	7e-43
gi 8659572 ref NP 035045.1 nerve growth factor, alpha [Mus	<u>176</u>	7e-43 G 7e-43 G
gi 21961233 gb AAH34518.1 Nerve growth factor, alpha [Musgi 33307053 gb AAQ02895.1 serine protease KN6 precursor [T	<u>176</u> 176	7e-43
gi 230371 pdb 1TON Tonin (E.C. Number Not Assigned) gi 6706013 emb CAB65936.1 beta-fibrinogenase [Agkistrodon	<u>175</u>	9e-43
gi 6706013 emb CAB65936.1 beta-fibrinogenase [Agkistrodon gi 33307092 gb AAQ02908.1 serine protease KN14 precursor [<u>175</u> 175	9e-43 9e-43
gi 13959639 sp Q9DF67 VSP2 TRIJE Venom serine proteinase 2	175	9e-43
gi 47131125 dbj BAD18893.1 blarina toxin [Blarina brevicauda]	<u>175</u>	9e-43
gi 54696292 gb AAV38518.1 kallikrein 10 [synthetic construct]	175	1e-42
gi 12803745 gb AAH02710.1 Kallikrein 10, precursor [Homo s gi 511857 gb AAA60193.1 prostate-specific antiqen	175	1e-42 G 1e-42 G
gi 511857 gb AAA60193.1 prostate-specific antigen gi 33307077 gb AAQ02903.1 serine protease KN5 precursor [T	$\frac{175}{175}$	1e-42 G 1e-42
gi 3122187 sp P81176 VSP1 AGKHA Halystase	175	le-42
gi 3044080 gb AAC13280.1 salmobin [Gloydius halys]	<u>174</u>	2e-42

gi 34862337 ref XP 343170.1 adipsin [Rattus norvegicus]gi 59956916 dbj BAD89852.1 kallikrein2 [Blarina brevicauda]gi 59956914 dbj BAD89851.1 kallikrein1 [Blarina brevicauda]gi 13959618 sp 013060 VSPA TRIGA Venom serine proteinase 2A	$\frac{174}{174} \\ \frac{174}{174}$	2e-42 2e-42 2e-42 2e-42
gi 762984 emb CAA25932.1 nerve growth factor alpha-subunit gi 19526892 ref NP 598473.1 kallikrein 10 [Mus musculus] > gi 33307095 gb AAQ02909.1 serine protease CL4 precursor [T	174 174 174	2e-42 G 3e-42 G 3e-42
gi 51870931 ref NP 001004100.1 kallikrein 10 [Rattus norve gi 38146946 gb AAR11859.1 thrombin-like enzyme [Gloydius s gi 33307089 gb AAQ02907.1 serine protease KN7 precursor [T gi 29468347 gb AAB70575.1 protein C activator [synthetic c gi 2407645 gb AAB70575.1 capillary permeability-increasing	173 173 173 172 172	3e-42 3e-42 3e-42 6e-42 6e-42
gi 7435610 pir JE0236 tissue kallikrein (EC 3.4.21.35) - m gi 6753734 ref NP 034245.1 kallikrein 13 [Mus musculus] >g gi 104457 pir A41456 venombin A (EC 3.4.21.74) [validated] gi 11036675 gb AAG27254.1 serpentokallikrein-1 [Protobothr	172 172 172 172	6e-42 G 7e-42 G 7e-42 7e-42
gi 49258367 pdb 10P2 A Chain A, Crystal Structure Of Aav-Sp gi 1633237 pdb 1DST Mutant Of Factor D With Enhanced Cata gi 62464 emb CAA31240.1 batroxobin [Bothrops atrox] > gi 86 gi 29293675 gb AAO67553.1 thrombin-like enzyme precursor P	172 172 172 172	7e-42 S 7e-42 S 1e-41 1e-41
gi 56789072 gb AAH88011.1 Hypothetical LOC496746 [Xenopus gi 11378386 pir JG0169 venombin A (EC 3.4.21.74) [validate gi 4378029 gb AAD19350.1 thrombin-like defibrase 1 [Deinag gi 86007 pir B32121 snake venom factor V activator (EC 3.4 gi 24266790 gb AAN52346.1 venom serine protease 1 [Trimere gi 280699 pir A60468 venombin A (EC 3.4.21.74) - southern gi 56566179 gb AAV98367.1 thrombin-like protein precursor gi 18072835 emb CAC80981.1 putative serine proteinase [Cro gi 3242120 emb CAA07315.1 trypsin [Dicentrarchus labrax] gi 33307059 gb AAQ02897.1 serine protease KN2 precursor [T	172 172 172 171 171 171 171 171 170	1e-41 G 1e-41 1e-41 2e-41 2e-41 2e-41 3e-41
gi 13959619 sp O13061 VSPB TRIGA Venom serine proteinase 2B gi 49258366 pdb 10P0 A Chain A, Crystal Structure Of Aav-Sp gi 31322299 gb AAP20638.1 thrombin-like enzyme defibrase [gi 33307068 gb AAQ02900.1 serine protease KN11 precursor [gi 3668352 gb AAC61838.1 salmobin [Gloydius halys] gi 211031 gb AAA48553.1 batroxobin gi 223879 prf 1003216A tonin	170 170 170 170 170 170 170 170	3e-41 3e-41 4e-41 4e-41 4e-41 4e-41 4e-41
gi 14646873 gb AAK71702.1 ARM1 [Homo sapiens] gi 28461159 ref NP 786935.1 kallikrein, submaxillary gland gi 57037477 ref XP 541466.1 PREDICTED: similar to kallikre gi 33307080 gb AAQ02904.1 serine protease CL5 precursor [T gi 33307050 gb AAQ02894.1 serine protease KN1 precursor [T	169 169 169 169 169	5e-41 G 5e-41 G 5e-41 G 6e-41 8e-41
gi 54650274 dbj BAD66927.1 hypothetical protein [Bothropsgi 14646869 gb AAK71700.1 ARM1 [Homo sapiens]gi 33307062 gb AAQ02898.1 serine protease CL1 precursor [Tgi 22417221 gb AAM96700.1 serine beta-fibrinogenase precurgi 6562944 emb CAB62591.1 serine proteinase, homolog [Macrgi 33307056 gb AAQ02896.1 serine protease KN9 precursor [Tgi 13959620 sp 013062 VSPC TRIGA Venom serine proteinase 2C	169 168 167 167 167 167	8e-41 1e-40 G 1e-40 2e-40 2e-40 2e-40 2e-40
gi 6754460 ref NP 034774.1 kallikrein 26 [Mus musculus] >g gi 2624768 pdb 1AO5 B Chain B, Mouse Glandular Kallikrein-1 gi 13959621 sp O13063 VSP3 TRIGA Venom serine proteinase 3 gi 20069139 gb AAM09695.1 serine proteinase precursor [Bot gi 33307071 gb AAQ02901.1 serine protease CL3 precursor [T gi 18652951 gb AAL77226.1 serine protease catroxase I prec	167 167 167 166 166 166	2e-40 G 2e-40 3e-40 4e-40 4e-40 5e-40

gi 8567983 gb AAF76377.1 thrombin-like protein acutobin prgi 885976 gb AAC59686.1 venom plasminogen activator precurgi 17933276 gb AAL48222.1 thrombin-like enzyme ussurase [Ggi 6093643 sp P81824 VSP1 BOTJA Platelet-aggregating protei	166 166 166 166	5e-40 7e-40 7e-40 7e-40
gi 35505509 gb AAH57807.1 Complement factor D, preproprote gi 41055921 ref NP 956439.1 similar to adrenal secretory s gi 17933274 gb AAL48221.1 thrombin-like enzyme ussurin [Gl gi 8567987 gb AAF76379.1 thrombin-like protein DAV-KN prec gi 57791760 gb AAW56633.1 thrombin-like enzyme 2 [Deinagki gi 479945 pir S35689 venombin A (EC 3.4.21.74) [validated] gi 13959617 sp 013059 VSP1 TRIGA Venom serine proteinase 1	165 165 165 165 165 164 164	9e-40 G 1e-39 1e-39 1e-39 2e-39 2e-39
gi 3915626 sp P00746 CFAD HUMAN Complement factor D precurs gi 33307098 gb AAQ02910.1 serine protease PA precursor [Tr gi 33307065 gb AAQ02899.1 serine protease KN10 precursor [gi 34784418 gb AAH57674.1 Tmprss6 protein [Mus musculus]	164 164 164 164	2e-39 G 2e-39 2e-39 3e-39 G 3e-39 G
gi 34856170 ref XP 218564.2 similar to kallikrein 5 prepro gi 31980537 gb AAP69827.1 matriptase-2 [Mus musculus] >gi gi 13095440 gb AAK12273.1 thrombin-like enzyme precursor [gi 54038701 gb AAH84389.1 LOC495174 protein [Xenopus laevis] gi 13959615 sp 013057 VSP2 TRIFL Venom serine proteinase 2	164 163 163 163	3e-39 G 3e-39 G 3e-39 G 3e-39 G 3e-39
gi 2134238 pir S65621 venombin AB (EC 3.4.21.55) [validate gi 627292 pir A54361 venombin A (EC 3.4.21.74) [validated] gi 7705572 ref NP 032483.1 kallikrein 8 [Mus musculus] >gi gi 24266799 gb AAN52349.1 stejnefibrase 2 [Trimeresurus st	163 163 163 163	5e-39 5e-39 5e-39 G
gi 55249559 gb AAH40146.1 DF protein [Homo sapiens] gi 33637115 gb AAQ23714.1 glandular kallikrein precursor [gi 56789422 gb AAH88038.1 LOC496767 protein [Xenopus tropi gi 30048431 gb AAH51001.1 DF protein [Homo sapiens]	163 163 163	5e-39 G 5e-39 G 5e-39 G 5e-39 G
gi 21961485 gb AAH34529.1 DF protein [Homo sapiens] >gi 67 gi 5360907 emb CAB46431.1 acubin [Deinagkistrodon acutus] gi 14646871 gb AAK71701.1 ARM1 [Homo sapiens] gi 33307074 gb AAQ02902.1 serine protease KN3 precursor [T gi 228276 prf 1802275A pro-renin-converting enzyme	163 162 162 162 162	6e-39 G 6e-39 G 6e-39 6e-39
gi 49168634 emb CAG38812.1 DF [Homo sapiens] gi 27229129 ref NP 082178.1 type II transmembrane serine p gi 18652953 gb AAL77227.1 serine protease catroxase II pre gi 33307104 gb AAQ02912.1 serine protease KN8 precursor [T gi 9988779 gb AAG10788.1 serine proteinase 1 precursor [Tr	162 162 162 162 162	8e-39 G 8e-39 G 8e-39 8e-39
gi 5822045 pdb 1DIC A Chain A, Structure Of 3,4-Dichloroiso gi 31322297 gb AAP20637.1 thrombin-like enzyme defibrase [gi 54650276 dbj BAD66928.1 hypothetical protein [Bothrops gi 32469800 sp P82981 VSP2 AGKCO Contortrixobin gi 673431 emb CAA28379.1 precursor adipsin [Mus musculus]	162 162 161 161	8e-39 S 1e-38 1e-38 1e-38 G
gi 7304867 ref NP 038487.1 adipsin [Mus musculus] >gi 6758 gi 13959616 sp 013058 VSP3 TRIFL Venom serine proteinase 3 gi 67580 pir DBHU complement factor D (EC 3.4.21.46) precu gi 915533 gb AAA73627.1 putative preproadipsin [Sus scrofa gi 47197455 emb CAF93307.1 unnamed protein product [Tetrao	161 161 160 160 160	2e-38 2e-38 2e-38 2e-38 2e-38
gi 21618854 gb AAH31798.1 Kallikrein 8 [Mus musculus]gi 54650278 dbj BAD66929.1 hypothetical protein [Bothropsgi 22417112 gb AAM96674.1 serine alpha-fibrinogenase precugi 9581530 emb CAC00530.1 acubin2 [Deinagkistrodon acutus]gi 1334162 emb CAA35231.1 kallikrein [Mastomys natalensis]	160 160 160 160 159	3e-38 G 3e-38 4e-38 4e-38 5e-38

gi 7019443 ref NP 032480.1 kallikrein 16 [Mus musculus] >g	<u>159</u>	5e-38 G
gi 50796084 ref XP 423832.1 PREDICTED: similar to MGC69002	159	5e-38 G
gi 38570060 gb AAR24534.1 serine protease 1 [Bitis gabonica]	159	7e-38
gi 57791683 gb AAW56609.1 thrombin-like protein 3 [Deinagk	<u>159</u>	7e-38
gi 178626 gb AAA35527.1 adipsin/complement factor D	15.8	1e-37 G
gi 8567989 gb AAF76380.1 thrombin-like protein precursor [<u>158</u>	1e-37
gi 39794386 gb AAH64208.1 Hypothetical protein MGC76105 [X	<u>158</u>	1e-37 G
gi 5821882 pdb 1BQY B Chain B, Plasminogen Activator (Tsv-P	158	1e-37 S
<u>gi 45383251 ref NP 989788.1 </u> granzyme A [Gallus gallus] >gi	<u> 157</u>	2e-37 G
gi 50746751 ref XP 420637.1 PREDICTED: similar to neurotry	<u>157</u>	2e-37 G
gi 480383 pir S36783 venombin A (EC 3.4.21.74) 2 precursor	<u>157</u>	2e-37
gi 57869385 gb AAW57544.1 neurotrypsin [Saguinus labiatus]	<u>157</u>	2e-37 .
gi 15042973 gb AAK52506.2 venom thrombin-like enzyme [Dein	<u>157</u>	3e-37
gi 52354657 gb AAH82912.1 LOC494791 protein [Xenopus laevis]	157	3e-37 G
gi 57791681 gb AAW56608.1 thrombin-like protein 1 [Deinagk	157	3e-37
gi 37181921 gb AAQ88764.1 PVAE354 [Homo sapiens]	156	4e-37 G
gi 13959622 sp O13069 VSP2 BOTJA Kinin-releasing and fibrin	156	6e-37
gi 57092775 ref XP 531743.1 PREDICTED: similar to transmem	155	7e-37 G
gi 33307083 gb AAQ02905.1 serine protease CL2 precursor [T	155	9e-37
gi 24158620 pdb 1GVZ A Chain A, Prostate Specific Antigen (155	9e-37 🙎
gi 23428417 gb AAL16414.1 type II transmembrane serine pro	155	1e-36 G
gi 56417706 emb CAI19335.1 OTTHUMP00000028798 [Homo sapiens]	<u>155</u>	1e-36 G
gi 23477115 emb CAC85953.1 matriptase-2 [Homo sapiens]	155	1e-36 G
gi 57869340 gb AAW57541.1 neurotrypsin [Hylobates leucogenys]	154	2e-36
gi 57869310 gb AAW57539.1 neurotrypsin [Gorilla gorilla]	154	2e-36
gi 47228305 emb CAG07700.1 unnamed protein product [Tetrao	154	2e-36
gi 56693556 gb AAW22597.1 neurotrypsin [Hylobates hoolock]	154	2e-36
gi 47229070 emb CAG03822.1 unnamed protein product [Tetrao	<u>154</u>	2e-36

Alignments

```
....Get selected sequences
                           Select all
                                     __Deselect all___
G neurosin [Mus musculus]
gi|14141579|dbj|BAB55605.1|
         Length = 253
Score = 544 bits (1401), Expect = e-154
 Identities = 253/253 (100%), Positives = 253/253 (100%)
Query: 1
          MPMKMLTMKMLALCLVLAKSAWSEEQEKVVHGGPCLKDSHPFQAALYTSGHLLCGGVLID 60
          MPMKMLTMKMLALCLVLAKSAWSEEQEKVVHGGPCLKDSHPFQAALYTSGHLLCGGVLID
Sbjct: 1
          MPMKMLTMKMLALCLVLAKSAWSEEQEKVVHGGPCLKDSHPFQAALYTSGHLLCGGVLID 60
Query: 61 PQWVLTAAHCKKPNLQVILGKHNLRQTETFQRQISVDRTIVHPRYNPETHDNDIMMVHLK 120
          PQWVLTAAHCKKPNLQVILGKHNLRQTETFQRQISVDRTIVHPRYNPETHDNDIMMVHLK
Sbjct: 61 PQWVLTAAHCKKPNLQVILGKHNLRQTETFQRQISVDRTIVHPRYNPETHDNDIMMVHLK 120
Query: 121 NPVKFSKKIQPLPLKNDCSEENPNCQILGWGKMENGDFPDTIQCADVHLVPREQCERAYP 180
          NPVKFSKKIQPLPLKNDCSEENPNCQILGWGKMENGDFPDTIQCADVHLVPREQCERAYP
Sbjct: 121 NPVKFSKKIQPLPLKNDCSEENPNCQILGWGKMENGDFPDTIQCADVHLVPREQCERAYP 180
```

MID_1110217140-2770401-1047747141031DTU016161 Query: 181 GKITQSMVCAGDMKEGNDSCQGDSGGPLVCGGRLRGLVSWGDMPCGSKEKPGVYTDVCTH 240 GKITQSMVCAGDMKEGNDSCQGDSGGPLVCGGRLRGLVSWGDMPCGSKEKPGVYTDVCTH Sbjet: 181 GKITQSMVCAGDMKEGNDSCQGDSGGPLVCGGRLRGLVSWGDMPCGSKEKPGVYTDVCTH 240 Query: 241 IRWIQNILRNKWL 253 IRWIQNILRNKWL Sbjct: 241 IRWIQNILRNKWL 253 >gi|6755180|ref|NP 035307.1|
G protease, serine, 18 [Mus musculus] gi|3241912|dbj|BAA28895.1| G serine protease (BSP) [Mus musculus] Length = 246Score = 530 bits (1365), Expect = e-149Identities = 246/246 (100%), Positives = 246/246 (100%) Query: 8 MKMLALCLVLAKSAWSEEQEKVVHGGPCLKDSHPFQAALYTSGHLLCGGVLIDPOWVLTA 67 MKMLALCLVLAKSAWSEEQEKVVHGGPCLKDSHPFQAALYTSGHLLCGGVLIDPQWVLTA ${\tt MKMLALCLVLAKSAWSEEQEKVVHGGPCLKDSHPFQAALYTSGHLLCGGVLIDPQWVLTA~60}$ Sbjct: 1 Query: 68 AHCKKPNLQVILGKHNLRQTETFQRQISVDRTIVHPRYNPETHDNDIMMVHLKNPVKFSK 127 AHCKKPNLQVILGKHNLRQTETFQRQISVDRTIVHPRYNPETHDNDIMMVHLKNPVKFSK Sbjct: 61 AHCKKPNLQVILGKHNLRQTETFQRQISVDRTIVHPRYNPETHDNDIMMVHLKNPVKFSK 120 Query: 128 KIQPLPLKNDCSEENPNCQILGWGKMENGDFPDTIQCADVHLVPREQCERAYPGKITQSM 187 KIQPLPLKNDCSEENPNCQILGWGKMENGDFPDTIQCADVHLVPREQCERAYPGKITOSM Sbjct: 121 KIQPLPLKNDCSEENPNCQILGWGKMENGDFPDTIQCADVHLVPREQCERAYPGKITQSM 180

SDJCT: 121 KIQPLPLKNDCSEENPNCQILGWGKMENGDFPDTIQCADVHLVPREQCERAYPGKITQSM 180

Query: 188 VCAGDMKEGNDSCQGDSGGPLVCGGRLRGLVSWGDMPCGSKEKPGVYTDVCTHIRWIQNI 247 VCAGDMKEGNDSCQGDSGGPLVCGGRLRGLVSWGDMPCGSKEKPGVYTDVCTHIRWIQNI Sbjct: 181 VCAGDMKEGNDSCQGDSGGPLVCGGRLRGLVSWGDMPCGSKEKPGVYTDVCTHIRWIQNI 240

Query: 248 LRNKWL 253 LRNKWL Sbict: 241 LRNKWL 246

Sbjct: 241 LRNKWL 246

Score = 492 bits (1266), Expect = e-138 Identities = 223/251 (88%), Positives = 241/251 (96%)

Query: 1 MPMKMLTMKMLALCLVLAKSAWSEEQEKVVHGGPCLKDSHPFQAALYTSGHLLCGGVLID 60 MP KMLT+K LALCL+LAKSAWSE+Q+KVVHGGPCLK+SHPFQAALYTSGHLLCGGVL+ Sbjct: 1 MPTKMLTVKTLALCLILAKSAWSEDQDKVVHGGPCLKNSHPFQAALYTSGHLLCGGVLVG 60

Query: 61 PQWVLTAAHCKKPNLQVILGKHNLRQTETFQRQISVDRTIVHPRYNPETHDNDIMMVHLK 120 PQWVLTAAHCKKPNL+V LGKHNLRQTETFQRQISVDRTIVHPRYNP+THDNDIMMVHLK

Sbjct: 61 PQWVLTAAHCKKPNLEVYLGKHNLRQTETFQRQISVDRTIVHPRYNPQTHDNDIMMVHLK 120

Query: 121 NPVKFSKKIQPLPLKNDCSEENPNCQILGWGKMENGDFPDTIQCADVHLVPREQCERAYP 180 PVKFS++IQPLPLK DCSE+NP+CQILGWGKMENG+FPDTIQCADV LV RE+CERAYP

```
Sbjct: 121 RPVKFSQRIQPLPLKKDCSEKNPDCQILGWGKMENGEFPDTIQCADVQLVSREECERAYP 180
Ouery: 181 GKITQSMVCAGDMKEGNDSCQGDSGGPLVCGGRLRGLVSWGDMPCGSKEKPGVYTDVCTH 240
           GKIT+SMVCAGD +EGNDSCQGDSGGPLVCGG LRG+VSWGDMPCGSKEKPGVYTDVCTH
Sbjct: 181 GKITRSMVCAGDKREGNDSCQGDSGGPLVCGGHLRGIVSWGDMPCGSKEKPGVYTDVCTH 240
Query: 241 IRWIQNILRNK 251
           IRWIQNI+RNK
Sbjct: 241 IRWIQNIIRNK 251
pqi|57036286|ref|XP 533605.1| G PREDICTED: similar to Kallikrein 6 precursor (Prote
           (Neurosin) (Zyme) (SP59) [Canis familiaris]
          Length = 528
 Score = 367 bits (943), Expect = e-100
 Identities = 167/238 (70%), Positives = 194/238 (81%)
Query: 12 ALCLVLAKSAWSEEQEKVVHGGPCLKDSHPFQAALYTSGHLLCGGVLIDPQWVLTAAHCK 71
              L SAW+EEQ KV+HGGPC + SHP+QAALYTSGHLLCGGVLI P WVLTAAHCK
Sbjct: 289 SLTQTLPFSAWAEEQNKVLHGGPCEQTSHPYQAALYTSGHLLCGGVLIHPLWVLTAAHCK 348
Query: 72 KPNLQVILGKHNLRQTETFQRQISVDRTIVHPRYNPETHDNDIMMVHLKNPVKFSKKIQP 131
           KPNLQV LGKHNL+Q E+FQ Q SV R + HP YN THD DIM++ L P KFS++IQP
Sbjct: 349 KPNLQVYLGKHNLQQRESFQEQSSVVRAVAHPGYNAATHDQDIMLLRLARPAKFSERIQP 408
Query: 132 LPLKNDCSEENPNCQILGWGKMENGDFPDTIQCADVHLVPREQCERAYPGKITQSMVCAG 191
           L L+ DCS + +C ILGWGK +GDFP+TIQCA +HLVPRE+CERAYP +ITQ+MVCAG
Sbjct: 409 LSLEQDCSANHSSCHILGWGKTADGDFPNTIQCAYIHLVPREECERAYPSQITQNMVCAG 468
Query: 192 DMKEGNDSCQGDSGGPLVCGGRLRGLVSWGDMPCGSKEKPGVYTDVCTHIRWIQNILR 249
           D K G DSCOGDSGGPLVCG RLRGLVSWG++PCGSKEKPGVYTDVC + WI+
Sbjct: 469 DEKYGKDSCQGDSGGPLVCGDRLRGLVSWGNVPCGSKEKPGVYTDVCRYGHWIRKTIQ 526
 Score = 192 bits (489), Expect = 5e-48
 Identities = 89/214 (41%), Positives = 123/214 (57%), Gaps = 4/214 (1%)
Query: 27 EKVVHGGPCLKDSHPFQAALYTSGHLLCGGVLIDPQWVLTAAHCKKPNLQVILGKHNLRQ 86
           EK++ G PC + SHP+Q AL
                                   L CGGVL++ QWVLTAAHC
Sbjct: 13 EKIIEGVPCTRGSHPWQVALLKGTQLHCGGVLLNEQWVLTAAHCMMSEYNVHMGSDQLSD 72
Query: 87 TETFQRQISVDRTIVHPRYNPETHDNDIMMVHLKNPVKFSKKIQPLPLKNDCSEENPNCQ 146
                      R+ HP Y+ +TH ND+M+V L
                                               + S +++ + L + C
Sbjct: 73 KRA--QKIRATRSFRHPGYSTQTHVNDLMLVKLSKQARLSSRVKKVNLPSRCEPPGTTCT 130
Query: 147 ILGWGKMENGD--FPDTIQCADVHLVPREQCERAYPGKITOSMVCAGDMKEGNDSCOGDS 204
                   + D FP + C DV L+ + C++ Y
                                                + +SM+CAG
Sbjct: 131 VSGWGTTTSPDVTFPSKLMCTDVKLISSQDCKKVYKDLLGKSMLCAGIPNSKTNACNGDS 190
Query: 205 GGPLVCGGRLRGLVSWGDMPCGSKEKPGVYTDVC 238
           GGPL+C G L+GLVSWG PCG
                                    PGVYT VC
Sbjct: 191 GGPLMCKGALQGLVSWGTFPCGQPNDPGVYTQVC 224
```

[>qi | 15930186 | gb | AAH15525.1 | G KLK6 protein [Homo sapiens]

```
gi 30582543 gb AAP35498.1 G kallikrein 6 (neurosin, zyme) [Homo sapiens]
sapiens]
gi 32448678 gb AAP82448.1 G kallikrein 6 precursor [Homo sapiens]
gi|32448674|gb|AAP82446.1| G kallikrein 6 precursor [Homo sapiens]
gi|2318115|gb|AAB66483.1| G serine protease [Homo sapiens]
gi|3914480|sp|Q92876|KLK6 HUMAN G Kallikrein 6 precursor (Protease M) (Neurosin) (Zy
gi|1805493|dbi|BAA11306.1|
                         G neurosin [Homo sapiens]
        Length = 244
 Score = 366 bits (940), Expect = e-100
 Identities = 167/244 (68%), Positives = 194/244 (79%)
         MKMLALCLVLAKSAWSEEQEKVVHGGPCLKDSHPFQAALYTSGHLLCGGVLIDPQWVLTA 67
Query: 8
         MK L + L L +AW+EEQ K+VHGGPC K SHP+QAALYTSGHLLCGGVLI P WVLTA
Sbjct: 1
         MKKLMVVLSLIAAAWAEEQNKLVHGGPCDKTSHPYQAALYTSGHLLCGGVLIHPLWVLTA 60
Query: 68 AHCKKPNLQVILGKHNLRQTETFQRQISVDRTIVHPRYNPETHDNDIMMVHLKNPVKFSK 127
         AHCKKPNLQV LGKHNLRQ E+ Q Q SV R ++HP Y+ +HD DIM++ L P K S+
Sbjct: 61 AHCKKPNLQVFLGKHNLRQRESSQEQSSVVRAVIHPDYDAASHDQDIMLLRLARPAKLSE 120
Query: 128 KIQPLPLKNDCSEENPNCQILGWGKMENGDFPDTIQCADVHLVPREQCERAYPGKITQSM 187
          IQPLPL+ DCS +C ILGWGK +GDFPDTIQCA +HLV RE+CE AYPG+ITQ+M
Sbjct: 121 LIQPLPLERDCSANTTSCHILGWGKTADGDFPDTIQCAYIHLVSREECEHAYPGQITQNM 180
Query: 188 VCAGDMKEGNDSCQGDSGGPLVCGGRLRGLVSWGDMPCGSKEKPGVYTDVCTHIRWIONI 247
         +CAGD K G DSCQGDSGGPLVCG LRGLVSWG++PCGSKEKPGVYT+VC + WIO
Sbjct: 181 LCAGDEKYGKDSCQGDSGGPLVCGDHLRGLVSWGNIPCGSKEKPGVYTNVCRYTNWIQKT 240
Query: 248 LRNK 251
         ++ K
Sbjct: 241 IQAK 244
| >gi|30585043|gb|AAP36794.1| Homo sapiens kallikrein 6 (neurosin, zyme) [synthetic (
        Length = 245
Score = 366 bits (940), Expect = e-100
Identities = 167/244 (68%), Positives = 194/244 (79%)
Query: 8
         MKMLALCLVLAKSAWSEEQEKVVHGGPCLKDSHPFQAALYTSGHLLCGGVLIDPQWVLTA 67
         MK L + L L +AW+EEQ K+VHGGPC K SHP+QAALYTSGHLLCGGVLI P WVLTA
Sbjct: 1
         MKKLMVVLSLIAAAWAEEQNKLVHGGPCDKTSHPYQAALYTSGHLLCGGVLIHPLWVLTA 60
Query: 68 AHCKKPNLQVILGKHNLRQTETFQRQISVDRTIVHPRYNPETHDNDIMMVHLKNPVKFSK 127
         AHCKKPNLQV LGKHNLRQ E+ Q Q SV R ++HP Y+ +HD DIM++ L P K S+
Sbjct: 61 AHCKKPNLQVFLGKHNLRQRESSQEQSSVVRAVIHPDYDAASHDQDIMLLRLARPAKLSE 120
Query: 128 KIQPLPLKNDCSEENPNCQILGWGKMENGDFPDTIQCADVHLVPREQCERAYPGKITQSM 187
                      +C ILGWGK +GDFPDTIQCA +HLV RE+CE AYPG+ITQ+M
Sbjct: 121 LIQPLPLERDCSANTTSCHILGWGKTADGDFPDTIQCAYIHLVSREECEHAYPGQITQNM 180
```

Query: 188 VCAGDMKEGNDSCQGDSGGPLVCGGRLRGLVSWGDMPCGSKEKPGVYTDVCTHIRWIQNI 247

+CAGD K G DSCQGDSGGPLVCG LRGLVSWG++PCGSKEKPGVYT+VC + WIQ

Sbjct: 181 LCAGDEKYGKDSCQGDSGGPLVCGDHLRGLVSWGNIPCGSKEKPGVYTNVCRYTNWIQKT 240

Query: 248 LRNK 251

++ K

Sbjct: 241 IQAK 244

>gi | 55233182 | gb | AAV48554.1 | kallikrein 6 preproprotein [synthetic construct]

Length = 283

Score = 366 bits (940), Expect = e-100
Identities = 167/244 (68%), Positives = 194/244 (79%)

Query: 8 MKMLALCLVLAKSAWSEEQEKVVHGGPCLKDSHPFQAALYTSGHLLCGGVLIDPQWVLTA 67

MK L + L L +AW+EEQ K+VHGGPC K SHP+QAALYTSGHLLCGGVLI P WVLTA

Sbjct: 1 MKKLMVVLSLIAAAWAEEQNKLVHGGPCDKTSHPYQAALYTSGHLLCGGVLIHPLWVLTA 60

Query: 68 AHCKKPNLQVILGKHNLRQTETFQRQISVDRTIVHPRYNPETHDNDIMMVHLKNPVKFSK 127

AHCKKPNLQV LGKHNLRQ E+ Q Q SV R ++HP Y+ +HD DIM++ L P K S+

Sbjct: 61 AHCKKPNLQVFLGKHNLRQRESSQEQSSVVRAVIHPDYDAASHDQDIMLLRLARPAKLSE 120

Query: 128 KIQPLPLKNDCSEENPNCQILGWGKMENGDFPDTIQCADVHLVPREQCERAYPGKITQSM 187

IQPLPL+ DCS +C ILGWGK +GDFPDTIQCA +HLV RE+CE AYPG+ITQ+M

Sbjct: 121 LIQPLPLERDCSANTTSCHILGWGKTADGDFPDTIQCAYIHLVSREECEHAYPGQITQNM 180

Query: 188 VCAGDMKEGNDSCQGDSGGPLVCGGRLRGLVSWGDMPCGSKEKPGVYTDVCTHIRWIQNI 247

+CAGD K G DSCQGDSGGPLVCG LRGLVSWG++PCGSKEKPGVYT+VC + WIQ

Sbjct: 181 LCAGDEKYGKDSCQGDSGGPLVCGDHLRGLVSWGNIPCGSKEKPGVYTNVCRYTNWIQKT 240

Query: 248 LRNK 251

++ K

Sbjct: 241 IQAK 244

>gi 21465525 pdb 1GVL A Chain A, Human Prokallikrein 6 (Hk6) PROZYME PROPROTEASE
Proneurosin
Length = 223

Score = 347 bits (891), Expect = 1e-94
Identities = 156/222 (70%), Positives = 181/222 (81%)

Query: 28 KVVHGGPCLKDSHPFQAALYTSGHLLCGGVLIDPQWVLTAAHCKKPNLQVILGKHNLRQT 87 K+VHGGPC K SHP+QAALYTSGHLLCGGVLI P WVLTAAHCKKPNLQV LGKHNLRQ

Sbjct: 1 KLVHGGPCDKTSHPYQAALYTSGHLLCGGVLIHPLWVLTAAHCKKPNLQVFLGKHNLRQQ 60

Query: 88 ETFQRQISVDRTIVHPRYNPETHDNDIMMVHLKNPVKFSKKIQPLPLKNDCSEENPNCQI 147 E+ Q Q SV R ++HP Y+ +HD DIM++ L P K S+ IQPLPL+ DCS + +C I

Sbjct: 61 ESSQEQSSVVRAVIHPDYDAASHDQDIMLLRLARPAKLSELIQPLPLERDCSAQTTSCHI 120

Query: 148 LGWGKMENGDFPDTIQCADVHLVPREQCERAYPGKITQSMVCAGDMKEGNDSCQGDSGGP 207

LGWGK +GDFPDTIQCA +HLV RE+CE AYPG+ITQ+M+CAGD K G DSCQGDSGGP

Sbjct: 121 LGWGKTADGDFPDTIQCAYIHLVSREECEHAYPGQITQNMLCAGDEKYGKDSCQGDSGGP 180

Query: 208 LVCGGRLRGLVSWGDMPCGSKEKPGVYTDVCTHIRWIQNILR 249 LVCG LRGLVSWG++PCGSKEKPGVYT+VC + WIQ ++ Sbjct: 181 LVCGDHLRGLVSWGNIPCGSKEKPGVYTNVCRYTNWIQKTIQ 222

```
sqi|21466131|pdb|1L06|A S Chain A, Human Kallikrein 6 (Hk6) Active Form With Benzar
         Inhibitor At 1.56 A Resolution
Inhibitor
        Length = 223
Score = 346 bits (887), Expect = 4e-94
Identities = 156/223 (69%), Positives = 180/223 (80%)
Query: 29 VVHGGPCLKDSHPFQAALYTSGHLLCGGVLIDPQWVLTAAHCKKPNLQVILGKHNLRQTE 88
         +VHGGPC K SHP+QAALYTSGHLLCGGVLI P WVLTAAHCKKPNLQV LGKHNLRQ E
        LVHGGPCDKTSHPYQAALYTSGHLLCGGVLIHPLWVLTAAHCKKPNLQVFLGKHNLRQRE 60
Sbjct: 1
Query: 89 TFQRQISVDRTIVHPRYNPETHDNDIMMVHLKNPVKFSKKIQPLPLKNDCSEENPNCOIL 148
         + Q Q SV R ++HP Y+ +HD DIM++ L P K S+ IQPLPL+ DCS
Sbjct: 61 SSQEQSSVVRAVIHPDYDAASHDQDIMLLRLARPAKLSELIQPLPLERDCSANTTSCHIL 120
Query: 149 GWGKMENGDFPDTIQCADVHLVPREQCERAYPGKITQSMVCAGDMKEGNDSCQGDSGGPL 208
         GWGK +GDFPDTIQCA +HLV RE+CE AYPG+ITQ+M+CAGD K G DSCQGDSGGPL
Sbjct: 121 GWGKTADGDFPDTIQCAYIHLVSREECEHAYPGQITQNMLCAGDEKYGKDSCOGDSGGPL 180
Query: 209 VCGGRLRGLVSWGDMPCGSKEKPGVYTDVCTHIRWIQNILRNK 251
         VCG LRGLVSWG++PCGSKEKPGVYT+VC + WIO ++ K
Sbjct: 181 VCGDHLRGLVSWGNIPCGSKEKPGVYTNVCRYTNWIQKTIQAK 223
gi|6005844|ref|NP 009127.1|  G kallikrein 8 isoform 1 preproprotein [Homo sapiens]
gi|3176387|dbj|BAA28673.1| G neuropsin [Homo sapiens]
gi | 5918518 | gb | AAD56050.1 |
                       serine protease TADG14 [Homo sapiens]
gi | 4588082 | gb | AAD25979.1 | G serine protease ovasin [Homo sapiens]
TADG-14) (Tumor-associated differentially expressed
         gene-14 protein) (UNQ283/PRO322)
gi | 5672473 | dbj | BAA82665.1 | G neuropsin type1 [Homo sapiens]
        Length = 260
Score = 241 bits (614), Expect = 2e-62
Identities = 112/246 (45%), Positives = 164/246 (66%), Gaps = 10/246 (4%)
Query: 15 LVLAKSAWS----EEQEKVVHGGPCLKDSHPFQAALYTSGHLLCGGVLIDPOWVLTAAHC 70
                    +++KV+ G C
                                S P+QAAL+
                                           LLCGGVL+
Sbjct: 15 LLLLGGAWAGHSRAQEDKVLGGHECQPHSQPWQAALFQGQQLLCGGVLVGGNWVLTAAHC 74
Query: 71 KKPNLQVILGKHNLRQTETFQRQISVDRTIVHPRYNP---ETHDNDIMMVHLKNPVKFSK 127
             V LG H+L+ + +++1 V ++1 HP YN
                                          E H++D+M++ L++
Sbjct: 75 KKPKYTVRLGDHSLQNKDGPEQEIPVVQSIPHPCYNSSDVEDHNHDLMLLQLRDQASLGS 134
Query: 128 KIQPLPLKNDCSEENPNCQILGWGKMENG--DFPDTIQCADVHLVPREQCERAYPGKITQ 185
```

```
Sbjct: 135 KVKPISLADHCTQPGQKCTVSGWGTVTSPRENFPDTLNCAEVKIFPQKKCEDAYPGQITD 194
Query: 186 SMVCAGDMKEGNDSCQGDSGGPLVCGGRLRGLVSWGDMPCGSKEKPGVYTDVCTHIRWIQ 245
           MVCAG K G D+CQGDSGGPLVC G L+G+ SWG PCG +KPGVYT++C ++ WI+
Sbjct: 195 GMVCAGSSK-GADTCQGDSGGPLVCDGALQGITSWGSDPCGRSDKPGVYTNICRYLDWIK 253
Query: 246 NILRNK 251
           I + +K
Sbjct: 254 KIIGSK 259
Sqi|55649729|ref|XP 512847.1| G PREDICTED: similar to kallikrein 8 isoform 1 prepro
          protease, serine, 19; neuropsin; ovasin;
          tumor-associated differentially expressed gene 14 [Pan
          troglodytes]
         Length = 505
 Score = 241 bits (614), Expect = 2e-62
 Identities = 112/246 (45%), Positives = 164/246 (66%), Gaps = 10/246 (4%)
Query: 15 LVLAKSAWS----EEQEKVVHGGPCLKDSHPFQAALYTSGHLLCGGVLIDPQWVLTAAHC 70
          L+L
                AW+
                        +++KV+ G C S P+QAAL+
                                                   LLCGGVL+
Sbjct: 260 LLLLGGAWAGHSRAQEDKVLGGHECQPHSQPWQAALFQGQQLLCGGVLVGGNWVLTAAHC 319
Query: 71 KKPNLQVILGKHNLRQTETFQRQISVDRTIVHPRYNP---ETHDNDIMMVHLKNPVKFSK 127
          KKP V LG H+L+ + +++I V ++I HP YN E H++D+M++ L++
Sbjct: 320 KKPKYTVRLGDHSLQNKDGPEQEIPVVQSIPHPCYNSSDVEDHNHDLMLLQLRDQASLGS 379
Query: 128 KIQPLPLKNDCSEENPNCQILGWGKMENG--DFPDTIQCADVHLVPREQCERAYPGKITQ 185
          K++P+L+C++ C + GWG + + +FPDT+ CA+V + P+++CE AYPG+IT
Sbjct: 380 KVKPISLADHCTQPGQKCTVSGWGTVTSPRENFPDTLNCAEVKIFPQKKCEDAYPGQITD 439
Query: 186 SMVCAGDMKEGNDSCQGDSGGPLVCGGRLRGLVSWGDMPCGSKEKPGVYTDVCTHIRWIQ 245
           MVCAG K G D+CQGDSGGPLVC G L+G+ SWG PCG +KPGVYT++C ++ WI+
Sbjct: 440 GMVCAGSSK-GADTCQGDSGGPLVCDGALQGITSWGSDPCGRSDKPGVYTNICRYLDWIK 498
Query: 246 NILRNK 251
           I + +K
Sbjct: 499 KIIGSK 504
 Score = 49.3 bits (116), Expect = 1e-04
 Identities = 20/39 (51%), Positives = 26/39 (66%)
Query: 35 CLKDSHPFQAALYTSGHLLCGGVLIDPQWVLTAAHCKKP 73
          C +S P+QA L+ L CG LI +W+LTAAHC+KP
Sbjct: 113 CRPNSQPWQAGLFHLTRLFCGATLISDRWLLTAAHCRKP 151
 Score = 44.3 bits (103), Expect = 0.003
 Identities = 19/62 (30%), Positives = 33/62 (53%), Gaps = 8/62 (12%)
Query: 98 RTIVHPRYNP-----ETHDNDIMMVHLKNPVKFSKKIQPLPLKNDCSEENPNCQILG 149
          R++VHP+Y+
                            T ++D+M++L PV ++LL
                                                         C++
Sbjct: 31 RSVVHPKYHQGSGPILPRRTDEHDLMLLKLARPVVLGPRARALQLPYRCAQPGDQCQVAG 90
Query: 150 WG 151
```

WG Sbjct: 91 WG 92

```
| >gi|26454807|gb|AAH40887.1| | G | Kallikrein 8, isoform 1 preproprotein [Homo sapiens]
         Length = 260
 Score = 240 \text{ bits } (612), \text{ Expect = } 3e-62
 Identities = 112/246 (45%), Positives = 164/246 (66%), Gaps = 10/246 (4%)
Query: 15 LVLAKSAWS----EEQEKVVHGGPCLKDSHPFQAALYTSGHLLCGGVLIDPQWVLTAAHC 70
                      +++KV+ G C
               AW+
                                   S P+QAAL+
                                               LLCGGVL+
         LLLLGGAWAGHSRAQEDKVLGGHECQPHSQPWQAALFQGQQLLCGGVLVGGNWVLTAAHC 74
Sbjct: 15
Query: 71 KKPNLQVILGKHNLRQTETFQRQISVDRTIVHPRYNP---ETHDNDIMMVHLKNPVKFSK 127
               V LG H+L+ + +++I V ++I HP YN
                                              E H++D+M++ L++
Sbjct: 75 KKPKYTVRLGDHSLQNKDGPEQEIPVVQSIPHPCYNSSDVEDHNHDLMLLQLRDQASLGS 134
Query: 128 KIQPLPLKNDCSEENPNCQILGWGKMENG--DFPDTIQCADVHLVPREQCERAYPGKITQ 185
          K++P+ L + C++ C + GWG + +
                                      +FPDT+ CA+V + P+++CE AYPG+IT
Sbjct: 135 KVKPISLADHCTQPGQKCTVSGWGTVTSPRENFPDTLNCAEVKIFPQKKCEDAYPGQITD 194
Query: 186 SMVCAGDMKEGNDSCQGDSGGPLVCGGRLRGLVSWGDMPCGSKEKPGVYTDVCTHIRWIQ 245
           MVCAG K G D+CQGDSGGPLVC G L+G+ SWG PCG +KPGVYT++C ++ WI+
Sbjct: 195 VMVCAGSSK-GADTCQGDSGGPLVCDGALQGITSWGSDPCGRSDKPGVYTNICRYLDWIK 253
Query: 246 NILRNK 251
           I + \cdot + K
Sbjct: 254 KIIGSK 259
| >qi|6679487|ref|NP 032966.1| | G protease, serine, 19 [Mus musculus]
 gi|33585579|gb|AAH55895.1| G Protease, serine, 19 [Mus musculus]
 gi 2137594 pir | 156559
                      neuropsin - mouse
 gi | 1582323 | prf | | 2118319A
                         neuropsin
         Length = 260
 Score = 239 bits (611), Expect = 4e-62
 Identities = 113/248 (45%), Positives = 159/248 (64%), Gaps = 10/248 (4%)
Query: 13 LCLVLAKSAWS----EEQEKVVHGGPCLKDSHPFQAALYTSGHLLCGGVLIDPQWVLTAA 68
                 AW+
                       + K++ G C+ S P+QAAL+
          + L+L
                                               L+CGGVL+ +WVLTAA
Sbjct: 13 ILLLLFMGAWAGLTRAQGSKILEGRECIPHSQPWQAALFQGERLICGGVLVGDRWVLTAA 72
Query: 69 HCKKPNLQVILGKHNLRQTETFQRQISVDRTIVHPRYN---PETHDNDIMMVHLKNPVKF 125
                 V LG H+L+ + +++1 V ++1 HP YN PE H +DIM++ L+N
          HCKK
Sbjct: 73 HCKKQKYSVRLGDHSLQSRDQPEQEIQVAQSIQHPCYNNSNPEDHSHDIMLIRLQNSANL 132
Query: 126 SKKIQPLPLKNDCSEENPNCQILGWGKMENG--DFPDTIQCADVHLVPREQCERAYPGKI 183
```

C I GWG + +

Sbjct: 133 GDKVKPVQLANLCPKVGQKCIISGWGTVTSPQENFPNTLNCAEVKIYSQNKCERAYPGKI 192

Query: 184 TQSMVCAGDMKEGNDSCQGDSGGPLVCGGRLRGLVSWGDMPCGSKEKPGVYTDVCTHIRW 243

+FP+T+ CA+V + + +CERAYPGKI

K++P+ L N C +

```
T+ MVCAG
                    G D+CQGDSGGPLVC G L+G+ SWG PCG EKPGVYT +C + W
Sbjct: 193 TEGMVCAGS-SNGADTCQGDSGGPLVCDGMLQGITSWGSDPCGKPEKPGVYTKICRYTTW 251
Query: 244 IQNILRNK 251
         Sbjct: 252 IKKTMDNR 259
Sqi|21464127|ref|NP 653088.1| G kallikrein 8 isoform 2 [Homo sapiens]
 gi|5672479|dbj|BAA82666.1| G neuropsin type2 [Homo sapiens]
 Score = 238 bits (608), Expect = 8e-62
 Identities = 108/232 (46%), Positives = 158/232 (68%), Gaps = 6/232 (2%)
Query: 25 EQEKVVHGGPCLKDSHPFQAALYTSGHLLCGGVLIDPQWVLTAAHCKKPNLQVILGKHNL 84
         +++KV+ G C S P+QAAL+
                                LLCGGVL+
                                          WVLTAAHCKKP
Sbjct: 74 QEDKVLGGHECQPHSQPWQAALFQGQQLLCGGVLVGGNWVLTAAHCKKPKYTVRLGDHSL 133
Query: 85 RQTETFQRQISVDRTIVHPRYNP---ETHDNDIMMVHLKNPVKFSKKIQPLPLKNDCSEE 141
         + + +++I V ++I HP YN
                                E H++D+M++ L++
Sbjct: 134 QNKDGPEQEIPVVQSIPHPCYNSSDVEDHNHDLMLLQLRDQASLGSKVKPISLADHCTQP 193
Query: 142 NPNCQILGWGKMENG--DFPDTIQCADVHLVPREQCERAYPGKITQSMVCAGDMKEGNDS 199
            C + GWG + +
                        +FPDT+ CA+V + P+++CE AYPG+IT MVCAG K G D+
Sbjct: 194 GQKCTVSGWGTVTSPRENFPDTLNCAEVKIFPQKKCEDAYPGQITDGMVCAGSSK-GADT 252
Query: 200 CQGDSGGPLVCGGRLRGLVSWGDMPCGSKEKPGVYTDVCTHIRWIQNILRNK 251
         CQGDSGGPLVC G L+G+ SWG PCG +KPGVYT++C ++ WI+ I+ +K
Sbjct: 253 CQGDSGGPLVCDGALQGITSWGSDPCGRSDKPGVYTNICRYLDWIKKIIGSK 304
gi | 10799399 | gb | AAG23260.1 | G Homo sapiens kallikrein-like protein 6
gi|12230294|sp|09P0G3|KLK14 HUMAN G Kallikrein 14 precursor (Kallikrein-like protein
        Length = 251
Score = 238 bits (606), Expect = 1e-61
Identities = 107/241 (44%), Positives = 156/241 (64%), Gaps = 4/241 (1%)
Query: 15 LVLAKSAWSEEQEKVVHGGPCLKDSHPFQAALYTSGH--LLCGGVLIDPQWVLTAAHCKK 72
                E++K++GC+SP+QAAL
                                           LCGG L+ QWV+TAAHC +
Sbjct: 11 LAIAMTQSQEDENKIIGGHTCTRSSQPWQAALLAGPRRRFLCGGALLSGQWVITAAHCGR 70
Query: 73 PNLQVILGKHNLRQTETFQRQISVDRTIVHPRYNPETHDNDIMMVHLKNPVKFSKKIOPL 132
         P LQV LGKHNLR+ E Q+ + V R + HP YN THDND+M++ L+ P + ++P+
Sbjct: 71 PILQVALGKHNLRRWEATQQVLRVVRQVTHPNYNSRTHDNDLMLLQLQQPARIGRAVRPI 130
Query: 133 PLKNDCSEENPNCQILGWGKMEN--GDFPDTIQCADVHLVPREQCERAYPGKITQSMVCA 190
          + C+ +C++ GWG + +
                               +P ++QC ++++ P E C++AYP IT MVCA
Sbjct: 131 EVTQACASPGTSCRVSGWGTISSPIARYPASLQCVNINISPDEVCQKAYPRTITPGMVCA 190
```

Query: 191 GDMKEGNDSCQGDSGGPLVCGGRLRGLVSWGDMPCGSKEKPGVYTDVCTHIRWIQNILRN 250 G + G DSCQGDSGGPLVC G+L+GLVSWG C PGVYT++C + WI+ +R+ Sbjct: 191 GVPQGGKDSCQGDSGGPLVCRGQLQGLVSWGMERCALPGYPGVYTNLCKYRSWIEETMRD 250 Query: 251 K 251 ' Sbjct: 251 K 251 Sqi | 50959826 | gb | AAH74905.1 | G Kallikrein 14, preproprotein [Homo sapiens] gi|50959637|gb|AAH74904.1| G Kallikrein 14, preproprotein [Homo sapiens] Length = 251

Score = 237 bits (605), Expect = 2e-61 Identities = 107/241 (44%), Positives = 156/241 (64%), Gaps = 4/241 (1%)

Query: 15 LVLAKSAWSEEQEKVVHGGPCLKDSHPFQAALYTSGH--LLCGGVLIDPQWVLTAAHCKK 72 E++ K++ G C + S P+QAAL LCGG L+ QWV+TAAHC + Sbjct: 11 LAIAMTRSQEDENKIIGGYTCTRSSQPWQAALLAGPRRRFLCGGALLSGQWVITAAHCGR 70

Ouery: 73 PNLQVILGKHNLRQTETFQRQISVDRTIVHPRYNPETHDNDIMMVHLKNPVKFSKKIQPL 132 P LQV LGKHNLR+ E Q+ + V R + HP YN THDND+M++ L+ P + ++P+

Sbjct: 71 PILQVALGKHNLRRWEATQQVLRVVRQVTHPNYNSRTHDNDLMLLQLQOPARIGRAVRPI 130

Query: 133 PLKNDCSEENPNCQILGWGKMEN--GDFPDTIQCADVHLVPREQCERAYPGKITQSMVCA 190 +C++ GWG + + +P ++QC ++++ P E C++AYP IT MVCA + . C+

Sbjct: 131 EVTQACASPGTSCRVSGWGTISSPIARYPASLQCVNINISPDEVCQKAYPRTITPGMVCA 190

Query: 191 GDMKEGNDSCQGDSGGPLVCGGRLRGLVSWGDMPCGSKEKPGVYTDVCTHIRWIQNILRN 250 G + G DSCQGDSGGPLVC G+L+GLVSWG C

PGVYT++C + WI+ +R+ Sbjct: 191 GVPQGGKDSCQGDSGGPLVCRGQLQGLVSWGMERCALPGYPGVYTNLCKYRSWIEETMRD 250

Query: 251 K 251 Sbjct: 251 K 251

Sgi|34856166|ref|XP 218643.2| G similar to glandular kallikrein KLK13 [Rattus norve Length = 277

Score = 235 bits (600), Expect = 7e-61 Identities = 110/226 (48%), Positives = 149/226 (65%), Gaps = 7/226 (3%)

Query: 32 GGPCLKDSHPFQAALYTSGHLLCGGVLIDPQWVLTAAHCKKPNLOVILGKHNLROTETFO 91 G CL S P+QAAL G LLCGGVL+ P+WVLTAAHC+K V LGKH L + E +

Sbjct: 41 GYTCLPHSQPWQAALLVRGRLLCGGVLVHPKWVLTAAHCRKDGYTVHLGKHALGRVENGE 100

Query: 92 RQISVDRTIVHPRYNPE----THDNDIMMVHLKNPVKFSKKIQPLPLK-NDCSEENPNCQ 146 + + V R+I HP Y HD+DIM++ LK+PV+ S ++ L L +DC

Sbjct: 101 QAMEVVRSIPHPEYQVSPTHLNHDHDIMLLELKSPVQLSNHVRTLQLSADDCLPTGTCCR 160

Query: 147 ILGWGKMENG--DFPDTIQCADVHLVPREQCERAYPGKITQSMVCAGDMKEGNDSCQGDS 204 ++P T+QCA++ L E+C + YPGKIT +M+CAG + G DSC+GDS

Sbjct: 161 VSGWGTTTSPQVNYPKTLQCANIELRSDEECRQVYPGKITANMLCAGTKEGGKDSCEGDS 220

Query: 205 GGPLVCGGRLRGLVSWGDMPCGSKEKPGVYTDVCTHIRWIONILRN 250 GGPL+C G+L G++SWGD PCG +PGVYT V ++RWIQ +RN

Sbjct: 221 GGPLICNGKLYGIISWGDFPCGQPNRPGVYTRVSKYLRWIQGTIRN 266

```
sgi 26891548 gb AAN78420.1 G glandular kallikrein KLK13 [Mus musculus]
         Length = 276
 Score = 235 bits (600), Expect = 7e-61
 Identities = 117/256 (45%), Positives = 161/256 (62%), Gaps = 19/256 (7%)
Query: 14 CLVLAKSAW-SEEQEKVVHGG-----PCLKDSHPFQAALYTSGHLLCGGVLIDP 61
          CL LA S S + K+++G
                                         CL S P+QAAL G LLCGGVL+ P
Sbjct: 10 CLTLALSEGISRDYPKILNGTNGTSGFLPGGYTCLPHSQPWQAALLIRGRLLCGGVLVHP 69
Query: 62 QWVLTAAHCKKPNLQVILGKHNLRQTETFQRQISVDRTIVHPRYNPE----THDNDIMMV 117
          +WVLTAAHC+K V LGKH L + E ++ + V R+I HP Y
Sbjct: 70 KWVLTAAHCRKDGYTVHLGKHALGRVENGEQAMEVVRSIPHPEYQVTPTHLNHDHDIMLL 129
Query: 118 HLKNPVKFSKKIQPLPLK-NDCSEENPNCQILGWGKMENG--DFPDTIQCADVHLVPREQ 174
           LK+PV+ S ++ L L +DC C++ GWG + ++P T+QCA++ L
Sbjct: 130 ELKSPVQLSSHVRTLKLSADDCLPTGTCCRVSGWGTTTSPQVNYPKTLQCANIELRSDEE 189
Query: 175 CERAYPGKITQSMVCAGDMKEGNDSCQGDSGGPLVCGGRLRGLVSWGDMPCGSKEKPGVY 234
          C + YPGKIT +M+CAG + G DSC+GDSGGPL+C G+L G++SWGD PCG
Sbjct: 190 CRQVYPGKITANMLCAGTKEGGKDSCEGDSGGPLICNGKLYGIISWGDFPCGQPNRPGVY 249
Query: 235 TDVCTHIRWIQNILRN 250
          T V ++RWI+ I+RN
Sbjct: 250 TRVSKYLRWIREIIRN 265
         Length = 246
```

Query: 205 GGPLVCGGRLRGLVSWGDMPCGSKEKPGVYTDVCTHIRWIQNILRN 250

Sbjct: 190 GGPLICNGKLYGIISWGDFPCGQPNRPGVYTRVSKYLRWIREIIRN 235

GGPL+C G+L G++SWGD PCG +PGVYT V ++RWI+ I+RN

```
>gi | 27731521 | ref | XP 218648.1 | Similar to Neuropsin precursor (NP) (Kallikrein 8)
protease 1) [Rattus norvegicus]
Length = 260
```

```
Score = 234 bits (597), Expect = 2e-60
Identities = 111/245 (45%), Positives = 155/245 (63%), Gaps = 10/245 (4%)
Query: 13 LCLVLAKSAWS----EEQEKVVHGGPCLKDSHPFQAALYTSGHLLCGGVLIDPQWVLTAA 68
          + L L
                                                    L+CGGVL+ +WVLTAA
                 AW+
                         + K++ G C
                                       S P+Q AL+
Sbjct: 13 ILLFLLMGAWAGLTRAQGSKILEGQECKPHSQPWQTALFQGERLVCGGVLVGDRWVLTAA 72
Query: 69 HCKKPNLQVILGKHNLRQTETFQRQISVDRTIVHPRY---NPETHDNDIMMVHLKNPVKF 125
                                                NPE H +DIM++ L+N
                 V LG H+L++ + +++I V R+I HP +
Sbjct: 73 HCKKDKYSVRLGDHSLQKRDEPEQEIQVARSIQHPCFNSSNPEDHSHDIMLIRLQNSANL 132
Query: 126 SKKIQPLPLKNDCSEENPNCQILGWGKMEN--GDFPDTIQCADVHLVPREQCERAYPGKI 183
            K++P+LNC+CIGWG++
                                         +FP+T+ CA+V + + +CERAYPGKI
Sbjct: 133 GDKVKPIELANLCPKVGQKCIISGWGTVTSPQENFPNTLNCAEVKIYSQNKCERAYPGKI 192
Query: 184 TQSMVCAGDMKEGNDSCQGDSGGPLVCGGRLRGLVSWGDMPCGSKEKPGVYTDVCTHIRW 243
          T+ MVCAG G D+CQGDSGGPLVC G L+G+ SWG PCG EKPGVYT +C + W
Sbjct: 193 TEGMVCAGS-SNGADTCQGDSGGPLVCNGVLQGITSWGSDPCGKPEKPGVYTKICRYTNW 251
Query: 244 IQNIL 248
          I+ +
Sbjct: 252 IKKTM 256
```

Score = 233 bits (594), Expect = 4e-60Identities = 110/245 (44%), Positives = 155/245 (63%), Gaps = 10/245 (4%)

Query: 13 LCLVLAKSAWS----EEQEKVVHGGPCLKDSHPFQAALYTSGHLLCGGVLIDPQWVLTAA 68
+ L L AW+ + K++ G C S P+Q AL+ L+CGGVL+ +WVLTAA

Sbjct: 13 ILLFLLMGAWAGLTRAQGSKILEGQECKPHSQPWQTALFQGERLVCGGVLVGDRWVLTAA 72

Query: 69 HCKKPNLQVILGKHNLRQTETFQRQISVDRTIVHPRY---NPETHDNDIMMVHLKNPVKF 125 HCKK V LG H+L++ + +++I V R+I HP + NPE H +DIM++ L+N

Sbjct: 73 HCKKDKYSVRLGDHSLQKRDEPEQEIQVARSIQHPCFNSSNPEDHSHDIMLIRLQNSANL 132

Query: 126 SKKIQPLPLKNDCSEENPNCQILGWGKMEN--GDFPDTIQCADVHLVPREQCERAYPGKI 183

K++P+ L N C + C I GWG + + +FP+T+ CA+V + + +CERAYPGKI

Sbjct: 133 GDKVKPIELANLCPKVGQKCIISGWGTVTSPQENFPNTLNCAEVKIYSQNKCERAYPGKI 192

Query: 184 TQSMVCAGDMKEGNDSCQGDSGGPLVCGGRLRGLVSWGDMPCGSKEKPGVYTDVCTHIRW 243
T+ MVCAG G D+CQGDSGGPLVC G L+G+ +WG PCG EKPGVYT +C + W

Sbjct: 193 TEGMVCAGS-SNGADTCQGDSGGPLVCNGVLQGITTWGSDPCGKPEKPGVYTKICRYTNW 251

Query: 244 IQNIL 248 I+ + Sbjct: 252 IKKTM 256

Series | Ser

```
Score = 233 \text{ bits } (593), \text{ Expect} = 5e-60
Identities = 107/242 (44%), Positives = 158/242 (65%), Gaps = 9/242 (3%)
Query: 15 LVLAKSAWS----EEQEKVVHGGPCLKDSHPFOAALYTSGHLLCGGVLIDPOWVLTAAHC 70
                AW+
                       ++ KV+ G C
                                     S P+Q AL+
                                                  LLCGGVLI+ WVLTAAHC
Sbjct: 133 LLLLLEAWAGHLRAQESKVLGGQECEAHSQPWQTALFQGVRLLCGGVLIEDNWVLTAAHC 192
Query: 71 KKPNLQVILGKHNLRQTETFQRQISVDRTIVHPRYN--PETHDNDIMMVHLKNPVKFSKK 128
                V LG H+L+ ++ ++++V ++I HP YN
                                                E H +D+M++ L+
Sbjct: 193 KKRKYTVRLGDHSLKNKDSSEQEMAVAQSIPHPCYNGSNEDHSHDLMLIRLRGRASLGPQ 252
Query: 129 IQPLPLKNDCSEENPNCQILGWGKMEN--GDFPDTIQCADVHLVPREQCERAYPGKITQS 186
          ++P+ L + C E
                         C I GWG + +
                                       +FPDT+ CA+V + P+++C+ YPG++T
Sbjct: 253 VKPINLADHCPEVGQKCTISGWGTVTSPRENFPDTLNCAEVEIFPQKKCKDVYPGEVTDG 312
Query: 187 MVCAGDMKEGNDSCQGDSGGPLVCGGRLRGLVSWGDMPCGSKEKPGVYTDVCTHIRWIQN 246
                   G DSCQGDSGGPLVCGG L+G+ SWG PCG E+PGVYT++C ++ WI+
Sbjct: 313 MICAGD-SNGADSCQGDSGGPLVCGGVLQGITSWGSDPCGRPERPGVYTNICRYLDWIKK 371
Query: 247 IL 248
Sbjct: 372 TI 373
| >gi | 9910298 | ref | NP 064358.1 | G protease, serine, 20 [Mus musculus]
gi | 6681653 | dbj | BAA88825.1 | G hippostasin [Mus musculus]
         Length = 249
Score = 233 bits (593), Expect = 5e-60
 Identities = 106/251 (42%), Positives = 157/251 (62%), Gaps = 9/251 (3%)
Query: 6
          LTMKMLALCLVLAKSAWSEEQEKVVHGGPCLKDSHPFQAALYTSGHLLCGGVLIDPOWVL 65
          + ++++AL LV
                             + +++ G C
                                          S P+Q AL+
                                                       LLCG LI P+W+L
Sbjct: 1 MILRLIALALVTGHVGG---ETRIIKGYECRPHSQPWQVALFQKTRLLCGATLIAPKWLL 57
Query: 66 TAAHCKKPNLQVILGKHNLRQTETFQRQISVDRTIVHPRYNP----ETHDNDIMMVHLKN 121
          TAAHC+KP+ ++LG+HNL +T+ +++
                                       + HP +N
                                                       + H NDIM+V + +
Sbjct: 58 TAAHCRKPHYVILLGEHNLEKTDGCEQRRMATESFPHPDFNNSLPNKDHRNDIMLVKMSS 117
Query: 122 PVKFSKKIQPLPLKNDCSEENPNCQILGWGKMENGDF--PDTIQCADVHLVPREQCERAY 179
          PV F++ +QPL L
                        С
                               +C I GWG
                                         +
                                                P +++CA+V ++ ++CE+AY
Sbjct: 118 PVFFTRAVQPLTLSPHCVAAGTSCLISGWGTTSSPQLRLPHSLRCANVSIIEHKECEKAY 177
Query: 180 PGKITQSMVCAGDMKEGNDSCQGDSGGPLVCGGRLRGLVSWGDMPCGSKEKPGVYTDVCT 239
                       KEG DSCQGDSGGPLVC G L+G++SWG PC
          PG IT +M+CA
Sbjct: 178 PGNITDTMLCASVRKEGKDSCQGDSGGPLVCNGSLQGIISWGQDPCAVTRKPGVYTKVCK 237
Query: 240 HIRWIQNILRN 250
          + WI ++RN
Sbjct: 238 YFNWIHEVMRN 248
Sgi | 6681654 | dbj | BAA36955.1 | G hippostasin prostate type [Mus musculus]
gi|26365926|dbj|BAB26461.2| G unnamed protein product [Mus musculus]
Length = 276
```

```
Score = 233 bits (593), Expect = 5e-60
 Identities = 106/251 (42%), Positives = 157/251 (62%), Gaps = 9/251 (3%)
Query: 6 LTMKMLALCLVLAKSAWSEEQEKVVHGGPCLKDSHPFQAALYTSGHLLCGGVLIDPOWVL 65
                            + +++ G C
                                         S P+Q AL+
                                                      LLCG LI P+W+L
Sbjct: 28 MILRLIALALVTGHVGG---ETRIIKGYECRPHSQPWQVALFQKTRLLCGATLIAPKWLL 84
Query: 66 TAAHCKKPNLQVILGKHNLRQTETFQRQISVDRTIVHPRYNP----ETHDNDIMMVHLKN 121
          TAAHC+KP+ ++LG+HNL +T+ ++++ + HP +N
                                                       + H NDIM+V + +
Sbjct: 85 TAAHCRKPHYVILLGEHNLEKTDGCEORRMATESFPHPDFNNSLPNKDHRNDIMLVKMSS 144
Query: 122 PVKFSKKIQPLPLKNDCSEENPNCQILGWGKMENGDF--PDTIQCADVHLVPREOCERAY 179
          PV F++ +QPL L C +C I GWG + P +++CA+V ++ ++CE+AY
Sbjct: 145 PVFFTRAVQPLTLSPHCVAAGTSCLISGWGTTSSPQLRLPHSLRCANVSIIEHKECEKAY 204
Query: 180 PGKITQSMVCAGDMKEGNDSCQGDSGGPLVCGGRLRGLVSWGDMPCGSKEKPGVYTDVCT 239
          PG IT +M+CA KEG DSCQGDSGGPLVC G L+G++SWG PC KPGVYT VC
Sbjct: 205 PGNITDTMLCASVRKEGKDSCQGDSGGPLVCNGSLQGIISWGQDPCAVTRKPGVYTKVCK 264
Query: 240 HIRWIQNILRN 250
         + WI ++RN
Sbjct: 265 YFNWIHEVMRN 275
```

Sgi|4699765|pdb|1NPM|B Chain B, Neuropsin, A Serine Protease Expressed In The Lir System Of Mouse Brain System Of Mouse Brain Length = 225 Score = 233 bits (593), Expect = 5e-60 Identities = 107/225 (47%), Positives = 148/225 (65%), Gaps = 6/225 (2%) Query: 29 VVHGGPCLKDSHPFQAALYTSGHLLCGGVLIDPQWVLTAAHCKKPNLQVILGKHNLROTE 88 ++ G C+ S P+QAAL+ L+CGGVL+ +WVLTAAHCKK V LG H+L+ + Sbjct: 1 ILEGRECIPHSQPWQAALFQGERLICGGVLVGDRWVLTAAHCKKQKYSVRLGDHSLQSRD 60 Query: 89 TFQRQISVDRTIVHPRY---NPETHDNDIMMVHLKNPVKFSKKIOPLPLKNDCSEENPNC 145 +++I V ++I HP Y NPE H +DIM++ L+N K++P+ L N C + Sbjct: 61 QPEQEIQVAQSIQHPCYNNSNPEDHSHDIMLIRLQNSANLGDKVKPVQLANLCPKVGQKC 120 Query: 146 QILGWGKMEN--GDFPDTIQCADVHLVPREQCERAYPGKITQSMVCAGDMKEGNDSCQGD 203 I GWG + + +FP+T+ CA+V + + +CERAYPGKIT+ MVCAG Sbjct: 121 IISGWGTVTSPQENFPNTLNCAEVKIYSQNKCERAYPGKITEGMVCAGS-SNGADTCQGD 179 Query: 204 SGGPLVCGGRLRGLVSWGDMPCGSKEKPGVYTDVCTHIRWIQNIL 248 SGGPLVC G L+G+ SWG PCG EKPGVYT +C + WI+ + Sbjct: 180 SGGPLVCDGMLQGITSWGSDPCGKPEKPGVYTKICRYTTWIKKTM 224

```
| Score = 232 bits (592), Expect = 6e-60
| Identities = 108/252 (42%), Positives = 163/252 (64%), Gaps = 7/252 (2%)
```

```
Query: 3
         MKMLTMKMLALCLVLAKSAWSEEQEKVVHGGPCLKDSHPFQAALYTS-GH-LLCGGVLID 60
         M + L + + AL + + A+S +
                                K++ G C+++S P+Q AL
Sbjct: 1 MFLLLIILQALAVAIAQS---QGDHKIIGGYRCVRNSQPWQVALQAGPGHRFLCGGVLLS 57
Query: 61 PQWVLTAAHCKKPNLQVILGKHNLRQTETFQRQISVDRTIVHPRYNPETHDNDIMMVHLK 120
          QWV+TAAHC +P L V LGKHN+R+ E Q+ + V R + HP+Y P+ HDND+M++ L+
Sbjct: 58 DQWVITAAHCARPILHVALGKHNIRRWEATQQVVRVARQVPHPQYQPQAHDNDLMLLKLQ 117
Query: 121 NPVKFSKKIQPLPLKNDCSEENPNCQILGWGKMEN--GDFPDTIQCADVHLVPREQCERA 178
           V+ + ++ + + + C+ C++ GWG + + + +P +QC +V+++ + C RA
Sbjct: 118 KKVRLGRAVKTISVASSCASPGTPCRVSGWGTIASPIARYPTALQCVNVNIMSEQACHRA 177
Query: 179 YPGKITQSMVCAGDMKEGNDSCQGDSGGPLVCGGRLRGLVSWGDMPCGSKEKPGVYTDVC 238
          YPG IT MVCAG + G DSCQGDSGGPLVCGG+L+GLVSWG C
Sbjct: 178 YPGIITSGMVCAGVPEGGKDSCQGDSGGPLVCGGQLQGLVSWGMERCAMPGYPGVYANLC 237
Query: 239 THIRWIQNILRN 250
           + WIQ +++
Sbjct: 238 NYHSWIQRTMQS 249
Length = 297
 Score = 231 bits (589), Expect = 1e-59
 Identities = 104/232 (44%), Positives = 151/232 (65%), Gaps = 4/232 (1%)
Query: 23 SEEQEKVVHGGPCLKDSHPFQAALYTSG--HLLCGGVLIDPQWVLTAAHCKKPNLQVILG 80
          S+ +K++ G C+++S P+Q AL
                                      LCGGVL+ QWV+TAAHC +P L V LG
Sbjct: 65 SQGDDKILGGYTCVQNSQPWQVALQAGPGRRFLCGGVLLSDQWVITAAHCARPLLHVALG 124
Query: 81 KHNLRQTETFQRQISVDRTIVHPRYNPETHDNDIMMVHLKNPVKFSKKIQPLPLKNDCSE 140
          KHNLR+ E Q+ + V R + HP+Y P+ HDND+M++ L+ V+ + ++ + P++ C+
Sbjct: 125 KHNLRRWEATQQVLRVVRQVPHPQYRPQAHDNDLMLKLQRKVRLGRAVRTIPVARSCAS 184
Query: 141 ENPNCQILGWGKMENG--DFPDTIQCADVHLVPREQCERAYPGKITQSMVCAGDMKEGND 198
             C++ GWG + +P +QC +V+++P + C RAYPG IT MVCAG + G D
Sbjct: 185 PGTPCRVSGWGTTASPIVRYPTALQCVNVNIMPEQVCHRAYPGTITSGMVCAGVPEGGKD 244
Query: 199 SCQGDSGGPLVCGGRLRGLVSWGDMPCGSKEKPGVYTDVCTHIRWIQNILRN 250
          SCQGDSGGPLVC G+L+GLVSWG C PGVYT++C + WIQ +++
Sbjct: 245 SCQGDSGGPLVCQGQLQGLVSWGMERCAMPGYPGVYTNLCNYHSWIQRTMQS 296
Length = 242
 Score = 230 \text{ bits } (587), Expect = 2e-59
 Identities = 104/234 (44%), Positives = 153/234 (65%), Gaps = 4/234 (1%)
Query: 21 AWSEEQEKVVHGGPCLKDSHPFQAALYTS-GH-LLCGGVLIDPQWVLTAAHCKKPNLQVI 78
                K++ G C+++S P+Q AL
                                     GH LCGGVL+ QWV+TAAHC +P L V
Sbjct: 8
         AQSQGDHKIIGGYRCVRNSQPWQVALQAGPGHRFLCGGVLLSDQWVITAAHCARPILHVA 67
Query: 79 LGKHNLRQTETFQRQISVDRTIVHPRYNPETHDNDIMMVHLKNPVKFSKKIQPLPLKNDC 138
```

```
Sbjct: 68 LGKHNIRRWEATQQVVRVARQVPHPQYQPQAHDNDLMLLKLQKKVRLGRAVKTISVASSC 127
Query: 139 SEENPNCQILGWGKMEN--GDFPDTIQCADVHLVPREQCERAYPGKITQSMVCAGDMKEG 196
              C++ GWG + + +P +QC +V+++ + C RAYPG IT MVCAG + G
Sbjct: 128 ASPGTPCRVSGWGTIASPIARYPTALQCVNVNIMSEQACHRAYPGIITSGMVCAGVPEGG 187
Query: 197 NDSCQGDSGGPLVCGGRLRGLVSWGDMPCGSKEKPGVYTDVCTHIRWIQNILRN 250
           DSCQGDSGGPLVCGG+L+GLVSWG C
                                         PGVY ++C + WIQ +++
Sbjct: 188 KDSCQGDSGGPLVCGGQLQGLVSWGMERCAMPGYPGVYANLCNYHSWIQRTMQS 241
Similar to prostin [Rattus norvegicus]
         Length = 480
 Score = 229 bits (585), Expect = 4e-59
 Identities = 110/261 (42%), Positives = 159/261 (60%), Gaps = 13/261 (4%)
          PMKMLTMKML-ALCLVLAKSAWSEEQEKVVHGGPCLKDSHPFQAALYTSGHLLCGGVLID 60
          PKL+KML + LLS S+++KV+GC+ SP+QAL+GCGLI
Sbjct: 218 PDKSLSAKMLQCVDLTLMSSDVSQDGDKVLEGEECVPHSQPWQVALFERGRFNCGAFLIS 277
Query: 61 PQWVLTAAHCKKPNLQVILGKHNLRQTETFQRQISVDRTIVHPRYNPETHDNDIMMVHLK 120
          P WVLTAAHC+ ++V LG+HNLR+ + ++ SV R I HP Y
Sbjct: 278 PHWVLTAAHCQTRFMRVRLGEHNLRKFDGPEQLRSVSRIIPHPGYEARTHRHDIMLLRLF 337
Query: 121 NPVKFSKKIQPLPLKNDCSEENPNCQILGWGKMENGD------FPDTIQCADVH 168
           P + + +++P+ L
                        C +C + GWG + +
Sbjct: 338 RPARLTPQVRPVALPTRCPLLGEDCVVSGWGLLSDNSPGATGSHKSQVRLPDTLHCANIS 397
Query: 169 LVPREQCERAYPGKITQSMVCAGDMKEGNDSCQGDSGGPLVCGGRLRGLVSWGDMPCGSK 228
              C + YPG++ +MVCAG G DSC+GDSGGPLVCGG L+G+VSWGD+PC +
Sbjct: 398 IISEASCNKDYPGRVLPTMVCAGVEGGGTDSCEGDSGGPLVCGGALQGIVSWGDVPCDTT 457
Query: 229 EKPGVYTDVCTHIRWIQNILR 249
           KPGVYT VC+++ WI+ +R
Sbjct: 458 TKPGVYTKVCSYMDWIRKNMR 478
| >gi|34856168|ref|XP 218645.2| G similar to hippostasin prostate type [Rattus norvection]
         Length = 270
 Score = 228 bits (582), Expect = 9e-59
 Identities = 105/252 (41%), Positives = 156/252 (61%), Gaps = 9/252 (3%)
Query: 5 MLTMKMLALCLVLAKSAWSEEQEKVVHGGPCLKDSHPFQAALYTSGHLLCGGVLIDPQWV 64
          LLCG LI P+W+
Sbjct: 21 MMILRFIALALVTGHVGG---ETRIIKGYECRPHSQPWQVALFQKTRLLCGATLIAPKWL 77
Query: 65 LTAAHCKKPNLQVILGKHNLRQTETFQRQISVDRTIVHPRYNP----ETHDNDIMMVHLK 120
          LTAAHC+KP+ ++LG+HNL +T+ \cdot ++++ + HP +N
                                                      + H NDIM+V +
Sbjct: 78 LTAAHCRKPHYVILLGEHNLEKTDGCEQRRMATESFPHPGFNNSLPNKDHRNDIMLVKMS 137
Query: 121 NPVKFSKKIOPLPLKNDCSEENPNCQILGWGKMENGDF--PDTIOCADVHLVPREOCERA 178
              ++ ++PL L + C +C I GWG + P +++CA+V ++ ++CERA
Sbjct: 138 SPAFITRAVRPLTLSSLCVTAGTSCLISGWGTTSSPQLRLPHSLRCANVSIIGHKECERA 197
```

Query: 179 YPGKITQSMVCAGDMKEGNDSCQGDSGGPLVCGGRLRGLVSWGDMPCGSKEKPGVYTDVC 238

Length = 247Score = 228 bits (580), Expect = 1e-58 Identities = 102/243 (41%), Positives = 154/243 (63%), Gaps = 4/243 (1%) Query: 10 MLALCLVLAKSAWSEEQEKVVHGGPCLKDSHPFQAALYTSGHLLCGGVLIDPQWVLTAAH 69 +L L +LA +A +++ +K++ G C S P+Q ALY G CG LI P WVL+AAH LLTLSFLLASTA-AQDGDKLLEGDECAPHSQPWQVALYERGRFNCGASLISPHWVLSAAH 62 Query: 70 CKKPNLQVILGKHNLRQTETFQRQISVDRTIVHPRYNPETHDNDIMMVHLKNPVKFSKKI 129 ++V LG+HNLR+ + ++ + R I HPRY +H NDIM++ L P + ++ Sbjct: 63 CQSRFMRVRLGEHNLRKRDGPEQLRTTSRVIPHPRYEARSHRNDIMLLRLVQPARLNPQV 122 Query: 130 QPLPLKNDCSEENPNCQILGWGKMENGD---FPDTIQCADVHLVPREQCERAYPGKITQS 186 C C + GWG + PDT+ CA++ ++ C+++YPG++T+Sbjct: 123 RPAVLPTRCPHPGEACVVSGWGLVPLSSPVSLPDTLHCANISIISDTSCDKSYPGRLTNT 182 Query: 187 MVCAGDMKEGNDSCQGDSGGPLVCGGRLRGLVSWGDMPCGSKEKPGVYTDVCTHIRWION 246 G +SC+GDSGGPLVCGG L+G+VSWGD+PC + KPGVYT VC ++ WI+ Sbjct: 183 MVCAGAEGRGAESCEGDSGGPLVCGGILQGIVSWGDVPCDNTTKPGVYTKVCHYLEWIRE 242

Query: 247 ILR 249 ++ Sbjct: 243 TMK 245

+L L +LA +A +++ +K++ G C S P+Q ALY G CG LI P WVL+AAH
Sbjct: 4 LLTLSFLLASTA-AQDGDKLLEGDECAPHSQPWQVALYERGRFNCGASLISPHWVLSAAH 62

Query: 70 CKKPNLQVILGKHNLRQTETFQRQISVDRTIVHPRYNPETHDNDIMMVHLKNPVKFSKKI 129 C+ ++V LG+HNLR+ + ++ + R I HPRY +H NDIM++ L P + + ++ Sbjct: 63 CQSRFMRVRLGEHNLRKRDGPEQLRTTSRVIPHPRYEARSHRNDIMLLRLVQPARLNPQV 122

Query: 130 QPLPLKNDCSEENPNCQILGWGKMENGD------FPDTIQCADVHLVPREQCER 177
+P L C C + GWG + + + PDT+ CA++ ++ C++

Sbjct: 123 RPAVLPTRCPHPGEACVVSGWGLVSHNEPGTAGSPRSQVSLPDTLHCANISIISDTSCDK 182

TT TITOTERIA DE CONTROL DE LOS LECONOMICES ()

Query: 178 AYPGKITQSMVCAGDMKEGNDSCQGDSGGPLVCGGRLRGLVSWGDMPCGSKEKPGVYTDV 237 +YPG++T +MVCAG G +SC+GDSGGPLVCGG L+G+VSWGD+PC + KPGVYT V

Sbjct: 183 SYPGRLTNTMVCAGAEGRGAESCEGDSGGPLVCGGILQGIVSWGDVPCDNTTKPGVYTKV 242

Query: 238 CTHIRWIQNILR 249

C ++ WI+ ++

Sbjct: 243 CHYLEWIRETMK 254

| >gi | 47480768 | gb | AAH69480.1 | G Kallikrein 15, isoform 4 preproprotein [Homo sapiens]
gi | 47479543 | gb | AAH69518.1 | G Kallikrein 15, isoform 4 preproprotein [Homo sapiens]
Length = 255

Score = 226 bits (576), Expect = 4e-58Identities = 102/252 (40%), Positives = 155/252 (61%), Gaps = 14/252 (5%)

Query: 10 MLALCLVLAKSAWSEEQEKVVHGGPCLKDSHPFQAALYTSGHLLCGGVLIDPQWVLTAAH 69
+L L +LA +A ++ +K++ G C S P+Q ALY G CG LI P WVL+AAH

Sbjct: 4 LLTLSFLLASTA--QDGDKLLEGDECAPHSQPWQVALYERGRFNCGASLISPHWVLSAAH 61

Query: 70 CKKPNLQVILGKHNLRQTETFQRQISVDRTIVHPRYNPETHDNDIMMVHLKNPVKFSKKI 129 C+ ++V LG+HNLR+ + ++ + R I HPRY +H NDIM++ L P + ++

Sbjct: 62 CQSRFMRVRLGEHNLRKRDGPEQLRTTSRVIPHPRYEARSHRNDIMLLRLVQPARLNPQV 121

Query: 130 QPLPLKNDCSEENPNCQILGWGKMENGD------FPDTIQCADVHLVPREQCER 177
+P L C C + GWG + + + PDT+ CA++ ++ C++

Sbjct: 122 RPAVLPTRCPHPGEACVVSGWGLVSHNEPGTAGSPRSQVSLPDTLHCANISIISDTSCDK 181

Query: 178 AYPGKITQSMVCAGDMKEGNDSCQGDSGGPLVCGGRLRGLVSWGDMPCGSKEKPGVYTDV 237

+YPG++T +MVCAG G +SC+GDSGGPLVCGG L+G+VSWGD+PC + KPGVYT V Sbjct: 182 SYPGRLTNTMVCAGAEGRGAESCEGDSGGPLVCGGILQGIVSWGDVPCDNTTKPGVYTKV 241

Query: 238 CTHIRWIQNILR 249

C ++ WI+ ++

Sbjct: 242 CHYLEWIRETMK 253

Score = 226 bits (575), Expect = 6e-58Identities = 102/252 (40%), Positives = 155/252 (61%), Gaps = 14/252 (5%)

Query: 10 MLALCLVLAKSAWSEEQEKVVHGGPCLKDSHPFQAALYTSGHLLCGGVLIDPQWVLTAAH 69
+L L +LA +A ++ +K++ G C S P+Q ALY G CG LI P WVL+AAH

Sbjct: 4 LLTLSFLLASTA--QDGDKLLEGDECAPHSQPWQVALYERGRFNCGASLISPHWVLSAAH 61

Query: 70 CKKPNLQVILGKHNLRQTETFQRQISVDRTIVHPRYNPETHDNDIMMVHLKNPVKFSKKI 129 C+ ++V LG+HNLR+ + ++ + R I HPRY +H NDIM++ L P + ++

Sbjct: 62 CQSRFMRVRLGEHNLRKRDGPEQLRTTSRVIPHPRYEARSHRNDIMLLRLVQPARLNPQV 121

Query: 130 QPLPLKNDCSEENPNCQILGWGKMENGD------FPDTIQCADVHLVPREQCER 177
+P L C C + GWG + + + PDT+ CA++ ++ C++

Sbjct: 122 RPAVLPTRCPHPGEACVVSGWGLVSHNEPGTAGSPRSQVSLPDTLHCANIGIISDTSCDK 181

Query: 178 AYPGKITQSMVCAGDMKEGNDSCQGDSGGPLVCGGRLRGLVSWGDMPCGSKEKPGVYTDV 237 +YPG++T +MVCAG G +SC+GDSGGPLVCGG L+G+VSWGD+PC + KPGVYT V

Sbjct: 182 SYPGRLTNTMVCAGAEGRGAESCEGDSGGPLVCGGILQGIVSWGDVPCDNTTKPGVYTKV 241

Query: 238 CTHIRWIQNILR 249

C ++ WI+ ++

Sbjct: 242 CHYLEWIRETMK 253

| >gi | 12834991 | dbj | BAB23113.1 | G unnamed protein product [Mus musculus]

Length = 293

Score = 225 bits (573), Expect = 1e-57
Identities = 97/232 (41%), Positives = 154/232 (66%), Gaps = 5/232 (2%)

Query: 23 SEEQEKVVHGGPCLKDSHPFQAALYTSGH-LLCGGVLIDPQWVLTAAHCKKPNLQVILGK 81 S+ ++V+G C KD+ P+Q AL + L CG VLI PQW+LTAAHC+KP ++ LG

Sbjct: 62 SDSSSRIVNGSDCQKDAQPWQGALLLGPNKLYCGAVLISPQWLLTAAHCRKPVFRIRLGH 121

Query: 82 HNLRQT-ETFQRQISVDRTIVHPRYNPETHDNDIMMVHLKNPVKFSKKIQPLPLKNDCSE 140 H++ E+ Q+ ++I HP Y+ H ND+M++ + ++ S ++P+ + DC+

Sbjct: 122 HSMSPVYESGQQMFQGIKSIPHPGYSHPGHSNDLMLIKMNRKIRDSHSVKPVEIACDCAT 181

Query: 141 ENPNCQILGWG--KMENGDFPDTIQCADVHLVPREQCERAYPGKITQSMVCAGDMKEGND 198 E C + GWG + +FP +QC ++ ++ E+C+ +YPG+I ++M CAGD +EG D

Sbjct: 182 EGTRCMVSGWGTTSSSHNNFPKVLQCLNITVLSEERCKNSYPGQIDKTMFCAGD-EEGRD 240

Query: 199 SCQGDSGGPLVCGGRLRGLVSWGDMPCGSKEKPGVYTDVCTHIRWIQNILRN 250 SCQGDSGGP+VC G+L+GLVSWGD PC + +PGVYT++C ++WI++ + +

Sbjct: 241 SCQGDSGGPVVCNGKLQGLVSWGDFPCAQRNRPGVYTNLCEFVKWIKDTMNS 292

>gi|57037473|ref|XP 541465.1| G PREDICTED: similar to glandular kallikrein KLK13 [(Length = 328

Score = 224 bits (572), Expect = 1e-57 Identities = 106/226 (46%), Positives = 145/226 (64%), Gaps = 7/226 (3%)

Query: 32 GGPCLKDSHPFQAALYTSGHLLCGGVLIDPQWVLTAAHCKKPNLQVILGKHNLRQTETFQ 91
G C S P+QAAL G L CGGVL+ P+WVLTAAHC K +V LGKH L + E +

Sbjct: 90 GYTCRPHSQPWQAALLVQGRLFCGGVLVHPKWVLTAAHCLKDGYRVYLGKHALGRVEAGE 149

Query: 92 RQISVDRTIVHPRYNPE----THDNDIMMVHLKNPVKFSKKIQPLPLK-NDCSEENPNCQ 146 + V R+I HP+Y HD+DIM++ L++PV+ + I+ LPL N+C C+

Sbjct: 150 QVREVVRSIPHPQYQISPTHLNHDHDIMLLELQSPVQPTNHIRVLPLSHNNCLPAGTCCR 209

Query: 147 ILGWGKMENGD--FPDTIQCADVHLVPREQCERAYPGKITQSMVCAGDMKEGNDSCQGDS 204 + GWG + +P T+QCA++ L E+C + YPGKIT +M+CAG + G DSC+GDS

Sbjct: 210 VSGWGTTTSPQVSYPQTLQCANIQLRSDEECRQVYPGKITPNMLCAGTKEGGKDSCEGDS 269

Query: 205 GGPLVCGGRLRGLVSWGDMPCGSKEKPGVYTDVCTHIRWIQNILRN 250

GGPL+C G L G++SWGD PCG +PGVYT V ++ WI+ +RN

Sbjct: 270 GGPLICNGTLHGIISWGDFPCGQPNRPGVYTRVSQYVLWIRETIRN 315

```
Score = 224 bits (572), Expect = 1e-57
 Identities = 106/244 (43%), Positives = 155/244 (63%), Gaps = 4/244 (1%)
Query: 7 TMKMLALCLVLAKSAWSEEQEKVVHGGPCLKDSHPFQAALYTSGHLLCGGVLIDPQWVLT 66
         TMK L + ++L + E+ +K+V G C K++ P+Q +L +G+ CGG LI+ QWV++
Sbjct: 4 TMKFLVILVLLGAAVAFEDDDKIVGGFTCAKNAVPYQVSL-NAGYHFCGGSLINSQWVVS 62
Query: 67 AAHCKKPNLQVILGKHNLRQTETFQRQISVDRTIVHPRYNPETHDNDIMMVHLKNPVKFS 126
         AAHC K +QV LG+HN+ E ++ I + I HP YN DNDIM++ L
Sbjct: 63 AAHCYKSRIQVRLGEHNIALNEGTEQFIDSQKVIKHPNYNSRNLDNDIMLIKLSTTARLS 122
Query: 127 KKIQPLPLKNDCSEENPNCQILGWGK-MENG-DFPDTIQCADVHLVPREQCERAYPGKIT 184
           IQ +PL + C+
                        NC I GWG + +G ++PD +QC + ++ OC +YPG+IT
Sbjct: 123 ANIQSVPLPSACASAGTNCLISGWGNTLSSGTNYPDLLQCLNAPILTDSQCSNSYPGEIT 182
Query: 185 QSMVCAGDMKEGNDSCQGDSGGPLVCGGRLRGLVSWGDMPCGSKEKPGVYTDVCTHIRWI 244
         ++M CAG + G DSCQGDSGGP+VC G+L+G+VSWG C + PGVYT VC + WI
Sbjct: 183 KNMFCAGFLAGGKDSCQGDSGGPVVCNGQLQGVVSWG-YGCAQRNYPGVYTKVCNFVTWI 241
Query: 245 QNIL 248
Sbjct: 242 QSTI 245
gi|26891552|gb|AAN78422.1| G prostin [Mus musculus]
        Length = 254
 Score = 224 bits (571), Expect = 2e-57
Identities = 107/252 (42%), Positives = 156/252 (61%), Gaps = 14/252 (5%)
Query: 11 LALCLVLAKSAWSEEQEKVVHGGPCLKDSHPFQAALYTSGHLLCGGVLIDPQWVLTAAHC 70
         L L VL SA +++ +KV+ G C+ S P+Q AL+ G
                                              CG LI P+WVLTAAHC
Sbjct: 3 LLLAFVLLVSA-AQDGDKVLEGEECVPHSQPWQVALFERGRFNCGAFLISPRWVLTAAHC 61
Query: 71 KKPNLQVILGKHNLRQTETFQRQISVDRTIVHPRYNPETHDNDIMMVHLKNPVKFSKKIQ 130
         + ++V LG+HNLR+ + ++ SV R I HP Y TH +DIM++ L P + ++
Sbjct: 62 QTRFMRVRLGEHNLRKFDGPEQLRSVSRIIPHPGYEARTHRHDIMLLRLFKPARLTAYVR 121
Query: 131 PLPLKNDCSEENPNCQILGWGKMENGD-----FPDTIQCADVHLVPREQCERA 178
         P+LC+GWG+++
                                            PDT+ CA++ ++
Sbjct: 122 PVALPRRCPLIGEDCVVSGWGLLSDNNPGATGSQKSHVRLPDTLHCANISIISEASCNKD 181
Query: 179 YPGKITQSMVCAGDMKEGNDSCQGDSGGPLVCGGRLRGLVSWGDMPCGSKEKPGVYTDVC 238
         YPG++ +MVCAG
                       G DSC+GDSGGPLVCGG L+G+VSWGD+PC + KPGVYT VC
Sbjct: 182 YPGRVLPTMVCAGVEGGGTDSCEGDSGGPLVCGGALQGIVSWGDVPCDTTTKPGVYTKVC 241
Query: 239 THIRWI-QNILR 249
         +++ WI +N+ R
Sbjct: 242 SYLEWIWENVRR 253
| >gi | 47481100 | gb | AAH69334.1 | G Kallikrein 13, precursor [Homo sapiens]
gi 47480821 gb AAH69543.1 G Kallikrein 13, precursor [Homo sapiens]
```

```
Length = 277
Score = 224 bits (571), Expect = 2e-57
Identities = 118/271 (43%), Positives = 162/271 (59%), Gaps = 24/271 (8%)
Query: 6
         LTMKMLALCLVLAKSAWSEEQEKVVH------GGPCLKDSHPFQAALYTSGHLLCG 55
         L + + +L L L+ S+E KV++
                                         G C S P+OAAL
                                                         G LLCG
         LALVIASLTLALSGGV-SQESSKVLNTNGTSGFLPGGYTCFPHSQPWQAALLVQGRLLCG 62
Sbjct: 4
Query: 56 GVLIDPQWVLTAAHCKKPNLQVILGKHNLRQTETFQRQISVDRTIVHPRYNPE----THD 111
         GVL+ P+WVLTAAHC K L+V LGKH L + E ++ V +I HP Y
Sbjct: 63 GVLVHPKWVLTAAHCLKEGLKVYLGKHALGRVEAGEQVREVVHSIPHPEYRRSPTHLNHD 122
Query: 112 NDIMMVHLKNPVKFSKKIQPLPLK-NDCSEENPNCQILGWGKMENG--DFPDTIQCADVH 168
         +DIM++ L++PV+ + IQ LPL N+ C++ GWG
Sbjct: 123 HDIMLLELQSPVQLTGYIQTLPLSHNNRLTPGTTCRVSGWGTTTSPQVNYPKTLQCANIQ 182
Query: 169 LVPREQCERAYPGKITQSMVCAGDMKEGNDSCQGDSGGPLVCGGRLRGLVSWGDMPCGSK 228
         L E+C + YPGKIT +M+CAG + G DSC+GDSGGPLVC
                                                L G+VSWGD PCG
Sbjct: 183 LRSDEECRQVYPGKITDNMLCAGTKEGGKDSCEGDSGGPLVCNRTLYGIVSWGDFPCGQP 242
Query: 229 EKPGVYTDVCTHIRWIQNILR-----NKWL 253
         ++PGVYT V ++ WI+ +R
Sbjct: 243 DRPGVYTRVSRYVLWIRETIRKYETQQQKWL 273
Length = 255
Score = 224 bits (571), Expect = 2e-57
Identities = 106/244 (43%), Positives = 155/244 (63%), Gaps = 4/244 (1%)
         TMKMLALCLVLAKSAWSEEQEKVVHGGPCLKDSHPFQAALYTSGHLLCGGVLIDPQWVLT 66
Query: 7
         TMK L + ++L + E+ +K+V G C K++ P+O +L +G+ CGG LI+ OWV++
Sbjct: 11 TMKFLVILVLLGAAVAFEDDDKIVGGFTCAKNAVPYQVSL-NAGYHFCGGSLINSQWVVS 69
Query: 67 AAHCKKPNLQVILGKHNLRQTETFQRQISVDRTIVHPRYNPETHDNDIMMVHLKNPVKFS 126
         AAHC K +QV LG+HN+ E ++ I + I HP YN
                                                DNDIM++ L
Sbjct: 70 AAHCYKSRIQVRLGEHNIALNEGTEQFIDSQKVIKHPNYNSRNLDNDIMLIKLSTTARLS 129
Query: 127 KKIQPLPLKNDCSEENPNCQILGWGK-MENG-DFPDTIQCADVHLVPREQCERAYPGKIT 184
           IQ +PL + C+ NC I GWG + +G ++PD +QC + ++
                                                    QC +YPG+IT
Sbjct: 130 ANIQSVPLPSACASAGTNCLISGWGNTLSSGTNYPDLLQCLNAPVLTDSQCSNSYPGEIT 189
Query: 185 QSMVCAGDMKEGNDSCQGDSGGPLVCGGRLRGLVSWGDMPCGSKEKPGVYTDVCTHIRWI 244
         ++M CAG + G DSCQGDSGGP+VC G+L+G+VSWG C + PGVYT VC + WI
Sbjct: 190 KNMFCAGFLAGGKDSCQGDSGGPVVCNGQLQGVVSWG-YGCAQRNYPGVYTKVCNFVTWI 248
```

Query: 245 QNIL 248 Q+ + Sbjct: 249 QSTI 252

| >gi | 59808136 | gb | AAH89741.1 | Unknown (protein for MGC:108396) [Xenopus tropicalis]
| Length = 244

```
Score = 224 bits (570), Expect = 2e-57
 Identities = 105/243 (43%), Positives = 154/243 (63%), Gaps = 4/243 (1%)
          MKMLALCLVLAKSAWSEEQEKVVHGGPCLKDSHPFQAALYTSGHLLCGGVLIDPOWVLTA 67
Ouery: 8
          MK L + ++L +
                        E+ +K+V G C K++ P+Q +L +G+ CGG LI+ QWV++A
          MKFLIVLVLLGAAVAFEDDDKIVGGFTCTKNAVPYQVSL-NAGYHFCGGSLINSQWVVSA 59
Sbjct: 1
Query: 68 AHCKKPNLQVILGKHNLRQTETFQRQISVDRTIVHPRYNPETHDNDIMMVHLKNPVKFSK 127
          AHC K +QV LG+HN+
                             E ++ I
                                       + I HP YN
                                                   DNDIM++ L
Sbjct: 60 AHCYKSRIQVRLGEHNIAVNEGTEQFIESQKVIKHPSYNSRNLDNDIMLIKLSTTARLSS 119
Query: 128 KIQPLPLKNDCSEENPNCQILGWGK-MENG-DFPDTIQCADVHLVPREQCERAYPGKITQ 185
           IQ + PL + C+
                         NC I GWG + +G ++PD +QC + ++
                                                        +C +YPG+IT
Sbjct: 120 NIQSVPLPSACASAGTNCLISGWGNTLSSGTNYPDLLQCLNAPILTASECSNSYPGEITN 179
Query: 186 SMVCAGDMKEGNDSCQGDSGGPLVCGGRLRGLVSWGDMPCGSKEKPGVYTDVCTHIRWIQ 245
          +M CAG + G DSCQGDSGGP+VC G+L+G+VSWG C + PGVYT VC ++ WIQ
Sbjct: 180 NMFCAGFLAGGKDSCQGDSGGPVVCNGQLQGVVSWG-YGCAQRNYPGVYTKVCNYVSWIQ 238
Query: 246 NIL 248
          N +
Sbjct: 239 NTI 241
gi | 104227 | pir | A35871 trypsin (EC 3.4.21.4) precursor, pancreatic - African clawed f
gi | 136433 | sp | P19799 | TRY1 | XENLA
                                Trypsin precursor
         Length = 243
 Score = 223 bits (569), Expect = 3e-57
 Identities = 109/243 (44%), Positives = 156/243 (64%), Gaps = 5/243 (2%)
Query: 8
          MKMLALCLVLAKSAWSEEQEKVVHGGPCLKDSHPFQAALYTSGHLLCGGVLIDPOWVLTA 67
          MK L LC++L +A + + +K++ G C K S P+ +L SG+ CGG LI QWV++A
Sbjct: 1
          MKFLLLCVLLGAAA-AFDDDKIIGGATCAKSSVPYIVSL-NSGYHFCGGSLITNQWVVSA 58
Query: 68 AHCKKPNLQVILGKHNLRQTETFQRQISVDRTIVHPRYNPETHDNDIMMVHLKNPVKFSK 127
          AHC K ++QV LG+HN+ +E ++ IS + I H YN T DNDIM++ L +P
Sbjct: 59 AHCYKASIQVRLGEHNIALSEGTEQFISSSKVIRHSGYNSYTLDNDIMLIKLSSPASLNA 118
Query: 128 KIQPLPLKNDCSEENPNCQILGWGK-MENG-DFPDTIQCADVHLVPREQCERAYPGKITQ 185
                        +C I GWG + NG ++PD +QC + ++
           + +PL + CS
Sbjct: 119 AVNTVPLPSGCSAAGTSCLISGWGNTLSNGSNYPDLLQCLNAPILTNAQCNSAYPGEITA 178
Query: 186 SMVCAGDMKEGNDSCQGDSGGPLVCGGRLRGLVSWGDMPCGSKEKPGVYTDVCTHIRWIQ 245
          +M+C G M+ G DSCQGDSGGP+VC G+L+G+VSWG C + PGVYT VC + WIQ
Sbjct: 179 NMICVGYMEGGKDSCQGDSGGPVVCNGQLQGVVSWG-YGCAMRNYPGVYTKVCNYNAWIQ 237
Query: 246 NIL 248
          N +
Sbjct: 238 NTI 240
                             G MGC64344 protein [Xenopus laevis]
>qi|32484229|qb|AAH54194.1|
```

Length = 243

```
Score = 223 bits (569), Expect = 3e-57
 Identities = 109/243 (44%), Positives = 156/243 (64%), Gaps = 5/243 (2%)
          MKMLALCLVLAKSAWSEEQEKVVHGGPCLKDSHPFQAALYTSGHLLCGGVLIDPOWVLTA 67
          MKFLLLCVLLGAAA-AFDDDKIIGGATCAKSSVPYIVSL-NSGYHFCGGSLITNQWVVSA 58
Sbjct: 1
Query: 68 AHCKKPNLQVILGKHNLRQTETFQRQISVDRTIVHPRYNPETHDNDIMMVHLKNPVKFSK 127
          AHC K ++QV LG+HN+ +E ++ IS + I H YN T DNDIM++ L +P
Sbjct: 59 AHCYKASIQVRLGEHNIALSEGTEQFISSSKVIRHSGYNSYTLDNDIMLIKLSSPASLNA 118
Query: 128 KIQPLPLKNDCSEENPNCQILGWGK-MENG-DFPDTIQCADVHLVPREQCERAYPGKITO 185
           + +PL + CS +C I GWG + NG ++PD +QC + ++ QC AYPG+IT
Sbjct: 119 AVNTVPLPSGCSAAGTSCLISGWGNTLSNGSNYPDLLQCLNAPILTNAQCNSAYPGEITA 178
Query: 186 SMVCAGDMKEGNDSCQGDSGGPLVCGGRLRGLVSWGDMPCGSKEKPGVYTDVCTHIRWIQ 245
          +M+C G M+ G DSCQGDSGGP+VC G+L+G+VSWG C + PGVYT VC + WIQ
Sbjct: 179 NMICVGFMEGGKDSCQGDSGGPVVCNGQLQGVVSWG-YGCAMRNYPGVYTKVCNYNAWIQ 237
Query: 246 NIL 248
          N +
Sbjct: 238 NTI 240
Sgi|57037469|ref|XP 541464.1| G PREDICTED: similar to kallikrein 14 preproprotein
          familiaris]
         Length = 492
 Score = 223 bits (569), Expect = 3e-57
 Identities = 98/231 (42%), Positives = 153/231 (66%), Gaps = 4/231 (1%)
Query: 25 EQEKVVHGGPCLKDSHPFQAALYTSG~-HLLCGGVLIDPQWVLTAAHCKKPNLQVILGKH 82
          ++ K++ G C+++S P+QAAL LCGG L+ QWV+TAAHC +P L++ LGKH
Sbjct: 262 DENKIIGGYTCIQNSQPWQAALLAGPFRRFLCGGALLSRQWVITAAHCARPILRIALGKH 321
Query: 83 NLRQTETFQRQISVDRTIVHPRYNPETHDNDIMMVHLKNPVKFSKKIQPLPLKNDCSEEN 142
          NL+ E Q+ + V R + HP+YN + TH+ND+M++ L+ P++ + ++P+ + + C+
Sbjct: 322 NLKNWEATQQVLRVVRQVPHPQYNSQTHNNDLMLLQLERPIQLGRAVRPITIASSCARPG 381
Query: 143 PNCQILGWGKMENG--DFPDTIQCADVHLVPREQCERAYPGKITQSMVCAGDMKEGNDSC 200
           +C + GWG + +P+++QC ++++ ++C +AY IT MVCAG + G DSC
Sbjct: 382 TSCLVSGWGTTSSPIVRYPNSLQCVNINISSDQECRQAYSQAITVGMVCAGVPQGGKDSC 441
Query: 201 QGDSGGPLVCGGRLRGLVSWGDMPCGSKEKPGVYTDVCTHIRWIQNILRNK 251
          QGDSGGPLVC G+L+GLVSWG C PGVYT++C + WIQN + +K
Sbjct: 442 QGDSGGPLVCKGQLQGLVSWGMEHCALPGYPGVYTNLCKYRTWIQNTIWSK 492
gi 2358087 gb AAB69058.1 trypsinogen 10 [Mus musculus]
        Length = 246
 Score = 223 bits (568), Expect = 4e-57
 Identities = 108/242 (44%), Positives = 159/242 (65%), Gaps = 5/242 (2%)
```

Query: 10 MLALCLVLAKSAWS-EEQEKVVHGGPCLKDSHPFQAALYTSGHLLCGGVLIDPQWVLTAA 68

+L L LV A A+ ++ +K+V G C ++S P+Q +L SG+ CGG LI+ QWV++AA

```
Sbjct: 4 LLFLALVGAAVAFPVDDDDKIVGGYTCRENSVPYQVSL-NSGYHFCGGSLINDQWVVSAA 62
Ouery: 69 HCKKPNLQVILGKHNLRQTETFQRQISVDRTIVHPRYNPETHDNDIMMVHLKNPVKFSKK 128
          HC K +QV LG+HN+ E ++ I I HP++ +T DNDIM++ L +PV ++
Sbjct: 63 HCYKSRIQVRLGEHNINVLEGNEQFIDAANIIKHPKFKKKTLDNDIMLIKLSSPVTLNAR 122
Query: 129 IQPLPLKNDCSEENPNCQILGWGK-MENG-DFPDTIQCADVHLVPREQCERAYPGKITQS 186
          + + L + C+ C I GWG + +G + PD +QC D L+P+ CE +YPGKIT++
Sbjct: 123 VATVALPSSCAAAGTQCLISGWGNTLSSGVNNPDLLQCLDAPLLPQADCEASYPGKITKN 182
Query: 187 MVCAGDMKEGNDSCQGDSGGPLVCGGRLRGLVSWGDMPCGSKEKPGVYTDVCTHIRWIQN 246
          M+C G ++ G DSCQGDSGGP+VC G+L+G+VSWG C K+ PGVYT VC ++ WION
Sbjct: 183 MICVGFLEGGKDSCQGDSGGPVVCNGQLQGIVSWG-YGCAQKDNPGVYTKVCNYVDWIQN 241
Query: 247 IL 248
Sbjct: 242 TI 243
sgi|2499865|sp|P70059|TRY2 XENLA Trypsin precursor
 qi | 1621633 | qb | AAB17274.1 |
                          G trypsinogen [Xenopus laevis]
         Length = 244
 Score = 223 bits (567), Expect = 5e-57
 Identities = 105/243 (43%), Positives = 154/243 (63%), Gaps = 4/243 (1%)
Query: 8
          MKMLALCLVLAKSAWSEEQEKVVHGGPCLKDSHPFQAALYTSGHLLCGGVLIDPQWVLTA 67
          Sbjct: 1 MKFLVILVLLGAAVAFEDDDKIVGGFTCAKNAVPYQVSL-NAGYHFCGGSLINSQWVVSA 59
Query: 68 AHCKKPNLQVILGKHNLRQTETFQRQISVDRTIVHPRYNPETHDNDIMMVHLKNPVKFSK 127
          AHC K +QV LG+HN+ E ++ I + I HP YN
                                                   DNDIM++ L
Sbjct: 60 AHCYKSRIQVRLGEHNIALNEGTEQFIDSQKVIKHPNYNSRNLDNDIMLIKLSTTARLSA 119
Query: 128 KIQPLPLKNDCSEENPNCQILGWGK-MENG-DFPDTIQCADVHLVPREQCERAYPGKITQ 185
           IQ + PL + C+ NC I GWG + +G ++PD +QC + ++ QC +YPG+IT+
Sbjct: 120 NIQSVPLPSACASAGTNCLISGWGNTLSSGTNYPDLLQCLNAPILTDSQCSNSYPGEITK 179
Query: 186 SMVCAGDMKEGNDSCQGDSGGPLVCGGRLRGLVSWGDMPCGSKEKPGVYTDVCTH1RWIQ 245
          +M CAG + G DSCQGDSGGP+VC G+L+G+VSWG C + PGVYT VC + WIQ
Sbjct: 180 NMFCAGFLAGGKDSCQGDSGGPVVCNGQLQGVVSWG-YGCAQRNYPGVYTKVCNFVTWIQ 238
Query: 246 NIL 248
Sbjct: 239 STI 241
____>gi|42759849|gb|AAS45302.1| KLK15 [Saguinus oedipus]
         Length = 255
 Score = 221 bits (564), Expect = 1e-56
 Identities = 100/252 (39%), Positives = 154/252 (61%), Gaps = 14/252 (5%)
Query: 10 MLALCLVLAKSAWSEEOEKVVHGGPCLKDSHPFOAALYTSGHLLCGGVLIDPOWVLTAAH 69
          +L L +L +A ++ K++ G C S P+Q ALY G CG LI P WVL+AAH
Sbjct: 4
          LLPLSFLLTSTA--QDGGKLLEGEECAPHSQPWQVALYERGRFNCGASLISPHWVLSAAH 61
```

```
Query: 70 CKKPNLQVILGKHNLRQTETFQRQISVDRTIVHPRYNPETHDNDIMMVHLKNPVKFSKKI 129
              ++V LG+HNLR+ + ++ + R I HPRY
                                            +H +DIM++ L P + ++
Sbjct: 62 CQSRFMRVRLGEHNLRKRDGPEQLRTASRVIPHPRYEARSHRHDIMLLRLVQPARLTPQV 121
Query: 130 QPLPLKNDCSEENPNCQILGWGKMENGD-----FPDTIQCADVHLVPREQCER 177
                      C + GWG + + +
                С
                                              PDT+ CA++ ++
Sbjct: 122 RPVVLPTRCPHPGEACVVSGWGLVSHNEPGTTGRPQSQVSLPDTLHCANISIISDASCDK 181
Query: 178 AYPGKITQSMVCAGDMKEGNDSCQGDSGGPLVCGGRLRGLVSWGDMPCGSKEKPGVYTDV 237
                         G +SC+GDSGGPLVCGG L+G+VSWGD+PC + KPGVYT V
          YPG++T +MVCAG
Sbjct: 182 NYPGRLTNTMVCAGAEGRGAESCEGDSGGPLVCGGILQGIVSWGDVPCDNTTKPGVYTKV 241
Query: 238 CTHIRWIQNILR 249
         C +++WI+ ++
Sbjct: 242 CRYVKWIRETMK 253
gi|5713131|gb|AAD47815.1| G trypsin-like serine protease [Homo sapiens]
 gi|18314498|gb|AAH22068.1| G Kallikrein 11, isoform 1 preproprotein [Homo sapiens]
 qi|11244769|qb|AAG33364.1| G keratinocyte trypsin-like serine protease [Homo sapiens
 gi|10799396|gb|AAG23257.1|
                         G Homo sapiens kallikrein 11
 (UNQ649/PRO1279)
 gi|6681454|dbj|BAA88713.1| . G Hippostasin [Homo sapiens]
        Length = 250
 Score = 221 bits (563), Expect = 1e-56
 Identities = 104/249 (41%), Positives = 151/249 (60%), Gaps = 6/249 (2%)
         MKMLALCLVLAKSAWSEEQEKVVHGGPCLKDSHPFQAALYTSGHLLCGGVLIDPQWVLTA 67
Query: 8
                         + +++ G C
                                     S P+QAAL+
Sbjct: 1
         MRILQLILLALATGLVGGETRIIKGFECKPHSQPWQAALFEKTRLLCGATLIAPRWLLTA 60
Query: 68 AHCKKPNLQVILGKHNLRQTETFQRQISVDRTIVHPRYNP----ETHDNDIMMVHLKNPV 123
                V LG+HNL++ E ++ + + HP +N
                                                + H NDIM+V + +PV
Sbjct: 61 AHCLKPRYIVHLGQHNLQKEEGCEQTRTATESFPHPGFNNSLPNKDHRNDIMLVKMASPV 120
Query: 124 KFSKKIQPLPLKNDCSEENPNCQILGWGKMENGDF--PDTIQCADVHLVPREQCERAYPG 181
                           +C I GWG
           + ++PL L + C
                                    +
                                          P T++CA++ ++ ++CE AYPG
Sbjct: 121 SITWAVRPLTLSSRCVTAGTSCLISGWGSTSSPQLRLPHTLRCANITIIEHQKCENAYPG 180
Query: 182 KITQSMVCAGDMKEGNDSCQGDSGGPLVCGGRLRGLVSWGDMPCGSKEKPGVYTDVCTHI 241
          IT +MVCA
                    + G DSCQGDSGGPLVC
                                      L+G++SWG PC
Sbjct: 181 NITDTMVCASVQEGGKDSCQGDSGGPLVCNQSLQGIISWGQDPCAITRKPGVYTKVCKYV 240
Query: 242 RWIQNILRN 250
          WIQ ++N
Sbjct: 241 DWIQETMKN 249
| >gi|21618357|ref|NP 659196.1| G kallikrein 11 isoform 2 precursor [Homo sapiens]
```

gi|3649791|dbj|BAA33404.1| G serine protease (TLSP) [Homo sapiens]

Length = 282Score = 221 bits (563), Expect = 1e-56 Identities = 104/249 (41%), Positives = 151/249 (60%), Gaps = 6/249 (2%) Query: 8 MKMLALCLVLAKSAWSEEQEKVVHGGPCLKDSHPFQAALYTSGHLLCGGVLIDPOWVLTA 67 M++L L L+ + ++++ G C S P+QAAL+ LLCG LI P+W+LTA Sbjct: 33 MRILQLILLALATGLVGGETRIIKGFECKPHSQPWQAALFEKTRLLCGATLIAPRWLLTA 92 Query: 68 AHCKKPNLQVILGKHNLRQTETFQRQISVDRTIVHPRYNP----ETHDNDIMMVHLKNPV 123 V LG+HNL++ E ++ + + HP +N AHC KP + H NDIM+V + +PV Sbjct: 93 AHCLKPRYIVHLGQHNLQKEEGCEQTRTATESFPHPGFNNSLPNKDHRNDIMLVKMASPV 152 Query: 124 KFSKKIQPLPLKNDCSEENPNCQILGWGKMENGDF--PDTIQCADVHLVPREQCERAYPG 181 Sbjct: 153 SITWAVRPLTLSSRCVTAGTSCLISGWGSTSSPQLRLPHTLRCANITIIEHOKCENAYPG 212 Query: 182 KITQSMVCAGDMKEGNDSCQGDSGGPLVCGGRLRGLVSWGDMPCGSKEKPGVYTDVCTHI 241 IT +MVCA + G DSCQGDSGGPLVC L+G++SWG PC Sbjct: 213 NITDTMVCASVQEGGKDSCQGDSGGPLVCNQSLQGIISWGQDPCAITRKPGVYTKVCKYV 272 Query: 242 RWIQNILRN 250 WIQ ++NSbjct: 273 DWIQETMKN 281 Sgi|51714016|ref|XP 489833.1| G similar to trypsinogen 12 [Mus musculus] gi 2358116 gb AAB69086.1 trypsinogen 12 [Mus musculus] Length = 245Score = 221 bits (562), Expect = 2e-56 Identities = 106/241 (43%), Positives = 156/241 (64%), Gaps = 4/241 (1%) Query: 10 MLALCLVLAKSAWSEEQEKVVHGGPCLKDSHPFQAALYTSGHLLCGGVLIDPQWVLTAAH 69 +L L LV A A+ + +K+V G C ++S P+Q +L SG+ CGG LI+ QWV++AAH Sbjct: 4 LLFLALVGAAVAFPVDDDKIVGGYTCRENSVPYQVSL-NSGYHFCGGSLINDQWVVSAAH 62 Query: 70 CKKPNLQVILGKHNLRQTETFQRQISVDRTIVHPRYNPETHDNDIMMVHLKNPVKFSKKI 129 C K +QV LG+HN++ E ++ ++ + I HP +N +T +NDIM++ L +PV + ++ Sbjct: 63 CYKTRIQVRLGEHNIKVLEGNEQFVNAAKIIKHPNFNRKTLNNDIMLIKLSSPVTLNARV 122 Query: 130 QPLPLKNDCSEENPNCQILGWGKMENGDF--PDTIQCADVHLVPREQCERAYPGKITQSM 187 + L + C+ C I GWG + PD +QC D L+P+ CE +YPGKIT +M Sbjct: 123 ATVALPSSCAPAGTQCLISGWGNTLSFGVSEPDLLQCLDAPLLPQADCEASYPGKITGNM 182 Query: 188 VCAGDMKEGNDSCQGDSGGPLVCGGRLRGLVSWGDMPCGSKEKPGVYTDVCTHIRWIQNI 247 VCAG ++ G DSCQGDSGGP+VC G L+G+VSWG C + PGVYT VC ++ WIQ+ Sbjct: 183 VCAGFLEGGKDSCQGDSGGPVVCNGELQGIVSWG-YGCALADNPGVYTKVCNYVDWIQDT 241 Query: 248 L 248

gi 2358119 gb AAB69089.1 G trypsinogen 20 [Mus musculus]

Sbjct: 242 I 242

```
trypsin (EC 3.4.21.4) precursor - mouse
gi | 91854 | pir | | B25528
Length = 246
Score = 220 bits (560), Expect = 3e-56
Identities = 107/242 (44%), Positives = 155/242 (64%), Gaps = 5/242 (2%)
Query: 10 MLALCLVLAKSAWS-EEQEKVVHGGPCLKDSHPFQAALYTSGHLLCGGVLIDPQWVLTAA 68
         +L L LV A A+ ++ +K+V G C + S P+Q +L +G+ CGG LI+ OWV++AA
         LLILALVGAAVAFPVDDDDKIVGGYTCRESSVPYQVSL-NAGYHFCGGSLINDOWVVSAA 62
Query: 69 HCKKPNLQVILGKHNLRQTETFQRQISVDRTIVHPRYNPETHDNDIMMVHLKNPVKFSKK 128
         HC K +QV LG+HN+
                         E ++ +
                                 + I HP YN T DNDIM++ L +PV + +
Sbjct: 63 HCYKYRIQVRLGEHNINVLEGNEQFVDSAKIIRHPNYNSWTLDNDIMLIKLASPVTLNAR 122
Query: 129 IQPLPLKNDCSEENPNCQILGWGK-MENG-DFPDTIQCADVHLVPREQCERAYPGKITQS 186
         + +PL + C+ C I GWG + NG + PD +QC D ++P+ CE +YPG IT +
Sbjct: 123 VASVPLPSSCAPAGTQCLISGWGNTLSNGVNNPDLLQCVDAPVLPQADCEASYPGDITNN 182
Query: 187 MVCAGDMKEGNDSCQGDSGGPLVCGGRLRGLVSWGDMPCGSKEKPGVYTDVCTHIRWIQN 246
         M+C G ++ G DSCQGDSGGP+VC G L+G+VSWG C + PGVYT VC ++ WIQN
Sbjct: 183 MICVGFLEGGKDSCQGDSGGPVVCNGELQGIVSWG-YGCAQPDAPGVYTKVCNYVDWIQN 241
Query: 247 IL 248
Sbjct: 242 TI 243
pgi|57036282|ref|XP 533604.1| G PREDICTED: similar to kallikrein 11 isoform 2 precu
         familiaris]
        Length = 554
Score = 220 bits (560), Expect = 3e-56
Identities = 101/254 (39%), Positives = 152/254 (59%), Gaps = 9/254 (3%)
Query: 3
         MKMLTMKMLALCLVLAKSAWSEEQEKVVHGGPCLKDSHPFQAALYTSGHLLCGGVLIDPO 62
         M M+ ++++ LV + + +++ G C S P+Q AL+
                                                   LLCG LI P+ .
Sbjct: 303 MAMMILRLIMFALV---TGHVRAETRIIKGYECSPHSQPWQVALFQKTRLLCGATLIAPK 359
Query: 63 WVLTAAHCKKPNLQVILGKHNLRQTETFQRQISVDRTIVHPRYNP----ETHDNDIMMVH 118
                    V LG+HNL++ + ++ +S
         W+LTAAHC+KP
                                        + HP +N
Sbjct: 360 WLLTAAHCRKPRYVVHLGEHNLQRRDGCEQTLSATESFPHPDFNNSLPNKDHRNDIMLVK 419
Query: 119 LKNPVKFSKKIQPLPLKNDCSEENPNCQILGWGKMENGDF--PDTIQCADVHLVPREQCE 176
               + ++PL L + C C + GWG
                                              P T++CA++ ++ E+CE
Sbjct: 420 MTRAAFITWAVRPLTLSSHCVTPGTRCLVSGWGSTSSPOLOLPHTLRCANITIINHEECE 479
Query: 177 RAYPGKITQSMVCAGDMKEGNDSCQGDSGGPLVCGGRLRGLVSWGDMPCGSKEKPGVYTD 236
         +AYPG IT +MVCA ++ G DSCQGDSGGPLVC G L+G++SWG PC
Sbjct: 480 KAYPGNITNTMVCASVLESGKDSCQGDSGGPLVCDGSLQGIISWGQDPCAVTRKPGVYTK 539
Query: 237 VCTHIRWIONILRN 250
         VC ++ WI+ + N
Sbjct: 540 VCKYVDWIRKTMEN 553
```

```
Score = 209 \text{ bits } (531), Expect = 7e-53
 Identities = 108/250 (43%), Positives = 145/250 (58%), Gaps = 7/250 (2%)
          MPMKMLTMKMLALCLVLAKSAWSEEQEKVVHGGPCLKDSHPFQAALYTSGHLLCGGVLID 60
           M + +T+
                       L L
                                     EK+V G C + S P+Q L+
Sbjct: 55
          MTWRWVTLGSSILLLFCVTGLSQPATEKIVKGKECARHSQPWQVGLFEGANLRCGGVLID 114
Query: 61 PQWVLTAAHCKKPNLQVILGKHNLRQTETFQRQISVDRTIVHPRYN--PETHDNDIMMVH 118
            +WVLTAAHC
                          V LG+H+L + + ++
                                                 ++ HP Y
                                                             +HDNDI ++
Sbjct: 115 RRWVLTAAHC-SGRYWVRLGEHSLSRLDWTEKIRRSGFSMTHPSYQGAQHSHDNDIRLLR 173
Query: 119 LKNPVKFSKKIQPLPLKNDCSEENPNCQILGWGKMEN--GDFPDTIQCADVHLVPREQCE 176
           L PV ++ IQPLPL C+ CQI GWG
                                                    FPD +QC +V +V
Sbjct: 174 LGTPVPLTRSIQPLPLPTTCAVAGTKCQISGWGITNQLWNPFPDLLQCLNVSIVSSAACR 233
Query: 177 RAYPGKITQSMVCAGDMKEGNDSCQGDSGGPLVCGGRLRGLVSWGDM-PCGSKEKPGVYT 235
             +PG+IT +MVCA EG D+CQGDSGGPLVCG L+GLVSWG + PCG K PGVYT
Sbjct: 234 AVFPGRITDNMVCASG-TEGADACQGDSGGPLVCGNVLQGLVSWGTVEPCGQKGIPGVYT 292
Query: 236 DVCTHIRWIQ 245
           ++C ++ WI+
Sbjct: 293 NICKYVDWIR 302
| >gi | 58257843 | gb | AAW69362.1 | try9 [Macaca mulatta]
         Length = 247
 Score = 219 \text{ bits } (559), Expect = 4e-56
 Identities = 104/227 (45%), Positives = 141/227 (62%), Gaps = 4/227 (1%)
Query: 24 EEQEKVVHGGPCLKDSHPFQAALYTSGHLLCGGVLIDPQWVLTAAHCKKPNLQVILGKHN 83
           ++ +K+V G C ++S P+Q LY SG+ CGG LI QWV++A HC KP +OVILG+HN
Sbjct: 19 DDDDKIVGGYTCKENSVPYQVFLY-SGYHFCGGALICEQWVISACHCYKPRIQVILGEHN 77
Query: 84 LRQTETFQRQISVDRTIVHPRYNPETHDNDIMMVHLKNPVKFSKKIOPLPLKNDCSEENP 143
              E ++ IS D+ I HP YNP T DNDIM++ L P
Sbjct: 78 INVLEGTEQFISADKIICHPEYNPTTLDNDIMLIKLSTPAIINDYVSIIPLPTHPPVPCT 137
Query: 144 NCQILGWGK--MENGDFPDTIQCADVHLVPREQCERAYPGKITQSMVCAGDMKEGNDSCQ 201
           C I GWG
                         D+PD +QC D ++ + +CE YPG+IT +M C G ++ G DSCQ
Sbjct: 138 ECLISGWGNTLSYGADYPDELQCLDAPVLTQAECEACYPGRITSNMFCIGFLEGGKDSCQ 197
Query: 202 GDSGGPLVCGGRLRGLVSWGDMPCGSKEKPGVYTDVCTHIRWIQNIL 248
          GDSGGP VC G L+G+VSWGD C K KPGVYT V ++ WI+ +
Sbjct: 198 GDSGGPAVCDGELQGIVSWGD-GCAQKNKPGVYTKVHNYLAWIKETI 243
| >gi|6981420|ref|NP 036767.1| | G pancreatic trypsin 1 [Rattus norvegicus]
                          G unnamed protein product [Rattus norvegicus]
gi | 57408 | emb | CAA24580.1 |
gi|67547|pir||TRRT1
                      trypsin (EC 3.4.21.4) I precursor - rat
gi|136409|sp|P00762|TRY1 RAT G Anionic trypsin I precursor (Pretrypsinogen I)
gi|206508|gb|AAA98518.1|
                          G trypsinogen I
         Length = 246
```

```
Score = 219 bits (558), Expect = 5e-56
 Identities = 109/242 (45%), Positives = 157/242 (64%), Gaps = 5/242 (2%)
Query: 10 MLALCLVLAKSAWS-EEQEKVVHGGPCLKDSHPFQAALYTSGHLLCGGVLIDPQWVLTAA 68
          +L L LV A A+ E+ +K+V G C + S P+Q +L SG+ CGG LI+ QWV++AA
Sbjct: 4
          LLILALVGAAVAFPLEDDDKIVGGYTCPEHSVPYQVSL-NSGYHFCGGSLINDOWVVSAA 62
Query: 69 HCKKPNLQVILGKHNLRQTETFQRQISVDRTIVHPRYNPETHDNDIMMVHLKNPVKFSKK 128
          HC K +QV LG+HN+
                         E ++ I+ + I HP Y+ T +NDIM++ L +PVK + +
Sbjct: 63 HCYKSRIQVRLGEHNINVLEGDEQFINAAKIIKHPNYSSWTLNNDIMLIKLSSPVKLNAR 122
Query: 129 IQPLPLKNDCSEENPNCQILGWGK-MENG-DFPDTIQCADVHLVPREQCERAYPGKITQS 186
          + P+ L + C+
                        C I GWG + NG + PD +QC D ++ + CE AYPG+IT S
Sbjct: 123 VAPVALPSACAPAGTQCLISGWGNTLSNGVNNPDLLQCVDAPVLSQADCEAAYPGEITSS 182
Query: 187 MVCAGDMKEGNDSCQGDSGGPLVCGGRLRGLVSWGDMPCGSKEKPGVYTDVCTHIRWIQN 246
          M+C G ++ G DSCQGDSGGP+VC G+L+G+VSWG C + PGVYT VC + WIQ+
Sbjct: 183 MICVGFLEGGKDSCQGDSGGPVVCNGQLQGIVSWG-YGCALPDNPGVYTKVCNFVGWIQD 241
Query: 247 IL 248
Sbjct: 242 TI 243
gi|2358085|gb|AAB69056.1|  G trypsinogen 8 [Mus musculus]
 gi 38511693 | gb | AAH61135.1 | G Trypsin 4 [Mus musculus]
 gi | 4239965 | dbj | BAA74761.1 | G pancreatic trypsin [Mus musculus]
 gi|12843002|dbj|BAB25821.1| G unnamed protein product [Mus musculus]
 Length = 246
 Score = 219 bits (558), Expect = 5e-56
 Identities = 106/242 (43%), Positives = 157/242 (64%), Gaps = 5/242 (2%)
Query: 10 MLALCLVLAKSAWS-EEQEKVVHGGPCLKDSHPFQAALYTSGHLLCGGVLIDPQWVLTAA 68
          +L L LV A A+ ++ +K+V G C ++S P+Q +L SG+ CGG LI+ QWV++AA
Sbjct: 4
         LLFLALVGAAVAFPVDDDDKIVGGYTCRENSVPYQVSL-NSGYHFCGGSLINDQWVVSAA 62
Query: 69 HCKKPNLQVILGKHNLRQTETFQRQISVDRTIVHPRYNPETHDNDIMMVHLKNPVKFSKK 128
         Sbjct: 63 HCYKSRIQVRLGEHNINVLEGNEQFVNSAKIIKHPNFNSRTLNNDIMLIKLASPVTLNAR 122
Query: 129 IQPLPLKNDCSEENPNCQILGWGKMEN--GDFPDTIQCADVHLVPREQCERAYPGKITQS 186
          + + L + C+
                        C I GWG
                                     + PD +QC D L+P+ CE +YPGKIT +
Sbjct: 123 VATVALPSSCAPAGTQCLISGWGNTLSFGVNNPDLLQCLDAPLLPQADCEASYPGKITNN 182
Query: 187 MVCAGDMKEGNDSCQGDSGGPLVCGGRLRGLVSWGDMPCGSKEKPGVYTDVCTHIRWIQN 246
         M+C G ++ G DSCQGDSGGP+VC G+L+G+VSWG C K+ PGVYT VC ++ WIQN
Sbjct: 183 MICVGFLEGGKDSCQGDSGGPVVCNGQLQGIVSWG-YGCALKDNPGVYTKVCNYVDWION 241
Query: 247 IL 248
Sbjct: 242 TI 243
```

```
>gi | 67548 | pir | | TRRT2
                          trypsin (EC 3.4.21.4) II precursor - rat
          Length = 246
 Score = 218 bits (556), Expect = 9e-56
 Identities = 107/242 (44%), Positives = 159/242 (65%), Gaps = 5/242 (2%)
Query: 10 MLALCLVLAKSAWS-EEQEKVVHGGPCLKDSHPFQAALYTSGHLLCGGVLIDPOWVLTAA 68
           +L L LV A A+ ++ +K+V G C ++S P+Q +L SG+ CGG LI+ QWV++AA
          LLFLALVGAAVAFPVDDDDKIVGGYTCQENSVPYQVSL-NSGYHFCGGSLINDQWVVSAA 62
Sbjct: 4
Query: 69 HCKKPNLQVILGKHNLRQTETFQRQISVDRTIVHPRYNPETHDNDIMMVHLKNPVKFSKK 128
           HC K +QV LG+HN+ E ++ I+ + I HP ++ +T +NDIM++ L +PVK + +
Sbjct: 63 HCYKSRIQVRLGEHNINVLEGDEQFINAAKIIKHPNFDRKTLNNDIMLIKLSSPVKLNAR 122
Query: 129 IQPLPLKNDCSEENPNCQILGWGK-MENG-DFPDTIQCADVHLVPREQCERAYPGKITQS 186
           + + L + C+
                         C I GWG + +G + PD +QC D L+P+ CE +YPGKIT +
Sbjct: 123 VATVALPSSCAPAGTQCLISGWGNTLSSGVNEPDLLQCLDAPLLPQADCEASYPGKITDN 182
Query: 187 MVCAGDMKEGNDSCQGDSGGPLVCGGRLRGLVSWGDMPCGSKEKPGVYTDVCTHIRWIQN 246
           MVC G ++ G DSCQGDSGGP+VC G L+G+VSWG C
                                                      + PGVYT VC ++ WIQ+
Sbjct: 183 MVCVGFLEGGKDSCQGDSGGPVVCNGELQGIVSWG-YGCALPDNPGVYTKVCNYVDWIQD 241
Query: 247 IL 248
Sbjct: 242 TI 243
>gi|6981422|ref|NP 036861.1| G protease, serine, 2 [Rattus norvegicus]
                           G trypsinogen II [Rattus norvegicus]
 gi|206506|qb|AAA98517.1|
 gi | 2851507 | sp | P00763 | TRY2 RAT G Anionic trypsin II precursor (Pretrypsinogen II)
          Length = 246
 Score = 218 bits (555), Expect = 1e-55
 Identities = 106/242 (43%), Positives = 159/242 (65%), Gaps = 5/242 (2%)
Query: 10 MLALCLVLAKSAWS-EEQEKVVHGGPCLKDSHPFQAALYTSGHLLCGGVLIDPQWVLTAA 68
           +L L LV A A+ ++ +K+V G C ++S P+Q +L SG+ CGG LI+ OWV++AA
Sbjct: 4 LLFLALVGAAVAFPVDDDDKIVGGYTCQENSVPYQVSL-NSGYHFCGGSLINDQWVVSAA 62
Query: 69 HCKKPNLQVILGKHNLRQTETFQRQISVDRTIVHPRYNPETHDNDIMMVHLKNPVKFSKK 128
           \mbox{HC K} + \mbox{QV LG+HN+} \qquad \mbox{E} \qquad ++ \ \ ++ \ \ + \ \mbox{I HP ++} \ \ +T \ \ +\mbox{NDIM++} \ \ \mbox{L} \ \ +\mbox{PVK +} \ \ +
Sbjct: 63 HCYKSRIQVRLGEHNINVLEGNEQFVNAAKIIKHPNFDRKTLNNDIMLIKLSSPVKLNAR 122
Query: 129 IQPLPLKNDCSEENPNCQILGWGK-MENG-DFPDTIQCADVHLVPREQCERAYPGKITQS 186
           + + L + C+
                          C I GWG + +G + PD +QC D L+P+ CE +YPGKIT +
Sbjct: 123 VATVALPSSCAPAGTQCLISGWGNTLSSGVNEPDLLQCLDAPLLPQADCEASYPGKITDN 182
Query: 187 MVCAGDMKEGNDSCQGDSGGPLVCGGRLRGLVSWGDMPCGSKEKPGVYTDVCTHIRWIQN 246
           MVC G ++ G DSCQGDSGGP+VC G L+G+VSWG
                                                С
                                                      + PGVYT VC ++ WIO+
Sbjct: 183 MVCVGFLEGGKDSCQGDSGGPVVCNGELQGIVSWG-YGCALPDNPGVYTKVCNYVDWIQD 241
Query: 247 IL 248
Sbjct: 242 TI 243
```

```
m>qi|47206216|emb|CAF90862.1| unnamed protein product [Tetraodon nigroviridis]
        Length = 240
 Score = 218 bits (554), Expect = 2e-55
 Identities = 100/230 (43%), Positives = 151/230 (65%), Gaps = 7/230 (3%)
Query: 24 EEQEKVVHGGPCLKDSHPFQAALYTSGHLLCGGVLIDPQWVLTAAHCK-KPNLQVILGKH 82
          ++ K+V G CLK+S P+Q +L+T G+ CGG+L+ +WVL+AAHCK K +++V LG+H
Sbjct: 11 KDDNKIVGGYECLKNSVPYQVSLFT-GYNFCGGILLSAEWVLSAAHCKPKSDVEVRLGEH 69
Query: 83 NLRQTETFQRQISVDRTIVHPRYNPETHDNDIMMVHLKNPVKFSKKIQPLPLKNDCSEEN 142
         ++ + + + + I + I HP YNP T D+DIM++ L P + + P L + C+ +
Sbjct: 70 DIWEPDGTEQHIMSSQFIRHPDYNPRTQDSDIMLIKLSRPATLNSFVSPAALPSRCAADG 129
Query: 143 PNCQILGWGKMENGD----FPDTIQCADVHLVPREQCERAYPGKITQSMVCAGDMKEGND 198
           CQI GWG + D +PD +QC + L+ + C AYP +IT++M+CAG ++ G D
Sbjct: 130 TMCQISGWGSLRPSDEGSRYPDKLQCLEAPLLSDDTCFNAYPFQITKNMICAGYLEGGKD 189
Query: 199 SCQGDSGGPLVCGGRLRGLVSWGDMPCGSKEKPGVYTDVCTHIRWIQNIL 248
          SCQGDSGGPL+C G L+G+VSWG
                                C + KPGVYT VC +I WI++ +
Sbjct: 190 SCQGDSGGPLMCNGELQGVVSWGH-GCAQRNKPGVYTKVCNYISWIKDTM 238
gi | 4239963 | dbj | BAA74760.1 | G TESP4 [Mus musculus]
gi|6016832|dbj|BAA85187.1| G TESP4 [Mus musculus]
 gi | 12841657 | dbj | BAB25300.1 | G unnamed protein product [Mus musculus]
        Length = 246
 Score = 217 bits (553), Expect = 2e-55
 Identities = 105/242 (43%), Positives = 157/242 (64%), Gaps = 5/242 (2%)
Query: 10 MLALCLVLAKSAWS-EEQEKVVHGGPCLKDSHPFQAALYTSGHLLCGGVLIDPQWVLTAA 68
          +L L LV A A+ ++ +K+V G C ++S P+O +L SG+ CGG LI+ OWV++AA
Sbjct: 4
         LLFLALVGAAVAFPVDDDDKIVGGYTCRENSIPYQVSL-NSGYHFCGGSLINDQWVVSAA 62
Query: 69 HCKKPNLQVILGKHNLRQTETFQRQISVDRTIVHPRYNPETHDNDIMMVHLKNPVKFSKK 128
         HC K +QV LG+HN+ E ++ ++ + I HP +N T +NDIM++ L +PV ++
Sbjct: 63 HCYKTRIQVRLGEHNINVLEGNEQFVNSAKIIKHPNFNSRTLNNDIMLIKLASPVTLNAR 122
Query: 129 IQPLPLKNDCSEENPNCQILGWGKMEN--GDFPDTIQCADVHLVPREQCERAYPGKITQS 186
          Sbjct: 123 VATVALPSSCAPAGTQCLISGWGNTLSFGVNNPDLLQCLDAPLLPQADCEASYPGKITNN 182
Query: 187 MVCAGDMKEGNDSCQGDSGGPLVCGGRLRGLVSWGDMPCGSKEKPGVYTDVCTHIRWIQN 246
         M+C G ++ .G DSCQGDSGGP+VC G+L+G+VSWG C K+ PGVYT VC ++ WIQ+
Sbjct: 183 MICVGFLEGGKDSCQGDSGGPVVCNGQLQGIVSWG-YGCALKDNPGVYTKVCNYVDWIQD 241
Query: 247 IL 248
Sbjct: 242 TI 243
```

| >gi|16716569|ref|NP 444473.1| | G trypsinogen 16 [Mus musculus]

```
gi|2358118|gb|AAB69088.1| G trypsinogen 16 [Mus musculus]
Length = 246
 Score = 217 bits (552), Expect = 3e-55
 Identities = 107/242 (44%), Positives = 155/242 (64%), Gaps = 5/242 (2%)
Query: 10 MLALCLVLAKSAWS-EEQEKVVHGGPCLKDSHPFQAALYTSGHLLCGGVLIDPOWVLTAA 68
          +L L LV A A+ ++ +K+V G C ++S P+Q +L SG+ CGG LI+ QWV++AA
         LLFLALVGAAVAFPVDDDDKIVGGYTCRENSVPYQVSL-NSGYHFCGGSLINDQWVVSAA 62
Sbjct: 4
Query: 69 HCKKPNLQVILGKHNLRQTETFQRQISVDRTIVHPRYNPETHDNDIMMVHLKNPVKFSKK 128
          HC K +QV LG+HN+ E ++ I + I HP +N +T +NDIM++ L +PV + +
Sbjct: 63 HCYKTRIQVRLGEHNINVLEGNEQFIDAAKIIKHPNFNRKTLNNDIMLIKLSSPVTLNAR 122
Query: 129 IQPLPLKNDCSEENPNCQILGWGKMENGDF--PDTIQCADVHLVPREQCERAYPGKITQS 186
          + + L + C+ C I GWG
                                +
                                       PD +QC D L+P+ CE +YPGKIT +
Sbjct: 123 VATVALPSSCAPAGTQCLISGWGNTLSFGVSEPDLLQCLDAPLLPQADCEASYPGKITGN 182
Query: 187 MVCAGDMKEGNDSCQGDSGGPLVCGGRLRGLVSWGDMPCGSKEKPGVYTDVCTHIRWIQN 246
          MVCAG ++ G DSCQGDSGGP+VC G L+G+VSWG C + PGVYT VC ++ WIQ+
Sbjct: 183 MVCAGFLEGGKDSCQGDSGGPVVCNGELQGIVSWG-YGCALPDNPGVYTKVCNYVDWIQD 241
```

Query: 247 IL 248 + Sbjct: 242 TI 243

```
Score = 217 bits (552), Expect = 3e-55
Identities = 106/242 (43%), Positives = 158/242 (65%), Gaps = 5/242 (2%)
```

Query: 10 MLALCLVLAKSAWS-EEQEKVVHGGPCLKDSHPFQAALYTSGHLLCGGVLIDPQWVLTAA 68
+L L LV A A+ ++ +K+V G C ++S P+Q +L SG+ CGG LI+ QWV++AA
Sbjct: 3 LLFLALVGAAVAFPVDDDDKIVGGYTCQENSVPYQVSL-NSGYHFCGGSLINDQWVVSAA 61

Query: 69 HCKKPNLQVILGKHNLRQTETFQRQISVDRTIVHPRYNPETHDNDIMMVHLKNPVKFSKK 128 HC K +QV LG+HN+ E ++ ++ + I HP ++ +T +NDIM++ L +PVK +

Sbjct: 62 HCYKSRIQVRLGEHNINVLEGNEQFVNAAKIIKHPNFDRKTLNNDIMLIKLSSPVKLNAH 121

Query: 129 IQPLPLKNDCSEENPNCQILGWGK-MENG-DFPDTIQCADVHLVPREQCERAYPGKITQS 186 + + L + C+ C I GWG + +G + PD +QC D L+P+ CE +YPGKIT +

Sbjct: 122 VATVALPSSCAPAGTQCLISGWGNTLSSGVNEPDLLQCLDAPLLPQADCEASYPGKITDN 181

Query: 187 MVCAGDMKEGNDSCQGDSGGPLVCGGRLRGLVSWGDMPCGSKEKPGVYTDVCTHIRWIQN 246 MVC G ++ G DSCQGDSGGP+VC G L+G+VSWG C + PGVYT VC ++ WIQ+

Sbjct: 182 MVCVGFLEGGKDSCQGDSGGPVVCNGELQGIVSWG-YGCALPDNPGVYTKVCNYVDWIQD 240

Query: 247 IL 248

Sbjct: 241 TI 242

[>qi|51871601|ref|NP 001004097.1| G trypsin 10 precursor [Rattus norvegicus]

```
gi|47169490|tpe|CAE48382.1| G TPA: trypsin 10 [Rattus norvegicus]
Length = 246
```

Score = 216 bits (551), Expect = 3e-55
Identities = 106/242 (43%), Positives = 157/242 (64%), Gaps = 5/242 (2%)

Query: 10 MLALCLVLAKSAW-SEEQEKVVHGGPCLKDSHPFQAALYTSGHLLCGGVLIDPQWVLTAA 68 +L L LV A A+ + + +K+V G 'C ++S P+Q +L SG+ CGG LI+ QWV++AA

Sbjct: 4 VLILALVGAAVAFPAADDDKIVGGYTCQENSVPYQVSL-NSGYHFCGGSLINEQWVVSAA 62

Query: 69 HCKKPNLQVILGKHNLRQTETFQRQISVDRTIVHPRYNPETHDNDIMMVHLKNPVKFSKK 128 HC K +QV LG+HN+ E ++ ++ + I HP + +T +NDIM++ L +PVK + +

Sbjct: 63 HCYKSRIQVRLGEHNINVLEGNEQFVNAAKIIKHPNFIRKTLNNDIMLIKLSSPVKLNSR 122

Query: 129 IQPLPLKNDCSEENPNCQILGWGKMEN--GDFPDTIQCADVHLVPREQCERAYPGKITQS 186 + + L + C+ C I GWG + + PD +QC D L+P+ CE +YPGKIT +

Sbjct: 123 VATVALPSSCAPAGTQCLISGWGNTLSFGVNEPDLLQCLDAPLLPQADCEASYPGKITDN 182

Query: 187 MVCAGDMKEGNDSCQGDSGGPLVCGGRLRGLVSWGDMPCGSKEKPGVYTDVCTHIRWIQN 246 MVCAG ++ G DSCQGDSGGP+VC G L+G+VSWG C + PGVYT VC ++ WIQ+

Sbjct: 183 MVCAGFLEGGKDSCQGDSGGPVVCNGELQGIVSWG-YGCALPDNPGVYTKVCNYVDWIQD 241

Query: 247 IL 248

Sbjct: 242 TI 243

>gi | 2358117 | gb | AAB69087.1 | trypsinogen 15 [Mus musculus] Length = 246

Score = 216 bits (551), Expect = 3e-55
Identities = 106/241 (43%), Positives = 155/241 (64%), Gaps = 5/241 (2%)

Query: 11 LALCLVLAKSAWS-EEQEKVVHGGPCLKDSHPFQAALYTSGHLLCGGVLIDPQWVLTAAH 69
L L LV A A+ ++ +K+V G C ++S P+Q +L SG+ CGG LI+ QWV++AAH

Sbjct: 5 LILALVGAAVAFPVDDDDKIVGGYTCQENSVPYQVSL-NSGYHFCGGSLINDQWVVSAAH 63

Query: 70 CKKPNLQVILGKHNLRQTETFQRQISVDRTIVHPRYNPETHDNDIMMVHLKNPVKFSKKI 129 C K +QV LG+HN+ E ++ ++ + I HP +N +T +NDIM++ L +PV + ++

Sbjct: 64 CYKTRIQVRLGEHNINVLEGNEQFVNAAKIIKHPNFNRKTLNNDIMLIKLSSPVTLNARV 123

Query: 130 QPLPLKNDCSEENPNCQILGWGKMENGDF--PDTIQCADVHLVPREQCERAYPGKITQSM 187
+ L + C+ C I GWG + PD +OC D L+P+ CE +YPGKIT +M

Sbjct: 124 ATVALPSSCAPAGTQCLISGWGNTLSFGVSEPDLLQCLDAPLLPQADCEASYPGKITGNM 183

Query: 188 VCAGDMKEGNDSCQGDSGGPLVCGGRLRGLVSWGDMPCGSKEKPGVYTDVCTHIRWIQNI 247

VCAG ++ G DSCQGDSGGP+VC G L+G+VSWG C + PGVYT VC ++ WIQ+

Sbjct: 184 VCAGFLEGGKDSCQGDSGGPVVCNGELQGIVSWG-YGCALPDNPGVYTKVCNYVDWIQDT 242

Query: 248 L 248

Sbjct: 243 I 243

>gi | 758266 | emb | CAA24581.1 | G unnamed protein product [Rattus norvegicus]

Length = 238

```
Score = 216 bits (550), Expect = 5e-55
 Identities = 100/227 (44%), Positives = 151/227 (66%), Gaps = 4/227 (1%)
Query: 24 EEQEKVVHGGPCLKDSHPFQAALYTSGHLLCGGVLIDPOWVLTAAHCKKPNLOVILGKHN 83
          ++ +K+V G C ++S P+Q +L SG+ CGG LI+ QWV++AAHC K +OV LG+HN
Sbjct: 11 DDDDKIVGGYTCQENSVPYQVSL-NSGYHFCGGSLINDQWVVSAAHCYKSRIQVRLGEHN 69
Query: 84 LRQTETFQRQISVDRTIVHPRYNPETHDNDIMMVHLKNPVKFSKKIQPLPLKNDCSEENP 143
          + E ++ ++ + I HP ++ +T +NDIM++ L +PVK + ++ + L + C+
Sbjct: 70 INVLEGNEQFVNAAKIIKHPNFDRKTLNNDIMLIKLSSPVKLNARVATVALPSSCAPAGT 129
Query: 144 NCQILGWGK-MENG-DFPDTIQCADVHLVPREOCERAYPGKITOSMVCAGDMKEGNDSCO 201
           C I GWG + +G + PD +QC D L+P+ CE +YPGKIT +MVC G ++ G DSCO
Sbjct: 130 QCLISGWGNTLSSGVNEPDLLQCLDAPLLPQADCEASYPGKITDNMVCVGFLEGGKDSCO 189
Query: 202 GDSGGPLVCGGRLRGLVSWGDMPCGSKEKPGVYTDVCTHIRWIQNIL 248
          GDSGGP+VC G L+G+VSWG C + PGVYT VC ++ WIQ+ +
Sbjct: 190 GDSGGPVVCNGELQGIVSWG-YGCALPDNPGVYTKVCNYVDWIQDTI 235
Similar to trypsinogen 9 [Rattus norvegicus]
         Length = 246
 Score = 216 bits (550), Expect = 5e-55
 Identities = 103/242 (42%), Positives = 156/242 (64%), Gaps = 5/242 (2%)
Query: 10 MLALCLVLAKSAWS-EEQEKVVHGGPCLKDSHPFQAALYTSGHLLCGGVLIDPQWVLTAA 68
          +L L LV A+ ++ +K+V G C ++S P+Q +L SG+ CGG LI+ QWV++AA
Sbjct: 4
          LLFLALVGVAVAFPVDDDDKIVGGYTCQENSVPYQVSL-NSGYHFCGGSLINDQWVVSAA 62
Query: 69 HCKKPNLQVILGKHNLRQTETFQRQISVDRTIVHPRYNPETHDNDIMMVHLKNPVKFSKK 128
          HC K +QV LG+HN+ E ++ ++ I HP +N
                                                  +NDIM++L+PVK++
Sbjct: 63 HCYKTRIQVRLGEHNINVLEGDEQFVNAAKIIKHPNFNARNLNNDIMLIKLSSPVKLNAR 122
Query: 129 IQPLPLKNDCSEENPNCQILGWGKMEN--GDFPDTIQCADVHLVPREQCERAYPGKITQS 186
          + + L + C+ C I GWG + + PD +QC D ++P+ CE +YPGKIT +
Sbjct: 123 VATVALPSSCAPAGTQCLISGWGNTLSLGVNNPDLLQCLDAPVLPQADCEASYPGKITNN 182
Query: 187 MVCAGDMKEGNDSCQGDSGGPLVCGGRLRGLVSWGDMPCGSKEKPGVYTDVCTHIRWION 246
          M+C G ++ G DSCQGDSGGP+VC G+L+G+VSWG C K+ PGVYT VC ++ WIQ+
Sbjct: 183 MICVGFLEGGKDSCQGDSGGPVVCNGQLQGIVSWG-YGCALKDNPGVYTKVCNYVDWIQD 241
Query: 247 IL 248
Sbjct: 242 TI 243
| >gi|34855<u>588|ref|XP 342672.1|</u> | G similar to trypsin (EC 3.4.21.4) II precursor - rat
          norvegicus]
         Length = 291
Score = 216 \text{ bits } (549), Expect = 6e-55
Identities = 106/250 (42%), Positives = 159/250 (63%), Gaps = 5/250 (2%)
          PMKMLTMKMLALCLVLAKSAWS-EEQEKVVHGGPCLKDSHPFQAALYTSGHLLCGGVLID 60
                +L
                     LV + A+ ++ +K+V G C + S P+Q +L SG+ CGG LI+
Sbjct: 41 PSRTLKDCLLNHLLVFIQVAFPVDDDDKIVGGYTCQEHSVPYQVSL-NSGYHYCGGSLIN 99
```

```
Query: 61 PQWVLTAAHCKKPNLQVILGKHNLRQTETFQRQISVDRTIVHPRYNPETHDNDIMMVHLK 120
           QWV++AAHC K +QV LG+HN+ E ++ ++ + 1 HP ++ +T +NDIM++ L
Sbjct: 100 DQWVVSAAHCYKSRIQVRLGEHNINVLEGDEQFVNAAKIIKHPNFDRKTLNNDIMLIKLS 159
Query: 121 NPVKFSKKIQPLPLKNDCSEENPNCQILGWGKMEN--GDFPDTIQCADVHLVPREQCERA 178
          Sbjct: 160 SPVKLNARVATVALPSSCAPAGTQCLISGWGNTLSFGVNDPDLLQCLDAPLLPQADCEAS 219
Query: 179 YPGKITQSMVCAGDMKEGNDSCQGDSGGPLVCGGRLRGLVSWGDMPCGSKEKPGVYTDVC 238
          YPGKIT +MVCAG ++ G DSCQGDSGGP+VC G L+G+VSWG C + PGVYT VC
Sbjct: 220 YPGKITNNMVCAGFLEGGKDSCQGDSGGPVVCNGELQGIVSWG-YGCALPDNPGVYTKVC 278
Query: 239 THIRWIQNIL 248
           ++ WIQ+ +
Sbjct: 279 NYVDWIQDTI 288
S | Sqi | 56541274 | gb | AAH87610.1 | G | Hypothetical LOC496627 [Xenopus tropicalis]
 gi|58332100|ref|NP 001011202.1| G hypothetical LOC496627 [Xenopus tropicalis]
         Length = 243
 Score = 216 bits (549), Expect = 6e-55
 Identities = 100/243 (41%), Positives = 155/243 (63%), Gaps = 5/243 (2%)
Query: 8
          MKMLALCLVLAKSAWSEEQEKVVHGGPCLKDSHPFQAALYTSGHLLCGGVLIDPOWVLTA 67
          MK+L +C++L +A + + +K++ G C ++S P+ +L SG+ CGG LI QWV++A
          MKLLLICVLLGAAA-AFDDDKIIGGSTCARNSVPYIVSL-NSGYHFCGGSLISNQWVVSA 58
Sbjct: 1
Query: 68 AHCKKPNLQVILGKHNLRQTETFQRQISVDRTIVHPRYNPETHDNDIMMVHLKNPVKFSK 127
          AHC K ++QV LG+HN+ +E ++ I+ + I HP YN T DNDIM++ L +P
Sbjct: 59 AHCYKASVQVRLGEHNIALSEGTEQFINSAKVIRHPSYNSRTIDNDIMLIKLASPASLNS 118
Query: 128 KIQPLPLKNDCSEENPNCQILGWGKME--NGDFPDTIQCADVHLVPREQCERAYPGKITQ 185
                       +C + GWG + ++PD +QC + ++ QC AYPG+IT
           + + L + C+
Sbjct: 119 AVNTVALPSSCAAAGTSCLVSGWGNLSTTTSNYPDLLQCLNAPILTTAQCSGAYPGQITN 178
Query: 186 SMVCAGDMKEGNDSCQGDSGGPLVCGGRLRGLVSWGDMPCGSKEKPGVYTDVCTHIRWIQ 245
          +M CAG ++ G DSCQGDSGGP+VC G L+G+VSWG + C + PGVY VC + WIQ
Sbjct: 179 NMFCAGFLEGGKDSCQGDSGGPVVCNGELQGVVSWG-IGCAQRNYPGVYAKVCNYNSWIQ 237
Query: 246 NIL 248
Sbjct: 238 STI 240
>gi|51711962|ref|XP 487918.1| G PREDICTED: similar to trypsinogen 9 [Mus musculus]
         Length = 264
 Score = 215 bits (548), Expect = 8e-55
 Identities = 99/227 (43%), Positives = 149/227 (65%), Gaps = 4/227 (1%)
Query: 24 EEQEKVVHGGPCLKDSHPFQAALYTSGHLLCGGVLIDPQWVLTAAHCKKPNLQVILGKHN 83
          ++ +K+V G C ++S P+Q +L SG+ CGG LI+ QWV++AAHC K +QV LG+HN
Sbjct: 37 DDDDKIVGGYTCRENSIPYQVSL-NSGYHFCGGSLINDQWVVSAAHCYKTRIQVRLGEHN 95
Query: 84 LRQTETFQRQISVDRTIVHPRYNPETHDNDIMMVHLKNPVKFSKKIQPLPLKNDCSEENP 143
```

```
E ++ ++ + I HP +N T +NDIM++ L +PV + ++ + L + C+
Sbjct: 96 INVLEGNEQFVNSAKIIKHPNFNSRTLNNDIMLIKLASPVTLNARVATVALPSSCAPAGT 155
Query: 144 NCQILGWGKMEN--GDFPDTIQCADVHLVPREQCERAYPGKITQSMVCAGDMKEGNDSCQ 201
            C I GWG + + PD +QC D L+P+ CE +YPGKIT +M+C G ++ G DSCQ
Sbjct: 156 QCLISGWGNTLSFGVNNPDLLQCLDAPLLPQADCEASYPGKITNNMICVGFLEGGKDSCQ 215
Query: 202 GDSGGPLVCGGRLRGLVSWGDMPCGSKEKPGVYTDVCTHIRWIQNIL 248
           GDSGGP+VC G+L+G+VSWG C K+ PGVYT VC ++ WIQ+ +
Sbjct: 216 GDSGGPVVCNGQLQGIVSWG-YGCALKDNPGVYTKVCNYVDWIQDTI 261
| >gi|27573668|pdb|1J14|A | Chain A, Benzamidine In Complex With Rat Trypsin Mutant >
                        Chain A, Factor Xa Specific Inhibitor In Complex With Rat T
 gi|10120746|pdb|1QL9|A
           Mutant X99rt
         Length = 223
 Score = 215 bits (548), Expect = 8e-55
 Identities = 100/222 (45%), Positives = 148/222 (66%), Gaps = 4/222 (1%)
Query: 29 VVHGGPCLKDSHPFQAALYTSGHLLCGGVLIDPQWVLTAAHCKKPNLQVILGKHNLRQTE 88
          +V G C ++S P+Q +L SG+ CGG LI+ QWV++AAHC K +QV LG+HN+
          IVGGYTCQENSVPYQVSL-NSGYHFCGGSLINDQWVVSAAHCYKSRIQVRLGEHNINVLE 59
Sbjct: 1
Query: 89 TFQRQISVDRTIVHPRYNPETHDNDIMMVHLKNPVKFSKKIQPLPLKNDCSEENPNCQIL 148
            ++ ++ + I HP ++ ET++NDIM++ L +PVK + ++ + L + C+
Sbjct: 60 GNEQFVNAAKIIKHPNFDRETYNNDIMLIKLSSPVKLNARVATVALPSSCAPAGTQCLIS 119
Query: 149 GWGK-MENG-DFPDTIQCADVHLVPREQCERAYPGKITQSMVCAGDMKEGNDSCQGDSGG 206
          GWG + +G + PD +QC D L+P+ CE +YPGKIT +MVC G ++ G DSCQGDSGG
Sbjct: 120 GWGNTLSSGVNEPDLLQCLDAPLLPQADCEASYPGKITDNMVCVGFLEGGKDSCQGDSGG 179
Query: 207 PLVCGGRLRGLVSWGDMPCGSKEKPGVYTDVCTHIRWIQNIL 248
          P+VC G L+G+VSWG
                          С
                                + PGVYT VC ++ WIQ+ +
Sbjct: 180 PVVCNGELQGIVSWG-YGCALPDNPGVYTKVCNYVDWIQDTI 220
🔄 >gi|4139560|pdb|3TGJ|E 🈂 Chain E, S195a Trypsinogen Complexed With Bovine Pancreat:
          Inhibitor (Bpti)
         Length = 233
 Score = 215 bits (547), Expect = 1e-54
 Identities = 99/227 (43%), Positives = 151/227 (66%), Gaps = 4/227 (1%)
Query: 24 EEQEKVVHGGPCLKDSHPFQAALYTSGHLLCGGVLIDPQWVLTAAHCKKPNLQVILGKHN 83
          ++ +K+V G C ++S P+Q +L SG+ CGG LI+ QWV++AAHC K +QV LG+HN
Sbjct: 6 DDDDKIVGGYTCQENSVPYQVSL-NSGYHFCGGSLINDQWVVSAAHCYKSRIQVRLGEHN 64
Query: 84 LRQTETFQRQISVDRTIVHPRYNPETHDNDIMMVHLKNPVKFSKKIQPLPLKNDCSEENP 143
              E ++++++L+T+NDIM++L+PVK++++L+C+
Sbjct: 65 INVLEGNEQFVNAAKIIKHPNFDRKTLNNDIMLIKLSSPVKLNARVATVALPSSCAPAGT 124
Query: 144 NCQILGWGK-MENG-DFPDTIQCADVHLVPREQCERAYPGKITQSMVCAGDMKEGNDSCQ 201
           C I GWG + +G + PD +QC D L+P+ CE +YPGKIT +MVC G ++ G DSCQ
Sbjct: 125 QCLISGWGNTLSSGVNEPDLLQCLDAPLLPQADCEASYPGKITDNMVCVGFLEGGKDSCQ 184
Query: 202 GDSGGPLVCGGRLRGLVSWGDMPCGSKEKPGVYTDVCTHIRWIQNIL 248
```

```
Ouery: 143 PNCQILGWGKMEN--GDFPDTIQCADVHLVPREOCERAYPGKITQSMVCAGDMKEGNDSC 200
           C + GWG + G + P + QC + ++ C+++YPG+IT +M C G ++ G DSC
Sbjct: 138 AQCLVSGWGNTVSIGGKYPALLQCLEAPVLSASSCKKSYPGQITSNMFCLGFLEGGKDSC 197
Query: 201 QGDSGGPLVCGGRLRGLVSWGDMPCGSKEKPGVYTDVCTHIRWIQNILRN 250
          GDSGGP+VC G ++G+VSWG + C + KPGVYT VC ++ WIQ + N
Sbjct: 198 DGDSGGPVVCNGEIQGIVSWGSV-CAMRGKPGVYTKVCNYLSWIQETMAN 246
| >gi|50054435|ref|NP 001001911.1| | G kallikrein 1, renal/pancreas/salivary [Sus scrot
Length = 263
 Score = 211 bits (536), Expect = 2e-53
 Identities = 98/238 (41%), Positives = 140/238 (58%), Gaps = 15/238 (6%)
Query: 26 QEKVVHGGPCLKDSHPFQAALYTSGHLLCGGVLIDPQWVLTAAHCKKPNLQVILGKHNLR 85
         Q +++ G C KDSHP+Q A+Y CGGVL+DP+WVLTAAHCK N QV LG+HNL
Sbjct: 22 QSRIIGGRECEKDSHPWQVAIYHYSSFQCGGVLVDPKWVLTAAHCKNDNYQVWLGRHNLF 81
Ouery: 86 QTETFQRQISVDRTIVHPRYN------PETHDNDIMMVHLKNPVKFSKKIOPLPL 134
         + E + V + HP +N + + +D+M++ L++P + K + ++ L + L
Sbjct: 82 ENEVTAQFFGVTADFPHPGFNLSLLKNHTKADGKDYSHDLMLLRLQSPAKITDAVKVLEL 141
Query: 135 KNDCSEENPNCQILGWGKMENG----DFPDTIQCADVHLVPREQCERAYPGKITQSMVCA 190
             E CQ GWG +E G +FPD IQC ++ L+ C A+P K+T+SM+CA
Sbjct: 142 PTQEPELGSTCQASGWGSIEPGPDDFEFPDEIQCVELTLLQNTFCADAHPDKVTESMLCA 201
Query: 191 GDMKEGNDSCQGDSGGPLVCGGRLRGLVSWGDMPCGSKEKPGVYTDVCTHIRWIQNIL 248
         G + G D+C GDSGGPL+C G +G+ SWG PCGS KP +YT + ++ WI + +
Sbjct: 202 GYLPGGKDTCMGDSGGPLICNGMWQGITSWGHTPCGSANKPSIYTKLIFYLDWINDTI 259
Sqi | 27819626 | ref | NP 777115.1 | G pancreatic anionic trypsinogen [Bos taurus]
 Length = 247
 Score = 211 bits (536), Expect = 2e-53
 Identities = 102/242 (42%), Positives = 157/242 (64%), Gaps = 5/242 (2%)
Query: 10 MLALCLVLAKSAW-SEEQEKVVHGGPCLKDSHPFQAALYTSGHLLCGGVLIDPQWVLTAA 68
         +L L V A A+ S++ +K+V G C ++S P+Q +L +G+ CGG LI+ QWV++AA
Sbjct: 4 LLILAFVGAAVAFPSDDDDKIVGGYTCAENSVPYQVSL-NAGYHFCGGSLINDQWVVSAA 62
Query: 69 HCKKPNLQVILGKHNLRQTETFQRQISVDRTIVHPRYNPETHDNDIMMVHLKNPVKFSKK 128
         HC + ++QV LG++N+ E ++ I + I HP+Y+ T DNDI+++ L P + +
Sbjct: 63 HCYQYHIQVRLGEYNIDVLEGGEQFIDASKIIRHPKYSSWTLDNDILLIKLSTPAVINAR 122
Query: 129 IQPLPLKNDCSEENPNCQILGWGK-MENG-DFPDTIQCADVHLVPREQCERAYPGKITQS 186
          + L L + C+ + C I GWG + +G ++PD +QC + L+
Sbjct: 123 VSTLALPSACASGSTECLISGWGNTLSSGVNYPDLLQCLEAPLLSHADCEASYPGEITNN 182
```

Query: 187 MVCAGDMKEGNDSCQGDSGGPLVCGGRLRGLVSWGDMPCGSKEKPGVYTDVCTHIRWIQN 246

Sbjct: 183 MICAGFLEGGKDSCQGDSGGPVACNGQLQGIVSWG-YGCAQKGKPGVYTKVCNYVDWIQE 241

M+CAG ++ G DSCQGDSGGP+ C G+L+G+VSWG C K KPGVYT VC ++ WIQ

```
Query: 24 EEQEKVVHGGPCLKDSHPFQAALYTSGHLLCGGVLIDPQWVLTAAHCKKPNLQVILGKHN 83
          ++ +K+V G C ++ P+Q +L SG+ CGG LI+ QWV++AAHC K +QV LG+ N
          DDDDKIVGGYTCGANTVPYQVSL-NSGYHFCGGSLINSQWVVSAAHCYKSGIQVRLGEDN 60
Sbict: 2
Query: 84 LRQTETFQRQISVDRTIVHPRYNPETHDNDIMMVHLKNPVKFSKKIQPLPLKNDCSEENP 143
              E ++ IS ++IVHP YN T +NDIM++ LK+
                                                 + ++ + L C+
Sbjct: 61 INVVEGNEQFISASKSIVHPSYNSNTLNNDIMLIKLKSAASLNSRVASISLPTSCASAGT 120
Ouery: 144 NCQILGWG--KMENGDFPDTIQCADVHLVPREQCERAYPGKITQSMVCAGDMKEGNDSCQ 201
           C I GWG K
                        +PD ++C .++
                                         C+ AYPG+IT +M CAG ++ G DSCQ
Sbjct: 121 QCLISGWGNTKSSGTSYPDVLKCLKAPILSDSSCKSAYPGQITSNMFCAGYLEGGKDSCQ 180
Ouery: 202 GDSGGPLVCGGRLRGLVSWGDMPCGSKEKPGVYTDVCTHIRWIQNIL 248
          GDSGGP+VC G+L+G+VSWG
                               C K KPGVYT VC ++ WI+ +
Sbjct: 181 GDSGGPVVCSGKLQGIVSWGS-GCAQKNKPGVYTKVCNYVSWIKQTI 226
| >qi | 17942679 | pdb | 1K90 | E | Chain E, Crystal Structure Of Michaelis Serpin-Trypsin Co
         Length = 223
 Score = 211 bits (536), Expect = 2e-53
 Identities = 98/222 (44%), Positives = 147/222 (66%), Gaps = 4/222 (1%)
Query: 29 VVHGGPCLKDSHPFQAALYTSGHLLCGGVLIDPQWVLTAAHCKKPNLQVILGKHNLRQTE 88
          +V G C ++S P+Q +L SG+ CGG LI+ QWV++AAHC K +QV LG+HN+
Sbjct: 1
          IVGGYTCQENSVPYQVSL-NSGYHFCGGSLINDQWVVSAAHCYKSRIQVRLGEHNINVLE 59
Ouery: 89 TFOROISVDRTIVHPRYNPETHDNDIMMVHLKNPVKFSKKIQPLPLKNDCSEENPNCQIL 148
            ++ ++ + I HP ++ +T +NDIM++ L +PVK + ++ + L + C+
Sbjct: 60 GNEOFVNAAKIIKHPNFDRKTLNNDIMLIKLSSPVKLNARVATVALPSSCAPAGTQCLIS 119
Query: 149 GWGK-MENG-DFPDTIQCADVHLVPREQCERAYPGKITQSMVCAGDMKEGNDSCQGDSGG 206
          GWG + +G + PD +OC D L+P+ CE +YPGKIT +MVC G ++ G DSCOGD+GG
Sbjct: 120 GWGNTLSSGVNEPDLLQCLDAPLLPQADCEASYPGKITDNMVCVGFLEGGKDSCQGDAGG 179
Query: 207 PLVCGGRLRGLVSWGDMPCGSKEKPGVYTDVCTHIRWIQNIL 248
          P+VC G L+G+VSWG C
                              + PGVYT VC ++ WIQ+ +
Sbjct: 180 PVVCNGELQGIVSWG-YGCALPDNPGVYTKVCNYVDWIQDTI 220
| >gi | 2358083 | gb | AAB69055.1 | G trypsinogen 4 [Mus musculus]
 gi | 12963793 | ref | NP 076196.1 | G RIKEN cDNA 1810009J06 [Mus musculus]
 Length = 247
 Score = 211 bits (536), Expect = 2e-53
 Identities = 97/230 (42%), Positives = 141/230 (61%), Gaps = 3/230 (1%)
Query: 23 SEEQEKVVHGGPCLKDSHPFQAALYTSGHLLCGGVLIDPQWVLTAAHCKKPNLQVILGKH 82
              +K+V G C K S P+Q +L CGG LI QWVL+AAHC K LQV LG+H
Sbjct: 18 ANSDDKIVGGYTCPKHSVPYQVSLNDGISHQCGGSLISDQWVLSAAHCYKRRLQVRLGEH 77
Query: 83 NLRQTETFQRQISVDRTIVHPRYNPETHDNDIMMVHLKNPVKFSKKIQPLPLKNDCSEEN 142
          N+ E ++ I ++ I HP YN +T DNDIM++ LK+P + ++ + L
Sbjct: 78 NIDVLEGGEQFIDAEKIIRHPDYNKDTVDNDIMLIKLKSPAILNSQVSTVSLPRSCASTN 137
```

Identities = 97/227 (42%), Positives = 143/227 (62%), Gaps = 4/227 (1%)

Copper (Ii) Chelate

- gi|13096614|pdb|1G3D|A Chain A, Bovine Beta-Trypsin Bound To Meta-Amidino Schiff B Copper (Ii) Chelate
- gi|13096613|pdb|1G3C|A Chain A, Bovine Beta-Trypsin Bound To Para-Amidino Schiff B Iron(Iii) Chelate

Score = 211 bits (538), Expect = 1e-53
Identities = 97/227 (42%), Positives = 143/227 (62%), Gaps = 4/227 (1%)

- Query: 24 EEQEKVVHGGPCLKDSHPFQAALYTSGHLLCGGVLIDPQWVLTAAHCKKPNLQVILGKHN 83 ++ +K+V G C ++ P+Q +L SG+ CGG LI+ QWV++AAHC K +QV LG+ N
- Sbjct: 1 DDDDKIVGGYTCGANTVPYQVSL-NSGYHFCGGSLINSQWVVSAAHCYKSGIQVRLGEDN 59
- Query: 84 LRQTETFQRQISVDRTIVHPRYNPETHDNDIMMVHLKNPVKFSKKIQPLPLKNDCSEENP 143 + E ++ IS ++IVHP YN T +NDIM++ LK+ + ++ L C+
- Sbjct: 60 INVVEGNEQFISASKSIVHPSYNSNTLNNDIMLIKLKSAASLNSRVASISLPTSCASAGT 119
- Query: 144 NCQILGWG--KMENGDFPDTIQCADVHLVPREQCERAYPGKITQSMVCAGDMKEGNDSCQ 201 C I GWG K +PD ++C ++ C+ AYPG+IT +M CAG ++ G DSCQ
- Sbjct: 120 QCLISGWGNTKSSGTSYPDVLKCLKAPILSDSSCKSAYPGQITSNMFCAGYLEGGKDSCQ 179
- Query: 202 GDSGGPLVCGGRLRGLVSWGDMPCGSKEKPGVYTDVCTHIRWIQNIL 248 GDSGGP+VC G+L+G+VSWG C K KPGVYT VC ++ WI+ +
- Sbjct: 180 GDSGGPVVCSGKLQGIVSWGS-GCAQKNKPGVYTKVCNYVSWIKQTI 225
- >gi|5542503|pdb|1ZZZ|A Chain A, Trypsin Inhibitors With Rigid Tripeptidyl Aldehyc Length = 237

Score = 211 bits (538), Expect = 1e-53Identities = 97/227 (42%), Positives = 143/227 (62%), Gaps = 4/227 (1%)

- Query: 24 EEQEKVVHGGPCLKDSHPFQAALYTSGHLLCGGVLIDPQWVLTAAHCKKPNLQVILGKHN 83
 ++ +K+V G C ++ P+Q +L SG+ CGG LI+ QWV++AAHC K +QV LG+ N
- Sbjct: 10 DDDDKIVGGYTCGANTVPYQVSL-NSGYHFCGGSLINSQWVVSAAHCYKSGIQVRLGEDN 68
- Query: 84 LRQTETFQRQISVDRTIVHPRYNPETHDNDIMMVHLKNPVKFSKKIQPLPLKNDCSEENP 143 + E ++ IS ++IVHP YN T +NDIM++ LK+ + ++ L C+
- Sbjct: 69 INVVEGNEQFISASKSIVHPSYNSNTLNNDIMLIKLKSAASLNSRVASISLPTSCASAGT 128
- Query: 144 NCQILGWG--KMENGDFPDTIQCADVHLVPREQCERAYPGKITQSMVCAGDMKEGNDSCQ 201 C I GWG K +PD ++C ++ C+ AYPG+IT +M CAG ++ G DSCQ
- Sbjct: 129 QCLISGWGNTKSSGTSYPDVLKCLKAPILSDSSCKSAYPGQITSNMFCAGYLEGGKDSCQ 188
- Query: 202 GDSGGPLVCGGRLRGLVSWGDMPCGSKEKPGVYTDVCTHIRWIQNIL 248 GDSGGP+VC G+L+G+VSWG C K KPGVYT VC ++ WI+ +
- Sbjct: 189 GDSGGPVVCSGKLQGIVSWGS-GCAQKNKPGVYTKVCNYVSWIKQTI 234
- >gi|1421532|pdb|1TGB| Trypsinogen-Ca From Peg Length = 229

Score = 211 bits (538), Expect = 1e-53

```
qi|809461|pdb|1TNJ|
                    Trypsin (E.C.3.4.21.4) Complexed With The Inhibitor
         2-Phenylethylamine
| qi|809460 | pdb | 1TNI |
                    Trypsin (E.C.3.4.21.4) Complexed With The Inhibitor
         4-Phenylbutylamine
gi|809459|pdb|1TNH|
                    Trypsin (E.C.3.4.21.4) Complexed With The Inhibitor
         4-Fluorobenzylamine
                    Trypsin (E.C.3.4.21.4) Complexed With The Inhibitor
qi | 809458 | pdb | 1TNG |
         Aminomethylcyclohexane
qi|230352|pdb|1TGT| Trypsinogen (173 Degrees K, 0.70 Methanol, 0.30 Water)
Trypsin Inhibitor
qi|230349|pdb|1TGN| Trypsinogen
qi|230347|pdb|1TGC| Trypsinogen (0.50 Methanol, 0.50 Water)
qi|1311387|pdb|1BTZ|A 📓 Chain A, Tripeptideboronate Methyl Ester Inhibited Mol_id: 1
         Molecule: Beta-Trypsin; Chain: A; Ec: 3.4.21.4; Mol id:
         2; Molecule: T-Butoxy-Ala-Val-Boro-Lys Methyl Ester;
         Chain: H
gi|1311388|pdb|1BTY|
                     Benzamidine Inhibited Mol id: 1; Molecule: Beta-Trypsin; Cha
         Null; Ec: 3.4.21.4; Heterogen: Benzamidine
qi|1311389|pdb|1BTX|A 🔯 Chain A, Tripeptideboronate Ethyl Ester Inhibited Mol_id: 1;
         Molecule: Beta-Trypsin; Chain: A; Ec: 3.4.21.4; Mol_id:
          2; Molecule: T-Butoxy-Ala-Val-Boro-Lys Ethyl Ester;
          Chain: H
Mol id: 1; Molecule: Beta-Trypsin; Chain: A; Ec:
          3.4.21.4; Mol id: 2; Molecule: T-Butoxy-Ala-Val-Boro-Lys
          1,3-Propanediol Monoester; Chain: H
gi|1310895|pdb|1BTP|
                     Mol id: 1; Molecule: Beta-Trypsin; Chain: Null; Ec: 3.4.21.4
         Heterogen:
         N-[3-[4-[4-(Amidinophenoxy)-Carbonyl]phenyl]-2-
          Methyl-2-Propencyl]-N-Allylglycine Methanesulfonate
         Length = 229
 Score = 211 bits (538), Expect = 1e-53
 Identities = 97/227 (42%), Positives = 143/227 (62%), Gaps = 4/227 (1%)
Query: 24 EEQEKVVHGGPCLKDSHPFQAALYTSGHLLCGGVLIDPQWVLTAAHCKKPNLQVILGKHN 83
          ++ +K+V G C ++ P+Q +L SG+ CGG LI+ QWV++AAHC K +QV LG+ N
          DDDDKIVGGYTCGANTVPYQVSL-NSGYHFCGGSLINSQWVVSAAHCYKSGIQVRLGEDN 60
Sbjct: 2
         LRQTETFQRQISVDRTIVHPRYNPETHDNDIMMVHLKNPVKFSKKIQPLPLKNDCSEENP 143
Query: 84
             E ++ IS ++IVHP YN T +NDIM++ LK+
                                                + ++ + L
Sbjct: 61 INVVEGNEQFISASKSIVHPSYNSNTLNNDIMLIKLKSAASLNSRVASISLPTSCASAGT 120
Query: 144 NCQILGWG--KMENGDFPDTIQCADVHLVPREQCERAYPGKITQSMVCAGDMKEGNDSCQ 201
                                        C+ AYPG+IT +M CAG ++ G DSCQ
           C I GWG K
                        +PD ++C
                                 ++
Sbjct: 121 QCLISGWGNTKSSGTSYPDVLKCLKAPILSDSSCKSAYPGQITSNMFCAGYLEGGKDSCQ 180
Query: 202 GDSGGPLVCGGRLRGLVSWGDMPCGSKEKPGVYTDVCTHIRWIQNIL 248
          GDSGGP+VC G+L+G+VSWG C K KPGVYT VC ++ WI+ +
Sbjct: 181 GDSGPVVCSGKLQGIVSWGS-GCAQKNKPGVYTKVCNYVSWIKQTI 226
```

```
🏿 >qi|559311|dbj|BAA07516.1| 🚨 pancreas cationic pretrypsinogen [Bos taurus]
gi 2507249 sp P00760 TRY1 BOVIN Cationic trypsin precursor (Beta-trypsin)
X-Ray Structures And Association Constant Measurements
gi|42543838|pdb|1UTP|A  Chain A, Trypsin Specificity As Elucidated By Lie Calculati
          X-Ray Structures And Association Constant Measurements
gi | 42543837 | pdb | 1UTO | A Chain A, Trypsin Specificity As Elucidated By Lie Calculati
          X-Ray Structures And Association Constant Measurements
gi|42543836|pdb|1UTN|A 🔛 Chain A, Trypsin Specificity As Elucidated By Lie Calculati
          X-Ray Structures And Association Constant Measurements
qi|31615517|pdb|1LQE|A 🔛 Chain A, Crystal Structure Of Trypsin In Complex With 79.
qi|11514323|pdb|1EZX|C Chain C, Crystal Structure Of A Serpin:protease Complex
qi|10835693|pdb|1F0U|A  Chain A, Bovine Trypsin Complexed With Rpr128515
                       Chain A, Bovine Trypsin Complexed With Rpr131247
qi|10835692|pdb|1F0T|A
         Length = 243
Score = 211 bits (538), Expect = 1e-53
Identities = 97/227 (42%), Positives = 143/227 (62%), Gaps = 4/227 (1%)
Query: 24 EEQEKVVHGGPCLKDSHPFQAALYTSGHLLCGGVLIDPQWVLTAAHCKKPNLQVILGKHN 83
          ++ +K+V G C ++ P+O +L SG+ CGG LI+ OWV++AAHC K +OV LG+ N
Sbjct: 16 DDDDKIVGGYTCGANTVPYQVSL-NSGYHFCGGSLINSQWVVSAAHCYKSGIQVRLGEDN 74
Ouery: 84 LROTETFQRQISVDRTIVHPRYNPETHDNDIMMVHLKNPVKFSKKIQPLPLKNDCSEENP 143
              E ++ IS ++IVHP YN T +NDIM++ LK+
Sbjct: 75 INVVEGNEQFISASKSIVHPSYNSNTLNNDIMLIKLKSAASLNSRVASISLPTSCASAGT 134
Query: 144 NCQILGWG--KMENGDFPDTIQCADVHLVPREQCERAYPGKITQSMVCAGDMKEGNDSCQ 201
           C I GWG K
                          +PD ++C
                                    ++
                                          C+ AYPG+IT +M CAG ++ G DSCQ
Sbjct: 135 QCLISGWGNTKSSGTSYPDVLKCLKAPILSDSSCKSAYPGQITSNMFCAGYLEGGKDSCQ 194
Query: 202 GDSGGPLVCGGRLRGLVSWGDMPCGSKEKPGVYTDVCTHIRWIQNIL 248
          GDSGGP+VC G+L+G+VSWG
                               C K KPGVYT VC ++ WI+
Sbjct: 195 GDSGGPVVCSGKLQGIVSWGS-GCAQKNKPGVYTKVCNYVSWIKQTI 240
| >gi | 67549 | pir | | TRBOTR
                         trypsin (EC 3.4.21.4) precursor - bovine
qi|231094|pdb|4TPI|Z Chain Z, Trypsinogen Complex With The Arg15-Analogue Of Pancr
          Trypsin Inhibitor And Val-Val
qi|230935|pdb|3TPI|Z Chain Z, Trypsinogen Complex With Pancreatic Trypsin Inhibito
          Ile-Val
 gi|230773|pdb|2TPI|Z Chain Z, Trypsinogen - Pancreatic Trypsin Inhibitor - Ile-Val
          Complex (2.4 M Magnesium Sulfate)
                      Trypsinogen (103 Degrees K, 0.70 Methanol, 0.30 Water)
 gi | 230764 | pdb | 2TGT |
 gi|230762|pdb|2TGP|Z Chain Z, Trypsinogen Complex With Pancreatic Trypsin Inhibito
                      Trypsinogen, Diisopropylphosphoryl Inhibited
 gi | 230761 | pdb | 2TGD |
                      Trypsinogen (2.4 M Magnesium Sulfate)
 gi | 230760 | pdb | 2TGA |
                      Trypsin (E.C.3.4.21.4) Complexed With The Inhibitor Tranylcyp
 gi | 809463 | pdb | 1TNL |
                      Trypsin (E.C.3.4.21.4) Complexed With The Inhibitor
 gi | 809462 | pdb | 1TNK |
          3-Phenylpropylamine
```

```
Query: 144 NCQILGWGKMEN--GDFPDTIQCADVHLVPREQCERAYPGKITQSMVCAGDMKEGNDSCQ 201
           C I GWG ++ ++PD +QC ++ C AYPG+I+ +M+C G M+ G DSCQ
Sbjct: 138 QCLISGWGNTQSIGQNYPDVLQCLKAPILSDSVCRNAYPGQISSNMMCLGYMEGGKDSCQ 197
Query: 202 GDSGGPLVCGGRLRGLVSWGDMPCGSKEKPGVYTDVCTHIRWIQNIL 248
          GDSGGP+VC G L+G+VSWG C K KPGVYT VC ++ WIQ +
Sbjct: 198 GDSGGPVVCNGELQGVVSWG-AGCAQKGKPGVYTRVCKYVSWIQQTI 243
Pancreatic Trypsin Inhibitor (Bpti)
gi|2098544|pdb|1ANE| Anionic Trypsin Wild Type
         Length = 223
 Score = 212 bits (539), Expect = 9e-54
 Identities = 99/222 (44%), Positives = 147/222 (66%), Gaps = 4/222 (1%)
Query: 29 VVHGGPCLKDSHPFQAALYTSGHLLCGGVLIDPQWVLTAAHCKKPNLQVILGKHNLRQTE 88
          +V G C ++S P+Q +L SG+ CGG LI+ QWV++AAHC K +QV LG+HN+
          IVGGYTCQENSVPYQVSL-NSGYHFCGGSLINDQWVVSAAHCYKSRIQVRLGEHNINVLE 59
Sbjct: 1
Query: 89 TFQRQISVDRTIVHPRYNPETHDNDIMMVHLKNPVKFSKKIQPLPLKNDCSEENPNCQIL 148
            ++ ++ + I HP ++ +T +NDIM++ L +PVK + ++ + L + C+
Sbjct: 60 GNEQFVNAAKIIKHPNFDRKTLNNDIMLIKLSSPVKLNARVATVALPSSCAPAGTQCLIS 119
Query: 149 GWGK-MENG-DFPDTIQCADVHLVPREQCERAYPGKITQSMVCAGDMKEGNDSCQGDSGG 206
          GWG + +G + PD +QC D L+P+ CE +YPGKIT +MVC G ++ G DSCQGDSGG
Sbjct: 120 GWGNTLSSGVNEPDLLQCLDAPLLPQADCEASYPGKITDNMVCVGFLEGGKDSCQGDSGG 179
Query: 207 PLVCGGRLRGLVSWGDMPCGSKEKPGVYTDVCTHIRWIQNIL 248
          P+VC G L+G+VSWG C + PGVYT VC ++ WIQ+ +
Sbjct: 180 PVVCNGELQGIVSWG-YGCALPDNPGVYTKVCNYVDWIQDTI 220
                         Anionic Trypsin Mutant With Arg 96 Replaced By His
>qi | 2098543 | pdb | 1AND |
         Length = 223
 Score = 212 \text{ bits } (539), Expect = 9e-54
 Identities = 99/222 (44%), Positives = 147/222 (66%), Gaps = 4/222 (1%)
Query: 29 VVHGGPCLKDSHPFQAALYTSGHLLCGGVLIDPQWVLTAAHCKKPNLQVILGKHNLRQTE 88
          +V G C ++S P+Q +L SG+ CGG LI+ QWV++AAHC K +QV LG+HN+
          IVGGYTCOENSVPYQVSL-NSGYHFCGGSLINDQWVVSAAHCYKSRIQVRLGEHNINVLE 59
Sbjct: 1
Query: 89 TFQRQISVDRTIVHPRYNPETHDNDIMMVHLKNPVKFSKKIQPLPLKNDCSEENPNCQIL 148
            ++ ++ + I HP ++ +T +NDIM++ L +PVK + ++ + L + C+
Sbjct: 60 GNEQFVNAAKIIKHPNFDHKTLNNDIMLIKLSSPVKLNARVATVALPSSCAPAGTQCLIS 119
Query: 149 GWGK-MENG-DFPDTIQCADVHLVPREQCERAYPGKITQSMVCAGDMKEGNDSCQGDSGG 206
          GWG + +G + PD +QC D L+P+ CE +YPGKIT +MVC G ++ G DSCQGDSGG
Sbjct: 120 GWGNTLSSGVNEPDLLQCLDAPLLPQADCEASYPGKITDNMVCVGFLEGGKDSCQGDSGG 179
Query: 207 PLVCGGRLRGLVSWGDMPCGSKEKPGVYTDVCTHIRWIQNIL 248
          P+VC G L+G+VSWG C + PGVYT VC ++ WIQ+ +
Sbjct: 180 PVVCNGELOGIVSWG-YGCALPDNPGVYTKVCNYVDWIQDTI 220
```

Sbjct: 78 IAVSEGGEQFINAAKIIRHPRYNANTIDNDIMLIKLSSPATLNSRVSAIALPKSCPAAGT 137

```
++ +K+V G C ++S P+Q +L SG+ CGG LI+ QWV++AAHC K +QV LG+HN
Sbjct: 19 DDDDKIVGGYTCQENSVPYQVSL-NSGYHFCGGSLINDQWVVSAAHCYKSRIQVRLGEHN 77
Query: 84 LRQTETFQRQISVDRTIVHPRYNPETHDNDIMMVHLKNPVKFSKKIQPLPLKNDCSEENP 143
             E ++ ++ + I HP +N
                                 +NDIM++L PV + ++ + L + C+
Sbjct: 78 INVLEGNEQFVNAAKIIKHPNFNARNLNNDIMLIKLSVPVTLNSRVATVALPSSCAPAGT 137
Query: 144 NCQILGWGKMEN--GDFPDTIQCADVHLVPREQCERAYPGKITQSMVCAGDMKEGNDSCQ 201
          C I GWG + + PD +QC D ++P+ CE +YPGKIT +M+C G ++ G DSCQ
Sbjct: 138 QCLISGWGNTLSLGVNNPDLLQCLDAPVLPQADCEASYPGKITNNMICVGFLEGGKDSCQ 197
Query: 202 GDSGGPLVCGGRLRGLVSWGDMPCGSKEKPGVYTDVCTHIRWIQNIL 248
          GDSGGP+VC G+L+G+VSWG C K+ PGVYT VC ++ WIQ+ +
Sbjct: 198 GDSGGPVVCNGQLQGIVSWG-YGCALKDNPGVYTKVCNYVDWIQDTI 243
🖺 >gi|1633121|pdb|1SLX|B 🔛 Chain B, Rat Anionic N143h, E151h Trypsin Complexed To A86
          Zinc-Bound
 Copper-Bound
                     Chain B, Rat Anionic N143h, E151h Trypsin Complexed To A86h
 gi | 1633127 | pdb | 1SLU | B
         Length = 223
 Score = 212 bits (540), Expect = 7e-54
 Identities = 99/222 (44%), Positives = 147/222 (66%), Gaps = 4/222 (1%)
Query: 29 VVHGGPCLKDSHPFQAALYTSGHLLCGGVLIDPQWVLTAAHCKKPNLQVILGKHNLRQTE 88
          +V G C ++S P+Q +L SG+ CGG LI+ QWV++AAHC K +QV LG+HN+
          IVGGYTCQENSVPYQVSL-NSGYHFCGGSLINDQWVVSAAHCYKSRIQVRLGEHNINVLE 59
Sbjct: 1
Query: 89 TFQRQISVDRTIVHPRYNPETHDNDIMMVHLKNPVKFSKKIQPLPLKNDCSEENPNCQIL 148
           ++ ++ + I HP ++ +T +NDIM++ L +PVK + ++ + L + C+
Sbjct: 60 GNEQFVNAAKIIKHPNFDRKTLNNDIMLIKLSSPVKLNARVATVALPSSCAPAGTQCLIS 119
Query: 149 GWGK-MENG-DFPDTIQCADVHLVPREQCERAYPGKITQSMVCAGDMKEGNDSCQGDSGG 206
          GWG + +G + PD +QC D L+P+ CE +YPGKIT +MVC G ++ G DSCQGDSGG
Sbjct: 120 GWGHTLSSGVNHPDLLQCLDAPLLPQADCEASYPGKITDNMVCVGFLEGGKDSCQGDSGG 179
Query: 207 PLVCGGRLRGLVSWGDMPCGSKEKPGVYTDVCTHIRWIQNIL 248
          P+VC G L+G+VSWG C + PGVYT VC ++ WIQ+ +
Sbjct: 180 PVVCNGELQGIVSWG-YGCALPDNPGVYTKVCNYVDWIQDTI 220
dog [Canis familiaris]
         Length = 246
 Score = 212 bits (539), Expect = 9e-54
 Identities = 98/227 (43%), Positives = 144/227 (63%), Gaps = 4/227 (1%)
Query: 24 EEQEKVVHGGPCLKDSHPFQAALYTSGHLLCGGVLIDPQWVLTAAHCKKPNLQVILGKHN 83
          ++ +K+V G C ++S P+Q +L SG+ CGG LI+ QWV++AAHC K +QV LG++N
Sbjct: 19 DDDDKIVGGYTCSRNSVPYQVSL-NSGYHFCGGSLINSQWVVSAAHCYKSRIQVRLGEYN 77
Query: 84 LRQTETFQRQISVDRTIVHPRYNPETHDNDIMMVHLKNPVKFSKKIQPLPLKNDCSEENP 143
          + +E ++ I+ + I HPRYN T DNDIM++ L +P + ++ + L C
```

Query: 24 EEQEKVVHGGPCLKDSHPFQAALYTSGHLLCGGVLIDPQWVLTAAHCKKPNLQVILGKHN 83

```
Length = 247
Score = 213 bits (541), Expect = 5e-54
 Identities = 104/248 (41%), Positives = 153/248 (61%), Gaps = 7/248 (2%)
         MKMLALCLVLAKSAWSEEQEKVVHGGPCLKDSHPFQAAL-YTSGHLLCGGVLIDPQWVLT 66
Query: 8
         MKM+ L++ A S + +K++ G C +S P+Q L Y +G CG LI+ +W ++
Sbjct: 1
         MKMIVFALLVLAVACSAD-DKIIGGYECSPNSOPWOIYLTYDNGQRWCGASLINDRWAVS 59
Ouery: 67 AAHCK--KPNLQVILGKHNLRQTETFQRQISVDRTIVHPRYNPETHDNDIMMVHLKNPVK 124
                 L V LG+HN+ E +++I ++ I HP+YN T DND M++ LK P
Sbjct: 60 AAHCYLVANRLTVHLGEHNVAVEEGTEQRIKAEKVIPHPKYNDYTLDNDFMLIKLKEPAV 119
Query: 125 FSKKIQPLPLKNDCSEENPNCQILGWGKMENGD--FPDTIQCADVHLVPREQCERAYPGK 182
         F++ +QP+PL CS E C + GWG + N
                                       +PD +QC ++ ++ R QCE AY +
Sbjct: 120 FNQYVQPVPLTTSCSSEGEQCLVSGWGNLINTGVVYPDVLQCLNLPVLTRAQCEGAYGWQ 179
Query: 183 ITQSMVCAGDMKEGNDSCQGDSGGPLVCGGRLRGLVSWGDMPCGSKEKPGVYTDVCTHIR 242
         IT++M CAG M+ G D+CQGDSGGP++C G LRG+VSWG C PGVYT+VC +
Sbjct: 180 ITKNMFCAGFMEGGKDACQGDSGGPVICNGELRGVVSWG-YGCADSGYPGVYTEVCRYTD 238
Ouery: 243 WIQNILRN 250
         W + + + N
Sbjct: 239 WVASTIAN 246
Nickel-Bound
         Length = 223
 Score = 213 bits (541), Expect = 5e-54
 Identities = 99/222 (44%), Positives = 147/222 (66%), Gaps = 4/222 (1%)
Query: 29 VVHGGPCLKDSHPFQAALYTSGHLLCGGVLIDPQWVLTAAHCKKPNLQVILGKHNLRQTE 88
          +V G C ++S P+Q +L SG+ CGG LI+ QWV++AAHC K +QV LG+HN+
         IVGGYTCQENSVPYQVSL-NSGYHFCGGSLINDQWVVSAAHCYKSRIQVRLGEHNINVLE 59
Sbjct: 1
Query: 89 TFQRQISVDRTIVHPRYNPETHDNDIMMVHLKNPVKFSKKIQPLPLKNDCSEENPNCQIL 148
           ++ ++ + I HP ++ +T +NDIM++ L +PVK + ++ + L + C+
Sbjct: 60 GNEQFVNAAKIIKHPNFDRKTLNNDIMLIKLSSPVKLNARVATIALPSSCAPAGTQCLIS 119
Ouery: 149 GWGK-MENG-DFPDTIQCADVHLVPREQCERAYPGKITQSMVCAGDMKEGNDSCQGDSGG 206
          GWG + +G + PD +QC D L+P+ CE +YPGKIT +MVC G ++ G DSCQGDSGG
Sbjct: 120 GWGHTLSSGVNHPDLLQCLDAPLLPQADCEASYPGKITDNMVCVGFLEGGKDSCQGDSGG 179
Query: 207 PLVCGGRLRGLVSWGDMPCGSKEKPGVYTDVCTHIRWIQNIL 248
          P+VC G L+G+VSWG C + PGVYT VC ++ WIQ+ +
Sbjct: 180 PVVCNGELQGIVSWG-YGCALPDNPGVYTKVCNYVDWIQDTI 220
Length = 246
 Score = 212 bits (540), Expect = 7e-54
 Identities = 97/227 (42%), Positives = 147/227 (64%), Gaps = 4/227 (1%)
```

gi|55742601|ref|NP 001007055.1| G zgc:92590 [Danio rerio]

```
[Rattus norvegicus]
          Length = 247
 Score = 213 bits (542), Expect = 4e-54
 Identities = 103/246 (41%), Positives = 154/246 (62%), Gaps = 10/246 (4%)
Query: 10 MLALCLVLAKSAWSEEQEKVVHGGPCLKDSHPFQAALYTSGHLLCGGVLIDPQWVLTAAH 69
           +L LC+V A ++EK+ +G C+K+S P+Q L+ +L CGGVL+D +WVLTAAH
           LLLLCVVGLSQA---DREKIYNGVECVKNSQPWQVGLFHGKYLRCGGVLVDRKWVLTAAH 62
Sbjct: 6
Query: 70 CKKPNLQVILGKHNLRQTETFQRQISVDRTIVHPRYNP--ETHDNDIMMVHLKNPVKFSK 127
                 V LG+H+L + ++ ++ +I HP Y+ + H++D+ ++ L P+ +
Sbjct: 63 C-SGKYMVRLGEHSLSKLDLTEQLRLTTFSITHPSYHGAYQNHEHDLRLRLNRPISLTY 121
Query: 128 KIQPLPLKNDCSEENPNCQILGWGKMEN--GDFPDTIQCADVHLVPREQCERAYPGKITQ 185
            FPD +QC D+ +V E C +PG++T+
Sbjct: 122 AVRPVALPSSCAPTGAKCHISGWGTTNKPWDPFPDRLQCLDLSIVSNETCRAVFPGRVTE 181
Query: 186 SMVCAGDMKEGNDSCQGDSGGPLVCGGRLRGLVSWGDM-PCGSKEKPGVYTDVCTHIRWI 244
           +M+CAG + G D+CQGDSGGPLVCGG L+GLVSWG + PCG K PGVYT VC + WI
 Sbjct: 182 NMLCAGG-EAGKDACQGDSGGPLVCGGVLQGLVSWGSVGPCGQKGIPGVYTKVCKYTDWI 240
 Query: 245 QNILRN 250
           + ++RN
 Sbjct: 241 RVVIRN 246
| sgi|27465583|ref|NP 775150.1| | G cationic trypsinogen [Rattus norvegicus] | gi|92925|pir||A27547 | trypsin (EC 3.4.21.4) precursor, cationic - rat
  gi|136417|sp|P08426|TRY3 RAT G Cationic trypsin III precursor (Pretrypsinogen III)
  Length = 247
  Score = 213 bits (541), Expect = 5e-54
  Identities = 98/224 (43%), Positives = 142/224 (63%), Gaps = 4/224 (1%)
 Query: 24 EEQEKVVHGGPCLKDSHPFQAALYTSGHLLCGGVLIDPQWVLTAAHCKKPNLQVILGKHN 83
           ++ +K+V G C K+S P+Q +L +G+ CGG LI+ QWV++AAHC K +QV LG+HN
 Sbjct: 20 DDDDKIVGGYTCQKNSLPYQVSL-NAGYHFCGGSLINSQWVVSAAHCYKSRIQVRLGEHN 78
 Query: 84 LRQTETFQRQISVDRTIVHPRYNPETHDNDIMMVHLKNPVKFSKKIQPLPLKNDCSEENP 143
               E ++ I + I HP YN T DNDIM++ L +P + ++ + L C
 Sbjct: 79 IDVVEGGEQFIDAAKIIRHPSYNANTFDNDIMLIKLNSPATLNSRVSTVSLPRSCGSSGT 138
 Ouery: 144 NCOILGWGK-MENG-DFPDTIQCADVHLVPREQCERAYPGKITQSMVCAGDMKEGNDSCQ 201
            C + GWG + +G ++P +QC D ++ C+ +YPGKIT +M C G ++ G DSCQ
 Sbjct: 139 KCLVSGWGNTLSSGTNYPSLLQCLDAPVLSDSSCKSSYPGKITSNMFCLGFLEGGKDSCQ 198
 Ouery: 202 GDSGGPLVCGGRLRGLVSWGDMPCGSKEKPGVYTDVCTHIRWIQ 245
           GDSGGP+VC G+L+G+VSWG C K KPGVYT VC ++ WIQ
 Sbjct: 199 GDSGGPVVCNGQLQGVVSWG-YGCAQKGKPGVYTKVCNYVNWIQ 241
 | >gi | 54035518 | gb | AAH83528.1 | G | Zgc:92590 [Danio rerio]
```

```
| >gi|37182171|gb|AAQ88888.1| | G KLK12 [Homo sapiens]
gi|22208987 ref NP 665901.1 G kallikrein 12 isoform 2 [Homo sapiens]
 gi 6166249 gb AAD26426.2 skallikrein-like protein 5 [Homo sapiens]
gi|9296989|sp|Q9UKR0|KLK12 HUMAN G Kallikrein 12 precursor (Kallikrein-like protein
          (UNQ669/PRO1303)
         Length = 248
 Score = 213 bits (543), Expect = 3e-54
 Identities = 107/250 (42%), Positives = 154/250 (61%), Gaps = 10/250 (4%)
          LTMKMLALCLVLAKSAWSEEQEKVVHGGPCLKDSHPFQAALYTSGHLLCGGVLIDPOWVL 65
Query: 6
                 L L+++A
                              K+ +G C ++S P+Q L+
          L+++L
                                                     L CGGVLID +WVL
Sbjct: 3
          LSIFLLLCVLGLSQAA----TPKIFNGTECGRNSQPWQVGLFEGTSLRCGGVLIDHRWVL 58
Query: 66 TAAHCKKPNLQVILGKHNLRQTETFQRQISVDRTIVHPRY--NPETHDNDIMMVHLKNPV 123
                    V LG+H+L Q + ++ ++ HP Y +H++D+ ++ L+ PV
          TAAHC
Sbjct: 59 TAAHCSGSRYWVRLGEHSLSQLDWTEQIRHSGFSVTHPGYLGASTSHEHDLRLLRLRLPV 118
Query: 124 KFSKKIQPLPLKNDCSEENPNCQILGWG--KMENGDFPDTIQCADVHLVPREQCERAYPG 181
          + + +QPLPL NDC+ C + GWG FPD +QC ++ +V
Sbjct: 119 RVTSSVQPLPLPNDCATAGTECHVSGWGITNHPRNPFPDLLQCLNLSIVSHATCHGVYPG 178
Query: 182 KITQSMVCAGDMKEGNDSCQGDSGGPLVCGGRLRGLVSWGDM-PCGSKEKPGVYTDVCTH 240
          +IT +MVCAG + G D+CQGDSGGPLVCGG L+GLVSWG + PCG PGVYT +C +
Sbjct: 179 RITSNMVCAGGV-PGQDACQGDSGGPLVCGGVLQGLVSWGSVGPCGQDGIPGVYTYICKY 237
Query: 241 IRWIQNILRN 250
          + WI+ I+RN
Sbjct: 238 VDWIRMIMRN 247
| >gi | 64388 | emb | CAA49679.1 | trypsin III [Salmo salar]
 gi|422585|pir||S31779 trypsin (EC 3.4.21.4) III precursor - Atlantic salmon (fragme
 gi|464949|sp|P35033|TRY3 SALSA Trypsin III precursor
         Length = 238
 Score = 213 bits (542), Expect = 4e-54
 Identities = 98/227 (43%), Positives = 142/227 (62%), Gaps = 4/227 (1%)
Query: 24 EEQEKVVHGGPCLKDSHPFQAALYTSGHLLCGGVLIDPQWVLTAAHCKKPNLQVILGKHN 83
          +E +K+V G C K+S +QA+L SG+ CGG LI WV++AAHC K +QV LG+HN
Sbjct: 11 DEDDKIVGGYECRKNSASYQASLQ-SGYHFCGGSLISSTWVVSAAHCYKSRIQVRLGEHN 69
Query: 84 LRQTETFQRQISVDRTIVHPRYNPETHDNDIMMVHLKNPVKFSKKIQPLPLKNDCSEENP 143
          + E ++ I + I+HP YN DNDIM++ L P + + + L + C+
Sbjct: 70 IAVNEGTEQFIDSVKVIMHPSYNSRNLDNDIMLIKLSKPASLNSYVSTVALPSSCASSGT 129
Query: 144 NCQILGWGKM--ENGDFPDTIQCADVHLVPREQCERAYPGKITQSMVCAGDMKEGNDSCQ 201
           C + GWG + + ++PDT++C D+ ++ C AYPG+IT +M CAG M+ G DSCO
Sbjct: 130 RCLVSGWGNLSGSSSNYPDTLRCLDLPILSSSSCNSAYPGQITSNMFCAGFMEGGKDSCQ 189
Query: 202 GDSGGPLVCGGRLRGLVSWGDMPCGSKEKPGVYTDVCTHIRWIQNIL 248
          GDSGGP+VC G+L+G+VSWG C + KPGVYT VC + WI + +
Sbjct: 190 GDSGGPVVCNGQLQGVVSWG-YGCAQRNKPGVYTKVCNYRSWISSTM 235
```

```
Trypsin Inhibitor
         Length = 233
 Score = 214 bits (544), Expect = 2e-54
 Identities = 99/227 (43%), Positives = 150/227 (66%), Gaps = 4/227 (1%)
Query: 24 EEQEKVVHGGPCLKDSHPFQAALYTSGHLLCGGVLIDPQWVLTAAHCKKPNLQVILGKHN 83
          ++ + +V G C ++S P+Q +L SG+ CGG LI+ QWV++AAHC K +QV LG+HN
Sbjct: 6
         DDDDAIVGGYTCQENSVPYQVSL-NSGYHFCGGSLINDQWVVSAAHCYKSRIQVRLGEHN 64
Query: 84 LRQTETFQRQISVDRTIVHPRYNPETHDNDIMMVHLKNPVKFSKKIQPLPLKNDCSEENP 143
          + E ++ ++ + I HP ++ +T +NDIM++ L +PVK + ++ + L + C+
Sbjct: 65 INVLEGNEQFVNAAKIIKHPNFDRKTLNNDIMLIKLSSPVKLNARVATVALPSSCAPAGT 124
Query: 144 NCQILGWGK-MENG-DFPDTIQCADVHLVPREQCERAYPGKITQSMVCAGDMKEGNDSCQ 201
          C I GWG + +G + PD +QC D L+P+ CE +YPGKIT +MVC G ++ G DSCQ
Sbjct: 125 QCLISGWGNTLSSGVNEPDLLQCLDAPLLPQADCEASYPGKITDNMVCVGFLEGGKDSCQ 184
Query: 202 GDSGGPLVCGGRLRGLVSWGDMPCGSKEKPGVYTDVCTHIRWIQNIL 248
          GDSGGP+VC G L+G+VSWG C + PGVYT VC ++ WIQ+ +
Sbjct: 185 GDSGGPVVCNGELQGIVSWG-YGCALPDNPGVYTKVCNYVDWIQDTI 230
| >gi | 6755891 | ref | NP 035775.1 | G protease, serine, 3 [Mus musculus]
qi|2358088|gb|AAB69059.1| G trypsinogen 11 [Mus musculus]
         Length = 246
 Score = 213 bits (543), Expect = 3e-54
 Identities = 105/242 (43%), Positives = 155/242 (64%), Gaps = 5/242 (2%)
Query: 10 MLALCLVLAKSAWS-EEQEKVVHGGPCLKDSHPFQAALYTSGHLLCGGVLIDPQWVLTAA 68
          +L L LV A A+ ++ +K+V G C ++S P+Q +L SG+ CGG LI+ QWV++AA
          LLILALVGAAVAFPVDDDDKIVGGYTCQENSVPYQVSL-NSGYHFCGGSLINDQWVVSAA 62
Sbjct: 4
Query: 69 HCKKPNLQVILGKHNLRQTETFQRQISVDRTIVHPRYNPETHDNDIMMVHLKNPVKFSKK 128
          HC K +QV LG+HN+ E ++ ++ + I HP +N +T +NDIM++ L +PV + +
Sbjct: 63 HCYKTRIQVRLGEHNINVLEGNEQFVNAAKIIKHPNFNRKTLNNDIMLLKLSSPVTLNAR 122
Query: 129 IQPLPLKNDCSEENPNCQILGWGKMENGDF--PDTIQCADVHLVPREQCERAYPGKITOS 186
          + + L + C+ C I GWG + PD +QC D L+P+ CE +YPGKIT +
Sbjct: 123 VATVALPSSCAPAGTQCLISGWGNTLSFGVSEPDLLQCLDAPLLPQADCEASYPGKITGN 182
Query: 187 MVCAGDMKEGNDSCQGDSGGPLVCGGRLRGLVSWGDMPCGSKEKPGVYTDVCTHIRWIQN 246
          MVCAG ++ G DSCQGDSGGP+VC L+G+VSWG C + PGVYT VC ++ WIQ+
Sbjct: 183 MVCAGFLEGGKDSCQGDSGGPVVCNRELQGIVSWG-YGCALPDNPGVYTKVCNYVDWIQD 241
Query: 247 IL 248
```

Sbjct: 242 TI 243

```
+ E ++ ++ + I HP +N T +NDIM++ L +PV + ++ + L + C+
Sbjct: 96 INVLEGNEOFVNSAKIIKHPNFNSRTLNNDIMLIKLASPVTLNARVATVALPSSCAPAGT 155
Query: 144 NCQILGWGKMEN--GDFPDTIQCADVHLVPREQCERAYPGKITQSMVCAGDMKEGNDSCQ 201
                    + + PD +QC D L+P+ CE +YPGKIT +M+C G ++ G DSCQ
           C I GWG
Sbjct: 156 QCLISGWGNTLSFGVNNPDLLQCLDAPLLPQADCEASYPGKITNNMICVGFLEGGKDSCQ 215
Query: 202 GDSGGPLVCGGRLRGLVSWGDMPCGSKEKPGVYTDVCTHIRWIQNIL 248
          GDSGGP+VC G+L+G+VSWG C K+ PGVYT VC ++ WIQ+ +
Sbjct: 216 GDSGGPVVCNGQLQGIVSWG-YGCALKDNPGVYTKVCNYVDWIQDTI 261
gi|10120746|pdb|1QL9|A
                       Chain A, Factor Xa Specific Inhibitor In Complex With Rat T
          Mutant X99rt
         Length = 223
 Score = 215 bits (548), Expect = 8e-55
 Identities = 100/222 (45%), Positives = 148/222 (66%), Gaps = 4/222 (1%)
Query: 29 VVHGGPCLKDSHPFQAALYTSGHLLCGGVLIDPQWVLTAAHCKKPNLQVILGKHNLROTE 88
          +V G C ++S P+Q +L SG+ CGG LI+ QWV++AAHC K +QV LG+HN+
          IVGGYTCQENSVPYQVSL-NSGYHFCGGSLINDQWVVSAAHCYKSRIQVRLGEHNINVLE 59
Sbjct: 1
Query: 89 TFQRQISVDRTIVHPRYNPETHDNDIMMVHLKNPVKFSKKIQPLPLKNDCSEENPNCQIL 148
            ++ ++ + I HP ++ ET++NDIM++ L +PVK + ++ + L + C+
Sbjct: 60 GNEQFVNAAKIIKHPNFDRETYNNDIMLIKLSSPVKLNARVATVALPSSCAPAGTQCLIS 119
Query: 149 GWGK-MENG-DFPDTIQCADVHLVPREQCERAYPGKITQSMVCAGDMKEGNDSCQGDSGG 206
          GWG + +G + PD +QC D L+P+ CE +YPGKIT +MVC G ++ G DSCQGDSGG
Sbjct: 120 GWGNTLSSGVNEPDLLQCLDAPLLPQADCEASYPGKITDNMVCVGFLEGGKDSCQGDSGG 179
Query: 207 PLVCGGRLRGLVSWGDMPCGSKEKPGVYTDVCTHIRWIQNIL 248
          P+VC G L+G+VSWG C + PGVYT VC ++ WIQ+ +
Sbjct: 180 PVVCNGELQGIVSWG-YGCALPDNPGVYTKVCNYVDWIQDTI 220
Sqi|4139560|pdb|3TGJ|E Chain E, S195a Trypsinogen Complexed With Bovine Pancreat:
          Inhibitor (Bpti)
         Length = 233
 Score = 215 bits (547), Expect = 1e-54
 Identities = 99/227 (43\%), Positives = 151/227 (66\%), Gaps = 4/227 (1\%)
Query: 24 EEQEKVVHGGPCLKDSHPFQAALYTSGHLLCGGVLIDPQWVLTAAHCKKPNLQVILGKHN 83
          ++ +K+V G C ++S P+Q +L SG+ CGG LI+ QWV++AAHC K +QV LG+HN
Sbjct: 6
          DDDDKIVGGYTCQENSVPYQVSL-NSGYHFCGGSLINDQWVVSAAHCYKSRIQVRLGEHN 64
Query: 84 LRQTETFQRQISVDRTIVHPRYNPETHDNDIMMVHLKNPVKFSKKIQPLPLKNDCSEENP 143
             E ++ ++ + I HP ++ +T +NDIM++ L +PVK + ++ + L + C+
Sbjct: 65 INVLEGNEQFVNAAKIIKHPNFDRKTLNNDIMLIKLSSPVKLNARVATVALPSSCAPAGT 124
Query: 144 NCQILGWGK-MENG-DFPDTIQCADVHLVPREQCERAYPGKITQSMVCAGDMKEGNDSCQ 201
           C I GWG + +G + PD +OC D L+P+ CE +YPGKIT +MVC G ++ G DSCO
Sbjct: 125 QCLISGWGNTLSSGVNEPDLLQCLDAPLLPQADCEASYPGKITDNMVCVGFLEGGKDSCQ 184
```

Query: 202 GDSGGPLVCGGRLRGLVSWGDMPCGSKEKPGVYTDVCTHIRWIQNIL 248

```
Query: 61 PQWVLTAAHCKKPNLQVILGKHNLRQTETFQRQISVDRTIVHPRYNPETHDNDIMMVHLK 120
          Sbjct: 100 DOWVVSAAHCYKSRIQVRLGEHNINVLEGDEQFVNAAKIIKHPNFDRKTLNNDIMLIKLS 159
Query: 121 NPVKFSKKIQPLPLKNDCSEENPNCQILGWGKMEN--GDFPDTIQCADVHLVPREQCERA 178
          Sbjct: 160 SPVKLNARVATVALPSSCAPAGTQCLISGWGNTLSFGVNDPDLLQCLDAPLLPQADCEAS 219
Query: 179 YPGKITQSMVCAGDMKEGNDSCQGDSGGPLVCGGRLRGLVSWGDMPCGSKEKPGVYTDVC 238
          YPGKIT +MVCAG ++ G DSCQGDSGGP+VC G L+G+VSWG C + PGVYT VC
Sbjct: 220 YPGKITNNMVCAGFLEGGKDSCQGDSGGPVVCNGELQGIVSWG-YGCALPDNPGVYTKVC 278
Query: 239 THIRWIQNIL 248
          ++ WIQ+ +
Sbjct: 279 NYVDWIQDTI 288
Sqi|56541274|gb|AAH87610.1| G Hypothetical LOC496627 [Xenopus tropicalis]
 Length = 243
 Score = 216 bits (549), Expect = 6e-55
 Identities = 100/243 (41%), Positives = 155/243 (63%), Gaps = 5/243 (2%)
          MKMLALCLVLAKSAWSEEOEKVVHGGPCLKDSHPFQAALYTSGHLLCGGVLIDPQWVLTA 67
Query: 8
          MK+L +C++L +A + + +K++ G C ++S P+ +L SG+ CGG LI QWV++A
          MKLLLICVLLGAAA-AFDDDKIIGGSTCARNSVPYIVSL-NSGYHFCGGSLISNQWVVSA 58
Sbjct: 1
Query: 68 AHCKKPNLQVILGKHNLRQTETFQRQISVDRTIVHPRYNPETHDNDIMMVHLKNPVKFSK 127
          AHC K ++QV LG+HN+ +E ++ I+ + I HP YN T DNDIM++ L +P
Sbjct: 59 AHCYKASVQVRLGEHNIALSEGTEQFINSAKVIRHPSYNSRTIDNDIMLIKLASPASLNS 118
Query: 128 KIQPLPLKNDCSEENPNCQILGWGKME--NGDFPDTIQCADVHLVPREQCERAYPGKITQ 185
           + + L + C+ +C + GWG + ++PD +QC + ++
                                                     OC AYPG+IT
Sbjct: 119 AVNTVALPSSCAAAGTSCLVSGWGNLSTTTSNYPDLLQCLNAPILTTAQCSGAYPGQITN 178
Query: 186 SMVCAGDMKEGNDSCQGDSGGPLVCGGRLRGLVSWGDMPCGSKEKPGVYTDVCTHIRWIQ 245
          +M CAG ++ G DSCQGDSGGP+VC G L+G+VSWG + C + PGVY VC + WIQ
Sbjct: 179 NMFCAGFLEGGKDSCQGDSGGPVVCNGELQGVVSWG-IGCAQRNYPGVYAKVCNYNSWIQ 237
Query: 246 NIL 248
Sbjct: 238 STI 240
| >qi|51711962|ref|XP 487918.1| | G PREDICTED: similar to trypsinogen 9 [Mus musculus]
         Length = 264
 Score = 215 bits (548), Expect = 8e-55
 Identities = 99/227 (43%), Positives = 149/227 (65%), Gaps = 4/227 (1%)
Query: 24 EEQEKVVHGGPCLKDSHPFQAALYTSGHLLCGGVLIDPQWVLTAAHCKKPNLQVILGKHN 83
          ++ +K+V G C ++S P+Q +L SG+ CGG LI+ QWV++AAHC K +QV LG+HN
Sbjct: 37 DDDDKIVGGYTCRENSIPYQVSL-NSGYHFCGGSLINDQWVVSAAHCYKTRIQVRLGEHN 95
Query: 84 LRQTETFQRQISVDRTIVHPRYNPETHDNDIMMVHLKNPVKFSKKIQPLPLKNDCSEENP 143
```

```
Identities = 100/227 (44%), Positives = 151/227 (66%), Gaps = 4/227 (1%)
Query: 24 EEQEKVVHGGPCLKDSHPFQAALYTSGHLLCGGVLIDPQWVLTAAHCKKPNLQVILGKHN 83
          ++ +K+V G C ++S P+Q +L SG+ CGG LI+ QWV++AAHC K +QV LG+HN
Sbjct: 11 DDDDKIVGGYTCQENSVPYQVSL-NSGYHFCGGSLINDQWVVSAAHCYKSRIQVRLGEHN 69
Query: 84 LRQTETFQRQISVDRTIVHPRYNPETHDNDIMMVHLKNPVKFSKKIQPLPLKNDCSEENP 143
          + E ++ ++ + I HP ++ +T +NDIM++ L +PVK + ++ + L + C+
Sbjct: 70 INVLEGNEQFVNAAKIIKHPNFDRKTLNNDIMLIKLSSPVKLNARVATVALPSSCAPAGT 129
Query: 144 NCQILGWGK-MENG-DFPDTIQCADVHLVPREQCERAYPGKITQSMVCAGDMKEGNDSCQ 201
           C I GWG + +G + PD +QC D L+P+ CE +YPGKIT +MVC G ++ G DSCQ
Sbjct: 130 QCLISGWGNTLSSGVNEPDLLQCLDAPLLPQADCEASYPGKITDNMVCVGFLEGGKDSCQ 189
Ouery: 202 GDSGGPLVCGGRLRGLVSWGDMPCGSKEKPGVYTDVCTHIRWIQNIL 248
          GDSGGP+VC G L+G+VSWG C + PGVYT VC ++ WIQ+ +
Sbjct: 190 GDSGGPVVCNGELQGIVSWG-YGCALPDNPGVYTKVCNYVDWIQDTI 235
| >qi|34855584|ref|XP 342669.1| G similar to trypsinogen 9 [Rattus norvegicus]
         Length = 246
 Score = 216 bits (550), Expect = 5e-55
 Identities = 103/242 (42%), Positives = 156/242 (64%), Gaps = 5/242 (2%)
Query: 10 MLALCLVLAKSAWS-EEQEKVVHGGPCLKDSHPFQAALYTSGHLLCGGVLIDPQWVLTAA 68
          +L L LV A+ ++ +K+V G C ++S P+Q +L SG+ CGG LI+ QWV++AA
Sbjct: 4 LLFLALVGVAVAFPVDDDDKIVGGYTCQENSVPYQVSL-NSGYHFCGGSLINDQWVVSAA 62
Query: 69 HCKKPNLQVILGKHNLRQTETFQRQISVDRTIVHPRYNPETHDNDIMMVHLKNPVKFSKK 128
          HC K +QV LG+HN+ E ++ ++ + I HP +N +NDIM++ L +PVK ++
Sbjct: 63 HCYKTRIQVRLGEHNINVLEGDEQFVNAAKIIKHPNFNARNLNNDIMLIKLSSPVKLNAR 122
Query: 129 IQPLPLKNDCSEENPNCQILGWGKMEN--GDFPDTIQCADVHLVPREQCERAYPGKITQS 186
          + + L + C+ C I GWG + + PD +QC D ++P+ CE +YPGKIT +
Sbjct: 123 VATVALPSSCAPAGTQCLISGWGNTLSLGVNNPDLLQCLDAPVLPQADCEASYPGKITNN 182
Query: 187 MVCAGDMKEGNDSCQGDSGGPLVCGGRLRGLVSWGDMPCGSKEKPGVYTDVCTHIRWIQN 246
          M+C G ++ G DSCQGDSGGP+VC G+L+G+VSWG C K+ PGVYT VC ++ WIQ+
Sbjct: 183 MICVGFLEGGKDSCQGDSGGPVVCNGQLQGIVSWG-YGCALKDNPGVYTKVCNYVDWIQD 241
Query: 247 IL 248
Sbjct: 242 TI 243
| >gi | 34855588 | ref | XP 342672.1 | G similar to trypsin (EC 3.4.21.4) II precursor - rat
          norvegicus]
         Length = 291
 Score = 216 bits (549), Expect = 6e-55
 Identities = 106/250 (42%), Positives = 159/250 (63%), Gaps = 5/250 (2%)
          PMKMLTMKMLALCLVLAKSAWS-EEQEKVVHGGPCLKDSHPFQAALYTSGHLLCGGVLID 60
          Sbjct: 41 PSRTLKDCLLNHLLVFIQVAFPVDDDDKIVGGYTCQEHSVPYQVSL-NSGYHYCGGSLIN 99
```

Score = 216 bits (550), Expect = 5e-55

qi|47169490|tpe|CAE48382.1| G TPA: trypsin 10 [Rattus norvegicus] Length = 246Score = 216 bits (551), Expect = 3e-55 Identities = 106/242 (43%), Positives = 157/242 (64%), Gaps = 5/242 (2%) Query: 10 MLALCLVLAKSAW-SEEQEKVVHGGPCLKDSHPFQAALYTSGHLLCGGVLIDPQWVLTAA 68 +L L LV A A+ + + +K+V G C ++S P+Q +L SG+ CGG LI+ QWV++AA VLILALVGAAVAFPAADDDKIVGGYTCQENSVPYQVSL-NSGYHFCGGSLINEQWVVSAA 62 Sbjct: 4 Query: 69 HCKKPNLQVILGKHNLRQTETFQRQISVDRTIVHPRYNPETHDNDIMMVHLKNPVKFSKK 128 HC K +QV LG+HN+ E ++ ++ + I HP + +T +NDIM++ L +PVK + + Sbjct: 63 HCYKSRIQVRLGEHNINVLEGNEQFVNAAKIIKHPNFIRKTLNNDIMLIKLSSPVKLNSR 122 Query: 129 IQPLPLKNDCSEENPNCQILGWGKMEN--GDFPDTIQCADVHLVPREQCERAYPGKITQS 186 + + L + C+ C I GWG + + PD +QC D L+P+ CE +YPGKIT + Sbjct: 123 VATVALPSSCAPAGTQCLISGWGNTLSFGVNEPDLLQCLDAPLLPQADCEASYPGKITDN 182 Query: 187 MVCAGDMKEGNDSCQGDSGGPLVCGGRLRGLVSWGDMPCGSKEKPGVYTDVCTHIRWIQN 246 MVCAG ++ G DSCQGDSGGP+VC G L+G+VSWG C + PGVYT VC ++ WIQ+ Sbjct: 183 MVCAGFLEGGKDSCQGDSGGPVVCNGELQGIVSWG-YGCALPDNPGVYTKVCNYVDWIQD 241 Query: 247 IL 248 Sbjct: 242 TI 243 | >gi|2358117|gb|AAB69087.1| trypsinogen 15 [Mus musculus] Length = 246Score = 216 bits (551), Expect = 3e-55 Identities = 106/241 (43%), Positives = 155/241 (64%), Gaps = 5/241 (2%) Query: 11 LALCLVLAKSAWS-EEQEKVVHGGPCLKDSHPFQAALYTSGHLLCGGVLIDPQWVLTAAH 69 L L LV A A+ ++ +K+V G C ++S P+Q +L SG+ CGG LI+ QWV++AAH Sbjct: 5 LILALVGAAVAFPVDDDDKIVGGYTCQENSVPYQVSL-NSGYHFCGGSLINDQWVVSAAH 63 Query: 70 CKKPNLQVILGKHNLRQTETFQRQISVDRTIVHPRYNPETHDNDIMMVHLKNPVKFSKKI 129 C K +OV LG+HN+ E ++ ++ + I HP +N +T +NDIM++ L +PV + ++ Sbjct: 64 CYKTRIQVRLGEHNINVLEGNEQFVNAAKIIKHPNFNRKTLNNDIMLIKLSSPVTLNARV 123 Query: 130 QPLPLKNDCSEENPNCQILGWGKMENGDF--PDTIQCADVHLVPREQCERAYPGKITQSM 187 + L + C+ C I GWG + PD +QC D L+P+ CE +YPGKIT +M Sbjct: 124 ATVALPSSCAPAGTQCLISGWGNTLSFGVSEPDLLQCLDAPLLPQADCEASYPGKITGNM 183 Query: 188 VCAGDMKEGNDSCQGDSGGPLVCGGRLRGLVSWGDMPCGSKEKPGVYTDVCTHIRWIQNI 247 VCAG ++ G DSCQGDSGGP+VC G L+G+VSWG C + PGVYT VC ++ WIQ+ Sbjct: 184 VCAGFLEGGKDSCQGDSGGPVVCNGELQGIVSWG-YGCALPDNPGVYTKVCNYVDWIQDT 242 Query: 248 L 248 Sbjct: 243 I 243

| >gi|758266|emb|CAA24581.1| | G unnamed protein product [Rattus norvegicus]

Length = 238

gi|2358118|gb|AAB69088.1| G trypsinogen 16 [Mus musculus] gi|3916748|gb|AAC79093.1| G trypsinogen 16 [Mus musculus] Length = 246 Score = 217 bits (552), Expect = 3e-55 Identities = 107/242 (44%), Positives = 155/242 (64%), Gaps = 5/242 (2%) Ouery: 10 MLALCLVLAKSAWS-EEQEKVVHGGPCLKDSHPFQAALYTSGHLLCGGVLIDPQWVLTAA 68 +L L LV A A+ ++ +K+V G C ++S P+Q +L SG+ CGG LI+ QWV++AA LLFLALVGAAVAFPVDDDDKIVGGYTCRENSVPYQVSL-NSGYHFCGGSLINDQWVVSAA 62 Sbjct: 4 Query: 69 HCKKPNLQVILGKHNLRQTETFQRQISVDRTIVHPRYNPETHDNDIMMVHLKNPVKFSKK 128 HC K +QV LG+HN+ E ++ I + I HP +N +T +NDIM++ L +PV + +Sbjct: 63 HCYKTRIQVRLGEHNINVLEGNEQFIDAAKIIKHPNFNRKTLNNDIMLIKLSSPVTLNAR 122 Query: 129 IQPLPLKNDCSEENPNCQILGWGKMENGDF--PDTIQCADVHLVPREQCERAYPGKITQS 186 + + L + C+ C I GWG + PD +QC D L+P+ CE +YPGKIT + Sbjct: 123 VATVALPSSCAPAGTQCLISGWGNTLSFGVSEPDLLQCLDAPLLPQADCEASYPGKITGN 182 Query: 187 MVCAGDMKEGNDSCQGDSGGPLVCGGRLRGLVSWGDMPCGSKEKPGVYTDVCTHIRWIQN 246 MVCAG ++ G DSCQGDSGGP+VC G L+G+VSWG C + PGVYT VC ++ WIQ+ Sbjct: 183 MVCAGFLEGGKDSCQGDSGGPVVCNGELQGIVSWG-YGCALPDNPGVYTKVCNYVDWIQD 241 Query: 247 IL 248 Sbjct: 242 TI 243 ogi|28373261|pdb|1C07|E Chain E, R117h Mutant Rat Anionic Trypsin Complexed With Pancreatic Trypsin Inhibitor (Bpti) Length = 245Score = 217 bits (552), Expect = 3e-55 Identities = 106/242 (43%), Positives = 158/242 (65%), Gaps = 5/242 (2%) Query: 10 MLALCLVLAKSAWS-EEQEKVVHGGPCLKDSHPFQAALYTSGHLLCGGVLIDPQWVLTAA 68 +L L LV A A+ ++ +K+V G C ++S P+Q +L SG+ CGG LI+ QWV++AA Sbjct: 3 LLFLALVGAAVAFPVDDDDKIVGGYTCQENSVPYQVSL-NSGYHFCGGSLINDQWVVSAA 61 Query: 69 HCKKPNLQVILGKHNLRQTETFQRQISVDRTIVHPRYNPETHDNDIMMVHLKNPVKFSKK 128 HC K +QV LG+HN+ E ++ ++ + I HP ++ +T +NDIM++ L +PVK + Sbjct: 62 HCYKSRIQVRLGEHNINVLEGNEQFVNAAKIIKHPNFDRKTLNNDIMLIKLSSPVKLNAH 121 Query: 129 IQPLPLKNDCSEENPNCQILGWGK-MENG-DFPDTIQCADVHLVPREQCERAYPGKITQS 186 + + L + C+ C I GWG + +G + PD +QC D L+P+ CE +YPGKIT + Sbjct: 122 VATVALPSSCAPAGTQCLISGWGNTLSSGVNEPDLLQCLDAPLLPQADCEASYPGKITDN 181 Query: 187 MVCAGDMKEGNDSCQGDSGGPLVCGGRLRGLVSWGDMPCGSKEKPGVYTDVCTHIRWIQN 246 MVC G ++ G DSCQGDSGGP+VC G L+G+VSWG C + PGVYT VC ++ WIQ+ Sbjct: 182 MVCVGFLEGGKDSCQGDSGGPVVCNGELQGIVSWG-YGCALPDNPGVYTKVCNYVDWIQD 240 Query: 247 IL 248 Sbjct: 241 TI 242

```
Query: 247 IL 248
```

Sbjct: 242 TI 243

```
| sqi | 27545370 | ref | NP 775423.1 | G | preprotrypsinogen IV [Rattus norvegicus] | qi | 56814 | emb | CAA33718.1 | G | preprotrypsinogen IV (AA -15 to 232) [Rattus norvegicus] | qi | 92924 | pir | | S05494 | trypsin (EC 3.4.21.4) IV precursor - rat | qi | 136419 | sp | P12788 | TRY4 RAT | G | Trypsin IV precursor (Pretrypsinogen IV) | Length = 247
```

Score = 210 bits (535), Expect = 2e-53 Identities = 95/228 (41%), Positives = 141/228 (61%), Gaps = 3/228 (1%)

Query: 25 EQEKVVHGGPCLKDSHPFQAALYTSGHLLCGGVLIDPQWVLTAAHCKKPNLQVILGKHNL 84 + +K+V G C K P+Q +L+ CGG LI QWVL+AAHC K LQV LG+HN+ Sbjct: 20 DDDKIVGGYTCPKHLVPYQVSLHDGISHQCGGSLISDQWVLSAAHCYKRKLQVRLGEHNI 79

Query: 85 RQTETFQRQISVDRTIVHPRYNPETHDNDIMMVHLKNPVKFSKKIQPLPLKNDCSEENPN 144 E ++ I ++ I HP YN +T DNDIM++ LK+P + ++ + L C+ +

Sbjct: 80 HVLEGGEQFIDAEKIIRHPEYNKDTLDNDIMLIKLKSPAVLNSQVSTVSLPRSCASTDAQ 139

Query: 145 CQILGWGKMEN--GDFPDTIQCADVHLVPREQCERAYPGKITQSMVCAGDMKEGNDSCQG 202 C + GWG + G +P +QC + ++ C+++YPG+IT +M C G ++ G DSC G Sbict: 140 CLVSGWGNTVSIGGKYPALLQCLEAPVLSASSCKKSYPGQITSNMFCLGFLEGGKDSCDG 199

Query: 203 DSGGPLVCGGRLRGLVSWGDMPCGSKEKPGVYTDVCTHIRWIQNILRN 250

DSGGP+VC G ++G+VSWG + C + KPGVYT VC ++ WIQ + N Sbjct: 200 DSGGPVVCNGEIQGIVSWGSV-CAMRGKPGVYTKVCNYLSWIQETMAN 246

>gi|67550|pir||TRPGTR trypsin (EC 3.4.21.4) precursor - pig (tentative sequence)
gi|136429|sp|P00761|TRYP PIG Trypsin precursor

Length = 231

Score = 210 bits (535), Expect = 2e-53 Identities = 95/228 (41%), Positives = 141/228 (61%), Gaps = 4/228 (1%)

Query: 23 SEEQEKVVHGGPCLKDSHPFQAALYTSGHLLCGGVLIDPQWVLTAAHCKKPNLQVILGKH 82 +++ +K+V G C +S P+Q +L + H CGG LI+ QWV++AAHC K +QV LG+H

Sbjct: 3 TDDDDKIVGGYTCAANSIPYQVSLNSGSHF-CGGSLINSQWVVSAAHCYKSRIQVRLGEH 61

Query: 83 NLRQTETFQRQISVDRTIVHPRYNPETHDNDIMMVHLKNPVKFSKKIQPLPLKNDCSEEN 142 N+ E ++ I+ + I HP +N T DNDIM++ L +P + ++ + L C+

Sbjct: 62 NIDVLEGNEQFINAAKIITHPNFNGNTLDNDIMLIKLSSPATLNSRVATVSLPRSCAAAG 121

Query: 143 PNCQILGWG--KMENGDFPDTIQCADVHLVPREQCERAYPGKITQSMVCAGDMKEGNDSC 200 C I GWG K +P +QC ++ C+ +YPG+IT +M+C G ++ G DSC

Sbjct: 122 TECLISGWGNTKSSGSSYPSLLQCLKAPVLSDSSCKSSYPGQITGNMICVGFLEGGKDSC 181

Query: 201 QGDSGGPLVCGGRLRGLVSWGDMPCGSKEKPGVYTDVCTHIRWIQNIL 248 QGDSGGP+VC G+L+G+VSWG C K KPGVYT VC ++ WIQ +

Sbjct: 182 QGDSGGPVVCNGQLQGIVSWG-YGCAQKNKPGVYTKVCNYVNWIQQTI 228

```
qi | 136411 | sp | P06872 | TRY2 CANFA Anionic trypsin precursor
gi|164095|gb|AAA30899.1| anionic trpysinogen precursor
         Length = 247
 Score = 210 bits (535), Expect = 2e-53
 Identities = 98/228 (42%), Positives = 149/228 (65%), Gaps = 4/228 (1%)
Query: 23 SEEQEKVVHGGPCLKDSHPFQAALYTSGHLLCGGVLIDPQWVLTAAHCKKPNLQVILGKH 82
          +++ +K+V G C ++S P+Q +L +G+ CGG LI QWV++AAHC K +QV LG++
Sbjct: 18 TDDDDKIVGGYTCEENSVPYQVSL-NAGYHFCGGSLISDQWVVSAAHCYKSRIQVRLGEY 76
Query: 83 NLRQTETFQRQISVDRTIVHPRYNPETHDNDIMMVHLKNPVKFSKKIQPLPLKNDCSEEN 142
              Sbjct: 77 NIDVLEGNEOFINSAKVIRHPNYNSWILDNDIMLIKLSSPAVLNARVATISLPRACAAPG 136
Query: 143 PNCQILGWGK-MENG-DFPDTIQCADVHLVPREQCERAYPGKITQSMVCAGDMKEGNDSC 200
            C I GWG + +G ++P+ +QC D ++ + QCE +YPG+IT++M+CAG ++ G DSC
Sbjct: 137 TQCLISGWGNTLSSGTNYPELLQCLDAPILTQAQCEASYPGQITENMICAGFLEGGKDSC 196
Query: 201 QGDSGGPLVCGGRLRGLVSWGDMPCGSKEKPGVYTDVCTHIRWIQNIL 248
          QGDSGGP+VC G L+G+VSWG C K KPGVYT VC + WIQ+ +
Sbjct: 197 QGDSGGPVVCNGELQGIVSWG-YGCAQKNKPGVYTKVCNFVDWIQSTI 243
similar to Try10-like trypsinogen [Mus musculus]
 gi|51092303|ref|NP 001003664.1| G Try10-like trypsinogen [Mus musculus]
 gi|33186826|tpe|CAD68170.1| G TPA: Try10-like trypsinogen [Mus musculus]
         Length = 246
 Score = 210 bits (535), Expect = 2e-53
 Identities = 96/227 (42%), Positives = 147/227 (64%), Gaps = 4/227 (1%)
Query: 24 EEQEKVVHGGPCLKDSHPFQAALYTSGHLLCGGVLIDPQWVLTAAHCKKPNLQVILGKHN 83
          ++ +++V G C ++S P+Q +L SG+ CG LI+ QWV++AAHC +QV LG+HN
Sbjct: 19 DDDDRIVGGYTCRENSVPYQVSL-NSGYHFCGDSLINDQWVVSAAHCYNSRIQVRLGEHN 77
Query: 84 LRQTETFQRQISVDRTIVHPRYNPETHDNDIMMVHLKNPVKFSKKIQPLPLKNDCSEENP 143
          + E ++ I + HP++ +T DNDIM++ L +PV + ++ + + + C+
Sbjct: 78 INVLEGNEQFIDAANIVKHPKFKKKTLDNDIMLIKLSSPVTLNARVATVAMPSSCALAGT 137
Query: 144 NCQILGWGK-MENG-DFPDTIQCADVHLVPREQCERAYPGKITQSMVCAGDMKEGNDSCQ 201
           C I GWG + +G + PD +QC D L+P+ CE +YPGKIT +M+C G ++ G DSCQ
Sbjct: 138 QCLISGWGNTLSSGVNNPDLLQCLDAPLLPQADCEASYPGKITNNMICVGFLEGGKDSCQ 197
Query: 202 GDSGGPLVCGGRLRGLVSWGDMPCGSKEKPGVYTDVCTHIRWIQNIL 248
          GDS GP+VC G+L+G+VSWG C K+ PGVYT VC ++ WIQN +
Sbjct: 198 GDSDGPVVCNGQLQGIVSWG-YGCAQKDNPGVYTKVCNYVDWIQNTI 243
sgi|6851258|gb|AAF29490.1| tissue kallikrein [Saguinus oedipus]
         Length = 261
 Score = 210 bits (535), Expect = 2e-53
 Identities = 101/257 (39%), Positives = 155/257 (60%), Gaps = 16/257 (6%)
```

```
MKMLALCLVLA---KSAWSEEQEKVVHGGPCLKDSHPFQAALYTSGHLLCGGVLIDPQWV 64
Ouery: 8
          M L LCL L+ A Q ++V G C + S P+QAALY
Sbjct: 1 MWFLVLCLALSLGGTGAVPPIQSRIVGGWDCKQHSQPWQAALYHYSTFQCGGVLVHPQWV 60
Query: 65 LTAAHCKKPNLQVILGKHNLRQTETFQRQISVDRTIVHPRYNP-----ETHDND 113
                  + Q+ LG+H+L + E + + V ++ HP +N
Sbjct: 61 LTAAHCISDHYQLWLGRHDLFENEDTAQFVFVSKSFPHPDFNMSLLKNHTRLPGEDYSHD 120
Query: 114 IMMVHLKNPVKFSKKIQPLPLKNDCSEENPNCQILGWG--KMENGDFPDTIQCADVHLVP 171
          +M++ LK PV+ + ++ + L + E C GWG K E FPD +QC D+ ++P
Sbjct: 121 LMLLQLKQPVQITDAVKVVELPTEGIEVGSTCLASGWGSIKPEKFSFPDILQCVDLKILP 180
Query: 172 REQCERAYPGKITQSMVCAGDMKEGNDSCQGDSGGPLVCGGRLRGLVSWGDMPCGSKEKP 231
            ++C++A+ K+T+ M+CAG +K+G D+C GDSGGPL C G L+G++SWG +PCGS KP
Sbjct: 181 NDECDKAHAQKVTEFMLCAGPLKDGQDTCVGDSGGPLTCDGVLQGIISWGYIPCGSPNKP 240
Query: 232 GVYTDVCTHIRWIQNIL 248
           V+ V ++++WI++ +
Sbjct: 241 SVFVRVLSYVKWIKDTI 257
💹 >qi | 34810822 | pdb | 10PH | B Chain B, Non-Covalent Complex Between Alpha-1-Pi-Pittsbur
          S195a Trypsin
         Length = 243
 Score = 210 bits (535), Expect = 2e-53
 Identities = 96/227 (42%), Positives = 143/227 (62%), Gaps = 4/227 (1%)
Query: 24 EEQEKVVHGGPCLKDSHPFQAALYTSGHLLCGGVLIDPQWVLTAAHCKKPNLQVILGKHN 83
           ++ +K+V G C ++ P+Q +L SG+ CGG LI+ QWV++AAHC K +QV LG+ N
Sbjct: 16 DDDDKIVGGYTCGANTVPYQVSL-NSGYHFCGGSLINSQWVVSAAHCYKSGIQVRLGEDN 74
Query: 84 LRQTETFQRQISVDRTIVHPRYNPETHDNDIMMVHLKNPVKFSKKIQPLPLKNDCSEENP 143
           + E ++ IS ++IVHP YN T +NDIM++ LK+ + ++ + L
Sbjct: 75 INVVEGNEQFISASKSIVHPSYNSNTLNNDIMLIKLKSAASLNSRVASISLPTSCASAGT 134
Query: 144 NCQILGWG--KMENGDFPDTIQCADVHLVPREQCERAYPGKITQSMVCAGDMKEGNDSCQ 201
            C I GWG K +PD ++C ++ C+ AYPG+IT +M CAG ++ G DSCQ
Sbjct: 135 QCLISGWGNTKSSGTSYPDVLKCLKAPILSDSSCKSAYPGQITSNMFCAGYLEGGKDSCQ 194
Query: 202 GDSGGPLVCGGRLRGLVSWGDMPCGSKEKPGVYTDVCTHIRWIQNIL 248
           GD+GGP+VC G+L+G+VSWG C K KPGVYT VC ++ WI+ +
Sbjct: 195 GDAGGPVVCSGKLQGIVSWGS-GCAQKNKPGVYTKVCNYVSWIKQTI 240
 Spi|2098545|pdb|1ANC| Anionic Trypsin Mutant With Ser 214 Replaced By Lys
          Length = 223
 Score = 210 bits (535), Expect = 2e-53
 Identities = 98/222 (44%), Positives = 146/222 (65%), Gaps = 4/222 (1%)
Query: 29 VVHGGPCLKDSHPFQAALYTSGHLLCGGVLIDPQWVLTAAHCKKPNLQVILGKHNLRQTE 88
           +V G C ++S P+Q +L SG+ CGG LI+ QWV++AAHC K +QV LG+HN+
 Sbjct: 1 IVGGYTCQENSVPYQVSL-NSGYHFCGGSLINDQWVVSAAHCYKSRIQVRLGEHNINVLE 59
 Query: 89 TFQRQISVDRTIVHPRYNPETHDNDIMMVHLKNPVKFSKKIQPLPLKNDCSEENPNCQIL 148
             ++ ++ + I HP ++ +T +NDIM++ L +PVK + ++ + L + C+ C I
```

```
Sbjct: 60 GNEQFVNAAKIIKHPNFDRKTLNNDIMLIKLSSPVKLNARVATVALPSSCAPAGTQCLIS 119
```

Query: 149 GWGK-MENG-DFPDTIQCADVHLVPREQCERAYPGKITQSMVCAGDMKEGNDSCQGDSGG 206

GWG + +G + PD +QC D L+P+ CE +YPGKIT +MVC G ++ G DSCQGDSGG

Sbjct: 120 GWGNTLSSGVNEPDLLQCLDAPLLPQADCEASYPGKITDNMVCVGFLEGGKDSCQGDSGG 179

Query: 207 PLVCGGRLRGLVSWGDMPCGSKEKPGVYTDVCTHIRWIQNIL 248

P+VC G L+G+V WG C + PGVYT VC ++ WIQ+ +

Sbjct: 180 PVVCNGELQGIVKWG-YGCALPDNPGVYTKVCNYVDWIQDTI 220

| >gi|2098541|pdb|1ANB| S Anionic Trypsin Mutant With Ser 214 Replaced By Glu Length = 223

Score = 210 bits (535), Expect = 2e-53 Identities = 98/222 (44%), Positives = 146/222 (65%), Gaps = 4/222 (1%)

Query: 29 VVHGGPCLKDSHPFQAALYTSGHLLCGGVLIDPQWVLTAAHCKKPNLQVILGKHNLRQTE 88
+V G C ++S P+Q +L SG+ CGG LI+ QWV++AAHC K +QV LG+HN+ E

Sbjct: 1 IVGGYTCQENSVPYQVSL-NSGYHFCGGSLINDQWVVSAAHCYKSRIQVRLGEHNINVLE 59

Sbjct: 60 GNEQFVNAAKIIKHPNFDRKTLNNDIMLIKLSSPVKLNARVATVALPSSCAPAGTQCLIS 119

Query: 149 GWGK-MENG-DFPDTIQCADVHLVPREQCERAYPGKITQSMVCAGDMKEGNDSCQGDSGG 206 GWG + +G + PD +QC D L+P+ CE +YPGKIT +MVC G ++ G DSCQGDSGG

Sbjct: 120 GWGNTLSSGVNEPDLLQCLDAPLLPQADCEASYPGKITDNMVCVGFLEGGKDSCQGDSGG 179

Query: 207 PLVCGGRLRGLVSWGDMPCGSKEKPGVYTDVCTHIRWIQNIL 248

P+VC G L+G+V WG C + PGVYT VC ++ WIQ+ +

Sbjct: 180 PVVCNGELQGIVEWG-YGCALPDNPGVYTKVCNYVDWIQDTI 220

Score = 210 bits (534), Expect = 3e-53
Identities = 98/219 (44%), Positives = 145/219 (66%), Gaps = 4/219 (1%)

Query: 32 GGPCLKDSHPFQAALYTSGHLLCGGVLIDPQWVLTAAHCKKPNLQVILGKHNLRQTETFQ 91 G C ++S P+O +L SG+ CGG LI+ OWV++AAHC K +OV LG+HN+ E +

Sbjct: 12 GYTCQENSVPYQVSL-NSGYHFCGGSLINDQWVVSAAHCYKSRIQVRLGEHNINVLEGNE 70

Query: 92 RQISVDRTIVHPRYNPETHDNDIMMVHLKNPVKFSKKIQPLPLKNDCSEENPNCQILGWG 151 + ++ + I HP ++ +T +NDIM++ L +PVK + ++ + L + C+ C I GWG

Sbjct: 71 QFVNAAKIIKHPNFDRKTLNNDIMLIKLSSPVKLNARVATVALPSSCAPAGTQCLISGWG 130

Query: 152 K-MENG-DFPDTIQCADVHLVPREQCERAYPGKITQSMVCAGDMKEGNDSCQGDSGGPLV 209 + +G + PD +QC D L+P+ CE +YPGKIT +MVC G ++ G DSCQGDSGGP+V

Sbjct: 131 NTLSSGVNEPDLLQCLDAPLLPQADCEASYPGKITDNMVCVGFLEGGKDSCQGDSGGPVV 190

Query: 210 CGGRLRGLVSWGDMPCGSKEKPGVYTDVCTHIRWIQNIL 248

C G L+G+VSWG C + PGVYT VC ++ WIQ+ +

Sbjct: 191 CNGELQGIVSWG-YGCALPDNPGVYTKVCNYVDWIQDTI 228

- 🛮 >gi|9257000|pdb|1EZU|D 🔼 Chain D, Ecotin Y69f, D70p Bound To D102n Trypsin gi|9256999|pdb|1EZU|C S Chain C, Ecotin Y69f, D70p Bound To D102n Trypsin gi|9256996|pdb|1EZS|D S Chain D, Crystal Structure Of Ecotin Mutant M84r, W67a, G68a D70a Bound To Rat Anionic Trypsin Ii qi|9256995|pdb|1EZS|C S Chain C, Crystal Structure Of Ecotin Mutant M84r, W67a, G68a D70a Bound To Rat Anionic Trypsin Ii Length = 223Score = 210 bits (534), Expect = 3e-53 Identities = 98/222 (44%), Positives = 147/222 (66%), Gaps = 4/222 (1%) Query: 29 VVHGGPCLKDSHPFQAALYTSGHLLCGGVLIDPQWVLTAAHCKKPNLQVILGKHNLROTE 88 +V G C ++S P+O +L SG+ CGG LI+ QWV++AAHC K +QV LG+HN+ IVGGYTCQENSVPYQVSL-NSGYHFCGGSLINDQWVVSAAHCYKSRIQVRLGEHNINVLE 59 Sbjct: 1 Query: 89 TFQRQISVDRTIVHPRYNPETHDNDIMMVHLKNPVKFSKKIQPLPLKNDCSEENPNCQIL 148 ++ ++ + I HP ++ +T +N+IM++ L +PVK + ++ + L + C+ Sbjct: 60 GDEQFVNAAKIIKHPNFDRKTLNNNIMLIKLSSPVKLNARVATVALPSSCAPAGTQCLIS 119 Query: 149 GWGK-MENG-DFPDTIQCADVHLVPREQCERAYPGKITQSMVCAGDMKEGNDSCQGDSGG 206 GWG + +G + PD +QC D L+P+ CE +YPGKIT +MVC G ++ G DSCQGDSGG Sbjct: 120 GWGNTLSSGVNEPDLLQCLDAPLLPQADCEASYPGKITDNMVCVGFLEGGKDSCQGDSGG 179 Query: 207 PLVCGGRLRGLVSWGDMPCGSKEKPGVYTDVCTHIRWIQNIL 248 C + PGVYT VC ++ WIQ+ + P+VC G L+G+VSWG Sbjct: 180 PVVCNGELQGIVSWG-YGCALPDNPGVYTKVCNYVDWIQDTI 220 Structure Of Rat Trypsin >qi|2392288|pdb|1DPO|
- Length = 223

Score = 210 bits (534), Expect = 3e-53 Identities = 98/222 (44%), Positives = 146/222 (65%), Gaps = 4/222 (1%)

Query: 29 VVHGGPCLKDSHPFQAALYTSGHLLCGGVLIDPQWVLTAAHCKKPNLQVILGKHNLRQTE 88 +V G C ++S P+Q +L SG+ CGG LI+ QWV++AAHC K +QV LG+HN+ IVGGYTCQENSVPYQVSL-NSGYHFCGGSLINDQWVVSAAHCYKSRIQVRLGEHNINVLE 59 Sbjct: 1

TFORQISVDRTIVHPRYNPETHDNDIMMVHLKNPVKFSKKIQPLPLKNDCSEENPNCQIL 148 Query: 89 ++ ++ + I HP ++ +T +NDIM++ L +PVK + ++ + L + C+

Sbjct: 60 GNEQFVNAAKIIKHPNFDRKTLNNDIMLIKLSSPVKLNARVATVALPSSCAPAGTQCLIS 119

Query: 149 GWGK-MENG-DFPDTIQCADVHLVPREQCERAYPGKITQSMVCAGDMKEGNDSCQGDSGG 206 GWG + +G + PD +QC D L+P+ CE +YPGKIT +MVC G ++ G DSCQGD GG Sbjct: 120 GWGNTLSSGVNEPDLLQCLDAPLLPQADCEASYPGKITDNMVCVGFLEGGKDSCQGDCGG 179

Query: 207 PLVCGGRLRGLVSWGDMPCGSKEKPGVYTDVCTHIRWIQNIL 248 P+VC G L+G+VSWG C + PGVYT VC ++ WIQ+ + Sbjct: 180 PVVCNGELQGIVSWG-YGCALPDNPGVYTKVCNYVDWIQDTI 220

Asn102Trypsin (E.C.3.4.21.4) (Mutant With Asp 102 Replaced >qi |230776 |pdb | 2TRM | (D102N) Complex With Benzamidine At pH 8 (Anionic Isozyme)

```
qi|230384|pdb|1TRM|B 📓 Chain B, Asnl02Trypsin (E.C.3.4.21.4) (Mutant With Asp 102 Re
          By Asn) (D102N) Complex With Benzamidine At pH 6
          (Anionic Isozyme)
 gi|230383|pdb|1TRM|A S Chain A, Asn102Trypsin (E.C.3.4.21.4) (Mutant With Asp 102 Re
          By Asn) (D102N) Complex With Benzamidine At pH 6
           (Anionic Isozyme)
         Length = 223
 Score = 210 bits (534), Expect = 3e-53
 Identities = 98/222 (44%), Positives = 147/222 (66%), Gaps = 4/222 (1%)
Query: 29 VVHGGPCLKDSHPFQAALYTSGHLLCGGVLIDPQWVLTAAHCKKPNLQVILGKHNLRQTE 88
          +V G C ++S P+Q +L SG+ CGG LI+ QWV++AAHC K +QV LG+HN+
          IVGGYTCQENSVPYQVSL-NSGYHFCGGSLINDQWVVSAAHCYKSRIQVRLGEHNINVLE 59
Sbjct: 1
Query: 89 TFQRQISVDRTIVHPRYNPETHDNDIMMVHLKNPVKFSKKIQPLPLKNDCSEENPNCQIL 148
            ++ ++ + I HP ++ +T +N+IM++ L +PVK + ++ + L + C+
Sbjct: 60 GNEQFVNAAKIIKHPNFDRKTLNNNIMLIKLSSPVKLNARVATVALPSSCAPAGTQCLIS 119
Query: 149 GWGK-MENG-DFPDTIQCADVHLVPREQCERAYPGKITQSMVCAGDMKEGNDSCQGDSGG 206
          GWG + +G + PD +OC D L+P+ CE +YPGKIT +MVC G ++ G DSCOGDSGG
Sbjct: 120 GWGNTLSSGVNEPDLLQCLDAPLLPQADCEASYPGKITDNMVCVGFLEGGKDSCQGDSGG 179
Query: 207 PLVCGGRLRGLVSWGDMPCGSKEKPGVYTDVCTHIRWIQNIL 248
          P+VC G L+G+VSWG C
                                + PGVYT VC ++ WIQ+ +
Sbjct: 180 PVVCNGELQGIVSWG-YGCALPDNPGVYTKVCNYVDWIQDTI 220
| >gi|56541161|qb|AAH87563.1| G Unknown (protein for MGC:97681) [Xenopus tropicalis]
 gi|58332102|ref|NP 001011199.1| G hypothetical LOC496623 [Xenopus tropicalis]
         Length = 243
 Score = 209 \text{ bits } (533), \text{ Expect = } 4e-53
 Identities = 101/243 (41%), Positives = 151/243 (62%), Gaps = 5/243 (2%)
          MKMLALCLVLAKSAWSEEQEKVVHGGPCLKDSHPFQAALYTSGHLLCGGVLIDPQWVLTA 67
Query: 8
          MK+ LC++L +A + + +K++ G C K+S P+ +L SG+ CGG LI+ QWV++A
Sbjct: 1
          MKLFLLCVLLGAAA-AFDDDKIIGGATCAKNSVPYIVSL-NSGYHFCGGSLINNQWVVSA 58
Query: 68 AHCKKPNLQVILGKHNLRQTETFQRQISVDRTIVHPRYNPETHDNDIMMVHLKNPVKFSK 127
          AHC K ++QV LG+HN+ +E ++ IS + I H YN T DNDIM++ L +
Sbjct: 59 AHCYKASIQVRLGEHNIALSEGTEQFISSSKVIRHSGYNSWTLDNDIMLIKLSSAASLNA 118
Query: 128 KIQPLPLKNDCSEENPNCQILGWGK--MENGDFPDTIQCADVHLVPREQCERAYPGKITQ 185
                          +C I GWG
           + + L + C+
                                         ++PD +QC
                                                          QC AYPG+IT
Sbjct: 119 AVNAVALPSGCAAAGASCLISGWGNTLSSGSNYPDLLQCLYAPILTDAQCNNAYPGEITN 178
Query: 186 SMVCAGDMKEGNDSCQGDSGGPLVCGGRLRGLVSWGDMPCGSKEKPGVYTDVCTHIRWIQ 245
           +M+C G ++ G DSCOGDSGGP+VC G L+G+VSWG C + PGVYT VC + WIO
Sbjct: 179 NMICLGFLEGGKDSCQGDSGGPVVCNGELQGVVSWG-YGCAQRNYPGVYTKVCNYNSWIQ 237
Query: 246 NIL 248
```

Sbjct: 238 STI 240

```
Ser (D189s)
gi|2781041|pdb|1AMH|A Chain A, Uncomplexed Rat Trypsin Mutant With Asp 189 Replace
          Ser (D189s)
         Length = 223
Score = 209 bits (533), Expect = 4e-53
Identities = 98/222 (44%), Positives = 146/222 (65%), Gaps = 4/222 (1%)
Query: 29 VVHGGPCLKDSHPFQAALYTSGHLLCGGVLIDPQWVLTAAHCKKPNLQVILGKHNLRQTE 88
          +V G C ++S P+Q +L SG+ CGG LI+ QWV++AAHC K +QV LG+HN+
Sbjct: 1
          IVGGYTCQENSVPYQVSL-NSGYHFCGGSLINDQWVVSAAHCYKSRIQVRLGEHNINVLE 59
Query: 89 TFQRQISVDRTIVHPRYNPETHDNDIMMVHLKNPVKFSKKIQPLPLKNDCSEENPNCQIL 148
           ++ ++ + I HP ++ +T +NDIM++ L +PVK + ++ + L + C+
Sbjct: 60 GNEQFVNAAKIIKHPNFDRKTLNNDIMLIKLSSPVKLNARVATVALPSSCAPAGTQCLIS 119
Query: 149 GWGK-MENG-DFPDTIQCADVHLVPREQCERAYPGKITQSMVCAGDMKEGNDSCQGDSGG 206
          GWG + +G + PD +QC D L+P+ CE +YPGKIT +MVC G ++ G SCQGDSGG
Sbjct: 120 GWGNTLSSGVNEPDLLQCLDAPLLPQADCEASYPGKITDNMVCVGFLEGGKSSCQGDSGG 179
Ouery: 207 PLVCGGRLRGLVSWGDMPCGSKEKPGVYTDVCTHIRWIQNIL 248
          P+VC G L+G+VSWG C + PGVYT VC ++ WIO+ +
Sbjct: 180 PVVCNGELQGIVSWG-YGCALPDNPGVYTKVCNYVDWIQDTI 220
| >gi | 55649807 | ref | XP 524358.1 | G PREDICTED: similar to variant form hippostasin/KLK.
       troglodytes]
         Length = 533
 Score = 209 bits (532), Expect = 6e-53
 Identities = 104/274 (37%), Positives = 153/274 (55%), Gaps = 31/274 (11%)
          MKMLALCLVLAKSAWSEEQEKVVHGGPCLKDSHPFQAALYTSGHLLCGGVLIDPQWVLTA 67
          M++L L L+ + ++++ G C S P+QAAL+ LLCG LI P+W+LTA
Sbjct: 259 MRILQLILLALATGLVGGETRIIKGFECKPHSQPWQAALFEKTRLLCGATLIAPRWLLTA 318
Query: 68 AHCKKPNLQ--------VILGKHNLRQTETFQRQISVDRTIVH 102
                                         V LG+HNL++ E ++ + H
          AHC+KP +
Sbjct: 319 AHCRKPWVSLTSPTHVSPDLSSSNYCLSHLSRYIVHLGQHNLQKEEGCEQTQTATESFPH 378
Query: 103 PRYNP----ETHDNDIMMVHLKNPVKFSKKIQPLPLKNDCSEENPNCQILGWGKMENGDF 158
                 + H NDIM+V + +PV + ++PL L + C +C I GWG
Sbjct: 379 PGFNDSLPNKDHRNDIMLVKMASPVSITWAVRPLTLSSRCVTAGTSCLISGWGSTSSPQL 438
Query: 159 --PDTIQCADVHLVPREQCERAYPGKITQSMVCAGDMKEGNDSCQGDSGGPLVCGGRLRG 216
            P T++CA++ ++ ++CE AYPG IT +MVCA + G DSCQGDSGGPLVC L+G
Sbjct: 439 RLPHTLRCANITIIEHQKCENAYPGNITDTMVCASVREGGKDSCQGDSGGPLVCNESLQG 498
Query: 217 LVSWGDMPCGSKEKPGVYTDVCTHIRWIQNILRN 250
          ++SWG PC KPGVYT VC ++ WIQ ++N
Sbjct: 499 IISWGQDPCAITRKPGVYTKVCKYVDWIQETMKN 532
 Score = 129 bits (325), Expect = 6e-29
 Identities = 75/231 (32%), Positives = 117/231 (50%), Gaps = 40/231 (17%)
```

```
Query: 6 LTMKMLALCLVLAKSAWSEEQEKVVHGGPCLKDSHPFQAALYTSGHLLCGGVLIDPOWVL 65
         L++ +L L L+++A K+ +G C ++S P+Q L+ L CGGVLID +WVL
Sbjct: 3 LSIFLLCVLGLSQAA----TPKIFNGTECGRNSQPWQVGLFEGTSLRCGGVLIDHRWVL 58
Query: 66 TAAHCKKPNLQ------
                                     ------94
          TAAHC +
                                                 V LG+H+L Q + ++
Sbjct: 59 TAAHCSGSGERQERLGVSVEGCKVGDCVPATRSAVATGSRYWVRLGEHSLSQLDWTEQIR 118
Query: 95 SVDRTIVHPRY--NPETHDNDIMMVHLKNPVKFSKKIQPLPLKNDCSEENPNCQILGWGK 152
             ++ HP Y +H++D+ ++ L+ PV+ + +QPLPL NDC+
Sbjct: 119 RSGFSVTHPGYLGASTSHEHDLRLLRLPVRVTSSVOPLPLPNDCATAGTECHVSGWGI 178
Query: 153 MEN--GDFPDTIQCADVHLVPREQCERAYPGKITQSMVCAGDMKEGNDSCO 201
                FPD +QC ++ +V C YPG+IT +MVCAG + G D+CQ
Sbjct: 179 TNHPWNPFPDLLQCLNLSIVSHATCHDVYPGRITSNMVCAGGV-PGQDACQ 228
| >gi | 58257847 | gb | AAW69366.1 | try14 [Macaca mulatta]
         Length = 247
Score = 209 bits (532), Expect = 6e-53
 Identities = 98/227 (43%), Positives = 146/227 (64%), Gaps = 4/227 (1%)
Query: 24 EEQEKVVHGGPCLKDSHPFQAALYTSGHLLCGGVLIDPQWVLTAAHCKKPNLQVILGKHN 83
          ++ +K+V G C ++S P+Q +L + H CGG LI+ QWV++AAHC KP +QV LG+HN
Sbjct: 19 DDDDKIVGGYTCEENSLPYQVSLNSGSHF-CGGSLINKQWVVSAAHCYKPRIQVRLGEHN 77
Query: 84 LRQTETFQRQISVDRTIVHPRYNPETHDNDIMMVHLKNPVKFSKKIQPLPLKNDCSEENP 143
          ++ E ++ I + I HP+YN ET DNDIM+V L P + ++ + L + +
Sbjct: 78 IKVLEGNEQFIHAAKIIRHPKYNNETLDNDIMLVKLSTPAIINARVSTISLPSALAAAGT 137
Query: 144 NCQILGWGKMEN--GDFPDTIQCADVHLVPREQCERAYPGKITQSMVCAGDMKEGNDSCO 201
           C I GWG + D+PD +QC D ++ + +CE +YPGKIT +M C G ++ G DSCQ
Sbjct: 138 ECLISGWGNTLSFGADYPDELQCLDAPVLTQAKCEASYPGKITSNMFCVGFLEGGKDSCQ 197
Query: 202 GDSGGPLVCGGRLRGLVSWGDMPCGSKEKPGVYTDVCTHIRWIONIL 248
         DSGGP+VC G+L+G+VSWG C K +PGVYT V ++ WI++ +
Sbjct: 198 RDSGGPVVCNGQLQGVVSWG-YGCARKNRPGVYTKVYNYVDWIRDTI 243
| >gi|50979094|ref|NP 001003284.1| | G kallikrein 2, prostatic [Canis familiaris]
gi|119586|sp|P09582|ESTA CANFA G Arginine esterase precursor
         Length = 260
Score = 209 bits (531), Expect = 7e-53
Identities = 97/257 (37%), Positives = 150/257 (58%), Gaps = 15/257 (5%)
Query: 8 MKMLALCLVLAKSAWSEE---QEKVVHGGPCLKDSHPFQAALYTSGHLLCGGVLIDPQWV 64
         M LALCL ++ E Q +++ G CLK+S P+Q A+Y +G CGGVL++P+WV
Sbjct: 1 MWFLALCLAMSLGWTGAEPHFQPRIIGGRECLKNSQPWQVAVYHNGEFACGGVLVNPEWV 60
Query: 65 LTAAHCKKPNLQVILGKHNLRQTETFQRQISVDRTIVHPRYNP------ETHDNDI 114
          LTAAHC N +V LG+HNL ++E + + V ++ +HP Y
Sbjct: 61 LTAAHCANSNCEVWLGRHNLSESEDEGQLVQVRKSFIHPLYKTKVPRAVIRPGEDRSHDL 120
Query: 115 MMVHLKNPVKFSKKIQPLPLKNDCSEENPNCQILGWGKMENGDF--PDTIQCADVHLVPR 172
```

```
Sbjct: 121 MLLHLEEPAKITKAVRVMDLPKKEPPLGSTCYVSGWGSTDPETIFHPGSLQCVDLKLLSN 180
Ouery: 173 EQCERAYPGKITQSMVCAGDMKEGNDSCQGDSGGPLVCGGRLRGLVSWGDMPCGSKEKPG 232
                                  D+C+GDSGGPL+C G L G+ SWG PCG + P
           OC + Y K+T+ M+CAG ++
Sbjct: 181 NQCAKVYTQKVTKFMLCAGVLEGKKDTCKGDSGGPLICDGELVGITSWGATPCGKPQMPS 240
Query: 233 VYTDVCTHIRWIQNILR 249
          +YT V H+ WI++ ++
Sbjct: 241 LYTRVMPHLMWIKDTMK 257
pgi|45382397|ref|NP 990715.1| G trypsinogen [Gallus gallus]
                         trypsin (EC 3.4.21.4) II precursor, pancreatic (clone 2-P29)
 gi | 1085254 | pir | | $55066
          chicken
 gi|2499864|sp|Q90629|TRY3 CHICK   Trypsin II-P29 precursor
 qi|603907|gb|AAA79914.1| G trypsinogen
         Length = 248
 Score = 209 bits (531), Expect = 7e-53
 Identities = 105/248 (42%), Positives = 158/248 (63%), Gaps = 5/248 (2%)
          MKMLTMKMLALCLVLAKSAWSEEQEKVVHGGPCLKDSHPFQAALYTSGHLLCGGVLIDPQ 62
Query: 3
          MKFLFLILSCLGAAVAFPGGADD-DKIVGGYTCPEHSVPYQVSL-NSGYHFCGGSLINSQ 58
Sbict: 1
Query: 63 WVLTAAHCKKPNLQVILGKHNLRQTETFQRQISVDRTIVHPRYNPETHDNDIMMVHLKNP 122
          WVL+AAHC K +QV LG++N+
                                 E + S I HP+Y+ T +NDIM++ L +
Sbjct: 59 WVLSAAHCYKSRIQVRLGEYNIDVQEDSEVVRSSSVIIRHPKYSSITLNNDIMLIKLASA 118
Query: 123 VKFSKKIQPLPLKNDCSEENPNCQILGWGK-MENG-DFPDTIQCADVHLVPREQCERAYP 180
           V++S IQP+ L + C++ C I GWG + NG ++P+ +QC + ++ ++C+ AYP
Sbjct: 119 VEYSADIQPIALPSSCAKAGTECLISGWGNTLSNGYNYPELLQCLNAPILSDQECQEAYP 178
Query: 181 GKITQSMVCAGDMKEGNDSCQGDSGGPLVCGGRLRGLVSWGDMPCGSKEKPGVYTDVCTH 240
           G IT +M+C G ++ G DSCQGDSGGP+VC G L+G+VSWG + C K PGVYT VC +
Sbjct: 179 GDITSNMICVGFLEGGKDSCQGDSGGPVVCNGELQGIVSWG-IGCALKGYPGVYTKVCNY 237
Query: 241 IRWIQNIL 248
           + WIO +
Sbjct: 238 VDWIQETI 245
 [ >gi|56971223|gb|AAH88079.1| G Hypothetical LOC496920 [Xenopus tropicalis]
 gi|58332720|ref|NP 001011435.1| G hypothetical LOC496920 [Xenopus tropicalis]
          Length = 251
 Score = 209 bits (531), Expect = 7e-53
 Identities = 97/250 (38%), Positives = 150/250 (60%), Gaps = 4/250 (1%)
           MLTMKMLALCLVLAKSAWSEEQEKVVHGGPCLKDSHPFQAALYTSGHLLCGGVLIDPQWV 64
Query: 5
                                                          CGG LI P+W+
                + + L +A +A ++ +K+V G C
                                           S P+Q
          MMMPLWVLMFLAVAAAAPLDDDDKIVGGYECTPHSQPWQVLFTFNGRNWCGGSLISPRWI 60
Sbjct: 1
Query: 65 LTAAHCKKP--NLQVILGKHNLRQTETFQRQISVDRTIVHPRYNPETHDNDIMMVHLKNP 122
           ++AAHC +P L +LG+H+L++ E ++ I V+
                                               H Y E +D+DIM+V L P
```

C + GWG +

P ++QC D+ L+

M++HL+ P K +K ++ + L

Sbjct: 61 ISAAHCYQPPKTLVALLGEHDLKKKEGTEQHIQVEAAYKHFGYKDEAYDHDIMLVKLAKP 120 Query: 123 VKFSKKIQPLPLKNDCSEENPNCQILGWGKM--ENGDFPDTIQCADVHLVPREOCERAYP 180 ++++ +QP+P+ C + C + G+G + N +PD +QC DV +V Sbjct: 121 AQYNQYVQPIPVARSCPTDGAKCLVSGYGNVLGYNTRYPDQLQCLDVPIVSDSSCKASYP 180 Query: 181 GKITQSMVCAGDMKEGNDSCQGDSGGPLVCGGRLRGLVSWGDMPCGSKEKPGVYTDVCTH 240 I+++M CAG ++ G SC+GDSGGPL+C G L G VSWG C SK PGVY VC + Sbjct: 181 RMISENMFCAGFLEGGKGSCKGDSGGPLICNGELYGAVSWGGSYCISKNSPGVYAKVCNY 240 Query: 241 IRWIQNILRN 250 + WI+NI N Sbjct: 241 LDWIKNITEN 250 Sgi 25814806 gb AAN75630.1 Gtrypsinogen [Gallus gallus] Length = 248Score = 208 bits (530), Expect = 9e-53 Identities = 100/226 (44%), Positives = 148/226 (65%), Gaps = 4/226 (1%) Query: 25 EQEKVVHGGPCLKDSHPFQAALYTSGHLLCGGVLIDPQWVLTAAHCKKPNLQVILGKHNL 84 + +K+V G C + S P+Q +L SG+ CGG LI+ QWVL+AAHC K +QV LG++N+ Sbjct: 22 DDDKIVGGYTCPEHSVPYQVSL-NSGYHFCGGSLINSQWVLSAAHCYKSRIQVRLGEYNI 80 Query: 85 RQTETFQRQISVDRTIVHPRYNPETHDNDIMMVHLKNPVKFSKKIQPLPLKNDCSEENPN 144 Sbjct: 81 DVQEDSEVVRSSSVIIRHPKYSSITLNNDIMLIKLASAVEYSADIQPIALPSSCAKAGTE 140 Query: 145 CQILGWGK-MENG-DFPDTIQCADVHLVPREOCERAYPGKITOSMVCAGDMKEGNDSCOG 202 C I GWG + NG ++P+ +QC + ++ ++C+ AYPG IT +M+C G ++ G DSCQG Sbjct: 141 CLISGWGNTLSNGYNYPELLQCLNAPILSDQECQEAYPGDITSNMICVGFLEGGKDSCQG 200 Query: 203 DSGGPLVCGGRLRGLVSWGDMPCGSKEKPGVYTDVCTHIRWIQNIL 248 DSGGP+VC G L+G+VSWG + C K PGVYT VC ++ WIQ + Sbjct: 201 DSGGPVVCNGELQGIVSWG-IGCALKGYPGVYTKVCNYVDWIQETI 245 Trypsin Inhibitor Length = 231Score = 208 bits (530), Expect = 9e-53 Identities = 97/219 (44%), Positives = 145/219 (66%), Gaps = 4/219 (1%)

🖭 >gi|14719439|pdb|1F5R|A 📓 Chain A, Rat Trypsinogen Mutant Complexed With Bovine Par

Query: 32 GGPCLKDSHPFQAALYTSGHLLCGGVLIDPQWVLTAAHCKKPNLQVILGKHNLROTETFO 91 G C ++S P+Q +L SG+ CGG LI+ QWV++AAHC K +QV LG+HN+ Sbjct: 12 GYTCQENSVPYQVSL-NSGYHFCGGSLINDQWVVSAAHCYKSRIQVRLGEHNINVLEGNE 70

Query: 92 RQISVDRTIVHPRYNPETHDNDIMMVHLKNPVKFSKKIQPLPLKNDCSEENPNCQILGWG 151 + ++ + I HP ++ +T +NDIM++ L +PVK + ++ + L + C+

Sbjct: 71 QFVNAAKIIKHPNFDRKTLNNDIMLIKLSSPVKLNARVATVALPSSCAPAGTQCLISGWG 130

Query: 152 K-MENG-DFPDTIQCADVHLVPREQCERAYPGKITQSMVCAGDMKEGNDSCQGDSGGPLV 209 + +G + PD ++C D L+P+ CE +YPGKIT +MVC G ++ G DSCQGDSGGP+V

Sbjct: 131 NTLSSGVNEPDLLKCLDAPLLPQADCEASYPGKITDNMVCVGFLEGGKDSCQGDSGGPVV 190

Query: 210 CGGRLRGLVSWGDMPCGSKEKPGVYTDVCTHIRWIQNIL 248

C G L+G+VSWG C + PGVYT VC ++ WIQ+ +

Sbjct: 191 CNGELQGIVSWG-YGCALPDNPGVYTKVCNYVDWIQDTI 228

| >gi | 108957 | pir | | S13813 | trypsin (EC 3.4.21.4) - bovine | gi | 2499861 | sp | Q29463 | TRY2 | BOVIN | Anionic trypsin precursor | gi | 830 | emb | CAA38513.1 | trypsinogen anionic precursor [Bos taurus] | Length = 247

Score = 208 bits (529), Expect = 1e-52 Identities = 102/242 (42%), Positives = 155/242 (64%), Gaps = 5/242 (2%)

Query: 10 MLALCLVLAKSAW-SEEQEKVVHGGPCLKDSHPFQAALYTSGHLLCGGVLIDPQWVLTAA 68 +L L V A A+ S++ +K+V G C ++S P+Q +L +G+ CGG LI+ QWV++AA

Sbjct: 4 LLILAFVGAAVAFPSDDDDKIVGGYTCAENSVPYQVSL-NAGYHFCGGSLINDQWVVSAA 62

Query: 69 HCKKPNLQVILGKHNLRQTETFQRQISVDRTIVHPRYNPETHDNDIMMVHLKNPVKFSKK 128 HC + ++QV LG++N+ E ++ I + I HP+Y+ T DNDI+++ L P + +

Sbjct: 63 HCYQYHIQVRLGEYNIDVLEGGEQFIDASKIIRHPKYSSWTLDNDILLIKLSTPAVINAR 122

Query: 129 IQPLPLKNDCSEENPNCQILGWGK-MENG-DFPDTIQCADVHLVPREQCERAYPGKITQS 186 + L L + C+ C I GWG + +G ++PD +QC L+ CE +YPG+IT +

Sbjct: 123 VSTLLLPSACASAGTECLISGWGNTLSSGVNYPDLLQCLVAPLLSHADCEASYPGQITNN 182

Query: 187 MVCAGDMKEGNDSCQGDSGGPLVCGGRLRGLVSWGDMPCGSKEKPGVYTDVCTHIRWIQN 246 M+CAG ++ G DSCQGDSGGP+ C G+L+G+VSWG C K KPGVYT VC ++ WIQ

Sbjct: 183 MICAGFLEGGKDSCQGDSGGPVACNGQLQGIVSWG-YGCAQKGKPGVYTKVCNYVDWIQE 241

Query: 247 IL 248

Sbjct: 242 TI 243

| >gi | 108118 | pir | | A37938 | tissue kallikrein (EC 3.4.21.35), prostatic, precursor - doc | gi | 163907 | gb | AAA30831.1 | G | arginine esterase | Length = 260

Score = 208 bits (529), Expect = 1e-52 Identities = 97/257 (37%), Positives = 149/257 (57%), Gaps = 15/257 (5%)

Query: 8 MKMLALCLVLAKSAWSEE---QEKVVHGGPCLKDSHPFQAALYTSGHLLCGGVLIDPQWV 64
M LALCL ++ E Q +++ G CLK+S P+Q A+Y +G CGGVL+ P+WV

Sbjct: 1 MWFLALCLAMSLGWTGAEPHFQPRIIGGRECLKNSQPWQVAVYHNGEFACGGVLVHPEWV 60

Query: 65 LTAAHCKKPNLQVILGKHNLRQTETFQRQISVDRTIVHPRYNP-----ETHDNDI 114 LTAAHC N +V LG+HNL ++E + + V ++ +HP Y E +D+

Sbjct: 61 LTAAHCANSNCEVWLGRHNLSESEDEGQLVQVRKSFIHPLYKTKVPRAVIRPGEDRSHDL 120

Query: 115 MMVHLKNPVKFSKKIQPLPLKNDCSEENPNCQILGWGKMENGDF--PDTIQCADVHLVPR 172 M++HL+ P K +K ++ + L C + GWG + P ++QC D+ L+

Sbjct: 121 MLLHLEEPAKITKAVRVMDLPKKEPPLGSTCYVSGWGSTDPETIFHPGSLQCVDLKLLSN 180

Query: 173 EQCERAYPGKITQSMVCAGDMKEGNDSCQGDSGGPLVCGGRLRGLVSWGDMPCGSKEKPG 232

QC + Y K+T+ M+CAG ++ D+C+GDSGGPL+C G L G+ SWG PCG + P

Sbjct: 181 NQCAKVYTQKVTKFMLCAGVLEGKKDTCKGDSGGPLICDGELVGITSWGATPCGKPQMPS 240

Query: 233 VYTDVCTHIRWIQNILR 249

+YT V H+ WI++ ++

Sbjct: 241 LYTRVMPHLMWIKDTMK 257

Query: 65 LTAAHCKKPNLQVILGKHNLRQTETFQRQISVDRTIVHPRYNPETHDNDIMMVHLKNPVK 124 ++AAHC K +QV LG+HN+ E ++ I + I HP YN T++NDIM++ LK

Sbjct: 60 VSAAHCYKSRIQVRLGEHNIDALEGGEQFIDAAKIIRHPNYNANTYNNDIMLIKLKTAAT 119

Query: 125 FSKKIQPLPLKNDCSEENPNCQILGWGK-MENG-DFPDTIQCADVHLVPREQCERAYPGK 182 + ++ + L C C + GWG + +G ++P +QC D ++ C +YPGK

Sbjct: 120 LNSRVSTVALPRSCPSAGTRCLVSGWGNTLSSGTNYPSLLQCLDAPVLSDSSCTSSYPGK 179

Query: 183 ITQSMVCAGDMKEGNDSCQGDSGGPLVCGGRLRGLVSWGDMPCGSKEKPGVYTDVCTHIR 242 IT +M C G ++ G DSCQGDSGGP+VC G+L+G+VSWG C + KPGVYT VC ++

Sbjct: 180 ITSNMFCLGFLEGGKDSCQGDSGGPVVCNGQLQGVVSWG-YGCAQRGKPGVYTKVCKYVN 238

Query: 243 WIQNIL 248 WIQ +

Sbjct: 239 WIQQTI 244

| >gi | 56556311 | gb | AAH87753.1 | G LOC496635 protein [Xenopus tropicalis] | Length = 252

Score = 208 bits (529), Expect = 1e-52 Identities = 96/245 (39%), Positives = 146/245 (59%), Gaps = 3/245 (1%)

Query: 10 MLALCLVLAKSAWSEEQEKVVHGGPCLKDSHPFQAALYTSGHLLCGGVLIDPQWVLTAAH 69 +L + L+L +A ++ +++ G C+ S P+Q ALY +CGGVLI+ WVLTAAH

Sbjct: 1 LLLVLLLLGSAAQTQTFHRIIGGEECVPHSQPWQVALYYFSDFICGGVLINEWWVLTAAH 60

Query: 70 CKKPNLQVILGKHNLRQTETFQRQISVDRTIVHPRYNPETHDNDIMMVHLKNPVKFSKKI 129 C + NLQV+LG HN + ++ + H ++P T+D+DIM++ L + +++

Sbjct: 61 CNQSNLQVLLGAHNRTKPTGHKQYTYAAKICPHCGFHPITYDHDIMLLKLASEADINTRV 120

Query: 130 QPLPLKNDCSEENPNCQILGWGKMENGD--FPDTIQCADVHLVPREQCERAYPGK-ITQS 186
P+PL + +N C GWG + +PD +QC +V V C+ YP IT +

Sbjct: 121 APIPLASYLVADNTECLASGWGSTTSPQETYPDNLQCVNVTTVSNSDCQACYPSDIITDN 180

 ${\tt Query:~187~MVCAGDMKEGNDSCQGDSGGPLVCGGRLRGLVSWGDMPCGSKEKPGVYTDVCTHIRWIQN~246}$

M+CAG+M G D+C GDSGGPLVC G L G+ SWGD CGS KPG++ V ++ WI +

 ${\tt Sbjct:~181~MLCAGNMAGGKDTCVGDSGGPLVCNGELHGITSWGDYVCGSPNKPGIFAKVFNYLNWISD~240}\\$

Query: 247 ILRNK 251

I++N+

Sbjct: 241 IMQNE 245

| >gi | 14719487 | pdb | 3TGK | E | Chain E, Trypsinogen Mutant D194n And Deletion Of Ile 16 | Complexed With Bovine Pancreatic Trypsin Inhibitor (Bpti)

Length = 231

Score = 208 bits (529), Expect = 1e-52
Identities = 97/219 (44%), Positives = 145/219 (66%), Gaps = 4/219 (1%)

Query: 32 GGPCLKDSHPFQAALYTSGHLLCGGVLIDPQWVLTAAHCKKPNLQVILGKHNLRQTETFQ 91 G C ++S P+Q +L SG+ CGG LI+ QWV++AAHC K +QV LG+HN+ E +

Sbjct: 12 GYTCQENSVPYQVSL-NSGYHFCGGSLINDQWVVSAAHCYKSRIQVRLGEHNINVLEGNE 70

Query: 92 RQISVDRTIVHPRYNPETHDNDIMMVHLKNPVKFSKKIQPLPLKNDCSEENPNCQILGWG 151 + ++ + I HP ++ +T +NDIM++ L +PVK + ++ + L + C+ C I GWG

Sbjct: 71 QFVNAAKIIKHPNFDRKTLNNDIMLIKLSSPVKLNARVATVALPSSCAPAGTQCLISGWG 130

Query: 152 K-MENG-DFPDTIQCADVHLVPREQCERAYPGKITQSMVCAGDMKEGNDSCQGDSGGPLV 209 + +G + PD +QC D L+P+ CE +YPGKIT +MVC G ++ G DSCQG+SGGP+V

Sbjct: 131 NTLSSGVNEPDLLQCLDAPLLPQADCEASYPGKITDNMVCVGFLEGGKDSCQGNSGGPVV 190

Query: 210 CGGRLRGLVSWGDMPCGSKEKPGVYTDVCTHIRWIQNIL 248 C G L+G+VSWG C + PGVYT VC ++ WIQ+ +

Sbjct: 191 CNGELQGIVSWG-YGCALPDNPGVYTKVCNYVDWIQDTI 228

Score = 207 bits (528), Expect = 2e-52Identities = 97/223 (43%), Positives = 139/223 (62%), Gaps = 3/223 (1%)

Query: 24 EEQEKVVHGGPCLKDSHPFQAALYTSGHLLCGGVLIDPQWVLTAAHCKKPNLQVILGKHN 83 + +++V G C + S P+Q +L H+ CGG LI QWVL+AAHC P LQV LG+HN

Sbjct: 20 DNDDRIVGGYTCQEHSVPYQVSLNAGSHI-CGGSLITDQWVLSAAHCYHPQLQVRLGEHN 78

Query: 84 LRQTETFQRQISVDRTIVHPRYNPETHDNDIMMVHLKNPVKFSKKIQPLPLKNDCSEENP 143

+ + E ++ I + I+HP Y+ T DNDIM++ LK+P + K+ +PL C Sbjct: 79 IYEIEGAEQFIDAAKMILHPDYDKWTVDNDIMLIKLKSPATLNSKVSTIPLPQYCPTAGT 138

Query: 144 NCQILGWGKMENG-DFPDTIQCADVHLVPREQCERAYPGKITQSMVCAGDMKEGNDSCQG 202 C + GWG ++ G + P +QC D ++ C +AYP +IT +M C G ++ G DSCQ

Sbjct: 139 ECLVSGWGVLKFGFESPSVLQCLDAPVLSDSVCHKAYPRQITNNMFCLGFLEGGKDSCQY 198

Query: 203 DSGGPLVCGGRLRGLVSWGDMPCGSKEKPGVYTDVCTHIRWIQ 245

DSGGP+VC G ++G+VSWGD C + KPGVYT VC ++ WIQ

Sbjct: 199 DSGGPVVCNGEVQGIVSWGD-GCALEGKPGVYTKVCNYLNWIQ 240

```
Length = 275
 Score = 207 bits (528), Expect = 2e-52
 Identities = 104/274 (37%), Positives = 152/274 (55%), Gaps = 31/274 (11%)
          MKMLALCLVLAKSAWSEEQEKVVHGGPCLKDSHPFOAALYTSGHLLCGGVLIDPOWVLTA 67
          M++L L L+ +
                          + +++ G C S P+QAAL+
                                                    LLCG LI P+W+LTA
Sbjct: 1
          MRILQLILLALATGLVGGETRIIKGFECKPHSQPWQAALFEKTRLLCGATLIAPRWLLTA 60
Query: 68 AHCKKPNLQ-------------------VILGKHNLRQTETFQRQISVDRTIVH 102
          AHC KP +
                                           V LG+HNL++ E ++ + H
Sbjct: 61 AHCLKPWVSLTSPTHVSPDLSSSNYCLSHLSRYIVHLGQHNLQKEEGCEQTRTATESFPH 120
Query: 103 PRYNP----ETHDNDIMMVHLKNPVKFSKKIQPLPLKNDCSEENPNCQILGWGKMENGDF 158
          P + N
                  + H NDIM+V + +PV + ++PL L + C +C I GWG
Sbjct: 121 PGFNNSLPNKDHRNDIMLVKMASPVSITWAVRPLTLSSRCVTAGTSCLISGWGSTSSPQL 180
Query: 159 --PDTIQCADVHLVPREQCERAYPGKITQSMVCAGDMKEGNDSCQGDSGGPLVCGGRLRG 216
            P T++CA++ ++ ++CE AYPG IT +MVCA
                                            + G DSCOGDSGGPLVC
Sbjct: 181 RLPHTLRCANITIIEHQKCENAYPGNITDTMVCASVQEGGKDSCQGDSGGPLVCNQSLQG 240
Query: 217 LVSWGDMPCGSKEKPGVYTDVCTHIRWIQNILRN 250
          ++SWG PC KPGVYT VC ++ WIQ ++N
Sbjct: 241 IISWGQDPCAITRKPGVYTKVCKYVDWIQETMKN 274
Sgi 47220857 emb CAG00064.1 unnamed protein product [Tetraodon nigroviridis]
         Length = 246
 Score = 207 bits (528), Expect = 2e-52
 Identities = 101/241 (41%), Positives = 147/241 (60%), Gaps = 7/241 (2%)
Query: 13 LCLVLAKSAWS---EEQEKVVHGGPCLKDSHPFQAALYTSGHLLCGGVLIDPQWVLTAAH 69
          + LVL +A++ +E +K+V G C K+S P+Q +L SG+ CGG LI
Sbjct: 5 IVLVLIAAAYAAPIDEDDKIVGGYECRKNSVPYQVSL-NSGYHFCGGSLISSSWVVSAAH 63
Query: 70 CKKPNLQVILGKHNLRQTETFQRQISVDRTIVHPRYNPETHDNDIMMVHLKNPVKFSKKI 129
          C K +QV LG+HN+ E ++ I + I HPRYN DNDIM++ L +P +
Sbjct: 64 CYKSRIQVRLGEHNIAVHEGTEQFIDSAKVITHPRYNSYNLDNDIMLIKLSSPARLDSYV 123
Query: 130 QPLPLKNDCSEENPNCQILGWGKMENG--DFPDTIQCADVHLVPREQCERAYPGKITQSM 187
          + + L + C+
                     C I GWG + +FPD + C D ++ C +YPG IT +M
Sbjct: 124 RTVSLPSSCAGAGTYCLISGWGNTSSSGVNFPDNLMCLDAPILSDTSCRNSYPGGITANM 183
Query: 188 VCAGDMKEGNDSCQGDSGGPLVCGGRLRGLVSWGDMPCGSKEKPGVYTDVCTHIRWIONI 247
           CAG ++ G DSCQ DSGGP+VC G+L+G+VSWG+ C K KPGVY VC + WI++
Sbjct: 184 FCAGFLEGGKDSCQVDSGGPVVCNGQLQGVVSWGE-GCAQKNKPGVYAKVCNYNSWIRDT 242
Query: 248 L 248
Sbjct: 243 M 243
```

| >gi|47220856|emb|CAG00063.1| unnamed protein product [Tetraodon nigroviridis]

Sqi|27530958|dbj|BAC54105.1| variant form hippostasin/KLK11 [Homo sapiens]

http://www.ncbi.nlm.nih.gov/BLAST/Blast.cgi

Length = 278

```
Score = 207 bits (528), Expect = 2e-52
Identities = 101/247 (40%), Positives = 153/247 (61%), Gaps = 8/247 (3%)
          TMKMLALCLVLAKSAWS---EEQEKVVHGGPCLKDSHPFQAALYTSGHLLCGGVLIDPQW 63
               + LVL +A++ +E +K+V G C K+S P+Q +L SG+ CGG LI
Sbjct: 34 TMKAF-IVLVLIAAAYAAPIDEDDKIVGGYECRKNSVPYQVSL-NSGYHFCGGSLISSSW 91
Query: 64 VLTAAHCKKPNLQVILGKHNLRQTETFQRQISVDRTIVHPRYNPETHDNDIMMVHLKNPV 123
          V++AAHC K +QV LG+HN+
                               E ++ I+ + I HPRYN
Sbjct: 92 VVSAAHCYKSRIQVRLGEHNIAVNEGTEQFINSAKVITHPRYNSYNLDNDIMLIKLSSPA 151
Query: 124 KFSKKIQPLPLKNDCSEENPNCQILGWGKMEN--GDFPDTIQCADVHLVPREQCERAYPG 181
               + + L + C+ +C I · GWG +
                                          ++PD + C + ++
Sbjct: 152 RLDSYARTVSLPSSCAGAGTSCLISGWGNTSSSGSNYPDRLMCLNAPILSDTSCRNSYPG 211
Query: 182 KITQSMVCAGDMKEGNDSCQGDSGGPLVCGGRLRGLVSWGDMPCGSKEKPGVYTDVCTHI 241
          +I+ +M CAG ++ G DSCQGDSGGP+VC G+L+G+VSWG C + KPGVYT VC +
Sbjct: 212 QISTNMFCAGFLEGGKDSCQGDSGGPVVCNGQLQGVVSWG-YGCAQRNKPGVYTKVCNYN 270
Query: 242 RWIQNIL 248
           W+++ +
Sbjct: 271 SWLRDTM 277
Sgi|4389387|pdb|1A0J|D Chain D, Crystal Structure Of A Non-Psychrophilic Trypsin
          Cold-Adapted Fish Species.
Cold-Adapted Fish Species.
 qi|4389385|pdb|1A0J|B Chain B, Crystal Structure Of A Non-Psychrophilic Trypsin Fr
          Cold-Adapted Fish Species.
 gi|4389384|pdb|1A0J|A S Chain A, Crystal Structure Of A Non-Psychrophilic Trypsin Fr
          Cold-Adapted Fish Species.
         Length = 223
 Score = 207 bits (528), Expect = 2e-52
 Identities = 96/222 (43%), Positives = 138/222 (62%), Gaps = 4/222 (1%)
Query: 29 VVHGGPCLKDSHPFQAALYTSGHLLCGGVLIDPQWVLTAAHCKKPNLQVILGKHNLRQTE 88
                                        WV++AAHC K +QV LG+HN+
          +V G C K+S +QA+L SG+ CGG LI
         IVGGYECRKNSASYQASLQ-SGYHFCGGSLISSTWVVSAAHCYKSRIQVRLGEHNIAVNE 59
Sbjct: 1
Query: 89 TFQRQISVDRTIVHPRYNPETHDNDIMMVHLKNPVKFSKKIQPLPLKNDCSEENPNCQIL 148
                  + I+HP YN
                              DNDIM++ L P + + L + C+
```

P+VC G+L+G+VSWG C + KPGVYT VC + WI + + Sbjct: 180 PVVCNGQLQGVVSWG-YGCAQRNKPGVYTKVCNYRSWISSTM 220

Query: 207 PLVCGGRLRGLVSWGDMPCGSKEKPGVYTDVCTHIRWIQNIL 248

>gi|2392548|pdb|1TAW|A Chain A, Bovine Trypsin Complexed To Appi Length = 223

Sbjct: 60 GTEQFIDSVKVIMHPSYNSRNLDNDIMLIKLSKPASLNSYVSTVALPSSCASSGTRCLVS 119

Query: 149 GWGKME--NGDFPDTIQCADVHLVPREQCERAYPGKITQSMVCAGDMKEGNDSCQGDSGG 206

Sbjct: 120 GWGNLSGSSSNYPDTLRCLDLPILSSSSCNSAYPGQITSNMFCAGFMEGGKDSCQGDSGG 179

+ ++PDT++C D+ ++ C AYPG+IT +M CAG M+ G DSCQGDSGG

- Score = 207 bits (528), Expect = 2e-52
 Identities = 96/222 (43%), Positives = 139/222 (62%), Gaps = 4/222 (1%)
- Query: 29 VVHGGPCLKDSHPFQAALYTSGHLLCGGVLIDPQWVLTAAHCKKPNLQVILGKHNLRQTE 88
 +V G C ++ P+Q +L SG+ CGG LI+ QWV++AAHC K +QV LG+ N+ E
- Sbjct: 1 IVGGYTCGANTVPYQVSL-NSGYHFCGGSLINSQWVVSAAHCYKSGIQVRLGEDNINVVE 59
- Query: 89 TFQRQISVDRTIVHPRYNPETHDNDIMMVHLKNPVKFSKKIQPLPLKNDCSEENPNCQIL 148 ++ IS ++IVHP YN T +NDIM++ LK+ + ++ + L C+ C I
- Sbjct: 60 GNEQFISASKSIVHPSYNSNTLNNDIMLIKLKSAASLNSRVASISLPTSCASAGTQCLIS 119
- Query: 149 GWG--KMENGDFPDTIQCADVHLVPREQCERAYPGKITQSMVCAGDMKEGNDSCQGDSGG 206 GWG K +PD ++C ++ C+ AYPG+IT +M CAG ++ G DSCQGDSGG
- Sbjct: 120 GWGNTKSSGTSYPDVLKCLKAPILSTSSCKSAYPGQITSNMFCAGYLEGGKDSCOGDSGG 179
- Query: 207 PLVCGGRLRGLVSWGDMPCGSKEKPGVYTDVCTHIRWIQNIL 248
 - P+VC G+L+G+VSWG C K KPGVYT VC ++ WI+ +
- Sbjct: 180 PVVCSGKLQGIVSWGS-GCAQKNKPGVYTKVCNYVSWIKQTI 220
- >gi | 60593451 | pdb | 1SOR | A Chain A, Bovine Pancreatic Trypsin Inhibited With Benzami Atomic Resolution
- gi|49258809|pdb|1RXP|A Chain A, Structure Of Trypsin (Orthorhombic) With 1-(4-Tert Butylcarbamoyl- Piperazine-1-Carbonyl)-3-(3-Guanidino-Propyl)-4-0xo-Azetidine-2-Carboxylic Acid
- gi|49258395|pdb|10X1|A Chain A, Crystal Structure Of The Bovine Trypsin Complex Wi Synthetic 11 Peptide Inhibitor
- gi|48425172|pdb|1P2K|A Chain A, Structural Consequences Of Accommodation Of Four N
 Cognate Amino-Acid Residues In The S1 Pocket Of Bovine
 Trypsin And Chymotrypsin
- gi|48425170|pdb|1P2J|A Chain A, Structural Consequences Of Accommodation Of Four N
 Cognate Amino-Acid Residues In The S1 Pocket Of Bovine
 Trypsin And Chymotrypsin
- gi|37926888|pdb|1NC6|A Chain A, Potent, Small Molecule Inhibitors Of Human Mast Ce Tryptase. Anti-Asthmatic Action Of A Dipeptide-Based Transition State Analogue Containing Benzothiazole Ketone
- gi|34810040|pdb|103N|A Chain A, Elaborate Manifold Of Short Hydrogen Bond Arrays M Binding Of Active Site-Directed Serine Protease Inhibitors

- Binding Of Active Site-Directed Serine Protease Inhibitors

- gi|34810034|pdb|103H|A Chain A, Elaborate Manifold Of Short Hydrogen Bond Arrays M

 Binding Of Active Site-Directed Serine Protease

 Inhibitors

- gi|34810030|pdb|103D|A Chain A, Elaborate Manifold Of Short Hydrogen Bond Arrays M
 Binding Of Active Site-Directed Serine Protease
 Inhibitors

- gi|34810024|pdb|1037|A Chain A, Elaborate Manifold Of Short Hydrogen Bond Arrays M
 Binding Of Active Site-Directed Serine Protease
 Inhibitors

- gi|34810020|pdb|1033|A Chain A, Elaborate Manifold Of Short Hydrogen Bond Arrays M
 Binding Of Active Site-Directed Serine Protease
 Inhibitors

- Binding Of Active Site-Directed Serine Protease Inhibitors

- gi|34810011|pdb|102U|A Chain A, Elaborate Manifold Of Short Hydrogen Bond Arrays M Binding Of Active Site-Directed Serine Protease Inhibitors
- gi|34810009|pdb|102S|A Chain A, Elaborate Manifold Of Short Hydrogen Bond Arrays M
 Binding Of Active Site-Directed Serine Protease
 Inhibitors
- gi|34810008|pdb|102R|A Chain A, Elaborate Manifold Of Short Hydrogen Bond Arrays M
 Binding Of Active Site-Directed Serine Protease
 Inhibitors
- gi|34810007|pdb|1020|A Chain A, Elaborate Manifold Of Short Hydrogen Bond Arrays M
 Binding Of Active Site-Directed Serine Protease
 Inhibitors

```
Binding Of Active Site-Directed Serine Protease
Inhibitors
```

- gi|31615748|pdb|102J|A
 Chain A, Elaborate Manifold Of Short Hydrogen Bond Arrays M Binding Of Active Site-Directed Serine Protease Inhibitors
- Binding Of Active Site-Directed Serine Protease Inhibitors
- gi|31615746|pdb|102H|A S Chain A, Elaborate Manifold Of Short Hydrogen Bond Arrays M Binding Of Active Site-Directed Serine Protease Inhibitors
- gi|30750054|pdb|10YQ|A Chain A, Trypsin Inhibitor Complex
- gi | 28948739 | pdb | 1N6Y | A Chain A, Rip-Phasing On Bovine Trypsin
- qi | 28948738 | pdb | 1N6X | A Chain A, Rip-Phasing On Bovine Trypsin
- Trypsin-Keto-Babim-Zn+2, Ph 8.2 gi|3891399|pdb|1XUJ|
- gi|20663566|pdb|1GJ6|A Chain A, Engineering Inhibitors Highly Selective For The S1 Of Ser190 Trypsin-Like Serine Protease Drug Targets
- gi | 20149797 | pdb | 1EB2 | A Chain A, Trypsin Inhibitor Complex (Bpo)
- Chain A, Bovine Trypsin-Inhibitor Complex gi | 17942817 | pdb | 1K1I | A
- gi | 17942816 | pdb | 1K1J | A Chain A, Bovine Trypsin-Inhibitor Complex
- Chain A, Bovine Trypsin-Inhibitor Complex gi | 17942815 | pdb | 1K1L | A
- Chain A, Bovine Trypsin-Inhibitor Complex gi | 17942814 | pdb | 1K1M | A
- Chain A, Bovine Trypsin-Inhibitor Complex gi | 17942813 | pdb | 1K1N | A
- Chain A, Bovine Trypsin-Inhibitor Complex gi | 17942812 | pdb | 1K10 | A
- Chain A, Bovine Trypsin-Inhibitor Complex gi | 17942811 | pdb | 1K1P | A
- Chain A, Trypsin Inhibitor Complex gi | 16975154 | pdb | 1G36 | A
- Chain A, Crystal Structure Of Trypsin Complex With Amylamin gi | 15826250 | pdb | 1JIR | A Cyclohexane
- Pancreatic Trypsin At 105k To 1.21a Resolution From Laboratory Source With High Number Of Waters Modelled
- With Bovine Trypsin gi|13399517|pdb|1EJM|C Chain C, Crystal Structure Of The Bpti Ala16leu Mutant In C
- With Bovine Trypsin Chain A, Crystal Structure Of The Bpti Ala16leu Mutant In C gi | 13399515 | pdb | 1EJM | A With Bovine Trypsin
- Chain A, Factor Xa Specific Inhibitor In Complex With Bovin gi|10120745|pdb|1QL8|A Trypsin
- Chain A, Factor Xa Specific Inhibitor In Complex With Bovin gi | 10120744 | pdb | 1QL7 | A Trypsin
- Chain F, Complex Of Bdellastasin With Bovine Trypsin gi | 9954886 | pdb | 1C9T | F
- Chain E, Complex Of Bdellastasin With Bovine Trypsin S gi | 9954885 | pdb | 1C9T | E
- Chain D, Complex Of Bdellastasin With Bovine Trypsin qi | 9954884 | pdb | 1C9T | D
- Chain C, Complex Of Bdellastasin With Bovine Trypsin gi | 9954883 | pdb | 1C9T | C
- Chain B, Complex Of Bdellastasin With Bovine Trypsin
- gi | 9954882 | pdb | 1C9T | B Chain A, Complex Of Bdellastasin With Bovine Trypsin gi | 9954881 | pdb | 1C9T | A
- Chain A, Crystal Structure Of Cancer Chemopreventive Bowmanqi | 8569655 | pdb | 1D6R | A

- Inhibitor In Ternary Complex With Bovine Trypsin At 2.3 A Resolution. Structural Basis Of Janus-Faced Serine Protease Inhibitor Specificity
- gi|8569286|pdb|1F2S|E Chain E, Crystal Structure Of The Complex Formed Between Bov Beta- Trypsin And Mcti-A, A Trypsin Inhibitor Of Squash Family At 1.8 A Resolution
- gi|5107687|pdb|1SBW|A Chain A, Crystal Structure Of Mung Bean Inhibitor Lysine Act
 Fragment Complex With Bovine Beta-Trypsin At 1.8a
 Resolutio
- gi | 7767179 | pdb | 1QAO | A Chain A, Bovine Trypsin 2-Aminobenzimidazole Complex
- gi | 7766894 | pdb | 1QB6 | A Chain A, Bovine Trypsin 3,3'-[3,5-Difluoro-4-Methyl-2, 6-Pyridinediylbis(Oxy)] bis(Benzenecarboximidamide)
 (Zk-805623 Complex
- gi|7766893|pdb|10B1|A Chain A, Bovine Trypsin With 1-[2-[5-[amino(Imino)methyl]-2-Hydroxyphenoxy]-6-[3-(4, 5-Dihydro-1-Methyl-1h-Imidazol-2-Yl

Phenoxy]pyridin-4-Yl]piperidine-3-Carboxylic Acid (Zk-806974)

- gi | 7766880 | pdb | 1QB9 | A Chain A, Bovine Trypsin
 7-[[2-[[1-(1-Iminoethyl)piperidin-4-Yl]oxy]9h-Carbozol-9-Yl] Methyl]naphthalene-2-Carboximidamide
 (Zk- 806450) Complex
- gi|7766865|pdb|10B0|A Chain A, Bovine Trypsin
 7-[[6-[[1-(1-Iminoethyl)piperidin-4-Yl]oxy]2-Methyl-Benzimidazol-1-Yl]methyl]naphthalene-2Carboximidamid Zk-806711 Inhibitor Complex
- gi|7766864|pdb|1QBN|A Chain A, Bovine Trypsin 2-[amino(Imino)methyl]-2-Hydroxyphen [3-(4,5-Dihydro-1h-Imidazol-2-Yl)phenoxy]pyridine-4-Carboxylic Acid (Zk-806688) Complex
- gi|4699788|pdb|2BZA|A Chain A, Bovine Pancreas Beta-Trypsin In Complex With Benzyl gi|4699733|pdb|1CE5|A Chain A, Bovine Pancreas Beta-Trypsin In Complex With Benzam
- gi|7546600|pdb|3BTW|E Chain E, The Crystal Structures Of The Complexes Between Bov Beta- Trypsin And Ten Pl Variants Of Bpti
- gi|7546598|pdb|3BTT|E Chain E, The Crystal Structures Of The Complexes Between Bov Beta- Trypsin And Ten Pl Variants Of Bpti
- gi|7546596|pdb|3BTO|E Chain E, The Crystal Structures Of The Complexes Between Bov Beta- Trypsin And Ten Pl Variants Of Bpti
- gi|7546594|pdb|3BTM|E Chain E, The Crystal Structures Of The Complexes Between Bov Beta- Trypsin And Ten Pl Variants Of Bpti
- gi | 7546592 | pdb | 3BTK | E Chain E, The Crystal Structures Of The Complexes Between Bov Beta- Trypsin And Ten Pl Variants Of Bpti
- gi|7546590|pdb|3BTH|E Chain E, The Crystal Structures Of The Complexes Between Bov Beta- Trypsin And Ten Pl Variants Of Bpti
- gi|7546588|pdb|3BTG|E Chain E, The Crystal Structures Of The Complexes Between Bov Beta- Trypsin And Ten Pl Variants Of Bpti
- gi|7546586|pdb|3BTF|E Chain E, The Crystal Structures Of The Complexes Between Bov Beta- Trypsin And Ten Pl Variants Of Bpti.
- gi|7546584|pdb|3BTD|E Chain E, The Crystal Structures Of The Complexes Between The Beta-Trypsin And Ten P1 Variants Of Bpti.
- gi|7546570|pdb|3BTE|E Chain E, The Crystal Structures Of The Complexes Between Bov Beta- Trypsin And Ten Pl Variants Of Bpti.
- gi|5107649|pdb|1QCP|A Chain A, Crystal Structure Of The Rwj-51084 Bovine Pancreati
 Trypsin At 1.8 A

```
gi|6980531|pdb|2BTC|E Chain E, Bovine Trypsin In Complex With Squash Seed Inhibito
          (Cucurbita Pepo Trypsin Inhibitor Ii)
gi|6729840|pdb|2TI0|A
                       Chain A, Low Packing Density Form Of Boyine Beta-Trypsin In
          Cyclohexane
                       Chain A, High Packing Density Form Of Bovine Beta-Trypsin In
qi|6729821|pdb|1TI0|A
          Cyclohexane
gi|5822405|pdb|1SFI|A
                       Chain A, High Resolution Structure Of A Potent, Cyclic Prote
          Inhibitor From Sunflower Seeds
                       Chain 1, Trypsin Inhibitors With Rigid Tripeptidyl Aldehydes
gi | 5542502 | pdb | 1YYY | 1
                          Bovine Trypsin Complexed To Meta-Cyano-Benzylic Inhibitor
qi|3891978|pdb|1AUJ|
                        Trypsin-Babim-Sulfate, Ph 5.9
qi|3891400|pdb|1XUK|
qi|3891398|pdb|1XUI|
                        Trypsin-Keto-Babim, Zn+2-Free, Ph 8.2
                        S
                          Trypsin-Keto-Babim-Co+2, Ph 8.2
gi|3891397|pdb|1XUH|
                        Trypsin-Babim-Zn+2, Ph 8.2
gi | 4139602 | pdb | 1XUG |
                        S
                          Trypsin-Babim-Zn+2, Ph 8.2
gi | 4139601 | pdb | 1XUF |
                        🖺 Beta-Trypsin Complexed With Appu
qi|4139819|pdb|1BJV|
                        S
                          Beta-Trypsin Complexed With Acpu
gi|4139818|pdb|1BJU|
                        Bovine Trypsin Complexed To Bis-Phenylamidine Inhibitor
qi | 4389362 | pdb | 1AZ8 |
                        Factor Xa Specific Inhibitor In Complex With Bovine Trypsin
gi | 2624542 | pdb | 1MTW |
                          Factor Xa Specific Inhibitor In Complex With Bovine Trypsin
qi | 2624541 | pdb | 1MTV |
                        Factor Xa Specific Inhibitor In Complex With Bovine Trypsin
gi 2624540 | pdb | 1MTU |
gi | 2392460 | pdb | 1MTS |
                           Factor Xa Specific Inhibitor In Complex With Bovine Trypsin
qi | 1827632 | pdb | 1MAY |
                           Beta-Trypsin Phosphonate Inhibited
                        S
qi|1827633|pdb|1MAX|
                           Beta-Trypsin Phosphonate Inhibited
gi|1827639|pdb|1JRT|A
                           Chain A, Hemiacetal Complex Between Leupeptin And Trypsin
gi | 1827641 | pdb | 1JRS | A
                           Chain A, Hemiacetal Complex Between Leupeptin And Trypsin
                        Trypsin With Inhibitor Aeruginosin 98-B
gi | 2982034 | pdb | 1AQ7 |
                       Trypsin (Trigonal, 2.4 M Ammonium Sulfate) (E.C.3.4.21.4)
qi | 230914 | pdb | 3PTN |
gi | 230913 | pdb | 3PTB |
                          Beta-Trypsin (Benzamidine Inhibited) At pH7 (E.C.3.4.21.4)
                       Trypsin (Orthorhombic, 2.4 M Ammonium Sulfate) (E.C.3.4.21.4)
gi | 230679 | pdb | 2PTN |
                       Chain E, Beta-Trypsin (E.C.3.4.21.4) Complex With Pancreatic
qi|230677|pdb|2PTC|E
          Trypsin Inhibitor
                       Beta Trypsin Complexed With Cyclotheonamide A
gi | 996178 | pdb | 1TYN |
qi | 1000005 | pdb | 1TPS |
                        Trypsin Complexed With Inhibitor A90720a
                       Beta-Trypsin (E.C.3.4.21.4) Complex With P-Amidino-Phenyl-Pyr
qi | 230378 | pdb | 1TPP |
          (Appa)
                       Beta-Trypsin (Orthorhombic) At pH5.0 (E.C.3.4.21.4)
gi 230377 pdb 1TP0
                       Chain E, Anhydro-Trypsin (E.C.3.4.21.4) Complex With Pancreat
gi|230372|pdb|1TPA|E
          Trypsin Inhibitor
                       Beta-Trypsin (Orthorhombic) At pH 5.3 (E.C.3.4.21.4)
gi 230361 pdb 1TLD
                       Chain E, Trypsin (E.C.3.4.21.4) Complex With Bowman-Birk Inhi
gi | 230338 | pdb | 1TAB | E
          (AB-I)
                       Chain E, Trypsin (E.C.3.4.21.4) Complexed With Bowman-Birk
gi | 576271 | pdb | 1SMF | E
          Inhibitor
gi | 494471 | pdb | 1PPH | E
                       Chain E, Trypsin (E.C.3.4.21.4) Complex With Noncovalently Bo
          3-Tapap
```

gi|494465|pdb|1PPE|E Chain E, Trypsin (E.C.3.4.21.4) Complex With (Cucurbita Maxim

Trypsin Inhibitor (Cmti-I)

```
gi|494464|pdb|1PPC|E Chain E, Trypsin (E.C.3.4.21.4) Complex With Noncovalently Bo
                      Beta-Trypsin (E.C.3.4.21.4) Guanidinobenzoylated At Serine 19
gi | 494034 | pdb | 1GBT |
         5.5)
         Length = 223
Score = 207 bits (527), Expect = 2e-52
Identities = 96/222 (43%), Positives = 139/222 (62%), Gaps = 4/222 (1%)
Ouery: 29 VVHGGPCLKDSHPFQAALYTSGHLLCGGVLIDPOWVLTAAHCKKPNLQVILGKHNLROTE 88
          +V G C ++ P+Q +L SG+ CGG LI+ QWV++AAHC K +QV LG+ N+
          IVGGYTCGANTVPYQVSL-NSGYHFCGGSLINSQWVVSAAHCYKSGIQVRLGEDNINVVE 59
Sbjct: 1
          TFORQISVDRTIVHPRYNPETHDNDIMMVHLKNPVKFSKKIQPLPLKNDCSEENPNCOIL 148
Query: 89
            ++ IS ++IVHP YN T +NDIM++ LK+
                                             + ++ + L
Sbjct: 60 GNEQFISASKSIVHPSYNSNTLNNDIMLIKLKSAASLNSRVASISLPTSCASAGTQCLIS 119
Query: 149 GWG--KMENGDFPDTIQCADVHLVPREQCERAYPGKITQSMVCAGDMKEGNDSCQGDSGG 206
                     +PD ++C ++
                                      C+ AYPG+IT +M CAG ++ G DSCQGDSGG
Sbjct: 120 GWGNTKSSGTSYPDVLKCLKAPILSDSSCKSAYPGQITSNMFCAGYLEGGKDSCQGDSGG 179
Query: 207 PLVCGGRLRGLVSWGDMPCGSKEKPGVYTDVCTHIRWIQNIL 248
          P+VC G+L+G+VSWG C K KPGVYT VC ++ WI+ +
Sbjct: 180 PVVCSGKLQGIVSWGS-GCAQKNKPGVYTKVCNYVSWIKQTI 220
gi|92889|pir||A31136 tissue kallikrein (EC 3.4.21.35) 7 precursor, submandibular - r
gi 547790 sp P36373 KLK7 RAT G Glandular kallikrein 7, submandibular/renal precursor kallikrein) (RGK-7) (RSKG-7) (Kallikrein-related protein
          K1) (Esterase B) (Proteinase A)
 gi|205000|gb|AAA41461.1| 🚨 kallikrein
         Length = 261
 Score = 207 bits (527), Expect = 2e-52
 Identities = 94/237 (39%), Positives = 140/237 (59%), Gaps = 13/237 (5%)
Query: 26 QEKVVHGGPCLKDSHPFQAALYTSGHLLCGGVLIDPQWVLTAAHCKKPNLQVILGKHNLR 85
          Q +V+ G C K+S P+Q ALY+
                                   LCGGVLIDP WV+TAAHC N QV LG++NL
Sbjct: 22 QSRVIGGYKCEKNSQPWQVALYSFTKYLCGGVLIDPSWVITAAHCSSNNYQVWLGRNNLL 81
Ouery: 86 OTETFOROISVDRTIVHPRYNP-----ETHDNDIMMVHLKNPVKFSKKIOPLPL 134
          + E F +
                  V ++ HP Y P
                                          + H ND+M++HL P
Sbjct: 82 EDEPFAQHRLVSQSFPHPDYKPFLMRNHTRKPGDDHSNDLMLLHLSQPADITDGVKVIDL 141
Query: 135 KNDCSEENPNCQILGWGKMEN--GDFPDTIQCADVHLVPREQCERAYPGKITQSMVCAGD 192
                    С
                        GWG +
                                  +FPD +QC ++HL+ E+C +AY K+T M+CAG+
Sbjct: 142 PTEEPKVGSTCLASGWGSTKPLIWEFPDDLQCVNIHLLSNEKCIKAYKEKVTDLMLCAGE 201
Query: 193 MKEGNDSCQGDSGGPLVCGGRLRGLVSWGDMPCGSKEKPGVYTDVCTHIRWIQNILR 249
          ++ G D+C GDSGGPL+C G L+G+ SWG +PC
                                               P + YT +
Sbjct: 202 LEGGKDTCTGDSGGPLLCDGVLQGITSWGSVPCAKTNMPAIYTKLIKFTSWIKEVMK 258
```

>gi | 2358071 | gb | AAB69043.1 | trypsinogen 5 [Mus musculus]

Length = 246

```
Score = 207 bits (527), Expect = 2e-52
Identities = 97/230 (42%), Positives = 142/230 (61%), Gaps = 4/230 (1%)
Query: 23 SEEQEKVVHGGPCLKDSHPFQAALYTSGHLLCGGVLIDPQWVLTAAHCKKPNLQVILGKH 82
              +K+V G C K S P+Q +L
                                       CGG LI+ QWVL+AAHC K LQV LG+H
Sbjct: 18 ANSDDKIVGGYTCPKHSVPYQVSLNDGISHQCGGSLINDQWVLSAAHCYK-RLQVRLGEH 76
Query: 83 NLRQTETFQRQISVDRTIVHPRYNPETHDNDIMMVHLKNPVKFSKKIQPLPLKNDCSEEN 142
              E ++ I ++ I HP YN +T DNDIM++ LK+P
Sbjct: 77 NIDVLEGGEQFIDAEKIIRHPDYNKDTVDNDIMLIKLKSPAILNSQVSTVSLPRSCASTN 136
Ouery: 143 PNCQILGWGKMEN--GDFPDTIQCADVHLVPREQCERAYPGKITQSMVCAGDMKEGNDSC 200
                     + G +P +QC + ++ C+++YPG+IT +M C G ++ G DSC
            C + GWG
Sbjct: 137 AQCLVSGWGNTVSIGGKYPALLQCLEAPVLSASSCKKSYPGQITSNMFCLGFLEGGKDSC 196
Query: 201 QGDSGGPLVCGGRLRGLVSWGDMPCGSKEKPGVYTDVCTHIRWIQNILRN 250
           GDSGGP+VC G ++G+VSWG + C + KPGVYT VC ++ WIQ + N
Sbjct: 197 DGDSGGPVVCNGEIQGIVSWGSV-CAMRGKPGVYTKVCNYLSWIQETMAN 245
pgi|22652265|gb|AAN03662.1| G kallikrein 7 long variant protein [Homo sapiens]
 qi|21327705|ref|NP 644806.1| G stratum corneum chymotryptic enzyme preproprotein [Ho
 qi|4826950|ref|NP 005037.1| G stratum corneum chymotryptic enzyme preproprotein [Hom
 qi|14582758|gb|AAK69624.1| G stratum corneum chymotryptic enzyme [Homo sapiens]
                         G stratum corneum chymotryptic enzyme
 qi|532504|gb|AAC37551.1|
 gi|11244765|gb|AAG33360.1| G stratum corneum chymotryptic enzyme [Homo sapiens]
                        serine proteinase SCCE precursor - human
 gi|1082780|pir||A53968
 qi|5733684|gb|AAD49718.1| G stratum corneum chymotryptic enzyme [Homo sapiens]
 (hSCCE)
         Length = 253
 Score = 207 bits (526), Expect = 3e-52
 Identities = 96/247 (38%), Positives = 140/247 (56%), Gaps = 4/247 (1%)
          MLTMKMLALCLVLAKSAWSEEQEKVVHGGPCLKDSHPFQAALYTSGHLLCGGVLIDPQWV 64
Query: 5
                             + +K++ G PC + SHP+Q AL +
                                                       L CGGVL++ +WV
           +L +++L L L L +
          LLPLQILLSLALETAGEEAQGDKIIDGAPCARGSHPWQVALLSGNQLHCGGVLVNERWV 65
Sbjct: 6
Query: 65 LTAAHCKKPNLQVILGKHNLRQTETFQRQISVDRTIVHPRYNPETHDNDIMMVHLKNPVK 124
                                          ++ HP Y+ +TH ND+M+V L +
                      V LG
                                    ++I
           LTAAHCK
Sbjct: 66 LTAAHCKMNEYTVHLGSDTLGDRRA--QRIKASKSFRHPGYSTQTHVNDLMLVKLNSQAR 123
Query: 125 FSKKIQPLPLKNDCSEENPNCQILGWGKMENGD--FPDTIQCADVHLVPREQCERAYPGK 182
                                       + D FP + C DV L+ + C + Y
                             C + GWG
           S ++ + L + C
Sbjct: 124 LSSMVKKVRLPSRCEPPGTTCTVSGWGTTTSPDVTFPSDLMCVDVKLISPQDCTKVYKDL 183
Query: 183 ITQSMVCAGDMKEGNDSCQGDSGGPLVCGGRLRGLVSWGDMPCGSKEKPGVYTDVCTHIR 242
                         ++C GDSGGPLVC G L+GLVSWG PCG
                                                         PGVYT VC
           + SM+CAG
Sbjct: 184 LENSMLCAGIPDSKKNACNGDSGGPLVCRGTLQGLVSWGTFPCGQPNDPGVYTQVCKFTK 243
Query: 243 WIQNILR 249
           WI + ++
Sbjct: 244 WINDTMK 250
```

```
gi | 4506145 | ref | NP 002760.1 | G protease, serine, 1 preproprotein [Homo sapiens]
                       trypsin (EC 3.4.21.4) I precursor [validated] - human
qi | 88941 | pir | | A25852
gi | 1552515 | gb | AAC80207.1 G trypsinogen A [Homo sapiens]
gi|136408|sp|P07477|TRY1 HUMAN G Trypsin I precursor (Cationic trypsinogen)
                          G trypsinogen
 gi | 521216 | gb | AAA61231.1 |
gi 224981 prf | 1205235A
                          trypsinogen I
         Length = 247
 Score = 207 bits (526), Expect = 3e-52
 Identities = 102/249 (40%), Positives = 155/249 (62%), Gaps = 10/249 (4%)
Query: 2
          PMKMLTMKMLALCLVLAKSAWSEEQEKVVHGGPCLKDSHPFQAALYTSGHLLCGGVLIDP 61
                           +A ++ +K+V G C ++S P+Q +L SG+ CGG LI+
Sbjct: 3
          PLLILTFVAAAL-----AAPFDDDDKIVGGYNCEENSVPYQVSL-NSGYHFCGGSLINE 55
Query: 62 QWVLTAAHCKKPNLQVILGKHNLRQTETFQRQISVDRTIVHPRYNPETHDNDIMMVHLKN 121
          QWV++A HC K +QV LG+HN+
                                  E ++ I+ + I HP+Y+ +T +NDIM++ L +
Sbjct: 56 QWVVSAGHCYKSRIQVRLGEHNIEVLEGNEQFINAAKIIRHPQYDRKTLNNDIMLIKLSS 115
Query: 122 PVKFSKKIQPLPLKNDCSEENPNCQILGWGKMENG--DFPDTIQCADVHLVPREQCERAY 179
                                C I GWG
                                              D+PD +QC D ++ + +CE +Y
Sbjct: 116 RAVINARVSTISLPTAPPATGTKCLISGWGNTASSGADYPDELQCLDAPVLSQAKCEASY 175
Query: 180 PGKITQSMVCAGDMKEGNDSCQGDSGGPLVCGGRLRGLVSWGDMPCGSKEKPGVYTDVCT 239
          PGKIT +M C G ++ G DSCQGDSGGP+VC G+L+G+VSWGD C K KPGVYT V
Sbjct: 176 PGKITSNMFCVGFLEGGKDSCQGDSGGPVVCNGQLQGVVSWGD-GCAQKNKPGVYTKVYN 234
Query: 240 HIRWIONIL 248
          +++WI+N +
Sbjct: 235 YVKWIKNTI 243
sgi|230196|pdb|1NTP| Modified Beta Trypsin (Monoisopropylphosphoryl Inhibited)
          (E.C.3.4.21.4) (Neutron Data)
         Length = 223
 Score = 207 bits (526), Expect = 3e-52
 Identities = 96/222 (43%), Positives = 138/222 (62%), Gaps = 4/222 (1%)
Query: 29 VVHGGPCLKDSHPFQAALYTSGHLLCGGVLIDPOWVLTAAHCKKPNLOVILGKHNLROTE 88
          +V G C ++ P+Q +L SG+ CGG LID QWV++AAHC K +QV LG+ N+
Sbjct: 1
          IVGGYTCGANTVPYQVSL-NSGYHFCGGSLIDSQWVVSAAHCYKSGIQVRLGEDNINVVE 59
Query: 89 TFQRQISVDRTIVHPRYNPETHDNDIMMVHLKNPVKFSKKIQPLPLKNDCSEENPNCQIL 148
            ++ IS ++IVHP Y+ T +NDIM++ LK+
                                                ++ + L
                                                        C+
Sbjct: 60 GNEQFISASKSIVHPSYDSNTLNNDIMLIKLKSAASLDSRVASISLPTSCASAGTOCLIS 119
Query: 149 GWG--KMENGDFPDTIQCADVHLVPREQCERAYPGKITQSMVCAGDMKEGNDSCQGDSGG 206
          GWG K
                     +PD ++C
                                     C+ AYPG+IT +M CAG ++ G DSCQGDSGG
Sbjct: 120 GWGNTKSSGTSYPDVLKCLKAPILSDSSCKSAYPGQITSNMFCAGYLEGGKDSCQGDSGG 179
Query: 207 PLVCGGRLRGLVSWGDMPCGSKEKPGVYTDVCTHIRWIQNIL 248
          P+VC G+L+G+VSWG
                           C K KPGVYT VC ++ WI+
Sbjct: 180 PVVCSGKLQGIVSWGS-GCAQKNKPGVYTKVCNYVSWIKQTI 220
```

```
| >qi|27710074|ref|XP 231718.1| | G similar to Trypsin V-A precursor [Rattus norvegicus
gi|57413|emb|CAA41751.1| trypsin V a-form [Rattus rattus]
gi|92926|pir||JQ1471
                     trypsin (EC 3.4.21.4) V precursor, a-form - rat
qi|418136|sp|P32821|TRYA RAT Trypsin V-A precursor
         Length = 246
Score = 206 bits (525), Expect = 4e-52
Identities = 99/229 (43%), Positives = 141/229 (61%), Gaps = 4/229 (1%)
Query: 24 EEQEKVVHGGPCLKDSHPFQAALYTSGHLLCGGVLIDPQWVLTAAHCKKPNLQVILGKHN 83
          + +++V G C + S P+Q +L
                                   H+ CGG LI QWVL+AAHC P LQV LG+HN
Sbjct: 20 DNDDRIVGGYTCQEHSVPYQVSLNAGSHI-CGGSLITDQWVLSAAHCYHPQLQVRLGEHN 78
Query: 84 LRQTETFQRQISVDRTIVHPRYNPETHDNDIMMVHLKNPVKFSKKIQPLPLKNDCSEENP 143
                      + I+HP Y+ T DNDIM++ LK+P
          + + E ++ I
Sbjct: 79 IYEIEGAEQFIDAAKMILHPDYDKWTVDNDIMLIKLKSPATLNSKVSTIPLPQYCPTAGT 138
Query: 144 NCQILGWGKMENG-DFPDTIQCADVHLVPREQCERAYPGKITQSMVCAGDMKEGNDSCQG 202
           C + GWG ++ G + P +QC D ++ C +AYP +IT +M C G ++ G DSCQ
Sbjct: 139 ECLVSGWGVLKFGFESPSVLQCLDAPVLSDSVCHKAYPRQITNNMFCLGFLEGGKDSCQY 198
Query: 203 DSGGPLVCGGRLRGLVSWGDMPCGSKEKPGVYTDVCTHIRWI-QNILRN 250
          DSGGP+VC G ++G+VSWGD C + KPGVYT VC ++ WI Q I N
Sbjct: 199 DSGGPVVCNGEVQGIVSWGD-GCALEGKPGVYTKVCNYLNWIHQTIAEN 246
sgi|67551|pir||TRDGC trypsin (EC 3.4.21.4) precursor, cationic - dog
gi|136406|sp|P06871|TRY1 CANFA
                                 Cationic trypsin precursor
 gi|164097|gb|AAA30900.1| cationic trypsinogen precursor
         Length = 246
 Score = 206 bits (525), Expect = 4e-52
 Identities = 96/227 (42%), Positives = 142/227 (62%), Gaps = .4/227 (1%)
Query: 24 EEQEKVVHGGPCLKDSHPFQAALYTSGHLLCGGVLIDPQWVLTAAHCKKPNLQVILGKHN 83
          ++ +K+V G C ++S P+Q +L SG+ CGG LI+ QWV++AAHC K +QV LG++N
          DDDDKIVGGYTCSRNSVPYQVSL-NSGYHFCGGSLINSQWVVSAAHCYKSRIQVRLGEYN 77
Sbjct: 19
          LRQTETFQRQISVDRTIVHPRYNPETHDNDIMMVHLKNPVKFSKKIQPLPLKNDCSEENP 143
Query: 84
           + +E ++ I+ + I HPRYN T DNDIM++ L +P
                                                  + ++ + L
Sbjct: 78 IAVSEGGEQFINAAKIIRHPRYNANTIDNDIMLIKLSSPATLNSRVSAIALPKSCPAAGT 137
Query: 144 NCQILGWGKMEN--GDFPDTIQCADVHLVPREQCERAYPGKITQSMVCAGDMKEGNDSCQ 201
                                   ++ C AYPG+I+ +M+C G M+ G DSCQ
                         ++PD +QC
           C I GWG ++
Sbjct: 138 QCLISGWGNTQSIGQNYPDVLQCLKAPILSDSVCRNAYPGQISSNMMCLGYMEGGKDSCQ 197
Query: 202 GDSGGPLVCGGRLRGLVSWGDMPCGSKEKPGVYTDVCTHIRWIQNIL 248
           GDSGGP+VC G L+G+VSWG C K KPGV VC ++ WIQ +
Sbjct: 198 GDSGGPVVCNGELQGVVSWG-AGCAQKGKPGVSPKVCKYVSWIQQTI 243
```

>gi|10835849|pdb|1FNI|A Chain A, Crystal Structure Of Porcine Beta Trypsin With (
Polydocanol
gi|10835848|pdb|1FN6|A Chain A, Crystal Structure Of Porcine Beta Trypsin With 0.1

```
Polydocanol
gi|10835846|pdb|1FMG|A Crystal Structure Of Porcine Beta Trypsin With 0.0
          Polydocanol
Acetate Ion
 gi | 494360 | pdb | 1MCT | A Chain A, Trypsin (E.C.3.4.21.4) Complexed With Inhibitor From
         Bitter Gourd
         Length = 223
 Score = 206 bits (525), Expect = 4e-52
 Identities = 94/222 (42%), Positives = 136/222 (61%), Gaps = 4/222 (1%)
Query: 29 VVHGGPCLKDSHPFQAALYTSGHLLCGGVLIDPQWVLTAAHCKKPNLQVILGKHNLRQTE 88
         +V G C +S P+Q +L + H CGG LI+ QWV++AAHC K +QV LG+HN+
Sbjct: 1
         IVGGYTCAANSIPYQVSLNSGSHF-CGGSLINSQWVVSAAHCYKSRIQVRLGEHNIDVLE 59
Query: 89 TFQRQISVDRTIVHPRYNPETHDNDIMMVHLKNPVKFSKKIQPLPLKNDCSEENPNCQIL 148
           ++ I+ + I HP +N T DNDIM++ L +P + ++ + L
Sbjct: 60 GNEQFINAAKIITHPNFNGNTLDNDIMLIKLSSPATLNSRVATVSLPRSCAAAGTECLIS 119
Query: 149 GWG--KMENGDFPDTIQCADVHLVPREQCERAYPGKITQSMVCAGDMKEGNDSCQGDSGG 206
                   +P +QC ++ C+ +YPG+IT +M+C G ++ G DSCQGDSGG
Sbjct: 120 GWGNTKSSGSSYPSLLQCLKAPVLSNSSCKSSYPGQITGNMICVGFLQGGKDSCQGDSGG 179
Query: 207 PLVCGGRLRGLVSWGDMPCGSKEKPGVYTDVCTHIRWIQNIL 248
         P+VC G+L+G+VSWG C K KPGVYT VC ++ WIQ +
Sbjct: 180 PVVCNGQLQGIVSWG-YGCAQKNKPGVYTKVCNYVNWIQQTI 220
🖺 >gi|576019|pdb|1BRC|E 🚨 Chain E, Trypsin (E.C.3.4.21.4) Variant (D189g,G226d) Compl
         With Amyloid Beta-Protein Precursor Inhibitor Domain
With Bpti Variant (C5a, C55a)
gi | 515094 | pdb | 1BRA |
                    Trypsin (E.C.3.4.21.4) Variant (D189g,G226d) Complexed With
         Benzamidine
        Length = 223
Score = 206 \text{ bits } (525), Expect = 4e-52
Identities = 97/222 (43%), Positives = 145/222 (65%), Gaps = 4/222 (1%)
Query: 29 VVHGGPCLKDSHPFQAALYTSGHLLCGGVLIDPQWVLTAAHCKKPNLQVILGKHNLROTE 88
         +V G C ++S P+Q +L SG+ CGG LI+ QWV++AAHC K +QV LG+HN+
Sbjct: 1
         IVGGYTCQENSVPYQVSL-NSGYHFCGGSLINDQWVVSAAHCYKSRIQVRLGEHNINVLE 59
Query: 89
         TFQRQISVDRTIVHPRYNPETHDNDIMMVHLKNPVKFSKKIQPLPLKNDCSEENPNCQIL 148
```

++ ++ + I HP ++ +T +NDIM++ L +PVK + ++ + L + C+ C I Sbjct: 60 GNEQFVNAAKIIKHPNFDRKTLNNDIMLIKLSSPVKLNARVATVALPSSCAPAGTQCLIS 119

Query: 149 GWGK-MENG-DFPDTIQCADVHLVPREQCERAYPGKITQSMVCAGDMKEGNDSCQGDSGG 206

Sbjct: 120 GWGNTLSSGVNEPDLLQCLDAPLLPQADCEASYPGKITDNMVCVGFLEGGKGSCOGDSGG 179

Query: 207 PLVCGGRLRGLVSWGDMPCGSKEKPGVYTDVCTHIRWIONIL 248

Sbjct: 180 PVVCNGELQGIVSWG-YGCALPDNPDVYTKVCNYVDWIQDTI 220

P+VC G L+G+VSWG C + P VYT VC ++ WIQ+ +

GWG + +G + PD +QC D L+P+ CE +YPGKIT +MVC G ++ G SCOGDSGG

```
sqi|45382399|ref|NP 990716.1| G trypsinogen [Gallus gallus]
qi|2499862|sp|Q90627|TRY1 CHICK G Trypsin I-P1 precursor
gi|603903|qb|AAA79912.1| G trypsinogen
         Length = 248
Score = 206 bits (524), Expect = 5e-52
Identities = 97/227 (42%), Positives = 140/227 (61%), Gaps = 4/227 (1%)
Query: 24 EEQEKVVHGGPCLKDSHPFQAALYTSGHLLCGGVLIDPQWVLTAAHCKKPNLQVILGKHN 83
          E+ +K+V G C + + P+Q +L SG+ CGG LI QWVL+AAHC K ++QV LG++N
Sbjct: 21 EDDDKIVGGYSCARSAAPYQVSL-NSGYHFCGGSLISSQWVLSAAHCYKSSIQVKLGEYN 79
Query: 84 LRQTETFQRQISVDRTIVHPRYNPETHDNDIMMVHLKNPVKFSKKIQPLPLKNDCSEENP 143
          L + ++ IS + I H YN T +NDIM++ L + + +PL
Sbjct: 80 LAAQDGSEQTISSSKVIRHSGYNANTLNNDIMLIKLSKAATLNSYVNTVPLPTSCVTAGT 139
Query: 144 NCQILGWGK-MENGD-FPDTIQCADVHLVPREQCERAYPGKITQSMVCAGDMKEGNDSCQ 201
           C I GWG + +G +PD +QC + ++ QC AYPG+IT +M+C G + G DSCQ
Sbjct: 140 TCLISGWGNTLSSGSLYPDVLQCLNAPVLSSSQCSSAYPGRITSNMICIGYLNGGKDSCQ 199
Query: 202 GDSGGPLVCGGRLRGLVSWGDMPCGSKEKPGVYTDVCTHIRWIQNIL 248
          GDSGGP+VC G+L+G+VSWG + C K PGVYT VC ++ WI+
Sbjct: 200 GDSGGPVVCNGQLQGIVSWG-IGCAQKGYPGVYTKVCNYVSWIKTTM 245
| >gi|51746022|ref|XP 355892.2| | G RIKEN cDNA 2310008B01 [Mus musculus]
         Length = 405
 Score = 206 bits (524), Expect = 5e-52
 Identities = 96/231 (41%), Positives = 147/231 (63%), Gaps = 7/231 (3%)
Query: 25 EQEKVVHGGPCLKDSHPFQAALYTSGHLLCGGVLIDPQWVLTAAHCKKPNLQVILGKHNL 84
           ++EK+ +G C+K+S P+Q L+ +L CGGVL+D +WVLTAAHC+ + V LG+H+L
Sbjct: 176 DREKIYNGVECVKNSQPWQVGLFHGKYLRCGGVLVDRKWVLTAAHCRDKYV-VRLGEHSL 234
Ouery: 85 ROTETFOROISVDRTIVHPRYNP--ETHDNDIMMVHLKNPVKFSKKIQPLPLKNDCSEEN 142
                        +I HP Y + H++D+ ++ L P+ ++ ++P+ L + C
Sbjct: 235 TKLDWTEQLRHTTFSITHPSYQGAYQNHEHDLRLLRLNRPIHLTRAVRPVALPSSCVTTG 294
Query: 143 PNCQILGWGKMEN--GDFPDTIQCADVHLVPREQCERAYPGKITQSMVCAGDMKEGNDSC 200
                           FPD +QC ++ V E C +PG++T++M+CAG + G D+C
Sbjct: 295 AMCHVSGWGTTNKPWDPFPDRLQCLNLSTVSNETCRAVFPGRVTENMLCAGG-EAGKDAC 353
Query: 201 QGDSGGPLVCGGRLRGLVSWGDM-PCGSKEKPGVYTDVCTHIRWIQNILRN 250
           QGDSGGPLVCGG L+GLVSWG + PCG K PGVYT VC + WI+ ++RN
Sbjct: 354 QGDSGGPLVCGGVLQGLVSWGSVGPCGQKGIPGVYTKVCKYTDWIRIVIRN 404
 Score = 115 bits (287), Expect = 1e-24
 Identities = 65/155 (41%), Positives = 88/155 (56%), Gaps = 17/155 (10%)
Query: 14 CLVLAKSAW-SEEQEKVVHGG------PCLKDSHPFQAALYTSGHLLCGGVLIDP 61
                   S + K+++G
                                           CL S P+QAAL
                                                        G LLCGGVL+ P
           CL LA S
Sbjct: 10 CLTLALSEGISRDYPKILNGTNGTSGFLPGGYTCLPHSQPWQAALLIRGRLLCGGVLVHP 69
```

- Query: 62 QWVLTAAHCKKPNLQVILGKHNLRQTETFQRQISVDRTIVHPRYNPE----THDNDIMMV 117
 - +WVLTAAHC+K V LGKH L + E ++ + V R+I HP Y
- Sbjct: 70 KWVLTAAHCRKDGYTVHLGKHALGRVENGEQAMEVVRSIPHPEYQVTPTHLNHDHDIMLL 129
- Query: 118 HLKNPVKFSKKIQPLPLK-NDCSEENPNCQILGWG 151
 - LK+PV+ S ++ L L +DC
- Sbjct: 130 ELKSPVQLSSHVRTLKLSADDCLPTGTCCRVSGWG 164
- | >gi | 34811715 | pdb | 1HJ9 | A | Chain A, Atomic Resolution Structures Of Trypsin Provide Into Structural Radiation Damage
- Multi- Centered Short Hydrogen Bonding Network At The Active Site
- Multi- Centered Short Hydrogen Bonding Network At The
- Serine Proteases
- Multi- Centered Short Hydrogen Bonding Network At The
- qi|18655756|pdb|1GI4|A 🔛 Chain A, A Novel Serine Protease Inhibition Motif Involving Multi- Centered Short Hydrogen Bonding Network At The Active Site
- qi|18655755|pdb|1GI3|A 📓 Chain A, A Novel Serine Protease Inhibition Motif Involving Multi- Centered Short Hydrogen Bonding Network At The Active Site
- qi|18655753|pdb|1GI1|A 📓 Chain A, A Novel Serine Protease Inhibition Motif Involving Multi- Centered Short Hydrogen Bonding Network At The Active Site
- Multi- Centered Short Hydrogen Bonding Network At The Active Site
- Multi- Centered Short Hydrogen Bonding Network At The
- Binding, Sub-Micromolar Inhibitor Of Urokinase Type Plasminogen Activator
- qi|12084303|pdb|1C5U|A 🚨 Chain A, Structural Basis For Selectivity Of A Small Molecu Binding, Sub-Micromolar Inhibitor Of Urokinase Type Plasminogen Activator
- Binding, Sub-Micromolar Inhibitor Of Urokinase Type Plasminogen Activator
- gi|12084301|pdb|1C5S|A Chain A, Structural Basis For Selectivity Of A Small Molecu Binding, Sub-Micromolar Inhibitor Of Urokinase Type Plasminogen Activator
- qi|12084300|pdb|1C5R|A 📓 Chain A, Structural Basis For Selectivity Of A Small Molecu Binding, Sub-Micromolar Inhibitor Of Urokinase Type Plasminogen Activator
- Binding, Sub-Micromolar Inhibitor Of Urokinase Type

```
Plasminogen Activator
```

- gi|9955064|pdb|1C2L|A Chain A, Recruiting Zinc To Mediate Potent, Specific Inhibit Serine Proteases
- gi|9955063|pdb|1C2K|A Chain A, Recruiting Zinc To Mediate Potent, Specific Inhibit Serine Proteases
- gi|9955061|pdb|1C21|A Chain A, Recruiting Zinc To Mediate Potent, Specific Inhibit Serine Proteases
- gi|9955059|pdb|1C2G|A Chain A, Recruiting Zinc To Mediate Potent, Specific Inhibit Serine Proteases
- gi|9955057|pdb|1C2E|A Chain A, Recruiting Zinc To Mediate Potent, Specific Inhibit Serine Proteases
- gi|9955056|pdb|1C2D|A Chain A, Recruiting Zinc To Mediate Potent, Specific Inhibit Serine Proteases
- gi|9955046|pdb|1C1T|A Chain A, Recruiting Zinc To Mediate Potent, Specific Inhibit Serine Proteases
- gi|9955043|pdb|1ClQ|A Chain A, Recruiting Zinc To Mediate Potent, Specific Inhibit Serine Proteases
- gi|9955042|pdb|1C1P|A Chain A, Recruiting Zinc To Mediate Potent, Specific Inhibit Serine Proteases
- gi|9955041|pdb|1C10|A Chain A, Recruiting Zinc To Mediate Potent, Specific Inhibit Serine Proteases
- gi|9955045|pdb|1C1S|A Chain A, Recruiting Zinc To Mediate Potent, Specific Inhibit

 Serine Proteases

 Length = 223
- Score = 206 bits (524), Expect = 5e-52 Identities = 96/221 (43%), Positives = 138/221 (62%), Gaps = 4/221 (1%)
- Query: 30 VHGGPCLKDSHPFQAALYTSGHLLCGGVLIDPQWVLTAAHCKKPNLQVILGKHNLRQTET 89
 V G C ++ P+Q +L SG+ CGG LI+ QWV++AAHC K +QV LG+ N+ E
- Sbjct: 2 VGGYTCGANTVPYQVSL-NSGYHFCGGSLINSQWVVSAAHCYKSGIQVRLGEDNINVVEG 60
- Query: 90 FQRQISVDRTIVHPRYNPETHDNDIMMVHLKNPVKFSKKIQPLPLKNDCSEENPNCQILG 149 ++ IS ++IVHP YN T +NDIM++ LK+ + ++ L C+ C I G
- Sbjct: 61 NEQFISASKSIVHPSYNSNTLNNDIMLIKLKSAASLNSRVASISLPTSCASAGTQCLISG 120
- Query: 150 WG--KMENGDFPDTIQCADVHLVPREQCERAYPGKITQSMVCAGDMKEGNDSCQGDSGGP 207
 - WG K +PD ++C ++ C+ AYPG+IT +M CAG ++ G DSCQGDSGGP
- Sbjct: 121 WGNTKSSGTSYPDVLKCLKAPILSDSSCKSAYPGQITSNMFCAGYLEGGKDSCQGDSGGP 180
- Query: 208 LVCGGRLRGLVSWGDMPCGSKEKPGVYTDVCTHIRWIQNIL 248

+VC G+L+G+VSWG C K KPGVYT VC ++ WI+ +
Sbjct: 181 VVCSGKLQGIVSWGS-GCAQKNKPGVYTKVCNYVSWIKQTI 220

Sore = 206 bits (524), Expect = 5e-52 Identities = 95/234 (40%), Positives = 142/234 (60%), Gaps = 2/234 (0%)

Query: 15 LVLAKSAWSEEQEKVVHGGPCLKDSHPFQAALYTSGHLLCGGVLIDPQWVLTAAHCKKPN 74
++L +A++ E +K+V G C S P Q +L SG+ CGG L++ WV++AAHC K

Sbjct: 4 ILLIGAAFATEDDKIVGGYECTPYSQPHQVSL-NSGYHFCGGSLVNENWVVSAAHCYKSR 62

Query: 75 LQVILGKHNLRQTETFQRQISVDRTIVHPRYNPETHDNDIMMVHLKNPVKFSKKIQPLPL 134 ++V +G+HNLR E ++ IS R I HP Y+ +NDIM++ L P ++ +QP+ L

Sbjct: 63 VEVRIGEHNLRVYEETEQFISSSRVIRHPNYSSYNINNDIMLIKLSEPATLNQYVQPVAL 122

Query: 135 KNDCSEENPNCQILGWGKMENGDFPDTIQCADVHLVPREQCERAYPGKITQSMVCAGDMK 194 C+ C + GWG + +QC D+ ++ CE +YPG IT +M CAG ++

Sbjct: 123 PTSCAPAGTMCTVSGWGDTMSSTDSSRLQCLDLPILSERDCENSYPGMITNAMFCAGYLE 182

Query: 195 EGNDSCQGDSGGPLVCGGRLRGLVSWGDMPCGSKEKPGVYTDVCTHIRWIQNIL 248 G DSCQGDSGGP+VC G+L+G+VSWG C ++ PGVY VC I W++ +

Sbjct: 183 GGKDSCQGDSGGPVVCNGQLQGVVSWG-YGCAQRDHPGVYAKVCIFIDWLERTM 235

| >gi | 12843871 | dbj | BAB26143.1 | G unnamed protein product [Mus musculus] Length = 234

Score = 206 bits (524), Expect = 5e-52 Identities = 96/231 (41%), Positives = 147/231 (63%), Gaps = 7/231 (3%)

Query: 25 EQEKVVHGGPCLKDSHPFQAALYTSGHLLCGGVLIDPQWVLTAAHCKKPNLQVILGKHNL 84 ++EK+ +G C+K+S P+Q L+ +L CGGVL+D +WVLTAAHC+ + V LG+H+L Sbjct: 5 DREKIYNGVECVKNSQPWQVGLFHGKYLRCGGVLVDRKWVLTAAHCRDKYV-VRLGEHSL 63

Query: 85 RQTETFQRQISVDRTIVHPRYNP--ETHDNDIMMVHLKNPVKFSKKIQPLPLKNDCSEEN 142 + + ++ +I HP Y + H++D+ ++ L P+ ++P+ L + C

Sbjct: 64 TKLDWTEQLRHTTFSITHPSYQGAYQNHEHDLRLLRLNRPIHLTRAVRPVALPSSCVTTG 123

Query: 143 PNCQILGWGKMEN--GDFPDTIQCADVHLVPREQCERAYPGKITQSMVCAGDMKEGNDSC 200

C + GWG FPD +QC ++ V E C +PG++T++M+CAG + G D+C

Sbjct: 124 AMCHVSGWGTTNKPWDPFPDRLQCLNLSTVSNETCRAVFPGRVTENMLCAGG-EAGKDAC 182

Query: 201 QGDSGGPLVCGGRLRGLVSWGDM-PCGSKEKPGVYTDVCTHIRWIQNILRN 250 QGDSGGPLVCGG L+GLVSWG + PCG K PGVYT VC + WI+ ++RN Sbjct: 183 QGDSGGPLVCGGVLQGLVSWGSVGPCGQKGIPGVYTKVCKYTDWIRIVIRN 233

| >gi | 56611170 | gb | AAH87830.1 | G | Hypothetical LOC496697 [Xenopus tropicalis] | gi | 58332206 | ref | NP | 001011251.1 | G | hypothetical LOC496697 [Xenopus tropicalis] | Length = 249

Score = 206 bits (523), Expect = 6e-52 Identities = 94/248 (37%), Positives = 146/248 (58%), Gaps = 6/248 (2%) --------

```
MKMLALCLVLAKSAWSEEQEKVVHGGPCLKDSHPFQAALYTSGHLLCGGVLIDPQWVLTA 67
Query: 8
          M + L + +A + +K+V G C S P+O + + CGG L+ P+W+++A
          MPLWILLFLAVAAAAPLDDDKIVGGYECTPHSQPWQVYFTQNSQVFCGGSLVTPRWIISA 61
Sbjct: 2
Query: 68 AHCKKPNLQVI--LGKHNLRQTETFQRQISVDRTIVHPRYNPETHDNDIMMVHLKNPVKF 125
          AHC +P ++ LG H+L + E ++ I V+ H Y E +D+DIM+V L P ++
Sbjct: 62 AHCYRPPKTLVAHLGDHDLTKEEGTEQHIQVEAAYKHSSYKDEAYDHDIMLVKLAKPAQY 121
Ouery: 126 SKKIQPLPLKNDCSEENPNCQILGWGKMEN---GDFPDTIQCADVHLVPREQCERAYPGK 182
          ++ +QP+P+ C E C + G+G + + G+FPD +QC DV ++ C+ + G
Sbjct: 122 NQYVQPIPVARSCPREGTECLVSGYGNLRSDHIGEFPDRLQCVDVPVLSDSSCKASCRGL 181
Ouery: 183 ITQSMVCAGDMKEGNDSCQGDSGGPLVCGGRLRGLVSWGDMPCGSKEKPGVYTDVCTHIR 242
           T++M CAG ++ G DSCQ DSGGPLVC G L G+VSWG C + PGVY VC ++R
Sbjct: 182 FTENMFCAGFLEGGKDSCQVDSGGPLVCNGELYGVVSWG-WGCAQRNAPGVYAKVCNYLR 240
Query: 243 WIQNILRN 250
          W+QNI+ N
Sbjct: 241 WVQNIIEN 248
| >gi|60599777|gb|AAT11803.2| pancreatic trypsinogen [Struthio camelus]
         Length = 231
 Score = 206 bits (523), Expect = 6e-52
 Identities = 97/226 (42%), Positives = 141/226 (62%), Gaps = 4/226 (1%)
Query: 25 EQEKVVHGGPCLKDSHPFQAALYTSGHLLCGGVLIDPQWVLTAAHCKKPNLQVILGKHNL 84
          + +K+V G C S P+Q +L +G+ CGG LI+ QWVL+AAHC K ++QV LG++N+
Sbjct: 5
          DDDKIVGGYNCPAHSVPYQVSL-NAGYHFCGGSLINSQWVLSAAHCYKSSIQVRLGEYNI 63
Query: 85 RQTETFQRQISVDRTIVHPRYNPETHDNDIMMVHLKNPVKFSKKIQPLPLKNDCSEENPN 144
             E + S I HP+Y+ + DNDIM++ L +PV +S +QP+ L + C +
Sbjct: 64 DVREDSEVVRSSAAVIRHPKYSSRSLDNDIMLIKLASPVAYSADVQPIALPSSCVKAGTK 123
Query: 145 CQILGWGK--MENGDFPDTIQCADVHLVPREQCERAYPGKITQSMVCAGDMKEGNDSCQG 202
        C I GWG FP+ +QC ++ +C AYPG+I+ +M+C G ++ G DSCQG
Sbjct: 124 CLISGWGNTLSSGSSFPEILQCLQAPVLSDRECRNAYPGEISSNMICVGFLEGGKDSCQG 183
Query: 203 DSGGPLVCGGRLRGLVSWGDMPCGSKEKPGVYTDVCTHIRWIQNIL 248
          DSGGP+VC G L+G+VSWG + C K PGVYT VC ++ WIQ +
Sbjct: 184 DSGGPVVCDGTLQGIVSWG-IGCAQKGYPGVYTKVCNYVSWIQETI 228
stratum corneum trypsin-like serine protease [Homo sa
         Length = 25\overline{3}
 Score = 206 bits (523), Expect = 6e-52
 Identities = 99/251 (39%), Positives = 151/251 (60%), Gaps = 5/251 (1%)
Query: 3
          MKMLTMKMLALCLVLAKSAWSEEQEKVVHGGPCLKDSHPFQAALYTS-GHLLCGGVLIDP 61
          M +L + AL L + + + ++++G C + P+QAAL L CG VL+ P
Sbjct: 1 MWVLCALITALLLGVTDARSDDSSSRIINGSDCDMHTQPWQAALLLRPNQLYCGAVLVHP 60
Query: 62 QWVLTAAHCKKPNLQVILGKHNLRQT-ETFORQISVDRTIVHPRYNPETHDNDIMMVHLK 120
          QW+LTAAHC+K +V LG ++L E+ Q+ ++I HP Y+ H ND+M++ L
```

```
Sbjct: 61 QWLLTAAHCRKKVFRVRLGHYSLSPVYESGQQMFQGVKSIPHPGYSHPGHSNDLMLIKLN 120
Query: 121 NPVKFSKKIQPLPLKNDCSEENPNCQILGWG--KMENGDFPDTIQCADVHLVPREOCERA 178
            ++ +K ++P+ + + C C + GWG K
                                             FP +QC ++ ++ +++CE A
Sbjct: 121 RRIRPTKDVRPINVSSHCPSAGTKCLVSGWGTTKSPQVHFPKVLQCLNISVLSQKRCEDA 180
Query: 179 YPGKITQSMVCAGDMKEGNDSCQGDSGGPLVCGGRLRGLVSWGDMPCGSKEKPGVYTDVC 238
          YP +I +M CAGD K G DSCQGDSGGP+VC G L+GLVSWGD PC
Sbjct: 181 YPRQIDDTMFCAGD-KAGRDSCQGDSGGPVVCNGSLQGLVSWGDYPCARPNRPGVYTNLC 239
Query: 239 THIRWIQNILR 249
             +WIQ
Sbjct: 240 KFTKWIQETIQ 250
gi|2118087|pir||S55067
                           trypsin (EC 3.4.21.4) I precursor, pancreatic - chicken
         Length = 248
 Score = 206 \text{ bits } (523), \text{ Expect = } 6e-52
 Identities = 102/248 (41%), Positives = 148/248 (59%), Gaps = 5/248 (2%)
          MKMLTMKMLALCLVLAKSAWSEEQEKVVHGGPCLKDSHPFQAALYTSGHLLCGGVLIDPQ 62
Query: 3
          MK L + + L + +A E + +K + V G C + + P + Q + L SG + CGG LI Q
Sbjct: 1
          MKFLVL-VAFLGVAVAFPISDEDDDKIVGGYSCARSAAPYQVSL-NSGYHFCGGSLISSQ 58
Query: 63 WVLTAAHCKKPNLQVILGKHNLRQTETFQRQISVDRTIVHPRYNPETHDNDIMMVHLKNP 122
          WVL+AAHC K ++QV LG++NL
                                 + ++ IS + I H YN T +NDIM++ L
Sbjct: 59 WVLSAAHCYKSSIQVKLGEYNLAAQDGSEQTISSSKVIRHSGYNSNTLNNDIMLIKLSKA 118
Query: 123 VKFSKKIQPLPLKNDCSEENPNCQILGWGK-MENGD-FPDTIQCADVHLVPREQCERAYP 180
             + + +PL C C I GWG + +G +PD +QC + ++
Sbjct: 119 ATLNSYVNTVPLPTSCVTAGTTCLISGWGNTLSSGSLYPDVLQCLNAPVLSSSQCSSAYP 178
Query: 181 GKITQSMVCAGDMKEGNDSCQGDSGGPLVCGGRLRGLVSWGDMPCGSKEKPGVYTDVCTH 240
          G+IT +M+C G + G DSCQGDSGGP+VC G+L+G VSWG + C K PGVYT VC +
Sbjct: 179 GRITSNMICIGYLNGGKDSCQGDSGGPVVCNGQLQGFVSWG-IGCAQKGYPGVYTKVCNY 237
Query: 241 IRWIQNIL 248
          + WI+
Sbjct: 238 VSWIKTTM 245
| >qi|2499863|sp|Q90628|TRY2 CHICK
                                    Trypsin I-P38 precursor
Length = 248
 Score = 206 bits (523), Expect = 6e-52
 Identities = 102/248 (41%), Positives = 148/248 (59%), Gaps = 5/248 (2%)
Query: 3
          MKMLTMKMLALCLVLAKSAWSEEQEKVVHGGPCLKDSHPFQAALYTSGHLLCGGVLIDPQ 62
          MK L + + L + +A
                               E+ +K+V G C + + P+Q +L SG+ CGG LI Q
Sbjct: 1
          MKFLVL-VAFLGVAVAFPISDEDDDKIVGGYSCARSAAPYQVSL-NSGYHFCGGSLISSQ 58
Query: 63 WVLTAAHCKKPNLQVILGKHNLRQTETFQRQISVDRTIVHPRYNPETHDNDIMMVHLKNP 122
          WVL+AAHC K ++QV LG++NL
                                 + ++ IS + I H YN T +NDIM++ L
Sbjct: 59 WVLSAAHCYKSSIQVKLGEYNLAAQDGSEQTISSSKVIRHSGYNANTLNNDIMLIKLSKA 118
```

- Query: 123 VKFSKKIQPLPLKNDCSEENPNCQILGWGK-MENGD-FPDTIQCADVHLVPREQCERAYP 180
- + + +PL C C I GWG + +G +PD +QC + ++ QC AYP
- Sbjct: 119 ATLNSYVNTVPLPTSCVTAGTTCLISGWGNTLSSGSLYPDVLQCLNAPVLSSSQCSSAYP 178
- Query: 181 GKITQSMVCAGDMKEGNDSCQGDSGGPLVCGGRLRGLVSWGDMPCGSKEKPGVYTDVCTH 240
 - G+IT +M+C G + G DSCQGDSGGP+VC G+L+G VSWG + C K PGVYT VC +
- Sbjct: 179 GRITSNMICIGYLNGGKDSCQGDSGGPVVCNGQLQGFVSWG-IGCAQKGYPGVYTKVCNY 237
- Query: 241 IRWIQNIL 248
 - + WI+ +
- Sbjct: 238 VSWIKTTM 245
- 💹 >gi|51247093|pdb|1H9I|E 🔯 Chain E, Complex Of Eeti-Ii Mutant With Porcine Trypsin

- qi|47169103|pdb|1S83|A Chain A, Porcine Trypsin Complexed With 4-Amino Propanol
- gi|47169101|pdb|1581|A Chain A, Porcine Trypsin With No Inhibitor Bound
- gi|47169077|pdb|1S6H|A Chain A, Porcine Trypsin Complexed With Guanidine-3-Propano Inhibitor
- gi|47169075|pdb|1S5S|A Chain A, Porcine Trypsin Complexed With Guanidine-3-Propano Inhibitor
- gi|40889515|pdb|1R0T|A Chain A, Crystal Structure Of Trypsin-Second Domain Of The Ovomucoid Turkey Egg White Inhibitor Complex
- gi|58176994|pdb|1V6D|A Chain A, The Crystal Structure Of The Trypsin Complex With Synthetic Heterochiral Peptide
- gi|13399521|pdb|1EJA|A Chain A, Structure Of Porcine Trypsin Complexed With Bdella An Antistasin-Type Inhibitor
- gi|3891587|pdb|1AVX|A Chain A, Complex Porcine Pancreatic TrypsinSOYBEAN TRYPSIN Inhibitor, Tetragonal Crystal Form
- gi|3891585|pdb|1AVW|A Chain A, Complex Porcine Pancreatic TrypsinSOYBEAN TRYPSIN Inhibitor, Orthorhombic Crystal Form
- gi|2914483|pdb|1TFX|B Chain B, Complex Of The Second Kunitz Domain Of Tissue Facto Pathway Inhibitor With Porcine Trypsin
- gi|2914482|pdb|1TFX|A Chain A, Complex Of The Second Kunitz Domain Of Tissue Facto
 Pathway Inhibitor With Porcine Trypsin
- gi|3212563|pdb|1LDT|T Chain T, Complex Of Leech-Derived Tryptase Inhibitor With Po
 Trypsin
 Length = 223
- Score = 206 bits (523), Expect = 6e-52 Identities = 94/222 (42%), Positives = 136/222 (61%), Gaps = 4/222 (1%)
- Query: 29 VVHGGPCLKDSHPFQAALYTSGHLLCGGVLIDPQWVLTAAHCKKPNLQVILGKHNLRQTE 88
 - +V G C +S P+Q +L + H CGG LI+ QWV++AAHC K +QV LG+HN+ E
- Sbjct: 1 IVGGYTCAANSIPYQVSLNSGSHF-CGGSLINSQWVVSAAHCYKSRIQVRLGEHNIDVLE 59

```
Ouery: 89 TFQRQISVDRTIVHPRYNPETHDNDIMMVHLKNPVKFSKKIQPLPLKNDCSEENPNCOIL 148
            ++ I+ + I HP +N T DNDIM++ L +P + ++ + L
Sbjct: 60 GNEOFINAAKIITHPNFNGNTLDNDIMLIKLSSPATLNSRVATVSLPRSCAAAGTECLIS 119
Query: 149 GWG--KMENGDFPDTIQCADVHLVPREQCERAYPGKITQSMVCAGDMKEGNDSCQGDSGG 206
                   +P +QC ++ C+ +YPG+IT +M+C G ++ G DSCQGDSGG
Sbjct: 120 GWGNTKSSGSSYPSLLQCLKAPVLSDSSCKSSYPGQITGNMICVGFLEGGKDSCQGDSGG 179
Query: 207 PLVCGGRLRGLVSWGDMPCGSKEKPGVYTDVCTHIRWIQNIL 248
          P+VC G+L+G+VSWG C K KPGVYT VC ++ WIQ +
Sbjct: 180 PVVCNGOLOGIVSWG-YGCAQKNKPGVYTKVCNYVNWIQQTI 220
                         Structure Of Hydrolase (Serine Proteinase)
>gi |2392803 | pdb | 5PTP |
         Length = 223
 Score = 206 bits (523), Expect = 6e-52
 Identities = 95/222 (42%), Positives = 138/222 (62%), Gaps = 4/222 (1%)
Query: 29 VVHGGPCLKDSHPFQAALYTSGHLLCGGVLIDPQWVLTAAHCKKPNLQVILGKHNLRQTE 88
          +V G C ++ P+Q +L SG+ CGG LI+ QWV++AAHC K +QV LG+ N+
Sbjct: 1
          IVGGYTCGANTVPYQVSL-NSGYHFCGGSLINSQWVVSAAHCYKSGIQVRLGEDNINVVE 59
Query: 89 TFQRQISVDRTIVHPRYNPETHDNDIMMVHLKNPVKFSKKIQPLPLKNDCSEENPNCQIL 148
           ++ IS ++IVHP YN T +NDIM++ LK+
                                             + ++ + L C+
Sbjct: 60 GNEQFISASKSIVHPSYNSNTLNNDIMLIKLKSAASLNSRVASISLPTSCASAGTQCLIS 119
Query: 149 GWG--KMENGDFPDTIQCADVHLVPREQCERAYPGKITQSMVCAGDMKEGNDSCQGDSGG 206
                     +PD ++C ++
                                     C+ AYPG+IT +M CAG ++ G DSCQGD GG
Sbjct: 120 GWGNTKSSGTSYPDVLKCLKAPILSDSSCKSAYPGQITSNMFCAGYLEGGKDSCQGDXGG 179
Query: 207 PLVCGGRLRGLVSWGDMPCGSKEKPGVYTDVCTHIRWIQNIL 248
                          C K KPGVYT VC ++ WI+ +
          P+VC G+L+G+VSWG
Sbjct: 180 PVVCSGKLQGIVSWGS-GCAQKNKPGVYTKVCNYVSWIKQTI 220
protease serine 4 isoform B [Homo sapiens]
         Length = 261
 Score = 205 bits (522), Expect = 8e-52
 Identities = 95/227 (41%), Positives = 144/227 (63%), Gaps = 4/227 (1%)
Query: 24 EEQEKVVHGGPCLKDSHPFQAALYTSGHLLCGGVLIDPQWVLTAAHCKKPNLQVILGKHN 83
          ++ +K+V G C ++S P+Q +L + H CGG LI QWV++AAHC K +QV LG+HN
Sbjct: 33 DDDDKIVGGYTCEENSLPYQVSLNSGSHF-CGGSLISEQWVVSAAHCYKSRIQVRLGEHN 91
Query: 84 LRQTETFQRQISVDRTIVHPRYNPETHDNDIMMVHLKNPVKFSKKIQPLPLKNDCSEENP 143
          ++ E ++ I+ + I HP+YN +T DNDIM++ L +P
                                                  + ++ + L
Sbjct: 92 IKVLEGNEQFINAAKIIRHPKYNRDTLDNDIMLIKLSSPAVINARVSTISLPTAPPAAGT 151
Query: 144 NCQILGWGKM--ENGDFPDTIQCADVHLVPREQCERAYPGKITQSMVCAGDMKEGNDSCQ 201
                        D+PD ++C D ++ + +C+ +YPGKIT SM C G ++ G DSCQ
           C I GWG
Sbjct: 152 ECLISGWGNTLSSGADYPDELKCLDAPVLTQAECKASYPGKITNSMFCVGFLEGGKDSCQ 211
```

Query: 202 GDSGGPLVCGGRLRGLVSWGDMPCGSKEKPGVYTDVCTHIRWIQNIL 248

Sbjct: 212 GDSGGPVVCNGQLQGVVSWGH-GCAWKNRPGVYTKVYNYVDWIKDTI 257

GDSGGP+VC G+L+G+VSWG C K +PGVYT V ++ WI++ +

```
pgi|18777665|ref|NP 036002.1| G kallikrein 7 [Mus musculus]
qi|20380020|gb|AAH27823.1| G Kallikrein 7 [Mus musculus]
qi|14582804|qb|AAK69652.1| G stratum corneum chymotryptic enzyme [Mus musculus]
gi|14141577|dbj|BAB55604.1| G thymopsin [Mus musculus]
gi|26325426|dbj|BAC26467.1|
                            G unnamed protein product [Mus musculus]
         Length = 249
Score = 205 bits (522), Expect = 8e-52
Identities = 99/244 (40%), Positives = 139/244 (56%), Gaps = 6/244 (2%)
Ouery: 10 MLALCLVLAKSAWSE--EQEKVVHGGPCLKDSHPFQAALYTSGHLLCGGVLIDPQWVLTA 67
                          + E+++ G C + SHP+Q AL
                                                    L CGGVL+D WVLTA
          +L+L VL
          LLSLITVLLSLALETAGQGERIIDGYKCKEGSHPWQVALLKGNQLHCGGVLVDKYWVLTA 64
Sbjct: 5
Query: 68 AHCKKPNLQVILGKHNLRQTETFQRQISVDRTIVHPRYNPETHDNDIMMVHLKNPVKFSK 127
                                      ++ HP Y+ +TH NDIM+V L PVK S
          AHCK
                 QV LG
                                ++I
Sbjct: 65 AHCKMGQYQVQLGSDKIGDQSA--QKIKATKSFRHPGYSTKTHVNDIMLVRLDEPVKMSS 122
Query: 128 KIQPLPLKNDCSEENPNCQILGWGKMENGD--FPDTIQCADVHLVPREQCERAYPGKITQ 185
                         +C + GWG
          K+++L
                                  + D FP + C+DV L+
                                                        +C++ Y
                   C
Sbjct: 123 KVEAVQLPEHCEPPGTSCTVSGWGTTTSPDVTFPSDLMCSDVKLISSRECKKVYKDLLGK 182
Query: 186 SMVCAGDMKEGNDSCQGDSGGPLVCGGRLRGLVSWGDMPCGSKEKPGVYTDVCTHIRWIQ 245
                 ++C GDSGGPLVC L+GLVSWG PCG
                                                     PGVYT VC + RW+
Sbjct: 183 TMLCAGIPDSKTNTCNGDSGGPLVCNDTLQGLVSWGTYPCGQPNDPGVYTQVCKYKRWVM 242
Query: 246 NILR 249
Sbjct: 243 ETMK 246
                         tissue kallikrein (EC 3.4.21.35), prostatic - quinea pig
>gi|93017|pir||A27207
qi|125173|sp|P12323|KLK2 CAVPO Glandular kallikrein, prostatic (Tissue kallikrein) (
          esterase)
         Length = 239
 Score = 205 bits (522), Expect = 8e-52
 Identities = 94/235 (40%), Positives = 139/235 (59%), Gaps = 15/235 (6%)
Query: 29 VVHGGPCLKDSHPFQAALYTSGHLLCGGVLIDPQWVLTAAHCKKPNLQVILGKHNLRQTE 88
          V+ G C +DSHP+QAA+Y
                                + CGGVL+DPQWVLTAAHC
                                                     + QV LG+HNL + E
Sbjct: 1
          VIGGQECARDSHPWQAAVYYYSDIKCGGVLVDPQWVLTAAHCINDSNQVKLGRHNLFEDE 60
          TFQRQISVDRTIVHPRYNP--
                                 ----ETHDNDIMMVHLKNPVKFSKKIQPLPLKND 137
Query: 89
                 V +++ HP +N
                                       E + +D+M++ L P + + +Q +PL
Sbjct: 61 DTAQHFLVSQSVPHPDFNMSLLEPHNVLPNEDYSHDLMLLRLNQPAQITDSVQVMPLPTQ 120
Ouery: 138 CSEENPNCOILGWGKMENGD----FPDTIOCADVHLVPREQCERAYPGKITQSMVCAGDM 193
                 C+ LGWG ++
                                 FPD +QC + ++P + C+ A+
                                                         +T +M+CAGD+
Sbjct: 121 EVQVGTTCRALGWGSIDPDPAHPVFPDELQCVGLEILPSKNCDDAHIANVTGTMLCAGDL 180
Query: 194 KEGNDSCQGDSGGPLVCGGRLRGLVSWGDMPCGSKEKPGVYTDVCTHIRWIQNIL 248
            G D+C GDSGGPL+C G L+GL SWGD PCG P +YT V + WI+ +
```

```
qi|9954879|pdb|1C9P|A Chain A, Complex Of Bdellastasin With Porcine Trypsin
         Length = 223
Score = 205 bits (522), Expect = 8e-52
Identities = 94/222 (42%), Positives = 135/222 (60%), Gaps = 4/222 (1%)
Query: 29 VVHGGPCLKDSHPFQAALYTSGHLLCGGVLIDPQWVLTAAHCKKPNLQVILGKHNLRQTE 88
          +V G C +S P+Q +L + H CGG LI+ QWV++AAHC K +QV LG+HN+
Sbjct: 1
          IVGGYTCAANSIPYQVSLNSGSHF-CGGSLINSQWVVSAAHCYKSRIQVRLGEHNIDVLE 59
Ouery: 89 TFOROISVDRTIVHPRYNPETHDNDIMMVHLKNPVKFSKKIOPLPLKNDCSEENPNCOIL 148
           ++ I+ + I HP +N T DNDIM++ L +P
                                              ++ + L
Sbjct: 60 GNEQFINAAKIITHPNFNGNTLDNDIMLIKLSSPATLXSRVATVSLPRSCAAAGTECLIS 119
Query: 149 GWG--KMENGDFPDTIQCADVHLVPREQCERAYPGKITQSMVCAGDMKEGNDSCQGDSGG 206
          GWG K
                    +P +QC ++ C+ +YPG+IT +M+C G ++ G DSCQGDSGG
Sbjct: 120 GWGNTKSSGSSYPSLLQCLKAPVLSDSSCKSSYPGQITGNMICVGFLEGGKDSCQGDSGG 179
Ouery: 207 PLVCGGRLRGLVSWGDMPCGSKEKPGVYTDVCTHIRWIONIL 248
          P+VC G+L+G+VSWG C K KPGVYT VC ++ WIO +
Sbjct: 180 PVVCNGQLQGIVSWG-YGCAQKNKPGVYTKVCNYVNWIQQTI 220
| >qi|31541863|ref|NP 075822.2| | G RIKEN cDNA 2210010C04 [Mus musculus]
gi | 12843046 | dbj | BAB25837.1 | G unnamed protein product [Mus musculus]
         Length = 247
 Score = 205 bits (521), Expect = 1e-51
 Identities = 99/246 (40%), Positives = 146/246 (59%), Gaps = 4/246 (1%)
Ouery: 5 MLTMKMLALCLVLAKSAWSEEQEKVVHGGPCLKDSHPFQAALYTSGHLLCGGVLIDPOWV 64
                          ++ +K V G C +++ P+Q +L SG+ CGG LI+ QWV
Sbjct: 1 MKTLIFLAFLGAAVALPPDDDDDKNVGGYTCQRNALPYQVSL-NSGYHFCGGSLINSQWV 59
Query: 65 LTAAHCKKPNLQVILGKHNLRQTETFQRQISVDRTIVHPRYNPETHDNDIMMVHLKNPVK 124
          ++AAHC K +QV LG+HN+ E ++ I + I + I + P + NDIM++ LK
Sbjct: 60 VSAAHCYKSRIQVRLGEHNIDALEGGEQFIDAAKIIRHPNYNANTYNNDIMLIKLKTAAT 119
Query: 125 FSKKIQPLPLKNDCSEENPNCQILGWGK-MENG-DFPDTIQCADVHLVPREQCERAYPGK 182
           + ++ + L C C + GWG + +G ++P +QC D ++
                                                           C +YPGK
Sbjct: 120 LNSRVSTVALPRSCPSAGTRCLVSGWGNTLSSGTNYPSLLQCLDAPVLSDSSCTSSYPGK 179
Query: 183 ITQSMVCAGDMKEGNDSCQGDSGGPLVCGGRLRGLVSWGDMPCGSKEKPGVYTDVCTHIR 242
          IT +M C G ++ G DSCQGDSGGP+VC G+L+G+VSWG C + KPGVYT VC ++
Sbjct: 180 ITSNMFCLGFLEGGKDSCQGDSGGPVVCNGQLQGVVSWG-YGCAQRGKPGVYTKVCKYVN 238
Query: 243 WIQNIL 248
          WIO +
Sbjct: 239 WIQQTI 244
```

```
Length = 248
 Score = 205 bits (521), Expect = 1e-51
 Identities = 96/247 (38%), Positives = 150/247 (60%), Gaps = 5/247 (2%)
Query: 8 MKMLALCLVLAKSAWSEEQEKVVHGGPCLKDSHPFQAALYTSGHLLCGGVLIDPQWVLTA 67
          M + L + +A + +K++G C
                                       S P+Q L +G CGG LI P+W+++A
Sbjct: 2
          MPIWVLMFLAVAAAAPLDDDKIIGGYECTPHSQPWQVYLTQNGDRWCGGSLILPRWIISA 61
Query: 68 AHCKKPNLQVI--LGKHNLRQTETFQRQISVDRTIVHPRYNPETHDNDIMMVHLKNPVKF 125
          AHC P ++ LG+H+L + ET ++ I V+ +H YN +T+DNDIM+V L P ++
Sbjct: 62 AHCYVPPETMVAHLGEHDLNKKETTEQHIQVESIYMHHGYNEDTYDNDIMLVKLVEPAQY 121
Query: 126 SKKIQPLPLKNDCSEENPNCQILGWGKM--ENGDFPDTIQCADVHLVPREOCERAYPGKI 183
          ++ +QP+P+ C + C + G+G + + D +QC D+ ++
Sbjct: 122 NQYVQPIPVARSCPKAATECLVSGYGNLLAYGVKYADQLQCLDLPILSESSCKASYPKKI 181
Query: 184 TQSMVCAGDMKEGNDSCQGDSGGPLVCGGRLRGLVSWGDMPCGSKEKPGVYTDVCTHIRW 243
          +++M CAG ++ G DSCQGDSGGPL+C G L G+VSWG C K+ PGVY VC ++ W
Sbjct: 182 SENMFCAGFLEGGKDSCQGDSGGPLICNGELYGVVSWG-WYCARKDLPGVYAKVCNYLDW 240
Query: 244 IQNILRN 250
         IQ+I N
Sbjct: 241 IQDITNN 247
gi|476488|pir||KQPG tissue kallikrein (EC 3.4.21.35), pancreatic - pig (tentative
          sequence)
         Length = 232
 Score = 205 bits (521), Expect = 1e-51
 Identities = 93/228 (40\%), Positives = 137/228 (60\%), Gaps = 8/228 (3\%)
Query: 29 VVHGGPCLKDSHPFQAALYTSGHLLCGGVLIDPQWVLTAAHCKKPNLQVILGKHNLRQTE 88
          ++ G C K+SHP+Q A+Y CGGVL++P+WVLTAAHCK N +V LG+HNL + E
Sbjct: 1
          IIGGRECEKNSHPWQVAIYHYSSFQCGGVLVNPKWVLTAAHCKNDNYEVWLGRHNLFENE 60
Query: 89 TFQRQISVDRTIVHPRYN----PETHDNDIMMVHLKNPVKFSKKIQPLPLKNDCSEENPN 144
                      HP + N
                               + + +D+M++ L++P K + ++ L L
Sbjct: 61 NTAQFFGVTADFPHPGFNLSADGKDYSHDLMLLRLQSPAKITDAVKVLELPTQEPELGST 120
Query: 145 CQILGWGKMENG----DFPDTIQCADVHLVPREQCERAYPGKITQSMVCAGDMKEGNDSC 200
          C+ GWG +E G +FPD IQC + L+ C A+P K+T+SM+CAG + G D+C
Sbjct: 121 CEASGWGSIEPGPDBFEFPDEIQCVQLTLLQNTFCABAHPBKVTESMLCAGYLPGGKDTC 180
Query: 201 QGDSGGPLVCGGRLRGLVSWGDMPCGSKEKPGVYTDVCTHIRWIQNIL 248
           GDSGGPL+C G +G+ SWG PCGS KP +YT + ++ WI + +
Sbjct: 181 MGDSGGPLICNGMWQGITSWGHTPCGSANKPSIYTKLIFYLDWINBTI 228
| >gi|58257845|gb|AAW69364.1| try13 [Macaca mulatta]
         Length = 247
 Score = 205 bits (521), Expect = 1e-51
 Identities = 98/233 (42%), Positives = 146/233 (62%), Gaps = 4/233 (1%)
```

Sqi|51593533|gb|AAH78492.1|
G MGC85264 protein [Xenopus laevis]

```
Ouery: 18 AKSAWSEEQEKVVHGGPCLKDSHPFQAALYTSGHLLCGGVLIDPQWVLTAAHCKKPNLOV 77
         A +A ++ +K+V G C K+S P+Q +L SG+ CGG LI+ QWV++A HC K +OV
Sbjct: 13 AVAAPFDDDDKIVGGYTCGKNSLPYQVSL-NSGYHFCGGSLINNQWVVSAGHCYKTRIQV 71
Query: 78 ILGKHNLRQTETFQRQISVDRTIVHPRYNPETHDNDIMMVHLKNPVKFSKKIQPLPLKND 137
                 E ++ I+ + I HP YN T +NDI+++ L +P
Sbjct: 72 RLGEHNIEVLEGTEQFINAAKIIRHPNYNRNTLNNDILLIKLSSPAVINARVSTISLPTA 131
Query: 138 CSEENPNCQILGWGKM--ENGDFPDTIQCADVHLVPREQCERAYPGKITQSMVCAGDMKE 195
                C I GWG
                            D+PD +QC + ++ + +CE +YPG+IT +M CAG ++
Sbjct: 132 PPAAGAKCLISGWGNTLSSGADYPDELQCLEAPVLTQAKCEASYPGRITSNMFCAGFLEG 191
Query: 196 GNDSCQGDSGGPLVCGGRLRGLVSWGDMPCGSKEKPGVYTDVCTHIRWIQNIL 248
         G DSCQGDSGGP+V G+L+G+VSWGD C K KPGVYT V ++ WI+N +
Sbjct: 192 GKDSCQGDSGGPVVSNGQLQGIVSWGD-GCAQKNKPGVYTKVYNYLTWIKNTI 243
Length = 261
 Score = 204 bits (519), Expect = 2e-51
 Identities = 100/252 (39%), Positives = 146/252 (57%), Gaps = 16/252 (6%)
Query: 13 LCLVLAKSAWSEE---QEKVVHGGPCLKDSHPFQAALYTSGHLLCGGVLIDPQWVLTAAH 69
         LCL L+ +
                        Q ++V G C K S P+Q A+Y CGGVL+ PQWVLTAAH
Sbjct: 6 LCLALSLAGTGAVFPIQSRIVGGQECEKHSQPWQVAIYHFSTFQCGGVLVAPQWVLTAAH 65
Query: 70 CKKPNLQVILGKHNLRQTETFQRQISVDRTIVHPRYN-----PETHDNDIMMVH 118
         CK N QV LG+HNL + E + V +P +N
                                                     E + +D+M++
Sbjct: 66 CKSDNYQVWLGRHNLFEDEDTAQFAGVSEDFPNPGFNLSLLENHTRHPGEDYSHDLMLLR 125
Query: 119 LKNPVKFSKKIQPLPLKNDCSEENPNCQILGWGKMENGDF--PDTIQCADVHLVPREQCE 176
         L+ PV+ ++ +Q L L + C GWG ++ +F PD +QC D+ L+P E+C
Sbjct: 126 LQEPVQLTQNVQVLGLPTKEPQLGTTCYASGWGSVKPDEFSYPDDLQCVDLTLLPNEKCA 185
Query: 177 RAYPGKITQSMVCAGDMKEGNDSCQGDSGGPLVCGGRLRGLVSWGDMPCGSKEKPGVYTD 236
          A+P ++T+ M+CAG ++ G D+C GDSGGPL+C G L+G+ SWG +PCG+ KP VYT
Sbjct: 186 TAHPQEVTEWMLCAGHLEGGKDTCVGDSGGPLICEGMLQGITSWGHIPCGTPNKPSVYTK 245
Query: 237 VCTHIRWIQNIL 248
         V ++ WI
Sbjct: 246 VILYLDWINKTM 257
gi|20141454|sp|P00752|KLK PIG Glandular kallikrein precursor (Tissue kallikrein)
        Length = 246
 Score = 204 bits (519), Expect = 2e-51
 Identities = 94/238 (39%), Positives = 139/238 (58%), Gaps = 15/238 (6%)
Query: 26 QEKVVHGGPCLKDSHPFQAALYTSGHLLCGGVLIDPQWVLTAAHCKKPNLQVILGKHNLR 85
         Q +++ G C K+SHP+Q A+Y CGGVL++P+WVLTAAHCK N +V LG+HNL
Sbjct: 5 QSRIIGGRECEKNSHPWQVAIYHYSSFQCGGVLVNPKWVLTAAHCKNDNYEVWLGRHNLF 64
Query: 86 QTETFORQISVDRTIVHPRYN-----PETHDNDIMMVHLKNPVKFSKKIQPLPL 134
          + E + V HP +N
                                      + + +D+M++ L++P K + ++ L L
```

```
Sbjct: 65 ENENTAQFFGVTADFPHPGFNLSLLKXHTKADGKDYSHDLMLLRLQSPAKITDAVKVLEL 124
Query: 135 KNDCSEENPNCQILGWGKMENG----DFPDTIQCADVHLVPREOCERAYPGKITQSMVCA 190
       E C+ GWG +E G +FPD IQC + L+ C A+P K+T+SM+CA
Sbjct: 125 PTQEPELGSTCEASGWGSIEPGPDBFEFPDEIQCVQLTLLQNTFCABAHPBKVTESMLCA 184
Query: 191 GDMKEGNDSCQGDSGGPLVCGGRLRGLVSWGDMPCGSKEKPGVYTDVCTHIRWIQNIL 248
         G + G D+C GDSGGPL+C G +G+ SWG PCGS KP +YT + ++ WI + +
Sbjct: 185 GYLPGGKDTCMGDSGGPLICNGMWQGITSWGHTPCGSANKPSIYTKLIFYLDWINDTI 242
| >gi|34856015|ref|XP 214932.2| | G similar to GLANDULAR KALLIKREIN 8, PROSTATIC PRECUI
         KALLIKREIN) (P1 KALLIKREIN) (RGK-8) [Rattus norvegicus]
        Length = 261
Score = 204 bits (518), Expect = 2e-51
 Identities = 99/259 (38%), Positives = 150/259 (57%), Gaps = 18/259 (6%)
Query: 8 MKMLALCLVLAKSAWSEE----QEKVVHGGPCLKDSHPFQAALYTSGHLLCGGVLIDPQW 63
         M +L L L+L+ W++ Q +++ G C K+S P+Q A+Y CGGVLI P W
Sbjct: 1 MWLLILFLILSLG-WNDAAPPGQSRIIGGFNCEKNSQPWQVAVYHFNEPQCGGVLIHPSW 59
Query: 64 VLTAAHCKKPNLQVILGKHNLRQTETFQRQISVDRTIVHPRYNPET------HDN 112
                 N QV LG++NL + E F + V ++ HP +N +
Sbjct: 60 VITAAHCYSVNYQVWLGRNNLLEDEPFAQHRLVSQSFPHPGFNLDIIKNHTRKPGNDYSN 119
Query: 113 DIMMVHLKNPVKFSKKIQPLPLKNDCSEENPNCQILGWGKME--NGDFPDTIQCADVHLV 170
          D+M++HLK P + ++ + L + + C GWG + +FPD +QC ++HL+
Sbjct: 120 DLMLLHLKTPADITDGVKVIDLPTEEPKVGSTCLTSGWGSITPLKWEFPDDLQCVNIHLL 179
Query: 171 PREQCERAYPGKITQSMVCAGDMKEGNDSCQGDSGGPLVCGGRLRGLVSWGDMPCGSKEK 230
           E+C +AY ++T M+CAG+M G D C+GDSGGPL+C G L+G+ SWG MPCG K
Sbjct: 180 SNEKCIKAYNDEVTDVMLCAGEMDGGKDICKGDSGGPLICDGVLQGITSWGSMPCGEPNK 239
Query: 231 PGVYTDVCTHIRWIQNILR 249
          P VYT + WI+ +++
Sbjct: 240 PSVYTKLIKFTSWIKKVMK 258
Length = 249
 Score = 203 bits (516), Expect = 4e-51
 Identities = 98/249 (39%), Positives = 142/249 (57%), Gaps = 5/249 (2%)
Query: 3 MKMLTMKMLALCLVLAKSAWSEEQEKVVHGGPCLKDSHPFQAALYTSGHLLCGGVLIDPQ 62
          M + + +L + L LA + + E+++ G C + SHP+Q AL L CGGVL+
Sbjct: 1 MGVWLLSLLTVLLSLALET-AGQGERIIDGYKCKEGSHPWQVALLKGDQLHCGGVLVGES 59
Query: 63 WVLTAAHCKKPNLQVILGKHNLRQTETFQRQISVDRTIVHPRYNPETHDNDIMMVHLKNP 122
          WVLTAAHCK V LG + ++I R+ HP Y+ TH NDIM+V + P
Sbjct: 60 WVLTAAHCKMGQYTVHLGSDKIEDQSA--QRIKASRSFRHPGYSTRTHVNDIMLVKMDKP 117
Query: 123 VKFSKKIQPLPLKNDCSEENPNCQILGWGKMENGD--FPDTIQCADVHLVPREQCERAYP 180
```

VK S K+Q + L + C C + GWG + D FP + C+DV L+ ++C++ Y

Sbjct: 118 VKMSDKVQKVKLPDHCEPPGTLCTVSGWGTTTSPDVTFPSDLMCSDVKLISSQECKKVYK 177

Query: 181 GKITQSMVCAGDMKEGNDSCQGDSGGPLVCGGRLRGLVSWGDMPCGSKEKPGVYTDVCTH 240

+ ++M+CAG ++C GDSGGPLVC L+GLVSWG PCG PGVYT VC +

Sbjct: 178 DLLGKTMLCAGIPDSKTNTCNGDSGGPLVCNDTLOGLVSWGTYPCGOPNDPGVYTOVCKY 237

Query: 241 IRWIQNILR 249

RW+++ ++

Sbjct: 238 QRWLEDTMK 246

| >gi | 56611173 | gb | AAH87759.1 | G | Hypothetical LOC496640 [Xenopus tropicalis]
| gi | 58332122 | ref | NP 001011209.1 | G | hypothetical LOC496640 [Xenopus tropicalis]
| Length = 243

Score = 203 bits (516), Expect = 4e-51
Identities = 100/248 (40%), Positives = 158/248 (63%), Gaps = 8/248 (3%)

Query: 5 MLTMKMLALCLVLAKSAWSEEQEKVVHGGPCLKDSHPFQAALYTSGHLLCGGVLIDPQWV 64

M T+ + +L L LA + E+ +K+V G C S P+Q +L +G+ CGG LI+ WV Sbjct: 1 MKTLLLFSL-LGLAVAQPIEDDDKIVGGYHC---SVPYQVSL-NAGYHFCGGSLINEHWV 55

Query: 65 LTAAHCKKPNLQVILGKHNLRQTETFQRQISVDRTIVHPRYNPETHDNDIMMVHLKNPVK 124 ++AAHC + +++ +G++N+ E ++ I + I HP+YN T DNDIM++ L+ P +

Sbjct: 56 VSAAHCYQSKMELRIGENNIELLEGTEQFIQSAKIIRHPQYNSWTIDNDIMLIQLQEPAQ 115

Query: 125 FSKKIQPLPLKNDCSEENPNCQILGWGK-MENG-DFPDTIQCADVHLVPREQCERAYPGK 182
+ ++QP+PL +C C I GWG + NG ++PD +QC + ++ ++C ++YPG

Sbjct: 116 LNNEVQPIPLPTECPPVGSICLISGWGNTLSNGVNYPDLLQCIEAPILSDQECRQSYPGS 175

DDJCC. 110 DMMDVQF1FDFFBCFFVODTCDIDOMONTDDNOVNTFDDDQCTDAF1DDDQDCXQSFFG5 17.

Query: 183 ITQSMVCAGDMKEGNDSCQGDSGGPLVCGGRLRGLVSWGDMPCGSKEKPGVYTDVCTHIR 242 IT +M+C G ++ G DSCQGDSGGP+VC G L+G+VSWG C PGVYT VC ++

Sbjct: 176 ITDNMICVGYLEGGIDSCQGDSGGPVVCDGELQGVVSWG-RGCALPGYPGVYTKVCNYLS 234

Query: 243 WIQNILRN 250

WI+++N

Sbjct: 235 WIRDTIAN 242

| >gi | 54038747 | gb | AAH84612.1 | G LOC495211 protein [Xenopus laevis]
Length = 254

Score = 203 bits (516), Expect = 4e-51
Identities = 94/245 (38%), Positives = 148/245 (60%), Gaps = 3/245 (1%)

Query: 10 MLALCLVLAKSAWSEEQEKVVHGGPCLKDSHPFQAALYTSGHLLCGGVLIDPQWVLTAAH 69 +L + ++L + ++ ++++ G C+ S P+Q ALY LCGG+LID WVLTAAH

Sbjct: 2 LLLVAILLGSAVQTKTFDRIIGGEECVPHSQPWQVALYYFSDYLCGGILIDEWWVLTAAH 61

Query: 70 CKKPNLQVILGKHNLRQTETFQRQISVDRTIVHPRYNPETHDNDIMMVHLKNPVKFSKKI 129 C + NLQV+LG HN + ++ ++P T++NDIM++ L + + +

Sbjct: 62 CNQSNLQVLLGAHNRTKPTDHKQYTYAVKICPRCDFDPVTYNNDIMLLKLASKANMNCHV 121

Query: 130 QPLPLKNDCSEENPNCQILGWGKMENGD--FPDTIQCADVHLVPREQCERAYP-GKITQS 186

+ + L +D E+N C GWG + + + +PD +QC ++ V +C+ YP IT +

Sbjct: 122 KTIQLASDLVEDNTECLASGWGTITSPEENYPDKLQCVNLSTVSNSECQACYPEDDITDN 181

Query: 187 MVCAGDMKEGNDSCQGDSGGPLVCGGRLRGLVSWGDMPCGSKEKPGVYTDVCTHIRWIQN 246 M+CAG+M G D+C+GDSGGPLVC G L G+ SWG CG KPGV+T V +I WI +

```
Query: 247 ILRNK 251
        I++N+
Sbjct: 242 IMQNE 246
| >gi | 30584501 | gb | AAP36503.1 | Homo sapiens kallikrein 5 [synthetic construct]
        Length = 294
Score = 202 bits (515), Expect = 5e-51
Identities = 94/230 (40%), Positives = 142/230 (61%), Gaps = 5/230 (2%)
Query: 24 EEQEKVVHGGPCLKDSHPFQAALYTS-GHLLCGGVLIDPQWVLTAAHCKKPNLQVILGKH 82
                    + P+QAAL L CG VL+ PQW+LTAAHC+K
            ++++G C
Sbjct: 62 DSSSRIINGSDCDMHTQPWQAALLLRPNQLYCGAVLVHPQWLLTAAHCRKKVFRVRLGHY 121
Query: 83 NLRQT-ETFQRQISVDRTIVHPRYNPETHDNDIMMVHLKNPVKFSKKIQPLPLKNDCSEE 141
             E+Q+ ++I HP Y+ H ND+M++ L ++ +K ++P+ + + C
Sbjct: 122 SLSPVYESGQQMFQGVKSIPHPGYSHPGHSNDLMLIKLNRRIRPTKDVRPINVSSHCPSA 181
Query: 142 NPNCQILGWG--KMENGDFPDTIQCADVHLVPREQCERAYPGKITQSMVCAGDMKEGNDS 199
           C + GWG K FP +QC ++ ++ +++CE AYP +I +M CAGD K G DS
Sbjct: 182 GTKCLVSGWGTTKSPQVHFPKVLQCLNISVLSQKRCEDAYPRQIDDTMFCAGD-KAGRDS 240
Query: 200 CQGDSGGPLVCGGRLRGLVSWGDMPCGSKEKPGVYTDVCTHIRWIQNILR 249
         COGDSGGP+VC G L+GLVSWGD PC +PGVYT++C
Sbjct: 241 CQGDSGGPVVCNGSLQGLVSWGDYPCARPNRPGVYTNLCKFTKWIQETIQ 290
qi|6063033|qb|AAF03101.1| G stratum corneum tryptic enzyme [Homo sapiens]
 qi|14165478|qb|AAH08036.1| G Kallikrein 5, preproprotein [Homo sapiens]
 gi|9296994|sp|Q9Y337|KLK5 HUMAN G Kallikrein 5 precursor (Stratum corneum tryptic en
         (Kallikrein-like protein 2) (KLK-L2) (UNQ570/PRO1132)
        Length = 293
 Score = 202 bits (515), Expect = 5e-51
 Identities = 94/230 (40%), Positives = 142/230 (61%), Gaps = 5/230 (2%)
Query: 24 EEQEKVVHGGPCLKDSHPFQAALYTS-GHLLCGGVLIDPQWVLTAAHCKKPNLQVILGKH 82
                    + P+QAAL L CG VL+ PQW+LTAAHC+K
            ++++G C
                                                    +V LG +
Sbjct: 62 DSSSRIINGSDCDMHTQPWQAALLLRPNQLYCGAVLVHPQWLLTAAHCRKKVFRVRLGHY 121
Query: 83 NLRQT-ETFQRQISVDRTIVHPRYNPETHDNDIMMVHLKNPVKFSKKIQPLPLKNDCSEE 141
              E+ Q+
                      ++I HP Y+
                               H ND+M++ L ++ +K ++P+ ++ C
Sbjct: 122 SLSPVYESGQQMFQGVKSIPHPGYSHPGHSNDLMLIKLNRRIRPTKDVRPINVSSHCPSA 181
Query: 142 NPNCQILGWG--KMENGDFPDTIQCADVHLVPREQCERAYPGKITQSMVCAGDMKEGNDS 199
           C + GWG K FP +QC ++ ++ +++CE AYP +I +M CAGD K G DS
```

Sbjct: 182 MLCAGNMAGGKDTCKGDSGGPLVCNGELHGITSWGHYICGLPNKPGVFTKVFNYIDWISD 241

```
Sbjct: 182 GTKCLVSGWGTTKSPQVHFPKVLQCLNISVLSQKRCEDAYPRQIDDTMFCAGD-KAGRDS 240
Query: 200 CQGDSGGPLVCGGRLRGLVSWGDMPCGSKEKPGVYTDVCTHIRWIQNILR 249
          CQGDSGGP+VC G L+GLVSWGD PC +PGVYT++C +WIQ ++
Sbjct: 241 CQGDSGGPVVCNGSLQGLVSWGDYPCARPNRPGVYTNLCKFTKWIQETIQ 290
图 >gi|112403|pir||A34079 tissue kallikrein (EC 3.4.21.35) Pl precursor - rat
gi|547791|sp|P36374|KLK8 RAT G Prostatic glandular kallikrein 8 precursor (Tissue ka
          kallikrein) (RGK-8)
 gi|206640|gb|AAA42036.1| kallikrein
         Length = 261
 Score = 202 bits (515), Expect = 5e-51
 Identities = 98/259 (37%), Positives = 150/259 (57%), Gaps = 18/259 (6%)
Query: 8
          MKMLALCLVLAKSAWSEE----QEKVVHGGPCLKDSHPFQAALYTSGHLLCGGVLIDPQW 63
          Sbjct: 1
          MWLLILFLILSLG-WNDAAPPGQSRIIGGFNCEKNSQPWQVAVYHFNEPQCGGVLIHPSW 59
Query: 64 VLTAAHCKKPNLQVILGKHNLRQTETFQRQISVDRTIVHPRYNPET------HDN 112
          V+TAAHC N QV LG++NL + E F + V ++ HP +N +
Sbjct: 60 VITAAHCYSVNYQVWLGRNNLLEDEPFAOHRLVSQSFPHPGFNLDIIKNHTRKPGNDYSN 119
Query: 113 DIMMVHLKNPVKFSKKIQPLPLKNDCSEENPNCQILGWGKME--NGDFPDTIQCADVHLV 170
          D+M++HLK P + ++ + L + + C GWG +
Sbjct: 120 DLMLLHLKTPADITDGVKVIDLPTEEPKVGSTCLTSGWGSITPLKWEFPDDLQCVNIHLL 179
Query: 171 PREQCERAYPGKITQSMVCAGDMKEGNDSCQGDSGGPLVCGGRLRGLVSWGDMPCGSKEK 230
            E+C +AY ++T M+CAG+M G D C+GDSGGPL+C G L+G+ SWG MPCG
Sbjct: 180 SNEKCIKAYNDEVTDVMLCAGEMDGGKDICKGDSGGPLICDGVLQGITSWGSMPCGEPNK 239
Query: 231 PGVYTDVCTHIRWIQNILR 249
          P VYT +
                     W++ +++
Sbjct: 240 PSVYTKLIKFTSWMKKVMK 258
Stratum corneum chymotryptic enzyme, preproprotein [F
        Length = 253
Score = 202 bits (515), Expect = 5e-51
 Identities = 95/247 (38%), Positives = 139/247 (56%), Gaps = 4/247 (1%)
Query: 5
          MLTMKMLALCLVLAKSAWSEEQEKVVHGGPCLKDSHPFQAALYTSGHLLCGGVLIDPQWV 64
          +L +++L L L L + + +K++ G PC + SHP+Q AL + L CGGVL++ +WV
Sbjct: 6 LLPLQILLLSLALETAGEEAQGDKIIDGAPCARGSHPWQVALLSGNQLHCGGVLVNERWV 65
Query: 65 LTAAHCKKPNLQVILGKHNLRQTETFQRQISVDRTIVHPRYNPETHDNDIMMVHLKNPVK 124
          LTAAHCK
                   V LG L ++I ++ HP Y+ +TH ND+M+V L + +
Sbjct: 66 LTAAHCKMNEYTVHLGSDTLGDRRA--QRIKASKSFRHPGYSTQTHVNDLMLVKLNSQAR 123
Query: 125 FSKKIQPLPLKNDCSEENPNCQILGWGKMENGD--FPDTIQCADVHLVPREQCERAYPGK 182
           S ++ + L + C C + GWG + D FP + C DV L+ + C + Y
Sbjct: 124 LSSMVKKVRLPSRCEPPGTTCTVSGWGTTTSPDVTFPSDLMCVDVKLISPQDCTKVYKDL 183
Query: 183 ITQSMVCAGDMKEGNDSCQGDSGGPLVCGGRLRGLVSWGDMPCGSKEKPGVYTDVCTHIR 242
```

+ SM+CAG ++C GDSGGPLVC G L+GLVSWG P G PGVYT VC +

Sbjct: 184 LENSMLCAGIPDSKKNACNGDSGGPLVCRGTLQGLVSWGTFPWGQPNDPGVYTQVCKFTK 243

Query: 243 WIQNILR 249

WI + ++

Sbjct: 244 WINDTMK 250

| >gi | 41054557 | ref | NP | 955899.1 | G Unknown (protein for MGC:66382) [Danio rerio] | gi | 33585756 | gb | AAH55625.1 | G Unknown (protein for MGC:66382) [Danio rerio] | Length = 242

Score = 202 bits (515), Expect = 5e-51Identities = 96/237 (40%), Positives = 147/237 (62%), Gaps = 3/237 (1%)

Query: 15 LVLAKSAWSEEQEKVVHGGPCLKDSHPFQAALYTSGHLLCGGVLIDPQWVLTAAHCKKPN 74 LVL +A++ + +K+V G C +S P+QA+L SG+ CGG L+ WV++AAHC K

Sbjct: 7 LVLLGAAFALDDDKIVGGYECQPNSQPWQASL-NSGYHFCGGSLVSEYWVVSAAHCYKSR 65

Query: 75 LQVILGKHNLRQTETFQRQISVDRTIVHPRYNPETHDNDIMMVHLKNPVKFSKKIQPLPL 134
++V LG+HN+ E ++ I+ ++ I +P Y+ D+DIM++ L P +K +QP+ L

Sbjct: 66 VEVRLGEHNIVINEGTEQFITSEKVIRNPNYDSWDLDSDIMLIKLSKPATLNKYVQPVAL 125

Query: 135 KNDCSEENPNCQILGWGK-MENGDFPDTIQCADVHLVPREQCERAYPGKITQSMVCAGDM 193
N C+ + C++ GWG M + + +QC ++ ++ C +YPG +T +M CAG +

Sbjct: 126 PNGCAADGTMCRVSGWGNTMSSTADSNKLQCLEIPILSDRDCNNSYPGMVTDTMFCAGYL 185

Query: 194 KEGNDSCQGDSGGPLVCGGRLRGLVSWGDMPCGSKEKPGVYTDVCTHIRWIQNILRN 250 + G DSCQGDSGGP+VC G L G+VSWG C K PGVY VC +WI + +RN

Sbjct: 186 EGGKDSCQGDSGGPVVCNGELHGIVSWG-YGCAEKNHPGVYGKVCMFSQWIADTMRN 241

| >gi|57162224 emb|CAI39655.1 | OTTHUMP00000045395 [Homo sapiens] gi|57160807 emb|CAI39514.1 | OTTHUMP00000045395 [Homo sapiens] Length = 247

Score = 202 bits (513), Expect = 9e-51 Identities = 94/227 (41%), Positives = 144/227 (63%), Gaps = 4/227 (1%)

Query: 24 EEQEKVVHGGPCLKDSHPFQAALYTSGHLLCGGVLIDPQWVLTAAHCKKPNLQVILGKHN 83 ++ +K+V G C ++S P+Q +L + H CGG LI QWV++AAHC K +QV LG+HN

Sbjct: 19 DDDDKIVGGYTCEENSLPYQVSLNSGSHF-CGGSLISEQWVVSAAHCYKTRIQVRLGEHN 77

Query: 84 LRQTETFQRQISVDRTIVHPRYNPETHDNDIMMVHLKNPVKFSKKIQPLPLKNDCSEENP 143 ++ E ++ I+ + I HP+YN +T DNDIM++ L +P + ++ L

Sbjct: 78 IKVLEGNEQFINAAKIIRHPKYNRDTLDNDIMLIKLSSPAVINARVSTISLPTTPPAAGT 137

Query: 144 NCQILGWGKMEN--GDFPDTIQCADVHLVPREQCERAYPGKITQSMVCAGDMKEGNDSCQ 201 C I GWG + D+PD ++C D ++ ++C+ +YPGKIT SM C G ++ G DSCQ

Sbjct: 138 ECLISGWGNTLSFGADYPDELKCLDAPVLTQAECKASYPGKITNSMFCVGFLEGGKDSCQ 197

Query: 202 GDSGGPLVCGGRLRGLVSWGDMPCGSKEKPGVYTDVCTHIRWIQNIL 248

DSGGP+VC G+L+G+VSWG C K +PGVYT V ++ WI++ +

Sbjct: 198 RDSGGPVVCNGOLOGVVSWGH-GCAWKNRPGVYTKVYNYVDWIKDTI 243

| >gi|55741639|ref|NP 001003262.1| | G kallikrein 1, renal/pancreas/salivary [Canis far

```
qi | 414019 | emb | CAA53210.1 | G kallikrein [Canis familiaris]
          Length = 261
 Score = 202 bits (513), Expect = 9e-51
 Identities = 99/257 (38%), Positives = 146/257 (56%), Gaps = 16/257 (6%)
          MKMLALCLVLAKS - - - AWSEEQEKVVHGGPCLKDSHPFOAALYTSGHLLCGGVLIDPOWV 64
Query: 8
          M L LCL L+ + A Q +++ G C K+S P+QAALY
                                                            CGGVL+ P+WV
Sbjct: 1
          MWFLVLCLALSLAGTGAAPPVQSRIIGGWDCTKNSQPWQAALYHYSKFQCGGVLVHPEWV 60
Query: 65 LTAAHCKKPNLQVILGKHNLRQTETFQRQISVDRTIVHPRYN-----PETHDND 113
           +TAAHC
                   N Q + LG + + NL + E + + V + HP + N
Sbjct: 61 VTAAHCINDNYQLWLGRYNLFEHEDTAQFVQVRESFPHPEFNLSLLKNHTRLPEEDYSHD 120
Query: 114 IMMVHLKNPVKFSKKIQPLPLKNDCSEENPNCQILGWGKMENGDF--PDTIQCADVHLVP 171
           IM++ L P + + + + L L + C GWG +E F PD +QC D+ L+
Sbjct: 121 IMLLRLAEPAQITDAVRVLDLPTQEPQVGSTCYASGWGSIEPDKFIYPDDLQCVDLELLS 180
Query: 172 REOCERAYPGKITQSMVCAGDMKEGNDSCQGDSGGPLVCGGRLRGLVSWGDMPCGSKEKP 231
            + C A+ K+T+ M+CAG ++ G D+C GDSGGPL+C G L+G+ SWG +PCGS
Sbjct: 181 NDICANAHSQKVTEFMLCAGHLEGGKDTCVGDSGGPLICDGVLQGITSWGHVPCGSPNMP 240
Query: 232 GVYTDVCTHIRWIQNIL 248
            VYT V +H+ WI+ +
Sbjct: 241 AVYTKVISHLEWIKETM 257
Sgi|55662968|emb|CAH69873.1| G protease, serine, 3 (mesotrypsin) [Homo sapiens]
 gi 57162227 emb CAI39658.1 protease, serine, 3 (mesotrypsin) [Homo sapiens] gi 57160808 emb CAI39515.1 protease, serine, 3 (mesotrypsin) [Homo sapiens]
         Length = 304
 Score = 202 bits (513), Expect = 9e-51
 Identities = 94/227 (41%), Positives = 144/227 (63%), Gaps = 4/227 (1%)
Query: 24 EEQEKVVHGGPCLKDSHPFQAALYTSGHLLCGGVLIDPQWVLTAAHCKKPNLQVILGKHN 83
           ++ +K+V G C ++S P+Q +L + H CGG LI QWV++AAHC K +QV LG+HN
Sbjct: 76 DDDDKIVGGYTCEENSLPYQVSLNSGSHF-CGGSLISEQWVVSAAHCYKTRIQVRLGEHN 134
Query: 84 LRQTETFQRQISVDRTIVHPRYNPETHDNDIMMVHLKNPVKFSKKIQPLPLKNDCSEENP 143
           ++ E ++ I+ + I HP+YN +T DNDIM++ L +P
                                                    + ++ + L
Sbjct: 135 IKVLEGNEQFINAAKIIRHPKYNRDTLDNDIMLIKLSSPAVINARVSTISLPTTPPAAGT 194
Query: 144 NCQILGWGKMEN--GDFPDTIQCADVHLVPREQCERAYPGKITQSMVCAGDMKEGNDSCQ 201
            C I GWG + D+PD ++C D ++ + +C+ +YPGKIT SM C G ++ G DSCQ
Sbjct: 195 ECLISGWGNTLSFGADYPDELKCLDAPVLTQAECKASYPGKITNSMFCVGFLEGGKDSCQ 254
Query: 202 GDSGGPLVCGGRLRGLVSWGDMPCGSKEKPGVYTDVCTHIRWIQNIL 248
            DSGGP+VC G+L+G+VSWG
                                 C K +PGVYT V ++ WI++ +
Sbjct: 255 RDSGGPVVCNGQLQGVVSWGH-GCAWKNRPGVYTKVYNYVDWIKDTI 300
| >gi|41350549|gb|AAS00515.1| trypsin [Oreochromis niloticus]
          Length = 245
 Score = 202 bits (513), Expect = 9e-51
```

qi|631512|pir||S45303 tissue kallikrein (EC 3.4.21.35) precursor - dog

```
Query: 11 LALCLVLAKSAWSEEQEKVVHGGPCLKDSHPFQAALYTSGHLLCGGVLIDPOWVLTAAHC 70
          + L L A A E +K++ G C K+S P+ +L G+ CGG LI
Sbjct: 5 ILLALFAAAYAAPIEDDKIIGGYECAKNSVPYMVSL-NIGYHFCGGSLISSTWAVSAAHC 63
Query: 71 KKPNLQVILGKHNLRQTETFQRQISVDRTIVHPRYNPETHDNDIMMVHLKNPVKFSKKIQ 130
          + ++Q+ LG+HN+ E ++ IS R I H YN T DNDIM++ L P
Sbjct: 64 YQSSIQLRLGEHNIAVNEGTEQFISSSRVIRHQSYNSYTLDNDIMLIKLSQPATLNSYVK 123
Query: 131 PLPLKNDCSEENPNCQILGWG--KMENGDFPDTIQCADVHLVPREQCERAYPGKITOSMV 188
                     +C I GWG
           + L + C+
                                    ++PD + C + ++
                                                     C +YPG+IT +M
Sbjct: 124 TVSLPSGCAGAGTSCLISGWGNTSTSGSNYPDRLMCLNAPILSDTDCRNSYPGEITNNMF 183
Query: 189 CAGDMKEGNDSCQGDSGGPLVCGGRLRGLVSWGDMPCGSKEKPGVYTDVCTHIRWIQNIL 248
          CAG ++ G DSCQGDSGGP+VC G+L+G+VSWG C +++PGVYT VC + WI N +
Sbjct: 184 CAGFLEGGKDSCQGDSGGPVVCNGQLQGIVSWG-YGCAORDRPGVYTKVCNYNSWISNTM 242
Query: 249 RN 250
Sbjct: 243 AN 244
sgi|55649803|ref|XP 524356.1| G PREDICTED: similar to Kallikrein 15 precursor (ACO
          troglodytes]
         Length = 405
 Score = 201 bits (512), Expect = 1e-50
Identities = 98/287 (34%), Positives = 151/287 (52%), Gaps = 60/287 (20%)
Query: 23 SEEQEKVVHGGPCLKDSHPFQAALYTSGHLLCGGVLIDPQWVLTAAHCK----- 71
          +++ +K++ G C S P+Q ALY G CG LI P WVL+AAHC+
Sbjct: 117 AQDGDKLLEGDECAPHSQPWQVALYERGRFNCGASLISPHWVLSAAHCQSRVLGKGNGVS 176
                                     ----KPN--LQVILGKHNLRQTETFQRQI 94
                                           +P+ ++V LG+HNLR+ + ++
Sbjct: 177 RFLKGRGTSGCPLFDLSVLYLRVTTGPHSTGGKTTRPHSFMRVRLGEHNLRKRDGPEQLR 236
Query: 95 SVDRTIVHPRYNPETHDNDIMMVHLKNPVKFSKKIOPLPLKNDCSEENPNCOILGWGKME 154
          + R I HPRY +H NDIM++ L P + + +++P L C C + GWG +
Sbjct: 237 TASRVIPHPRYEARSHRNDIMLLRLVQPARLTPQVRPAVLPTRCPHPGEACVVSGWGLVS 296
Query: 155 NGD------FPDTIQCADVHLVPREQCERAYPGKITQSMVCAGDMKEGNDSCOG 202
                        PDT+ CA++ ++ C+++YPG++T +MVCAG
Sbjct: 297 HNEPGTAGSPRSQVSLPDTLHCANISIISDTSCDKSYPGRLTNTMVCAGAEGRGAESCEG 356
Query: 203 DSGGPLVCGGRLRGLVSWGDMPCGSKEKPGVYTDVCTHIRWIQNILR 249
          DSGGPLVCGG L+G+VSWGD+PC + KPGVYT VC ++ WI+ ++
Sbjct: 357 DSGGPLVCGGILQGIVSWGDVPCDNTTKPGVYTKVCHYLEWIRETMK 403
gi|47481110|gb|AAH69476.1| G Mesotrypsin, preproprotein [Homo sapiens]
gi | 47479560 | gb | AAH69494.1 | G Mesotrypsin, preproprotein [Homo sapiens]
gi 21536452 | ref | NP 002762.2 | G mesotrypsin preproprotein [Homo sapiens]
gi | 1321640 | dbj | BAA08257.1 | G mesotrypsinogen [Homo sapiens]
```

Identities = 96/242 (39%), Positives = 143/242 (59%), Gaps = 4/242 (1%)

```
Score = 201 bits (512), Expect = 1e-50
 Identities = 94/227 (41%), Positives = 144/227 (63%), Gaps = 4/227 (1%)
Query: 24 EEQEKVVHGGPCLKDSHPFQAALYTSGHLLCGGVLIDPQWVLTAAHCKKPNLQVILGKHN 83
          ++ +K+V G C ++S P+Q +L + H CGG LI QWV++AAHC K +QV LG+HN
Sbjct: 19 DDDDKIVGGYTCEENSLPYQVSLNSGSHF-CGGSLISEQWVVSAAHCYKTRIQVRLGEHN 77
Query: 84 LRQTETFQRQISVDRTIVHPRYNPETHDNDIMMVHLKNPVKFSKKIQPLPLKNDCSEENP 143
          ++ E ++ I+ + I HP+YN +T DNDIM++ L +P + ++ L
Sbjct: 78 IKVLEGNEQFINAAKIIRHPKYNRDTLDNDIMLIKLSSPAVINARVSTISLPTAPPAAGT 137
Query: 144 NCQILGWGKMEN--GDFPDTIQCADVHLVPREQCERAYPGKITQSMVCAGDMKEGNDSCQ 201
          C I GWG + D+PD ++C D ++ + +C+ +YPGKIT SM C G ++ G DSCQ
Sbjct: 138 ECLISGWGNTLSFGADYPDELKCLDAPVLTQAECKASYPGKITNSMFCVGFLEGGKDSCQ 197
Query: 202 GDSGGPLVCGGRLRGLVSWGDMPCGSKEKPGVYTDVCTHIRWIQNIL 248
           DSGGP+VC G+L+G+VSWG
                              C K +PGVYT V ++ WI++ +
Sbjct: 198 RDSGGPVVCNGQLQGVVSWGH-GCAWKNRPGVYTKVYNYVDWIKDTI 243
Length = 251
 Score = 201 bits (512), Expect = 1e-50
 Identities = 94/227 (41%), Positives = 144/227 (63%), Gaps = 4/227 (1%)
Query: 24 EEQEKVVHGGPCLKDSHPFQAALYTSGHLLCGGVLIDPQWVLTAAHCKKPNLQVILGKHN 83
          ++ +K+V G C ++S P+Q +L + H CGG LI QWV++AAHC K +QV LG+HN
Sbjct: 23 DDDDKIVGGYTCEENSLPYQVSLNSGSHF-CGGSLISEQWVVSAAHCYKTRIQVRLGEHN 81
Ouery: 84 LROTETFOROISVDRTIVHPRYNPETHDNDIMMVHLKNPVKFSKKIOPLPLKNDCSEENP 143
          ++ E ++ I+ + I HP+YN +T DNDIM++ L +P
                                                + ++ + L
Sbjct: 82 IKVLEGNEQFINAAKIIRHPKYNRDTLDNDIMLIKLSSPAVINARVSTISLPTAPPAAGT 141
Query: 144 NCQILGWGKMEN--GDFPDTIQCADVHLVPREQCERAYPGKITQSMVCAGDMKEGNDSCQ 201
           C I GWG + D+PD ++C D ++ + +C+ +YPGKIT SM C G ++ G DSCQ
Sbjct: 142 ECLISGWGNTLSFGADYPDELKCLDAPVLTQAECKASYPGKITNSMFCVGFLEGGKDSCQ 201
Query: 202 GDSGGPLVCGGRLRGLVSWGDMPCGSKEKPGVYTDVCTHIRWIQNIL 248
           DSGGP+VC G+L+G+VSWG
                              C K +PGVYT V ++ WI++ +
Sbjct: 202 RDSGGPVVCNGQLQGVVSWGH-GCAWKNRPGVYTKVYNYVDWIKDTI 247
pqi|1064991|pdb|1TRN|B Chain B, Trypsin (E.C.3.4.21.4) Complexed With The Inhibit
          Diisopropyl-Fluorophosphofluoridate (Dfp)
 qi|1064990|pdb|1TRN|A Chain A, Trypsin (E.C.3.4.21.4) Complexed With The Inhibitor
          Diisopropyl-Fluorophosphofluoridate (Dfp)
         Length = 224
 Score = 201 bits (512), Expect = 1e-50
 Identities = 95/222 (42%), Positives = 142/222 (63%), Gaps = 4/222 (1%)
Query: 29 VVHGGPCLKDSHPFQAALYTSGHLLCGGVLIDPQWVLTAAHCKKPNLQVILGKHNLRQTE 88
          +V G C ++S P+Q +L SG+ CGG LI+ QWV++A HC K +QV LG+HN+
```

IVGGYNCEENSVPYQVSL-NSGYHFCGGSLINEQWVVSAGHCYKSRIQVRLGEHNIEVLE 59

Sbjct: 1

```
Query: 89 TFQRQISVDRTIVHPRYNPETHDNDIMMVHLKNPVKFSKKIQPLPLKNDCSEENPNCQIL 148
           ++ I+ + I HP+Y+ +T +NDIM++ L +
                                           + ++ + L
Sbjct: 60 GNEQFINAAKIIRHPQYDRKTLNNDIMLIKLSSRAVINARVSTISLPTAPPATGTKCLIS 119
Query: 149 GWGKMENG--DFPDTIQCADVHLVPREQCERAYPGKITQSMVCAGDMKEGNDSCQGDSGG 206
                   D+PD +QC D ++ + +CE +YPGKIT +M C G ++ G DSCQGDSGG
Sbjct: 120 GWGNTASSGADYPDELQCLDAPVLSQAKCEASYPGKITSNMFCVGFLEGGKDSCQGDSGG 179
Query: 207 PLVCGGRLRGLVSWGDMPCGSKEKPGVYTDVCTHIRWIQNIL 248
          P+VC G+L+G+VSWGD C K KPGVYT V +++WI+N +
Sbjct: 180 PVVCNGQLQGVVSWGD-GCAQKNKPGVYTKVYNYVKWIKNTI 220
Sgi|6066378|emb|CAB58178.1| G trypsinogen IV a-form [Homo sapiens]
         Length = 261
 Score = 201 bits (512), Expect = 1e-50
 Identities = 94/227 (41%), Positives = 144/227 (63%), Gaps = 4/227 (1%)
Query: 24 EEQEKVVHGGPCLKDSHPFQAALYTSGHLLCGGVLIDPQWVLTAAHCKKPNLQVILGKHN 83
          ++ +K+V G C ++S P+Q +L + H CGG LI QWV++AAHC K +QV LG+HN
Sbjct: 33 DDDDKIVGGYTCEENSLPYQVSLNSGSHF-CGGSLISEQWVVSAAHCYKTRIQVRLGEHN 91
Query: 84 LRQTETFQRQISVDRTIVHPRYNPETHDNDIMMVHLKNPVKFSKKIQPLPLKNDCSEENP 143
          ++ E ++ I+ + I HP+YN +T DNDIM++ L +P
                                               + ++ + L
Sbjct: 92 IKVLEGNEQFINAAKIIRHPKYNRDTLDNDIMLIKLSSPAVINARVSTISLPTAPPAAGT 151
Query: 144 NCQILGWGKMEN--GDFPDTIQCADVHLVPREQCERAYPGKITQSMVCAGDMKEGNDSCQ 201
           C I GWG + D+PD ++C D ++ + +C+ +YPGKIT SM C G ++ G DSCQ
Sbjct: 152 ECLISGWGNTLSFGADYPDELKCLDAPVLTQAECKASYPGKITNSMFCVGFLEGGKDSCQ 211
Query: 202 GDSGGPLVCGGRLRGLVSWGDMPCGSKEKPGVYTDVCTHIRWIQNIL 248
           DSGGP+VC G+L+G+VSWG C K +PGVYT V ++ WI++ +
Sbjct: 212 RDSGGPVVCNGQLQGVVSWGH-GCAWKNRPGVYTKVYNYVDWIKDTI 257
(Trypsin IV)
         Length = 304
 Score = 201 bits (512), Expect = 1e-50
 Identities = 94/227 (41%), Positives = 144/227 (63%), Gaps = 4/227 (1%)
Query: 24 EEQEKVVHGGPCLKDSHPFQAALYTSGHLLCGGVLIDPQWVLTAAHCKKPNLQVILGKHN 83
          ++ +K+V G C ++S P+Q +L + H CGG LI QWV++AAHC K +QV LG+HN
Sbjct: 76 DDDDKIVGGYTCEENSLPYQVSLNSGSHF-CGGSLISEQWVVSAAHCYKTRIQVRLGEHN 134
Query: 84 LRQTETFQRQISVDRTIVHPRYNPETHDNDIMMVHLKNPVKFSKKIQPLPLKNDCSEENP 143
          ++ E ++ I+ + I HP+YN +T DNDIM++ L +P
                                               + ++ + L
Sbjct: 135 IKVLEGNEQFINAAKIIRHPKYNRDTLDNDIMLIKLSSPAVINARVSTISLPTAPPAAGT 194
Query: 144 NCQILGWGKMEN--GDFPDTIQCADVHLVPREQCERAYPGKITQSMVCAGDMKEGNDSCQ 201
           C I GWG + D+PD ++C D ++ + +C+ +YPGKIT SM C G ++ G DSCQ
Sbjct: 195 ECLISGWGNTLSFGADYPDELKCLDAPVLTQAECKASYPGKITNSMFCVGFLEGGKDSCQ 254
```

Query: 202 GDSGGPLVCGGRLRGLVSWGDMPCGSKEKPGVYTDVCTHIRWIQNIL 248

DSGGP+VC G+L+G+VSWG C K +PGVYT V ++ WI++ +

Sbjct: 255 RDSGGPVVCNGQLQGVVSWGH-GCAWKNRPGVYTKVYNYVDWIKDTI 300

```
| >gi|30584977|gb|AAP36761.1| Homo sapiens kallikrein 2, prostatic [synthetic construent Length = 262
```

Score = 201 bits (511), Expect = 2e-50 Identities = 99/236 (41%), Positives = 136/236 (57%), Gaps = 13/236 (5%)

Query: 26 QEKVVHGGPCLKDSHPFQAALYTSGHLLCGGVLIDPQWVLTAAHCKKPNLQVILGKHNLR 85 Q ++V G C K S P+Q A+Y+ G CGGVL+ PQWVLTAAHC K N OV LG+HNL

Sbjct: 22 QSRIVGGWECEKHSQPWQVAVYSHGWAHCGGVLVHPQWVLTAAHCLKKNSQVWLGRHNLF 81

Query: 86 QTETFQRQISVDRTIVHPRYN------PETHDNDIMMVHLKNPVKFSKKIQPLPL 134
+ E +++ V + HP YN E +D+M++ L P K + ++ L L

Sbjct: 82 EPEDTGQRVPVSHSFPHPLYNMSLLKHQSLRPDEDSSHDLMLLRLSEPAKITDVVKVLGL 141

Query: 135 KNDCSEENPNCQILGWGKMENGDF--PDTIQCADVHLVPREQCERAYPGKITQSMVCAGD 192 C GWG +E +F P ++QC ++HL+ + C RAY K+T+ M+CAG

Sbjct: 142 PTQEPALGTTCYASGWGSIEPEEFLRPRSLQCVSLHLLSNDMCARAYSEKVTEFMLCAGL 201

Query: 193 MKEGNDSCQGDSGGPLVCGGRLRGLVSWGDMPCGSKEKPGVYTDVCTHIRWIQNIL 248

G D+C GDSGGPLVC G L+G+ SWG PC EKP VYT V + +WI++ +

Sbjct: 202 WTGGKDTCGGDSGGPLVCNGVLQGITSWGPEPCALPEKPAVYTKVVHYRKWIKDTI 257

gi|88862|pir||A29586 tissue kallikrein (EC 3.4.21.35) hGK-1 precursor - human

Score = 201 bits (511), Expect = 2e-50 Identities = 99/236 (41%), Positives = 136/236 (57%), Gaps = 13/236 (5%)

Query: 26 QEKVVHGGPCLKDSHPFQAALYTSGHLLCGGVLIDPQWVLTAAHCKKPNLQVILGKHNLR 85 Q ++V G C K S P+Q A+Y+ G CGGVL+ PQWVLTAAHC K N QV LG+HNL

Sbjct: 22 QSRIVGGWECEKHSQPWQVAVYSHGWAHCGGVLVHPQWVLTAAHCLKKNSQVWLGRHNLF 81

Query: 86 QTETFQRQISVDRTIVHPRYN-----PETHDNDIMMVHLKNPVKFSKKIQPLPL 134 + E +++ V + HP YN E +D+M++ L P K + ++ L L

Sbjct: 82 EPEDTGQRVPVSHSFPHPLYNMSLLKHQSLRPDEDSSHDLMLLRLSEPAKITDVVKVLGL 141

Query: 135 KNDCSEENPNCQILGWGKMENGDF--PDTIQCADVHLVPREQCERAYPGKITQSMVCAGD 192

C GWG +E +F P ++QC +HL+ + C RAY K+T+ M+CAG

Sbjct: 142 PTQEPALGTTCYASGWGSIEPEEFLRPRSLQCVSLHLLSNDMCARAYSEKVTEFMLCAGL 201

```
Query: 193 MKEGNDSCQGDSGGPLVCGGRLRGLVSWGDMPCGSKEKPGVYTDVCTHIRWIQNIL 248
```

G D+C GDSGGPLVC G L+G+ SWG PC EKP VYT V + +WI++ +

Sbjct: 202 WTGGKDTCGGDSGGPLVCNGVLQGITSWGPEPCALPEKPAVYTKVVHYRKWIKDTI 257

| >gi|422723|pir||S33772 tissue kallikrein (EC 3.4.21.35) precursor, renal - crab-eat macaque

gi|585360|sp|Q07276|KLK1 MACFA Kallikrein 1 precursor (Tissue kallikrein) (Kidney/pancreas/salivary gland kallikrein)

gi|293141|gb|AAA36853.1| pre-pro-protein for kallikrein Length = 257

Score = 201 bits (511), Expect = 2e-50 Identities = 98/256 (38%), Positives = 146/256 (57%), Gaps = 18/256 (7%)

Query: 8 MKMLALCLVLAKSAWSEE---QEKVVHGGPCLKDSHPFQAALYTSGHLLCGGVLIDPQWV 64
M L LCL L+ Q ++V G C S P+QAALY CGG+L+ POWV

Sbjct: 1 MWFLVLCLALSLGGTGRAPPIQSRIVGGWEC---SQPWQAALYHFSTFQCGGILVHPQWV 57

Query: 65 LTAAHCKKPNLQVILGKHNLRQTETFQRQISVDRTIVHPRYN-----PETHDNDI 114 LTAAHC N Q+ LG+HNL E + + V + HP +N + + +D+

Sbjct: 58 LTAAHCISDNYQLWLGRHNLFDDEDTAQFVHVSESFPHPGFNMSLLKNHTRQADDYSHDL 117

Query: 115 MMVHLKNPVKFSKKIQPLPLKNDCSEENPNCQILGWGKME--NGDFPDTIQCADVHLVPR 172 M++ L P + + +Q + L E C GWG +E N FPD +QC D+ ++P

Sbjct: 118 MLLRLTQPAEITDAVQVVELPTQEPEVGSTCLASGWGSIEPENFSFPDDLQCVDLEILPN 177

Query: 173 EQCERAYPGKITQSMVCAGDMKEGNDSCQGDSGGPLVCGGRLRGLVSWGDMPCGSKEKPG 232 ++C +A+ K+T+ M+CAG ++ G D+C GDSGGPL C G L+G+ SWG +PCGS KP

Sbjct: 178 DECAKAHTQKVTEFMLCAGHLEGGKDTCVGDSGGPLTCDGVLQGVTSWGYIPCGSPNKPA 237

Query: 233 VYTDVCTHIRWIQNIL 248

V+ V ++++WI++ +

Sbjct: 238 VFVKVLSYVKWIEDTI 253

Score = 201 bits (511), Expect = 2e-50 Identities = 95/232 (40%), Positives = 142/232 (61%), Gaps = 4/232 (1%)

Query: 10 MLALCLVLAKSAWSEEQEKVVHGGPCLKDSHPFQAALYTSGHLLCGGVLIDPQWVLTAAH 69
+LAL V + ++ +K+V G C K+ P+Q +L SG+ CGG LI WV++AAH

Sbjct: 6 LLALFAVAYAAPLGDDDDKIVGGYECTKNGVPYQVSL-NSGYHFCGGSLISNLWVVSAAH 64

Query: 70 CKKPNLQVILGKHNLRQTETFQRQISVDRTIVHPRYNPETHDNDIMMVHLKNPVKFSKKI 129 C K +QV LG+HN+ TE ++ I+ ++ I HP YN T DND+M++ L + + + +

Sbjct: 65 CYKSRVQVRLGEHNIDVTEGTEQFINSEKVIRHPSYNSNTLDNDVMLIKLSSSAQINSYV 124

Query: 130 QPLPLKNDCSEENPNCQILGWGKM--ENGDFPDTIQCADVHLVPREQCERAYPGKITQSM 187
+ + L + C+ +C I GWG M ++P + C + ++ C AYPG+I+ +M

Sbjct: 125 KTVSLPSSCASSGTSCLISGWGNMSASGSNYPSRLMCLNAPILSDSTCRNAYPGQISSNM 184

Query: 188 VCAGDMKEGNDSCQGDSGGPLVCGGRLRGLVSWGDMPCGSKEKPGVYTDVCT 239
CAG M+ G DSCQGDSGGP+VC +L+G+VSWG C + KPGVY VCT

Sbjct: 185 FCAGFMEGGKDSCQGDSGGPVVCNNQLQGIVSWG-YGCAQRNKPGVYAKVCT 235

| >gi|58257846|gb|AAW69365.1| try12 [Macaca mulatta] | Length = 247

Score = 201 bits (511), Expect = 2e-50 Identities = 93/227 (40%), Positives = 142/227 (62%), Gaps = 4/227 (1%)

Query: 24 EEQEKVVHGGPCLKDSHPFQAALYTSGHLLCGGVLIDPQWVLTAAHCKKPNLQVILGKHN 83
++ +K+V G C ++S P+Q +L SG+ CGG LI QWV++A HC KP+++V LG+HN
Sbjct: 19 DDDDKIVGGNTCEENSVPYQVSL-NSGYHFCGGSLISEQWVVSAGHCYKPHIEVRLGEHN 77

bojec. 15 bbbbkivoonichanoviiqvon hooinireeoobalobgwvvbAchelikinihvkhomm

Query: 84 LRQTETFQRQISVDRTIVHPRYNPETHDNDIMMVHLKNPVKFSKKIQPLPLKNDCSEENP 143
+ E ++ I+ + I H +YN T +NDIM++ L P + + +PL N

Sbjct: 78 IEVLEGNEQFINATKIIRHSKYNGNTLNNDIMLIKLSTPAVINDYVSTIPLPNAPPAAGT 137

Query: 144 NCQILGWGK--MENGDFPDTIQCADVHLVPREQCERAYPGKITQSMVCAGDMKEGNDSCQ 201 C I GWG D+PD +QC D ++ + +C+ +YP +IT +M C G ++ G DSCQ

Sbjct: 138 ECLISGWGNTLSSGADYPDELQCLDAPVLTQTKCKLSYPFRITSNMFCVGFLEGGKDSCQ 197

Query: 202 GDSGGPLVCGGRLRGLVSWGDMPCGSKEKPGVYTDVCTHIRWIQNIL 248
GDSGGP+VC G+L+G+VSWG C K +PGVYT V ++ WI++ +
Sbjct: 198 GDSGGPVVCNGQLQGIVSWG-YGCALKRRPGVYTKVYNYVDWIKDTI 243

| >gi | 41350551 | gb | AAS00516.1 | trypsin [Oreochromis aureus] Length = 245

Score = 201 bits (511), Expect = 2e-50 Identities = 96/242 (39%), Positives = 142/242 (58%), Gaps = 4/242 (1%)

Query: 11 LALCLVLAKSAWSEEQEKVVHGGPCLKDSHPFQAALYTSGHLLCGGVLIDPQWVLTAAHC 70 + L L A A E +K++ G C K+S P+ +L G+ CGG LI W ++AAHC

Sbjct: 5 ILLALFAAAYAAPIEDDKIIGGYECAKNSVPYMVSL-NIGYHFCGGSLISSTWAVSAAHC 63

Query: 71 KKPNLQVILGKHNLRQTETFQRQISVDRTIVHPRYNPETHDNDIMMVHLKNPVKFSKKIQ 130 + ++Q+ LG+HN+ E ++ IS R I H YN T DNDIM++ L P + ++

Sbjct: 64 YQSSIQLRLGEHNIAVNEGTEQFISSSRVIRHQSYNSYTLDNDIMLIKLSQPATLNSYVK 123

Query: 131 PLPLKNDCSEENPNCQILGWG--KMENGDFPDTIQCADVHLVPREQCERAYPGKITQSMV 188 + L + C+ +C I GWG ++PD + C + ++ C +YPG+IT +M

Sbjct: 124 TVSLPSGCAGAGTSCLISGWGNTSTSGSNYPDRLMCLNAPILSDTDCRNSYPGEITNNMF 183

Query: 189 CAGDMKEGNDSCQGDSGGPLVCGGRLRGLVSWGDMPCGSKEKPGVYTDVCTHIRWIQNIL 248 CAG ++ G DSCQGDSGGP+VC G+L+G+VSWG C + +PGVYT VC + WI N +

Sbjct: 184 CAGFLEGGKDSCQGDSGGPVVCNGQLQGIVSWG-YGCAQRNRPGVYTKVCNYNSWISNTM 242

Query: 249 RN 250

N

Sbjct: 243 AN 244

>gi|27573671|pdb|1J17|T Chain T, Factor Xa Specific Inhibitor In Complex With Rat
Mutant X99175190RT

```
Score = 201 bits (511), Expect = 2e-50
Identities = 95/222 (42%), Positives = 144/222 (64%), Gaps = 4/222 (1%)
Query: 29 VVHGGPCLKDSHPFQAALYTSGHLLCGGVLIDPQWVLTAAHCKKPNLQVILGKHNLRQTE 88
          +V G C ++S P+Q +L SG+ CGG LI+ QWV++AAHC K +QV LG+HN+ E
          IVGGYTCQENSVPYQVSL-NSGYHFCGGSLINDQWVVSAAHCYKSRIQVRLGEHNINVLE 59
Sbjct: 1
Ouery: 89 TFQRQISVDRTIVHPRYNPETHDNDIMMVHLKNPVKFSKKIQPLPLKNDCSEENPNCQIL 148
           ++ ++ + I HP ++ ET++NDIM++ L +PVK + ++ + L + C+
Sbjct: 60 GNEQFVNAAKIIKHPNFDRETYNNDIMLIKLSSPVKLNARVATVALPSSCAPAGTQCLIS 119
Query: 149 GWGK-MENG-DFPDTIQCADVHLVPREQCERAYPGKITQSMVCAGDMKEGNDSCQGDSGG 206
          GWG + +G + PD +QC D L+P+ CE + IT +MVC G ++ G D+CQGDSGG
Sbjct: 120 GWGNTLSSGVNEPDLLQCLDAPLLPQADCEASSSFIITDNMVCVGFLEGGKDACQGDSGG 179
Query: 207 PLVCGGRLRGLVSWGDMPCGSKEKPGVYTDVCTHIRWIQNIL 248
          P+VC G L+G+VSWG C + PGVYT VC ++ WIQ+ +
Sbjct: 180 PVVCNGELQGIVSWG-YGCALPDNPGVYTKVCNYVDWIQDTI 220
oqi|5441853|dbj|BAA82362.1| trypsinogen 1 [Paralichthys olivaceus]
         Length = 242
 Score = 201 bits (511), Expect = 2e-50
 Identities = 96/242 (39%), Positives = 148/242 (61%), Gaps = 4/242 (1%)
Query: 8 MKMLALCLVLAKSAWSEEQEKVVHGGPCLKDSHPFQAALYTSGHLLCGGVLIDPOWVLTA 67
               L++ +A++ E +K+V G C S P Q +L SG+ CGG L++ WV++A
Sbjct: 1
         MRSLVFVLLIG-AAFAMEDDKIVGGYECTPYSQPHQVSL-NSGYHFCGGSLVNENWVVSA 58
Query: 68 AHCKKPNLQVILGKHNLRQTETFQRQISVDRTIVHPRYNPETHDNDIMMVHLKNPVKFSK 127
          AHC K ++V +G+H+++ E ++ IS +R I HP Y+ +NDIM++ L+ P
Sbjct: 59 AHCYKSRVEVRMGEHHIKINEGTEQFISSERVIRHPNYSSYNINNDIMLIKLREPATLNQ 118
Query: 128 KIQPLPLKNDCSEENPNCQILGWGK-MENGDFPDTIQCADVHLVPREQCERAYPGKITQS 186
           +QP+ L C+ C + GWG M + D +QC D+ ++ CE +YPG IT +
Sbjct: 119 YVQPVALPTSCAPAGTMCTVSGWGNTMSSTANRDMLQCLDLPILSDRDCENSYPGMITPA 178
Ouery: 187 MVCAGDMKEGNDSCOGDSGGPLVCGGRLRGLVSWGDMPCGSKEKPGVYTDVCTHIRWION 246
          M CAG ++ G DSCOGDSGGP+VC G L+G+VSWG C ++ PGVY VC I W++
Sbjct: 179 MFCAGYLEGGKDSCQGDSGGPVVCNGELQGVVSWG-YGCAERDHPGVYARVCIFIDWLET 237
Query: 247 IL 248
Sbjct: 238 TM 239
```

| >gi | 9665236 | ref | NP 062544.1 | G | kallikrein 12 isoform 1 [Homo sapiens]
| gi | 6249632 | gb | AAF06065.1 | G | kallikrein-like protein 5-related protein 1 [Homo sapien | gi | 10799397 | gb | AAG23258.1 | G | kallikrein 12 [Homo sapiens]

Length = 254

Score = 201 bits (510), Expect = 2e-50

```
Identities = 102/238 (42%), Positives = 145/238 (60%), Gaps = 10/238 (4%)
Query: 6 LTMKMLALCLVLAKSAWSEEQEKVVHGGPCLKDSHPFQAALYTSGHLLCGGVLIDPQWVL 65
         L++ +L L L+++A K+ +G C ++S P+Q L+
         LSIFLLCVLGLSQAA----TPKIFNGTECGRNSQPWQVGLFEGTSLRCGGVLIDHRWVL 58
Sbjct: 3
Query: 66 TAAHCKKPNLQVILGKHNLRQTETFQRQISVDRTIVHPRY--NPETHDNDIMMVHLKNPV 123
                   V LG+H+L Q + ++ ++ HP Y
                                                 +H++D+ ++ L+ PV
Sbjct: 59 TAAHCSGSRYWVRLGEHSLSQLDWTEQIRHSGFSVTHPGYLGASTSHEHDLRLLRLPLV 118
Query: 124 KFSKKIQPLPLKNDCSEENPNCQILGWG--KMENGDFPDTIQCADVHLVPREQCERAYPG 181
          + + +OPLPL NDC+ C + GWG FPD +QC ++ +V C YPG
Sbjct: 119 RVTSSVQPLPLPNDCATAGTECHVSGWGITNHPRNPFPDLLQCLNLSIVSHATCHGVYPG 178
Query: 182 KITQSMVCAGDMKEGNDSCQGDSGGPLVCGGRLRGLVSWGDM-PCGSKEKPGVYTDVC 238
          +IT +MVCAG + G D+CQGDSGGPLVCGG L+GLVSWG + PCG PGVYT +C
Sbjct: 179 RITSNMVCAGGV-PGQDACQGDSGGPLVCGGVLQGLVSWGSVGPCGQDGIPGVYTYIC 235
| >gi | 52345790 | ref | NP 001004941.1 | G MGC89184 protein [Xenopus tropicalis]
Length = 249
 Score = 200 bits (508), Expect = 3e-50
 Identities = 96/244 (39%), Positives = 143/244 (58%), Gaps = 6/244 (2%)
Query: 12 ALCLVLAKSAWSEEQEKVVHGGPCLKDSHPFQAALYTSGHLLCGGVLIDPQWVLTAAHCK 71
          A+ + +A + ++V G C S P+Q L G CGG LI P+W+++AAHC
          AMMFLAVAAAGPLDDSRIVGGYECAPHSKPWQVHLNYKGSFFCGGSLIAPRWIVSAAHCY 65
Sbjct: 6
Query: 72 KPNLQVI--LGKHNLRQTETFQRQISVDRTIVHPRYNPETHDNDIMMVHLKNPVKFSKKI 129
              V+ +G H++ + E + I V+++ H +YN
                                               DNDIM++ L P +F+ +
Sbjct: 66 LLPKYVVAHIGMHDVSKAEGTVQIIQVEKSFQHYKYNSSNIDNDIMLIKLAEPAQFNHHV 125
Query: 130 QPLPLKNDCSEENPNCQILGWGKMENG---DFPDTIQCADVHLVPREQCERAYPGKITQS 186
          Sbjct: 126 QPIPLAHSCPMKGTRCVVSGYGNMRPGFFGEFPDRLQCLDLPVLPEDSCKSSYGDDITNN 185
Query: 187 MVCAGDMKEGNDSCQGDSGGPLVCGGRLRGLVSWGDMPCGSKEKPGVYTDVCTHIRWIQN 246
          M CAG + G DSCQGDSGGPLVC G L G+VSWG C K PGVYT VC +I W+ +
Sbjct: 186 MFCAGFQEGGKDSCQGDSGGPLVCDGELFGVVSWGH-ECAKKGYPGVYTKVCHYIDWVND 244
Query: 247 ILRN 250
          I+ +
Sbjct: 245 IMED 248
| >gi|13516891|dbj|BAB40329.1| trypsinogen [Engraulis japonicus]
         Length = 240
 Score = 200 bits (508), Expect = 3e-50
 Identities = 93/234 (39%), Positives = 142/234 (60%), Gaps = 3/234 (1%)
Query: 15 LVLAKSAWSEEQEKVVHGGPCLKDSHPFQAALYTSGHLLCGGVLIDPQWVLTAAHCKKPN 74
          LVL +A++E+ +K+V G C S P +L SG+ CGG L++ WV++AAHC K
Sbjct: 7 LVLLGAAFAED-DKIVGGYECQAHSQPHTVSL-NSGYHFCGGSLVNENWVVSAAHCYKSR 64
```

```
Query: 75 LQVILGKHNLRQTETFQRQISVDRTIVHPRYNPETHDNDIMMVHLKNPVKFSKKIOPLPL 134
         ++V LG+H++ Q E ++ I R I HP+Y+
                                         DND+M++ L P
                                                       ++ +QP+ L
Sbjct: 65 VEVRLGEHHIGQNENTEQFIDSSRVIRHPQYSSYNIDNDVMLIKLSTPATLNQYVQPVAL 124
Query: 135 KNDCSEENPNCQILGWGKMENGDFPDTIQCADVHLVPREQCERAYPGKITQSMVCAGDMK 194
                  C + GWG
                          + D +QC + ++
                                            C+ +YPG IT +M CAG ++
Sbjct: 125 PSRCASAGTMCLVAGWGNTMSNVSGDKLQCLQIPILSDRDCDNSYPGMITDAMFCAGYLE 184
Query: 195 EGNDSCQGDSGGPLVCGGRLRGLVSWGDMPCGSKEKPGVYTDVCTHIRWIQNIL 248
          G DSCQGDSGGP+VC G L+G+VSWG C ++ PGVY VC
Sbjct: 185 GGKDSCQGDSGGPVVCNGELQGVVSWG-YGCAERDHPGVYAKVCIFTDWLQSTM 237
🖲 >gi|230765|pdb|2TLD|E 🔛 Chain E, Bovine Trypsin (E.C.3.4.21.4) Complex With A Modif
         (Streptomyces Subtilisin Inhibitor) With Met 70 Replaced
         By Gly And Met 73 Replaced By Lys (SSI(M70G,M73K))
        Length = 220
Score = 200 \text{ bits } (508), \text{ Expect = } 3e-50
 Identities = 97/222 (43%), Positives = 139/222 (62%), Gaps = 7/222 (3%)
Query: 29 VVHGGPCLKDSHPFQAALYTSGHLLCGGVLIDPQWVLTAAHCKKPNLQVILGKHNLROTE 88
         +V G C ++ P+Q +L SG+ CGG LI+ QWV++AAHC K +QV LG+ N+
Sbjct: 1
         IVGGYTCGANTVPYQVSL-NSGYHFCGGSLINSQWVVSAAHCYKSGIQVRLGEDNINVVE 59
Query: 89 TFQRQISVDRTIVHPRYNPETHDNDIMMVHLKNPVKFSKKIQPLPLKNDCSEENPNCQIL 148
           ++ IS ++IVHP YN T +NDIM++ LK+
                                          + ++ + L
Sbjct: 60 GNEQFISASKSIVHPSYNSNTLNNDIMLIKLKSAASLNSRVASISLPTSCASAGTQCLIS 119
Query: 149 GWG--KMENGDFPDTIQCADVHLVPREQCERAYPGKITQSMVCAGDMKEGNDSCQGDSGG 206
                   +PD ++C
                             ++
                                  C+ AYPG+IT +M CAG
                                                    EG DSCQGDSGG
Sbjct: 120 GWGNTKSSGTSYPDVLKCLKAPILSDSSCKSAYPGQITSNMFCAG--LEGGDSCQGDSGG 177
Query: 207 PLVCGGRLRGLVSWGDMPCGSKEKPGVYTDVCTHIRWIONIL 248
         P+VC G+L+G+VSWG
                        C +K KPGVYT VC ++ WI+
Sbjct: 178 PVVCSGKLQGIVSWGS-GC-AKNKPGVYTKVCNYVSWIKQTI 217
gi|5919239|gb|AAD26427.2| G kallikrein-like protein 3 [Homo sapiens]
Length = 250
Score = 199 bits (507), Expect = 4e-50
Identities = 101/247 (40%), Positives = 142/247 (57%), Gaps = 8/247 (3%)
Query: 10 MLALCLVLAKSAWSEEQEKVVHGGPCLKDSHPFQAALYTSGHLLCGGVLIDPQWVLTAAH 69
         + AL +LA
                    W++
                         + +
                               C +S P+QA L+
                                              L CG LI +W+LTAAH
Sbjct: 6 LCALLSLLAGHGWADT--RAIGAEECRPNSQPWQAGLFHLTRLFCGATLISDRWLLTAAH 63
Query: 70 CKKPNLQVILGKHNLRQTETFQRQISVDRTIVHPRYNPET----HDNDIMMVHLKNPVKF 125
         C+KP L V LG+H+L + E ++
                                    HP + N +
                               V
                                                H++DIM++ L
Sbjct: 64 CRKPYLWVRLGEHHLWKWEGPEQLFRVTDFFPHPGFNKDLSANDHNDDIMLIRLPRQARL 123
```

```
Query: 126 SKKIQPLPLKNDCSEENPNCQILGWGKMENGD--FPDTIQCADVHLVPREQCERAYPGKI 183
         S +QPL L C C I GWG + + FP T+QCA++ ++ + C AYPG I
Sbjct: 124 SPAVQPLNLSQTCVSPGMQCLISGWGAVSSPKALFPVTLQCANISILENKLCHWAYPGHI 183
Query: 184 TQSMVCAGDMKEGNDSCQGDSGGPLVCGGRLRGLVSWGDMPCGSKEKPGVYTDVCTHIRW 243
          + SM+CAG + G SCQGDSGGPLVC G L G+VS G PC +P VYT VC ++ W
Sbjct: 184 SDSMLCAGLWEGGRGSCQGDSGGPLVCNGTLAGVVSGGAEPCSRPRRPAVYTSVCHYLDW 243
Query: 244 IQNILRN 250
          IQ I+ N
Sbjct: 244 IQEIMEN 250
Poi | 57113723 | ref | XP 537938.1 | G PREDICTED: similar to KLK15 [Canis familiaris]
         Length = 643
 Score = 199 bits (507), Expect = 4e-50
Identities = 88/227 (38%), Positives = 138/227 (60%), Gaps = 12/227 (5%)
Query: 39 SHPFQAALYTSGHLLCGGVLIDPQWVLTAAHCKKPNLQVILGKHNLRQTETFQRQISVDR 98
          S +Q AL+ G CG LI WVL+AAHC+ ++ LG+HNLR+ + ++ ++ R
Sbjct: 397 SPTWQVALFERGRFNCGASLISEHWVLSAAHCQTRFMRARLGEHNLRKRDGPEQLRTLAR 456
Query: 99 TIVHPRYNPETHDNDIMMVHLKNPVKFSKKIQPLPLKNDCSEENPNCQILGWGKMENG-- 156
           I HP Y +H +D+M++ L P + S++++P+ L C +
                                                     C + GWG + +
Sbjct: 457 IIPHPLYEAHSHRHDVMLLRLTRPARLSRQVRPVALPTRCPQPAEACVVSGWGLVSDHKP 516
Query: 157 -----DFPDTIQCADVHLVPREQCERAYPGKITQSMVCAGDMKEGNDSCQGDSGG 206
                                                         G +SC+GDSGG
                      PDT+ CA++ ++P C + YPG++ SM+CAG
Sbjct: 517 GTKGSTDSQVSLPDTLHCANISVIPAASCNKDYPGRLVASMLCAGAEGGGTESCEGDSGG 576
Query: 207 PLVCGGRLRGLVSWGDMPCGSKEKPGVYTDVCTHIRWIQNILRNKWL 253
          PLVC G L+G+VSWGD+PC + KPGVYT VC+++ WI+ ++ +L
Sbjct: 577 PLVCRGVLQGIVSWGDVPCDTTTKPGVYTKVCSYLEWIKETMKRNYL 623
 Score = 87.0 bits (214), Expect = 4e-16
 Identities = 53/192 (27%), Positives = 80/192 (41%), Gaps = 50/192 (26%)
Query: 40 HPFQAALYTSGHLLCGGVLIDPQWVLTAAHC----- 70
          HP QAALY CGGVL+ P+WVLTAAHC
Sbjct: 25 HPLQAALYHYSKFQCGGVLVHPEWVLTAAHCINSKWGQGIADDGDGSERDPQRTGRDYPD 84
Query: 71 ------KKPNLQVILGKHNLRQTETFQRQISVDRTIVHPRYN------PETHD 111
                   + N Q+ LG++NL + E + + + + HP +N E +
Sbjct: 85 MCVYDKDALQGNYQLWLGRYNLFEHEDTAQLVQIRESFPHPEFNLSFLKNHTRLPEEDYS 144
Query: 112 NDIMMVHLKNPVKFSKKIQPLPLKNDCSEENPNCQILGWGKMENGDF--PDTIQCADVHL 169
           +D+M++ L P + + + + L L + C GWG +E F PD +QC D+ L
Sbjct: 145 HDLMLLRLAEPTQITDAVRVLDLPTQEPQVGSTCCASGWGCIEPDKFIYPDDLQCVDLQL 204
Query: 170 VPREQCERAYPG 181
          + + C Y G
Sbjct: 205 LSNDVCGNTYTG 216
```

```
Score = 199 bits (507), Expect = 4e-50
 Identities = 104/245 (42%), Positives = 145/245 (59%), Gaps = 5/245 (2%)
Query: 8 MKMLALCLVLAKSAWSEEQEKVVHGGPCLKDSHPFQAALYTSGHLLCGGVLIDPQWVLTA 67
         MRSLVL-LLLVGACFALEDDKIVGGYECTPYSQPWQVSLNVGYHF-CGGSLINQNWVVSA 58
Sbjct: 1
Query: 68 AHCKKPNLQVILGKHNLRQTETFQRQISVDRTIVHPRYNPETHDNDIMMVHLKNPVKFSK 127
         AHC + ++V LG+HN++ E ++ IS R I HP YN T DNDIM++ L
Sbjct: 59 AHCYQSRIEVRLGEHNIQINEGTEQFISSSRVIRHPNYNSWTIDNDIMLIKLSQSASVNN 118
Query: 128 KIQPLPLKNDCSEENPNCQILGWGK-MENGDFPDTIQCADVHLVPREQCERAYPGKITQS 186
           +QP+L+C C+GWGM++QC+V++EC+YPGIT++
Sbjct: 119 YVQPVALPSSCPPAGTWCIVSGWGNTMSSTADRNKLQCVEVPILSDEDCNNSYPGMITKA 178
Query: 187 MVCAGDMKEGNDSCQGDSGGPLVCGGRLRGLVSWGDMPCGSKEKPGVYTDVCTHIRWI-Q 245
         M CAG ++ G DSCQGDSGGP+VC G L+G+VSWG C K PGVYT VC
Sbjct: 179 MFCAGFLEGGKDSCQGDSGGPVVCNGELQGIVSWG-YGCAEKNHPGVYTKVCIFTDWIAQ 237
Query: 246 NILRN 250
         I N
Sbjct: 238 TIASN 242
Sgi|34856017|ref|XP 214931.2| G similar to kallikrein [Rattus norvegicus]
        Length = 410
 Score = 199 bits (506), Expect = 6e-50
 Identities = 94/236 (39%), Positives = 142/236 (60%), Gaps = 17/236 (7%)
Query: 26 QEKVVHGGPCLKDSHPFQAALYTSGHLLCGGVLIDPQWVLTAAHCKKPNLQVILGKHNLR 85
         Q +VV G C K+S P+Q A+ LCGGVLIDP WV+TAAHC N V+LG++NL
Sbjct: 177 QSRVVGGFKCEKNSQPWQVAVINED--LCGGVLIDPSWVITAAHCYSDNYHVLLGQNNL- 233
Query: 86 QTETFQRQISVDRTIVHPRYNP-----ETHDNDIMMVHLKNPVKFSKKIQPLPLK 135
+E Q ++ V ++ HP Y P + + ND+M++HL P + ++ L
Sbjct: 234 -SEDVQHRL-VSQSFRHPDYKPFLMRNHTRKPKDYSNDLMLLHLSEPADITDGVKVIDLP 291
Query: 136 NDCSEENPNCQILGWGKMENGD--FPDTIQCADVHLVPREQCERAYPGKITQSMVCAGDM 193
                 C + GWG + FPD +QC ++HL+ E+C +AY K+T M+CAG++
Sbjct: 292 TKEPKVGSTCLVSGWGSTNPSEWEFPDDLQCVNIHLLSNEKCIKAYKEKVTDLMLCAGEL 351
Query: 194 KEGNDSCQGDSGGPLVCGGRLRGLVSWGDMPCGSKEKPGVYTDVCTHIRWIONILR 249
         + G D+C+GDSGGPL+C G L+G+ SWG +PCG KPG+YT + WI+ +++
Sbjct: 352 EGGKDTCRGDSGGPLICDGVLQGITSWGSVPCGEPNKPGIYTKLIKFTSWIKEVMK 407
gi|1086279|pir||S49489 trypsin (EC 3.4.21.4) precursor - Paranotothenia magellanica
        Length = 242
Score = 199 bits (506), Expect = 6e-50
Identities = 94/244 (38%), Positives = 148/244 (60%), Gaps = 4/244 (1%)
```

| >gi|32402373|gb|AAP81159.1| trypsinogen [Pangasius hypophthalmus]

Length = 242

```
MKMLALCLVLAKSAWSEEQEKVVHGGPCLKDSHPFQAALYTSGHLLCGGVLIDPQWVLTA 67
Query: 8
          M+ L L++ +A++ E++K+V G C S P Q +L SG+ CGG L++ WV++A
          MRSLVFVLLIG-AAFATEEDKIVGGKECSPYSQPHQVSL-NSGYHFCGGSLVNENWVVSA 58
Sbjct: 1
Query: 68 AHCKKPNLQVILGKHNLRQTETFQRQISVDRTIVHPRYNPETHDNDIMMVHLKNPVKFSK 127
          AHC K ++V +G+H++R TE ++ IS R I HP Y+
                                                    DNDIM++ L P
Sbjct: 59 AHCYKSRVEVRMGEHHIRVTEGKEQFISSSRVIRHPNYSSYNIDNDIMLIKLSKPATLNQ 118
Query: 128 KIQPLPLKNDCSEENPNCQILGWGKMENGDFP-DTIQCADVHLVPREQCERAYPGKITQS 186
           +Q + L + C+ C + GWG ++ + +QC ++ ++
                                                        C+ +YPG IT +
Sbjct: 119 YVQAVALPSSCAPAGTMCTVSGWGSTQSSSADGNKLQCLNIPILSDRDCDNSYPGMITDA 178
Query: 187 MVCAGDMKEGNDSCQGDSGGPLVCGGRLRGLVSWGDMPCGSKEKPGVYTDVCTHIRWIQN 246
          M CAG ++ G DSCQGDSGGP+VC G L+G+VSWG C ++ PGVY VC
Sbjct: 179 MFCAGYLQGGKDSCQGDSGGPVVCNGELQGVVSWG-YGCAERDHPGVYAKVCLFNDWLET 237
Query: 247 ILRN 250
           + N
Sbjct: 238 SMAN 241
```

++ IS ++IVHP YN ET++NDIM++ LK+ + ++ + L C+

Score = 199 bits (506), Expect = 6e-50Identities = 94/236 (39%), Positives = 142/236 (60%), Gaps = 17/236 (7%)

Query: 26 QEKVVHGGPCLKDSHPFQAALYTSGHLLCGGVLIDPQWVLTAAHCKKPNLQVILGKHNLR 85 Q +VV G C K+S P+Q A+ LCGGVLIDP WV+TAAHC N V+LG++NL

```
Sbjct: 6
          QSRVVGGFKCEKNSQPWQVAVINED--LCGGVLIDPSWVITAAHCYSDNYHVLLGQNNL- 62
Query: 86 QTETFQRQISVDRTIVHPRYNP-----ETHDNDIMMVHLKNPVKFSKKIQPLPLK 135
           +E Q ++ V ++ HP Y P
                                        + + ND+M++HL P + ++ #
Sbjct: 63 -SEDVQHRL-VSQSFRHPDYKPFLMRNHTRKPKDYSNDLMLLHLSEPADITDGVKVIDLP 120
Query: 136 NDCSEENPNCQILGWGKMENGD--FPDTIQCADVHLVPREQCERAYPGKITQSMVCAGDM 193
                   C + GWG + FPD +QC ++HL+ E+C +AY K+T M+CAG++
Sbjct: 121 TKEPKVGSTCLVSGWGSTNPSEWEFPDDLQCVNIHLLSNEKCIKAYKEKVTDLMLCAGEL 180
Query: 194 KEGNDSCQGDSGGPLVCGGRLRGLVSWGDMPCGSKEKPGVYTDVCTHIRWIQNILR 249
          + G D+C+GDSGGPL+C G L+G+ SWG +PCG
                                             KPG+YT +
Sbjct: 181 EGGKDTCRGDSGGPLICDGVLQGITSWGSVPCGEPNKPGIYTKLIKFTSWIKEVMK 236
| >gi | 1552516 | gb | AAC80208.1 | trypsinogen C [Homo sapiens]
         Length = 247
 Score = 198 bits (504), Expect = 1e-49
 Identities = 93/227 (40%), Positives = 139/227 (61%), Gaps = 4/227 (1%)
Query: 24 EEQEKVVHGGPCLKDSHPFQAALYTSGHLLCGGVLIDPQWVLTAAHCKKPNLQVILGKHN 83
          ++ +K+V G C ++S P+Q +L + H CGG LI QWV++A HC KP++QV LG+HN
Sbjct: 19 DDDDKIVGGYTCEENSVPYQVSLNSGSHF-CGGSLISEQWVVSAGHCYKPHIQVRLGEHN 77
Query: 84 LRQTETFQRQISVDRTIVHPRYNPETHDNDIMMVHLKNPVKFSKKIQPLPLKNDCSEENP 143
              E ++ I+ + I HP+YN T +NDIM++ L P + + + L
Sbjct: 78 IEVLEGNEQFINAAKIIRHPKYNRITLNNDIMLIKLSTPAVINAHVSTISLPTAPPAAGT 137
Query: 144 NCQILGWGK--MENGDFPDTIQCADVHLVPREQCERAYPGKITQSMVCAGDMKEGNDSCQ 201
                        D+PD +QC D ++ + +C+ +YP KIT M C G ++ G DSCQ
           C I GWG
Sbjct: 138 ECLISGWGNTLSSGADYPDELQCLDAPVLTQAKCKASYPLKITSKMFCVGFLEGGKDSCQ 197
Query: 202 GDSGGPLVCGGRLRGLVSWGDMPCGSKEKPGVYTDVCTHIRWIONIL 248
          GDSGGP+VC G+L+G+VSWG C K +PGVYT V ++ WI++ +
Sbjct: 198 GDSGGPVVCNGQLQGIVSWG-YGCAQKRRPGVYTKVYNYVDWIKDTI 243
gi|51094519|gb|EAL23774.1| G protease, serine, 2 (trypsin 2) [Homo sapiens]
 gi | 4506147 | ref | NP 002761.1 | G protease, serine, 2 preproprotein [Homo sapiens]
gi | 88942 | pir | | B25852 trypsin (EC 3.4.21.4) II precursor [validated] - human
gi|1552517|gb|AAC80209.1| G trypsinogen E [Homo sapiens]
gi|136413|sp|P07478|TRY2 HUMAN G Trypsin II precursor (Anionic trypsinogen)
 gi|521218|qb|AAA61232.1| G trypsinogen
gi | 224982 | prf | | 1205235B
                         trypsinogen II
         Length = 247
 Score = 198 bits (504), Expect = 1e-49
 Identities = 95/245 (38%), Positives = 147/245 (60%), Gaps = 4/245 (1%)
Query: 6
          LTMKMLALCLVLAKSAWSEEQEKVVHGGPCLKDSHPFQAALYTSGHLLCGGVLIDPQWVL 65
          + + + + + A +A ++ +K+V G C ++S P+Q +L SG+ CGG LI QWV+
Sbjct: 1
          MNLLLILTFVAAAVAAPFDDDDKIVGGYICEENSVPYOVSL-NSGYHFCGGSLISEOWVV 59
Query: 66 TAAHCKKPNLQVILGKHNLRQTETFQRQISVDRTIVHPRYNPETHDNDIMMVHLKNPVKF 125
```

```
Sbjct: 60 SAGHCYKSRIQVRLGEHNIEVLEGNEQFINAAKIIRHPKYNSRTLDNDILLIKLSSPAVI 119
Query: 126 SKKIQPLPLKNDCSEENPNCQILGWGKM--ENGDFPDTIQCADVHLVPREQCERAYPGKI 183
          + ++ + L I GWG
                                     D+PD +QC D ++ + +CE +YPGKI
Sbjct: 120 NSRVSAISLPTAPPAAGTESLISGWGNTLSSGADYPDELQCLDAPVLSQAECEASYPGKI 179
Query: 184 TQSMVCAGDMKEGNDSCQGDSGGPLVCGGRLRGLVSWGDMPCGSKEKPGVYTDVCTHIRW 243
          T +M C G ++ G DSCQGDSGGP+V G L+G+VSWG C K +PGVYT V ++ W
Sbjct: 180 TNNMFCVGFLEGGKDSCQGDSGGPVVSNGELQGIVSWG-YGCAQKNRPGVYTKVYNYVDW 238
Query: 244 IQNIL 248
          I++ +
Sbjct: 239 IKDTI 243
| >qi|55629564|ref|XP 519441.1| | G PREDICTED: similar to trypsinogen C [Pan troglodyte
         Length = 247
 Score = 198 bits (504), Expect = 1e-49
 Identities = 93/227 (40%), Positives = 140/227 (61%), Gaps = 4/227 (1%)
Query: 24 EEQEKVVHGGPCLKDSHPFQAALYTSGHLLCGGVLIDPQWVLTAAHCKKPNLQVILGKHN 83
          ++ +K+V G C ++S P+Q +L + H CGG LI QWV++A HC KP++QV LG+HN
Sbjct: 19 DDDDKIVGGYTCEENSVPYQVSLNSGSHF-CGGSLISEQWVVSAGHCYKPHIQVRLGEHN 77
Query: 84 LRQTETFQRQISVDRTIVHPRYNPETHDNDIMMVHLKNPVKFSKKIQPLPLKNDCSEENP 143
          + E ++ I+ + I HP+YN T +NDIM++ L P + + L
Sbjct: 78 IEVLEGNEQFINAAKIIRHPKYNRITLNNDIMLIKLSTPAVINAHVSNISLPTAPPAAGT 137
Query: 144 NCQILGWGK--MENGDFPDTIQCADVHLVPREQCERAYPGKITQSMVCAGDMKEGNDSCQ 201
           C I GWG D+PD +QC D ++ + +C+ +YP KIT +M C G ++ G DSCQ
Sbjct: 138 ECLISGWGNTLSSGADYPDELQCLDAPVLTQAKCKASYPLKITSNMFCVGFLEGGKDSCQ 197
Query: 202 GDSGGPLVCGGRLRGLVSWGDMPCGSKEKPGVYTDVCTHIRWIQNIL 248
           GDSGGP+VC G+L+G+VSWG C K +PGVYT V ++ WI++ +
Sbjct: 198 GDSGGPVVCNGQLQGIVSWG-YGCAQKRRPGVYTKVYNYVDWIKDTI 243
🎮 >qi|49259460|pdb|1V2N|T 🚨 Chain T, Potent Factor Xa Inhibitor In Complex With Bovir
           Variant X(99175190)BT
          Length = 223
 Score = 198 bits (504), Expect = 1e-49
 Identities = 93/222 (41%), Positives = 137/222 (61%), Gaps = 4/222 (1%)
Query: 29 VVHGGPCLKDSHPFQAALYTSGHLLCGGVLIDPQWVLTAAHCKKPNLQVILGKHNLRQTE 88
           +V G C ++ P+Q +L SG+ CGG LI+ QWV++AAHC K +QV LG+ N+ E
           IVGGYTCGANTVPYOVSL-NSGYHFCGGSLINSQWVVSAAHCYKSGIQVRLGEDNINVVE 59
Sbjct: 1
Query: 89 TFQRQISVDRTIVHPRYNPETHDNDIMMVHLKNPVKFSKKIQPLPLKNDCSEENPNCQIL 148
             ++ IS ++IVHP YN ET++NDIM++ LK+ + ++ + L
Sbjct: 60 GNEQFISASKSIVHPSYNSETYNNDIMLIKLKSAASLNSRVASISLPTSCASAGTQCLIS 119
Query: 149 GWG--KMENGDFPDTIQCADVHLVPREQCERAYPGKITQSMVCAGDMKEGNDSCQGDSGG 206
           GWG K +PD ++C ++ C+ A IT +M CAG ++ G D+CQGDSGG
Sbjct: 120 GWGNTKSSGTSYPDVLKCLKAPILSDSSCKSASSFIITSNMFCAGYLEGGKDACQGDSGG 179
```

+A HC K +QV LG+HN+ E ++ I+ + I HP+YN T DNDI+++ L +P

Query: 207 PLVCGGRLRGLVSWGDMPCGSKEKPGVYTDVCTHIRWIQNIL 248

P+VC G+L+G+VSWG C K KPGVYT VC ++ WI+

Sbjct: 180 PVVCSGKLQGIVSWGS-GCAQKNKPGVYTKVCNYVSWIKQTI 220

| >gi|3024066|sp|Q28773|KLK1_PAPHA Kallikrein 1 precursor (Tissue kallikrein) (Kidney/pancreas/salivary gland kallikrein)

gi|871814|gb|AAA73523.1| tissue kallikrein Length = 258

Score = 198 bits (504), Expect = 1e-49
Identities = 99/257 (38%), Positives = 147/257 (57%), Gaps = 19/257 (7%)

Query: 8 MKMLALCLVLA---KSAWSEEQEKVVHGGPCLKDSHPFQAALYTSGHLLCGGVLIDPQWV 64
M L LCL L+ A Q ++V G C S P+QAALY CGG+L+ PQWV

Sbjct: 1 MWFLVLCLALSLGGTGAAPPIQSRIVGGWEC---SQPWQAALYHFSTFQCGGILVHPQWV 57

Query: 65 LTAAHCKKPNLQVILGKHNLRQTETFQRQISVDRTIVHPRYN------PETHDND 113 LTAAHC N O+ LG+HNL E + + V + HP +N E + +D

Sbjct: 58 LTAAHCIGDNYQLWLGRHNLFDDEDTAQFVHVSESFPHPCFNMSLLKNHTRQADEDYSHD 117

Query: 114 IMMVHLKNPVKFSKKIQPLPLKNDCSEENPNCQILGWGKME--NGDFPDTIQCADVHLVP 171
+M++ L P + + + O + L E C GWG +E N +PD +OC D+ ++P

Sbjct: 118 LMLLRLTQPAEITDAVQVVELPTQEPEVGSTCLASGWGSIEPENFSYPDDLQCVDLKILP 177

Query: 172 REQCERAYPGKITQSMVCAGDMKEGNDSCQGDSGGPLVCGGRLRGLVSWGDMPCGSKEKP 231

++C +A+ K+T+ M+CAG ++ G D+C GDSGGPL C G L+G+ SWG +PCGS KP

Sbjct: 178 NDKCAKAHTQKVTEFMLCAGHLEGGKDTCVGDSGGPLTCDGVLQGVTSWGYIPCGSPNKP 237

Query: 232 GVYTDVCTHIRWIQNIL 248

V+ V ++++WI++ +

Sbjct: 238 AVFVRVLSYVKWIEDTI 254

Score = 198 bits (503), Expect = 1e-49
Identities = 94/227 (41%), Positives = 144/227 (63%), Gaps = 5/227 (2%)

Query: 24 EEQEKVVHGGPCLKDSHPFQAALYTSGHLLCGGVLIDPQWVLTAAHCKKPNLQVILGKHN 83 ++ +K+V G C ++S P+Q +L + H CGG LI QWV++AAHC K +QV LG+HN

Sbjct: 32 DDDDKIVGGYTC-ENSLPYQVSLNSGSHF-CGGSLISEQWVVSAAHCYKTRIQVRLGEHN 89

Query: 84 LRQTETFQRQISVDRTIVHPRYNPETHDNDIMMVHLKNPVKFSKKIQPLPLKNDCSEENP 143 ++ E ++ I+ + I HP+YN +T DNDIM++ L +P + ++ + L

Sbjct: 90 IKVLEGNEQFINAAKIIRHPKYNRDTLDNDIMLIKLSSPAVINARVSTISLPTAPPAAGT 149

Query: 144 NCQILGWGKMEN--GDFPDTIQCADVHLVPREQCERAYPGKITQSMVCAGDMKEGNDSCQ 201 C I GWG + D+PD ++C D ++ ++C+ +YPGKIT SM C G ++ G DSCQ

Sbjct: 150 ECLISGWGNTLSFGADYPDELKCLDAPVLTQAECKASYPGKITNSMFCVGFLEGGKDSCQ 209

Query: 202 GDSGGPLVCGGRLRGLVSWGDMPCGSKEKPGVYTDVCTHIRWIQNIL 248

DSGGP+VC G+L+G+VSWG C K +PGVYT V ++ WI++ +

Sbjct: 210 RDSGGPVVCNGQLQGVVSWGH-GCAWKNRPGVYTKVYNYVDWIKDTI 255

Score = 198 bits (503), Expect = 1e-49Identities = 94/227 (41%), Positives = 144/227 (63%), Gaps = 5/227 (2%)

Query: 24 EEQEKVVHGGPCLKDSHPFQAALYTSGHLLCGGVLIDPQWVLTAAHCKKPNLQVILGKHN 83 ++ +K+V G C ++S P+Q +L + H CGG LI QWV++AAHC K +QV LG+HN

Sbjct: 32 DDDDKIVGGYTC-ENSLPYQVSLNSGSHF-CGGSLISEQWVVSAAHCYKTRIQVRLGEHN 89

Query: 84 LRQTETFQRQISVDRTIVHPRYNPETHDNDIMMVHLKNPVKFSKKIQPLPLKNDCSEENP 143 ++ E ++ I+ + I HP+YN +T DNDIM++ L +P + ++ L

Sbjct: 90 IKVLEGNEQFINAAKIIRHPKYNRDTLDNDIMLIKLSSPAVINARVSTISLPTAPPAAGT 149

Query: 144 NCQILGWGKMEN--GDFPDTIQCADVHLVPREQCERAYPGKITQSMVCAGDMKEGNDSCQ 201 C I GWG + D+PD ++C D ++ ++ +C+ +YPGKIT SM C G ++ G DSCQ

Sbjct: 150 ECLISGWGNTLSFGADYPDELKCLDAPVLTQAECKASYPGKITNSMFCVGFLEGGKDSCQ 209

Query: 202 GDSGGPLVCGGRLRGLVSWGDMPCGSKEKPGVYTDVCTHIRWIQNIL 248
DSGGP+VC G+L+G+VSWG C K +PGVYT V ++ WI++ +

Sbjct: 210 RDSGGPVVCNGQLQGVVSWGH-GCAWKNRPGVYTKVYNYVDWIKDTI 255

>gi|51539252|gb|AAU06121.1| trypsinogen [Takifugu rubripes] Length = 235

Score = 197 bits (502), Expect = 2e-49 Identities = 100/230 (43%), Positives = 141/230 (61%), Gaps = 7/230 (3%)

Query: 25 EQEKVVHGGPCLKDSHPFQAALYTSGHLLCGGVLIDPQWVLTAAHC--KKPNLQVILGKH 82 E +++ G C S P+ A+L G+ CGGVLI+ QWVL+ AHC +QV+LG+H

Sbjct: 5 EDGRIIGGQECEPHSRPYMASL-NYGYHFCGGVLINKQWVLSVAHCWYNPYAMQVMLGEH 63

Query: 83 NLRQTETFQRQISVDRTIVHPRYNPETHDNDIMMVHLKNPVKFSKKIQPLPLKNDCSEEN 142 ++R E ++ + D I HP Y+ +T D+DIM++ L +PV+ ++ + P+ L C

Sbjct: 64 DVRVFEGTEQLMKTDTIIWHPDYDYQTLDHDIMLIKLFHPVEVTESVAPISLPTGCPYGG 123

Query: 143 PNCQILGWGKM-ENGD--FPDTIQCADVHLVPREQCERAYPGKITQSMVCAGDMKEGNDS 199 C + GWG +GD P+ +QC DV V E CE+AYPG IT+ MVCAG M G D+

Sbjct: 124 MPCSVSGWGNTASSGDAIMPNRLQCLDVPAVSNEDCEKAYPGMITRRMVCAGYMDGGRDA 183

Query: 200 CQGDSGGPLVCGGRLRGLVSWGDMPCGSKEKPGVYTDVCTHIRWIQNILR 249 C GDSG PLVC G ++GLVSWG C E PGVY VC + WI+++L+

Sbjct: 184 CNGDSGSPLVCFGEVQGLVSWG-QGCALPEYPGVYVKVCEFLYWIEDVLQ 232

>gi|4809136|gb|AAD30107.1| trypsinogen-like serine protease [Notothenia coriiceps] Length = 249

Score = 197 bits (502), Expect = 2e-49Identities = 105/247 (42%), Positives = 144/247 (58%), Gaps = 8/247 (3%)

Query: 8 MKMLALCLVL-AKSAWSEEQEKVVHGGPCLKDSHPFQAALYTSGHLLCGGVLIDPQWVLT 66 M +LAL L++ A +A E ++V G C S P+ A+L G+ CGGVLI+ QWVL+

```
Query: 67 AAHC--KKPNLQVILGKHNLRQTETFQRQISVDRTIVHPRYNPETHDNDIMMVHLKNPVK 124
                    +QVILG HNLR E ++ + D I HP Y+ +T D DIM++ L +PV+
           AHC
Sbjct: 60 VAHCWYNPYYMQVILGDHNLRVFEGTEQLMKTDTIIWHPSYDYQTLDFDIMLIKLYHPVE 119
Ouery: 125 FSKKIQPLPLKNDCSEENPNCQILGWGKMENGD---FPDTIQCADVHLVPREQCERAYPG 181
                                      G P +QC +V +V + CE AYPG
                            +C + GWG
           ++ + P+PL
                     С
Sbjct: 120 VTEAVAPIPLPTRCPYGGLSCSVSGWGNTNLGGEVYMPTLLQCLNVPIVDLQVCENAYPG 179
Query: 182 KITQSMVCAGDMKEGNDSCQGDSGGPLVCGGRLRGLVSWGDMPCGSKEKPGVYTDVCTHI 241
                                                  C
           I+ MVCAG M+ G D+C GDSG PLVC G ++GLVSWG
                                                         PGVY +C
Sbjct: 180 MISPRMVCAGYMEGGKDACNGDSGSPLVCDGEVQGLVSWG-QGCAEPNYPGVYVKLCEFH 238
Query: 242 RWIQNIL 248
           W + +L
Sbjct: 239 SWFEEVL 245
Length = 237
Score = 197 bits (502), Expect = 2e-49
 Identities = 94/235 (40%), Positives = 143/235 (60%), Gaps = 3/235 (1%)
Query: 15 LVLAKSAWSEEQEKVVHGGPCLKDSHPFQAALYTSGHLLCGGVLIDPQWVLTAAHCKKPN 74
          + A +A +E +K+V G C K+S +Q +L SG+ CGG L++ WV++AAHC K
Sbjct: 2
          IAAAYAAPIDEDDKIVGGYECRKNSVAYQVSL-NSGYHFCGGSLVNENWVVSAAHCYKSR 60
Query: 75 LQVILGKHNLRQTETFQRQISVDRTIVHPRYNPETHDNDIMMVHLKNPVKFSKKIQPLPL 134
          + V LG+HN+R E ++ IS R I HP Y+
                                             DNDIM++ L P
Sbjct: 61 VVVRLGEHNIRANEGTEQFISSSRVIRHPNYSSYNIDNDIMLIKLSKPATLNQYVQPVAL 120
Query: 135 KNDCSEENPNCQILGWGK-MENGDFPDTIQCADVHLVPREQCERAYPGKITQSMVCAGDM 193
                                   + +QC ++ ++
                                                 CE +YPG IT +M CAG +
                    C++ GWG M +
Sbjct: 121 PSSCAAAGTMCKVSGWGNTMSSTADRNKLQCLNIPILSDRDCENSYPGMITDAMFCAGYL 180
Ouery: 194 KEGNDSCQGDSGGPLVCGGRLRGLVSWGDMPCGSKEKPGVYTDVCTHIRWIQNIL 248
                            L+G+VSWG C ++ PGVY VC
          + G DSCOGDSGGP+VC
Sbjct: 181 EGGKDSCQGDSGGPVVCNNELQGVVSWG-YGCAERDHPGVYAKVCLFNDWLESTM 234
sgi|13994131|ref|NP 113711.1| G nerve growth factor, gamma [Rattus norvegicus]
 qi|51261180|qb|AAH78784.1| G Nerve growth factor, gamma [Rattus norvegicus]
 gi|220794|dbj|BAA00346.1| G kallikrein precursor [Rattus norvegicus]
 gi|67565|pir||KQRTP
                      tissue kallikrein (EC 3.4.21.35) precursor - rat
 gi|205030|gb|AAA41464.1| G PS kallikrein
                          true tissue kallikrein
 gi|364506|prf||1508215A
         Length = 265
 Score = 197 bits (501), Expect = 2e-49
 Identities = 98/260 (37%), Positives = 148/260 (56%), Gaps = 16/260 (6%)
Ouery: 6 LTMKMLALCLVLA---KSAWSEEQEKVVHGGPCLKDSHPFQAALYTSGHLLCGGVLIDPQ 62
                                Q +VV G C +S P+Q A+Y G LCGGVLIDP
          +TM L L L L+
                           Α
          VTMWFLILFLALSLGRNDAAPPVQSRVVGGYNCEMNSQPWQVAVYYFGEYLCGGVLIDPS 62
Sbict: 3
```

Sbjct: 1 MTLLALLLLIGAAAAVPREDGRIVGGYECSPHSRPYMASL-NYGYHFCGGVLINNQWVLS 59

```
Ouery: 63 WVLTAAHCKKPNLQVILGKHNLRQTETFQRQISVDRTIVHPRYNPET-------HD 111
         WV+TAAHC N QV LG++NL + E F + V ++ HP +N +
Sbjct: 63 WVITAAHCATDNYQVWLGRNNLYEDEPFAQHRLVSQSFPHPGFNQDLIWNHTRQPGDDYS 122
Query: 112 NDIMMVHLKNPVKFSKKIQPLPLKNDCSEENPNCQILGWGKM--ENGDFPDTIQCADVHL 169
         ND+M++L P + ++ L + + C GWG + + + D +QC ++ L
Sbjct: 123 NDLMLHLSQPADITDGVKVIDLPIEEPKVGSTCLASGWGSITPDGLELSDDLQCVNIDL 182
Query: 170 VPREQCERAYPGKITQSMVCAGDMKEGNDSCQGDSGGPLVCGGRLRGLVSWGDMPCGSKE 229
         + E+C A+ ++T M+CAG+M G D+C+GDSGGPL+C G L+G+ SWG PCG +
Sbjct: 183 LSNEKCVEAHKEEVTDLMLCAGEMDGGKDTCKGDSGGPLICNGVLQGITSWGFNPCGEPK 242
Query: 230 KPGVYTDVCTHIRWIQNILR 249
         KPG+YT +
                     WI+ +++
Sbjct: 243 KPGIYTKLIKFTPWIKEVMK 262
(T-kininogenase) (K10) (Proteinase B) (Endopeptidase K)
          [Rattus norvegicus]
        Length = 374
 Score = 197 bits (501), Expect = 2e-49
 Identities = 101/265 (38%), Positives = 150/265 (56%), Gaps = 19/265 (7%)
         PMKMLTMKML-ALCLVLAKS---AWSEEQEKVVHGGPCLKDSHPFQAALYTSGHLLCGGV 57
         PKL+KML + LLS A Q ++V G CK+SP+QA+ LCGGV
Sbjct: 109 PDKSLSAKMLQCVDLTLMSSDVYAAPPGQSRIVGGYKCEKNSQPWQVAIINE--YLCGGV 166
Ouery: 58 LIDPOWVLTAAHCKKPNLQVILGKHNLRQTETFQRQISVDRTIVHPRYNP------ 107
         LIDP WV+TAAHC V+LG++NL + E F + V+++ HP Y P
Sbjct: 167 LIDPSWVITAAHCYSNYYHVLLGRNNLFEDEPFAQYRFVNQSFPHPDYKPFLMRNHTRQR 226
Query: 108 -ETHDNDIMMVHLKNPVKFSKKIQPLPLKNDCSEENPNCQILGWGKME--NGDFPDTIQC 164
          + + ND+M++HL P + ++ + L + + C GWG + N + PD +QC
Sbjct: 227 GDDYSNDLMLLHLSEPADITDGVKVIDLPTEEPKVGSTCLASGWGSTKPLNWELPDDLQC 286
Query: 165 ADVHLVPREQCERAYPGKITQSMVCAGDMKEGNDSCQGDSGGPLVCGGRLRGLVSWGDMP 224
          ++HL+ E+C AY K+T M+CAG+M D+C+GDSGGPL+C G L+G+ SWG++P
Sbjct: 287 VNIHLLSNEKCIEAYEQKVTDLMLCAGEMDGRKDTCKGDSGGPLICDGVLQGITSWGNVP 346
Query: 225 CGSKEKPGVYTDVCTHIRWIQNILR 249
               PGVYT +
                         WI+ +++
Sbjct: 347 CAEPYNPGVYTKLIKFTSWIKEVMK 371
dog [Canis familiaris]
        Length = 769
 Score = 197 bits (501), Expect = 2e-49
 Identities = 93/215 (43%), Positives = 141/215 (65%), Gaps = 4/215 (1%)
Query: 23 SEEQEKVVHGGPCLKDSHPFQAALYTSGHLLCGGVLIDPQWVLTAAHCKKPNLQVILGKH 82
         +++ +K+V G C ++S P+Q +L +G+ CGG LI QWV++AAHC K +QV LG++
Sbjct: 262 TDDDDKIVGGYTCEENSVPYQVSL-NAGYHFCGGSLISDQWVVSAAHCYKSRIQVRLGEY 320
```

- Query: 83 NLRQTETFQRQISVDRTIVHPRYNPETHDNDIMMVHLKNPVKFSKKIQPLPLKNDCSEEN 142 N+ E ++ I+ + I HP YN DNDIM++ L +P + ++ + L C+
- Sbjct: 321 NIDVLEGNEQFINSAKVIRHPNYNSWILDNDIMLIKLSSPAVLNARVATISLPRACAAPG 380
- Query: 143 PNCQILGWGK-MENG-DFPDTIQCADVHLVPREQCERAYPGKITQSMVCAGDMKEGNDSC 200
- C I GWG + +G ++P+ +QC D ++ + QCE +YPG+IT++M+CAG ++ G DSC
- Sbjct: 381 TQCLISGWGNTLSSGTNYPELLQCLDAPILTQAQCEASYPGQITENMICAGFLEGGKDSC 440
- Query: 201 QGDSGGPLVCGGRLRGLVSWGDMPCGSKEKPGVYT 235
 - QGDSGGP+VC G L+G+VSWG C K KPGVYT
- Sbjct: 441 QGDSGGPVVCNGELQGIVSWG-YGCAQKNKPGVYT 474
- | >gi | 33126583 | gb | AAL14244.1 | G protease serine 2 isoform B [Homo sapiens]
 | Length = 261
- Score = 197 bits (501), Expect = 2e-49Identities = 93/227 (40%), Positives = 139/227 (61%), Gaps = 4/227 (1%)
- ${\tt Query:~24~EEQEKVVHGGPCLKDSHPFQAALYTSGHLLCGGVLIDPQWVLTAAHCKKPNLQVILGKHN~83}$
 - ++ +K+V G C ++S P+Q +L SG+ CGG LI QWV++A HC K +QV LG+HN
- Sbjct: 33 DDDDKIVGGYICEENSVPYQVSL-NSGYHFCGGSLISEQWVVSAGHCYKSRIQVRLGEHN 91
- Query: 84 LRQTETFQRQISVDRTIVHPRYNPETHDNDIMMVHLKNPVKFSKKIQPLPLKNDCSEENP 143
- + E ++ I+ + I HP+YN T DNDI+++ L +P + ++ L
- Sbjct: 92 IEVLEGNEQFINAAKIIRHPKYNSRTLDNDILLIKLSSPAVINSRVSAISLPTAPPAAGT 151
- Query: 144 NCQILGWGKM--ENGDFPDTIQCADVHLVPREQCERAYPGKITQSMVCAGDMKEGNDSCQ 201
- I GWG D+PD +QC D ++ + +CE +YPGKIT +M C G ++ G DSCQ Sbjct: 152 ESLISGWGNTLSSGADYPDELQCLDAPVLSQAECEASYPGKITNNMFCVGFLEGGKDSCQ 211
- Query: 202 GDSGGPLVCGGRLRGLVSWGDMPCGSKEKPGVYTDVCTHIRWIQNIL 248
 - GDSGGP+V G L+G+VSWG C K +PGVYT V ++ WI++ +
- Sbjct: 212 GDSGGPVVSNGELQGIVSWG-YGCAQKNRPGVYTKVYNYVDWIKDTI 257
- | >gi | 20988034 | gb | AAH30260.1 | G | PRSS2 protein [Homo sapiens] | Length = 239
- Score = 197 bits (501), Expect = 2e-49
 Identities = 95/241 (39%), Positives = 144/241 (59%), Gaps = 4/241 (1%)
 - Query: 6 LTMKMLALCLVLAKSAWSEEQEKVVHGGPCLKDSHPFQAALYTSGHLLCGGVLIDPQWVL 65
 - + + ++ + A +A ++ +K+V G C ++S P+Q +L SG+ CGG LI QWV+
 - Sbjct: 1 MNLLLILTFVAAAVAAPFDDDDKIVGGYICEENSVPYQVSL-NSGYHFCGGSLISEQWVV 59
 - Query: 66 TAAHCKKPNLQVILGKHNLRQTETFQRQISVDRTIVHPRYNPETHDNDIMMVHLKNPVKF 125
 - +A HC K +QV LG+HN+ E ++ I+ + I HP+YN T DNDI+++ L +P
 - Sbjct: 60 SAGHCYKSRIQVRLGEHNIEVLEGNEQFINAAKIIRHPKYNSRTLDNDILLIKLSSPAVI 119
 - Query: 126 SKKIQPLPLKNDCSEENPNCQILGWGKM--ENGDFPDTIQCADVHLVPREQCERAYPGKI 183
 - + ++ + L I GWG D+PD +QC D ++ + +CE +YPGKI
 - Sbjct: 120 NSRVSAISLPTAPPAAGTESLISGWGNTLSSGADYPDELQCLDAPVLSQAECEASYPGKI 179
 - Query: 184 TQSMVCAGDMKEGNDSCQGDSGGPLVCGGRLRGLVSWGDMPCGSKEKPGVYTDVCTHIRW 243
 T +M C G ++ G DSCQGDSGGP+V G L+G+VSWG C K +PGVYT V ++ W

Sbjct: 180 TNNMFCVGFLEGGKDSCQGDSGGPVVSNGELQGIVSWG-YGCAQKNRPGVYTKVYNYVDW 238

Query: 244 I 244 I Sbjct: 239 I 239

| >gi | 56611148 | gb | AAH87751.1 | G | Hypothetical LOC496633 [Xenopus tropicalis] | gi | 58332104 | ref | NP | 001011204.1 | G | hypothetical LOC496633 [Xenopus tropicalis] | Length = 249

Score = 197 bits (501), Expect = 2e-49

Identities = 92/248 (37%), Positives = 142/248 (57%), Gaps = 6/248 (2%)

Query: 8 MKMLALCLVLAKSAWSEEQEKVVHGGPCLKDSHPFQAALYTSGHLLCGGVLIDPQWVLTA 67

M + L + +A + +K+V G C S P+Q + CGG L+ P+W+++A

Sbjct: 2 MPLWILLFLAVAAAAPLDDDKIVGGYECTPHSQPWQVYFTQENQVFCGGSLVTPRWIISA 61

Query: 68 AHCKKPNLQVI--LGKHNLRQTETFQRQISVDRTIVHPRYNPETHDNDIMMVHLKNPVKF 125 AHC + ++ LG H+L + E ++ I V+ H Y D+DIM+V L P ++

Sbjct: 62 AHCYRTPKTLVAHLGDHDLTKEEGTEQHIQVENIYKHFSYKDNDVDHDIMLVKLAKPAQY 121

Query: 126 SKKIQPLPLKNDCSEENPNCQILGWGKMEN---GDFPDTIQCADVHLVPREQCERAYPGK 182 ++ +QP+P+ C E C + G+G M + G+FPD +QC DV ++ C+ +Y G

Sbjct: 122 NQYVQPIPVARSCPREGTECLVSGYGNMRSDNIGEFPDRLQCVDVPVLSDSSCKASYRGL 181

Query: 183 ITQSMVCAGDMKEGNDSCQGDSGGPLVCGGRLRGLVSWGDMPCGSKEKPGVYTDVCTHIR 242
T++M CAG ++ G DSCQ DSGGPLVC G L G+VSWG C + PGVY VC ++

Sbjct: 182 FTENMFCAGFLEGGKDSCQVDSGGPLVCNGELYGVVSWG-QGCAERNAPGVYAKVCNYLG 240

Query: 243 WIQNILRN 250 W+Q+I+ N
Sbjct: 241 WVQDIIEN 248

>qi|3452120|gb|AAC32752.1| trypsinogen 2 precursor [Pseudopleuronectes americanus]
Length = 242

Score = 197 bits (501), Expect = 2e-49
Identities = 94/242 (38%), Positives = 144/242 (59%), Gaps = 4/242 (1%)

Query: 8 MKMLALCLVLAKSAWSEEQEKVVHGGPCLKDSHPFQAALYTSGHLLCGGVLIDPQWVLTA 67
M+ L L++ +A++ E +K+V G C S Q +L SG+ CGG L++ WV++A

Sbjct: 1 MRSLVFVLLIG-AAFALEDDKIVGGYECTPHSQAHQVSL-NSGYHFCGGSLVNENWVVSA 58

Query: 68 AHCKKPNLQVILGKHNLRQTETFQRQISVDRTIVHPRYNPETHDNDIMMVHLKNPVKFSK 127 AHC K ++V +G+H +R E ++ +S R I HP Y+ DNDIM++ L P ++

Sbjct: 59 AHCYKSRVEVRMGEHKIRVNEGTEQFVSSSRVIRHPNYDSWNIDNDIMLIKLSKPATLNQ 118

Query: 128 KIQPLPLKNDCSEENPNCQILGWGK-MENGDFPDTIQCADVHLVPREQCERAYPGKITQS 186 ++ + L + C+ C++ GWG M + D D +QC D+ ++ C AYPG IT S

Sbjct: 119 YVKTVALPSSCAPAGTMCKVSGWGNTMSSADNGDLLQCLDIPILSFSDCNNAYPGMITDS 178

Query: 187 MVCAGDMKEGNDSCQGDSGGPLVCGGRLRGLVSWGDMPCGSKEKPGVYTDVCTHIRWIQN 246 M CAG ++ G DSCQGDSGGP++C G L+G+VSWG C + PGVY VC W+++

Sbjct: 179 MFCAGYLEGGKDSCQGDSGGPVICNGELQGVVSWG-YGCAERGNPGVYAKVCLFNDWLES 237

Query: 247 IL 248

Sbjct: 238 TM 239

```
| >gi|51539247|gb|AAU06120.1| trypsinogen [Takifugu rubripes]
Length = 247
```

Score = 197 bits (500), Expect = 3e-49Identities = 99/242 (40%), Positives = 148/242 (61%), Gaps = 6/242 (2%)

Query: 11 LALCLVLAKSAWSEEQEKVVHGGPCLKDSHPFQAALYTSGHLLCGGVLIDPQWVLTAAHC 70 L L VL +A + +++V G C S P+Q ++ G+ CGG LI+ QW+++AAHC

Sbjct: 4 LVLLTVLGAAAAAPTDDRIVGGYECTAHSQPWQVSI-NIGYHYCGGSLINDQWIISAAHC 62

Query: 71 -KKPNLQV-ILGKHNLRQTETFQRQISVDRTIVHPRYNPETHDNDIMMVHLKNPVKFSKK 128 + P Q+ ILG H++ E ++ +SVD H Y+ T D DIM++ L +PV ++

Sbjct: 63 WQNPYTQIAILGDHHIWMHEGTEQYMSVDAIYWHQSYDYTTLDYDIMLLKLAHPVTQNQY 122

Query: 129 IQPLPLKNDCSEENPNCQILGWGKMENGDF--PDTIQCADVHLVPREQCERAYPGKITQS 186 ++P+ L C E C + GWG + + D P +QC +V ++ ++C+ +YPGKIT+

Sbjct: 123 VKPVALPKACPEAGDKCTVSGWGNIYSDDVFNPFNLQCVEVPILSDKECDNSYPGKITER 182

Query: 187 MVCAGDMKEGNDSCQGDSGGPLVCGGRLRGLVSWGDMPCGSKEKPGVYTDVCTHIRWIQN 246
MVCAG ++ G D+CQGDSGGPLVC L G+VSWG C PGVYT VC+ + WIO+

Sbjct: 183 MVCAGYLEGGKDACQGDSGGPLVCNNELHGIVSWG-QGCAQPNYPGVYTKVCSLLPWIQD 241

Query: 247 IL 248

+L

Sbjct: 242 VL 243

Score = 197 bits (500), Expect = 3e-49 Identities = 93/222 (41%), Positives = 135/222 (60%), Gaps = 4/222 (1%)

Query: 29 VVHGGPCLKDSHPFQAALYTSGHLLCGGVLIDPQWVLTAAHCKKPNLQVILGKHNLRQTE 88 +V G C ++ P+Q +L SG+ CGG LI+ QWV++AAHC K +QV LG+ N+ E

Sbjct: 1 IVGGYTCGANTVPYQVSL-NSGYHFCGGSLINSQWVVSAAHCYKSGIQVRLGEDNINVVE 59

Query: 89 TFQRQISVDRTIVHPRYNPETHDNDIMMVHLKNPVKFSKKIQPLPLKNDCSEENPNCQIL 148 ++ IS ++IVHP YN T +NDIM++ LK+ + ++ + L C+ C I

Sbjct: 60 GNEQFISASKSIVHPSYNSNTLNNDIMLIKLKSAASLNSRVASISLPTSCASAGTQCLIS 119

Query: 149 GWG--KMENGDFPDTIQCADVHLVPREQCERAYPGKITQSMVCAGDMKEGNDSCQGDSGG 206 GWG K +PD ++C ++ C+ A IT +M CAG ++ G DSCOGDSGG

Sbjct: 120 GWGNTKSSGTSYPDVLKCLKAPILSDSSCKSASSAIITSNMFCAGYLEGGKDSCQGDSGG 179

Query: 207 PLVCGGRLRGLVSWGDMPCGSKEKPGVYTDVCTHIRWIQNIL 248 P+VC G+L+G+VSWG C K KPGVYT VC ++ WI+ + Sbjct: 180 PVVCSGKLQGIVSWGS-GCAQKNKPGVYTKVCNYVSWIKQTI 220

Score = 197 bits (500), Expect = 3e-49Identities = 93/222 (41%), Positives = 140/222 (63%), Gaps = 4/222 (1%)

Query: 29 VVHGGPCLKDSHPFQAALYTSGHLLCGGVLIDPQWVLTAAHCKKPNLQVILGKHNLRQTE 88 +V G C ++S P+Q +L + H CGG LI QWV++AAHC K +QV LG+HN++ E Sbjct: 1 IVGGYTCEENSLPYQVSLNSGSHF-CGGSLISEQWVVSAAHCYKTRIQVRLGEHNIKVLE 59

Query: 89 TFQRQISVDRTIVHPRYNPETHDNDIMMVHLKNPVKFSKKIQPLPLKNDCSEENPNCQIL 148

++ I+ + I HP+YN +T DNDIM++ L +P + ++ + L C I
Sbjct: 60 GNEQFINAVKIIRHPKYNRDTLDNDIMLIKLSSPAVINARVSTISLPTAPPAAGTECLIS 119

Query: 149 GWGKMEN--GDFPDTIQCADVHLVPREQCERAYPGKITQSMVCAGDMKEGNDSCQGDSGG 206 GWG + D+PD ++C D ++ ++ +C+ +YPGKIT SM C G ++ G DSCQ DSGG

Sbjct: 120 GWGNTLSFGADYPDELKCLDAPVLTQAECKASYPGKITNSMFCVGFLEGGKDSCQRDSGG 179

Query: 207 PLVCGGRLRGLVSWGDMPCGSKEKPGVYTDVCTHIRWIQNIL 248 P+VC G+L+G+VSWG C K +PGVYT V ++ WI++ +

Sbjct: 180 PVVCNGQLQGVVSWGH-GCAWKNRPGVYTKVYNYVDWIKDTI 220

Score = 197 bits (500), Expect = 3e-49Identities = 91/228 (39%), Positives = 134/228 (58%), Gaps = 8/228 (3%)

Query: 29 VVHGGPCLKDSHPFQAALYTSGHLLCGGVLIDPQWVLTAAHCKKPNLQVILGKHNLRQTE 88 ++ G C K+SHP+Q A+Y CGGVL++P+WVLTAAHCK N +V +HNL + E

Sbjct: 1 IIGGRECEKNSHPWQVAIYHYSSFQCGGVLVNPKWVLTAAHCKNDNYEVGWLRHNLFENE 60

Query: 89 TFQRQISVDRTIVHPRYN----PETHDNDIMMVHLKNPVKFSKKIQPLPLKNDCSEENPN 144 + V HP +N + + +D+M++ L++P K + ++ L L E

Sbjct: 61 NTAQFFGVTADFPHPGFNLSADGKDYSHDLMLLRLQSPAKITDAVKVLELPTQEPELGST 120

Query: 145 CQILGWGKMENG----DFPDTIQCADVHLVPREQCERAYPGKITQSMVCAGDMKEGNDSC 200 C+ GWG +E G +FPD IQC + L+ C A P K+T+SM+CAG + G D+C

Sbjct: 121 CEASGWGSIEPGPDDFEFPDEIQCVQLTLLQNTFCAHABPBKVTESMLCAGYLPGGKDTC 180

Query: 201 QGDSGGPLVCGGRLRGLVSWGDMPCGSKEKPGVYTDVCTHIRWIQNIL 248 GDSGGPL+C G +G+ SWG PCGS KP +YT + ++ WI + +

Sbjct: 181 MGDSGGPLICNGMWQGITSWGHTPCGSANKPSIYTKLIFYLDWIBBTI 228

>gi | 13516893 | dbj | BAB40330.1 | trypsinogen II [Engraulis japonicus] Length = 241

Score = 196 bits (499), Expect = 4e-49Identities = 94/234 (40%), Positives = 141/234 (60%), Gaps = 3/234 (1%)

Query: 15 LVLAKSAWSEEQEKVVHGGPCLKDSHPFQAALYTSGHLLCGGVLIDPQWVLTAAHCKKPN 74

```
LVL +A++E+ +K+V G C S P Q +L SG+ CGG L+ WV++AAHC K
Sbjct: 7 LVLLGAAFAED-DKIVGGYECQPYSQPHQVSL-NSGYHFCGGSLVSDSWVVSAAHCYKSR 64

Query: 75 LQVILGKHNLRQTETFQRQISVDRTIVHPRYNPETHDNDIMMVHLKNPVKFSKKIQPLPL 134
++V +G+H++ TE ++ I R I HP+Y+ DNDIM++ L P ++ +Q + L
Sbjct: 65 VEVRMGEHHIGMTEGNEQFIDSSRVIRHPQYDSYNIDNDIMLIKLSKPATLNQYVQTVAL 124

Query: 135 KNDCSEENPNCQILGWGKMENGDFPDTIQCADVHLVPREQCERAYPGKITQSMVCAGDMK 194
```

Sbjct: 125 PSSCAPAGTMCLVSGWGNTMSNVSGDKLQCLQIPILSDRDCKNSYPGMITESMFCAGYLE 184

Query: 195 EGNDSCQGDSGGPLVCGGRLRGLVSWGDMPCGSKEKPGVYTDVCTHIRWIQNIL 248
G DSCQGDSGGP+VC G L+G+VSWG C ++ PGVY VC WI + +
Sbjct: 185 GGKDSCQGDSGGPVVCNGELQGIVSWG-YGCAERDHPGVYAKVCLFNDWIDSTM 237

+

C + GWG

>gi | 1399811 | gb | AAB57732.1 | pretrypsinogen-like serine protease [Dissostichus mawsor Length = 249

D +QC + ++ C+ +YPG IT+SM CAG ++

Score = 196 bits (499), Expect = 4e-49Identities = 102/247 (41%), Positives = 147/247 (59%), Gaps = 8/247 (3%)

Query: 8 MKMLALCLVL-AKSAWSEEQEKVVHGGPCLKDSHPFQAALYTSGHLLCGGVLIDPQWVLT 66
M +LAL L++ A +A E +++ G C S P+ A+L G+ CGGVLI+ OWVL+

Sbjct: 1 MTLLALLLLIGAAAAVPREDGRIIGGYECSPHSRPYMASL-NYGYHFCGGVLINNQWVLS 59

Query: 67 AAHC--KKPNLQVILGKHNLRQTETFQRQISVDRTIVHPRYNPETHDNDIMMVHLKNPVK 124
AHC ++QVILG HNLR E ++ + I HP Y+ +T D DIM++ L +PV+

Sbjct: 60 VAHCWYNPYSMQVILGDHNLRVFEGTEQLMKTNTIIWHPSYDYQTLDFDIMLIKLYHPVE 119

Query: 125 FSKKIQPLPLKNDCSEENPNCQILGWGKMENGD---FPDTIQCADVHLVPREQCERAYPG 181
++ + P+PL C +C + GWG + G P +QC +V +V ++ CE YPG

Sbjct: 120 VTEAVAPIPLPTSCPYGGLSCSVSGWGIAKLGGEAYMPTLLQCLNVPIVDQQVCENTYPG 179

Query: 182 KITQSMVCAGDMKEGNDSCQGDSGGPLVCGGRLRGLVSWGDMPCGSKEKPGVYTDVCTHI 241
I+ +MVCAG M+ G D+C GDSG PLVC G ++GLVSWG C PGVY +C

Sbjct: 180 LISTTMVCAGYMEGGKDACNGDSGSPLVCDGEVQGLVSWG-QGCAEPNYPGVYVKLCEFH 238

Query: 242 RWIQNIL 248 W + +L Sbjct: 239 SWFEEVL 245

| >gi | 58257842 | gb | AAW69361.1 | Try4 [Macaca mulatta] Length = 248

Score = 196 bits (499), Expect = 4e-49 Identities = 95/234 (40%), Positives = 146/234 (62%), Gaps = 5/234 (2%)

Query: 18 AKSAWSEEQEKVVHGGPCLKDSHPFQAALYTSGHLLCGGVLIDPQWVLTAAHCKKPNLQV 77
A +A ++ +K+V G C ++S P+Q +L G+ CGG LI+ QWV++AAHC KP +QV

Sbjct: 13 AVAAPFDDDDKIVGGYTCEENSVPYQVSL-NYGYHFCGGSLINKQWVVSAAHCYKPRIQV 71

Query: 78 ILGKHNLRQTETFQRQISVDRTIVHPRYNP-ETHDNDIMMVHLKNPVKFSKKIQPLPLKN 136 LG+HN+ E ++ I+ + I HP+YN + ++NDIM++ L P + ++ L

Sbjct: 72 RLGEHNIEVLEGTEQFINAAKIIPHPKYNEVKKYNNDIMLIKLSTPAVINARVSTISLPT 131

```
KID=1110912140-32309-1043243/4103.DLA31Q4,
Query: 137 DCSEENPNCQILGWGK--MENGDFPDTIQCADVHLVPREQCERAYPGKITQSMVCAGDMK 194
                             D+PD ++C D ++ + +CE +YPGKIT +M C G ++
                 C I GWG
Sbjct: 132 APPAPGTVCLISGWGNTLSSGADYPDELKCLDAPVLTQAECEASYPGKITSNMFCVGFLE 191
Query: 195 EGNDSCQGDSGGPLVCGGRLRGLVSWGDMPCGSKEKPGVYTDVCTHIRWIQNIL 248
           G DSCQGDSGGP+V G+L+G+VSWG C K +PGVYT V ++ WI++ +
Sbjct: 192 GGKDSCQGDSGGPVVYNGQLQGVVSWG-YGCAQKNRPGVYTKVYNYLAWIKDTI 244
☑ >gi|49259466|pdb|1V2T|T ☑ Chain T, Trypsin Inhibitor In Complex With Bovine Trypsin
          X(Ssfi.Glu)bt.B4
 X(Ssfi.Glu)bt.D1
         Length = 223
 Score = 196 bits (499), Expect = 4e-49
 Identities = 93/222 (41%), Positives = 136/222 (61%), Gaps = 4/222 (1%)
Query: 29 VVHGGPCLKDSHPFQAALYTSGHLLCGGVLIDPQWVLTAAHCKKPNLQVILGKHNLRQTE 88
          +V G C ++ P+Q +L SG+ CGG LI+ QWV++AAHC K +QV LG+ N+
Sbjct: 1 IVGGYTCGANTVPYQVSL-NSGYHFCGGSLINSQWVVSAAHCYKSGIQVRLGEDNINVVE 59
Query: 89 TFQRQISVDRTIVHPRYNPETHDNDIMMVHLKNPVKFSKKIQPLPLKNDCSEENPNCQIL 148
            ++ IS ++IVHP YN T +NDIM++ LK+ + ++ + L
Sbjct: 60 GNEQFISASKSIVHPSYNSNTLNNDIMLIKLKSAASLNSRVASISLPTSCASAGTQCLIS 119
Query: 149 GWG--KMENGDFPDTIQCADVHLVPREQCERAYPGKITQSMVCAGDMKEGNDSCQGDSGG 206
          GWG K +PD ++C ++ C+ A IT +M CAG ++ G DSCQGDSGG
Sbjct: 120 GWGNTKSSGTSYPDVLKCLKAPILSDSSCKSASSFIITSNMFCAGYLEGGKDSCQGDSGG 179
Query: 207 PLVCGGRLRGLVSWGDMPCGSKEKPGVYTDVCTHIRWIQNIL 248
          P+VC G+L+G+VSWG+ C K KPGVYT VC ++ WI+ +
Sbjct: 180 PVVCSGKLQGIVSWGE-GCAQKNKPGVYTKVCNYVSWIKQTI 220
```

>qi|1213631|emb|CAA40068.1| trypsin [Pleuronectes platessa] gi|7435607|pir||T01779 trypsin (EC 3.4.21.4) - plaice Length = 250

Score = 196 bits (498), Expect = 5e-49 Identities = 105/248 (42%), Positives = 144/248 (58%), Gaps = 9/248 (3%)

MKMLALCLVL-AKSAWSEEQEKVVHGGPCLKDSHPFQAALYTSGHLLCGGVLIDPQWVLT 66 Query: 8 M++LAL L++ A A E +++ G C S PF A+L G+ CGGVLI+ QWVL+ MRLLALLLMVGAAVAVPREDGRIIGGHECAAHSRPFMASL-NYGYHFCGGVLINNQWVLS 59 Sbjct: 1

Query: 67 AAHC--KKPNLQVILGKHNLRQTETFQRQISVDRTIVHPRYNPETHDNDIMMVHLKNPVK 124 +QV+LG+H+LR+ E ++ + D I HP Y+ +T D DIM++ L +PV+

Sbjct: 60 VAHCWYNPYAMQVMLGEHDLRKFEGTEQLMKTDTIIWHPNYDYQTLDFDIMLIKLYHPVE 119

Query: 125 FSKKIQPLPLKNDCSEENPNCQILGWGKM-ENGD---FPDTIQCADVHLVPREQCERAYP 180 S + P+PL C C + GWG +GD P +QC DV +V EQC ++YP

Sbjct: 120 VSHAVGPIPLPTSCPVAGTPCSVSGWGNTARDGDEVYLPTLLQCMDVPIVDEEQCMKSYP 179

Query: 181 GKITQSMVCAGDMKEGNDSCQGDSGGPLVCGGRLRGLVSWGDMPCGSKEKPGVYTDVCTH 240 I+ MVCAG M D+C GDSG PLVC G + GLVSWG C PGVY +C

Sbjct: 180 DMISPRMVCAGFMDGSRDACNGDSGSPLVCRGEVYGLVSWG-QGCAQPNYPGVYVKLCEF 238

Query: 241 IRWIQNIL 248

+ WI+ L

Sbjct: 239 LGWIERTL 246

| >gi | 2102686 | gb | AAB57728.1 | preprotrypsin-like protease [Dissostichus mawsoni] | Length = 249

Score = 196 bits (498), Expect = 5e-49
Identities = 102/247 (41%), Positives = 147/247 (59%), Gaps = 8/247 (3%)

Query: 8 MKMLALCLVL-AKSAWSEEQEKVVHGGPCLKDSHPFQAALYTSGHLLCGGVLIDPQWVLT 66 M +LAL L++ A +A E +++ G C S P+ A+L G+L C GVLI+ QWVL+

Sbjct: 1 MTLLALLLIGAAAAVPREDGRIIGGYECSPHSRPYMASL-NYGYLFCDGVLINNQWVLS 59

Query: 67 AAHC--KKPNLQVILGKHNLRQTETFQRQISVDRTIVHPRYNPETHDNDIMMVHLKNPVK 124
AHC ++QVILG HNLR E ++ + I HP Y+ +T D DIM++ L +PV+

Sbjct: 60 VAHCWYNPYSMQVILGDHNLRVFEGTEQLMKTNTIIWHPSYDYQTLDFDIMLIKLYHPVE 119

Query: 125 FSKKIQPLPLKNDCSEENPNCQILGWGKMENGD---FPDTIQCADVHLVPREQCERAYPG 181

++ + P+PL C +C +GWG + G P +QC +V +V ++ CE YPG

Sbjct: 120 VTEAVAPIPLPTSCPYGGLSCSVSGWGIAKLGGEAYMPTLLQCLNVPIVVQQVCENTYPG 179

Query: 182 KITQSMVCAGDMKEGNDSCQGDSGGPLVCGGRLRGLVSWGDMPCGSKEKPGVYTDVCTHI 241

I+ +MVCAG M+ G D+C GDSG PLVC G ++GLVSWG C PGVY +C

Sbjct: 180 LISTTMVCAGYMEGGKDACNGDSGSPLVCDGEVQGLVSWG-QGCAEPNYPGVYVKLCEFH 238

Query: 242 RWIQNIL 248

W + +L

Sbjct: 239 SWFEEVL 245

Score = 196 bits (498), Expect = 5e-49 Identities = 97/240 (40%), Positives = 142/240 (59%), Gaps = 3/240 (1%)

Query: 10 MLALCLVLAKSAWSEEQEKVVHGGPCLKDSHPFQAALYTSGHLLCGGVLIDPQWVLTAAH 69 M +L VL A E++K+V G C + S Q +L SG+ CGG L+ WV++AAH

Sbjct: 1 MKSLIFVLLLGAVFAEEDKIVGGYECTRHSQAHQVSL-NSGYHFCGGSLVSKDWVVSAAH 59

Query: 70 CKKPNLQVILGKHNLRQTETFQRQISVDRTIVHPRYNPETHDNDIMMVHLKNPVKFSKKI 129 C K L+V LG+H++R E ++ IS I HP Y+ DNDIM++ L P ++ +

Sbjct: 60 CYKSVLRVRLGEHHIRVNEGTEQFISSSSVIRHPNYSSYNIDNDIMLIKLTEPATLNQYV 119

Query: 130 QPLPLKNDCSEENPNCQILGWGK-MENGDFPDTIQCADVHLVPREQCERAYPGKITQSMV 188 + L +C+ + C + GWG M + D D +QC ++ ++ C +YPG ITQSM

Sbjct: 120 HAVALPTECAADATMCTVSGWGNTMSSVDDGDKLQCLNLPILSHADCANSYPGMITQSMF 179

Query: 189 CAGDMKEGNDSCQGDSGGPLVCGGRLRGLVSWGDMPCGSKEKPGVYTDVCTHIRWIQNIL 248

CAG ++ G DSCOGDSGGP+VC G L+G+VSWG C ++ PGVY VC W+++ +

Sbjct: 180 CAGYLEGGKDSCQGDSGGPVVCNGVLQGVVSWG-YGCAERDNPGVYAKVCVLSGWVRDTM 238

```
🔊 >qi|49259464|pdb|1V2R|T 🔯 Chain T, Trypsin Inhibitor In Complex With Bovine Trypsin
          X(Ssri)bt.B4
qi|49259456|pdb|1V2J|T Mariant Chain T, Benzamidine In Complex With Bovine Trypsin Variant
          Bt.C1
         Length = 223
Score = 196 bits (498), Expect = 5e-49
 Identities = 93/222 (41%), Positives = 135/222 (60%), Gaps = 4/222 (1%)
Query: 29 VVHGGPCLKDSHPFQAALYTSGHLLCGGVLIDPQWVLTAAHCKKPNLQVILGKHNLRQTE 88
          +V G C ++ P+Q +L SG+ CGG LI+ QWV++AAHC K +QV LG+ N+
          IVGGYTCGANTVPYQVSL-NSGYHFCGGSLINSQWVVSAAHCYKSGIQVRLGEDNINVVE 59
Sbjct: 1
Query: 89 TFQRQISVDRTIVHPRYNPETHDNDIMMVHLKNPVKFSKKIQPLPLKNDCSEENPNCQIL 148
            ++ IS ++IVHP YN T +NDIM++ LK+
                                               + ++ + L
Sbjct: 60 GNEQFISASKSIVHPSYNSNTLNNDIMLIKLKSAASLNSRVASISLPTSCASAGTQCLIS 119
Query: 149 GWG--KMENGDFPDTIQCADVHLVPREQCERAYPGKITQSMVCAGDMKEGNDSCQGDSGG 206
                     +PD ++C
                                      C+ A
                                              IT +M CAG ++ G DSCQGDSGG
Sbjct: 120 GWGNTKSSGTSYPDVLKCLKAPILSDSSCKSASSRIITSNMFCAGYLEGGKDSCQGDSGG 179
Query: 207 PLVCGGRLRGLVSWGDMPCGSKEKPGVYTDVCTHIRWIQNIL 248
          P+VC G+L+G+VSWG
                           C K KPGVYT VC ++ WI+ +
Sbjct: 180 PVVCSGKLQGIVSWGS-GCAQKNKPGVYTKVCNYVSWIKQTI 220
>gi | 49259463 | pdb | 1V2Q | T
                           Chain T, Trypsin Inhibitor In Complex With Bovine Trypsin
          X(Sswi)bt.B4
         Length = 223
 Score = 196 bits (498), Expect = 5e-49
 Identities = 93/222 (41%), Positives = 135/222 (60%), Gaps = 4/222 (1%)
Query: 29 VVHGGPCLKDSHPFQAALYTSGHLLCGGVLIDPQWVLTAAHCKKPNLQVILGKHNLRQTE 88
           +V G C ++ P+Q +L SG+ CGG LI+ QWV++AAHC K +QV LG+ N+
          IVGGYTCGANTVPYQVSL-NSGYHFCGGSLINSQWVVSAAHCYKSGIQVRLGEDNINVVE 59
Sbjct: 1
Query: 89 TFQRQISVDRTIVHPRYNPETHDNDIMMVHLKNPVKFSKKIQPLPLKNDCSEENPNCQIL 148
             ++ IS ++IVHP YN T +NDIM++ LK+
                                               + ++ + L
                                                           C+
Sbjct: 60 GNEQFISASKSIVHPSYNSNTLNNDIMLIKLKSAASLNSRVASISLPTSCASAGTQCLIS 119
Query: 149 GWG--KMENGDFPDTIQCADVHLVPREQCERAYPGKITQSMVCAGDMKEGNDSCQGDSGG 206
                                      C+ A
                                              IT +M CAG ++ G DSCQGDSGG
                      +PD ++C
                                ++
           GWG K
Sbjct: 120 GWGNTKSSGTSYPDVLKCLKAPILSDSSCKSASSWIITSNMFCAGYLEGGKDSCQGDSGG 179
Query: 207 PLVCGGRLRGLVSWGDMPCGSKEKPGVYTDVCTHIRWIQNIL 248
                           C K KPGVYT VC ++ WI+ +
           P+VC G+L+G+VSWG
Sbict: 180 PVVCSGKLQGIVSWGS-GCAQKNKPGVYTKVCNYVSWIKQTI 220
```

Score = 196 bits (498), Expect = 5e-49
Identities = 97/241 (40%), Positives = 142/241 (58%), Gaps = 4/241 (1%)

Query: 10 MLALCLVLA-KSAWSEEQEKVVHGGPCLKDSHPFQAALYTSGHLLCGGVLIDPQWVLTAA 68 M++L VL +A++ E +K+V G C S P Q +L SG+ CGG L++ WV++AA

Sbjct: 1 MISLVFVLLIGAAFATEDDKIVGGYECKPYSQPHQVSL-NSGYHFCGGSLVNENWVVSAA 59

Query: 69 HCKKPNLQVILGKHNLRQTETFQRQISVDRTIVHPRYNPETHDNDIMMVHLKNPVKFSKK 128 HC K ++V LG+HN++ TE ++ IS R I HP Y+ DNDIM++ L P +

Sbjct: 60 HCYKSRVEVRLGEHNIKVTEGSEQFISSSRVIRHPNYSSYNIDNDIMLIKLSKPATLNTY 119

Query: 129 IQPLPLKNDCSEENPNCQILGWGK-MENGDFPDTIQCADVHLVPREQCERAYPGKITQSM 187 +QP+ L C+ C+GWG M+ ++QC+++++ C+YPG IT+M

Sbjct: 120 VQPVALPTSCAPAGTMCTVSGWGNTMSSTADSNKLQCLNIPILSYSDCNNSYPGMITNAM 179

Query: 188 VCAGDMKEGNDSCQGDSGGPLVCGGRLRGLVSWGDMPCGSKEKPGVYTDVCTHIRWIQNI 247
CAG ++ G DSCQGDSGGP+VC G L+G+VSWG C PGVY VC W+ +

Sbjct: 180 FCAGYLEGGKDSCQGDSGGPVVCNGELQGVVSWG-YGCAEPGNPGVYAKVCIFNDWLTST 238

Query: 248 L 248

Sbjct: 239 M 239

| >gi|547788|sp|P00758|KLK1 RAT | G Glandular kallikrein, pancreatic 1 precursor (Tissu (PS kallikrein) (RGK-1) | | gi|205009|gb|AAA41462.1| | | kallikrein | Length = 261

Score = 196 bits (497), Expect = 6e-49Identities = 96/254 (37%), Positives = 147/254 (57%), Gaps = 14/254 (5%)

Query: 10 MLALCLVLAKS-AWSEEQEKVVHGGPCLKDSHPFQAALYTSGHLLCGGVLIDPQWVLTAA 68 +L L L ++ A Q +VV G C +S P+Q A+Y G LCGGVLIDP WV+TAA

Sbjct: 5 ILFLALSLGRNDAAPPVQSRVVGGYNCEMNSQPWQVAVYYFGEYLCGGVLIDPSWVITAA 64

Query: 69 HCKKPNLQVILGKHNLRQTETFQRQISVDRTIVHPRYNPET------HDNDIMMV 117 HC N QV LG++NL + E F + V ++ HP +N + + ND+M++

Sbjct: 65 HCATDNYQVWLGRNNLYEDEPFAQHRLVSQSFPHPGFNQDLIWNHTRQPGDDYSNDLMLL 124

Query: 118 HLKNPVKFSKKIQPLPLKNDCSEENPNCQILGWGKM--ENGDFPDTIQCADVHLVPREQC 175 HL P + ++ + L + + C GWG + + + D +QC ++ L+ E+C

Sbjct: 125 HLSQPADITDGVKVIDLPIEEPKVGSTCLASGWGSITPDGLELSDDLQCVNIDLLSNEKC 184

Query: 176 ERAYPGKITQSMVCAGDMKEGNDSCQGDSGGPLVCGGRLRGLVSWGDMPCGSKEKPGVYT 235
A+ ++T M+CAG+M G D+C+GDSGGPL+C G L+G+ SWG PCG +KPG+YT

Sbjct: 185 VEAHKEEVTDLMLCAGEMDGGKDTCKGDSGGPLICNGVLQGITSWGFNPCGEPKKPGIYT 244

Query: 236 DVCTHIRWIQNILR 249

WI+ +++

Sbjct: 245 KLIKFTPWIKEVMK 258

```
G PREDICTED: similar to enamel matrix serine proteina
図>qi|57037493|ref|XP 541470.1|
          [Canis familiaris]
         Length = 314
Score = 196 bits (497), Expect = 6e-49
Identities = 93/223 (41%), Positives = 130/223 (58%), Gaps = 1/223 (0%)
Query: 29 VVHGGPCLKDSHPFQAALYTSGHLLCGGVLIDPQWVLTAAHCKKPNLQVILGKHNLRQT- 87
                                  CGGVL+ PQWVL+AAHC + + + LG H+L
                    S P+QAAL+T
          +++G C
Sbjct: 91 IINGEDCSPHSQPWQAALFTEDEFFCGGVLVHPQWVLSAAHCFQNSYTIGLGLHSLEPNQ 150
Query: 88 ETFQRQISVDRTIVHPRYNPETHDNDIMMVHLKNPVKFSKKIQPLPLKNDCSEENPNCQI 147
            R + D + I HP YN ND+M++ LK V S IQ + + + C
Sbjct: 151 EPGSRMMETDLSIQHPEYNKPFVANDLMLIKLKESVSESDTIQNISIASQCPTAGDSCLV 210
Query: 148 LGWGKMENGDFPDTIQCADVHLVPREQCERAYPGKITQSMVCAGDMKEGNDSCQGDSGGP 207
           GWG++ +G P +QC ++ +VP E C Y
                                               SM CAG ++ DSC GDSGGP
Sbjct: 211 SGWGQLIDGRQPQVLQCVNISVVPEETCNAFYAPVYHPSMFCAGGGQDRKDSCHGDSGGP 270
Query: 208 LVCGGRLRGLVSWGDMPCGSKEKPGVYTDVCTHIRWIQNILRN 250
                                 PGVYT++C
          LVC G L+GLVS+G
                         CG
                                             WIQ +++
Sbjct: 271 LVCNGSLQGLVSFGQAQCGLPHVPGVYTNLCKFKDWIQKTIQD 313
>gi|49259462|pdb|1V2P|T Chain T, Trypsin Inhibitor In Complex With Bovine Trypsin
          X(Ssyi)bt.A4
 gi|49259461|pdb|1V20|T Chain T, Trypsin Inhibitor In Complex With Bovine Trypsin V
          X(Ssyi)bt.B4
          Length = 223
 Score = 196 bits (497), Expect = 6e-49
 Identities = 93/222 (41%), Positives = 135/222 (60%), Gaps = 4/222 (1%)
Query: 29 VVHGGPCLKDSHPFQAALYTSGHLLCGGVLIDPQWVLTAAHCKKPNLQVILGKHNLRQTE 88
           +V G C ++ P+O +L SG+ CGG LI+ QWV++AAHC K +QV LG+ N+
          IVGGYTCGANTVPYQVSL-NSGYHFCGGSLINSQWVVSAAHCYKSGIQVRLGEDNINVVE 59
Sbjct: 1
Query: 89 TFQRQISVDRTIVHPRYNPETHDNDIMMVHLKNPVKFSKKIQPLPLKNDCSEENPNCQIL 148
            ++ IS ++IVHP YN T +NDIM++ LK+ + ++ L
                                                         C+
Sbjct: 60 GNEQFISASKSIVHPSYNSNTLNNDIMLIKLKSAASLNSRVASISLPTSCASAGTQCLIS 119
Query: 149 GWG--KMENGDFPDTIQCADVHLVPREQCERAYPGKITQSMVCAGDMKEGNDSCQGDSGG 206
                                             IT +M CAG ++ G DSCQGDSGG
                     +PD ++C
                              ++
                                      C+ A
           GWG K
Sbjct: 120 GWGNTKSSGTSYPDVLKCLKAPILSDSSCKSASSYIITSNMFCAGYLEGGKDSCQGDSGG 179
Query: 207 PLVCGGRLRGLVSWGDMPCGSKEKPGVYTDVCTHIRWIQNIL 248
                           C K KPGVYT VC ++ WI+ +
           P+VC G+L+G+VSWG
Sbjct: 180 PVVCSGKLQGIVSWGS-GCAQKNKPGVYTKVCNYVSWIKQTI 220
```

| >gi|34856013|ref|XP 214939.2| | G similar to kallikrein [Rattus norvegicus]
| Length = 275

Score = 195 bits (496), Expect = 8e-49 Identities = 91/237 (38%), Positives = 135/237 (56%), Gaps = 15/237 (6%)

```
Query: 86 QTETFQRQISVDRTIVHPRYNP-----ETHDNDIMMVHLKNPVKFSKKIQPLPL 134
         + E F + V ++ HP YNP
                                     + ND+M++HL P + ++ L
Sbjct: 96 EDEPFAQYRFVSQSFPHPDYNPFLMRNHTRQTGYDYSNDLMLLHLSEPADITDGVKVIDL 155
```

Query: 26 QEKVVHGGPCLKDSHPFQAALYTSGHLLCGGVLIDPQWVLTAAHCKKPNLQVILGKHNLR 85 Q ++V G C K+S P+Q A+ LCGGVLIDP WV+TAAHC

Sbjct: 38 QSRIVGGYNCEKNSQPWQVAVIN--RYLCGGVLIDPSWVITAAHCYSHYYHVLLGRHNLF 95

V+LG+HNL

Query: 135 KNDCSEENPNCQILGWGKMEN--GDFPDTIQCADVHLVPREQCERAYPGKITQSMVCAGD 192 + + C + GWG + + PD +QC ++ L+ E+C AY K+T M+CAG

Sbjct: 156 PTEEPKVGSTCLVSGWGSTKPLISELPDDLQCVNIDLLSNEKCIEAYRWKVTDLMLCAGK 215

Query: 193 MKEGNDSCQGDSGGPLVCGGRLRGLVSWGDMPCGSKEKPGVYTDVCTHIRWIQNILR 249 ++ G D+C GDSGGPL+C G L+GL SWG +PC PG+YT + Sbjct: 216 LEGGKDACNGDSGGPLICDGVLQGLTSWGSVPCSEPHNPGIYTKIIKFTSWIKEVMK 272

>gi|40647097|gb|AAR88364.1| pretrypsinogen [Tautogolabrus adspersus] Length = 242

Score = 195 bits (496), Expect = 8e-49 Identities = 93/242 (38%), Positives = 146/242 (60%), Gaps = 4/242 (1%)

MKMLALCLVLAKSAWSEEQEKVVHGGPCLKDSHPFQAALYTSGHLLCGGVLIDPQWVLTA 67 Query: 8 M+ L L++ +A++ + +K+V G C S P +L SG+ CGG L++ WV++A Sbjct: 1 MRSLVFVLLIG-AAFAIDDDKIVGGYECTPHSQPHTVSLQ-SGYHFCGGSLVNEDWVVSA 58

Query: 68 AHCKKPNLQVILGKHNLRQTETFQRQISVDRTIVHPRYNPETHDNDIMMVHLKNPVKFSK 127 AHC K +QV LG+H++R E ++ IS R I HPRY+ DNDIM++ L

Sbjct: 59 AHCYKSRIQVRLGEHHIRVNEGTEQIISSSRVIRHPRYSSYNIDNDIMLIKLSQSATLNQ 118

Query: 128 KIQPLPLKNDCSEENPNCQILGWGK-MENGDFPDTIQCADVHLVPREQCERAYPGKITQS 186 ++ + L C+ · C++ GWG M + D +QC ++ ++ C+ +YPG IT +

Sbjct: 119 YVKTVALPTSCAPAGTMCKVAGWGNTMSSSADGDKLQCLNIPILSERDCDNSYPGMITDA 178

Query: 187 MVCAGDMKEGNDSCQGDSGGPLVCGGRLRGLVSWGDMPCGSKEKPGVYTDVCTHIRWIQN 246 M CAG ++ G DSCQGDSGGP+VC G+L+G+VSWG C ++ PGVY VC

Sbjct: 179 MFCAGYLEGGKDSCQGDSGGPVVCNGQLQGVVSWG-YGCAERDHPGVYAKVCLFNDWLES 237

Query: 247 IL 248 Sbjct: 238 TM 239

| >gi|58257844|gb|AAW69363.1| try10 [Macaca mulatta] Length = 248

Score = 195 bits (496), Expect = 8e-49 Identities = 95/228 (41%), Positives = 139/228 (60%), Gaps = 5/228 (2%)

Query: 24 EEQEKVVHGGPCLKDSHPFQAALYTSGHLLCGGVLIDPQWVLTAAHC-KKPNLQVILGKH 82 ++ +K+V G C ++S P+Q +L SG+ CGG LI QWV++A HC K +QV LG+H

Sbjct: 19 DDDDKIVGGYTCEENSVPYQVSL-NSGYHFCGGSLIREQWVVSAGHCWKLGRIQVRLGEH 77

Query: 83 NLRQTETFQRQISVDRTIVHPRYNPETHDNDIMMVHLKNPVKFSKKIQPLPLKNDCSEEN 142 E ++ I+ + I HP+YN +T DNDI+++ L P + + +PL

Sbjct: 78 NIEVLEGNEQFINAAKKIRHPKYNRKTLDNDILLIKLSTPAVINDHVSTIPLPTAPPAAG 137

```
Query: 143 PNCQILGWGK--MENGDFPDTIQCADVHLVPREQCERAYPGKITQSMVCAGDMKEGNDSC 200
              I GWG D+PD +QC D ++ + +CE +YPGKIT +M C G ++ G DSC
Sbjct: 138 AEALISGWGNTLSSGADYPDELQCLDAPVLSQAECEASYPGKITSNMFCVGFLEGGKDSC 197
Query: 201 QGDSGGPLVCGGRLRGLVSWGDMPCGSKEKPGVYTDVCTHIRWIQNIL 248
          QGDSGGP+V G L+G+VSWG C K KPGVYT V ++ WI++ +
Sbjct: 198 QGDSGGPVVSNGELQGIVSWG-YGCAQKNKPGVYTKVYNYVDWIEDTI 244
g >qi|3452117|gb|AAC32751.1| trypsinogen 1 precursor [Pseudopleuronectes americanus]
         Length = 250
 Score = 195 bits (496), Expect = 8e-49
 Identities = 104/248 (41%), Positives = 144/248 (58%), Gaps = 9/248 (3%)
Query: 8 MKMLALCLVL-AKSAWSEEQEKVVHGGPCLKDSHPFQAALYTSGHLLCGGVLIDPQWVLT 66
          M +LAL L++ A A E +++ G C S P+ A+L G+ CGGVLI+ QWVL+
Sbjct: 1
          MNLLALLLMVGAAVAVPREDGRIIGGHECAAHSRPYMASL-NYGYHFCGGVLINNQWVLS 59
Query: 67 AAHC--KKPNLQVILGKHNLRQTETFQRQISVDRTIVHPRYNPETHDNDIMMVHLKNPVK 124
                   +QV+LG+HNLR E ++ + D I HP Y+ +T D DIM++ L +PV+
Sbjct: 60 VAHCWYNPYAMQVMLGEHNLRVFEGTEQLMKTDTIIWHPNYDYQTLDFDIMLIKLYHPVE 119
Ouery: 125 FSKKIQPLPLKNDCSEENPNCQILGWGKM-ENGD---FPDTIQCADVHLVPREQCERAYP 180
           ++ + P+ L + C C + GWG +GD P +OC DV ++ EQC ++YP
Sbjct: 120 VTEAVAPISLPSSCPVGGTPCSVSGWGNTARDGDDVYMPTLLQCMDVPIIDEEQCMKSYP 179
Query: 181 GKITQSMVCAGDMKEGNDSCQGDSGGPLVCGGRLRGLVSWGDMPCGSKEKPGVYTDVCTH 240
                         D+C GDSG PLVC G + GLVSWG C
          G I+ MVCAG M
Sbjct: 180 GMISPRMVCAGFMDGSRDACNGDSGSPLVCRGEVTGLVSWG-QGCAQPNYPGVYVKLCEF 238
Query: 241 IRWIQNIL 248
            WI+N L
Sbjct: 239 HAWIENTL 246
Length = 235
 Score = 195 bits (496), Expect = 8e-49
 Identities = 91/234 (38%), Positives = 134/234 (57%), Gaps = 15/234 (6%)
Query: 29 VVHGGPCLKDSHPFQAALYTSGHLLCGGVLIDPQWVLTAAHCKKPNLQVILGKHNLRQTE 88
          +V G C K+S P+Q A+ LCGGVLIDP WV+TAAHC
                                                       V+LG+HNL + E
Sbjct: 1 IVGGYKCEKNSQPWQVAVIN--RYLCGGVLIDPSWVITAAHCYSHYYHVLLGRHNLFEDE 58
Query: 89 TFQRQISVDRTIVHPRYNP-----ETHDNDIMMVHLKNPVKFSKKIQPLPLKND 137
               V ++ HP YNP
                                       + ND+M++HL P + ++ L +
Sbjct: 59 PFAQYRFVSQSFPHPDYNPFLMRNHTRQTGYDYSNDLMLLHLSEPADITDGVKVIDLPTE 118
Query: 138 CSEENPNCQILGWGKMEN--GDFPDTIQCADVHLVPREQCERAYPGKITQSMVCAGDMKE 195
                 C + GWG +
                             + PD +QC ++ L+ E+C AY K+T M+CAG ++
```

Sbjct: 119 EPKVGSTCLVSGWGSTKPLISELPDDLQCVNIDLLSNEKCIEAYRWKVTDLMLCAGKLEG 178

Query: 196 GNDSCQGDSGGPLVCGGRLRGLVSWGDMPCGSKEKPGVYTDVCTHIRWIQNILR 249 G D+C GDSGGPL+C G L+GL SWG +PCG PG+YT + WI+ +++

| >gi | 1334753 | emb | CAA54215.1 | trypsinogen X [Gadus morhua] | Length = 240

Score = 195 bits (495), Expect = 1e-48
Identities = 96/238 (40%), Positives = 141/238 (59%), Gaps = 3/238 (1%)

Query: 12 ALCLVLAKSAWSEEQEKVVHGGPCLKDSHPFQAALYTSGHLLCGGVLIDPQWVLTAAHCK 71 +L VL A E++K+V G C + S Q +L SG+ CGG L+ WV++AAHC

Sbjct: 2 SLIFVLLLGAVFAEEDKIVGGYECTRHSQAHQVSL-NSGYHFCGGSLVSKDWVVSAAHCY 60

Query: 72 KPNLQVILGKHNLRQTETFQRQISVDRTIVHPRYNPETHDNDIMMVHLKNPVKFSKKIQP 131
K L+V LG+H++R E ++ IS I HP Y+ DNDIM++ L P ++ +

Sbjct: 61 KSVLRVRLGEHHIRVNEGTEQFISSSSVIRHPNYSSYNIDNDIMLIKLTEPATLNQYVHA 120

Query: 132 LPLKNDCSEENPNCQILGWGK-MENGDFPDTIQCADVHLVPREQCERAYPGKITQSMVCA 190
+ L +C+ + C + GWG M + D D +QC ++ ++ C +YPG ITQSM CA

Sbjct: 121 VALPTECAADATMCTVSGWGNTMSSVDDGDKLQCLNLPILSHADCANSYPGMITQSMFCA 180

Query: 191 GDMKEGNDSCQGDSGGPLVCGGRLRGLVSWGDMPCGSKEKPGVYTDVCTHIRWIQNIL 248 G ++ G DSCQGDSGGP+VC G L+G+VSWG C ++ PGVY VC W+++ +

Sbjct: 181 GYLEGGKDSCQGDSGGPVVCNGVLQGVVSWG-YGCAERDNPGVYAKVCVLSGWVRDTM 237

>gi | 58257848 | gb | AAW69367.1 | try16 [Macaca mulatta] Length = 247

Score = 195 bits (495), Expect = 1e-48Identities = 96/242 (39%), Positives = 150/242 (61%), Gaps = 5/242 (2%)

Query: 10 MLALCLV-LAKSAWSEEQEKVVHGGPCLKDSHPFQAALYTSGHLLCGGVLIDPQWVLTAA 68 +L L V +A +A ++ +K+V G C ++S P+Q +L SG+ CGG LI+ OWV++AA

Sbjct: 4 LLILAFVGVAVAAPFDDDDKIVGGYTCEENSVPYQVSL-NSGYHFCGGSLINEQWVVSAA 62

Query: 69 HCKKPNLQVILGKHNLRQTETFQRQISVDRTIVHPRYNPETHDNDIMMVHLKNPVKFSKK 128 HC K +QV LG+HN+ E ++ I + I HP Y+ +T +NDI+++ L +P + +

Sbjct: 63 HCYKTRIQVRLGEHNIEVLEGTEQFINAAKIIRHPDYDRKTLNNDILLIKLSSPAVINAR 122

Query: 129 IQPLPLKNDCSEENPNCQILGWGKM--ENGDFPDTIQCADVHLVPREQCERAYPGKITQS 186 + + L I GWG D+PD +QC + ++ + +CE +YPGKIT +

Sbjct: 123 VSTISLPTAPPAAGAEALISGWGNTLSSGADYPDELQCLEAPVLSQAECEASYPGKITSN 182

Query: 187 MVCAGDMKEGNDSCQGDSGGPLVCGGRLRGLVSWGDMPCGSKEKPGVYTDVCTHIRWIQN 246 M C G ++ G DSCQGDSGGP+V G+L+G+VSWG C K +PGVYT V ++ WI++

Sbjct: 183 MFCVGFLEGGKDSCQGDSGGPVVSNGQLQGIVSWG-YGCAQKNRPGVYTKVYNYVDWIRD 241

Query: 247 IL 248

Sbjct: 242 TI 243

| >qi | 476825 | pir | | A44284 | tissue kallikrein (EC 3.4.21.35) homolog - rat (fragment) | gi | 259431 | gb | AAB24071.1 | G T-kininogenase [Rattus sp.]

gi|547792|sp|P36375|KLK10 RAT G Glandular kallikrein 10 precursor (Tissue kallikrein (T-kininogenase) (K10) (Proteinase B) (Endopeptidase K)

Length = 244

Score = 195 bits (495), Expect = 1e-48
Identities = 91/237 (38%), Positives = 138/237 (58%), Gaps = 15/237 (6%)

Query: 26 QEKVVHGGPCLKDSHPFQAALYTSGHLLCGGVLIDPQWVLTAAHCKKPNLQVILGKHNLR 85 Q ++V G C K+S P+Q A+ LCGGVLIDP WV+TAAHC V+LG++NL

Sbjct: 7 QSRIVGGYKCEKNSQPWQVAIINE--YLCGGVLIDPSWVITAAHCYSNYYHVLLGRNNLF 64

Query: 86 QTETFQRQISVDRTIVHPRYNP-----ETHDNDIMMVHLKNPVKFSKKIQPLPL 134 + E F + V+++ HP Y P + + ND+M++HL P + ++ L

Sbjct: 65 EDEPFAQYRFVNQSFPHPDYKPFLMRNHTRQRGDDYSNDLMLLHLSEPADITDGVKVIDL 124

Query: 135 KNDCSEENPNCQILGWGKME--NGDFPDTIQCADVHLVPREQCERAYPGKITQSMVCAGD 192 + + C GWG + N + PD +QC ++HL+ E+C AY K+T M+CAG+

Sbjct: 125 PTEEPKVGSTCLASGWGSTKPLNWELPDDLQCVNIHLLSNEKCIEAYEQKVTDLMLCAGE 184

Query: 193 MKEGNDSCQGDSGGPLVCGGRLRGLVSWGDMPCGSKEKPGVYTDVCTHIRWIQNILR 249
M D+C+GDSGGPL+C G L+G+ SWG++PC PGVYT + WI+ +++

Sbjct: 185 MDGRKDTCKGDSGGPLICDGVLQGITSWGNVPCAEPYNPGVYTKLIKFTSWIKEVMK 241

>gi | 2507250 | sp | P16049 | TRY1 GADMO Trypsin I precursor Length = 241

Score = 194 bits (493), Expect = 2e-48

Identities = 97/242 (40%), Positives = 141/242 (58%), Gaps = 3/242 (1%)

Query: 10 MLALCLVLAKSAWSEEQEKVVHGGPCLKDSHPFQAALYTSGHLLCGGVLIDPQWVLTAAH 69
M +L VL A E++K+V G C K S Q +L SG+ CGG L+ WV++AAH

Sbjct: 1 MKSLIFVLLLGAVFAEEDKIVGGYECTKHSQAHQVSL-NSGYHFCGGSLVSKDWVVSAAH 59

Query: 70 CKKPNLQVILGKHNLRQTETFQRQISVDRTIVHPRYNPETHDNDIMMVHLKNPVKFSKKI 129 C K L+V LG+H++R E ++ IS I HP Y+ +NDIM++ L P ++ +

Sbjct: 60 CYKSVLRVRLGEHHIRVNEGTEQYISSSSVIRHPNYSSYNINNDIMLIKLTKPATLNQYV 119

Query: 130 QPLPLKNDCSEENPNCQILGWGK-MENGDFPDTIQCADVHLVPREQCERAYPGKITQSMV 188 + L +C+ + C + GWG M + D +QC + ++ C +YPG ITQSM

Sbjct: 120 HAVALPTECAADATMCTVSGWGNTMSSVADGDKLQCLSLPILSHADCANSYPGMITQSMF 179

SDJCC: 120 HAVALIPIECAADAINCIVSGWGNIMSSVADGDRDQCISHFIBSHADCANSIIGMIIQSM 175

Query: 189 CAGDMKEGNDSCQGDSGGPLVCGGRLRGLVSWGDMPCGSKEKPGVYTDVCTHIRWIQNIL 248 CAG ++ G DSCQGDSGGP+VC G L+G+VSWG C ++ PGVY VC W+++ +

Sbjct: 180 CAGYLEGGKDSCQGDSGGPVVCNGVLQGVVSWG-YGCAERDHPGVYAKVCVLSGWVRDTM 238

Query: 249 RN 250

Sbjct: 239 AN 240

>gi|57037489|ref|XP 541469.1| G PREDICTED: similar to kallikrein 5 preproprotein [(Length = 464

Score = 194 bits (493), Expect = 2e-48

Identities = 91/248 (36%), Positives = 148/248 (59%), Gaps = 26/248 (10%)

```
Query: 28 KVVHGGPCLKDSHPFQAALYTSGH-LLCGGVLIDPQWVLTAAHCKKPNLQVILGKHNLRQ 86
          ++V+G C K++ P+Q AL + L CG VL++PQW+LTAAHC+KP ++ LG H+L
Sbjct: 216 RIVNGTDCEKNAQPWQGALLLGPNKLYCGAVLVNPQWLLTAAHCRKPFFRIRLGHHSLSP 275
Query: 87 T-ETFQRQISVDRTIVHPRYNPETHDNDIMMVHLKNPVKFSKKIQPLPLKNDCSEENPNC 145
            E Q+ ++I HP Y+ H ND+M++ L ++ ++++P+ + + C
Sbjct: 276 VYEAGQQLFKGIKSIPHPGYSHPGHSNDLMLIKLNRKIRETQRVKPINISSKCPSAGTSC 335
Query: 146 QILGWGKMENGD------FPDTIQCADVHLVPREQCERAYPGKITQSMVCAGDMK 194
                        FP +QC ++ ++ ++C +AYP +I +M CAGD +
Sbjct: 336 MVSGWGTTNSPNVALLCVFLTVQFPKVLQCLNITVLSDDRCRKAYPRQIDSTMFCAGD-E 394
Query: 195 EGNDSCQ-----GDSGGPLVCGGRLRGLVSWGDMPCGSKEKPGVYTDVCTHIR 242
                            GDSGGP+VC G L+GLVSWGD PC
Sbjct: 395 AGRDSCQTSSGFSYQFVVRGDSGGPVVCNGSLQGLVSWGDFPCAQPNRPGVYTNLCQFTK 454
Query: 243 WIQNILRN 250
          WI++ +++
Sbjct: 455 WIKDTIQS 462
>gi|33307101|gb|AAQ02911.1| serine protease KN13 precursor [Trimeresurus stejneger:
         Length = 258
 Score = 194 bits (493), Expect = 2e-48
 Identities = 99/248 (39%), Positives = 143/248 (57%), Gaps = 4/248 (1%)
Query: 5 MLTMKMLALCLVLAKSAWSEEQEKVVHGGPCLKDSHPFQAALYTSGHLLCGGVLIDPQWV 64
          M+ +++LA L+L S E V+ G C + H F ALY SG
                                                          CGG LI+ +WV
Sbjct: 1 MVLIRVLANLLILQLSYAQRSSELVIGGDECNINEHRFLVALYKSGRFRCGGTLINQEWV 60
Query: 65 LTAAHCKKPNLQVILGKHNLR-QTETFQRQISVDRTIVHPRYNPETHDNDIMMVHLKNPV 123
          LTAAHC + N+++ LG H+ E QR++ ++ N
Sbjct: 61 LTAAHCDRRNMEIKLGMHSKNVPNEDEQRRVPKEKFFCDSNKNHTQWNKDIMLIRLNSPV 120
Query: 124 KFSKKIQPLPLKNDCSEENPNCQILGWGKME--NGDFPDTIQCADVHLVPREQCERAYPG 181
            S I PL L ++ C+I+GWG + N +PD CA+++L
Sbjct: 121 NNSTHIAPLSLPSNPPIVGSVCRIMGWGTITSPNETYPDVPHCANINLFNYTVCHGAHAG 180
Query: 182 -KITQSMVCAGDMKEGNDSCQGDSGGPLVCGGRLRGLVSWGDMPCGSKEKPGVYTDVCTH 240
                 +CAG ++EG D+C+GDSGGPL+C G+ +G+VSWG PC +PGVYT V H
Sbjct: 181 LPATSRTLCAGVLEEGKDTCKGDSGGPLICNGQFQGIVSWGGDPCAQPREPGVYTKVFDH 240
Query: 241 IRWIQNIL 248
          + WIONI+
Sbjct: 241 LDWIQNII 248
| >gi | 33637113 | gb | AAQ23713.1 | glandular kallikrein precursor [Equus caballus]
         Length = 261
Score = 194 \text{ bits } (492), \text{ Expect = } 2e-48
Identities = 96/257 (37%), Positives = 144/257 (56%), Gaps = 16/257 (6%)
Query: 8 MKMLALCLVLA---KSAWSEEQEKVVHGGPCLKDSHPFQAALYTSGHLLCGGVLIDPQWV 64
          M + LCL L + A Q + + + G C S P + QAA + Y
                                                         CGGVL+DPOWV
Sbjct: 1
          MWLPVLCLALSLVGTGAAPPIQSRIIGGWECKNHSKPWQAAVYHYSSFQCGGVLVDPQWV 60
```

- Query: 65 LTAAHCKKPNLQVILGKHNLRQTETFQRQISVDRTIVHPRYNP------ETHDND 113
 LTAAHCK Q+ LG+HNL + E + V ++ HP +N E + +D
 Sbjct: 61 LTAAHCKGDYYQIWLGRHNLFEDEDTAQFFLVAKSFPHPDFNMSLLENNNRLPGEDYSHD 120

 Query: 114 IMMVHLKNPVKFSKKIQPLPLKNDCSEENPNCQILGWGKMENGDF--PDTIQCADVHLVP 171
 +M++ ++ P + + +Q L L C GWG +E F PD ++C D+ L+
 Sbjct: 121 LMLLQVEQPDQITVAVQVLALPTQEPVLGSTCYASGWGSIEPDKFTYPDELRCVDLTLLS 180

 Query: 172 REQCERAYPGKITQSMVCAGDMKEGNDSCQGDSGGPLVCGGRLRGLVSWGDMPCGSKEKP 231
 + C+ A+ +T+ M+CAG ++ G D+C GDSGGPL+C G +G+ SWG +PCG KP
 Sbjct: 181 NDVCDNAHSQNVTEYMLCAGHLEGGKDTCVGDSGGPLICDGVFQGVTSWGHIPCGRPNKP 240
- Query: 232 GVYTDVCTHIRWIQNIL 248

 VYT + H++WIQ+ +

 Sbjct: 241 AVYTKLIPHVQWIQDTI 257

| >gi | 1334752 | emb | CAA54214.1 | trypsinogen I [Gadus morhua] | gi | 481640 | pir | | S39047 | trypsin (EC 3.4.21.4) I - Atlantic cod | Length = 240

Score = 193 bits (490), Expect = 4e-48

Identities = 96/240 (40%), Positives = 140/240 (58%), Gaps = 3/240 (1%)

- Query: 12 ALCLVLAKSAWSEEQEKVVHGGPCLKDSHPFQAALYTSGHLLCGGVLIDPQWVLTAAHCK 71 +L VL A E++K+V G C K S Q +L SG+ CGG L+ WV++AAHC
- Sbjct: 2 SLIFVLLLGAVFAEEDKIVGGYECTKHSQAHQVSL-NSGYHFCGGSLVSKDWVVSAAHCY 60
- Query: 72 KPNLQVILGKHNLRQTETFQRQISVDRTIVHPRYNPETHDNDIMMVHLKNPVKFSKKIQP 131 K L+V LG+H++R E ++ IS I HP Y+ +NDIM++ L P ++ +
- Sbjct: 61 KSVLRVRLGEHHIRVNEGTEQYISSSSVIRHPNYSSYNINNDIMLIKLTKPATLNQYVHA 120
- Query: 132 LPLKNDCSEENPNCQILGWGK-MENGDFPDTIQCADVHLVPREQCERAYPGKITQSMVCA 190 + L +C+ + C + GWG M + D +QC + ++ C +YPG ITQSM CA
- Sbjct: 121 VALPTECAADATMCTVSGWGNTMSSVADGDKLQCLSLPILSHADCANSYPGMITQSMFCA 180
- Query: 191 GDMKEGNDSCQGDSGGPLVCGGRLRGLVSWGDMPCGSKEKPGVYTDVCTHIRWIQNILRN 250 G ++ G DSCQGDSGGP+VC G L+G+VSWG C ++ PGVY VC W+++ N
- Sbjct: 181 GYLEGGKDSCQGDSGGPVVCNGVLQGVVSWG-YGCAERDHPGVYAKVCVLSGWVRDTMAN 239

||S|| > gi | 64382 | emb | CAA49676.1 | trypsin IA [Salmo salar] |gi | 422582 | pir | | S31776 | trypsin (EC 3.4.21.4) IA precursor - Atlantic salmon Length = 242

Score = 193 bits (490), Expect = 4e-48
Identities = 96/241 (39%), Positives = 141/241 (58%), Gaps = 4/241 (1%)

- Query: 10 MLALCLVLA-KSAWSEEQEKVVHGGPCLKDSHPFQAALYTSGHLLCGGVLIDPQWVLTAA 68 M++L VL +A++ E +K+V G C S Q +L SG+ CGG L++ WV++AA
- Sbjct: 1 MISLVFVLLIGAAFATEDDKIVGGYECKAYSQAHQVSL-NSGYHFCGGSLVNENWVVSAA 59
- Query: 69 HCKKPNLQVILGKHNLRQTETFQRQISVDRTIVHPRYNPETHDNDIMMVHLKNPVKFSKK 128 HC K ++V LG+HN++ TE ++ IS R I HP Y+ DNDIM++ L P +
- Sbjct: 60 HCYKSRVEVRLGEHNIKVTEGSEQFISSSRVIRHPNYSSYNIDNDIMLIKLSKPATLNTY 119

```
Query: 129 IQPLPLKNDCSEENPNCQILGWGK-MENGDFPDTIQCADVHLVPREQCERAYPGKITQSM 187
          +OP+ L
                 C+
                          C + GWG M +
                                          + +QC ++ ++
                                                        C +YPG IT +M
Sbjct: 120 VQPVALPTSCAPAGTMCTVSGWGNTMSSTADSNKLQCLNIPILSYSDCNNSYPGMITNAM 179
Query: 188 VCAGDMKEGNDSCQGDSGGPLVCGGRLRGLVSWGDMPCGSKEKPGVYTDVCTHIRWIQNI 247
           CAG ++ G DSCQGDSGGP+VC G L+G+VSWG C
                                                    PGVY VC
Sbjct: 180 FCAGYLEGGKDSCQGDSGGPVVCNGELQGVVSWG-YGCAEPGNPGVYAKVCIFNDWLTST 238
Query: 248 L 248
Sbjct: 239 M 239
```

| >gi|64380|emb|CAA49680.1| trypsin I [Salmo salar] gi|422581|pir||S31775 trypsin (EC 3.4.21.4) I precursor - Atlantic salmon gi 464944 sp P35031 TRY1 SALSA Trypsin I precursor Length = 242Score = 193 bits (490), Expect = 4e-48Identities = 96/241 (39%), Positives = 141/241 (58%), Gaps = 4/241 (1%) Query: 10 MLALCLVLA-KSAWSEEQEKVVHGGPCLKDSHPFQAALYTSGHLLCGGVLIDPQWVLTAA 68 +A++ E +K+V G C S Q +L SG+ CGG L++ WV++AAM++L VL Sbjct: 1 MISLVFVLLIGAAFATEDDKIVGGYECKAYSQTHQVSL-NSGYHFCGGSLVNENWVVSAA 59 Query: 69 HCKKPNLQVILGKHNLRQTETFQRQISVDRTIVHPRYNPETHDNDIMMVHLKNPVKFSKK 128 HC K ++V LG+HN++ TE ++ IS R I HP Y+ DNDIM++ L P Sbjct: 60 HCYKSRVEVRLGEHNIKVTEGSEQFISSSRVIRHPNYSSYNIDNDIMLIKLSKPATLNTY 119 Query: 129 IQPLPLKNDCSEENPNCQILGWGK-MENGDFPDTIQCADVHLVPREQCERAYPGKITQSM 187 C+ C + GWG M + + +QC ++ +++QP+ L

Query: 188 VCAGDMKEGNDSCQGDSGGPLVCGGRLRGLVSWGDMPCGSKEKPGVYTDVCTHIRWIQNI 247 CAG ++ G DSCQGDSGGP+VC G L+G+VSWG C PGVY VC Sbjct: 180 FCAGYLEGGKDSCQGDSGGPVVCNGELQGVVSWG-YGCAEPGNPGVYAKVCIFNDWLTST 238

Sbjct: 120 VQPVALPTSCAPAGTMCTVSGWGNTMSSTADSNKLQCLNIPILSYSDCNNSYPGMITNAM 179

Query: 248 L 248 Sbjct: 239 M 239

similar to Kallikrein 9 precursor (Kallikrein-like (KLK-L3) [Rattus norvegicus] Length = 252

C +YPG IT +M

Score = 193 bits (490), Expect = 4e-48Identities = 96/223 (43%), Positives = 133/223 (59%), Gaps = 8/223 (3%)

Query: 28 KVVHGGPCLKDSHPFQAALYTSGHLLCGGVLIDPQWVLTAAHCKKPNLQVILGKHNLRQT 87 + V C ++S P+QA L+ LCG LI+ QW+LTAAHC+KP L V LG+H+L Q

Sbjct: 22 RAVGARECQRNSQPWQAGLFYLTRQLCGATLINDQWLLTAAHCRKPYLWVRLGEHHLWQW 81

Query: 88 ETFQRQISVDRTIVHPRYNPET----HDNDIMMVHLKNPVKFSKKIQPLPLKNDCSEENP 143 E ++ + VHP +NP+ H++DIM++LV+ S

Sbjct: 82 EGPEKLLLVTDFFPHPGFNPDLSANDHNDDIMLIRLPRKVRLSPAVQPLNLSQSLPSVGT 141

```
Ouery: 144 NCQILGWGKMENGDFPDTIQCADVHLVPREQCERAYPGKITQSMVCAGDMKEGNDSCQGD 203
                       FP T+QCA++ ++ + C AYPG I++ M+CAG + G SCQGD
Sbjct: 142 QCLISGWGIQ----FPMTLQCANISILDNKLCRWAYPGHISEKMLCAGLWEGGRGSCQGD 197
Query: 204 SGGPLVCGGRLRGLVSWGDMPCGSKEKPGVYTDVCTHIRWIQN 246
          SGGPLVC G L G+VS G PC ++P VYT V ++ WI+N
Sbjct: 198 SGGPLVCKGTLAGIVSGGSEPCSRPQRPAVYTSVFHYLDWIEN 240
🖭 >gi|52851385|ref|NP 001005382.1| 🕒 glandular kallikrein 12, submandibular/renal [Ra
gi|92888|pir||B31136 tissue kallikrein (EC 3.4.21.35) 3 precursor, submandibular - r
 gi|547793|sp|P36376|KLK12 RAT G Glandular kallikrein 12, submandibular/renal precurs
          kallikrein) (RSKG-3)
         Length = 259
 Score = 193 bits (490), Expect = 4e-48
 Identities = 88/237 (37%), Positives = 139/237 (58%), Gaps = 15/237 (6%)
Ouery: 26 OEKVVHGGPCLKDSHPFQAALYTSGHLLCGGVLIDPQWVLTAAHCKKPNLQVILGKHNLR 85
          O +VV G C K+S P+Q A+ LCGGVLIDP WV+TAAHC N V+LG++NL
Sbjct: 22 QSRVVGGYKCEKNSQPWQVAVIN--RYLCGGVLIDPSWVITAAHCYSHNYHVLLGRNNLF 79
Query: 86 QTETFQRQISVDRTIVHPRYNP------ETHDNDIMMVHLKNPVKFSKKIQPLPL 134
          + E F + V+++ HP YNP + H ND+M++HL P + ++ L
Sbjct: 80 KDEPFAQYRVVNQSFPHPDYNPFFMKNHTLFPGDDHSNDLMLLHLSEPADITDGVKVIDL 139
Query: 135 KNDCSEENPNCQILGWGKME--NGDFPDTIQCADVHLVPREQCERAYPGKITQSMVCAGD 192
            + + C GW + +FPD +QC +++++ E+C +A+ +T M+CAG+
Sbjct: 140 PTEEPKVGSTCLASGWSSTKPLEWEFPDDLQCVNINILSNEKCIKAHTQMVTDVMLCAGE 199
Query: 193 MKEGNDSCQGDSGGPLVCGGRLRGLVSWGDMPCGSKEKPGVYTDVCTHIRWIQNILR 249
          ++ G D+C GDSGGPL+C G L+G+ SW · +PCG +P +YT + WI+ +++
Sbjct: 200 LEGGKDTCNGDSGGPLLCDGVLQGITSWSSVPCGETNRPAIYTKLIKFTSWIKEVMK 256
// >gi|64386|emb|CAA49678.1| trypsin II [Salmo salar]
 gi | 422584 | pir | | S31778 trypsin (EC 3.4.21.4) II precursor - Atlantic salmon (fragmen
 gi | 464946 | sp | P35032 | TRY2 SALSA Trypsin II precursor
         Length = 231
 Score = 192 bits (489), Expect = 5e-48
 Identities = 92/230 (40\%), Positives = 136/230 (59\%), Gaps = 3/230 (1\%)
Query: 20 SAWSEEQEKVVHGGPCLKDSHPFQAALYTSGHLLCGGVLIDPQWVLTAAHCKKPNLQVIL 79
          +A++ E +K+V G C S P Q +L SG+ CGG L++ WV++AAHC + ++V L
Sbjct: 1 AAFATEDDKIVGGYECKAYSQPHQVSL-NSGYHFCGGSLVNENWVVSAAHCYQSRVEVRL 59
Query: 80 GKHNLRQTETFQRQISVDRTIVHPRYNPETHDNDIMMVHLKNPVKFSKKIQPLPLKNDCS 139
          G+HN++ TE ++ IS R I HP Y+ DNDIM++ L P + +QP+ L
Sbjct: 60 GEHNIQVTEGSEQFISSSRVIRHPNYSSYNIDNDIMLIKLSKPATLNTYVQPVALPTSCA 119
Query: 140 EENPNCQILGWGK-MENGDFPDTIQCADVHLVPREQCERAYPGKITQSMVCAGDMKEGND 198
               C + GWG M + + +QC ++ ++ C +YPG IT +M CAG ++ G D
Sbjct: 120 PAGTMCTVSGWGNTMSSTADKNKLQCLNIPILSYSDCNNSYPGMITNAMFCAGYLEGGKD 179
```

Query: 199 SCQGDSGGPLVCGGRLRGLVSWGDMPCGSKEKPGVYTDVCTHIRWIQNIL 248

| Si | 51591907 | ref | NP 001003977.1 | G glandular kallikrein 11 [Rattus norvegicus] qi|47169500|tpe|CAE48387.1| G TPA: glandular kallikrein-11 [Rattus norvegicus] Length = 257Score = 192 bits (489), Expect = 5e-48 Identities = 92/237 (38%), Positives = 139/237 (58%), Gaps = 17/237 (7%) Query: 26 QEKVVHGGPCLKDSHPFQAALYTSGHLLCGGVLIDPQWVLTAAHCKKPNLQVILGKHNLR 85 O +VV G C K+S P+O A+ + LCGGVLIDP WV+TAAHC + V+LG++NL

Query: 86 QTETFQRQISVDRTIVHPRYNP-----ETHDNDIMMVHLKNPVKFSKKIQPLPL 134 + E F + V ++ HP YNP ++ ND+M++HL P

Sbjct: 22 QSRVVGGYKCEKNSQPWQVAVISRS--LCGGVLIDPSWVITAAHCY--SYHVLLGRNNLS 77

Sbjct: 78 EDEPFAQYRFVSQSFPHPDYNPFFMRNHTRQPGDDYSNDLMLLHLSKPADITDGVKVIDL 137

Query: 135 KNDCSEENPNCQILGWGKMENGDF--PDTIQCADVHLVPREQCERAYPGKITQSMVCAGD 192 + + C GWG + D+ PD +QC ++HL+ E+C AY K+T M+CAGD

Sbjct: 138 PTEEPKVGSTCLASGWGSTKPLDWELPDDLQCVNIHLLSNEKCIEAYNEKVTDLMLCAGD 197

Query: 193 MKEGNDSCQGDSGGPLVCGGRLRGLVSWGDMPCGSKEKPGVYTDVCTHIRWIQNILR 249 ++ G D+C+GDSGGPL+C G L+G+ SWG PC P +YT + Sbjct: 198 LEGGKDTCKGDSGGPLICDGVLQGITSWGSDPCAEPNMPAIYTKLIKFTSWIKEVMK 254

ori|809221|pdb|1BIT| The Crystal Structure Of Anionic Salmon Trypsin In A Second Form Length = 237

Score = 192 bits (489), Expect = 5e-48 Identities = 93/235 (39%), Positives = 138/235 (58%), Gaps = 3/235 (1%)

Query: 15 LVLAKSAWSEEQEKVVHGGPCLKDSHPFQAALYTSGHLLCGGVLIDPQWVLTAAHCKKPN 74 ++L +A++ E +K+V G C S Q +L SG+ CGG L++ WV++AAHC K

Sbjct: 2 VLLIGAAFATEDDKIVGGYECKAYSQAHQVSL-NSGYHFCGGSLVNENWVVSAAHCYKSR 60

Query: 75 LQVILGKHNLRQTETFQRQISVDRTIVHPRYNPETHDNDIMMVHLKNPVKFSKKIQPLPL 134 ++V LG+HN++ TE ++ IS R I HP Y+ DNDIM++ L P + +QP+ L

Sbjct: 61 VEVRLGEHNIKVTEGSEQFISSSRVIRHPNYSSYNIDNDIMLIKLSKPATLNTYVQPVAL 120

Query: 135 KNDCSEENPNCQILGWGK-MENGDFPDTIQCADVHLVPREQCERAYPGKITQSMVCAGDM 193 C + GWG M + + +QC ++ ++ C + YPG IT +M CAG +

Sbjct: 121 PTSCAPAGTMCTVSGWGNTMSSTADSNKLQCLNIPILSYSDCNNSYPGMITNAMFCAGYL 180

Ouery: 194 KEGNDSCOGDSGGPLVCGGRLRGLVSWGDMPCGSKEKPGVYTDVCTHIRWIONIL 248 + G DSCQGDSGGP+VC G L+G+VSWG C PGVY VC

Sbjct: 181 EGGKDSCQGDSGGPVVCNGELQGVVSWG-YGCAEPGNPGVYAKVCIFNDWLTSTM 234

gi|67558|pir||KQHU tissue kallikrein (EC 3.4.21.35) precursor [validated] - human (Kidney/pancreas/salivary gland kallikrein)

Score = 192 bits (488), Expect = 7e-48
Identities = 97/258 (37%), Positives = 145/258 (56%), Gaps = 17/258 (6%)

Query: 8 MKMLALCLVLA---KSAWSEEQEKVVHGGPCLKDSHPFQAALYTSGHLLCGGVLIDPQWV 64
M L LCL L+ A Q ++V G C + S P+QAALY CGG+L+ QWV

Sbjct: 1 MWFLVLCLALSLGGTGAAPPIQSRIVGGWECEQHSQPWQAALYHFSTFQCGGILVHRQWV 60

Query: 65 LTAAHCKKPNLQVILGKHNLRQTETFQRQISVDRTIVHPRYN-----PETHDND 113 LTAAHC N Q+ LG+HNL E + + V + HP +N E + +D

Sbjct: 61 LTAAHCISDNYQLWLGRHNLFDDENTAQFVHVSESFPHPGFNMSLLENHTRQADEDYSHD 120

Query: 114 IMMVHLKNPVK-FSKKIQPLPLKNDCSEENPNCQILGWGKME--NGDFPDTIQCADVHLV 170 +M++ L P + ++ + L E C GWG +E N FPD +QC D+ ++

Sbjct: 121 LMLLRLTEPADTITDAVKVVELPTQEPEVGSTCLASGWGSIEPENFSFPDDLQCVDLKIL 180

Query: 171 PREQCERAYPGKITQSMVCAGDMKEGNDSCQGDSGGPLVCGGRLRGLVSWGDMPCGSKEK 230 P ++CE+A+ K+T M+C G ++ G D+C GDSGGPL+C G L+G+ SWG +PCG+ K

Sbjct: 181 PNDECEKAHVQKVTDFMLCVGHLEGGKDTCVGDSGGPLMCDGVLQGVTSWGYVPCGTPNK 240

Query: 231 PGVYTDVCTHIRWIQNIL 248
P V V ++++WI++ +
Sbjct: 241 PSVAVRVLSYVKWIEDTI 258

gi|20379615|gb|AAH27736.1| G Kallikrein 6 [Mus musculus]

gi|14789646|gb|AAH10754.1| G Kallikrein 6 [Mus musculus]

qi|31657181|qb|AAH53697.1| G Kallikrein 6 [Mus musculus]

gi | 12832144 | dbj | BAB21982.1 | G unnamed protein product [Mus musculus]

Length = 261

Score = 192 bits (487), Expect = 9e-48Identities = 98/257 (38%), Positives = 141/257 (54%), Gaps = 16/257 (6%)

Query: 8 MKMLALCLVLAKS---AWSEEQEKVVHGGPCLKDSHPFQAALYTSGHLLCGGVLIDPQWV 64 M+ L L L + A Q ++V G C K+S P+Q A+Y CGG+L++ WV

Sbjct: 1 MRFLILFLALSLGGIDAAPPVQSRIVGGFNCEKNSQPWQVAVYRFTKYQCGGILLNANWV 60

Query: 65 LTAAHCKKPNLQVILGKHNLRQTETFQRQISVDRTIVHPRYN------PETHD---ND 113 LTAAHC QV LGK+N + E + V + I HP +N P+ D ND

Sbjct: 61 LTAAHCHNDKYQVWLGKNNFLEDEPSAQHRLVSKAIPHPDFNMSLLNEHTPQPEDDYSND 120

Query: 114 IMMVHLKNPVKFSKKIQPLPLKNDCSEENPNCQILGWGKME--NGDFPDTIQCADVHLVP 171
+M++ LK P + ++P+ L + + C GWG + ++PD +QC ++ L+P

Sbjct: 121 LMLLRLKKPADITDVVKPIDLPTEEPKLGSTCLASGWGSITPVKYEYPDELQCVNLKLLP 180

Query: 172 REQCERAYPGKITQSMVCAGDMKEGNDSCQGDSGGPLVCGGRLRGLVSWGDMPCGSKEKP 231 E C +A+ K+T M+CAGDM G D+C GDSGGPL+C G L+G+ SWG PCG P

Sbjct: 181 NEDCAKAHIEKVTDDMLCAGDMDGGKDTCAGDSGGPLICDGVLQGITSWGPSPCGKPNVP 240

Query: 232 GVYTDVCTHIRWIQNIL 248

G+YT V WI+ +

Sbjct: 241 GIYTRVLNFNTWIRETM 257

Get selected sequences Select all Deselect all

Database: All non-redundant GenBank CDS

translations+PDB+SwissProt+PIR+PRF excluding environmental samples

Posted date: Mar 13, 2005 9:25 AM Number of letters in database: 802,641,970 Number of sequences in database: 2,366,628

Lambda K H

0.320 0.137 0.451

Gapped

Lambda K H

0.267 0.0410 0.140

Matrix: BLOSUM62

Gap Penalties: Existence: 11, Extension: 1

Number of Hits to DB: 92,770,297 Number of Sequences: 2366628 Number of extensions: 4131687

Number of successful extensions: 9988

Number of sequences better than 10.0: 906

Number of HSP's better than 10.0 without gapping: 779 Number of HSP's successfully gapped in prelim test: 127

Number of HSP's that attempted gapping in prelim test: 6964

Number of HSP's gapped (non-prelim): 977

length of query: 253

length of database: 802,641,970

effective HSP length: 124

effective length of query: 129

effective length of database: 509,180,098

effective search space: 65684232642

effective search space used: 65684232642

T: 11 A: 40

X1: 16 (7.4 bits)

X2: 38 (14.6 bits)

X3: 64 (24.7 bits)

S1: 41 (21.8 bits)

S2: 73 (32.7 bits)

ARTICLE

Human TIMP-3 Is Expressed During Fetal Development, Hair Growth Cycle, and Cancer Progression

Kristiina Airola, Matti Ahonen, Nina Johansson, Päivi Heikkilä, Juha Kere, Veli-Matti Kähäri, and Ulpu K. Saarialho-Kere

Department of Dermatology, Helsinki University Central Hospital, Helsinki, Finland (KA,UKS-K); Departments of Medical Genetics (KA,JK,UKS-K) and Pathology (PH), Haartman Institute, University of Helsinki, Helsinki, Finland; Department of Dermatology, Turku University Central Hospital, and Department of Medical Biochemistry and Medicity Research Laboratory, University of Turku (MA,NJ,V-MK), Turku, Finland

SUMMARY We studied the expression and regulation of TIMP-3, a recently cloned member of the tissue inhibitor of the metalloproteinase family, during human fetal development and in various human tissues, with emphasis on epithelial structures. Expression of TIMP-3 mRNA was detected by in situ hybridization in developing bone, kidney, and various mesenchymal structures. At 16 weeks of gestation, ectoderm-derived cells of hair germs expressed TIMP-3 mRNA, and beginning from the twentieth week consistent expression was detected in epithelial outer root sheath cells of growing hair follicles. In normal adult human skin, expression of TIMP-3 mRNA was limited to hair follicles, starting at the early anagen (growing) phase and vanishing at the catagen (regressing) phase. TIMP-3 mRNA was not detected in benign hair follicle-derived tumors but was present in tumor cells of infiltrative basal cell carcinomas and in surrounding stromal cells in squamous cell carcinomas. Human primary keratinocytes in culture expressed TIMP-3 mRNAs, the levels of which were upregulated by transforming growth factor-β (TGF-β), whereas interleukin-1β (IL-1 β) and tumor necrosis factor- α (TNF- α) had no effect. Our results suggest a role for TIMP-3 in connective tissue remodeling during fetal development, hair growth cycle, and cancer progression. (J Histochem Cytochem 46:437-447, 1998)

KEY WORDS

carcinogenesis extracellular matrix hair TGF-B

The matrix metalloproteinases (MMPs, matrixins) are a family of structurally related neutral proteinases involved in the remodeling of extracellular matrix (ECM) in processes such as fetal development, wound healing, inflammation, and tumor invasion (Birkedal–Hansen 1995). These enzymes have overlapping specificities, being able to degrade important ECM macromolecules such as different types of collagens, laminin, proteoglycans, elastin, and fibronectin (Woessner 1991). The activity of metalloproteinases is regulated at several levels, including gene transcription, activation of secreted proenzymes, and inhibition by a class of natural inhibitors called TIMPs (tissue inhibitors of metal-

Correspondence to: Ulpu K. Saarialho-Kere, MD, PhD, Dept. of Dermatology, Helsinki U. Central Hospital, Meilahdentie 2, 00250 Helsinki, Finland.

Received for publication December 26, 1996; accepted May 15, 1997 (6A4180).

loproteinases). TIMPs are secreted proteins that inhibit MMPs by binding to their active site in a 1:1 stoichiometric ratio. Recently, two new members of the TIMP family have been cloned: TIMP-3 (Apte et al. 1994b; Silbiger et al. 1994; Uria et al. 1994) and TIMP-4 (Greene et al. 1996; Leco et al. 1997). TIMP-3 shares an identity of 39% to TIMP-1, 46% to TIMP-2, and 45% to TIMP-4 in amino acid sequence (Silbiger et al. 1994; Leco et al. 1997), and inhibits interstitial collagenase (MMP-1), collagenase-3 (MMP-13), stromelysin-1 (MMP-3), 72-kD and 92-kD gelatinases (MMP-2 and -9), and membrane Type 1 MMP (MMP-14) (Apte et al. 1995; Knäuper et al. 1996; Will et al. 1996). Instead of being soluble like TIMP-1 and -2, it is tightly bound to the extracellular matrix and has a distinctive pattern of expression compared to the other TIMPs (Leco et al. 1994).

TIMP-3 mRNA was first detected in human breast tumors (Uria et al. 1994), in metastatic melanoma cell

lines (Silbiger et al. 1994), and in various normal adult tissues such as placenta, kidney, heart, prostate, small intestine, and lung, and in fetal tissues including heart, lung, and kidney by Northern blot hybridization (Apte et al. 1994b; Wick et al. 1994; Wilde et al. 1994). With in situ hybridization, expression of murine TIMP-3 mRNA has been reported during mouse embryo implantation (Harvey et al. 1995; Reponen et al. 1995; Alexander et al. 1996; Leco et al. 1996) and in developing kidney, cartilage, and various epithelial structures, including epidermis and intestinal mucosa (Apte et al. 1994a). Little is known, however, about the role of TIMP-3 in human tissues in vivo, because expression of TIMP-3 mRNA has only been localized to cells of early placental structures (Byrne et al. 1995; Higuchi et al. 1995; Hurskainen et al. 1996), fetal retinal epithelium (Ruiz et al. 1996), and fibroblastic cells within breast cancer stroma (Byrne et al. 1995). Furthermore, TIMP-3 protein has been found to be an extracellular matrix component of Bruch's membrane of the human eye (Fariss et al. 1997).

TIMP-3 is induced in response to mitogenic stimulation and is regulated during normal cell cycle progression (Wick et al. 1994). A potential role for TIMP-3 in carcinogenesis has been proposed. Chicken TIMP-3 promotes oncogenic transformation in cultured cells (Yang and Hawkes 1992), and TIMP-3 overexpression inhibits human colon carcinoma growth in vivo (Bian et al. 1996). A direct implication for a human disease is the presence of point mutations in the TIMP-3 gene in patients with Sorsby's fundic dystrophy, an autosomal dominant disorder leading to visual loss (Weber et al. 1994).

To explore the physiological role of TIMP-3 in human tissues, we have determined its spatial and temporal expression during fetal development. We have also examined its expression in adult skin and various organs of the body, with special emphasis on epithelial components based on previous data on mouse tissues (Apte et al. 1994a). We report here that in early human fetus TIMP-3 is expressed in cartilage, bone, kidney, and in mesenchymal cells within the connective tissue. At 16 weeks of gestation, ectoderm-derived cells of hair germs express TIMP-3 mRNA, and beginning from the twentieth week consistent expression is detected in epithelial outer root sheath cells of growing hair follicles. In fully developed follicles, expression of TIMP-3 mRNA is cyclic, starting at the early anagen (growing) phase and vanishing at the catagen (regressing) phase. TIMP-3 mRNA is not detected in benign hair follicle-derived tumors but is present in tumor cells of infiltrative basal cell carcinomas and in surrounding stromal cells in squamous cell carcinomas. In vitro TIMP-3 gene expression in primary human epidermal keratinocytes is induced by TGF-β, but not by IL-1 β or TNF- α . Our results substantiate the role

of TIMP-3 in development, hair growth cycle, and tumor growth.

Materials and Methods

Tissues

Formalin-fixed, paraffin-embedded specimens were obtained from the Departments of Dermatology and Pathology, University of Helsinki, Finland. All fetal material originated from medical abortions and was obtained from the Department of Pathology, University of Oulu, Finland. Fetal age was estimated by menstrual age and histological examination. This study was approved by the ethics committee of the Department of Dermatology, Helsinki, Finland. The following subgroups of histological sections were examined.

- 1. Fetal tissues: complete fetus at gestational age of 7, 8–9, 10, and 12 weeks and biopsies of the scalp and trunk skin at gestational age of 16, 20, 21, and 23 weeks.
- 2. Adult skin specimens: basal cell carcinoma n=8 (infiltrative n=5, keratotic n=3), squamous cell carcinoma n=5, trichofolliculoma n=4, trichoepithelioma n=4, blistering skin diseases n=11 (dermatitis herpetiformis n=5, pemphigus n=2, pemphigoid n=2, epidermolysis bullosa n=2), and normal skin from various parts of the body n=9.
- 3. Various organs with epithelial components displaying normal histology: kidney n=3, liver n=3, pancreas n=3, parotic gland n=3, prostatic gland n=3, mammary gland n=3, testis n=3, bronchus n=3, normal gastric mucosa n=3, normal duodenal mucosa n=3, and normal colon mucosa n=3.
- 4. Carcinoma ductale mammae n=4 and carcinoma adenomatosum coli n=6.

Probes

A 518-BP fragment corresponding to positions 382-900 from the 5' end of the human TIMP-3 cDNA (Silbiger et al. 1994) was generated by PCR from a fetal cDNA library and was designed with a T7 RNA polymerase promoter at the 3' end and an SP6 RNA polymerase promoter at the 5' end. Probe transcribed from TIMP-3 cDNA in sense orientation was used as a control for nonspecific hybridization. For control purposes, another TIMP-3 cDNA fragment (positions 282–917) was generated with RT-PCR using the Gene Amp RNA PCR kit (Perkin-Elmer/Roche; Branchburg, NJ). Total cellular RNA from cultured normal human skin fibroblasts was used as template (manuscript in preparation) and the fragment was subcloned to pBluescript (Stratagene; La Jolla, CA). The production and specificity of the TIMP-1 RNA probe have been described (Sudbeck et al. 1992). By FASTA alignment, highest similarities between the TIMP-3 probes and TIMP-1 and -2 were 53-55% making cross-hybridization at high stringency unlikely.

In Situ Hybridization

In vitro transcribed anti-sense and sense RNA probes were labeled with $\alpha[^{35}S]$ -UTP. Sections were hybridized with probes (2.5–4 \times 10⁴ cpm/ μ l of hybridization buffer) and were washed under stringent conditions, including treatment with RNase A, as described (Saarialho–Kere et al. 1993). After autoradiography for 10–35 days, the photographic emul-

sion was developed and the slides were stained with hematoxylin and eosin. Samples of breast carcinomas were used as positive controls (Uria et al. 1994). Each sample was hybridized in at least two experiments, and a sense probe was used as a negative control. The slides were independently analyzed by two investigators.

Keratinocyte Cultures

Primary cultures of normal human epidermal keratinocytes were established from skin specimens from a woman undergoing mammoplasty for nonmalignant disease, as described previously (Boyce and Ham 1985). The cells were maintained in Keratinocyte Growth Medium (Clonetics; San Diego, CA) supplemented with epidermal growth factor (0.2 ng/ml) and bovine pituitary extract (30 μ g/ml) (both from Life Technologies; Paisley, UK). Cells were incubated for 24 hr with human recombinant IL-1 β (5 U/ml), TNF- α (20 ng/ml) (both from Boehringer Mannheim; Mannheim, Germany) and bovine TGF- β 2 (5 ng/ml) (kindly provided by Dr. David R. Olsen, Celtrix Co., Santa Clara, CA).

HaCaT cells, transformed human epidermal keratinocytes (obtained from Dr. Norbert Fusenig, DKFZ, Heidelberg, Germany) (Boukamp et al. 1988), were cultivated in Dulbecco's modified Eagle's medium (DMEM) containing 10% fetal calf serum. At confluence, cells were washed twice with PBS and incubated under serum-free conditions for 18–20 hr, followed by incubation with 5–50 ng/ml EGF (epidermal growth factor), 1–100 nM PMA (phorbol myristate acetate) (both from Sigma Chemical; St Louis, MO), or 0.1–10 ng/ml TGF-β1 (R & D Systems; Minneapolis, MN) for 6 hr.

RNA Analysis

Total cellular RNA was isolated from primary keratinocyte cultures using the guanidine thiocyanate–cesium chloride method (Chirgwin et al. 1979), and from HaCaT cells using the guanidine thiocyanate–phenol–chloroform extraction (Parks et al. 1988). Fifteen μg of RNA was fractionated on formal-dehyde–agarose gel and transferred to nylon membranes. Northern blot hybridizations were performed as described previously (Thomas 1980) with cDNAs labeled with $[\alpha \text{-}^{32}\text{P}]\text{-}\text{dCTP}$ using random priming and $[^{32}\text{P}]\text{-}\text{cDNA-mRNA}$ hybrids were visualized by autoradiography. The mRNA levels were quantitated by densitometric scanning of the X-ray films on gray scale with background subtraction using MCID software (Imaging Research; St Catharines, Ontario, Canada), and corrected for the levels of rRNA visualized by ethidium bromide staining.

Results

TIMP-3 mRNA Is Expressed in Fetal Kidney, Cartilage, Bone, and Mesenchyme

The youngest fetal sample studied was an embryo 7 weeks of age whose main organ systems had developed. Epidermis, seen as a single layer of cells, showed no signal for TIMP-3 mRNA, but expression was detected in neuroepithelium (data not shown), in developing

kidney, and in the adjacent gonadal ridge (Figures 1A, 1B, and 1D), and in cells within mesenchymal tissues (data not shown). Developing bone, heart, liver, and lungs, as well as bronchial epithelium, remained negative. At 8-9 weeks of gestation, chondrocytes of hand and foot plate cartilages (Figures 2A and 2B) and vertebral bodies (data not shown) expressed TIMP-3 mRNA. In other organs the distribution of TIMP-3 mRNA remained the same. At 10 weeks, signal was again detected in chondrocytes of ribs and limbs, and surrounding mesenchymal cells were positive (data not shown). At 12 weeks of gestation, expression of TIMP-3 mRNA was seen in hypertrophic chondrocytes of developing ribs and in surrounding mesenchymal cells that become osteoblasts (Figures 2C and 2D). In the same sample, bones that were already undergoing ossification had TIMP-3-expressing osteoblasts within the newly formed bone matrix (data not shown). Unlike in mouse embryos (Apte et al. 1994a), TIMP-3 mRNA was not detected in developing epidermis or in the epithelium of gastrointestinal tract or bronchial trees (data not shown).

At 7 and 8–9 weeks of gestation, no expression of TIMP-1 mRNA was detected. However, at 12 weeks mesenchymal cells surrounding hypertrophic cartilage (Figures 2E and 2F) were positive. In addition, osteoblasts within the bone matrix showed intense signal, as described earlier (Nomura et al. 1989). Chondrocytes remained negative.

Outer Root Sheath Cells of Hair Follicles Express TIMP-3 mRNA at the Anagen Phase

Biopsies of armpit and scalp skin at 16 weeks of gestation showed hair germs and early hair buds penetrating the underlying dermis. Epidermis was devoid of signal, but epithelial cells of the hair germs showed expression of TIMP-3 mRNA (Figure 3A, Inset a). By 20 weeks, follicles of the scalp showed established morphology, with epithelial cells forming the outer root sheath and mesenchymal cells forming the dermal papilla. Cells of the outer root sheath were consistently positive for TIMP-3 mRNA (Figure 3B, Inset b). In trunk skin, signal was again detected in hair germs and buds, and some follicles already in a more advanced stage of development showed signal in the outer root sheath cells (data not shown). In skin biopsies at 21 and 23 weeks of gestation, outer root sheath cells of each follicle were positive for TIMP-3 mRNA in the biopsies of both scalp and trunk (data not shown).

In adult hair follicles, TIMP-3 gene was activated during the early anagen (growing) phase and the expression persisted until the follicle entered the catagen phase and started to regress. TIMP-3 mRNA localized mainly to basal cell layer of the outer root sheath in the lower portion of the follicle (Figure 3C, Inset c). In some anagen follicles, a few pale-staining medulla




Figure 1 Expression of TIMP-3 mRNA in fetal and adult kidney. Samples were hybridized with TIMP-3 cRNA antisense (A,B,D-F) or TIMP-3 sense (C) probe as described in Materials and Methods. (A) Darkfield image of embryonal kidney (K) and gonadal ridge (GD) at 7 weeks of gestation. TIMP-3 mRNA is detected in cells of developing kidney (arrows) and gonadal ridge (small arrows). (B) Corresponding brightfield image. (C) A sense control. (D) High-power image of TIMP-3 mRNA in cells of developing kidney (arrows). In adult kidney, cortex expression of TIMP-3 mRNA is detected in both glomeruli and tubules, as seen in darkfield (E) and high power brightfield (F) images. Glomerular cells (arrows) and tubule epithelial cells (small arrows) express TIMP-3 mRNA. Bars: A-E = 34 μm; D,F = 8 μm.

cells within the hair matrix were also positive (Figure 3C). No expression was seen in telogen (resting) follicles (data not shown).

TIMP-3 was not upregulated during re-epithelialization of blistering skin diseases, and expression was not detected in normal epidermis or in sebaceous and sweat glands. However, expression was often seen in

fibroblast-like stromal cells surrounding sweat glands and some blood vessels (data not shown). TIMP-1 mRNA was commonly detected in sebaceous glands and in perivascular cells (data not shown) but only occasionally in some outer root sheath cells of anagen hair follicles (Figure 3D). Expression was not detected in fetal hair follicles.




Figure 2 Fetal hypertrophic chondrocytes express TIMP-3, but not TIMP-1 mRNA. Samples were hybridized with TIMP-3 (A–D) and TIMP-1 (E,F) anti-sense probes. (A,B) A sample of a fetus at 8–9 weeks of gestation with TIMP-3-expressing chondrocytes of foot plates. (C,D) Expression of TIMP-3 mRNA in a developing rib at 12 weeks. Both hypertrophic chondrocytes (arrows) and mesenchymal cells (small arrows) that became osteoblasts express TIMP-3 mRNA. (E,F) TIMP-1 expression is limited to the mesenchymal cells (small arrows). A, C, and E are dark-field images. Bars: A,C,E = 34 μ m; B,D,F = 17 μ m.




Figure 3 TIMP-3 is expressed during the hair growth cycle. In situ hybridizations with TIMP-3 (A–C, Inset d) and TIMP-1 anti-sense probe (D) were performed as described in Materials and Methods. (A) Skin of a fetus at 16 weeks of gestation shows expression of TIMP-3 mRNA in the epithelial cells of a hair germ (Inset a). (B) At 20 weeks of gestation, fetal scalp has many structurally complete hair follicles. Expression of TIMP-3 is detected in the outer root sheath cells of epidermal origin (arrows). Lower magnification shows a brightfield image of fetal scalp (Inset b). (C, Inset c) Outer root sheath cells of adult anagen hair follicles express TIMP-3 mRNA consistently. A few pale-staining cells in the middle of the hair matrix are also positive for TIMP-3 (arrows). (D) TIMP-1 mRNA is occasionally detected in outer root sheath cells (arrows) of anagen follicles. (Inset d) Lower magnification of adult scalp. A–D are darkfield images. Bars: A = 17 μm; B–D = 34 μm; a,c = 8 μm; b,d = 170 μm.

TIMP-3 Expression Is Induced by TGF- β in Primary Human Keratinocytes

Because TIMP-3 was expressed in hair follicles, we studied its expression in keratinocytes treated with various growth factors known to influence hair growth cycle. Primary human epidermal keratinocytes were treated with TGF- β 2, IL-1 β , and TNF- α , and levels of TIMP-3 mRNAs were assayed by Northern blot hybridizations. As shown in Figure 4, epidermal keratinocytes expressed clearly detectable levels of three distinct TIMP-3 mRNAs (2.4, 2.8, and 4.8 kb), and the TIMP-1 probe detected a single 0.9-kb mRNA. Interestingly, treatment of epidermal keratinocytes with TGF- β 2 (5 ng/ml) markedly (4.3-fold) enhanced TIMP-3 mRNA abundance in these cells. In contrast, IL-1 β (5 U/ml) and TNF- α (20 ng/ml) had no marked effect (Figure 4). It has previously been shown that epider-

mal keratinocytes in culture express TIMP-1 (Petersen et al. 1992). However, none of the treatments markedly altered the levels of TIMP-1 mRNA (Figure 4). HaCaT cells, transformed human epidermal keratinocytes, expressed basally low levels of TIMP-3 mRNA. Treatment with EGF, PMA, or TGF- β 1 did not alter the levels of TIMP-3 mRNA (data not shown).

TIMP-3 Is Expressed in Cancer Tissues

To determine whether TIMP-3 also plays a role in the behavior of benign and malignant skin tumors, samples of hair follicle-derived tumors, trichofolliculomas and trichoepitheliomas, and epidermal skin cancers were examined. Interestingly, no signal for TIMP-3 mRNA was detected in the benign tumors (data not shown). Basal cell carcinomas with keratotic (hairlike) differentiation were also negative, whereas in

TIMP-3 in Human Skin 443




Figure 4 Expression of TIMP-3 mRNAs in epidermal keratinocytes is enhanced by TGF-β. Human primary epidermal keratinocytes were maintained as described in Materials and Methods and treated for 24 h with IL-1β (5 U/ml), TNF-α (20 ng/ml), and TGF-β2 (5 ng/ml). TIMP-1 and -3 mRNA levels were examined by Northern blot hybridizations of 15 μg of total RNA, and 18S and 28S rRNAs were visualized by ethidium bromide staining. IL-1β and TNF-α had no marked effect on TIMP-3 mRNA expression, whereas TGF-β2 induced the expression by 4.3-fold. None of these cytokines markedly altered TIMP-1 mRNA levels.

four of five infiltrative basal cell carcinomas TIMP-3 mRNA was detected in tumor cells at the margins of this aggressively growing tumor. In these samples, TIMP-3 mRNA was also detected in areas showing nodular tumor growth (Figure 5A, Inset a) but not in stromal cells. In squamous cell carcinomas, all of which were well- or rather well-differentiated, some stromal cells located diffusively adjacent to the tumor expressed TIMP-3 mRNA (Figures 5C and 5D, Inset c), while malignant cells were negative. There was no correlation between the number of cells expressing TIMP-3 mRNA and the histopathology of the tumor. As in the samples representing normal skin, TIMP-3 mRNA was present in fibroblast-like cells surrounding sweat glands deeper in the dermis.

Normal gastrointestinal mucosa and mammary gland showed no signal for TIMP-3 mRNA. However, in samples of colon carcinoma intense expression was detected in both macrophages and spindle-like fibroblasts adjacent to the tumor tissue (data not shown). In agreement with the results of Byrne et al. (1995), myoepithelial cells as well as some fibroblasts surrounding tumor nodules of intraductal mammary carcinoma consistently expressed TIMP-3, whereas tumor cells remained negative (Figures 5E and 5F). In both colon and mammary carcinomas expression of TIMP-1 co-localized with that of TIMP-3 (data not shown).

Constitutive expression of TIMP-3 mRNA was also studied in some other organs with epithelial structures. In normal adult kidney, tubule epithelial and glomerular cells expressed TIMP-3 mRNA (Figures 1E and 1F). However, the glandular epithelia of liver, pancreas, parotid gland, testis, and prostate were neg-

ative. In addition, bronchial epithelium and adult bronchial cartilage were devoid of signal. The abundance of mRNA in Northern blot hybridizations of these organs (Apte et al. 1994b; Wick et al. 1994; Wilde et al. 1994) can be explained by the presence of various amounts of TIMP-3-expressing stromal cells, especially if any inflammation is present.

Discussion

The controlled physiological degradation of the ECM requires a fine balance between MMPs and their inhibitors, whereas in processes such as arthritis and tumor invasion MMP activity predominates, leading to excessive tissue degradation. There are accumulating data on the role of TIMPs and synthetic MMP inhibitors in suppressing tumor growth and invasion. Additional functions independent of metalloproteinase inhibitory activity have also been reported: TIMP-1 and -2 are anti-angiogenic (Moses et al. 1990; Johnson et al. 1994) and they possess growth-promoting activity towards a number of cell types (Hayakawa et al. 1992,1994). The role of TIMP-3 in development and connective tissue turnover has thus far been studied mostly in cell cultures, in animal models, and by analyzing mRNA from tissues by Northern hybridization. In the present study we have extended the analysis of TIMP-3 in vivo by examining its expression in human tissues. We also show that the levels of TIMP-3 transcripts are induced in human primary keratinocytes by TGF-B.

Various metalloproteinases and their inhibitors are involved in mammalian development. During the murine peri-implantation period, interstitial collagenase and stromelysin-1 mRNAs are produced by the embryo (Brenner et al. 1989). In later stages of murine embryogenesis, collagenase expression is restricted to hypertrophied chondrocytes, osteoblasts, endothelial cells, and osteoclasts of developing bones (Mattot et al. 1995). Rodent collagenase is suggested to be analogous to human collagenase-3, and these findings are consistent with our recent report on the expression of human collagenase-3 in hypertrophic chondrocytes and osteoblasts during human fetal bone development (Johansson et al. 1997). The 72-kD gelatinase is expressed widely in murine mesenchymal tissues, whereas 92-kD gelatinase mRNA production is limited to osteoclastic cells (Reponen et al. 1994). TIMP-1 and -2 are also predominantly expressed in osteogenic tissues, with some expression of TIMP-1 mRNA also in kidney, lung, ovary, and amnion (Nomura et al. 1989; Flenniken and Williams 1990; Mattot et al. 1995). TIMP-3 transcripts were found at sites of active matrix remodeling, such as developing bone and hair follicles. Co-localization of MMPs and their inhibitors in these areas suggests a coordinate process of ECM for-




Figure 5 Expression of TIMP-3 mRNA in malignant tumor tissues. Samples were hybridized with TIMP-3 anti-sense and sense probes as described. (A,a) A basal cell carcinoma. Tumor cells at the margins of tumor nodules express TIMP-3 mRNA. No expression is detected in stromal cells. (B) Serial section hybridized with a sense probe. (C) Edge of a well-differentiated squamous cell carcinoma of the skin. (c) Lower magnification of the tumor. (D) TIMP-3 mRNA is not expressed by tumor cells but by fibroblastic stromal cells adjacent to the tumor. (E,F) Intraductal mammary carcinoma. TIMP-3 mRNA is expressed by myoepithelial cells (arrows) surrounding tumor cells and by some adjacent fibroblasts (small arrow). A, B, and E are darkfield images. Bars: $A-C = 34 \mu m$; $a,D-F = 17 \mu m$; $c = 170 \mu m$.

mation and degradation in the development and maintenance of normal tissue architecture. TIMP-3 does not appear to have a major role in the epithelial folding and branching during human fetal development, in

contrast to the results of Apte et al. (Apte et al. 1994a) in mouse embryos. However, their samples represented murine embryos of 12.5 to 14.5 days of gestation as well as newborn mice, and we cannot exclude

TIMP-3 in Human Skin 445

the possibility that in human development TIMP-3 is very transiently expressed during a time period that is not covered by our samples.

Expression of TIMP-3 was detected throughout fetal hair development, starting from the hair germ stage. Hair germ formation begins in the scalp and face during the third month of gestation and gradually extends in a cephalocaudal direction. The germ consists of a group of epidermal basal cells that protrude into the dermis, forming a hair bud. Mesenchymal cells beneath each bud give rise to the dermal papilla. Further differentiation leads to the formation of the hair cuticle with the surrounding layers of inner and outer root sheath. From the beginning of the fifth month of gestation, different developmental stages are found, ranging from mature follicles to new developing ones (Lever and Schaumburg-Lever 1990). The factors that regulate the process of follicle development and growth cycle are not well understood, but they include epithelial-mesenchymal interactions and cytokines, such as epidermal growth factor (EGF), transforming growth factor- α (TGF- α), and members of the TGF-β family (Messenger 1993). The expression of TIMP-3 is stimulated in mouse cells by various agents, including PMA, EGF, TGF-β, dexamethasone, and TNF-α (Leco et al. 1994; Sun et al. 1995). However, in human primary keratinocytes only TGF-B induced expression of TIMP-3, while IL-1β and TNF-α had no effect. None of these cytokines markedly affected TIMP-1 expression. TGF-B2 mRNA co-localizes with TIMP-3 in the basal cells of the outer root sheath (Schmid et al. 1996), and since TGF-β inhibits growth of cultured hair follicles (Philpott et al. 1990) it may induce TIMP-3 to control follicle growth and degradation of the surrounding ECM.

Immunoreactivity for interstitial collagenase and matrilysin (MMP-7) has been detected in human hair follicles (Karelina et al. 1994; McGowan et al. 1994). Cultured hair follicles synthesize and secrete various MMPs, including interstitial collagenase, stromelysin-1, and gelatinases (Weinberg et al. 1990; Goodman and Ledbetter 1992; Paus et al. 1994). Cyclic expression of TIMP-1 in the inner root sheath of mouse hair follicles has been reported, with gene activation during midanagen phase (Kawabe et al. 1991). Our results demonstrate constitutive expression of TIMP-3 in both fetal and adult anagen follicles. TIMP-3 appears to contribute to the inhibition of proteolysis associated with degradation of the dermal matrix during the initial hair follicle formation, and later during the early anagen phase as the cells proliferate and invade the deeper dermis. On the basis of our studies, TIMP-1 does not have a consistent role in the growth cycle of human hair follicle. Our findings on the expression patterns of TIMP-1 and -3 in human tissues indicate that there are differences among species, and therefore

the results obtained using animal models can not be directly applied to humans.

In cutaneous squamous cell carcinomas as well as mammary and intestinal carcinomas, TIMP-3 mRNA was detected in stromal cells adjacent to the malignant tumor, which is a common expression pattern for both MMPs and TIMPs. TIMP-3 was not expressed in the benign tumors and the nonaggressive keratotic basal cell carcinomas, but the signal was distinct in the infiltrative subtype and was localized to the malignant cells at the margins of tumor islands. In contrast, both TIMP-1 and -2 are detected only in the stromal cells of surrounding basal cell carcinoma (Childers et al. 1987; Wagner et al. 1996). Furthermore, expression of TIMP-2 mRNA is lower in cutaneous squamous cell carcinomas and infiltrative subtypes of basal cell carcinoma, compared to less infiltrative subtypes (Poulsom et al. 1993; Wagner et al. 1996). In cutaneous malignant melanomas, induction of both TIMP-1 and -3 mRNA expression in vivo correlates with increased depth of invasion (manuscript in preparation). Therefore, malignant transformation appears to induce the TIMP-3 gene, and in skin tumors invasive growth is associated with enhanced TIMP-3 expression, concomitantly with increased expression of matrix metalloproteinases (Ray and Stetler-Stevenson 1994). This suggests a role for TIMP-3 in the inhibition of metalloproteinase-mediated basement membrane and matrix degradation required for malignant growth.

In this study, TIMP-3 and -1 were differentially expressed during human fetal development. Furthermore, they were differently regulated in keratinocyte cultures by various growth factors. Further studies are needed to determine the level and specific functions of TIMP-3 protein in various human tissues. On the basis of the expression pattern of TIMP-3 mRNA, TIMP-3 appears to protect the matrix from proteolytic activity and thus regulate normal tissue turnover and inhibit malignant growth. Our results demonstrate a role for TIMP-3 in human fetal development and in remodeling processes of the extracellular matrix.

Acknowledgments

Supported by the Sigrid Jusélius Foundation, the Academy of Finland, the Finnish Cancer Foundation, the Paulo Foundation, the Finska Läkaresällskapet, and grants from Helsinki and Turku University Central Hospitals.

We thank Dr David Carmichael for the TIMP-1 cDNA, Dr Jorma Keski–Oja for the HaCaT cells and TGF-β1. Dr Juha Peltonen for primary keratinocytes, Dr Riitta Herva for pathology expertise, and Ms Alli Tallqvist for excellent technical assistance.

Literature Cited

Alexander CM, Hansell EJ, Behrendtsen O, Flannery ML, Kishnani NS, Hawkes SP, Werb Z (1996) Expression and function of ma-

- trix metalloproteinases and their inhibitors at the maternal-embryonic boundary during mouse embryo implantation. Development 122:1723–1736
- Apte SS, Hayashi K, Seldin MF, Mattei MG, Hayashi M, Olsen BR (1994a) Gene encoding a novel murine tissue inhibitor of metalloproteinases (TIMP), TIMP-3, is expressed in developing mouse epithelia, cartilage, and muscle, and is located on mouse chromosome 10. Dev Dyn 200:177-197
- Apte SS, Mattei MG, Olsen BR (1994b) Cloning of the cDNA encoding tissue inhibitor of metalloproteinases (TIMP-3) and mapping of the TIMP-3 gene to chromosome 22. Genomics 19:86–90
- Apte SS, Olsen BR, Murphy G (1995) The gene structure of tissue inhibitor of metalloproteinases (TIMP)-3 and its inhibitory activities define the distinct TIMP gene family. J Biol Chem 270:14313-14318
- Bian J, Wang Y, Smith MR, Kim H, Jacobs C Jackman J, Kung HF, Colburn NH, Sun Y (1996) Suppression of in vivo tumor growth and induction of suspension cell death by tissue inhibitor of metalloproteinases (TIMP)-3. Carcinogenesis 17:1805–1811
- Birkedal-Hansen H (1995) Proteolytic remodeling of extracellular matrix. Curr Opin Cell Biol 7:728-735
- Boukamp P, Petrussevska RT, Breitkreutz D, Hornung J, Markham A, Fusenig NE (1988) Normal keratinization in a spontaneously immortalized aneuploid human keratinocyte cell line. J Cell Biol 106:761-771
- Boyce S, Ham R (1985) Cultivation, frozen storage, and clonal growth of normal human keratinocytes in serum free media. J Tissue Cult Methods 9:83–93
- Brenner CA, Adler RR, Rappolee DA, Pedersen RA, Werb Z (1989)
 Genes for extracellular matrix-degrading metalloproteinases and their inhibitor, TIMP, are expressed during early mammalian development. Genes Dev 3:848–857
- Byrne JA, Tomasetto C, Rouyer N, Bellocq JP, Rio MC, Basset P (1995) The tissue inhibitor of metalloproteinases-3 gene in breast carcinoma: identification of multiple polyadenylation sites and a stromal pattern of expression. Mol Med 1:418–427
- Childers JW, Hernandez AD, Kim JH, Stricklin GP (1987) Immunolocalization of collagenase inhibitor in normal skin and basal cell carcinoma. J Am Acad Dermatol 17:1025-1032
- Chirgwin JM, Przybyla AE, MacDonald RJ, Rutter WJ (1979) Isolation of biologically active ribonucleic acid from sources enriched in ribonuclease. Biochemistry 18:5294–5299
- Fariss RN, Apte SS, Olsen BR, Iwata K, Milam AH (1997) Tissue inhibitor of metalloproteinases-3 is a component of Bruch's membrane of the eye. Am J Pathol 150:323–328
- Flenniken AM, Williams BRG (1990) Developmental expression of the endogenous TIMP gene and a TIMP-lacZ fusion gene in transgenic mice. Genes Dev 4:1094–1106
- Goodman LV, Ledbetter SR (1992) Secretion of stromelysin by cultured dermal papilla cells: differential regulation by growth factors and functional role in mitogen-induced cell proliferation. J Cell Physiol 151:41–49
- Greene J. Wang M, Liu YE, Raymond LA, Rosen C, Shi YE (1996) Molecular cloning and characterization of human tissue inhibitor of metalloproteinase 4. J Biol Chem 271:30375–30380
- Harvey MB, Leco KJ, Arcellana-Panlilio MY, Zhang X, Edwards DR, Schultz GA (1995) Proteinase expression in early mouse embryos is regulated by leukaemia inhibitory factor and epidermal growth factor. Development 121:1005–1014
- Hayakawa T, Yamashita K, Ohuchi E, Shinagawa A (1994) Cell growth-promoting activity of tissue inhibitor of metalloprotein-ases-2 (TIMP-2). J Cell Sci 107:2373-2379
- Hayakawa T, Yamashita K, Tanzawa K, Uchijima E, Iwata K (1992) Growth-promoting activity of tissue inhibitor of metallo-proteinases-1 (TIMP-1) for a wide range of cells. A possible new growth factor in serum. FEBS Lett 298:29–32
- Higuchi T, Kanzaki H, Nakayama H, Fujimoto M, Hatayama H, Kojima K, Iwai M, Mori T, Fujita J (1995) Induction of tissue inhibitor of metalloproteinases 3 gene expression during in vitro decidualization of human endometrial stromal cells. Endocrinology 136:4973–4981

- Hurskainen T, Höyhtyä M, Tuuttila A, Oikarinen A, Autio-Harmainen H (1996) mRNA expressions of TIMP-1, -2, and -3 and 92-kD type IV collagenase in early human placenta and decidual membrane as studied by in situ hybridization. J Histochem Cytochem 44:1379-1388
- Johansson N, Saarialho-Kere U, Airola K, Herva R, Nissinen L, Westermarck J, Vuorio E, Heino J, Kähäri VM (1997) Collagenase-3 (MMP-13) is expressed by hypertrophic chondrocytes, periosteal cells, and osteoblasts during fetal bone development. Dev Dyn 208:387-397
- Johnson MD, Kim H-RC, Chesler L, Tsao-Wu G, Bouck N, Polverini PJ (1994) Inhibition of angiogenesis by tissue inhibitor of metalloproteinase. J Cell Physiol 160:194-202
- Karelina TV, Goldberg GI, Eisen AZ (1994) Matrilysin (PUMP) correlates with dermal invasion during appendageal development and cutaneous neoplasia. J Invest Dermatol 103:482-487
- Kawabe TT, Rea TJ, Flenniken AM, Williams BRG, Groppi VE, Buhl AE (1991) Localization of TIMP in cycling mouse hair. Development 111:877–879
- Knäuper V, Lopez-Otin C, Smith B, Knight G, Murphy G (1996) Biochemical characterization of human collagenase-3. J Biol Chem 271:1544-1550
- Leco KJ, Apte SS, Taniguchi GT, Hawkes SP, Khokha R, Schultz GA, Edwards DR (1997) Murine tissue inhibitor of metalloproteinases-4 (TIMP-4): cDNA isolation and expression in adult mouse tissues. FEBS Lett 401:213–217
- Leco KJ, Edwards DR, Schultz GA (1996) Tissue inhibitor of metalloproteinases-3 is the major metalloproteinase inhibitor in the decidualizing murine uterus. Mol Reprod Dev 45:458–465
- Leco KJ, Khokha R, Pavloff N, Hawkes S, Edwards DR (1994) Tissue inhibitor of metalloproteinases-3 (TIMP-3) is an extracellular matrix-associated protein with a distinctive pattern of expression in mouse cells and tissues. J Biol Chem 269:352–360
- Lever WF, Schaumburg–Lever G (1990) Embryology of the skin. In Lever WF, Schaumburg–Lever G, eds. Histopathology of the Skin. Philadelphia, JB Lippincott, 3–8
- Mattot V, Raes MB, Henriet P, Eeckhout Y, Stehelin D, Vandenbunder B, Desbiens X (1995) Expression of interstitial collagenase is restricted to skeletal tissue during mouse embryogenesis. J Cell Sci 108:529-535
- McGowan KA, Bauer EA, Smith LT (1994) Localization of type I human skin collagenase in developing embryonic and fetal skin. J Invest Dermatol 102:951–957
- Messenger AG (1993) The control of hair growth: an overview. J Invest Dermatol 101(suppl 1):4S-9S
- Moses MA, Sudhalter J, Langer R (1990) Identification of an inhibitor of neovascularization from cartilage. Science 248:1408–1410
- Nomura S, Hogan BLM, Wills AJ, Heath JK, Edwards DR (1989) Developmental expression of tissue inhibitor of metalloproteinase (TIMP) RNA. Development 105:575-583
- Parks WC, Secrist H, Wu LC, Mecham RP (1988) Developmental regulation of tropoelastin isoforms. J Biol Chem 263:4416-4423
- Paus R, Krejci-Papa N, Li L, Czarnetzki BM, Hoffman RM (1994) Correlation of proteolytic activities of organ cultured intact mouse skin with defined hair-cycle stages. J Derm Sci 7:202-209
- Petersen MJ, Woodley DT, Stricklin GP, O'Keefe EJ (1992) Synthesis and regulation of keratinocyte collagenase. Matrix (suppl 1):192-197
- Philpott MP, Green MR, Kealey T (1990) Human hair growth in vitro. J Cell Sci 97:463-471
- Poulsom R, Hanby AM, Pignatelli M, Jeffrey RE, Longcroft JM, Rogers L, Stamp GWH (1993) Expression of gelatinase A and TIMP-2 mRNAs in desmoplastic fibroblasts in both mammary carcinomas and basal cell carcinomas. J Clin Pathol 46:429-436
- Ray JM, Stetler-Stevenson WG (1994) The role of matrix metalloproteinases and their inhibitors in tumour invasion, metastasis and angiogenesis. Eur Respir J 7:2062-2072
- Reponen P, Leivo I, Sahlberg C, Apte SS, Olsen BR, Thesleff I, Tryggvason K (1995) The 92 kDa type IV collagenase and TIMP-3, but not 72 kDa type IV collagenase, or TIMP-1 or -2

447

- are highly expressed during mouse embryo implantation. Dev Dyn 202:388–396
- Reponen P, Sahlberg C, Munaut C, Thesleff I, Tryggvason K (1994) High expression of 92-kDa type IV collagenase (gelatinase B) in the osteoclast lineage during mouse development. J Cell Biol 124:1091-1102
- Ruiz A, Brett P, Bok D (1996) TIMP-3 is expressed in the human retinal pigment epithelium. Biochem Biophys Res Commun 226:467-474
- Saarialho-Kere UK, Kovacs SO, Pentland AP, Olerud JE, Welgus HG, Parks WC (1993) Cell-matrix interactions modulate interstitial collagenase expression by human keratinocytes actively involved in wound healing. J Clin Invest 92:2858–2866
- Schmid P, Itin P, Rufli TH (1996) In situ analysis of transforming growth factors- β (TGF- β 1, TGF- β 2, TGF- β 3) and TGF- β type II receptor expression in basal cell carcinomas. Br J Dermatol 134:1044-1051
- Silbiger SM, Jacobsen VL, Cupples RL, Koski RA (1994) Cloning of cDNA encoding human TIMP-3, a novel member of the tissue inhibitor of metalloproteinase family. Gene 141:293–297
- Sudbeck BD, Jeffrey JJ, Welgus HG, Mecham RP, McCourt D, Parks WC (1992) Purification and characterization of bovine collagenase and tissue inhibitor of metalloproteinases. Arch Biochem Biophys 293:370-376
- Sun Y, Hegamyer G, Kim H, Sithanandam K, Li H, Watts R, Colburn NC (1995) Molecular cloning of mouse tissue inhibitor of metalloproteinases-3 and its promoter. J Biol Chem 270:19312–19319
- Thomas PS (1980) Hybridization of denatured RNA and small DNA fragments transferred to nitrocellulose. Proc Natl Acad Sci USA 77:5201–5205
- Uria JA, Ferrando AA, Velasco G, Freije JP, Lopez-Otin C (1994)

- Structure and expression in breast tumors of human TIMP-3, a new member of the metalloproteinase inhibitor family. Cancer Res 54:2091–2094
- Wagner SN, Ockenfels HM, Wagner C, Soyer HP, Goos M (1996) Differential expression of tissue inhibitor of metalloproteinases-2 by cutaneous squamous and basal cell carcinomas. J Invest Dermatol 106:321–326
- Weber BHF, Vogt G, Pruett RC, Stöhr H, Felbor U (1994) Mutations in the tissue inhibitor of metalloproteinases-3 (TIMP-3) in patients with Sorsby's fundus dystrophy. Nature Genet 8:352–356
- Weinberg WC, Brown PD, Stetler-Stevenson WG, Yuspa SH (1990) Growth factors specifically alter hair follicle proliferation and collagenolytic activity alone and in combination. Differentiation 45:168-178
- Wick M, Burger C, Brusselbach S, Lucibello FC, Muller R (1994) A novel member of human tissue inhibitor of metalloproteinases (TIMP) gene family is regulated during G1 progression, mitogenic stimulation, differentiation, and senesence. J Biol Chem 269:18953–18960
- Wilde CG, Hawkins PR, Coleman RT, Levine WB, Delegeane AM, Okamoto PM, Ito LY, Scott RW, Seilhamer JJ (1994) Cloning and characterization of human tissue inhibitor of metalloproteinases-3. DNA Cell Biol 13:711–718
- Will H, Atkinson SJ, Butler GS, Smith B, Murphy G (1996) The soluble catalytic domain of membrane type 1 matrix metalloproteinase cleaves the propeptide of progelatinase A and initiates autoproteolytic activation. J Biol Chem 271:17119–17123
- Woessner JF (1991) Matrix metalloproteinases and their inhibitors in connective tissue remodeling. FASEB J 5:2145–2154
- Yang TT, Hawkes SP (1992) Role of the 21-kDa protein TIMP-3 in oncogenic transformation of cultured chicken embryo fibroblasts. Proc Natl Acad Sci USA 89:10676–10680

0163-769X/01/\$03.00/0 Endocrine Reviews 22(2): 184-204 Copyright © 2001 by The Endocrine Society Printed in U.S.A.

The New Human Tissue Kallikrein Gene Family: Structure, Function, and Association to Disease*

GEORGE M. YOUSEF AND ELEFTHERIOS P. DIAMANDIS

Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, Toronto, Ontario, Canada M5G 1X5; and Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada M5G 1L5

ABSTRACT

The human tissue kallikrein gene family was, until recently, thought to consist of only three genes. Two of these human kallikreins, prostate-specific antigen and human glandular kallikrein 2, are currently used as valuable biomarkers of prostatic carcinoma. More recently, new kallikrein-like genes have been discovered. It is now clear that the human tissue kallikrein gene family contains at least 15 genes. All genes share important similarities, including mapping at the same chromosomal locus (19q13.4), significant homology at both the nucleotide and protein level, and similar genomic organization.

All genes encode for putative serine proteases and most of them are regulated by steroid hormones. Recent data suggest that at least a few of these kallikrein genes are connected to malignancy. In this review, we summarize the recently accumulated knowledge on the human tissue kallikrein gene family, including gene and protein structure, predicted enzymatic activities, tissue expression, hormonal regulation, and alternative splicing. We further describe the reported associations of the human kallikreins with various human diseases and identify future avenues for research. (Endocrine Reviews 22: 184–204, 2001)

- I. Introduction
- . II. The Human and Rodent Families of Kallikrein Genes
- III. Nomenclature
- IV. The Human Kallikrein Gene Locus
 - A. Locus organization
 - B. Gene organization
- V. Protein Homologies and Predicted Enzymatic Activity
- VI. Hormonal Regulation of Kallikrein Genes
- VII. Tissue Expression of Kallikreins
- VIII. Variants of Kallikrein Transcripts
- IX. Association of Kallikreins with Human Diseases
- X. Physiological Functions
- XI. Future Directions
- XII. Conclusions

I. Introduction

ALLIKREINS are a group of serine proteases that are found in diverse tissues and biological fluids. The term "Kallikrein" was introduced in the 1930s by Werle and colleagues (1, 2) who found high levels of their original isolates in the pancreas (in Greek, the "Kallikreas"). The kallikrein enzymes are now divided into two major categories: plasma kallikrein and tissue kallikrein (3, 4). These two categories differ significantly in their molecular weight, substrate specificity, immunological characteristics, gene struc-

ture, and type of kinin released. Plasma kallikrein or Fletcher factor (official symbol KLKB1)1 is encoded by a single gene, which is located on human chromosome 4q35 (5, 6). The gene is composed of 15 exons and encodes for an enzyme that releases the bioactive peptide bradykinin from a high molecular weight precursor molecule (high mol wt kininogen) produced by the liver. Plasma kallikrein is exclusively expressed by liver cells. The function of plasma kallikrein includes its participation in the process of blood clotting and fibrinolysis and, through the release of bradykinin, in the regulation of vascular tone and inflammatory reactions (7). Plasma kallikrein will not be discussed further in this review since the gene encoding for this enzyme has no similarities with the tissue kallikrein genes and clearly, is not a member of this multigene family. A historical perspective on the discovery of the kallikrein-kinin system and bradykinin has recently been published (8).

Tissue kallikreins are members of a large multigene family and demonstrate considerable similarities at the gene and protein level as well as in tertiary structure. In this review, we will describe recent developments, exclusively pertinent to the human family of enzymes.

The term "kallikrein" is usually used to describe an enzyme that acts upon a precursor molecule (kininogen) for release of a bioactive peptide (kinin) (7–10). Another term that is also frequently used to describe these enzymes is

Address reprint requests to: Dr. E.P. Diamandis, Pathology and Laboratory Medicine, Mount Sinai Hospital, 600 University Avenue, Toronto, Ontario, Canada M5G 1X5. E-mail: ediamandis@mtsinai.on.ca; Web site: http://www.kallikreins.com

^{*} The work done in the authors' laboratory was supported by grants from the National Cancer Institute of Canada (NCIC), the Natural Sciences and Engineering Research Council (NSERC), the Medical Research Council of Canada (MRC), MDS Nordion and Diagnostics Systems Laboratories, Inc., The US Army, The Canadian Breast Cancer Research Initiative, The National Institutes of Health (NCI branch), and MDS Proteomics.

 $^{^1}$ KLK, kallikrein; KLK-L, kallikrein-like; EMSP1, enamel matrix serine proteinase 1; hGK-1, human glandular kallikrein-1; HSCTE, human stratum corneum tryptic enzyme; HSCCE, human stratum corneum chymotryptic enzyme; TADG-14, tumor-associated differentially expressed gene-14; TLSP, trypsin-like serine protease; NES1, normal epithelial cell-specific 1 gene; PRSS, protease serine; PRSSL, protease serine-like; HRE, hormone response element; ARE, androgen response element; CNS, central nervous system; HUGO, human genome organization; uPA, urokinase type plasminogen activator; TGF- β , transforming growth factor β ; PSA, prostate specific antigen.

"kininogenases." The term "kininase" is used to describe other enzymes that can inactivate kinins. Among the known human and animal tissue kallikreins, only one enzyme has the ability to release efficiently a bioactive kinin from a kininogen. In humans, this enzyme is known as pancreatic/renal kallikrein or, with the new nomenclature, as the KLK1 gene, encoding for human kallikrein 1 (hK1 protein) (9–12). This enzyme acts upon a liver-derived kininogen (low mol wt kininogen) to release lysyl-bradykinin (also known as kallidin), which is involved in the control of blood pressure, electrolyte balance, inflammation, and other diverse physiological processes. Tissue kallikrein (hK1) may further enzymatically digest other substrates, including growth factors, hormones, and cytokines, to mediate pleiotropic effects (7).

It should be emphasized that the generic term "tissue kallikrein" is not restricted to the description of enzymes that release bioactive peptides from precursor molecules. The term is used to describe a group of enzymes with highly conserved gene and protein structure, which also share considerable sequence homology and colocalize in the same chromosomal locus as the KLK1 gene. In this review, the term "kallikrein" will be used to describe a family of 15 genes that have a number of striking similarities, as outlined in point format in Table 1 (13). The use of the term "kallikrein" does not necessarily imply that any of these family members (with the exception of KLK1) have kininogenase activity. In fact, for human family members that have been functionally tested, it was found that they possess very low (hK2) (14, 15) or no kininogenase activity [prostate-specific antigen (PSA)] (14). These enzymes are grouped together with KLK1, based on the similarities outlined in Table 1.

II. The Human and Rodent Families of Kallikrein Genes

The tissue kallikrein literature can be roughly separated into various periods as follows. Early in the 1920s and 30s, researchers discovered the basic components of the kallikrein-kinin system and identified the molecular structure of bradykinin and kallidin (lysyl-bradykinin) in the 1960s (8). The molecular biology of the tissue kallikrein gene family was worked out in detail in both the human and rodents in the 1980s (16–19). It was then concluded that the mouse and rat gene families were composed of many genes, clustered in the same chromosomal locus. In particular, the mouse tissue kallikrein gene family is localized on chromosome 7 and consists of 24 genes, of which at least 14 encode for active

proteins (the remaining being pseudogenes) (16, 20–22). The area on chromosome 7 encompassing the mouse kallikreins is homologous to an area on human chromosome 19q13.4 that harbors the human kallikrein gene family. The rat tissue kallikrein gene family is composed of approximately 20 homologous genes of which at least 10 are expressed (18, 23–30).

Most of the rodent tissue kallikreins are expressed in the salivary glands, but a few, including the prostate, pituitary gland, and endometrium, have more diverse tissue expression (7, 9, 31–33). It is not the purpose of this review to describe in detail the rodent or other animal tissue kallikrein gene families. Excellent reviews on this subject already exist (9, 16, 17, 21, 22).

The human tissue kallikrein gene family was also discovered in the 1980s and it was then concluded that the entire family is composed of only three genes, namely KLK1, encoding for pancreatic/renal kallikrein (hK1 protein), the KLK2 gene, encoding for human glandular kallikrein 2 (hK2), and the KLK3 gene, encoding for PSA (hK3) (34-38). The major interest in human kallikreins lies in the very restricted tissue expression of hK2 and hK3 in the prostate, which qualifies them as candidate biomarkers for prostatic diseases (39-43). hK3 (PSA), in particular, has gained prominence in recent years as the most valuable tumor marker ever discovered and is currently used widely for the diagnosis, monitoring, and population screening for prostate cancer (44-51). The introduction of this test has had a major impact on prostate cancer diagnosis and monitoring and this field is still evolving (52, 53). More recently, PSA applications have extended beyond the prostate, including breast and other cancers (54-57). Over the last few years, human glandular kallikrein 2 is emerging as an additional prostatic and breast cancer biomarker, and it is now clear that it can supplement PSA testing for improved identification and differential diagnosis of prostate cancer (43, 58-66). It is thus logical to exploit the possible applications of other members of this gene family for cancer and other disease diagnosis and monitoring.

In the last 3 yr, we have witnessed the emergence of new knowledge related to the human kallikrein gene family (13). Independent researchers have cloned a number of new serine protease genes that show significant homologies with the classical human kallikreins; in addition, when these new protease genes were mapped, they were found to colocalize in the known human kallikrein gene locus on chromosome 19q13.3-q13.4 (67–90). The recent detailed molecular description of the human kallikrein gene locus (67, 68) enabled us to construct a physical map containing 15 genes that share

TABLE 1. Similarities between members of the new human kallikrein gene family

^{1.} All genes localize to the same chromosomal region (19q13.4).

All genes encode for putative serine proteases with a conserved catalytic triad (histidine, aspartic acid, and serine in the appropriate positions).

^{3.} All genes have five coding exons (some members contain one or more 5'-untranslated exons).

Coding exon sizes are similar or identical.

^{5.} Intron phases are fully conserved among all 15 human members and among members of the rodent kallikrein gene families.

^{6.} All genes have significant sequence homologies at the DNA and amino acid levels (40-80%).

^{7.} Many of these genes are regulated by steroid hormones.

[&]quot;Intron phase refers to the location of the intron within the codon: intron phase I, the intron occurs after the first nucleotide of the codon; II, the intron occurs after the second nucleotide; 0, the intron occurs between codons.

significant structural similarities (Table 1). Some of these genes appear to be related to breast, ovarian, and other human cancers, and a few of them appear to encode for functional tumor suppressor genes. In view of these very recent developments, we will describe, in this review, the knowledge that has accumulated on these genes, with special emphasis on the structure of the genes and proteins, their tissue expression and hormonal regulation, and their connection to various human diseases. Where possible, functional aspects of these enzymes will also be described. We hope that the summary of these new findings on the human kallikrein gene family will facilitate further research toward better understanding their physiological function, their pathophysiology and connection to human diseases, and their possible applications in the diagnosis and monitoring of various malignancies and their future suitability as therapeutic targets.

III. Nomenclature

Until 2–3 yr ago, only three human kallikrein genes were recognized: the pancreatic/renal kallikrein (KLK1), the human glandular kallikrein 2 (KLK2), and PSA (KLK3). Rittenhouse and co-workers (43, 49) have recently published the revised nomenclature for these three genes. New developments led to the identification of 15 different genes exhibiting significant homologies and other similarities, as described in Table 1 (13). Since many of these genes were cloned independently by different investigators, various empirical names were initially used for their description.

The Human Genome Organization (HUGO) has recently proposed guidelines for human gene nomenclature. Initially, some members of the new kallikrein gene family were classified by HUGO along with other serine proteases under the prefix "PRSS", standing for "protease serine." It is now clear that this designation does not serve well the needs of the future since members of this multigene family are classified together with other serine proteases that map in different locations of the genome.

TABLE 2. Proposed new nomenclature for human kallikreins

The construction of the first detailed map of the human kallikrein gene locus (13, 67, 68) allows for a more rational assignment of official gene symbols. Since the rodent and other animal species kallikrein multigene families were known before 1992, an international working party had reached agreement in 1992 on uniform nomenclature of the animal kallikreins and the three human kallikreins known at that time (91). Based on this paradigm and the guidelines of HUGO (for details please visit the Website: http://www. gene.ucl.ac.uk/nomenclature/), an international group of scientists working in the field agreed to adopt a nomenclature for the newer human kallikreins, consistent with that already defined for KLK1-3, as shown in Table 2 (92). In the same table, we also include previous symbols based on the PRSS system as well as names originally proposed by the discoverers of these genes (93-100). Gene numbering starts from centromere to telomere on chromosome 19q13.4 with the exception of the three classical kallikreins for which the existing nomenclature was retained and one newly discovered gene, which maps between KLK1 and KLK2 genes (69). It is possible that, in the future, new members of this gene family may be identified, either centromeric to KLK1 or telomeric to KLK14 (see below). If new kallikrein genes are identified in this locus, they will be sequentially numbered, starting with KLK16.

IV. The Human Kallikrein Gene Locus

A. Locus organization

The availability of linear genomic sequences around chromosome 19q13.3–q13.4 from the human genome project (the sequences were generated by the Lawrence Livermore National Laboratory) allowed the precise localization of the 15 members of the new human kallikrein gene family with high accuracy (±1 nucleotide) (68) (Fig. 1). The three classical kallikreins, KLK1, KLK3, and KLK2, cluster together within a 60-kb region, as previously described by Riegman *et al.* (36,

New gene symbol ^{a,b}	Previous gene symbol(s)	New protein symbol	Other protein names/symbols	GenBank accession no.	Reference
KLK1	KLK1	hK1	Pancreatic/renal kallikrein, hPRK	M25629, M33105	34, 93
KLK2	KLK2	hK2	Human glandular kallikrein 1, hGK-1	M18157	94
KLK3	KLK3	hK3	Prostate-specific antigen, PSA	X14810, M24543, M27274	95-97
KLK4	PRSS17, KLK-L1, KLK4	hK4	Prostase, KLK-L1 protein, EMSP1	AF113141, AF135023, AF148532	70-72, 79
KLK5	KLK-L2	hK5	KLK-L2 protein; HSCTE	AF135028, AF168768	80, 81
KLK6	PRSS9	hK6	Zyme, protease M, neurosin	AF013988, AF149289, U62801, D78203	73, 74, 82, 83
KLK7	PRSS6	hK7	HSCCE	L33404, AF166330	84, 85
KLK8	PRSS19	hK8	Neuropsin; ovasin; TADG-14	AB009849, AF095743, AB010780, AF055982	86, 98
KLK9	KLK-L3	hK9	KLK-L3 protein	AF135026	67
KLK10	PRSSL1, NES1	hK10	NES1 protein	AF055481, NM_002776	76, 99, 87
KLK11	PRSS20	hK11	TLSP/hippostasin	AB012917, AF164623	88, 89, 100
KLK12	KLK-L5	hK12	KLK-L5 protein	AF135025	77
KLK13	KLK-L4	hK13	KLK-L4 protein	AF135024	78
KLK14	KLK-L6	hK14	KLK-L6 protein	AF161221	90
KLK15		hK15	,	AF242195	69

[&]quot;The order of the genes on chromosome 19q13.4 is shown in Fig. 1.

^b For full gene names, see abbreviation footnote.

37). and Richards et al. (35). Another newly discovered gene, KLK15, maps between KLK1 and KLK2 (69). The remaining kallikrein genes are aligned within this locus, as shown in Fig. 1, without intervention by other genes. The direction of transcription is from telomere to centromere with the exception of KLK3 and KLK2. The genomic lengths of all these genes are relatively small, ranging from 4-10 kb. It is unlikely that this locus harbors more kallikrein-like genes either centromeric from KLK1 or telomeric from KLK14. The next neighboring gene to KLK1 is testicular acid phosphatase (ACPT; GenBank Accession no. AF321918), which is not related to kallikreins. The next neighboring gene from KLK14 is Sigelec 9 (101). Siglecs belong to the immunoglobulin superfamily and encode for transmembrane receptors that have the ability to bind sialic acid (102, 103). These genes have no structural or functional relationship to the human kallikreins.


B. Gene organization

All members of the new human kallikrein multigene family encode for serine proteases. All genes consist of five coding exons, as shown in Fig. 2. The organization of all genes is very similar, with the first coding exon having a short 5'-untranslated region, the second exon harboring the amino acid histidine of the catalytic triad toward the end of the exon, the third exon harboring the aspartic acid of the catalytic triad around the middle, and the fifth exon harboring the serine of the catalytic triad, at the beginning of the exon. Beyond the stop codon, there is a 3'-untranslated region of variable length.

While it is certain that the classical kallikreins do not have 5'-untranslated exons, most other members of this multigene family have one or two 5'-untranslated exons, as shown in Fig. 2. It is possible that some other members of this gene family also harbor 5'-untranslated exons, which have not as yet been identified. In addition, the 3'-untranslated region of many of these genes is sometimes variable, giving rise to variants with different mRNA lengths, but encoding for the same protein (variant kallikrein transcripts are described under a separate heading). It is thus possible that the actual lengths of these genes, as shown in Figs. 1 and 2, may change slightly in the future.

Although the intron lengths of these genes vary considerably, the exon lengths are quite comparable or identical. Additionally, the intron phases between coding exons of all these genes (and those of the rodent kallikreins) are completely conserved among all members, with phases I–II–I–O. The intron phases are defined in Fig. 2.

Although TATA boxes have been identified within the proximal promoter of the classical kallikrein genes (Table 3), no such elements were found for most of the other kallikreins. This may be due to the absence of these elements or to the fact that the proximal promoter of some of these genes has not been accurately defined due to the presence of as yet unidentified 5'-untranslated exons. This issue merits further investigation. Classical (AATAAA) or variant polyadenylation signals have been identified 10–20 bases away from the poly A tail of all kallikrein mRNAs (Table 3). With only one exception, all splice-junction sites are fully conserved among the human kallikrein genes (Table 3).



Chromosomal locus 19q13.3-q13.4

Fig. 1. An approximate 300-kb region of contiguous genomic sequence around chromosome 19q13.4. The direction of transcription of each gene is illustrated by arrows. Boxes represent genes and contain the gene names and their genomic length, in base pairs. Other commonly used names for these genes are also mentioned. Distances between genes in base pairs are shown between boxes. The Siglec and ACPT (testicular acid phosphatase) genes do not belong to the tissue kallikrein gene family. Figure is not drawn to scale. For full gene names, see Table 2 and abbreviation footnote.

V. Protein Homologies and Predicted Enzymatic Activity

The 15 members of the new human kallikrein gene family have been aligned to identify similarities (Fig. 3). Maximum homology between all these proteins is found around the catalytic amino acids histidine (with the conserved region




Fig. 2. Schematic diagram showing the comparison of the coding regions of the 15 kallikrein genes. Exons are shown by solid bars and introns by the connecting lines. Letters above boxes indicate relative positions of the catalytic triad that was found to be conserved in all genes; H, histidine; D, aspartic acid; and S, serine. Roman numbers indicate intron phases. The intron phase refers to the location of the intron within the codon; I denotes that the intron occurs after the first nucleotide of the codon; II, the intron occurs after the second nucleotide; 0, the intron occurs between codons. The intron phases are conserved in all genes. Numbers inside boxes indicate exon lengths and numbers outside boxes indicate intron lengths (in base pairs). The arrowhead represents the position of the start codon and the arrow indicates the position of the stop codon. Question mark denotes that region length is unknown. Figure is not drawn to scale.

TABLE 3. TATA, polyadenylation signals, and splice/junctions for the KLK genes^a

Gene	TATA box	Polyadenylation signal ^b	Splice junctions
KLK1	TTTAAA (-21 bp) ^c	AGTAAA (-15 bp)	Fully conserved
KLK2	TTTATA (-35 bp)	AATAAA (-19 bp)	Fully conserved
KLK3	TTTATA (-22 bp)	AATAAA (-16 bp)	Fully conserved
KLK4	TTATAA (-30 bp)	AATAAA (-15 bp)	Fully conserved
KLK5	Not found	AATAAA $(-8 \text{ to } -11 \text{ bp})$	Fully conserved
KLK6	Not found	AATAAA (-14 bp)	Fully conserved
KLK7	Not found	AATAAA (-16 bp)	Fully conserved
KLK8	Not found	AATAAA $(-15 \text{ to } -18 \text{ bp})$	Fully conserved
KLK9	Not found	AGTAAA (-14 bp)	Fully conserved
KLK10	TTAAAA (-35 bp)	ACTAAA (-17 bp)	gc for gt at beginning of intron 4^d
KLK11	Not found	AATAAA (-17 bp)	Fully conserved
KLK12	Not found	AATAAA (-16 bp)	Fully conserved
KLK13	Not found	TATAAA (-16 bp)	Fully conserved
KLK14	Not found	Putative AATAAA	Fully conserved
KLK15	Not founde	ATTAAA (-17 bp)	Fully conserved

^a The information was derived from the GenBank entries shown in Table 2.

WVLTAAHC), aspartic acid (DLMLL), and serine (GDSG-GPL). In general, the amino acid identity between the various members of this family ranges from about 40–80%. The number and position of cysteine residues are highly con-

served among the 15 human kallikreins and among other serine proteases. All members of this family possess between 10–12 cysteine residues, which are expected to form disulfide bridges. A number of other invariant amino acids (~25–30),

^b Position of polyadenylation signal in base pairs before the poly-A tail.

^c Denotes position of TATA box considering first nucleotide of start codon as 1.

d See Ref. 87.

TATA box may be present in some genes for which the 5'-proximal promoter sequences have not as yet been accurately defined.

especially those around the active site of serine proteases, have been described (104). In the case of the human family of genes, there are 39 amino acids that are completely conserved among all 15 kallikreins (Fig. 3). Numerous other conservative amino acid substitutions are shown in Fig. 3. A phylogenetic tree of all human kallikreins and a few other serine proteases is shown in Fig. 4.

All proteins encoded by these genes are initially synthesized as preproenzymes that are then proteolytically processed to yield proenzymes by removal of the signal peptide, followed by activation (also by proteolysis) to the mature, enzymatically active forms. In Table 4, we present the reported signal and activation peptides as well as the length of the mature proteins that are encoded by these genes. It is important to mention that most of these cleavage sites have been predicted by computer programs and have been verified experimentally for only a few members.

The data of Table 4 suggest that most of the pro-forms of these enzymes are activated by cleavage at the carboxyterminal end of either arginine (R) or lysine (K) residues (the preferred trypsin cleavage site). Since most of the human kallikrein enzymes have trypsin-like activity, they may potentially act as activating enzymes for either themselves (autoactivation) or other pro-forms of kallikreins. Kallikreins may participate in cascade pathways similar to those demonstrated for the digestive enzymes, coagulation, and apoptosis. These possibilities merit further investigation.

Protein sequence examination (Fig. 3) reveals that the three classical kallikreins possess an amino acid sequence of approximately 9–11 amino acids (the kallikrein loop) preceding the aspartic acid residue of serine proteases, which is not present in its entirety in any of the other 12 enzymes. This short sequence is thought to confer specificity for kininogenase activity but, as already mentioned, only hK1 is a potent kininogenase. KLK15 has a unique 8-amino acid sequence at positions 148–155, not found in any other kallikrein protein. Similarly, KLK13 possesses a unique amino-terminal and a unique carboxy-terminal end.

Serine proteases can be divided into two main evolutionary families, the trypsin-like serine proteases and the subtilisin-like pro-protein convertases, which presumably evolved through convergent evolution (105). The trypsin-like serine proteases are believed to have evolved from a single ancestral gene that duplicated in the course of evolution to give rise to other genes that have gradually mutated and evolved to related proteases and protease subfamilies with new functions. The various serine proteases can be markedly different in relation to their substrate specificity (106, 107). The differences are due to very subtle variations in the substrate binding pocket. Trypsin-like serine proteases have an aspartic acid in their binding pocket, which can form strong electrostatic bonds with arginine or lysine residues, which are usually present at the carboxyl-terminal part of the cleavage site. The important amino acid of the binding pocket, responsible for substrate specificity, is usually found six amino acids before the catalytic serine residue. From the 15 proteins aligned in Fig. 3, 11 have aspartic acid in this position and are expected to have trypsin-like activity. The four remaining enzymes, namely hK3 (has serine), hK7 (has asparagine), hK9 (has glycine), and hK15 (has glutamic acid),

are expected to have chymotrypsin-like or other specific enzymatic activity (see also Table 4). The cleavage specificity of these enzymes needs to be established experimentally, with the exception of hK3, which has already been characterized (50).

VI. Hormonal Regulation of Kallikrein Genes

KLK1 expression has been studied in animals, and it was concluded, by using gene-specific probes, that this enzyme is not directly regulated by androgens either in the salivary glands or the kidney (31, 108–111). Similarly, no regulation of the KLK1 gene by thyroid hormones has been demonstrated (109–111). Results of KLK1 regulation by mineralocorticoids are inconclusive (112, 113). Other data support the transcriptional up-regulation of KLK1 by estrogens (114, 115) and by dopamine in rat pituitary (116). The demonstration that KLK1 expression in human endometrium is higher during the middle of the menstrual cycle is also suggestive of KLK1 up-regulation by estrogens in this tissue (117).

Murray et al. (19) have reported the presence of various motifs that are reminiscent of consensus estrogen-, progestin-, glucocorticoid-, or cAMP-response elements in the 5'-flanking sequence of the human KLK1 gene (19). However, these putative elements have not been functionally tested. Consequently, no conclusion can be drawn regarding direct regulation of KLK1 transcription by steroid or other hormones.

The regulation of the PSA (KLK3) gene by steroid hormones has been extensively studied. Initially, two androgenresponse elements were identified in the proximal PSA promoter, at positions -170 [ARE1] and -394 (ARE2), respectively (118-120). These AREs have been functionally tested and found to be active in LNCaP prostate cancer cells. More recently, Schuur et al. have identified various regions of 5'-sequences of the PSA gene around -6 to -4 kb and demonstrated presence of a putative androgen-response element at position -4,136 (ARE3), which markedly affects PSA transcription upon induction by androgens (121). It was also demonstrated that this area harbors an enhancer that is contained within a 440-bp fragment (121, 122). The upstream enhancer, containing the putative ARE3, has a dramatic effect on PSA transcription, in comparison to the two AREs in the proximal promoter (122). The hormonal regulation of the PSA gene is not tissue specific since PSA has also been found to be regulated by steroid hormones in vitro and in vivo in breast tissues and breast carcinoma cell lines (123-125). Despite this, a number of investigators have used the PSA promoter and enhancer region to deliver and express therapeutic vectors to prostate tissue, in experimental gene therapy protocols (126-132).

A number of investigations have clearly demonstrated hormonal regulation of the PSA gene primarily by androgens in the prostatic carcinoma cell line LNCaP (133) and by androgens and progestins in the breast carcinoma cell lines BT-474, T-47D, and MFM223 (123, 125, 134).

The 5'-promoter sequences of the KLK2 gene have been studied by Murtha *et al.* (135) who have identified functional androgen response elements in the promoter of this gene.




Fig. 3. Alignment of the deduced amino acid sequence of the 15 kallikrein proteins. Dashes represent gaps to bring the sequences to better alignment. The amino acids of the catalytic triad (H, D, S) are shown in italics. Identical amino acids are highlighted in black and similar residues in gray. The 29 invariant serine protease residues are marked by () on the bottom, and the cysteine residues by (+') on top of each block. The dotted area represents the kallikrein loop sequence. The asterisk denotes the position of the amino acid of the binding pocket that is crucial for substrate specificity (for trypsin-like enzymes the amino acid is D). For more details, see text.

The same group has subsequently shown that KLK2 is upregulated by androgens and progestins in the breast carcinoma cell line T47-D (136) while Riegman *et al.* (137) showed up-regulation by androgens. More recently, it has been demonstrated that, similarly to PSA, a 5'-enhancer region exists

about 3–5 kb upstream from the transcription site of the KLK2 gene (138). The enhancer region contains an androgen response element that was shown to be functionally active. Consistent with these data are the findings of hK2 protein secretion and up-regulation by androgens and progestins in




FIG. 4. Dendrogram of the predicted phylogenetic tree for the 15 kallikrein proteins and a few other related serine proteases. The neighbor-joining method was used to align these proteins. The classical kallikreins (hK1, hK2, and PSA) were grouped together; other kallikreins and serine proteases were separated in different groups, as shown. For full protein names, please see Table 2 and abbreviation footnote.

the breast cancer cell lines BT-474, T47-D, and MFM223 (134). Although the KLK2 gene promoter is not exclusively functional in the prostate, gene therapy protocols have used it for prostate cancer therapy (139).

The KLK4 gene was found to be up-regulated by androgens in the prostatic carcinoma cell line LNCaP (70) and by androgens and progestins in the breast carcinoma cell line BT-474 (71). The mode of regulation of KLK2 and KLK4 genes appears to be very similar to the mode of regulation of PSA (KLK3). Stephenson *et al.* (72) have identified putative androgen response elements in the proximal promoter region of the KLK4 gene (up to 553 bp from the transcription initiation site). However, such putative AREs have not been functionally tested, and no data have been published as yet on the characterization of possible enhancer regions further upstream from the proximal KLK4 promoter.

For the remaining 11 human kallikrein genes that have been recently identified, in none of them was the promoter functionally tested for the presence for hormone response elements (HREs). Most studies regarding hormonal regulation of these new genes have been performed with the breast carcinoma cell line BT-474 and, in some cases, with the prostatic carcinoma cell line LNCaP and other breast carcinoma cell lines. It is clear that for 10 of 11 genes under discussion (KLK5-KLK15), transcription is affected by steroid hormones, with the selectivities and potencies shown in Table 5.

Most genes appear to be up-regulated by estrogens, androgens, and progestins but with different potencies. It is possible that some of these genes are hormonally regulated through indirect mechanisms, involving *trans*-acting elements (140).

Clearly, there is a need to functionally characterize the promoter and enhancer regions of these genes to understand better the mechanism of transcriptional and posttranscriptional regulation by steroid hormones.

VII. Tissue Expression of Kallikreins

KLK1 gene expression is highest in the pancreas, kidney, and salivary glands (9). The other two classical kallikrein genes, KLK3 and KLK2, were thought, for many years, to be expressed exclusively in the prostate (39-42, 46, 141, 142). By using highly sensitive immunological techniques (143), RT-PCR technology (144) as well as immunohistochemistry (145), it has now been demonstrated unequivocally that both KLK3 and KLK2 genes are expressed in diverse tissues but at relatively much lower concentrations than prostatic tissues (55-57, 146-148). Especially, hK3 (PSA) and hK2 proteins and mRNA have been found in significant amounts in the female breast and at lower levels in many other tissues (Table 6). KLK4 also appears to have prostatic-restricted expression (70) but by RT-PCR, it was demonstrated that it is also expressed in breast and other tissues (71, 72). None of the remaining kallikreins is tissue-specific, although certain genes are preferentially expressed in breast (e.g., KLK5, KLK6, KLK10, KLK13), skin (KLK5, KLK7, KLK8), central nervous system (KLK6, KLK7, KLK8, KLK9,KLK14), salivary glands (almost all kallikreins), etc. A diagrammatic representation of expression of all these kallikreins in human tissues is shown in Fig. 5. Most data have been generated by RT-PCR.

It is clear that there is frequent coexpression of many kallikreins in the same tissues, and this may point to a functional relationship. For example, it has been shown that hK3 and hK2 are regulated by similar mechanisms (134) (see also previous section) and that they are frequently coexpressed in tissues and body fluids (146–148). *In vitro* data have demonstrated that hK2, which has trypsin-like activity, can activate the proform of PSA (149–151). Other functional relationships between members of the kallikrein gene family have not been demonstrated as yet.

VIII. Variants of Kallikrein Transcripts

A relatively large number of variant transcripts have already been identified for the classic and the new human kallikrein genes (Table 7). The functional and diagnostic importance of these transcripts has not as yet been studied in detail. It will be interesting to examine whether any of these transcripts are specific for certain disease states or tissues. Although other forms of some kallikreins in serum have already been described (e.g., kallikreins bound to proteinase inhibitors, internally clipped kallikreins, circulating proforms, etc.), these will not be described in this review. Excellent accounts of these forms and their clinical signifi-

TABLE 4. Proteins encoded by kallikrein genes

Kallikrein	Length of pre- proenzyme	Length of signal peptide (cleavage) ^a	Length of activation peptide/cleavage"	Length of mature protein	Amino acid of substrate binding pocket	Reference
hK1	262	17 (A ↓ A)	7 (R ↓ I)	238	D	34, 35, 43, 49
hK2	261	17 (A ↓ V)	7 (R ↓ 1)	237	D	43, 49, 94
hK3	261	17 (A ↓ A)	7 (R ↓ I)	237	S	43, 49, 95-97
hK4	254	26 (G \ S)	4 (Q ↓ I)	224	D	70-72
hK5	293	29 (A ↓ N)	37 (R ↓ I)	227	D	80, 81
hK6	244	16 (A ↓ E)	5 (K ↓ L)	223	D	73, 74, 82, 83
hK7	253	22 (G \ E)	7 (K ↓ I)	224	N	84, 85, 107
hK8	260	28 (A ↓ Q)	4 (K ↓ V)	228	D	86, 98
hK9	251	19 (A ↓ D)	3 (R ↓ A)	229	G	67
hK10	276	33 (A A)	9 (R ↓ L)	234	D	76
hK11	250	18 (G ↓ E)	3 (R ↓ I)	229	D	88, 89, 100
hK12	248	17 (A ↓ A)	4 (K I)	227	D	77
hK13	277	20 (S ↓ Q)	5 (K ↓ V)	252	D	78
hK14	251	18 (S ↓ Q)	6 (K ↓ I)	227	D	90
hK15	256	16 (A ↓ Q)	5 (K ↓ L)	235	E	69

^a Most are predicted; need verification by experiment.

TABLE 5. Hormonal regulation of human kallikreins

Gene	Systems tested	HREsª	Functionally tested?	Up-regulating hormone(s)	Reference
KLK1	In vivo humans, rodents	Putative	No	Uncertain	19
KLK2	LNCaP; BT-474, T-47D	Yes (2 AREs)	Yes	Androgen, progestin	134 - 137
KLK3	LNCaP, BT-474, T-47D	Yes (3 AREs)	Yes	Androgen, progestin	118 - 125
				5 . 1 . 5	133-134
KLK4	LNCaP; BT-474	Putative (AREs)	No	Androgen, progestin	70-72
KLK5	BT-474	NS (not studied)		Estrogen, progestin > androgen	80
KLK6	BT-474	NS		Estrogen, progestin > androgen	83
KLK7	BT-474	NS		Estrogen > glucocorticoid	85
KLK8	Not studied			•••	
KLK9	BT-474	NS	•	Estrogen, progestin > androgen	67
KLK10	BT-474	Not found		Estrogen > androgen > progestin	140
KLK11	BT-474	NS		Estrogen, glucocorticoid	89
KLK12	LNCaP, BT-474, T-47D	NS		Androgen, progestin > estrogen but in BT-474, estrogen > androgen > progestin	77
KLK13	BT-474	NS		Androgen, progestin > estrogen	78
KLK14	Not studied				
KLK15	LNCaP		No	Androgen > progestin, estrogen	69

LNCaP, Prostate carcinoma cell line; BT-474, T-47D, breast carcinoma cell lines.

cance already exist (43, 47–49, 152–158). It should be emphasized that, in general, the putative proteins encoded by these variant transcripts have not been isolated. By open reading frame analysis, it has been predicted that most transcripts will produce truncated proteins due to frameshifts originating from deleted exons. More details on these variant transcripts and the predicted encoded proteins can be found in the literature cited in Table 7 (34, 69, 77, 78, 86, 94, 96–98, 137, 159–165).

IX. Association of Kallikreins with Human Diseases

As already mentioned, the only enzyme with efficient kininogenase activity, among the human kallikrein family members, is hK1. The biological effects of this enzyme, and of plasma kallikrein, are mediated mainly by kinin release. Kinin binds to specific G protein-coupled cell surface receptors to mediate diverse biological functions. The kallikrein-kinin system is involved in many disease processes, including inflammation (9), hypertension (166), renal disease (167, 168), pancreatitis (169), and cancer (170–174). A recent book summarizes elegantly the physiology, molecular biology,

and pathophysiology of the kallikrein-kinin system and its association to various disease processes (175).

Among all other kallikreins, the best studied, by far, is PSA (hK3) and especially, its application to prostate cancer diagnostics. A comprehensive volume on PSA as a tumor marker has been recently published (176). The extensive literature on PSA and prostate cancer does not warrant further discussion in this review.

Although PSA concentration is generally elevated in the serum of prostate cancer patients, one less known and usually not well understood finding is PSA down-regulation in prostate cancer tissue, in comparison to normal or hyperplastic prostatic tissues (177–182). Furthermore, it has been demonstrated that lower tissue PSA concentration is associated with more aggressive forms of prostate cancer (182, 183). These data agree with those published for breast cancer, where it was found that PSA is down-regulated in cancerous breast tissues, in comparison to normal or hyperplastic breast tissues, and in more aggressive forms of breast cancer. Patients with PSA-positive tumors usually have earlier disease stage, live longer, and relapse less frequently (184–186). Furthermore, it was found that lower PSA levels in nipple as-

^a Hormone response elements.

TABLE 6. Tissue expression of human kallikreins

Gene	Tissue expression ^a			
	Highest	Other tissues	Reference	
KLK1	Pancreas, kidney, salivary glands	Sweat glands, intestine, CNS, b neutrophils, uterus, prostate, testis, breast, placenta	7, 9	
KLK2	Prostate	Breast, thyroid, salivary glands	46, 147, 148	
KLK3	Prostate	Breast, thyroid, salivary glands, lung, trachea	39-45, 54-57	
KLK4	Prostate	Breast, thyroid, testis, uterus, adrenal, colon, spinal cord	70-72	
KLK5	Breast, brain, testis, skin	Salivary glands, thymus, CNS, prostate, thyroid, trachea	80, 81	
KLK6	CNS, breast, kidney, uterus	Salivary gland, spleen, testis	73, 74, 82, 83	
KLK7	Skin, CNS, kidney, breast	Salivary glands, thymus, uterus, thyroid, placenta, trachea, testis, ovary	84, 85, 107	
KLK8	CNS, skin, ovary	, , ,	86, 98	
KLK9	Thymus, testis, CNS, trachea	Breast, prostate, salivary glands, ovary, skin	67	
KLK10	Breast, ovary, testis, prostate	Small intestine, lung, colon, pancreas, uterus, CNS, salivary glands, trachea	76	
KLK11	Brain, skin, salivary gland, stomach, uterus, lung, thymus, prostate, spleen, liver, small intestine, trachea	Heart, fetal liver, breast, thyroid, skeletal muscle	88, 89	
KLK12	Salivary glands, stomach, uterus, trachea, prostate, thymus, lung, colon, brain, breast, thyroid	Testis, pancreas, small intestine, spinal cord	77	
KLK13	Breast, prostate, salivary glands, testis	Lung, heart, thymus, adrenal, colon, thyroid, trachea	78	
KLK14	CNS	Breast, thyroid, uterus, thymus, colon, spleen, placenta, small intestine, kidney, bone marrow	90	
KLK15	Thyroid, salivary glands, prostate	Adrenal, colon, testis, kidney	69	

^a Most data have been produced by RT-PCR technology.

pirate fluid of women are associated with higher risk for developing breast cancer (187). Other published data suggest that PSA may be a tumor suppressor (188), an inducer of apoptosis (188), a negative regulator of cell growth (189), and an inhibitor of angiogenesis (190, 191) and bone resorption (192, 193). These data have recently been reviewed (194).

Another set of investigations suggests that PSA may be associated with unfavorable prognosis/outcomes in breast, prostate, and other cancers. More specifically, it was found that breast tumors with higher PSA content do not respond well to tamoxifen therapy (195). Further, patients with breast tumors, which produce PSA after stimulation by medroxyprogesterone acetate (a synthetic progestin/androgen), have a worse prognosis than patients with tumors that do not produce PSA (196). A number of reports have indicated that PSA may cleave insulin-like growth factor binding protein-3, thus liberating insulin-like growth factor I (IGF-I), which is a mitogen for prostatic stromal and epithelial cells (197-199). PSA may activate latent transforming growth factor- β (TGF β), stimulate cell detachment and facilitate tumor spread (200). Like other serine proteases, PSA may mediate proteolysis of basement membrane, leading to invasion and metastasis (201).

These confusing clinical data are due to differences in methodology, purity, and source of PSA preparations used, selection of patients, etc. Furthermore, the lack of knowledge of the biological pathways in which PSA is participating poses significant difficulties in interpreting these clinical observations, as further exemplified in a recent commentary (194).

Human glandular kallikrein 2 (hK2) appears to be a new, promising biomarker for prostatic carcinoma (43). It is clear that the diagnostic value of hK2 measurement in serum is not

superior to PSA; hK2 may aid in the differential diagnosis between prostate cancer and benign prostatic hyperplasia (57–66) as well as in the identification of organ-confined *vs.* non-organ-confined disease (202). Immunohistochemical studies have shown that prostate cancer tissue produces more hK2 than normal or hyperplastic tissue (203, 204). However, recent quantitative data demonstrate that hK2 concentration, although to a lesser extent than PSA, is also decreased in cancerous tissue, in comparison to adjacent normal tissue (181). Although hK2 has been detected in breast and other tissues (146–148), no studies have as yet been performed to examine its biological action or its value as a breast disease biomarker.

Although it has been shown that KLK4 expression is relatively high in prostate (70, 71), there are no reports describing association or usefulness of this kallikrein in prostatic disease. It will be worthwhile to examine the possible clinical value of this kallikrein as a biomarker in prostatic and other diseases. Recently, KLK4 was found to be overexpressed in a subset of ovarian tumors (205).

A single report describes overexpression of KLK5 in ovarian carcinomas and association with less favorable clinical outcomes (206). Further, KLK6 appears to be dramatically down-regulated at metastatic breast cancer sites and upregulated in a subset of primary breast and ovarian tumors (73). These data should be interpreted with caution since the number of patients was small and the techniques used were qualitative. Additionally, Little *et al.* (74) suggested that KLK6 may be amyloidogenic and may play a role in the development of Alzheimer's disease by cleaving amyloid precursor proteins. Recently, a number of newly cloned aspartyl proteinases were also shown to be amyloidogenic (207). The connection between various types of proteases and

^b CNS, central nervous system.




Fig. 5. Schematic representation of tissue kallikrein expression in various tissues. Higher level of expression is shown in *bold*. For more information and discussion, see text and Table 6.

this disease is still ill-defined. The connections of KLK7 with skin diseases, including pathological keratinization and psoriasis, have already been reported (75, 208). KLK7 was also found to be overexpressed in a subset of ovarian carcinomas (107). There are reports describing connection of KLK8 expression with diseases of the central nervous system, including epilepsy (209–212), injury (213, 214), and learning disturbances (215). Another report describes KLK8 overex-

pression in a subset of ovarian carcinomas (98). Although KLK10 has been shown to be a breast cancer tumor suppressor in animal models (76, 99), there is no report as yet describing prognostic or diagnostic value of KLK10 in breast carcinomas. Recently, KLK10 was found to be down-regulated in more aggressive forms of prostate cancer (216). Preliminary data suggest that KLK12, KLK13, and KLK14 may be down-regulated in a subset of breast carcinomas (77, 78,

90) while KLK15 may be overexpressed in more aggressive forms of prostate cancer (69).

The associations of kallikreins to human diseases are summarized in Table 8. Clearly, except for hK1, hK2, and hK3, the literature is quite limited and the value of the new kallikreins as disease biomarkers is just starting to be examined. Since most studies thus far used small numbers of clinical samples and qualitative methodologies, the data should be interpreted with caution. The knowledge that these kallikreins are secreted proteins supports the idea that they likely circulate in blood and that their concentration may be altered in cer-

TABLE 7. Variant transcripts of human kallikreins

Gene	No. of known variant transcripts	GenBank accession no.	References
KLK1	3	Not available (N/A)	34, 159, 160
KLK2	6	AF188746	94, 137, 161
KLK3	5	M21896 M21897	96, 97, 162, 163
KLK4	2	N/A	Our unpublished data"
KLK7	4	AF166330	85
KLK8	5	AB010780 AF095743 AF251125	86, 98, 164
KLK11	2	AF164623 AB041036	89, 100
KLK12	3	AF135025	77
KLK13	7	AF135024	78, 165
KLK15	3	AF242195	69

^a Also, J. Clements, personal communication.

TABLE 8. Association of kallikreins to human disease

tain human diseases, including cancer. The experience with hK3 (PSA) and hK2 in prostate cancer may be used to exploit other cancers, including those of breast, ovarian, lung, etc. These possibilities deserve further investigation.

X. Physiological Functions

Among the 15 new human kallikrein genes, only 3 have been assigned to a specific biological function (Fig. 6). hK1 exerts its biological activity mainly through the release of lysyl-bradykinin (kallidin) from low molecular weight kiningen. However, the diverse expression pattern of hK1 has led to the suggestion that the functional role of this enzyme may be specific to different cell types (7, 22). Apart from its kininogenase activity, tissue kallikrein has been implicated in the processing of growth factors and peptide hormones (217–220) in light of its presence in pituitary, pancreas, and other tissues. As summarized by Bhoola et al. (7), hK1 has been shown to cleave pro-insulin, low density lipoprotein, the precursor of atrial natriuretic factor, prorenin, vasoactive intestinal peptide, procollagenase, and angiotensinogen. Kallikreins, in each cell type, may possess single or multiple functions, common or unique, but Bhoola *et al.* (7) suggest that the release of kinin should still be considered the primary effect of hK1 (7).

The physiological function of hK2 protein has been examined only recently, with the availability of preparations of recombinant origin, which are essentially free of hK3 (PSA)

	Disease	Effect/use	Reference
KLK1	Inflammation; sepsis; pancreatitis; bone metabolism; heart disease; renal disease; cancer	Mediation by bradykinin or lysyl-bradykinin	9, 166-178
KLK2	Prostate cancer	Biomarker for diagnosis, monitoring, prognosis	43, 57-66, 202
	Breast cancer	Expressed in breast cancer but prognostic/diagnostic value not as yet examined	146-148
KLK3	Prostate cancer	Biomarker for diagnosis and monitoring	42-53
		Inducer of apoptosis; decreases cell proliferation; inhibitor of angiogenesis	188-191
	Breast cancer	Favorable prognostic indicator; down-regulated in more aggressive disease	184-187
KLK4	Ovarian cancer	Overexpression in a subset of more aggressive ovarian tumors	205
KLK5	Ovarian cancer	Overexpression in a subset of more aggressive ovarian tumors	206
KLK6	Breast cancer	Down-regulation at metastatic sites and up-regulation in a subset of primary tumors	73
	Ovarian cancer	Up-regulation in a subset of ovarian tumors	73
	Alzheimer's disease	Has amyloidogenic potential	74
KLK7	Pathological keratinization	Overexpression in lichen planus and benign oval keratosis	208
	Psoriasis	Overexpression	75
	Ovarian cancer	Overexpression; may be involved in tumor growth and metastasis	107
KLK8	CNS injury	Increased KLK8 expression	213, 214
	Kindling epilepsy	Increased KLK8 expression	209 - 212
	Ovarian cancer	Overexpression in a subset of tumors	98
KLK10	Breast cancer	Down-regulation; KLK10 may be a tumor suppressor	76, 99
	Prostate cancer	Down-regulated in more aggressive prostate cancer	216
KLK12	Breast cancer	Down-regulated in a subset of breast tumors	77
KLK13	Breast cancer	Down-regulated in a subset of breast and testicular tumors	78
KLK14	Breast cancer	Down-regulation	90
KLK15	Prostate cancer	Overexpressed in more aggressive forms	69



Low-molecular weight kininogen:




Fig. 6. Biological functions of the three classical kallikreins. hK1 cleaves low molecular weight kininogen and releases lysyl-bradykinin which mediates pleiotropic effects. Human glandular kallikrein 2 activates the pro-form of PSA. Other possible biological functions and substrates of hK2 are described in the text. hK3 (PSA) cleaves semenogelins and fibronectin and mediates seminal clot liquefaction, which increases the motility of spermatozoa. [Adapted with permission from H. G. Rittenhouse et al.: Crit Rev Clin Lab Sci 35:275–368, 1998 (43). © CRC Press.]

or other kallikrein contaminations (221–224). Three independent groups have reported activation of the pro-form of PSA by hK2 (Fig. 6) (149–151) with a process that is very similar to the autoactivation of hK2 (removal of 7 amino acids) (225). The study of substrate specificities between hK1 and hK2 reveals important differences (106, 226) suggesting that the two proteins have different natural substrates, a notion that is supported by the finding of very low kininogenase activity of hK2 in comparison to hK1 (14, 15). Seminal plasma hK2 was found to be able to cleave seminogelin I and seminogelin II but at different cleavage sites and at a lower efficiency than PSA (227). Since the amount of hK2 in seminal plasma is much lower than PSA (1–5%), the contribution of hK2 in the process of seminal clot liquefaction is expected to be relatively small (43).

In any biological fluid thus far studied, hK3 (PSA) and hK2 were found to coexist (146–148), suggesting a possible functional relationship along the lines described above. Furthermore, a role of hK2 in regulating growth factors, through IGFBP-3 proteolysis, has been suggested (228).

Recently, hK2 was found to activate the zymogen or

single-chain form of urokinase-type plasminogen activator (uPA) *in vitro* (229). Since uPA has been implicated in the promotion of cancer metastasis, hK2 may be part of this pathway in prostate cancer.

While both hK1 and hK2 have trypsin-like enzymatic activities, hK3 has chymotrypsin-like substrate specificity (230–233). Since PSA is present at very high levels in seminal plasma, most studies focused on its biological activity within this fluid. Lilja (234) has shown that PSA hydrolyzes rapidly both seminogelin I and seminogelin II, as well as fibronectin, resulting in liquefaction of the seminal plasma clot after ejaculation (234) (Fig. 6). Several other potential substrates for PSA have been identified, including IGFBP-3 (197, 199), TGF β (200), basement membrane (201), PTH-related peptide (192, 193), and plasminogen (191). The physiological relevance of these findings is still not clear.

hK3 is now known to be found at relatively high levels in nipple aspirate fluid (187, 235), breast cyst fluid (236–240), milk of lactating women (241), amniotic fluid (242), and tumor extracts (184–186). It is thus very likely that hK3 has biological extraprostatic functions in breast and other tissues

TABLE 9. Future directions in kallikrein research

Physiology	Identification of physiological substrates and metabolic pathways in various tissues Delineate mode of regulation—functional characterization of gene promoters Mode of activation and participation in cascade pathways Secretion and deactivation; binding to proteinase inhibitors/serpins Characterization and physiology of enzyme isoforms in different tissues
Pathobiology	Differential expression (overexpression/underexpression) between normal and diseased tissue Tumor promotion/metastasis or tumor suppressor activity Aberrant/ectopic expression, mutation. Activation or inactivation of other effector molecules (growth factors; peptide hormones; cytokines)
Diagnostics	Development of analytical tools (highly sensitive and specific immunoassays) Measurement in biological fluids (especially serum or plasma) Diagnosis; monitoring; prognosis; prediction of therapeutic response; population screening Tumor localization
Therapeutics	Overexpression; underexpression by using external modulators (e.g., steroid hormone agonists/antagonists Serine protease inhibitors; activators Immunotherapy; vaccination Tissue-specific delivery of therapeutic agents by using gene promoters

and may also play a role during fetal development (243). These possibilities merit further investigation.

Among all other human kallikreins, some have been connected to physiological processes and pathological conditions (as described in *Section IX*) but none has been assigned to cleave a specific substrate. Human kallikrein enzymes, with the exception of hK1, hK2, and hK3, are not commercially available and the study of their biological function has not as yet been published. Below, we will attempt to formulate some functional hypotheses for the human kallikreins.

First, all kallikreins are predicted to be secreted proteases, and it is very likely that their biological function is related to their ability to digest one or more substrates. The diversity of expression in human tissues further suggests that they may act on different substrates in different tissues. Their enzymatic activity may initiate, by activation, or terminate, by inactivation, events mediated by other molecules, including hormones, growth factors, receptors, and cytokines. The parallel expression of many kallikreins in the same tissues further suggests that they may participate in cascade reactions similar to those established for the processes of digestion, fibrinolysis, coagulation, and apoptosis. The role of these enzymes in tumor metastasis, as suggested for other proteases (244, 245), should be further investigated.

XI. Future Directions

In Table 9, we summarize some areas that may be fruitful for future kallikrein research. We have already indicated that it will be important to identify the physiological substrates of these enzymes in different tissues and the metabolic pathways in which they participate. The mode of hormonal regulation has been extensively studied only for KLK3 and KLK2. It will be important to functionally characterize gene promoters in view of the preliminary knowledge that the expression of most of these proteases in breast and prostate cancer cell lines is affected by steroid hormones. In addition, the details of activation and deactivation of these enzymes are still obscure. For some of these genes, we already have

some information regarding differential expression between normal and diseased tissues. More data are needed. The possible mutational spectrum of these genes in cancer has not been examined.

The most successful clinical application of hK3 (PSA) is currently in the diagnosis and monitoring of prostate cancer. It is anticipated that all these serine proteases circulate in the peripheral blood since they are secreted proteins. It will be important to develop the tools necessary to allow specific and highly sensitive detection of these proteins in biological fluids. Once these tools are available, we should examine whether any of these enzymes have value for diagnosis, monitoring, prediction of therapeutic response, and population screening for diseases such as prostate, breast, ovarian, and other cancers. Applicability to nonmalignant diseases, e.g., Alzheimer's disease, skin pathologies, and inflammatory, autoimmune, and other chronic diseases of many organs in which kallikreins are expressed, should also be examined. Some of these enzymes may be useful targets for tumor localization with specific binding reagents or for therapeutic interventions. If any of these enzymes are shown to participate in cancer metastasis, it may be useful to examine proteinase inhibitors for therapeutic applications. Other possibilities include the use of some of these genes and their promoters for tissue-specific delivery of gene therapy or for over- or underexpression, using exogenously administered modulators (e.g., hormones or hormone blockers) that are known to affect their expression.

XII. Conclusions

In this review, we attempted to summarize the very latest progress in research related to the human kallikrein gene family. For many years, this family was thought to consist of only three genes. We have provided strong evidence suggesting that the human kallikrein gene family now includes at least 15 genes, which are tandemly localized on chromosome 19q13.4 and have significant similarities at both the gene and protein level. Genomic analysis of a large region around the human kallikrein gene locus allowed not only the

precise mapping of these genes but also the delineation of the genomic organization, the prediction of protein sequence and structure, the construction of phylogenetic trees, and the comparison of homologies between all human kallikreins. The diverse tissue expression patterns and the parallel expression of many kallikreins in the same tissues suggest multiple physiological roles as well as possible interactions between the kallikrein enzymes. Many fruitful avenues of investigation are now possible. Most kallikrein genes are regulated by steroid hormones. Protein sequence variation among the kallikreins suggests that each one of them interacts with a specific substrate or a very restricted number of substrates to mediate specific biological events. Much needs to be learned about the substrate specificity of these kallikreins in diverse tissues and the mediation of biological effects from their enzymatic action.

The human kallikrein gene family has contributed the best tumor marker ever developed (PSA). It is possible that other kallikrein members may have applicability as biomarkers in cancer and other chronic and acute diseases. Unfortunately, no methods currently exist to monitor the newly discovered kallikreins with high sensitivity and specificity. The emergence of these new technologies may eventually lead to novel clinical applications of kallikreins other than PSA. We hope that this update will facilitate new developments in this field and lead to practical applications in diverse human diseases.

Acknowledgments

We would like to thank the current and previous members of the Diamandis laboratory, as well as our numerous national and international collaborators who have contributed to the work described in this review.

Note Added in Proof

Since preparation of this review, a few important developments have occurred as follows: The publication of a draft form of the sequence of the human genome will facilitate further genomic analysis within and around the human kallikrein gene locus. A recent paper further summarizes tissue expression data of kallikreins by array analysis (246). Highly sensitive and specific immunoassays for hK6 (247) and hK10 (248) have been published. With these methods, it was found that hK6 may be a biomarker for Alzheimer's disease (249) and a circulating tumor marker for ovarian cancer (250) and that hK10 is a promising new serum tumor marker for ovarian cancer (251).

References

- Kraut H, Frey EK, Werle E 1930 Der Nachweis eines Kreislaufhormon in de Pankreasdruse. Hoppe-Seylers Z Physiol Chem 189: 97–106
- 2. Werle E 1934 Zur Kenntnis des haushalts des Kallikreins. Biochem Z 269:415–434
- Fiedler F 1979 Enzymology of glandular kallikreins. In: Erdos EG (ed) Bradykinin, Kallidin and Kallikrein. Springer-Verlag, Berlin, pp 103–161
- 4. Movat HZ 1979 The plasma kallikrein-kinin system ad its inter-

- relationship with other components of blood. In: Erdos EG (ed) Bradykinin, Kallidin and Kallikrein, Springer-Verlag, Berlin, pp 1–89
- Asakai R, Davie EW, Chung DW 1987 Organization of the gene for human Factor XI. Biochemistry 26:7221–7228
- Yu H, Bowden DW, Spray BJ, Roch SS, Freedman BI 1998 Identification of human plasma kallikrein gene polymorphisms and evaluation of their role in end-stage renal disease. Hypertension 31:906–911
- Bhoola KD, Figueroa CD, Worthy K 1992 Bioregulation of kinins: kallikreins, kininogens, and kininases. Pharmacol Rev 44:1–80
- Beraldo WT, Andrade SP 1997 Discovery of bradykinin and the kallikrein-kinin system. In: Farmer SG (ed) The Kinin System. Academic Press, San Diego, CA, vol 1:1–8
- Clements JA 1997 The molecular biology of the kallikreins and their roles in inflammation. In: Farmer SG (ed) The Kinin System. Academic Press, San Diego, CA, vol 5:71–97
- Clements JA 1989 The glandular kallikrein family of enzymes: tissue-specific expression and hormonal regulation. Endocr Rev 10:393–419
- Margolius HS 1998 Kallikreins, kinins and cardiovascular diseases: a short review. Biol Res 31:135–141
- Margolius HS 1998 Tissue kallikreins structure, regulation, and participation in mammalian physiology and disease. Clin Rev Allergy Immunol 16:337–349
- Diamandis EP, Yousef GM, Luo LY, Magklara A, Obiezu CV 2000
 The new human kallikrein gene family: implications in carcinogenesis. Trends Endocrinol Metab 11:54–60
- Deperthes D, Marceau F, Frenette G, Lazure C, Tremblay RR, Dube JY 1997 Human kallikrein hK2 has low kininogenase activity while prostate specific antigen (hK2) has none. Biochim Biophys Acta 1343:102–106
- Charlesworth MC, Young CYE, Miller VM, Tindall DJ 1999 Kininogenase activity of prostate-derived human glandular kallikrein (hK2) purified from seminal fluid. J Androl 20:220–229
- Evans BA, Drinkwater CC, Richards RI 1987 Mouse glandular kallikrein genes. Structure and partial sequence analysis of the kallikrein gene locus. J Biol Chem 262:8027–8034
- Bell RA, Fahnestock M 1988 Sequence and comparative analysis of three cDNAs from Mastomys natalensis, an African rat. J Cell Biol 107:615a
- Wines DR, Brady JM, Pritchett DB, Roberts JL, MacDonald RJ 1989 Organization and expression of the rat kallikrein gene family. J Biol Chem 264:7653–7662
- Murray SR, Chao J, Lin F, Chao L 1990 Kallikrein multigene families and the regulation of their expression. J Cardiovasc Pharmacol 15[Suppl]:S7–S15
- 20. Howies PN, Dickinson DP, DiCaprio LL, Woodworth-Gutai M, Gross KW 1984 Use of a cDNA recombinant for the γ-subunit of mouse nerve growth factor to localize members of the multigene family near the TAM-1 locus on chromosome 7. Nucleic Acids Res 12:2791–2805
- Mason AJ, Evans BA, Cox DR, Shine J, Richards RI 1983 Structure of mouse kallikrein gene family suggests a role in specific processing of biologically active peptides. Nature 303:300–307
- Drinkwater CC, Evans BA, Richards RI 1987 Mouse glandular kallikrein genes: identification and characterization of the genes encoding the epidermal growth factor binding proteins. Biochemistry 26:6750-6756
- Ashley PL, MacDonald RJ 1985 Kallikrein-related mRNAs of the rat submaxilliary gland: nucleotide sequences of four distinct types including tonin. Biochemistry 24:4512–4519
- Chen Y, Chao J, Chen L 1988 Molecular cloning and characterization of two rat renal kallikrein genes. Biochemistry 27:7189–7196
- Brady JM, Wines DR, MacDonald RJ 1989 Expression of two kallikrein gene family members in the rat prostate. Biochemistry 28:5203–5210
- Inoue H, Fukui K, Miyake Y 1989 Identification and structure of the rat true tissue kallikrein gene expressed in the kidney. J Biochem (Tokyo) 108:834–840
- 27. Shai S, Woodley-Miller C, Chao J, Chao L 1989 Characterization of genes encoding rat tonin and a kallikrein-like serine protease. Biochemistry 28:5334–5343

- Wines DR, Brady JM, Southard EM, MacDonald RJ 1991 Evolution of the rat kallikrein gene family: gene conversion leads to functional diversity. J Mol Evol 32:476–492
- Brady JM, MacDonald RJ 1990 The expression of two kallikrein gene family members in the rat kidney. Arch Biochem Biophys 278:342–349
- Ma JX, Chao J, Chao L 1992 Molecular cloning and characterization of rKLK10, a cDNA encoding T-kininogenase from rat submandibular gland and kidney. Biochemistry 31:10922–10928
- Clements JA, Matheson BA, Funder JW 1990 Tissue-specific developmental expression of the kallikrein gene family in the rat. J Biol Chem 265:1077–1081
- Clements JA, Mukhtar A, Verity K, Pullar M, McNeill P, Cummins J, Fuller PJ 1996 Kallikrein gene expression in human pituitary tissues. Clin Endocrinol (Oxf) 44:223–231
- Clements JA, Mukhtar A, Ehrlich A, Fuller P 1992 A re-evaluation
 of the tissue-specific pattern of expression of the rat kallikrein gene
 family. In: Fritz H, Muller-Esterl W, Jochum M, Roscher A, Lyuppertz K (eds) Recent Progress on Kinins. Agents and Actions Supplement. Birkhauser Verlag, Basel, vol 38/I:34-41
- 34. Evans BA, Yun ZX, Close JA, Tregear GW, Kitamura N, Nakanishi S, Callen DF, Baker E, Hyland VJ, Sutherland GR, Richards RI 1988 Structure and chromosomal localization of the human renal kallikrein gene. Biochemistry 27:3124–3129
- 35. Richards RI, Holman K, Shen Y, Kozman H, Harley H, Brook D, Shaw D 1991 Human glandular kallikrein genes: genetic and physical mapping of the KLK1 locus using a highly polymorphic microsatellite PCR marker. Genomics 11:77–82
- 36. Riegman PHJ, Vlietstra RJ, Klaassen P, Van der Korput JAGM, Guerts van Kessel A, Romijn JC, Trapman J 1989 The prostatespecific antigen gene and the human glandular kallikrein-1 gene are tandemly located on chromosome 19. FEBS Lett 247:123–126
- Riegman PHJ, Vlietstra RJ, Suurmeijer L, Cleutjens CBJM, Trapman J 1992 Characterization of the human kallikrein locus. Genomics 14:6–11
- Qin H, Kemp J, Yip M, Lam-Po-Tang PRL, Morris BJ 1991 Localization of human glandular kallikrein-1 gene to chromosome 19q13.3-13.4 by in-situ hybridization. Hum Hered 41:222-226
- Wang MC, Valenzuela LA, Murphy GP, Chu TM 1979 Purification of a human prostate-specific antigen. Invest Urol 17:159–163
- Wang MC, Papsidero LD, Kuriyama M, Valenzuela LA, Murphy GP, Chu TM 1981 Prostate antigen: a new potential marker for prostatic cancer. Prostate 21:89–96
- Wang MC, Valenzuela LA, Murphy GP, Chu TM 1977 Tissue specific and tumor specific antigens in human prostate. Fed Proc 36:1254
- Papsidero LD, Wang MC, Valenzuela LA, Murphy GP, Chu TM 1980 A prostate antigen in sera of prostatic cancer patients. Cancer Res 40:2428–2432
- Rittenhouse HG, Finlay JA, Mikolajczyk SD, Partin AW 1998 Human kallikrein 2 (hK2) and prostate-specific antigen (PSA): two closely related, but distinct, kallikreins in the prostate. Crit Rev Clin Lab Sci 35:275–368
- 44. Diamandis EP 1999 Prostate specific antigen—its usefulness in clinical medicine. Trends Endocrinol Metab 25:14–16
- Oesterling JE 1991 Prostate-specific antigen: a critical assessment of the most useful tumor marker for adenocarcinoma of the prostate. J Urol 145:907–923
- Catalona WJ, Smith DS, Ratliff TL, Dodds KM, Coplen DE, Yuan JJ, Petros JA, Andriole GL 1991 Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N Engl J Med 324:1156–1161
- 47. Catalona WJ 1996 Clinical utility of measurements of free and total prostate-specific antigen (PSA): a review. Prostate Suppl 7:64-69
- Pannek J, Partin AW 1997 Prostate-specific antigen: what's new in 1997. Oncology 9:1273–1278
- McCormack RT, Rittenhouse HG, Finlay JA, Sokoloff RL, Wang TJ, Wolfert RL, Lilja H, Oesterling JE 1995 Molecular forms of prostate-specific antigen and the human kallikrein gene family: a new era. Urology 45:729-744
- 50. Lilja H 1993 Structure, function and regulation of the enzyme activity of prostate-specific antigen. World J Urol 11:188-191

- Malm J, Lilja H 1995 Biochemistry of prostate-specific antigen, PSA. Scand J Clin Lab Invest Suppl 221:15–22
- Chu TM 1997 Prostate-specific antigen and early detection of prostate cancer. Tumour Biol 18:123–134
- Stamey TA, Yang N, Hay AR, McNeal JE, Freiha FS, Redwine E 1987 Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med 317:909–916
- Diamandis EP, Yu H 1995 New biological function of prostatespecific antigen? J Clin Endocrinol Metab 80:1515–1517
- Diamandis EP 1998 Prostate-specific antigen or human kallikrein
 Recent developments. Tumor Biol 19:65–68
- 56. Diamandis EP, Yu H 1997 Nonprostatic sources of prostate-specific antigen. In: Oesterling JE (ed) The Urologic Clinics of North America: Prostate-Specific Antigen: The Best Prostatic Tumor Marker. WB Saunders, Philadelphia, PA, vol 14:275–282
- WB Saunders, Philadelphia, PA, vol 14:275–282
 57. Black MH, Diamandis EP 2000 The diagnostic and prognostic utility of prostate specific antigen for diseases of the breast. Breast Cancer Res Treat 59:1–14
- Stenman U-H 1999 New ultrasensitive assays facilitate studies on the role of human glandular kallikrein (hK2) as a marker for prostatic disease. Clin Chem 45:753–754
- Klee G, Goodmanson M, Jacobsen S, Young C, Finlay J, Rittenhouse HG, Wolfert RL, Tindall DJ 1999 Highly sensitive automated chemiluminometric assay for measuring free human glandular kallikrein-2. Clin Chem 45:800–806
- Black M, Magklara A, Obiezu C, Melegos D, Diamandis EP 1999
 Development of an ultrasensitive immunoassay for human glandular kallikrein with no cross-reactivity from prostate-specific antigen. Clin Chem 45:790–799
- 61. Kwiatkowski MK, Recker F, Piironen T, Pettersson K, Otto T, Wernli M, Tscholl R 1998 In prostatism patients the ratio of human glandular kallikrein to free PSA improves the discrimination between prostate cancer and benign hyperplasia within the diagnostic "gray zone" of total PSA 4 to 10 ng/mL. Urology 52:360–365
- tic "gray zone" of total PSA 4 to 10 ng/mL. Urology 52:360–365
 62. Magklara A, Scorilas A, Catalona WJ, Diamandis EP 1999 The combination of human glandular kallikrein and free prostate-specific antigen (PSA) enhances discrimination between prostate cancer and benign prostatic hyperplasia in patients with moderately increased total PSA. Clin Chem 45:1960–1966
- 63. Nam RK, Diamandis EP, Toi A, Trachtenberg J, Magklara A, Scorilas A, Papanastasiou P, Jewett MAS, Narod SA 2000 Serum human glandular kallikrein-2 protease levels predict the presence of prostate cancer among men with elevated prostate-specific antigen. J Clin Oncol 18:1036-1042
- 64. Partin AW, Catalona WJ, Finlay JA, Darte C, Tindall DJ, Young CY, Klee GG, Chan DW, Rittenhouse HG, Wolfert RL, Woodrum DL 1999 Use of human glandular kallikrein 2 for the detection of prostate cancer: preliminary analysis. Urology 54:839–845
- Becker C, Piironen T, Kiviniemi J, Lilja H, Pettersson K 2000 Sensitive and specific immunodetection of human glandular kallikrein 2 in serum. Clin Chem 46:198–206
- 66. Becker C, Piironen T, Pettersson K, Bjork T, Wojno KJ, Oesterling JE, Lilja H 2000 Discrimination of men with prostate cancer from those with benign disease by measurements of human glandular kallikrein 2 (hK2) in serum. J Urol 163:311–316
- Yousef GM, Diamandis EP 2000 The expanded human kallikrein gene family: locus characterization and molecular cloning of a new member KLK-L3. Genomics 65:184–194
- Yousef GM, Chang A, Scorilas A, Diamandis EP 2000 Genomic organization of the human kallikrein gene family on chromosome 19q13.3-q13.4. Biochem Biophys Res Commun 16:125–133
- Yousef GM, Scorilas A, June K, Ahsworth LK, Diamandis EP 2001 Molecular cloning of the human kallikrein 15 gene (KLK15): upregulation in prostate cancer. J Biol Chem 276:53–61
- Nelson PS, Gan L, Ferguson C, Moss P, Gelinas R, Hood L, Wang K 1999 Molecular cloning and characterization of prostase, an androgen-regulated serine protease with prostate-restricted expression. Proc Natl Acad Sci USA 96:3114-3119
- Yousef GM, Obiezu CV, Luo LY, Black MH, Diamandis EP 1999
 Prostase/KLK-L1 is a new member of the human kallikrein gene
 family, is expressed in prostate and breast tissues, and is hormon ally regulated. Cancer Res 59:4252–4256
- 72. Stephenson SA, Verity K, Ashworth LK, Clements JA 1999 Local-

- ization of a new prostate-specific antigen-related serine protease gene, KLK4, is evidence for an expended human kallikrein gene family cluster on chromosome 19q13.3–13.4. J Biol Chem 274:23210–23214
- Anisowicz A, Sotiropoulou G, Stenman G, Mok SC, Sager R 1996
 A novel protease homolog differentially expressed in breast and ovarian cancer. Mol Med 2:624–636

200

- 74. Little SP, Dixon EP, Norris F, Buckley W, Becker GW, Johnson M, Dobbins JR, Wyrick T, Miller JR, MacKellar W, Hepburn D, Corvalan J, McClure D, Liu X, Stephenson D, Clements J, Johnstone EM 1997 Zyme, a novel and potentially amyloidogenic enzyme cDNA isolated from Alzheimer's disease brain. J Biol Chem 272:25135–25142
- Ekholm E, Egelrud T 1999 Stratum corneum chymotryptic enzyme in psoriasis. Arch Dermatol Res 291:195–200
- Liu XL, Wazer DE, Watanabe K, Band V 1996 Identification of a novel serine protease-like gene, the expression of which is downregulated during breast cancer progression. Cancer Res 56:3371– 3379
- 77. Yousef GM, Magklara A, Diamandis EP 2000 KLK12 is a novel serine protease and a new member of the human kallikrein gene family-differential expression in breast cancer. Genomics 69:331– 341
- Yousef GM, Chang A, Diamandis EP 2000 Identification and characterization of KLK-L4, a new kallikrein-like gene which appears to be down-regulated in breast cancer tissues. J Biol Chem 275: 11891–11898
- Hu JC-C, Zhang C, Sun X, Yang Y, Cao X, Ryu O, Simmer JP 2000 Characterization of the mouse and human PRSS17 genes their relationship to other serine proteases and the expression of PRSS17 in developing mouse incisors. Gene 251:1–8
- Yousef GM, Diamandis EP 1999 The new kallikrein-like gene KLK-L2: molecular characterization, mapping, tissue expression and hormonal regulation. J Biol Chem 274:37511–37516
- 81. **Brattsand M, Egelrud** T 1999 Purification, molecular cloning, and expression of a human stratum corneum trypsin-like serine protease with possible function in desquamation. J Biol Chem 274: 30033–30040
- 82. Yamashiro K, Tsuruoko N, Kodama S, Tsujimoto M, Yamamura T, Tanaka T, Nakazato H, Yamaguchi N 1997 Molecular cloning of a novel trypsin-like serine protease (neurosin) preferentially expressed in brain. Biochim Biophys Acta 1350:11–14
- 83. Yousef GM, Luo LY, Scherer SW, Sotiropoulou G, Diamandis EP 1999 Molecular characterization of zyme/protease M/neurosin, a hormonally-regulated kallikrein-like serine protease. Genomics 62: 251–259
- 84. Hansson L, Stromqvist M, Backman A, Wallbrandt P, Carlstein A Egelrud T 1994 Cloning, expression and characterization of stratum corneum chymotryptic enzyme. A skin-specific human serine proteinase. J Biol Chem 269:19420–19426
- 85. Yousef GM, Scorilas A, Magklara A, Soosaipillai A, Diamandis EP 2000 The KLK7 (PRSS6) gene encoding for the stratum corneum chymotryptic enzyme is a new member of the human kallikrein gene family—genomic characterization mapping tissue expression and hormonal regulation. Gene 254:119–128
- 86. Yoshida S, Taniguchi M, Hirata A Shiosaka S 1998 Sequence analysis and expression of human neuropsin cDNA and gene. Gene 213:9–16
- 87. Luo L, Herbrick J-A, Scherer SW, Beatty B, Squire J, Diamandis EP 1998 Structural characterization and mapping of the normal epithelial cell-specific 1 gene. Biochem Biophys Res Commun 247: 580–586
- 88. Yoshida S, Taniguchi M, Suemoto T, Oka T, He X, Shiosaka S 1998 cDNA cloning and expression of a novel serine protease, TLSP. Biochim Biophys Acta 1399:225–228
- 89. Yousef GM, Scorilas A, Diamandis EP 2000 Genomic organization mapping tissue expression and hormonal regulation of trypsin-like serine protease (TLSP PRSS20), a new member of the human kallikrein gene family. Genomics 63:88–96
- Yousef GM, Magklara A, Chang A, Jung K, Katsaros D, Diamandis EP, Cloning of a new member of the human kallikrein gene family, KLK14, which is down-regulated in different malignancies. Cancer Res, in press
- 91 Berg T, Bradshaw RA, Carretero OA, Chao J, Chao L, Clements

- JA, Fahnestock M, Fritz H, Gauthier F, MacDonald RJ, Margolius HS, Morris BJ, Richards RI, Scicli AG 1992 A common nomenclature for members of the tissue (glandular) kallikrein gene families. In: Fritz H, Muller-Esterl W, Jochum M, Roscher A, Luppertz K(eds) Recent Progress on Kinins. Agents and Actions Supplement. Birkhauser Verlag, Basel, vol 38/1:19-25
- Diamandis EP, Yousef GM, Clements J, Ashworth LK, Yoshida S, Egelrud T, Nelson PS, Shiosaka S, Little S, Lilja H, Stenman U-H, Rittenhouse HG, Wain 2000 New nomenclature for the human tissue kallikrein gene family. Clin Chem 46:1855–1858
- Fukushima D, Kitamura N, Nakanishi S 1985 Nucleotide sequence of cloned cDNA for human pancreatic kallikrein. Biochemistry 24:8037–8043
- 94. Schedlich LJ, Bennetts BH, Morris BJ 1987 Primary structure of a human glandular kallikrein gene. DNA 6:429-437
- Lundwall A 1989 Characterization of the gene for prostate-specific antigen, a human glandular kallikrein. Biochem Biophys Res Commun 161:1151–1159
- Riegman PHJ, Klassen P, Van der Korput JAGM, Romijn JC, Trapman J 1988 Molecular cloning and characterization of novel prostate antigen cDNAs. Biochem Biophys Res Commun 155: 181–188
- Riegman PHJ, Vlietstra RJ, Van der Korput JAGM, Romijn JC, Trapman J 1989 Characterization of the prostate-specific antigen gene: a novel human kallikrein-like gene. Biochem Biophys Res Commun 159:95–102
- 98. Underwood LJ, Tanimoto H, Wang Y, Shigemasa K, Parmley TH, O'Brien TJ 1999 Cloning of tumor-associated differentially expressed gene-14, a novel serine protease overexpressed by ovarian carcinoma. Cancer Res 59:4435–4439
- Goyal J, Cowan JM, Wazer DE, Lee SW, Band V 1998 The role for NES1 serine. Protease as a novel tumor suppressor. Cancer Res 58:4782–4786
- 100. Mitsui S, Yamada T, Okui A, Kominami K, Uemura H, Yamaguchi N 2000 A novel isoform of a kallikrein-like protease TLSP/Hippostasin (PRSS20), is expressed in the human brain and prostate. Biochem Biophys Res Commun 272:205–211
- Foussias G, Yousef GM, Diamandis EP 2000 Identification and molecular characterization of a novel member of the siglec family (Siglec 9). Genomics 67:171–178
- 102. Crocker PR, Clark EA, Filbin M, Gordon S, Jones Y, Kehrl JH, Kelm S, Le Douarin N, Powell L, Roder J, Schnaar RL, Sgroi DC, Stamenkovic K, Schauer R, Schachner M, van den Berg TK, van der Merwe PA, Watt SM, Varki A 1998 Siglecs: a family of sialicacid binding lectins. Glycobiology 8:5-6
- 103. Kelm S, Schauer R, Crocker PR 1996 The sialoadhesins–a family of sialic acid-dependent cellular recognition molecules within the immunoglobulin superfamily. Glycoconj J 13:913–926
- 104. Dayhoff MO 1978 Atlas of protein sequence and structure. Nat Biomed Res Found [Suppl 3]:79-81
- Creighton TE 1993 Proteins: Structures and Molecular Properties, ed 2. WH Freeman and Company, New York
- 106. Lovgren J, Airas K, Lilja H 1999 Enzymatic action of human glandular kallikrein 2 (hK2) substrate specificity and regulation by Zn²⁺ and extracellular protease inhibitors. Eur J Biochem 262:781–789
- 107. Tanimoto H, Underwood LJ, Shigemasa K, Yan Y, Clarke J, O'Brien TJ 1999 The stratum corneum chymotryptic enzyme that mediates shedding and desquamation of skin cells is highly overexpressed in ovarian tumor cells. Cancer 86:2074–2082
- 108. Van Leeuwen BH, Evans BA, Tregear GW, Richards R 1986 Mouse glandular kallikrein genes. Identification, structure and expression of the renal kallikrein gene. J Biol Chem 261:5529–5535
- 109. Van Leeuwen BH, Penschow JD, Coghlan JP, Richards RI 1987 Cellular basis for the differential response of mouse kallikrein genes to hormonal induction. EMBO J 6:1705–1713
- 110. Clements JA, Matheson BA, Wines DR, Brady JM, MacDonald RJ, Funder JW 1988 Androgen dependence of specific kallikrein gene family members expressed in the rat prostate. J Biol Chem 31:16132–16137
- 111. Penschow JD, Drinkwater CC, Haralambidis J, Coghlan JP 1991 Sites of expression and induction of glandular kallikrein gene expression in mice. Mol Cell Endocrinol 81:135–146
- 112. Miller DH, Chao J, Margolius HS 1984 Tissue kallikrein synthesis

- and its modification by testosterone or low dietary sodium. Biochem J 218:237–243
- 113. Miller DH, Lindley JG, Margolius HS 1985 Tissue kallikrein levels and synthesis rates are not changed by an acute physiological dose of aldosterone. Proc Soc Exp Biol Med 180:121–125
- 114. Clements JA, Fuller PJ, McNally M, Nikolaidis I, Funder JW 1986 Estrogen regulation of kallikrein gene expression in the rat anterior pituitary. Endocrinology 119:268–273
- 115. Clements JA, Matheson BA, MacDonald RJ, Funder JW 1989 The expression of the kallikrein gene family in the rat pituitary oestrogen effects and the expression of an additional family member in the neurointermediate lobe. J Neuroendocrinol 1:199-203
- Pritchett DB, Roberts JL 1987 Dopamine regulates expression of the glandular-type kallikrein gene at the transcriptional level in the pituitary. Proc Natl Acad Sci USA 84:5545–5549
- Clements JA, Mukhtar A, Ehrlich A, Yap B 1994 Kallikrein gene expression in the human uterus. Braz J Med Biol Res 27:1855–1863
- 118. Riegman PHJ, Vlietstra RJ, van der Korput JAGM, Brinkmann AO, Trapman J 1991 The promoter of the prostate-specific antigen gene contains a functional androgen responsive element. Mol Endocrinol 5:1921–1930
- 119. Cleutjens KBJM, van Eekelen CCEM, van der Korput HAGM, Brinkman AO, Trapman J 1996 Two androgen response regions cooperate in steroid hormone regulated activity of the prostatespecific antigen promoter. J Biol Chem 271:6379-6388
- 120. Luke MC, Coffey DS 1994 Human androgen receptor binding to the androgen response element of prostate specific antigen. J Androl 15:41-51
- 121. Schuur ER, Henderson GA, Kmetec LS, Miller JD, Lamparski HG, Henderson DR 1996 Prostate-specific antigen expression is regulated by an upstream enhancer. J Biol Chem 271:7043–7051
- 122. Cleutjens KB, van der Korput HA, van Eekelen CC, van Rooij HCJ, Faber PW, Trapman J 1997 An androgen response element in a far upstream enhancer region is essential for high, androgen-regulated activity of the prostate-specific antigen promoter. Mol Endcrinol 11:148–161
- 123. Yu H, Diamandis EP, Zarghami N, Grass L 1994 Induction of prostate specific antigen production by steroids and tamoxifen in breast cancer cell lines. Breast Cancer Res Treat 32:291–300
- 124. Yu H, Diamandis EP, Monne M, Croce CM 1995 Oral contraceptive-induced expression of prostate specific antigen in the female breast. J Biol Chem 270:6615–6618
- 125. Zarghami N, Grass L, Diamandis EP 1997 Steroid hormone regulation of prostate specific antigen gene expression in breast cancer. Br J Cancer 75:579–588
- 126. Rodriguez R, Schuur ER, Lim HY, Henderson GA, Simons JW, Henderson DR 1997 Prostate attenuated replication competent adenovirus (ARCA) CN706: a selective cytotoxic for prostatespecific antigen-positive prostate cancer cells. Cancer Res 57: 2559–2563
- 127. Cleutjens KB, van der Korput HA, Ehren-van Eekelen CC, Sikes RA, Fasciana C, Chung LW, Trapman J 1997 A 6-kb promoter fragment mimics in transgenic mice the prostate-specific and androgen-regulated expression of the endogenous prostate-specific antigen gene in humans. Mol Endocrinol 11:1256–1265
- 128. Latham JP, Searle PF, Mautner V, James ND 2000 Prostate-specific antigen promoter/enhancer driven gene therapy for prostate cancer: construction and testing of a tissue-specific adenovirus vector. Cancer Res 60:334–341
- 129. Martiniello-Wilks R, Garcia-Aragon J, Daja MM, Russell P, Both GW, Molloy PL, Lockett LJ, Russell PJ 1998 *In vivo* gene therapy for prostate cancer: preclinical evaluation of two different enzyme-directed prodrug therapy systems delivered by identical adenovirus vectors. Hum Gene Ther 9:1617–1626
- 130. Gotoh A, Ko SC, Shirakawa T, Cheon J, Kao C, Miyamoto T, Gardner TA, Ho LJ, Cleutjens CB, Trapman J, Graham FL, Chung LW 1998 Development of prostate-specific antigen promoter-based gene therapy for androgen-independent human prostate cancer. J Urol 160:220–229
- Dannul J, Belldegrun AS 1997 Development of gene therapy for prostate cancer using a novel promoter of prostate-specific antigen. Br J Urol 79[Suppl 1]:97–103
- 132. Lee CG, Liu M, Sie KL, Lee MS 1996 Prostate-specific antigen

- promoter driven gene therapy targeting DNA polymerase- α and topoisomerase II α in prostate cancer. Anticancer Res 16:1805–1811
- Young CYF, Andrews PE, Tindall DJ 1995 Expression and androgenic regulation of human prostate-specific kallikreins. J Androl 16:97–99
- 134. Magklara A, Grass L, Diamandis EP 2000 Differential steroid hormone regulation of human glandular kallikrein (hK2) and prostate-specific antigen (PSA) in breast cancer cell lines. Breast Cancer Res Treat 59:263–270
- 135. Murtha P, Tindall DJ, Young CYF 1993 Androgen induction of a human prostate-specific kallikrein, IrKLK2: characterization of an androgen response element in the 5' promoter region of the gene. Biochemistry 32:6459-6464
- 136. Hsieh M-L, Charlesworth C, Goodmanson M, Zhang S, Seay T, Klee GG, Tindall DJ, Young CY 1997 Expression of human prostate-specific glandular kallikrein protein (hK2) in the breast cancer cell line T47-D. Cancer Res 57:2651–2656
- 137. Riegman PHJ, Vlietstra RJ, van der Korput HA, Romijn JC, Trapman J 1991 Identification and androgen-regulated expression of two major human glandular kallikrein-1 (hGK-1) mRNA species. Mol Cell Endocrinol 76:181–190
- 138. Yu D-C, Sakamoto GT, Henderson DR 1999 Identification of the transcriptional regulatory sequences of human kallikrein 2 and their use in the construction of Calydon virus 764, an attenuated replication competent adenovirus for prostate cancer therapy. Cancer Res 59:1498–1504
- 139. Gotoh A; Kamidono S, Chung LW 1997 Clinical application for gene therapy in prostate cancer. Hinyokika Kiyo 43:829–833
- 140. Luo LY, Grass L, Diamandis EP 2000 The normal epithelial cellspecific 1 (NES1) gene is up-regulated by steroid hormones in the breast carcinoma cell line BT-474. Anticancer Res 20:981–986
- Young CY, Andrews PE, Montgomery BT, Tindall DJ 1992 Tissuespecific and hormonal regulation of human prostate-specific glandular kallikrein. Biochemistry 31:818–824
- 142. Morris BJ 1989 hGK-1: a kallikrein gene expressed in human prostate. Clin Exp Pharmacol Physiol 16:345–351
- 143. Ferguson RA, Yu H, Kalyvas M, Zammit S, Diamandis EP 1996 Ultrasensitive detection of prostate specific antigen by a timeresolved immunofluorometric assay and the Immulite® Immunochemiluminescent third generation assay: potential applications in prostate and breast cancers. Clin Chem 42:675–684
- 144. Zarghami N, Diamandis EP 1996 Detection of prostate specific antigen mRNA and protein in breast tumors. Clin Chem 42:361–366
- 145. Howarth DJC, Aronson IB, Diamandis EP 1997 Immunohistochemical localization of prostate specific antigen in benign and malignant breast tissues. Br J Cancer 75:1646–1651
- 146. Magklara A, Scorilas A, López-Otin C, Vizoso F, Ruibal A, Diamandis EP 1999 Human glandular kallikrein in breast milk, amniotic fluid, and breast cyst fluid. Clin Chem 45:1774-1780
- 147 Black MA, Magklara A, Obiezu C, Levesque MA, Sutherland DJA, Tindall DJ, Young CYF, Sauter ER, Diamandis EP 2000 Expression of a prostate-associated protein human glandular kallikrein (hK2), in breast tumors and in normal breast secretions. Br J Cancer 82:361–367
- 148. Lovgren J, Valtonen-Andre C, Marsal K, Lilja H, Lundwall A 1999 Measurement of prostate-specific antigen and human glandular kallikrein 2 in different body fluids. J Androl 20:348–355
- Lovgren J, Rajakoski K, Karp M, Lundwall A, Lilja H 1997 Activation of the zymogen form of prostate-specific antigen by human glandular kallikrein 2. Biochem Biophys Res Commun 238:549 –555
- 150. Kumar A, Mikolajczyk SD, Goel AS, Millar LS, Saedi MS 1997 Expression of pro form of prostate-specific antigen by mammalian cells and its conversion to mature, active form by human kallikrein 2. Cancer Res 57:3111–3114
- 151. Takayama TK, Fujikawa K, Davie EW 1997 Characterization of the precursor of prostate-specific antigen-activation by trypsin and by human glandular kallikrein. J Biol Chem 272:21582–21588
- 152. Catalona WJ, Partin AW, Slawin KM, Brawer MK, Flanigan RC, Patel A Richie JP, deKernion JB, Walsh PC, Scardino PT, Lange PH, Subong EN, Parson RE, Gasior GH, Loveland KG, Southwick PC 1998 Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic

- disease: a prospective multicenter clinical trial. JAMA 279:1542-1547
- 153. Lilja H, Haese A, Bjork T, Frederich MG, Piironen T, Pettersson K, Huland E, Huland H 1999 Significance and metabolism of complexed and noncomplexed prostate specific antigen forms, and human glandular kallikrein 2 in clinically localized prostate cancer before and after radical prostatectomy. J Urol 162:2029–2034
- 154. Lilja H 1997 Prostate-specific antigen: molecular forms and the human kallikrein gene family. Br J Urol 79[Suppl 1]:44-48
- 155. Zhang WM, Finne P, Leinonen J, Vesalainen S, Nordling S, Stenman UH 1999 Measurement of the complex between prostate-specific antigen and α1-protease inhibitor in serum. Clin Chem 45:814-821
- 156. Mikolajczyk SD, Millar LS, Wang TJ, Rittenhouse HG, Marks LS, Song W, Wheeler TM, Slawin KM 2000 A precursor form of prostate-specific antigen is more highly elevated in prostate cancer compared to benign transition zone prostate tissue. Cancer Res 60:756-759
- 157. Christensson A, Laurell CB, Lilja H 1990 Enzymatic activity of prostate-specific antigen and its reactions with extracellular serine proteinase inhibitors. Eur J Biochem 194:755–763
- 158. Stenman UH, Leinonen J, Alfthan H, Rannikko S, Tuhkanen K, Alfthan O 1991 A complex between prostate-specific antigen and α1-antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostatic cancer: assay of the complex improves clinical sensitivity for cancer. Cancer Res 51:222–226
- 159. Chen LM, Murray SR, Chai KX, Chao L, Chao J 1994 Molecular cloning and characterization of a novel kallikrein transcript in colon and its distribution in human tissues. Braz J Med Biol Res 27:1829– 1838
- 160. Rae F, Bulmer B, Nicol D, Clements J 1999 The human tissue kallikreins (KLKs 1–3) and a novel KLK1 mRNA transcript are expressed in renal cell carcinoma cDNA library. Immunopharmacology 45:83–88
- 161. Liu XF, Essand M, Vasmatzis G, Lee B, Pastan I 1999 Identification of three new alternate human kallikrein 2 transcripts: evidence of long transcript and alternative splicing. Biochem Biophys Res Commun 264:833–839
- 162. Heuze N, Olayat S, Gutman N, Zani ML, Courty Y 1999 Molecular cloning and expression of an alternative hKLK3 transcript coding for a variant protein of prostate- specific antigen. Cancer Res 59: 2820–2824
- 163. Tanaka T, Isono T, Yoshiki T, Yuasa T, Okada Y 2000 A novel form of prostate-specific antigen transcript produced by alternative splicing. Cancer Res 60:56–59
- 164. Magklara A, Scorilas A, Katsaros D, Fracchioli S, Yousef GM, Diamandis EP, The human KLK8 (neuropsin/ovasin) gene: identification of two novel splice variants and its prognostic value in ovarian cancer. Cancer Res, in press
- 165. Chang A, Yousef GM, Jung K, Rajpert-De Meyts E, Diamandis EP, Identification and molecular characterization of five novel kallikrein gene 13 (KLK13; KLK-L4) splice variants: differential expression in testicular cancer. Gene, in press
- 166. Margolius HS, Horwitz D, Pisano JJ, Keiser HR 1974 Urinary kallikrein in hypertension: relationship to sodium intake and sodium-retaining steroids. Circ Res 35:820–825
- Horwitz D, Margolius HS, Keiser HR 1978 Effects of dietary potassium and race on urinary excretion of kallikrein and aldosterone in man. J Clin Endocrinol Metab 47:296–299
- 168. Holland OB, Chud JM, Braunstein H 1980 Urinary kallikrein excretion in essential and mineralocorticoid hypertension. J Clin Invest 65:347–356
- 169. Griesbacher T, Lembeck F 1997 Putative roles of bradykinin and the kinin system in pancreatitis: In: Farmer SG (ed) The Kinin System. Academic Press, London, vol 12:197–217
- 170. Matsumara Y, Kimura M, Yamamoto T, Maeda H 1988 Involvement of the kinin generating cascade in enhanced vascular permeability in tumour tissue. Jpn J Cancer Res 79:1327–1334
- 171. Roberts RA, Gullick WJ 1989 Bradykinin receptor number and sensitivity to ligand stimulation of mitogenesis by expression of mutant ras oncogene. J Cell Sci 94:527–535
- 172. Berg T, Johansen L, Bergundhaugen H, Hansen LJ, Reddy JK,

- Poulsen K 1985 Demonstration of kallikrein in a rat pancreatic acinar cell carcinoma. Cancer Res 45:226–234
- 173. Jones TH, Brown BL, Dobson PRM 1989 Bradykinin stimulates phosphoinositide metabolism and prolactin secretion in rat anterior pituitary cells. J Mol Endocrinol 2:47–53
- 174. Jones TH, Figueroa CD, Smith C, Cullen DR, Bhoola KD 1990 Characterization of a tissue kallikrein in human prolactin-secreting adenomas. J Endocrinol 124:327–331
- 175. Farmer SG (ed) 1997 The Kinin System. Academic Press, London
 176. Oesterling JE (ed) 1997 Prostate-specific antigen. The best prostatic tumor marker. Urol Clin North Am 24:247–458
- 177. Qiu SD, Young CY, Billhartz DL, Prescott JL, Farrow GM, He WW, Tindall DJ 1990 In situ hybridization of prostate-specific antigen RNA in human prostate. J Urol 144:1550-1556
- 178. Hakalahti L, Vihko P, Henttu P, Autio-Harmainen H, Soini Y, Vihko R 1993 Evaluation of PAP and PSA gene expression in prostatic hyperplasia and prostatic carcinoma using Northern-blot analyses, in situ hybridization and immunohistochemical stainings with monoclonal and bispecific antibodies. Int J Cancer 55:590–597
- 179. Gallee MP, Visser-de Jong E, van der Korput JA, van der Kwast TH, Kate FJ, Schroeder FH, Trapman J 1990 Variation of prostatespecific antigen expression in different tumour growth patterns present in prostatectomy specimens. Urol Res 18:181–187
- 180. Pretlow TG, Pretlow TP, Yang P, Kaetzel CS, Delmoro CM, Kamis S, Bodner DR, Kursh E, Resnick MI, Bradley Jr EL 1991 Tissue concentrations of prostate specific antigen in prostatic carcinoma and benign prostatic hyperplasia. Int J Cancer 49:645–649
- 181. Magklara A, Scorilas A, Stephan C, Kristiansen GO, Hauptmann S, Jung K, Diamandis EP 2000 Decreased concentrations of prostate-specific antigen and human glandular kallikrein 2 in malignant vs. nonmalignant prostatic tissue. Urology 56:527–532
- 182. Abrahamsson PA, Lilja H, Falkmer S, Wadstrom LB 1988 Immunohistochemical distribution of the three predominant secretory proteins in the parenchyma of hyperplastic and neoplastic prostate glands. Prostate 12:39–46
- 183. Stege R, Grande M, Carlstrom K, Tribukait B, Pousette A 2000 Prognostic significance of tissue prostate-specific antigen in endocrine-treated prostate carcinomas. Clin Cancer Res 6:160–165
- 184. Yu H, Giai M, Diamandis EP, Katsaros D, Sutherland DJA, Levesque MA, Roagna R, Ponzone R, Sismondi P 1995 Prostate specific antigen is a new favourable prognostic indicator for women with breast cancer. Cancer Res 55:2104–2110
- 185. Yu H, Levesque MS, Clark GM, Diamandis EP 1998 Prognostic value of prostate-specific antigen for women with breast cancer. A large U.S. cohort study. Clin Cancer Res 4:1489–1497
- 186. Yu H, Diamandis EP, Levesque M, Giai M, Roagna R, Ponzone R, Sismondi P, Monne M, Croce C 1996 Prostate specific antigen in breast cancer, benign breast disease and normal breast tissue. Breast Cancer Res Treat 40:171–178
- 187. Sauter ER, Daly M, Linahan K, Ehya H, Engstrom PF, Bonney G, Ross EA, Yu H, Diamandis E 1996 Prostate specific antigen levels in nipple aspirate fluid correlate with breast cancer risk. Cancer Epidemiol Biomarkers Prevent 5:967–970
- 188. Balbay MD, Juang P, Ilansa N, Williams S, McConkey D, Fidler IJ, Pettaway CA 1999 Stable transfection of human prostate cancer cell line PC-3 with prostate specific antigen induces apoptosis both in-vivo and in-vitro. Proc Am Assoc Cancer Res 40:225–226 (Abstract)
- 189. Lai LC, Erbas H, Lennard TWJ, Peaston RT 1996 Prostate-specific antigen in breast cyst fluid: possible role of prostate-specific antigen in hormone-dependent breast cancer. Int J Cancer 66:743–746
- Fortier AH, Nelson BJ, Grella DK, Holaday JW 1999 Antiangiogenic activity of prostate-specific antigen. J Natl Cancer Inst 91: 1635–1640
- 191. Heidtmann HH, Nettelbeck DM, Mingels A, Jager R, Welker HG, Kontermann RE 1999 Generation of angiostatin-like fragments from plasminogen by prostate-specific antigen. Br J Cancer 81: 1269-1273
- 192. Iwamura M, Hellman J, Crockett ATK, Lilha H, Gershagen S 1996 Alteration of the hormonal bioactivity of parathyroid hormone-related protein (PTHrP) as a result of limited proteolysis by prostate-specific antigen. Urology 48:317–325
- 193. Cramer SD, Chen Z, Peehl DM 1996 Prostate specific antigen

- cleaves parathyroid hormone-related protein in the PTH-like domain: inactivation of PTHrP-stimulated cAMP accumulation in mouse osteoblasts. J Urol 156:526–531
- 194. Diamandis EP 2000 Prostate-specific antigen: a cancer fighter and a valuable messenger? Clin Chem 46:896–900
- 195. Foekens JA, Diamandis EP, Yu H, Look MP, Meijer-van Gelder ME, van Putten WLJ, Klijn JGM 1999 Expression of prostate-specific antigen (PSA) correlates with poor response to tamoxifen therapy in recurrent breast cancer. Br J Cancer 79:888–894
- 196. Diamandis EP, Helle SJ, Yu H, Melegos DN, Lundgren S, Lonning PE 1999 Prognostic value of plasma prostate specific antigen after megestrol acetate treatment in patients with metastatic breast carcinoma. Cancer 85:891–898
- 197. Cohen P, Graves HCB, Peehl DM, Kamarei M, Guidice LC, Rosenfeld RD 1991 Prostate-specific antigen (PSA) is an insulinlike growth factor binding protein-3 protease found in seminal plasma. J Clin Endocrinol Metab 73:401–407
- 198. Pollak M, Beamer W, Zhang JC 1998 Insulin-like growth factors and prostate cancer. Cancer Metastasis Rev 17:383–390
- 199. Sutkowski DM, Goode RL, Baniel J, Teater C, Cohen P, McNulty AM, Hsiung HM, Becker GW, Neubauer BL 1999 Growth regulation of prostatic stromal cells by prostate-specific antigen. J Natl Cancer Inst 91:1663–1669
- 200. Killian CS, Corral DA, Kawinski E, Constantine RI 1993 Mitogenic response of osteoblast cells to prostate-specific antigen suggests an activation of latent TGF-β and a proteolytic modulation of cell adhesion receptor. Biochem Biophys Res Commun 192:940–947
- Webber MM, Waghray A, Bello D 1995 Prostate-specific antigen, a serine protease, facilitates human prostate cancer cells invasion. Clin Cancer Res 1:1089–1094
- 202. Heese A, Becker C, Noldus J, Graefen M, Huland E, Huland H, Lilja H 2000 Human glandular kallikreins 2: a potential serum marker for predicting the organ confined vs. non-organ confined growth of prostate cancer. J Urol 163:1491–1497
- 203. Darson MF, Pacelli A, Roche Rittenhouse HG, Wolfert RL, Young CY, Klee GG, Tindall DJ, Bostwick DG 1997 Human glandular kallikrein 2 (hK2) expression in prostatic intraepithelial neoplasia and adenocarcinoma: a novel prostate cancer marker. Urology 49:857–862
- 204. Darson MF, Pacelli A, Roche Rittenhouse HG, Wolfert RL, Saeid MS, Young CY, Klee GG, Tindall DJ, Bostwick DG 1999 Human glandular kallikrein 2 expression in prostate adenocarcinoma and lymph node metastases. Urology 53:939–944
- 205. Óbiezu CV, Scorilas A, Kim H, Diamandis EP 2000 Prostase/ KLK-L1 is differentially expressed in normal/benign vs. malignant ovarian tissues. Clin Biochem 33:234 (Abstract)
- 206. Kim H, Scorilas A, Katsaros D, Yousef GM, Fracchioli S, Diamandis EP 2001 Human kallikrein gene 5 (KLK5) expression is an indicator of poor prognosis in ovarian cancer. Br J Cancer 84:643–650
- 207. Haas C, De Strooper B 1999 The presentilins in Alzheimer's disease –proteolysis holds the key. Science 286:916–919
- 208. Sondell B, Dyberg P, Anneroth GK, Ostman PO, Egelrud T 1996 Association between expression of stratum corneum chymotryptic enzyme and pathological keratinization in human oral mucosa. Acta Derm Venereol 76:177–181
- Okabe A, Momota Y, Yoshida S, Hirata A, Ito J, Nishino H, Shiosaka S 1996 Kindling induces neuropsin mRNA in the mouse brain. Brain Res 728:116–120
- 210. Momota Y, Yoshida S, Ito J, Shibata M, Kato K, Sakurai K, Matsumoto K, Shiosaka S 1998 Blockage of neuropsin, a serine protease, ameliorates kindling epilepsy. Eur J Neurosci 10:760-764
- 211. Kishi T, Kato M, Shimizu T, Kato K, Matsumoto K, Yoshida S, Shiosaka S, Hakoshima T 1999 Crystal structure of neuropsin, a hippocampal protease involved in kindling epileptogenesis. J Biol Chem 274:4220–4224
- 212. Yoshida S, Shiosaka S 1999 Plasticity-related serine proteases in the brain. Int J Mol Med 3:405–409
- 213. Mitsui S, Tsuruoka N, Yamashiro K, Nakazato H, Yamaguchi N 1999 A novel form of human neuropsin, a brain-related serine protease, is generated by alternative splicing a is expressed preferentially in human adult brain. Eur J Biochem 260:627–634
- 214. Scarisbrick IA, Towner MD, Isackson PJ 1997 Nervous system-

- specific expression of a novel serine protease: regulation in the adult rat spinal cord by excitotoxic injury. J Neurosci 17:8156-8168
- 215. Akita H, Matsuyama T, Iso H, Sugita M, Yoshida S 1997 Effects of exidative stress on the expression of limbic-specific protease neuropsin and avoidance learning in mice. Brain Res 769:86–96
- 216. Luo LY, Diamandis EP 2000 Down-regulation of the normal epithelial cell-specific 1 (NES1) gene is associated with unfavourable outcome of prostate cancer. Clin Biochem 33:237 (Abstract)
- Schachter M 1980 Kallikreins (kininogenases): a group of serine proteases with bioregulatory actions. Pharmacol Rev 31:1–17
- 218. Bhoola KD 1971 Comment on the conversion of pro-insulin to insulin. In: Heller G, Lederis K (eds) Subcellular Organisation and Function in Endocrine Tissues. Cambridge University Press, Cambridge, UK, pp 493–494
- Bothwell MA, Wilson WH, Shooter EM 1979 The relationship between glandular kallikrein and growth factor-processing proteases of mouse submaxillary gland. J Biol Chem 254:7287–7294
 Mason AJ, Evans BA, Cox DR, Shine J, Richards RL 1983 Structure
- 220. Mason AJ, Evans BA, Cox DR, Shine J, Richards RL 1983 Structure of mouse kallikrein gene family suggests a role in specific processing of biological active peptides. Nature 303:300–307
- 221. Kumar A, Goel AS, Hill TM Mikolajczyk SD, Millar LS, Kuus-Reichel K, Saedi MS 1996 Expression of human glandular kallikrein, hK2, in mammalian cells. Cancer Res 56:5397–5402
- 222. Saedi MS, Cass MM, Goel AS, Granger L, Hogen KL, Okaneya T, Griffin BY, Klee GG, Young CY, Tindall DJ 1995 Overexpression of a human prostate-specific glandular kallikrein, hK2, in E. coli and generation of antibodies. Mol Cell Endocrinol 109:237–241
- 223. Lovgren J, Piironen T, Overmo C, Dowell B, Karp M, Pettersson K, Lilja H, Lundwall A 1995 Production of recombinant PSA and hK2 and analysis of their immunologic cross-reactivity. Biochem Biophys Res Commun 213:888–895
- 224. Herrala A, Kurkela R, Porvari K, Isomaki R, Henttu P, Vihko P 1997 Human prostate-specific glandular kallikrein is expressed as an active and an inactive protein. Clin Chem 43:279–284
- 225. Mikolajczyk SD, Millar LS, Marker KM, Grauer LS, Goel A, Cass MM, Kumar A, Saedi MS 1997 Ala217 is important for the catalytic function and autoactivation of prostate-specific human kallikrein 2. Eur J Biochem 246:440–446
- 226. Bourgeois L, Brillard-Bourdet M, Deperthes D, Juliano MA, Juliano L, Tremblay RR, Dube JY, Gauthier F 1997 Serpin-derived peptide substrates for investigating the substrate specificity of human tissue kallikreins hK1 and hK2. J Biol Chem 272:29590–29595
- 227. Deperthes D, Frenette G, Brillard-Bourdet M, Bourgeois L, Gauthier F, Tremblay RR, Dube JY 1996 Potential involvement of kallikrein hK2 in the hydrolysis of the human seminal vesicle proteins after ejaculation. J Androl 17:659-665
- Dube JY, Tremblay RR 1997 Biochemistry and potential roles of prostatic kallikrein hK2. Mol Urol 1:279 –285
- Frenette G, Tremblay RR, Lazure C, Dube JY 1997 Prostatic kallikrein hK2, but not prostate-specific antigen (hK3), activates single-chain urokinase-type plasminogen activator. Int J Cancer 71:897–899
- 230. Watt KW, Lee PJ, M'Timkulu T, Chan WP, Loor R 1986 Human prostate-specific antigen: structural and functional similarity with serine proteases. Proc Natl Acad Sci USA 83:3166–3170
- 231. Ban Y, Wang MC, Watt KW, Loor R, Chu TM 1984 The proteolytic activity of human prostate-specific antigen. Biochem Biophys Res Commun 123:482–488
- Christensson A, Laurell CB, Lilja H 1990 Enzymatic activity of prostate-specific antigen and its reactions with extracellular serine proteinase inhibitors. Eur J Biochem 194:755–763
- 233. Akiyama K, Nakamura T, Iwanaga S, Hara M 1987 The chymotrypsin-like activity of human prostate-specific antigen, γ-seminoprotein. FEBS Lett 225:168–172
- 234. Lilja H 1985 A kallikrein-like serine protease in prostatic fluid cleaves the predominant seminal vesicle protein. J Clin Invest 76: 1899–1903
- Foretova L, Garber JE, Sadowski NL, Verselis SJ, Li FP 1996
 Prostate-specific antigen in nipple aspirate. Lancet 347:1631
- 236. Diamandis EP, Yu H, Lopez-Otin C 1996 Prostate specific antigen—a new constituent of breast cyst fluid. Breast Cancer Res Treat 38:259–264
- 237. Mannello F, Bocchiotti G, Bianchi G, Marcheggiani F, Gazzanelli

- G 1996 Quantification of prostate-specific antigen immunoreactivity in human breast cyst fluids. Breast Cancer Res Treat 38:247–252
- 238. Filella X, Molina R, Alcover J, Carretero P, Ballesta AM 1996 Detection of nonprostatic PSA in serum and non-serum samples from women. Int J Cancer 68:424-427
- 239. Filella X, Molina R, Alcover J, Menendez V, Gimenez N, Jo J, Carretero P, Ballesta AM 1996 Prostate-specific antigen detection by ultrasensitive assay in samples from women. Prostate 29: 311-316
- 240. Borchert G, Yu H, Tomlinson G, Giai M, Roagna R, Ponzone R, Sgro L, Diamandis EP 1999 Prostate specific antigen molecular forms in breast cyst fluid and serum of women with fibrocystic breast disease. J Clin Lab Anal 13:75–81
- 241. Yu H, Diamandis EP 1995 Prostate specific antigen in milk of lactating women. Clin Chem 41:54-58
- 242. Yu H, Diamandis EP 1995 Prostate specific antigen immunoreactivity in amniotic fluid. Clin Chem 41:204-210
- 243. Melegos DN, Yu H, Allen LC, Diamandis EP 1996 Prostate specific antigen in amniotic fluid of normal and abnormal pregnancies. Clin Biochem 29:555–562
- 244. Woodhouse EC, Chuaqui RF, Liotta LA 1997 General mechanisms of metastasis. Cancer [Suppl] 80:1529–1537
- 245. Chambers AF, Matrisian LM 1997 Changing views of the role of

- matrix metalloproteinases in metastasis. J Natl Cancer Inst 80: 1260-1270
- 246. Harvey TJ, Hooper JD, Myers SA, Stephenson SA, Ashworth LK, Clements JA 2000 Tissue-specific expression patterns and fine mapping of the human kallikrein (KLK) locus on proximal 19q13.4. J Biol Chem 275:37397–37406
- 247. Diamandis EP, Yousef GM, Soosaipillai AR, Grass L, Porter A, Little S, Sotiropoulou G 2000 Immunofluorometric assay of the human kallikrein 6 and preliminary clinical applications. Clin Biochem 33:369–375
- 248. Luo LY, Grass L, Howarth DJ, Thibault P, Ong H, Diamandis EP 2001 Immunofluorometric assay of human kallikrein 10 and its identification in biological fluids and tissues. Clin Chem 47:237–246
- 249. Diamandis EP, Yousef GM, Petraki C, Soosaipillai A 2000 Human kallikrein 6 as a biomarker of Alzheimer's disease. Clin Biochem 33:663–667
- 250. Diamandis EP, Yousef GM, Soosaipillai A, Bunting P 2000 Human kallikrein 6 (zyme/protease M neurosin): a new biomarker of ovarian carcinoma. Clin Biochem 33:369–375
- 251. Ying LY, Bunting P, Scorilas A, Diamandis EP, Human kallikrein 10: a novel tumor marker for ovarian carcinoma? Clin Chim Acta, in press

Office Action Response U.S. Ser. No. 09/486,247

EXHIBIT C: Comparison of active site homology with PVP and kallkrein/protease proteins

1. Kallikrein 6 – [Rattus norvegicus]

gi|9506997|ref|NP 062048.1| G kallikrein 6 [Rattus norvegicus] norvegicus] Length = 251Score = 492 bits (1266), Expect = e-138 Identities = 223/251 (88%), Positives = 241/251 (96%) Query: 1 MPMKMLTMKMLALCLVLAKSAWSEEQEKVVHGGPCLKDSHPFQAALYTSGHLLCGGVLID 60 MP KMLT+K LALCL+LAKSAWSE+Q+KVVHGGPCLK+SHPFQAALYTSGHLLCGGVL+ Sbjct: 1 MPTKMLTVKTLALCLILAKSAWSEDQDKVVHGGPCLKNSHPFQAALYTSGHLLCGGVLVG 60 . Histidine motif Query: 61 PQWVLTAAHCKKPNLQVILGKHNLRQTETFQRQISVDRTIVHPRYNPETHDNDIMMVHLK 120 PQWVLTAAHCKKPNL+V LGKHNLRQTETFQRQISVDRTIVHPRYNP+THDNDIMMVHLK Sbjct: 61 PQWVLTAAHCKKPNLEVYLGKHNLRQTETFQRQISVDRTIVHPRYNPQTHDNDIMMVHLK 120 Query: 121 NPVKFSKKIQPLPLKNDCSEENPNCQILGWGKMENGDFPDTIQCADVHLVPREQCERAYP 180 PVKFS++IQPLPLK DCSE+NP+CQILGWGKMENG+FPDTIQCADV LV RE+CERAYP Sbjct: 121 RPVKFSQRIQPLPLKKDCSEKNPDCQILGWGKMENGEFPDTIOCADVOLVSREECERAYP 180 Serine motif Query: 181 GKITQSMVCAGDMKEGNDSCQGDSGGPLVCGGRLRGLVSWGDMPCGSKEKPGVYTDVCTH 240 GKIT+SMVCAGD +EGNDSCQGDSGGPLVCGG LRG+VSWGDMPCGSKEKPGVYTDVCTH Sbjct: 181 GKITRSMVCAGDKREGNDSCQGDSGGPLVCGGHLRGIVSWGDMPCGSKEKPGVYTDVCTH 240 Query: 241 IRWIQNILRNK 251

NOTE: Query – represents PVP protein query sequence Subject – represents the comparison protein

IRWIQNI+RNK

Sbjct: 241 IRWIQNIIRNK 251

2. Kallikrein 8, isoform 2 [Homo sapiens]

gi|5672479|dbj|BAA82666.1| G neuropsin type2 [Homo sapiens] Length = 305Score = 238 bits (608), Expect = 8e-62 Identities = 108/232 (46%), Positives = 158/232 (68%), Gaps = 6/232 (2%) Histidine motif Quéry: 25 EQEKVVHGGPCLKDSHPFQAALYTSGHLLCGGVLIDPQWVLTAAHCKKPNLQVILGKHNL 84 +++KV+ G C S P+QAAL+ LLCGGVL+ WVLTAAHCKKP V LG H+L Sbjct: 74 QEDKVLGGHECQPHSQPWQAALFQGQQLLCGGVLVGGNWVLTAAHCKKPKYTVRLGDHSL 133 Query: 85 RQTETFQRQISVDRTIVHPRYNP---ETHDNDIMMVHLKNPVKFSKKIQPLPLKNDCSEE 141 + + +++I V ++I HP YN E H++D+M++ L++ K++P+ L + C++ Sbjct: 134 QNKDGPEQEIPVVQSIPHPCYNSSDVEDHNHDLMLLQLRDQASLGSKVKPISLADHCTQP 193 Query: 142 NPNCQILGWGKMENG--DFPDTIQCADVHLVPREQCERAYPGKITQSMVCAGDMKEGNDS 199 C + GWG + + +FPDT+ CA+V + P+++CE AYPG+IT MVCAG K G D+ Sbjct: 194 GQKCTVSGWGTVTSPRENFPDTLNCAEVKIFPOKKCEDAYPGOITDGMVCAGSSK-GADT 252 Serine motif Query: 200 CQGDSGGPLVCGGRLRGLVSWGDMPCGSKEKPGVYTDVCTHIRWIQNILRNK 251 CQGDSGGPLVC G L+G+ SWG PCG +KPGVYT++C ++ WI+ I+ +K Sbjct: 253 CQGDSGGPLVCDGALQGITSWGSDPCGRSDKPGVYTNICRYLDWIKKIIGSK 304

3. Kallikrein 14 preproprotein [Homo sapiens]

```
gi|6715552|gb|AAD50773.2| G kallikrein-like protein 6 [Homo sapiens]
gi|13897995|gb|AAK48524.1| G kallikrein 14 [Homo sapiens]
protein 6) (KLK-L6)
       Length = 251
Score = 238 bits (606), Expect = 1e-61
Identities = 107/241 (44%), Positives = 156/241 (64%), Gaps = 4/241 (1%)
                                             Histidine motif
Query: 15 LVLAKSAWSEEQEKVVHGGPCLKDSHPFQAALYTSGH--LLCGGVLIDPQWVLTAAHCKK 72
        L +A +
               E++ K++ G C + S P+OAAL
                                        LCGG L+ OWV+TAAHC +
Sbjct: 11 LAIAMTQSQEDENKIIGGHTCTRSSQPWQAALLAGPRRRFLCGGALLSGQWVITAAHCGR 70
                                    Aspartic acid motif
Query: 73 PNLQVILGKHNLRQTETFQRQISVDRTIVHPRYNPETHDNDIMMVHLKNPVKFSKKIQPL 132
        P LQV LGKHNLR+ E Q+ + V R + HP YN THDND+M++ L+ P + ++P+
Sbjct: 71 PILQVALGKHNLRRWEATQQVLRVVRQVTHPNYNSRTHDNDLMLLQLQQPARIGRAVRPI 130
Query: 133 PLKNDCSEENPNCQILGWGKMEN--GDFPDTIQCADVHLVPREQCERAYPGKITQSMVCA 190
                 +C++ GWG + +
                             +P ++QC ++++ P E C++AYP. IT MVCA
Sbjct: 131 EVTQACASPGTSCRVSGWGTISSPIARYPASLQCVNINISPDEVCQKAYPRTITPGMVCA 190
               Serine motif
Query: 191 GDMKEGNDSCQGDSGGPLVCGGRLRGLVSWGDMPCGSKEKPGVYTDVCTHIRWIQNILRN 250
        G + G DSCQGDSGGPLVC G+L+GLVSWG
                                  ·C
                                        PGVYT++C + WI+ +R+
Sbjct: 191 GVPQGGKDSCQGDSGGPLVCRGQLQGLVSWGMERCALPGYPGVYTNLCKYRSWIEETMRD 250
Query: 251 K 251
Sbjct: 251 K 251
```

4. KLK (kallikrein) 15 [Saguinus oedipus]

qi|42759849|gb|AAS45302.1| KLK15 [Saguinus oedipus] Length = 255 Score = 221 bits (564), Expect = 1e-56 Identities = 100/252 (39%), Positives = 154/252 (61%), Gaps = 14/252 (5%) Histidine motif Query: 10 MLALCLVLAKSAWSEEQEKVVHGGPCLKDSHPFQAALYTSGHLLCGGVLIDPQWVLTAAH 69 +L L +L +A ++ K++ G C S P+Q ALY G CG LI P WVL+AAH LLPLSFLLTSTA - - QDGGKLLEGEECAPHSQPWQVALYERGRFNCGASLISPHWVLSAAH 61 Sbjct: 4 Aspartic acid motif Query: 70 CKKPNLQVILGKHNLRQTETFQRQISVDRTIVHPRYNPETHDNDIMMVHLKNPVKFSKKI 129 C+ ++V LG+HNLR+ + ++ + R I HPRY +H +DIM++ L P + +++ Sbjct: 62 CQSRFMRVRLGEHNLRKRDGPEQLRTASRVIPHPRYEARSHRHDIMLLRLVQPARLTPQV 121 Query: 130 QPLPLKNDCSEENPNCQILGWGKMENGD------FPDTIQCADVHLVPREQCER 177 C + GWG + + + +P+ L -C PDT+ CA++ ++ Sbjct: 122 RPVVLPTRCPHPGEACVVSGWGLVSHNEPGTTGRPQSQVSLPDTLHCANISIISDASCDK 181 Serine motif. Query: 178 AYPGKITQSMVCAGDMKEGNDSCQGDSGGPLVCGGRLRGLVSWGDMPCGSKEKPGVYTDV 237 YPG++T +MVCAG G +SC+GDSGGPLVCGG L+G+VSWGD+PC + KPGVYT V Sbjct: 182 NYPGRLTNTMVCAGAEGRGAESCEGDSGGPLVCGGILQGIVSWGDVPCDNTTKPGVYTKV 241 Query: 238 CTHIRWIQNILR 249 C +++WI+ .++ Sbjct: 242 CRYVKWIRETMK 253

5. Kallikrein 11 isoform 2 precursor [Homo sapiens]

```
gi|3649791|dbj|BAA33404.1| G serine protease (TLSP) [Homo sapiens]
Length = 282
 Score = 221 bits (563), Expect = 1e-56
 Identities = 104/249 (41%), Positives = 151/249 (60%), Gaps = 6/249 (2%)
                                                    Histidine motif
         MKMLALCLVLAKSAWSEEQEKVVHGGPCLKDSHPFQAALYTSGHLLCGGVLIDPQWVLTA 67
         M++L L L+
                  + + +++ G C S P+QAAL+
                                             LLCG LI P+W+LTA
Sbjct: 33 MRILQLILLALATGLVGGETRIIKGFECKPHSQPWQAALFEKTRLLCGATLIAPRWLLTA 92
                                             Aspartic acid motif
Query: 68 AHCKKPNLQVILGKHNLRQTETFQRQISVDRTIVHPRYNP----ETHDNDIMMVHLKNPV 123
         AHC KP V LG+HNL++ E ++ + + HP +N + H NDIM+V + +PV
Sbjct: 93 AHCLKPRYIVHLGQHNLQKEEGCEQTRTATESFPHPGFNNSLPNKDHRNDIMLVKMASPV 152
Query: 124 KFSKKIQPLPLKNDCSEENPNCQILGWGKMENGDF--PDTIQCADVHLVPREQCERAYPG 181
           + ++PL L + C
                         +C I GWG +
                                        P T++CA++ ++ ++CE AYPG
Sbjct: 153 SITWAVRPLTLSSRCVTAGTSCLISGWGSTSSPQLRLPHTLRCANITIIEHQKCENAYPG 212
                          Serine motif
Query: 182 KITQSMVCAGDMKEGNDSCQGDSGGPLVCGGRLRGLVSWGDMPCGSKEKPGVYTDVCTHI 241
          IT +MVCA + G DSCQGDSGGPLVC
                                    L+G++SWG PC
                                                  KPGVYT VC ++
Sbjct: 213 NITDTMVCASVQEGGKDSCQGDSGGPLVCNQSLQGIISWGQDPCAITRKPGVYTKVCKYV 272
Query: 242 RWIQNILRN 250
          WIQ ++N
Sbjct: 273 DWIQETMKN 281
```

6. Serine protease [Rattus rattus]

gi|3559978|emb|CAA06643.1| serine protease [Rattus rattus] gi | 6093538 | sp | 088780 | NRPN RAT Neuropsin precursor (NP) (Kallikrein 8) (Brain serine protease 1) Length = 260Score = 233 bits (594), Expect = 4e-60 Identities = 110/245 (44%), Positives = 155/245 (63%), Gaps = 10/245 (4%) Histidine motif Query: 13 LCLVLAKSAWS----EEQEKVVHGGPCLKDSHPFQAALYTSGHLLCGGVLIDPQWVLTAA 68 + K++ G C S P+Q AL+ L+CGGVL+ +WVLTAA + L L AW+ILLFLLMGAWAGLTRAQGSKILEGQECKPHSQPWQTALFQGERLVCGGVLVGDRWVLTAA 72 Aspartic acid motif Query: 69 HCKKPNLQVILGKHNLRQTETFQRQISVDRTIVHPRY---NPETHDNDIMMVHLKNPVKF 125 V LG H+L++ + +++I V R+I HP + NPE H +DIM++ L+N HCKK Sbjct: 73 HCKKDKYSVRLGDHSLQKRDEPEQEIQVARSIQHPCFNSSNPEDHSHDIMLIRLQNSANL 132 Query: 126 SKKIQPLPLKNDCSEENPNCQILGWGKMEN--GDFPDTIQCADVHLVPREQCERAYPGKI 183 K++P+ L N C + C I GWG + + +FP+T+ CA+V + + +CERAYPGKI Sbjct: 133 GDKVKPIELANLCPKVGQKCIISGWGTVTSPQENFPNTLNCAEVKIYSQNKCERAYPGKI 192 Serine motif Query: 184 TQSMVCAGDMKEGNDSCQGDSGGPLVCGGRLRGLVSWGDMPCGSKEKPGVYTDVCTHIRW 243 T+ MVCAG G D+CQGDSGGPLVC G L+G+ +WG PCG EKPGVYT +C + W Sbjct: 193 TEGMVCAGS-SNGADTCQGDSGGPLVCNGVLQGITTWGSDPCGKPEKPGVYTKICRYTNW 251 Query: 244 IQNIL 248 I+ + Sbjct: 252 IKKTM 256

Trypsin-Induced Follicular Papilla Apoptosis Results in Delayed Hair Growth and Pigmentation

M. SEIBERG,* S. WISNIEWSKI, G. CAUWENBERGH, AND S.S. SHAPIRO Skin Research Center, Johnson and Johnson CPWW, Skillman, New Jersey 08558

ABSTRACT Programmed cell death is a controlled process that leads to the elimination of single cells via apoptosis. Programmed cell death is fundamental to development, morphogenesis, and homeostasis. Proteases play a major role in the death process. We have previously shown that a serine protease, secreted by a keratinocyte cell line, can induce apoptosis in numerous cell lines. Here we show that serine proteases can induce cell death in vivo as well. Using a synchronized hair growth mouse model, we show that topical trypsin treatment following depilation induces cell death at the follicular papilla. This results in delaying hair growth and pigmentation. We speculate that trypsin might affect a receptor-mediated signaling pathway that leads to follicular papilla cell death. Dev. Dyn. 208:553-564, 1997. © 1997 Wiley-Liss, Inc.

Key words: apoptosis; hair cycle; hair follicle; trypsin; liposomes

INTRODUCTION

The hair follicle is an epithelial structure that undergoes cycles of active growth (anagen), regression (catagen), and rest (telogen) (Panaretto, 1993). The anagen phase involves the growth of the hair follicle down into the dermis, forming a complex layered structure with a pigmented shaft. Melanogenesis had been shown to be coupled to anagen (Slominski and Paus, 1993). During the catagen phase, the hair follicle shortens as its lower two thirds undergoes programmed cell death and apoptosis. In telogen the epithelial cells are resting and the hair shaft remains inside the short follicle until a new hair shaft is produced. Although the morphological changes throughout the hair cycle are well documented (Chase, 1954), only limited information on the molecular biology of that cycle has been described (see Panaretto, 1993; Stenn et al., 1994b, 1996; Seiberg et al., 1995).

The hair follicle is one of the few organs that cycle throughout adult life. This implies that a portion of the follicle must be permanent and responsive to the signal of cycle-reinitiation. Two regions of the follicle might fulfill these requirements (Cotsarelis et al., 1990; Reynolds and Jahoda, 1991a,b). One is the bulge area, an epithelial structure that contains a keratinocyte stem cell population that can generate a new follicle (Cotsarelis et al., 1990; Sun et al., 1991; Lavker et al., 1993). The other is the follicular (dermal) papilla, a mesenchymal

structure that interacts with epithelial cells to induce hair growth (Reynolds and Jahoda, 1991b; Oliver, 1966; Jahoda et al., 1984; Oliver and Jahoda, 1988; Jahoda, 1992; Messenger, 1993). The follicular papilla dictates the nature of the follicle, and it can induce hair growth even from epithelia that are not normally associated with hair formation (Reynolds and Jahoda, 1990, 1991b; Jahoda, 1992). In order for the follicle to cycle, it is assumed that the bulge and the papilla must be protected from cell death. We have previously shown that bcl-2, a survival gene that rescues cells from programmed cell death, is expressed in the bulge region during anagen, and in the follicular papilla throughout the hair cycle (Stenn et al., 1994a).

Programmed cell death (PCD) is a fundamental aspect of development, morphogenesis, and tissue homeostasis. Many PCD pathways lead to apoptosis, a mode of cell death involving cytoplasmic condensation and specific DNA fragmentation (reviewed in Cohen, 1993; Fesus, 1993; Barr and Tomei, 1994; Martin et al., 1994; Bellamy et al., 1995; Kroemer et al., 1995; Vaux and Strasser, 1996). The controls and signals initiating cell death are only partially shared between different biological systems, but a common final pathway seems to be shared by all apoptotic pathways.

Cytoplasmic proteases play a functional role in PCD. The *Caenorhabditis elegans* protein *Ced-3* is essential for cell death and its mammalian-homologue cysteine proteases act as vertebrate PCD genes. Cell granule proteases (granzymes) induce apoptosis in permeabilized cells. Viral proteins that inhibit apoptosis have protease inhibitor activity. Experimental inhibition of cysteine or serine proteases inhibits apoptotic cell death in many in vitro systems (reviewed in Patel et al., 1996).

We have previously shown that a serine protease, secreted by the keratinocyte cell line Pam212, can induce apoptosis in numerous cell lines. Moreover, the induction of apoptosis in vitro was reproducible using trypsin (Marthinuss et al., 1995b). Here we show that serine proteases were able to induce apoptosis in vivo as well. Using a synchronized hair growth mouse model we show that a topical trypsin treatment immediately following depilation induces apoptosis in the follicular papillae. Cell death within the papillae results in a delay in hair growth and pigmentation.

^{*}Correspondence to: Miri Seiberg, Skin Research Center, J&J CPWW, 199 Grandview Rd., Skillman, NJ 08558. Received 21 August 1996; Accepted 14 January 1997

554 SEIBERG ET AL.




Fig. 1. Trypsin delivery into hair follicles. Untreated (a) and 12-day trypsin-treated mice (b) were painted with fluorescently labeled trypsin. Animals were sacrificed after 4 hr, and skins were processed for frozen sections. Bars = 10 µm.

RESULTS Synchronization of Hair Growth in C57BI/6 Mice

To determine whether serine proteases could induce apoptosis in vivo, we examined the effect of Trypsin on the mouse hair cycle. C57Bl/6 mice, at 6–10 weeks of age, are in the telogen phase of the hair cycle. Hair growth is induced by wax depilation (plucking) of the animal's back fur (Stenn et al., 1993). The growth phase (anagen) starts synchronously in all hair follicles at the time of depilation. The first histological changes are observed after one day (early anagen), when a new follicle starts to grow out from the bulge area. Several days after depilation, the hair growth is visible as the pink skin of the animal starts darkening. This is due to

pigmentation in the shaft, as the C57Bl/6 mouse contains melanocytes only in their follicles and not in the epidermis (Slominski and Paus, 1993). By 3–4 days the hair follicle is fully developed, but the hair shaft is not yet visible. By 8 days (late anagen) the mouse has a very dark skin, and the hair shafts start to penetrate through the epidermis at days 11–12. At day 14 the mouse back is covered with short hairs. By days 19–21 the regression of the follicle (catagen) is observed histologically, and by days 21–25 the hair follicle is back to resting phase. A similar synchronized hair cycle could also be induced by chemical depilation. In that case, the lower portion of the follicle remains intact. Hair shafts of the previous cycle remain intact in the







Fig. 2. Trypsin delays hair growth and pigmentation. C57BI/6 mice were depilated and treated with vehicle or trypsin (1%) immediately after depilation. (a) 8 days post depilation. Left is treated, right is untreated. (b)

11 days and (c) 14 days post depilation. Left is untreated, middle is vehicle, and right is trypsin treated. Darker skin color indicates a more progressive stage of the hair cycle, before hair shafts are visible.

dermis, until pushed out by the new hairs. It is important to note that the murine hair cycle varies not only between strains, but also among individual animals. Therefore, each skin sample was examined histologically, to verify the phase of the hair cycle.

Delivery of Serine Proteases Into Hair Follicles

To examine the effect of trypsin on the hair cycle of the mouse, we needed to deliver serine proteases, 20–40 kD in size, into the hair follicles. The potential for the use of non-ionic liposomes to target the pilosebaceous unit has been previously demonstrated (Niemiec et al., 1995; Lauer et al., 1996). Using that delivery system, we were able to target proteases into the mouse hair follicles. The specificity of the delivery system was tested with fluorescently labeled trypsin using anagen animals (most stringent condition). Mice were topically treated with the labeled trypsin, sacrificed at 1 and 4 hr after treatment, and their skin was analyzed histologically.

As shown in Figure 1a almost all of the fluorescent labeling was found within the hair follicle. The 1-hr (not shown) and 4-hr (Fig. 1a) treatments with the tagged trypsin displayed an identical staining pattern, with no apparent additional skin penetration at the later time point. This observation rules out a possible non-specific skin extracellular matrix digestion by the protease (which would show as deeper penetration of the fluorescent stain into the stratum corneum at the later time point).

The effect of long-term trypsin treatment on the delivery system was also studied. Mice depilated (both chemically and by wax) and treated with trypsin daily for 12 days, were treated with the fluorescently labeled trypsin for 4 hr (Fig. 1b). No major change was observed in the delivery route into the hair follicles of the treated skin. A minimal staining at the outer portion of the stratum corneum of the trypsin-treated skins indicated some loss of barrier integrity. This was confirmed by measuring transepidermal water loss (TEWL, see Table 4 and Discussion).

In contrast to the non-ionic liposomes, using aqueous buffered solutions or lipid-based delivery vehicles (Granulex) was shown to be ineffective. We were unable to demonstrate the delivery of the protease into the hair follicle and observed no biological effects (not shown).

Trypsin Delays Hair Growth and Pigmentation

A single topical application of trypsin (1%) immediately after depilation had a dramatic effect on the hair cycle. As shown in Figure 2, both hair growth and pigmentation were delayed. Untreated controls exhibited dark skin at 7–8 days after hair growth induction, while trypsin-treated animals remained pink (not pigmented) until day 8 (Fig. 2a). The hair shafts of control and vehicle treated mice were visible at 11–13 days after depilation. At that time, the skin color of the trypsin-treated mice was darker, but still pink, and no hair shafts were visible (Fig. 2b). By 14 days, the

control mice were covered with short fur, while trypsintreated animals exhibited gray skin with no hair shafts (Fig. 2c). The hair shafts of the trypsin-treated mice were first visible at days 16–19. These hair shafts were of reduced quality (e.g., unequal shaft thickness), but within 4–7 more days, except for length, they were almost indistinguishable from the controls.

Histology of Trypsin-Treated Hair Follicles

Histological analysis of untreated, liposome control (identical to untreated, not shown) and trypsin-treated skins revealed major changes in the trypsin-treated animals. As shown in Figure 3, the hair follicles were delayed in their development. The characteristic layered structure, the expanded follicular papilla, and the new pigmentation were observed 5-7 days later than the controls, and the follicles displayed a dialated infundibulum (compare untreated follicles, Fig. 3A-a,b to trypsin-treated, Fig. 3B-a-e). At 7-8 days after treatment about half of the treated follicles started to overcome the trypsin effect and exhibited characteristic follicular development of a 3-4-day control follicle. The upper part of these follicles was still distorted, exhibiting a dialated infundibulum (See Fig. 3B-d). By 11-12 days most of the treated follicles matured, but still displayed reduced pigmentation and shorter shafts, resembling a 4-5-day control follicle (delay of 7 days, compare Fig. 3A-d to Fig. 3B-f). One fourth of the mature follicles remained histologically atypical (bends, kinks, unequal shaft thickness) throughout the observation period (14 days). The trypsin treatment results also in epidermal hyperplasia (see Fig. 3B), as it induces epidermal differentiation and increases the number of cell layers of the epidermis.

Trypsin Induces Apoptosis at the Follicular Papilla

Following wax depilation, we expected trypsin to induce apoptosis within the follicular papilla and around it, as the previous telogen follicle is removed. Upon chemical depilation we could affect the lower epithelial portion of the follicle as well. Terminal transferase end-labeling (TUNEL staining) revealed an increase in apoptotic figures in the trypsin-treated follicles, relative to untreated and vehicle-treated controls, regardless of the depilation system. As shown in Figure 4, apoptotic bodies were detected within the treated follicular papilla throughout the first week after hair growth induction (Fig. 4B-a-e). At a given time, only a few cells within a single papilla were affected. No other portions of the follicle, epidermis, or dermis were affected by the serine protease treatment. While a minimal level of apoptosis was occasionally detected in untreated early anagen follicles (see Fig. 4A-a-c), it was always at the isthmus of the follicle, well above the follicular papilla. Most of the untreated follicles did not display any cell

Continuous daily applications of trypsin also had a later effect on the growing follicle. At day 8 post




Fig. 3. Trypsin delays hair follicle development. Mice treated as indicated in Figure 2 were sacrificed daily and their skins were processed for histology using H&E staining. A: Untreated, days 4 (a), 5 (b), 8 (c), and 12 (d). Bar = 10 μ m in a–c, 5 μ m in d. B: Trypsin treated, days 4 (a), 5 (b), 6 (c), 8 (d,e), and 12 (f). Bar = 10 μ m in a–e, 5 μ m in f. Note that the follicular papilla of treated follicles (dark arrowhead) remains condensed

up to 6 days post depilation (a-c). Layering structure and minimal shaft pigmentation (white arrowhead) appear in some, but not all follicles, only 8 days post depilation (d,e). **C:** Lower portion of a hair follicle, indicating the papilla (DP), the epithelial layering structure (L), and the developing pigmented shaft (P).




Fig. 4. Trypsin induces apoptosis in the follicular papillae. Mice were treated as indicated in Figure 2 and sacrificed daily. Paraffin sections were stained for apoptosis using a TUNEL stain with a peroxidase end point (brown), and methyl green counter-stain. A: Untreated, days 1 (a), 2 (b), and 3 (c) after depilation. Bar = 10 µm. B: Trypsin treated. a—e, 1–5 days

after depilation, single trypsin application. f, daily treated for 8 days after depilation. Bar = $10 \mu m$, in a,d,e and $5 \mu m$ in b,c,f. Apoptosis is detected only in the treated follicular papillae (arrowheads). Note the black pigmented shaft (P) forming above the follicular papilla, which is different from the brown TUNEL staining (f, see also pigment localization in Fig. 3).

depilation, about half of the daily treated follicles were able to overcome the protease effect and started to form layers (see Fig. 3B-d,e). These follicles exhibited minimal cell death at the upper follicular region, around the bulge area (Fig. 4B-f). Surprisingly, cell death at such an important region of the follicle had no effect on follicular development.

Trypsin Can Induce Changes in Gene Expression During the Hair Cycle

Several serine proteases have been recently implicated as mediators of signal transduction and regulators of gene expression (e.g., Patel et al., 1996). Our previous work suggests that serine protease(s) induce apoptosis in cultured cells via a signal transduction




Fig. 5. Gene expression during the delayed hair cycle. Mice were treated as indicated in Figure 2 and sacrificed daily for RNA extraction. RT-PCR was used to compare steady-state mRNA levels of the genes indicated. A: mRNA levels (the RT-PCR product of 25 ng total RNA) throughout the delayed hair cycle. B: mRNA levels (the RT-PCR product

of 250 ng total RNA, 5 ng for G3PDH) at day 8 of the cycle. For each gene tested in panel B, left is untreated, right is trypsin treated. (See also Table 1.)

mechanism (Marthinuss et al., 1995a,b), and we had shown changes in gene expression following serine protease treatment of cultured cells. Therefore, we examined the pattern of expression of a series of genes, throughout the hair growth-delay period. We chose the RT-PCR amplification assay for its sensitivity, even though it is semi-quantitative only. We clearly demonstrate trypsin-induced changes in mRNA levels along the hair cycle using this assay.

A strong increase was demonstrated for 1L-1 β and IFN γ mRNAs (Fig. 5A,B, Table 1), genes which are upregulated in Alopecia Areata and are associated with the inhibition of hair growth. A moderate upregulation was observed in IL-1 α mRNA level (Fig. 5B, Table 1), a gene associated with the inhibition of hair growth in culture. Since IL-1 α induction could also result from the loss of the epidermal barrier function, we analyzed the barrier integrity by measuring TEWL. A moderate increase in TEWL, which did not correlate with trypsin concentration, was always observed (see Table 4).

To verify that the delay in follicular development was not the result of a non-specific irritation or an inflammatory response, we analyzed the mRNA levels of genes that are upregulated during such situations. We found no change in the mRNA levels of IL-6, IL-10, and GM-CSF, a slight upregulation of $TNF\alpha$, a slight down-regulation of $TNF\beta$ and TNF-RI, and a moderate

TABLE 1. Patterns of Gene Expression at Day 8
Post Depilation^a

Gene	Untreated	Trypsin	
IL-6	_	_	
IL-10	±	±	
GM-CSF	-	_	
TNFα	<u>±</u>	+	
TNFβ	+	· ±	
TNF-RI	±	+/	
TNF-RII	· <u>-</u>	_	
MIP	+	_	
IL-1α	+	++	
IL-1β	<u>±</u>	+++	
IL-1R	_	-	
IFN_{γ}		+++	
c-myc	+	-	
c-myb	++	+	
c-fos	+	<u>±</u>	
c-jun	· ±	+	
Collagenase	+	±	
Tyrosinase	+++	±	
POMC	+	± ±	
Transglutaminase	+	+	

*For experimental details see Figure 5. Note that RT-PCR is semi-quantitative only. Comparisons are valid only for each amplified sequence, within the different hair cycles, and not among the different genes. -, no detectable expression; +/--, a very weak band; \pm , a weak band; \pm , a strong band; ++, a stronger band; +++, a very strong band.

downregulation in macrophage inducible protein (MIP). This profile of gene expression (see Fig. 5B, Table 1) rules out an inflammatory reaction or a response to dermal irritation. Moreover, mice treated with known irritants like hexadecane or SDS (1%), either at a single dose or using daily applications for 2 weeks, showed no effect on hair growth or pigmentation (not shown). Their gene expression profile was very similar to an irritation-induced gene expression profile (Kondo et al., 1994).

A slight reduction was detected in the mRNA levels of *c-myb, c-myc,* and *c-fos,* while the *c-jun* level was slightly increased throughout the delay period (see Table 1). Collagenase, a gene regulated via an AP-1 response element, was slightly reduced as well.

Tyrosinase, a key enzyme for hair pigmentation, was downregulated during the delay in hair growth period. Its mRNA level increased as the follicles start to overcome the delay (Fig. 5A). Proopiomelanocortin (POMC), the precursor of the melanogenic peptide melanocyte stimulating hormone (MSH), was moderately downregulated throughout the delay period (Fig. 5A). This indicates that trypsin could, directly or indirectly, affect the regulation of melanogenesis as well.

Transglutaminase, a gene induced in apoptosis and during catagen, did not exhibit a change in mRNA level during the delayed hair cycle (Fig. 5A, Table 1). This reflects the limited number of cells within the skin that are induced to death. At a given time, only a few of the papilla cells are affected by the protease death signal (see Fig. 4B). Changes in gene expression within such a small fraction of the skin could not be detected in a whole skin assay.

Correlations of gene expression patterns with the hair cycle should not be confused with expression within the hair follicle itself, since many cell types within skin could contribute to a cycle-dependent expression pattern. Some gene expression in total skin is hair cycle dependent. This includes changes in expression both within the changing follicle and within the skin itself (see Seiberg et al., 1995, and references therein).

Other Serine Proteases Have a Reduced Delaying Effect on Hair Growth

Our delivery studies (Fig. 1) indicate that the effect of trypsin on hair growth and pigmentation is not the result of non-specific proteolytic digestion within skin. To further address this question, the effect of several serine proteases on the mouse hair growth was analyzed. Chromameter measurements were used to compared skin color of mice, as skin darkness results from follicular development (Slominski and Paus, 1993). Mice treated with different serine proteases were analyzed for this pigmentation effect at 8 days post depilation.

Both Carboxypeptidase-Y (hydrolyses L-amino acids at the C-termini of proteins) and a nonspecific endopeptidase (Protease IV, cuts 56% of peptide bonds at neutral PH) had only a minimal delaying effect on hair

TABLE 2. Chromameter Measurements of Serine Protease-Treated Skins^a

Treatment	Sample size	L*
Untreated	6	49 ± 0.30
1% Trypsin	6	56.1 ± 0.81
1% Subtilysin	4	42.9 ± 2.87
1% Endo-pep	4	51.8 ± 0.11
1% Carboxy-Y	4	51.9 ± 0.47

 a C57Bl/6 mice, 8 days post depilation, were analyzed for skin brightness (L* scale: 0 = black, 100 = white). Animals were treated with a single dose of protease immediately after depilation. Carboxy-Y, carboxypeptidase Y; Endo-pep, non-specific endopeptidase.

growth. Subtilysin (nonspecific peptidase at alkaline PH), on the other hand, slightly increased the rate of hair growth. Trypsin (endopeptidase, cuts at the C-side of Arg, Lys), in comparison, induced the longest delay in hair growth. Chromameter readings of skin color fully correlate with the delaying effect (Table 2). Trypsintreated skins were less pigmented than the Carboxypeptidase-Y- or Protease IV-treated skins; untreated skins (natural development of pigmentation) were slightly brighter than the Subtilysin-treated skin. This clearly demonstrates that non-specific proteolytic digestion is not the major cause for the delayed growth.

Trypsin Affects an Early Step in Hair Growth Induction

Additional daily trypsin treatments did not prolong the delay in hair growth. Two, three, and seven treatments per week, up to 2 weeks, resulted in an identical hair growth profile, both morphologically and histologically, when compared to a single application (not shown). Even though the follicular delivery is not changed (see Fig. 1b), no further delay in the hair cycle is observed with the additional treatments.

To analyze the timing of the papilla sensitivity to the death signal, mice were treated with a single dose of trypsin at different time points. Mice treated immediately post depilation showed the longest delay in hair growth and pigmentation (see Table 3). Mice treated 2 and 4 hr after hair growth induction still exhibited a delayed hair cycle, but progressively shorter. Mice treated 6 hr after depilation or at later time points were not delayed for hair growth and were indistinguishable from untreated control. Skin color measurements (Table 3) demonstrated an increase in darkness (more pigment, less of the delay) that correlates with the increased time between depilation and trypsin application.

Trypsin Effect Might Involve a Receptor-Mediated Mechanism

Mice induced for hair growth were treated with reduced concentrations of trypsin, from 1% down to 0.01% (4 \times 10⁻⁴M-4 \times 10⁻⁶M), and analyzed morphologically and colorimetrically for the dose effect on hair growth. Reducing the trypsin concentration prolonged

TABLE 3. Chromameter Measurements of Trypsin-Treated Skin^a

Treatment	Sample size	L*
Untreated	6	49 ± 0.32
At depilation	6	56.1 ± 1.54
After 2 hr	4	54.4 ± 1.30
After 4 hr	4	53.3 ± 1.23
After 6 hr	4	48.0 ± 2.01
After 18 hr	4	49.2 ± 1.07
After 48 hr	4	50.4 ± 1.01

 a C57Bl/6 mice, 8 days post depilation, were analyzed for skin brightness (L* scale: 0 = black, 100 = white). Animals were treated with a single dose of trypsin (1%) immediately following depilation, or as indicated.

TABLE 4. Physical Properties of Trypsin-Treated Skins^a

Treatment	Sample size	L*	TEWL
Untreated	6	45 ± 0.97	27.01 ± 3.8
Liposomes	4	45 ± 1.03	29.81 ± 2.9
0.01% Trypsin	4	48.6 ± 1.01	36.89 ± 4.6
0.1% Trypsin	4	49.5 ± 1.07	43.2 ± 5.2
0.5%	4	47.7 ± 0.3	34.53 ± 4.9
1% Trypsin	4	47.9 ± 0.08	37.5 ± 3.9
1% Trypsin—inactive	3	51.2 ± 0.17	33.99 ± 6.2

 $^{\rm a}$ C57Bl/6 mice, 9 days post depilation, were analyzed for skin brightness (L* scale: 0 = black, 100 = white) and transepidermal water loss (TEWL; increases when barrier function of the epidermis is disrupted). Animals were treated with a single dose of trypsin, immediately after depilation. Trypsin was inactivated by incubating at room temperature for 48 hr, in aqueous solution.

the delay in hair growth and pigmentation by 1-2 days. Chromameter measurements of the treated skins revealed an increase in brightness (L*, more white, less pigment) that correlates with the decrease in trypsin concentration (down to 0.01%) and with the increase in the delay of the hair cycle (Table 4). This could suggest a receptor-mediated mechanism including desensitization with higher doses.

A receptor-based mechanism could involve the occupancy of the receptor by a ligand, or receptor activation by a proteolytic cleavage. To further analyze the mechanism of the trypsin death signal we used an inactivated preparation of trypsin (1%, 48 hr at room temperature in aqueous solution). This preparation was enzymatically inactive, but was not completely denatured. Such a preparation further enhanced the delay in hair growth. Chromameter measurements of treated skins show that animals treated with the inactive trypsin had the highest L* score (Table 4). The inactive and native trypsin preparations induced similar histological changes, with an increased delay in hair growth for the inactive preparation (not shown). This clearly indicates that the proteolytic activity of trypsin does not play a role in the delay of hair growth. Boiled trypsin, which is inactive as well but is completely denatured, did not have any effect on the hair cycle, morphologically or histologically (not shown). This indicates that the 3-D

structure of trypsin, and not its proteolytic activity, might be essential for the delaying effect.

DISCUSSION

Using a synchronized hair growth mouse model (Slominski and Paus, 1993; Stenn et al., 1993) we show that topical trypsin treatment, immediately after depilation, induces cell death at the follicular papilla. This death signal, which is independent of the proteolytic activity of the protease, results in delaying hair growth and pigmentation. We speculate that trypsin affects a receptor-mediated signaling pathway that leads to follicular papilla cell death.

We had previously shown that keratinocytes can undergo spontaneous apoptosis in vitro (Marthinuss et al., 1995a). We had further demonstrated that a serine protease, secreted by the keratinocyte cell line Pam212, can induce cell death of numerous cell lines (Marthinuss et al., 1995b). Using cycloheximide, we demonstrated that this serine protease activates the death mechanism via a signal transduction pathway (Marthinuss et al., 1995b). We excluded the proteolytic activation of the thrombin receptor, PAR-2 (a protease-activated receptor expressed in keratinocytes; Santulli et al., 1995) and urokinase plasminogen activator, as a part of the death signaling pathway (Marthinuss et al., 1995b).

Here we demonstrate that serine proteases could also induce apoptosis in vivo, and probably via a receptor-mediated mechanism. We clearly demonstrate that the proteolytic activity itself is not necessary to induce the cell death. Reducing the trypsin concentration results in an increase in the delaying activity, suggesting receptor desensitization with higher doses. Since boiled trypsin did not affect hair growth, we speculate that the 3-D structure of the molecule might be important for this process. The timing of the protease application is very critical. The follicular papilla is sensitive to the death signal only during the early steps of hair growth induction. Daily application of trypsin had no additive effect on the hair cycle.

One possible mechanism for serine protease-induced apoptosis is the perforin-granzyme mechanism, employed by cytotoxic lymphocytes. The combined effect of perforin, a pore-forming protein, and granzymes, a family of granule proteins that includes many serine proteases, leads to apoptosis and DNA fragmentation of target cells (reviewed in Patel et al., 1996). One might claim that wax depilation causes enough damage to the remaining cells to enable the entry of trypsin without additional perforin activity. However, the waxing damage is not unique to the follicular papilla, so one might expect the induction of apoptosis in dermal and epidermal cells as well. Moreover, depilatory creams induce hair growth of telogen mice without physically damaging the lower portion of the follicle or the follicular papillae. Trypsin could induce the same delay in hair growth in the wax and chemically depilated animals.

The epithelial-mesenchymal interactions which lead to skin appendage formation are well studied (Hardy, 1992; Jahoda, 1992), demonstrating the important role of the follicular papilla in hair formation. The follicular papilla could induce follicle formation from the epithelium of the palm, which is usually not associated with hair follicles (Reynolds and Jahoda, 1991b; Jahoda, 1992). The combination of follicular papilla fibroblasts with epithelial cells results in pigmentation and hair follicle formation in nude mice (see Prouty et al., 1996, and references therein). Inducing cell death at the follicular papilla has not yet been described. Here we show that the induction of apoptosis in the follicular papillae results in perturbation of the hair cycle, and in delaying hair growth and pigmentation.

During the hair cycle the papilla changes its size by the addition of extracellular matrix molecules. The number of cells within this structure remains constant throughout the hair cycle (Messenger et al., 1991). The trypsin-induced apoptosis might result in a decrease in the number of cells within the papilla. It is possible that the delay in hair growth equals the time needed to regenerate these missing papillae cells. Maybe only when a damaged papilla is recovered, then new hair formation can take place. It is possible, also, that atypical hair follicles rise from a papilla that is not completely recovered. Such a mechanism could further demonstrate the importance of this mesenchymal structure in hair follicle formation. We cannot exclude the possibility that amelanotic melanocytes or endothelial cells were induced to death by the protease. The distribution of the apoptotic bodies within the papilla, however, does not resemble the localization of follicular melanocytes or endothelial cells.

We had previously shown that the localization of Bcl-2 (a protein that negatively regulates apoptosis) within the hair follicle is hair cycle dependent (Stenn et al., 1994a). The papilla continues to express bcl-2 throughout the cycle, as well as during telogen, while the bulge area, where follicular stem cells reside, expresses this protective protein only during the growth phase. This supports the notion that the follicular papilla is a long-lived structure, and that its function is continuously necessary. The induction of papilla cell death by the proteases, therefore, might reflect on a special property of the papilla at the time of hair growth induction, which makes it sensitive to the death signal. This timing could correlate with the reduced expression of one or several members of the Bcl-2 family. Alternatively, the protease signal could act downstream of the bcl-2 protection check point, as was shown for epidermal keratinocytes apoptosis (Marthinuss et al., 1995b).

Nexin-1, a serine protease inhibitor, is expressed within intact skin at the late anagen papilla only (Yu et al., 1995). Nexin-1 provides a mechanistic control for serine proteases at and near the cell surface of fibroblasts (Wagner et al., 1989). Nexin-1 had been shown to rescue neuronal cells from apoptosis (Houenou et al., 1995). It is conceivable that the expression of Nexin-1

enables the papillae to survive the protease death signal, possibly by complexing with the catalytic site serine residue and internalizing and degrading the complex. This would have the effect of changing putative follicular death into delayed growth.

Some gene expression within skin is hair cycledependent. We had demonstrated a change in patterns of gene expression immediately before and during catagen, which might be involved in the regulation, initiation, or execution of the regression of the lower follicle (Seiberg et al., 1995). The changes in gene expression induced by trypsin do not reproduce the pattern of gene expression during catagen. The general reduction in mRNA levels of several genes observed here is reflective of the overall slow down in hair growth, and not of catagen. This implies that the serine proteases do not induce premature catagen. Indeed, trypsin treatments during anagen did not induce the regression of the follicle. Moreover, while TNF α , EGF, and IL-1β can abrogate hair growth in organ culture, a catagen-like morphology is formed with TNFa and EGF, but not with IL-1β (Hoffmann et al., 1996). Here we show that IL-1 β , but not TNF α , is highly upregulated by the serine protease induced papilla death, suggesting a mechanism different from premature catagen. Transglutaminase, a gene upregulated in apoptosis and catagen, is not upregulated by the trypsin signal. This also supports the notion that the death signal does not induce premature catagen. Changes in mRNA level of a few of the papilla cells cannot be detected by RT-PCR of total skin, while transglutaminase gene expression of regressing follicles is easily detected (Seiberg et al., 1995).

IL- 1α and IL- 1β are related proteins with broad biological activity, associated mainly with inflammation, but also expressed in non-immune cells including epidermal keratinoytes and fibroblasts. Both IL-1α and IL-1β can inhibit follicular growth in organ culture (Harmon and Nevins, 1993; Hoffmann et al., 1996), and transgenic mice overexpressing IL-1 α in the skin exhibit patchy hair loss (Groves et al., 1995). In Alopecia Areata, when a cascade of immunological events results in hair loss, high levels of IL-1ß expression has been reported (Hoffmann et al., 1994; Telegdy et al., 1994). We observe the highest increase in gene expression of the trypsin delayed hair cycle at the mRNA levels of IL-1β and IFNy. The increase observed in IFNy level also correlates with the IFNy upregulation in Alopecia Areata (Hoffmann et al., 1994; Telegdy et al., 1994).

We demonstrate a significant increase in IL-1 β mRNA, and a moderate upregulation in IL-1 α mRNA level. While both could affect hair growth, it is important to note that IL-1 α expression is also stimulated by epidermal barrier disruption (Wood et al., 1996). Our observation of increased TEWL indicates that the moderate increase in IL-1 α could reflect the barrier effect, and might not be related to the hair growth delay. The increase in IL-1 β during the delayed hair cycle might provide a clue to the mechanism of the perturbed

562 SEIBERG ET AL.

follicular growth. If IL-1 β is involved in the maintenance of the delayed growth, then one might expect the follicle to remain dormant as long as IL-1 β is expressed. This is, indeed, the situation in our study. When $IL-1\beta$ levels start to decrease, the follicles start to overcome the inhibitory signal. This is observed histologically, and later also morphologically. At day 14, when the growth delay is over, the level of IL-1B mRNA is below detection. It would be interesting to analyze the levels of IL-1 receptor antagonist (IL-1ra) and melanocyte stimulating hormone (\alpha MSH), two potent inhibitors of IL-1β, and find out whether an increase in one of these molecules downregulates IL-1ß and abrogates the growth inhibition. These two regulators are expressed in skin: MSH has a major role in pigmentation (Wintzen et al., 1996), and IL-1ra gene polymorphism is associated with the severity of Alopecia Areata (Tarlow et al., 1994; Cork et al., 1995). IL-1 expression is high in undifferentiated keratinocytes, and is reduced when they become terminally differentiated (Ansel et al., 1988). Whether it is possible to draw an analogy to an undifferentiated (telogen) follicle vs. the growing, more differentiated (anagen) one, remains to be studied.

The increase in IL-1 β and IFN γ could also reflect an inflammatory response or could result from epidermal irritation. To verify that the delay in follicular development is not the result of such non-specific processes, we analyzed the mRNA levels of several other genes that are upregulated during irritation and inflammatory situations (Kondo et al., 1994). The profile of gene expression demonstrated (see Table 1) rules out an inflammatory reaction or a response to dermal irritation. Moreover, animals treated with known irritants had no effect on hair growth and pigmentation. Their gene expression profile was very different, resembling the described irritant-induced gene expression profile (Kondo et al., 1994).

Tyrosinase, the major regulator of hair pigmentation (Sanchez-Ferrer et al., 1995; Mishima, 1994) was down-regulated during the delay in hair growth period. Its mRNA level increased as the follicles started to overcome the delay (Fig. 5). Proopiomelanocortin (POMC), the precursor of several peptides including the melanogenic peptide MSH (Jimbow, 1995; Wintzen et al., 1996), was slightly downregulated throughout the delayed hair cycle. The cell death induced by the protease at the papilla, therefore, affects the pigmentation of the follicle. This implies that the follicular papilla has an important role in the regulation of melanogenesis as well.

In this study, we were able to manipulate the hair cycle via trypsin-induced apoptosis at the follicular papilla. This is the first demonstration of induced apoptosis in the follicular papilla, a structure thought to be protected from cell death. The proteolytic activity of the protease is not necessary for the death signal. We speculate that trypsin might affect a receptor-mediated signaling pathway that leads to follicular cell death.

Whether trypsin blocks a survival signal or activates a death receptor remains to be studied.

MATERIALS AND METHODS

Chemicals

Serine proteases and other chemicals were from Sigma (St. Louis, MO). Granulex (Dow Hickam Pharmaceuticals Inc., Sugar Land, TX) contains 1.25% trypsin in Balsam Peru and Castor Oil. Trypsin was inactivated by either incubating at room temperature for 48 hr, or boiling for 10 min, in 0.05M Hepes PH 7.4. Proteolytic activity was analyzed by the PanVera kit (Madison, WI). Trypsin was labeled fluorescently using a Molecular Probes kit (Eugene, OR). GDL liposomes (50 mg lipids/ml) were prepared as described in Niemiec et al. (1995). The non-ionic liposomal formulation contains glycerol dilaurate/cholesterol/polyoxyethylene-10-stearyl ether ratio 58/15/27.

Animals and Hair Growth Induction

C57Bl/6 female mice, 7-8 weeks old, were purchased from Charles River (Kingston, NY). Hair growth was induced by wax depilation as previously described (Stenn et al., 1993), or by chemical depilation (Neat, Nair). Each experiment described was performed using both chemical and wax depilation, with similar results. A skin sample from each animal was examined histologically, using H&E stain. One hundred microliters of the protease solution were applied to the back of each animal. Each experiment was repeated at least four times, with at least three animals per group. Transepidermal water loss (TEWL) was measured with an Evaporimeter using standard techniques (Evaporimeter EPI, Servomed AB, Stockholm, Sweden). Color measurements were performed using the Minolta Chromameter model CR300 using standard techniques (Osaka, Japan).

TUNEL Assay

Apoptotic staining was performed on paraffin sections using Apoptag (Oncor, Gaithersburg, MD, manufacturer's protocol), a technique based on the labeling of fragmented-DNA ends (Gavrieli et al., 1992). Each experiment was repeated at least three times. Pictures presented are of a single experiment. Apoptotic cells were defined by both morphology (condensed or fragmented nuclei and cytoplasm or apoptotic bodies), and staining (fragmented DNA within the condensed nuclei or apoptotic bodies).

RT-PCR

At the time points indicated animals were sacrificed and total RNAs were extracted from whole skins (RNA Stat-60, Tel-Test B, Friendswood, TX, manufacturer's protocol). At least 3 animals were used for each time point studied, and samples were analyzed individually. Total skin DNased-RNA (200 ng) (Promega, Madison, WI, RQ1 RNase-free DNase, manufacturer's protocol) from each sample was reverse transcribed (Gibco-BRL,

Gaithersburg, MD, Superscript II reverse transcriptase, manufacturer's protocol), using random hexamers (Gibco-BRL). RT products were PCR-amplified (Tag polymerase, Perkin-Elmer-Cetus, Branchburg, NJ), using Clontech primers, Clontech positive control and Clontech PCR protocol (Clontech, Palo Alto, CA) for mouse glyceraldehyde-3-phosphate-dehydrogenase (G3PDH), transcription factors and cytokines. Transglutaminase primers were: sense: 5'AACCCCAAGTTCCT-GAAG and antisense: 5'TTTGTGCTGGGCCACTTC. The reaction contained 2.5 mM MgCl₂ and the cycle was of 1 min at 94°C, 2 min 55°C, and 3 min at 72°C, for 35 cycles. Tyrosinase primers were: sense: 5'TCAGCCCAG-CATCCTTCTTC and antisense: 5'CAGCCATTGTTC-AAAAATACTGTCC. The reaction contained 5 mM $MgCl_2$ and the cycle was of 1 min at 94°C, 2 min at 45°C, and 3 min at 72°C, for 35 cycles. POMC primers were: sense: 5'AAAAGAAGAGAGAGAGCGAC and antisense: 5'AGAGCTGAGACACCCTTACC. The reaction contained 2.5 mM MgCl₂ and the cycle was of 1 min at 94°C, 2 min at 55°C, and 3 min at 72°C, for 35 cycles. Collagenase primers were: sense: 5'AAGACCCCAAC-CCTAAGCAC and antisense: 5'CAGCACTGACGGTTT-TCACC. The reaction contained 2.5 mM MgCl₂ and the cycle was of 1 min at 94°C, 2 min at 53°C, and 3 min at 72°C, for 35 cycles. PCR products were ethanol precipitated when required. For G3PDH, only 10% of the PCR reaction was used. PCR products were analyzed on 2% agarose/ethidium bromide gels. An RNA sample that was not reverse-transcribed was used as a negative control for each PCR amplification. Obtaining no band indicates the lack of genomic DNA contaminants. A six-month-old mouse skin (non-synchronized hair cycle) RT was used as a positive control when plasmids were not available. The migration of the RT-PCR products on the gels was always identical to the positive controls, and to the reported amplimer sizes. To compare the relative quality of the RT-PCR reactions, the transcription level of G3PDH, a "housekeeping" gene, was used as a control. G3PDH gene expression was found to be similar at all the time points examined (see Fig. 5), enabling analysis of the relative levels of gene expression for the desired genes.

ACKNOWLEDGMENTS

We thank Dr. S. Niemiec for the preparation of liposomes and advising on delivery systems, Ms. A.G. Johnson and Mr. P. Siock for excellent technical assistance, Mr. J. Pote for assisting with chromameter readings, Dr. S. Prouty for fruitful discussions throughout this study, and Drs. M. Eisinger, A. Gosiewska, S. Niemic, and S. Prouty for a critical reading of this manuscript.

REFERENCES

- Ansel, J.C., Luger, T.A., Lowry, D., Perry, P., Roop, D.S.R., Mountz, J.D. (1988) The expression and modulation of IL-1 alpha in murine keratinocytes. J. Immunol. 140:2274-2278.
- Barr, P.J., Tomei, D.L. (1994) Apoptosis and its role in human disease. Biotechnology 12:487–493.

- Bellamy, C.O.C., Malcomson, R.D.G., Harrison, D.J., Wyllie, A.H. (1995) Cell death in health and disease: The biology and regulation of apoptosis. Semin. Cancer Biol. 6:3–16.
- Chase, H.B. (1954) Growth of the hair. Physiol Rev. 34:113–126.
- Cohen, J.J. (1993) Apoptosis. Immunol. Today 14:126-130.
- Cork, M.J., Tarlow, J.K., Clay, F.E., Crane, A., Blakemore, A.I.F., McDonagh, A.J.G., Messenger, A.G., Duff, G.W. (1995) An allele of the IL-1 receptor antagonist as a genetic severity factor in alopecia areata. J. Invest. Dermatol. 104(Suppl. 5):15s-16s.
- Cotsarelis, G., Sun, T.T., Lavker, R.M. (1990) Label-retaining cells reside in the bulge area of pilosebaceous unit: Implications for follicular stem cells, hair cycle, and skin carcinogenesis. Cell 61:1329–1337.
- Fesus, L. (1993) Biochemical events in naturally occuring forms of cell death. Fed. Eur. Biochem. Soc. 328:1–5.
- Gavrieli, Y., Sherman, Y., Ben-Sasson, S.A. (1992) Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. J. Cell Biol. 119:493–501.
- Groves, R.W., Mizutani, H., Kieffer, D.J., Kupper, T.S. (1995) Inflammatory skin disease in transgenic mice that express high levels of IL-1 alpha in basal epidermis. Proc. Natl. Acad. Sci. U.S.A. 92:11874–11878.
- Hardy, M.H. (1992) The secret life of the hair follicle. Trends Genet. 8:55-61.
- Harmon, C.S., Nevins, T.D. (1993) IL-1 alpha inhibits human hair follicle growth and hair fiber production in whole organ culture. Lymphokine Cytokine Res. 12:197–303.
- Hoffmann, R., Wenzel, E., Huth, A., Steen, P., Schaufele, M., Henninger, H.P., Happle, R. (1994) Cytokine mRNA lévels in alopecia areata before and after treatment with the contact alergan diphenyl-cyclopropenone. J. Invest. Dermatol. 103:530–533.
- Hoffmann, R., Eicheler, W., Huth, A., Wenzel, E., Happle, R. (1996) Cytokine and growth factors influence hair growth in vitro. Possible implications for the pathogenesis and treatment of alopecia areata. Arch. Dermatol. Res. 288:153–156.
- Houenou, L.J., Turner, P.L., Li, L., Oppenheim, R.W., Festoff, B.W. (1995) A serine protease inhibitor, protease nexin-1, rescues motoneurons from naturally occurring and axotomy-induced cell death. Proc. Natl. Acad. Sci. U.S.A. 92:895–899.
- Jahoda, C.A.B. (1992) Induction of follicle formation and hair growth by vibrissa dermal papillae implanted into rear wounds: Vibrissatype fibres are specified. Development 115:1103–1109.
- Jahoda, C.A.B., Horne, K.A., Oliver, R.F. (1984) Induction of hair growth by implantation of cultured dermal papilla cells. Nature 311:560-562.
- Jimbow, K. (1995) Current update and trends in melanin pigmentation and melanin biology. Keio J. Med. 44:9–18.
- Kondo, S., Pastore, S., Shivji, G.M., Mckenzie, R.C., Sauder, D.N. (1994) Characterization of epidermal cytokine profiles in sensitization and elicitation phases of allergic contact dermatitis as well as irritant contact dermatitis in mouse skin. Lymphokine Cytokine Res. 13:367–375.
- Kroemer, G., Petit, P., Zamzami, N., Vayssiere, J.-L., Mignotte, B. (1995) The biochemistry of programmed cell death. FASEB J. 9:1277-1287.
- Lauer, A.C., Ramachandran, C., Lieb, L.M., Niemiec, S., Weiner, N.D. (1996) Targeted delivery to the pilosebaceous unit via liposomes. Adv. Drug Delivery Rev. 18:311–324.
- Lavker, R.M., Miller, S., Wilson, C., Costarelis, G., Wei, Z.-G., Yang, J.-S., Sun, T.-T. (1993) Hair follicle stem cells: Their location, role in hair cycle, and involvement in tumor formation. J. Invest. Dermatol. 101:16s–26s.
- Marthinuss, J., Lawrence, L., Seiberg, M. (1995a) Apoptosis in Pam212, an epidermal keratinocyte cell line: A possible role for bcl-2 in epidermal differentiation. Cell Growth Differ. 6:239–250.
- Marthinuss, J., Andrade-Gordon, P., Seiberg, M. (1995b) A secreted serine protease can induce apoptosis in Pam212 keratinocytes. Cell Growth Differ. 6:807–816.
- Martin, S.J., Green, D.R., Cotter, T.G. (1994) Dicing with death: Dissecting the components of the apoptosis machinery. Trends Biol. Sci. 19:26–31.

- Messenger, A.G. (1993) The control of hair growth: An overview. J. Invest. Dermatol. 101:4s-9s.
- Messenger, A.G., Elliot, K., Westgate, G.E., Gibson, W.T. (1991) Distribution of extracellular matrix molecules in human hair follicles. Ann. N.Y. Acad. Sci. 642:253-262.
- Mishima, Y. (1994) Molecular and biological control of melanogenesis through tyrosinase genes and intrinsic and extrinsic regulatory factors. Pigment Cell Res. 7:376–387.
- Niemiec, S., Ramachandran, C., Wiener, N. (1995) Influence of nonionic liposomal composition on topical delivery of peptide drugs into pilosebaceous units: An in vivo study using the hamster ear model. Pharm. Res. 12:1184–1188.
- Oliver, R.F. (1966) Whisker growth after removal of the dermal papilla and lengths of follicle in the hooded rat. J. Embryol. Exp. Morphol. 3:331–347.
- Oliver, R.F., Jahoda, C.A.B. (1988) The dermal papilla and maintenance of hair growth. In: "The Biology of Wool and Hair," Marshall, R.C., Rogers, G.E., Reis, P.J. and Ward, K.A. (eds). London: Chapman and Hall, pp. 51–67.
- Panaretto, B.A. (1993) Gene expression of potential morphogenes during hair follicle and tooth formation: A review. Reprod. Fertil. Dev. 5:345-360.
- Patel, T., Gores, G.J., Kaufmann, S.H. (1996) The role of proteases during apoptosis. FASEB J. 10:587–597.
- Prouty, S.M., Lawrence, L., Stenn, K.S. (1996) Fibroblast dependent induction of a murine skin lesion with similarity to human common blue nevus, Am. J. Pathol. 148:1871–1885.
- Reynolds, A.J., Jahoda, C.A.B. (1990) Adult rat pelage dermal papilla cells induce type-specific follicle formation and hair growth in adult footpad skin, J. Invest. Derm. 95:485.
- Reynolds, A.J., Jahoda, C.A.B. (1991a) Hair follicle stem cells? A distinct germinative epidermal cell population is activated in vitro by the presence of hair dermal papilla cells. J. Cell Sci. 99:373–385.
- Reynolds, A.J., Jahoda, C.A.B. (1991b) Inductive properties of hair follicle cells. Ann. N.Y. Acad. Sci. 642:226-42.
- Sanchez-Ferrer, A., Rodrigez-Lopez, J.N., Garcia-Canovas, F., Garcia-Carmona, F. (1995) Tyrosinase: A comprehensive review of its mechanism. Biochem. Biophys. Acta. 1247:1-11.
- Santulli, R.J., Derian, C.K., Darrow, A.L., Tomko, K.A., Eckardt, A.J., Seiberg, M., Scarborough, R.M., Andrade-Gordon, P. (1995) Evidence for the presence of a protease-activated receptor distinct from thrombin receptor in human keratinocytes. Proc. Natl. Acad. Sci. U.S.A. 92:9151–9155.

- Seiberg, M., Marthinuss, J., Stenn, K.S. (1995) Changes in expression of apoptosis-associated genes in skin mark early catagen. J. Invest. Dermatol. 104:78–82.
- Slominski, A., Paus, R. (1993) Melanogenesis is coupled to murine anagen: Towards new concepts for the role of melanocytes and the regulation of melanogenesis in hair growth. J. Invest. Dermatol. 101:90s–97s.
- Stenn, K.S., Paus, R., Dutton, T., Sarba, B. (1993) Glucocorticoid effect on hair growth initiation: A reconsideration. Skin Pharmacol. 6:125-134.
- Stenn, K.S., Lawrence, L., Veis, D., Korsmeyer, S., Seiberg, M. (1994a) Expression of the bcl-2 protooncogene in the cycling adult mouse hair follicle. J. Invest. Dermatol. 103:107–111.
- Stenn, K.S., Prouty, S., Seiberg, M. (1994b) Molecules of hair follicle cycling: a tabulated review. J. Dermatol. Sci. 7:s109-s124.
- Stenn, K.S., Combates, N.J., Eilertsen, K.J., Gordon, J.S., Pardinas, J.R., Parimoo, S., Prouty, S.M. (1996) Hair follicle growth controls. Dermatol. Clin. 14:543.
- Sun. T.-T., Costarelis, G., Lavkar, R.M. (1991) Follicular stem cells: The bulge-activation hypothesis. J. Invest. Dermatol. 96:77s-78s.
- Tarlow, J.K., Clay, F.E., Cork, M.J., Blakemore, A.I.F., McDonagh, A.J.G., Messenger, A.G., Duff, G.W. (1994) Severity of alopecia areata is associated with a polymorphism in the IL-1 receptor agonist gene. J. Invest. Dermatol. 103:387–390.
- Telegdy, E., Lutz, G., Mojzes, J., Kreysel, H.W., Schneider, I. (1994) Cytokine expression on keratinocytes in alopecia areata. Exp. Dermatol. 3:147.
- Vaux, D.L., Strasser, A. (1996) The molecular biology of apoptosis. Proc. Natl. Acad. Sci. U.S.A. 93:2239–2244.
- Wagner, S.L., Lau, A.L., Cunningham, D.D. (1989) Binding of protease nexin-1 to the fibroblast surface alters its target proteinase specificity. J. Biol. Chem. 264:611–615.
- Wintzen, M., Yaar, M., Peter, J., Burbach, H., Gilchrest, B.A. (1996) Proopiomelanocortin gene product regulation in keratinocytes. J. Invest. Dermatol. 106:673–678.
- Wood, L.C., Elias, P.M., Calhoum, C., Tsai, J.C., Grunfeld, C., Feingold, K.R. (1996) Barrier disruption stimulates IL-1 alpha expression and release from a pre-formed pool in murine epidermis. J. Invest. Dermatol. 106:397–403.
- Yu, D.-W., Yang, T., Sonoda, T., Gaffney, K., Jensen, P.J., Dooley, T., Ledbetter, S., Freedberg, I.M., Lavker, R., Sun, T.-T. (1995) Message of nexin 1, a serine protease inhibitor, is accumulated in the follicular papilla during anagen of the hair cycle. J. Cell Sci. 108:3867-3874.

This Page is Inserted by IFW Indexing and Scanning Operations and is not part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

□ BLACK BORDERS
□ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
□ FADED TEXT OR DRAWING
□ BLURRED OR ILLEGIBLE TEXT OR DRAWING
□ SKEWED/SLANTED IMAGES
□ COLOR OR BLACK AND WHITE PHOTOGRAPHS
□ GRAY SCALE DOCUMENTS
□ LINES OR MARKS ON ORIGINAL DOCUMENT
□ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY

IMAGES ARE BEST AVAILABLE COPY.

OTHER:

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.

